
<html lang="en"     class="pb-page"  data-request-id="b04fdc58-cb19-4f98-9739-196f1aca7001"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-10;article:article:10.1021/acs.jmedchem.0c00424"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist" /></meta><meta name="dc.Creator" content="Amy E.  Moritz" /></meta><meta name="dc.Creator" content="R. Benjamin  Free" /></meta><meta name="dc.Creator" content="Warren S.  Weiner" /></meta><meta name="dc.Creator" content="Emmanuel O.  Akano" /></meta><meta name="dc.Creator" content="Disha  Gandhi" /></meta><meta name="dc.Creator" content="Ara  Abramyan" /></meta><meta name="dc.Creator" content="Thomas M.  Keck" /></meta><meta name="dc.Creator" content="Marc  Ferrer" /></meta><meta name="dc.Creator" content="Xin  Hu" /></meta><meta name="dc.Creator" content="Noel  Southall" /></meta><meta name="dc.Creator" content="Joseph  Steiner" /></meta><meta name="dc.Creator" content="Jeffrey  Aubé" /></meta><meta name="dc.Creator" content="Lei  Shi" /></meta><meta name="dc.Creator" content="Kevin J.  Frankowski" /></meta><meta name="dc.Creator" content="David R.  Sibley" /></meta><meta name="dc.Description" content="To identify novel D3 dopamine receptor (D3R) agonists, we conducted a high-throughput screen using a β-arrestin recruitment assay. Counterscreening of the hit compounds provided an assessment of th..." /></meta><meta name="Description" content="To identify novel D3 dopamine receptor (D3R) agonists, we conducted a high-throughput screen using a β-arrestin recruitment assay. Counterscreening of the hit compounds provided an assessment of th..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 28, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00424" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00424" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00424" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00424" /></link>
        
    
    

<title>Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00424" /></meta><meta property="og:title" content="Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0026.jpeg" /></meta><meta property="og:description" content="To identify novel D3 dopamine receptor (D3R) agonists, we conducted a high-throughput screen using a β-arrestin recruitment assay. Counterscreening of the hit compounds provided an assessment of their selectivity, efficacy, and potency. The most promising scaffold was optimized through medicinal chemistry resulting in enhanced potency and selectivity. The optimized compound, ML417 (20), potently promotes D3R-mediated β-arrestin translocation, G protein activation, and ERK1/2 phosphorylation (pERK) while lacking activity at other dopamine receptors. Screening of ML417 against multiple G protein-coupled receptors revealed exceptional global selectivity. Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity. ML417 was also found to protect against neurodegeneration of dopaminergic neurons derived from iPSCs. Together with promising pharmacokinetics and toxicology profiles, these results suggest that ML417 is a novel and uniquely selective D3R agonist that may serve as both a research tool and a therapeutic lead for the treatment of neuropsychiatric disorders." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00424"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00424">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00424&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00424&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00424&amp;href=/doi/10.1021/acs.jmedchem.0c00424" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 5526-5567</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00442" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00431" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D<sub>3</sub> Dopamine Receptor Agonist</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Amy E. Moritz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy E. Moritz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy+E.++Moritz">Amy E. Moritz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">R. Benjamin Free</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">R. Benjamin Free</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=R.+Benjamin++Free">R. Benjamin Free</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2428-0487" title="Orcid link">http://orcid.org/0000-0002-2428-0487</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Warren S. Weiner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Warren S. Weiner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Kansas Specialized Chemistry Center, University of Kansas, Lawrence, Kansas 66047, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Warren+S.++Weiner">Warren S. Weiner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emmanuel O. Akano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emmanuel O. Akano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emmanuel+O.++Akano">Emmanuel O. Akano</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Disha Gandhi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Disha Gandhi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Disha++Gandhi">Disha Gandhi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ara Abramyan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ara Abramyan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Computational Chemistry and Molecular Biophysics Unit, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ara++Abramyan">Ara Abramyan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas M. Keck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas M. Keck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry & Biochemistry, Department of Molecular & Cellular Biosciences, College of Science and Mathematics, Rowan University, 201 Mullica Hill Road, Glassboro, New Jersey 08028, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+M.++Keck">Thomas M. Keck</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1845-9373" title="Orcid link">http://orcid.org/0000-0003-1845-9373</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marc Ferrer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marc Ferrer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marc++Ferrer">Marc Ferrer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Hu">Xin Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Noel Southall</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Noel Southall</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Noel++Southall">Noel Southall</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joseph Steiner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph Steiner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">NeuroTherapeutics Development Unit, National Institute for Neurological Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++Steiner">Joseph Steiner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey Aubé</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey Aubé</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Kansas Specialized Chemistry Center, University of Kansas, Lawrence, Kansas 66047, United States</div><div class="loa-info-affiliations-info">Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Aub%C3%A9">Jeffrey Aubé</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1049-5767" title="Orcid link">http://orcid.org/0000-0003-1049-5767</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Computational Chemistry and Molecular Biophysics Unit, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland, 333 Cassell Drive, Baltimore, Maryland 21224, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Shi">Lei Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin J. Frankowski</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin J. Frankowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Kansas Specialized Chemistry Center, University of Kansas, Lawrence, Kansas 66047, United States</div><div class="loa-info-affiliations-info">Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#5f343a293631391f2a313c713a3b2a"><span class="__cf_email__" data-cfemail="9df6f8ebf4f3fbdde8f3feb3f8f9e8">[email protected]</span></a>. Phone: (919)-966-1659. Fax: (919)-843-8465.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+J.++Frankowski">Kevin J. Frankowski</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">David R. Sibley</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David R. Sibley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#13607a717f766a77537d7a7d77603d7d7a7b3d747c65"><span class="__cf_email__" data-cfemail="c6b5afa4aaa3bfa286a8afa8a2b5e8a8afaee8a1a9b0">[email protected]</span></a>. Phone: (301)-496-9316. Fax: (301)-480-3726.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+R.++Sibley">David R. Sibley</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0624-962X" title="Orcid link">http://orcid.org/0000-0002-0624-962X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00424&amp;href=/doi/10.1021%2Facs.jmedchem.0c00424" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 5526–5567</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 28, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 March 2020</li><li><span class="item_label"><b>Published</b> online</span>28 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00424" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00424</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5526%26pageCount%3D42%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAmy%2BE.%2BMoritz%252C%2BR.%2BBenjamin%2BFree%252C%2BWarren%2BS.%2BWeiner%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D10%26contentID%3Dacs.jmedchem.0c00424%26title%3DDiscovery%252C%2BOptimization%252C%2Band%2BCharacterization%2Bof%2BML417%253A%2BA%2BNovel%2Band%2BHighly%2BSelective%2BD3%2BDopamine%2BReceptor%2BAgonist%26numPages%3D42%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5567%26publicationDate%3DMay%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00424"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1550</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00424" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;E. Moritz&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Benjamin Free&quot;},{&quot;first_name&quot;:&quot;Warren&quot;,&quot;last_name&quot;:&quot;S. Weiner&quot;},{&quot;first_name&quot;:&quot;Emmanuel&quot;,&quot;last_name&quot;:&quot;O. Akano&quot;},{&quot;first_name&quot;:&quot;Disha&quot;,&quot;last_name&quot;:&quot;Gandhi&quot;},{&quot;first_name&quot;:&quot;Ara&quot;,&quot;last_name&quot;:&quot;Abramyan&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;M. Keck&quot;},{&quot;first_name&quot;:&quot;Marc&quot;,&quot;last_name&quot;:&quot;Ferrer&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Noel&quot;,&quot;last_name&quot;:&quot;Southall&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;Steiner&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Aubé&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;J. Frankowski&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;R. Sibley&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5526-5567&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00424&quot;},&quot;abstract&quot;:&quot;To identify novel D3 dopamine receptor (D3R) agonists, we conducted a high-throughput screen using a β-arrestin recruitment assay. Counterscreening of the hit compounds provided an assessment of their selectivity, efficacy, and potency. The most promising scaffold was optimized through medicinal chemistry resulting in enhanced potency and selectivity. The optimized compound, ML417 (20), potently promotes D3R-mediated β-arrestin translocation, G protein activation, and ERK1/2 phosphorylation (pERK) while lacking activity at other dopamine receptors. Screening of ML417 against multiple G protein-coupled receptors revealed exceptional global selectivity. Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity. ML417 was also found to protect against neurodegeneration of dopaminergic neurons derived from iPSCs. Together with promising pharmacokinetics and toxicology profiles, these results suggest that ML417 is a novel and uniquely selective&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00424&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00424" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00424&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00424" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00424&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00424" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00424&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00424&amp;href=/doi/10.1021/acs.jmedchem.0c00424" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00424" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00424" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00424%26sid%3Dliteratum%253Aachs%26pmid%3D32342685%26genre%3Darticle%26aulast%3DMoritz%26date%3D2020%26atitle%3DDiscovery%252C%2BOptimization%252C%2Band%2BCharacterization%2Bof%2BML417%253A%2BA%2BNovel%2Band%2BHighly%2BSelective%2BD3%2BDopamine%2BReceptor%2BAgonist%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D10%26spage%3D5526%26epage%3D5567%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291285" title="Ethers">Ethers</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/jmcmar.2020.63.issue-10/20200528/jmcmar.2020.63.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">To identify novel D<sub>3</sub> dopamine receptor (D3R) agonists, we conducted a high-throughput screen using a β-arrestin recruitment assay. Counterscreening of the hit compounds provided an assessment of their selectivity, efficacy, and potency. The most promising scaffold was optimized through medicinal chemistry resulting in enhanced potency and selectivity. The optimized compound, ML417 (<b>20</b>), potently promotes D3R-mediated β-arrestin translocation, G protein activation, and ERK1/2 phosphorylation (pERK) while lacking activity at other dopamine receptors. Screening of ML417 against multiple G protein-coupled receptors revealed exceptional global selectivity. Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity. ML417 was also found to protect against neurodegeneration of dopaminergic neurons derived from iPSCs. Together with promising pharmacokinetics and toxicology profiles, these results suggest that ML417 is a novel and uniquely selective D3R agonist that may serve as both a research tool and a therapeutic lead for the treatment of neuropsychiatric disorders.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78068" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78068" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Dysregulation of dopamine receptors is linked to the etiology and/or therapy of many neuropsychiatric disorders, including Parkinson’s disease (PD), schizophrenia, and substance use disorders.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a> These receptors are categorized into two subfamilies: D1-like (D1R and D5R) and D2-like (D2R, D3R, and D4R) based on the protein structure, pharmacology, and physiological signaling.<a onclick="showRef(event, 'ref1 ref3 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref3 ref5">(1,3,5)</a> Dopamine receptor subfamilies exhibit high sequence homology, particularly the D2R and D3R, which share 74% identity between their transmembrane domains (TMs) and 94% identity between their putative orthosteric binding sites, where the endogenous agonist dopamine (DA) binds.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Not surprisingly, most currently available drugs that target these receptors, including antipsychotics, anti-PD medications, and research tool compounds, are not highly subtype-selective but instead modulate both D2R and D3R subtypes to varying degrees.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Further, most known compounds that target the D2R and/or D3R also cross-react with other related G protein-coupled receptors (GPCRs), especially those for biogenic amines, creating the potential for profound off-target side effects. Thus, more selective agents are critically needed not only for the delineation of dopamine receptor action <i>in vivo</i> but also for the development of more selective therapeutics with fewer side effects.</div><div class="NLM_p">D3R activation is known to have important therapeutic effects. Agonists that are D3R-preferring (e.g., ∼10-fold D3R > D2R-selective), including pramipexole and ropinirole, are effective in treating both PD and restless legs syndrome (RLS). These compounds are clinically active in relieving motor deficits and slowing the loss of dopaminergic terminals upon long-term administration to PD patients.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Further, in animal models, D3R-preferring agonists are the most potent neuroprotective agents identified to date against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration in mice<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11−14)</a> and primates<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and against 6-hydroxydopamine (6-OHDA)-induced lesions in rats.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Importantly, studies with D3R-knockout mice support that the neuroprotective effects are mediated directly by the D3R.<a onclick="showRef(event, 'ref14 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref17 ref18">(14,17,18)</a> Unfortunately, clinical treatment with drugs such as pramipexole and ropinirole is frequently associated with impulse control disorders, including pathological gambling, shopping, eating, and hypersexuality. These side effects typically occur at higher doses that would fully activate the D2R, which may underlie the loss of impulse control.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Thus, a highly selective D3R agonist that lacks D2R activity may hold significant therapeutic potential, as well as filling an important role as a probe compound for dissecting signaling pathways underlying D3R signaling from those of D2R.</div><div class="NLM_p">Not surprisingly, extensive efforts have been directed toward the development of selective agonists and antagonists that target the D3R.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Significant progress has been made in the development of antagonists that are selective for the D3R vs other dopamine receptors, which has been aided by the availability of a crystal structure of the D3R in an inactive state.<a onclick="showRef(event, 'ref6 ref23'); return false;" href="javascript:void(0);" class="ref ref6 ref23">(6,23)</a> The most selective D3R antagonists are extended-length compounds that are structurally bivalent, in that they possess a primary pharmacophore that binds to the orthosteric site and, connected via a linker, a secondary pharmacophore that binds to a secondary site, which may confer allosteric effects.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30">(23−30)</a> Bivalent compounds that possess allosteric properties are considered to be bitopic in nature.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35">(31−35)</a> No D3R-selective antagonists have yet reached the clinic;<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> however, newer antagonists have shown promise, especially for the treatment of substance use disorders.<a onclick="showRef(event, 'ref28 ref29 ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref38 ref39 ref40 ref41">(28,29,38−41)</a></div><div class="NLM_p">Less progress has been made in the development of D3R-selective agonists for clinical use. In part, this is due to the unavailability of a crystal structure of the D3R in an active state. As might be expected, virtual screens based on the inactive-state D3R structure have yielded mostly compounds with antagonist-like effects.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> In contrast, synthetic medicinal chemistry approaches to D3R-selective agonists have been more successful with some agents achieving good pharmacological separation between the D3R and D2R.<a onclick="showRef(event, 'ref22 ref44 ref45 ref46 ref47 ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref22 ref44 ref45 ref46 ref47 ref48 ref49 ref50">(22,44−50)</a> Various examples of D3R-preferring agonists and their structures have recently been described in Moritz et al.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, nearly all such compounds have been based on a single precursor scaffold, pramipexole, and their global GPCR selectivity and suitability for clinical advancement are unclear. Clearly, novel chemical scaffolds for designing highly selective D3R agonists are greatly needed. Very recently, the approach of designing extended-length bivalent compounds with D3R-selective agonist properties has been reported.<a onclick="showRef(event, 'ref34 ref51'); return false;" href="javascript:void(0);" class="ref ref34 ref51">(34,51)</a></div><div class="NLM_p last">Here, we report the identification and development of a novel agonist scaffold that exhibits high selectivity for the D3R. Starting from an unbiased high-throughput screening approach, we identified a hit compound with promising pharmacological and structural characteristics. From this initial hit compound, over 100 structural analogues were synthesized and characterized to develop a comprehensive structure–activity relationship (SAR) investigation and to establish the structural determinants for potency, efficacy, and selectivity at the D3R. An optimized lead compound, <b>20</b> (ML417), was identified that promotes potent D3R-mediated β-arrestin translocation, G protein-mediated signaling, and ERK1/2 phosphorylation (pERK) with minimal effects on other GPCR-mediated signaling. In addition, <b>20</b> was found to exhibit neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons. In summary, <b>20</b> is a novel and uniquely selective D3R agonist that will prove useful as a research tool and may show utility as a therapeutic lead for the treatment of neuropsychiatric disorders.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07810" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07810" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> High-Throughput Screening and Hit Compound Identification</h3><div class="NLM_p">To identify novel agonist scaffolds for the D3R, we conducted a high-throughput screen (HTS) of the NIH Molecular Libraries Probe Production Centers Network (MLPCN) small molecule library consisting of ∼400 000 diverse compounds.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The HTS utilized two concentrations (10 and 50 μM) of each library compound and measured their ability to stimulate β-arrestin recruitment to the D3R. The primary screen identified 4165 compounds that stimulated β-arrestin recruitment greater than 30% (>3 standard deviations) over basal (vehicle control) at either the lower (10 μM) or higher (50 μM) concentration of library compound. Primary screening data were deposited in PubChem (AID 652050 and 652048). Hit compounds were first chemoinformatically triaged based on results from a previously executed D2R HTS of the same library<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> to eliminate compounds that also possess D2R agonist activity. In addition, compounds were further triaged if they contained known chemically reactive moieties and/or promiscuous scaffolds resulting in ∼2500 unique compounds that were then tested in secondary assays. These triaged hit compounds were characterized using 7-point concentration–response assays of β-arrestin recruitment to the D3R and D2R, as well as β-arrestin recruitment to the unrelated prostaglandin E receptor 2 (PTGER2) to assess selectivity and eliminate compounds that modulate β-arrestin recruitment in a nonspecific manner. One hundred and fifty-two unique agonist compounds replicated in a concentration-dependent manner with demonstrated D3R > D2R selectivity (data not shown) and were selected for further characterization.</div><div class="NLM_p">All 152 vetted hit compounds were evaluated using D3R radioligand binding competition assays that employed the orthosteric antagonist [<sup>3</sup>H]-methylspiperone. Ninety of these compounds inhibited radioligand binding by greater than 50% at a dose of 40 μM and were thus initially classified as orthosteric. In contrast, 62 compounds failed to inhibit binding by greater than 50% (but were functionally active) and thus initially classified as potentially allosteric in nature. As allosteric compounds have the potential for global GPCR selectivity,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> we focused on those 62 compounds that were relatively ineffective at inhibiting [<sup>3</sup>H]-methylspiperone binding. These compounds were ranked via potency, D3R > D2R selectivity, and chemical tractability resulting in lead compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of the HTS lead, compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The HTS lead <b>1</b> is a full agonist (compared to dopamine) in a D3R-mediated β-arrestin recruitment assay, displaying an EC<sub>50</sub> of 710 nM (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). No measurable agonist activity was detected at the D2R using the same β-arrestin recruitment assay at concentrations up to 100 μM (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Interestingly, when <b>1</b> was tested for its ability to inhibit DA-stimulated β-arrestin recruitment to the D2R, we found that it was able to antagonize the receptor with an IC<sub>50</sub> of 16 μM (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). We next sought to determine the affinity of <b>1</b> at the orthosteric binding site by conducting competition binding studies with [<sup>3</sup>H]-methylspiperone at both the D2R and D3R. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D, the compound weakly inhibited radioligand binding to the D3R with an IC<sub>50</sub> > 10 μM and no measurable ability to displace binding to the D2R. This observation suggests an apparent disconnect between the potency of <b>1</b> as an agonist in the D3R β-arrestin functional assay and its limited, but demonstrable, ability to inhibit the binding of [<sup>3</sup>H]-methylspiperone to the D3R. One possible explanation is that <b>1</b> is a weak partial (orthosteric) agonist of the D3R that appears as a potent full agonist in the functional assay due to spare receptors and/or signal amplification. This is not likely, however, as the β-arrestin recruitment assay only produces a signal when the receptor and β-arrestin are complemented 1:1—there are no spare receptors or signal amplification. Regardless of the mechanism, the overall activity profile of <b>1</b> appeared to warrant further investigation and its optimization.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pharmacological activity of lead compound <b>1</b> on the D3R and D2R. (A, B) Agonist concentration–response curves for stimulating β-arrestin recruitment in response to either dopamine (DA) or <b>1</b> using cells expressing either the D3R (A) or D2R (B). Cells were stimulated as indicated, and β-arrestin recruitment was assessed using the DiscoverX assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data are expressed as a percentage of the maximum dopamine (DA) signal and are shown as means ± standard error of the mean (SEM) of at least three experiments performed in triplicate. In (A), the EC<sub>50</sub> value for DA is 6.4 ± 0.6 nM (mean ± SEM, <i>n</i> = 12) and of <b>1</b> is 710 ± 150 nM (mean ± SEM, <i>n</i> = 13). In (B), the EC<sub>50</sub> value for DA is 140 ± 23 nM (mean ± SEM, <i>n</i> = 13). (C) Antagonist concentration–response curves of either sulpiride or <b>1</b> for inhibiting β-arrestin recruitment to the D2R. Cells were incubated with the indicated concentrations of the compound in the presence of an EC<sub>80</sub> concentration of DA (1 μM). Data are expressed as a percentage of signal seen in the absence of test compounds and are shown as means ± SEM of at least three experiments performed in triplicate. The IC<sub>50</sub> value of sulpiride is 42 ± 4.9 nM (mean ± SEM, <i>n</i> = 8) and of <b>1</b> is 16 ± 3.0 μM (mean ± SEM, <i>n</i> = 10). (D) Radioligand binding assays using [<sup>3</sup>H]-methylspiperone were performed as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data are representative of six independent experiments and expressed as a percentage of the specific binding. The IC<sub>50</sub> values of <b>1</b> were determined to be >100 μM for the D3R and D2R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">We employed several complementary synthetic routes to construct the target analogue compounds all based on a central strategy of iterative derivatization of the piperazine core. Our initial strategy to the HTS hit compound resynthesis and analogue exploration coupled the <i>N</i>-acylated piperazines <b>111</b> with the alkyl bromides <b>112</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) utilizing General Procedure A or B (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for general procedure details and the synthesis of components <b>111</b> and <b>112</b>). For specific target analogues, we utilized slightly modified conditions as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Exploration of the <i>N</i>-acyl moiety was most efficiently achieved through a reversal in the order of piperazine functionalization. Thus, alkylation of 1-Boc-piperazine and subsequent Boc deprotection afforded the 1-(2-(aryloxy)ethyl)piperazines <b>114</b>, which were then acylated utilizing General Procedures D or E (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>) to provide the final analogues (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Again, specific target analogues required slightly modified conditions, as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. We utilized this broadly defined acylation strategy to access a total of 59 analogues, the most common approach that we employed in these SAR studies. The sulfonamide analogue <b>44</b> was synthesized using an analogous protocol to acylation by replacing the acid chloride component with 4-methoxybenzene-1-sulfonyl chloride (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The racemic methyl derivative <b>46</b> was synthesized via reductive amination of carboxamide fragment <b>111a</b> and 1-(4-methoxyphenoxy)propan-2-one (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). To efficiently explore the aryl ether composition of (2-indoyl)-substituted piperazine analogues, we employed a nucleophilic displacement approach on the alkyl chloride <b>116</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) utilizing General Procedure F or G (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). This displacement protocol also furnished the piperidine analogue <b>50</b> and 1,2-dimethylethylenediamine analogue <b>51</b> using the corresponding amine starting materials <b>117</b> and <b>119</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Select individual analogue syntheses utilized a complementary Mitsunobu reaction protocol on the 1-(2-hydroxyethyl)piperazine <b>121</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). Minor modifications to these strategies were utilized to construct other target analogues. Thus, starting with 1-(2-hydroxyethyl)piperidine <b>117</b> and using a nucleophilic displacement approach allowed ready access to compound <b>108</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). In an analogous approach to the late-stage acylation used in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, the alkylated piperazine <b>114a</b> was subjected to a second alkylation to afford compound <b>109</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). Overall, the routes summarized here enabled the efficient and modular construction of the numerous analogues synthesized and facilitated the survey of structural modifications on all regions of compound <b>1</b>. The activity of these analogues and our optimization strategy will be discussed in detail in the following section.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Summary of Alkylation Routes to SAR Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) potassium iodide (0.1 or 1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), MeCN or DMF, 60 °C, 14–20 h, 27–81% yield; (b) <b>112a</b> (1.1 equiv), Et<sub>3</sub>N (1.4 equiv), MeCN, 60 °C, 18 h, 68% yield; (c) <b>112a</b> (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), <i>N</i>,<i>N</i>-dimethylformamide (DMF), 100 °C, 5 h, 37% yield; and (d) 1-(3-bromopropoxy)-4-methoxybenzene or 1-(4-bromobutoxy)-4-methoxybenzene, potassium iodide (1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), MeCN, 60 °C, 19 h, 76–83% yield.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Summary of Late-Stage Acylation Routes to SAR Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), potassium iodide (0.1 equiv), MeCN or DMF, 70 or 90 °C, 16–21 h, 70–79% yield; (b) Et<sub>3</sub>SiH (1.5–2.0 equiv), trifluoroacetic acid (15–20 equiv), CH<sub>2</sub>Cl<sub>2</sub>, room temperature (rt), 4–26 h, 80–91% yield; (c) Ar<sup>1</sup>C(O)Cl (1.0–1.3 equiv), Et<sub>3</sub>N (1.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 16–20 h, 61–69% yield; (d) Ar<sup>1</sup>CO<sub>2</sub>H (1.0–1.3 equiv), PyBOP (1.2 equiv), <i>i</i>-Pr<sub>2</sub>EtN (3.0 equiv), DMF, rt, 16–20 h, 15–93% yield; (e) 1<i>H</i>-indole-2-carboxylic acid (1.2 equiv), diisopropylcarbodiimide (3.0 equiv), 4-dimethylaminopyridine (DMAP, 0.1 equiv), tetrahydrofuran (THF), rt, 15 h, 73% yield; (f) 2-chloroproponyl chloride (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.5 equiv), 4-methoxyphenol or 4-chlorophenol (1.2 equiv), DMF, 80 °C, 4 h, 24–28% yield; and (g) BH<sub>3</sub>·THF (3.1–3.2 equiv), THF, 65 °C, 0.5–4 h, 86–88% yield.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the Sulfonamide Analogue <b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-methoxybenzene-1-sulfonyl chloride (1.0 equiv), Et<sub>3</sub>N (2.0 equiv), toluene, rt, 19 h, 55% yield.</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Reductive Amination Protocol for the Synthesis of the Methyl-Substituted Analogue <b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-(4-methoxyphenoxy)propan-2-one (1.0 equiv), NaBH(OAc)<sub>3</sub> (1.5 equiv), ClCH<sub>2</sub>CH<sub>2</sub>Cl, AcOH (0.3 equiv), 50 °C, 7 d, 57% yield.</p></p></figure><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0014.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Summary of Alkyl Chloride Displacement Routes to SAR Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1<i>H</i>-indole-2-carbonyl chloride (1.1 equiv), Et<sub>3</sub>N (1.2 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 20 h, 75% yield; (b) triphosgene (0.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 3 h, 53% yield; (c) Ar<sup>2</sup>OH (1.1–1.9 equiv), Ar<sup>2</sup>SH (1.6 equiv) or Ar<sup>2</sup>NHMe (1.6 equiv), K<sub>2</sub>CO<sub>3</sub> (1.8–3.3 equiv), DMF, 50–80 °C, 7–19 h, 5–73% yield; (d) 4-methoxybenzoyl chloride (1.1 equiv), Et<sub>3</sub>N (1.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 80% yield; (e) thionyl chloride (1.0–1.5 equiv), CHCl<sub>3</sub>, 50–55 °C, 0.5 or 46 h, 54–86% yield; and (f) 2-(methylamino)ethanol (5.1 equiv), MeCN, 80 °C, 25 h, 67% yield.</p></p></figure><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0015.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Mitsunobu Reaction Route to SAR Analogues <b>6</b>, <b>8</b>, and <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-methoxybenzoyl chloride (1.1 equiv), Et<sub>3</sub>N (1.3 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 24 h, 68% yield; and (b) Ar<sup>2</sup>OH (1.0 equiv), Ph<sub>3</sub>P (1.0 equiv), diisopropyl azodicarboxylate (DIAD, 1.3 equiv), CH<sub>2</sub>Cl<sub>2</sub> or THF, 60 °C, 16–40 h, 15–46% yield.</p></p></figure><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0016.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of the Piperidine Analogue <b>108</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) indole-2-carboxylic acid (1.0 equiv), HOBt (1.0 equiv), EDC·HCl (1.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 18 h, 49% yield; (b) TsCl (2.0 equiv), Et<sub>3</sub>N (4.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 46% yield; and (c) 4-methoxyphenol (3.0 equiv), K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), MeCN, 60 °C, 17 h, 70% yield.</p></p></figure><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0017.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of the Dibasic Piperazine Analogue <b>109</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-chloro-1-(1<i>H</i>-indol-2-yl)ethan-1-one (1.0 equiv), KI (1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (4.0 equiv), MeCN, 65 °C, 18 h, 51% yield.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Structure–Activity Relationships and HTS Hit Compound <b>1</b> Optimization</h3><div class="NLM_p">In an effort to increase the functional potency of <b>1</b> at the D3R, while at the same time eliminate its D2R antagonist activity, we explored SAR studies of this scaffold by synthesizing over 100 unique analogues of <b>1</b>. These analogues were designed to investigate four regions of the scaffold, including substitutions of the aryl ether and aryl carboxamide groups, modifications of the piperazine core, and changes to the central tether of the molecule, as illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. All analogues were analyzed in the D2R and D3R β-arrestin recruitment assays to generate a comprehensive SAR survey around the scaffold.</div><figure id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Illustration of structural modifications to compound <b>1</b> to investigate structure–activity relationships.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We began our SAR studies by examining modifications to the 4-methoxyphenyl groups on the left and right termini of compound <b>1</b> (i.e., aryl carboxamide and aryl ether moieties, respectively). In the latter case, replacing the 4-methoxyphenyl ether with other aryl ethers afforded analogues possessing a wide range of D3R agonist potencies (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The 2-methoxyphenyl ether <b>2</b> was found to be more than twice as potent, while the 3-methoxyphenyl ether <b>3</b> was more than 7-fold as potent, compared to compound <b>1</b>. Other monosubstituted phenyl ether analogues were less potent (entries <b>4</b>–<b>6</b>). In fact, the 4-(trifluoromethoxy)phenyl (<b>6</b>) and 3,5-dimethoxyphenyl (<b>7</b>) ethers were found to be inactive even at the highest tested concentrations. All compounds in this subset possessed no D2R agonism and only negligible, if any, D2R antagonism. The unsubstituted phenyl ether <b>8</b> was almost as potent as the 3-methoxyphenyl ether (EC<sub>50</sub> = 115 nM); however, this analogue was found to also possess D2R agonism (EC<sub>50</sub> = 2300 nM). Aryl ether <b>9</b>, which contained bridged 3,4-dialkoxy substitution, possessed a 2-fold improved D3R agonist potency and excellent selectivity, albeit with reduced agonist efficacy at the D3R. The 3-pyridyl ether analogue <b>10</b> was 35-fold more potent than the hit compound <b>1</b> in the D3R agonist assay (EC<sub>50</sub> = 17 nM); however, it also exhibited modestly potent D2R agonist activity (EC<sub>50</sub> = 2900 nM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Analogues Exploring 2-(4-Methoxyphenylether)ethyl Replacement</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0018.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">β-arrestin recruitment activity was assessed as described in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. <i>E</i><sub>max</sub> values are expressed as a percentage of the maximum dopamine response observed in the same assay. <i>I</i><sub>max</sub> values are expressed as a percentage of the maximum inhibition of a dopamine (EC<sub>80</sub> concentration) response observed with the antagonist sulpiride in the same assay.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">ND curve did not plateau.</p></div></div><div></div></div><div class="NLM_p">In a more extensive effort than above, we investigated replacements of the 4-methoxybenzamide on the left-hand portion of compound <b>1</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The unsubstituted benzamide analogue <b>11</b> was approximately an equipotent D3R agonist compared to the hit compound <b>1</b>, along with ablation of the D2R antagonism. The 2-methoxybenzamide (<b>12</b>) possessed only modest potency, while the 3-methoxybenzamide (<b>13</b>) was marginally more potent. Other monosubstituted benzamides were less promising, with the 4-chloro analogue <b>14</b> inactive as a D3R agonist and the 4-ethyl analogue <b>15</b> on par in potency compared to the hit. However, both <b>14</b> and <b>15</b> also possessed limited D2R antagonist activity. We next examined a number of heterocyclic carboxamides at this position, beginning with the two pyridyl analogues <b>16</b> and <b>17</b>, neither of which possessed significant D3R agonist activity. We next investigated a series of indole carboxamide analogues. While all three of the 5-, 3-, and 2-indole carboxamide analogues (<b>18</b>, <b>19</b>, and <b>20</b>, respectively) tested possessed potent D3R agonist activity, only <b>20</b> was completely D3R-selective and also possessed the greatest potency (EC<sub>50</sub> = 38 nM), almost a 20-fold improvement compared to the hit. Thus, we delved more systematically into the substitution of 2-indole carboxamide analogues, examining methoxy, methyl, and chloro substitutions around the benzene of the indole moiety (i.e., 4-, 5-, 6-, and 7-position substitutions). The methoxy-substituted analogues <b>21</b>–<b>24</b> were all D3R agonists of reasonably high potency (EC<sub>50</sub>s = 155–980 nM); however, all of these analogues also possessed measurable D2R agonist activity (EC<sub>50</sub>s = 5200–7800 nM). The methyl-substituted analogues <b>25</b>–<b>28</b> were also all fairly potent D3R agonists (EC<sub>50</sub>s = 130–611 nM), along with a reduced D2R agonism (EC<sub>50</sub>s = 1100 to >50 000 nM). The 5-methyl analogue <b>27</b> was the most selective and possessed D3R agonist potency (EC<sub>50</sub> = 611 nM) on par with the hit compound <b>1</b>. Similarly, the chloro-substituted analogues <b>29</b>–<b>32</b> were all D3R agonists of modest potency (EC<sub>50</sub>s = 160–2900 nM), with D2R agonist activity similar to the methyl-substituted series (EC<sub>50</sub>s = 3500 to > 50 000 nM). In this series, only the 5-chloro analogue was fully D3R-selective; however, the D3R agonism was not very potent (EC<sub>50</sub> = 2900 nM). None of these substituted analogues approached the potency of the unsubstituted indole <b>20</b>, and we did not further investigate substitution of this region of the indole.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Analogues Exploring 4-Methoxybenzamide Replacement</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0019.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0020.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">β-arrestin recruitment activity was assessed as described in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. <i>E</i><sub>max</sub> values are expressed as a percentage of the maximum dopamine response observed in the same assay. <i>I</i><sub>max</sub> values are expressed as a percentage of the maximum inhibition of a dopamine (EC<sub>80</sub> concentration) response observed with the antagonist sulpiride in the same assay.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">ND curve did not plateau.</p></div></div><div></div></div><div class="NLM_p">Next, we probed the substitution on the nitrogen-containing ring of the indole by testing the <i>N</i>- and 3-methyl analogues <b>33</b> and <b>34</b>, respectively. While the <i>N</i>-methyl analogue retained D3R agonist activity on par with compound <b>1</b>, it also exhibited D2R antagonism. The 3-methyl analogue was nonselective, showing only weak activity in all three assays (EC<sub>50</sub>s = 1900–4400 nM). We next examined other bicyclic heterocycles attached to the carboxamide, beginning with an additional nitrogen incorporation into the indole ring. Moving the additional nitrogen atom around the ring afforded analogues (<b>35</b>–<b>39</b>) of modest D3R agonist potency (EC<sub>50</sub>s = 167–2800 nM), though often with modest (<b>35</b>, EC<sub>50</sub> = 413 nM) to weak (<b>36</b> and <b>37</b>, EC<sub>50</sub>s = 7800 and 5500 nM, respectively) D2R agonism. Only the benzimidazole analogue <b>39</b> was both reasonably potent (EC<sub>50</sub> = 192 nM) and D3R-selective. Replacement of the indole with a benzofuran moiety afforded analogue <b>40</b>, a D3R agonist of modest potency (EC<sub>50</sub> = 430 nM), though with weak D2R antagonism (IC<sub>50</sub> = 7700 nM). The benzothiophene analogue <b>41</b> was both less potent and selective than the benzofuran. The cyclohexyl and methyl carboxamides (<b>42</b> and <b>43</b>, respectively) did not show any appreciable activity, with only <b>43</b> possessing any measurable D3R agonist potency (EC<sub>50</sub> = 9700 nM). The 4-methoxyphenyl sulfonamide <b>44</b> possessed no measurable activity across the three SAR assays, indicating that the sulfonamide isostere is not a suitable replacement for the carboxamide functional group in this instance. The directly attached 4-methoxyphenyl piperizine <b>45</b> was similarly inactive, again indicating the importance of the carboxamide for potency.</div><div class="NLM_p">We explored a number of modifications to the piperazine or alkyl chain of the tethered ether, most often through the addition of a single methyl group to the HTS lead compound <b>1</b> structure (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Thus, analogues <b>46</b> and <b>47</b> contained an additional methyl group on the two-carbon tether bridging the piperazine and aryl ether groups. While both were D3R-selective agonists, the position of the methyl group was critical to the effect on potency. Analogue <b>46</b> (where the methyl group was adjacent to the piperazine) possessed weak D3R agonist potency (EC<sub>50</sub> = 9300 nM), while the constitutional isomer <b>47</b> (with a methyl group adjacent to the ether moiety) was almost 3-fold more potent than hit compound <b>1</b> (EC<sub>50</sub> = 160 nM). The effect of methyl substitution on the piperazine ring exhibited an analogous dependence on position. Analogue <b>48</b> (with the methyl group adjacent to the basic piperazine nitrogen) displayed greatly diminished potency and efficacy, while analogue <b>49</b> (with a methyl group adjacent to the amide nitrogen) was slightly more potent than the hit compound <b>1</b> (EC<sub>50</sub> = 510 nM), although <b>49</b> was not fully selective, possessing weak D2R agonism (EC<sub>50</sub> = 4200 nM). The profound detrimental effect observed from the methyl group introduction adjacent to the basic piperazine nitrogen indicates the importance of this moiety for activity, although whether this arises from steric interactions or through the induction of an unfavorable conformation is not immediately clear. Other structural modifications were explored and found to cause an almost complete loss of any activity. The piperidine analogue <b>50</b> was inactive in all assays, and the ring-opened analogue <b>51</b> possessed only very weak D2R antagonist activity (IC<sub>50</sub> = 18 000 nM).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Analogues Exploring the Modification of the Tether or Piperazine Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0021.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">β-arrestin recruitment activity was assessed as described in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. <i>E</i><sub>max</sub> values are expressed as a percentage of the maximum dopamine response observed in the same assay. <i>I</i><sub>max</sub> values are expressed as a percentage of the maximum inhibition of a dopamine (EC<sub>80</sub> concentration) response observed with the antagonist sulpiride in the same assay.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">ND curve did not plateau.</p></div></div><div></div></div><div class="NLM_p">Having identified potency-enhancing replacements for either the 4-methoxyphenyl ether or 4-methoxybenzamide group of compound <b>1</b>, we were interested in exploring simultaneous changes to both ends of the molecule (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The 3-methoxyphenyl (<b>3</b>) and 3-pyridyl ethers (<b>10</b>) were two of the most potent aryl ether analogues identified (EC<sub>50</sub>s = 98 and 17 nM, respectively) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), though both also possessed weak D2R activity. We thus explored a range of carboxamide analogues to better identify SAR trends that could lead to potent and selective analogues. The 3-methoxyphenyl ether analogues <b>52</b>–<b>56</b> contained some of the most promising carboxamide groups from earlier SAR studies and, gratifyingly, all afforded potent D3R analogues (EC<sub>50</sub>s = 34–285 nM). The most potent was the 2-indolyl carboxamide analogue <b>54</b> (EC<sub>50</sub> = 34 nM), although it also possessed slight D2R agonist activity (EC<sub>50</sub> = 2300 nM). The other 3-methoxyphenyl ether analogues were both less potent and even less selective than <b>54</b>. The 3-pyridyl ether analogue <b>10</b> was the most potent ether replacement identified (EC<sub>50</sub> = 17 nM), and we explored a more comprehensive survey of carboxamide replacements paired with this ether, primarily focused on substituted 2-indole carboxamides. The 4-methoxy-2-methylphenyl carboxamide <b>57</b> was almost 7-fold less potent than the corresponding 4-methoxyphenyl analogue <b>10</b>. In an effort that mirrored the original exploration of carboxamide groups, we tested a series of methoxy-, methyl-, and chloro-substituted 2-indoles. These analogues (<b>58</b>–<b>70</b>) possessed good potency (EC<sub>50</sub>s = 3–116 nM), with six analogues (<b>58</b>, <b>61</b>, <b>63</b>, <b>66</b>, <b>68</b>, and <b>70</b>) in the single-digit nanomolar range. Unfortunately, none of these analogues were highly selective D3R agonists and the more potent compounds were generally the least selective. Upon comparing the 3-pyridyl ether series to the 4-methoxyphenyl ether series, we also noted poor correlation between indole substitution position and rank order of potency, suggesting that the SAR trends might not be independent of the substitution at other positions of the molecule. Additional nitrogen incorporation on the indole moiety afforded a set of 3-pyridyl analogues (<b>71</b>–<b>76</b>) with excellent to good D3R agonist potency (EC<sub>50</sub>s = 13–200 nM) and all but analogue <b>74</b> possessing EC<sub>50</sub> values <100 nM. However, as observed with the substituted indole set, none of these analogues were fully D3R > D2R-selective. Three other heterocyclic carboxamide analogues were tested, benzofuran <b>77</b>, benzothiophene <b>78</b>, and pyrrole <b>79</b>, and all three were found to be potent D3R agonists. Contrary to the 4-methoxyphenyl ether series, in this set, <b>78</b> was found to be more potent (EC<sub>50</sub> =13 nM) than <b>77</b> (EC<sub>50</sub> = 42 nM), further supporting that SAR trends might be dependent upon all of the groups in the molecule and a cautionary note against the extrapolation of SAR trends across all analogues. Pyrrole <b>79</b> was over 15-fold less potent (EC<sub>50</sub> = 118 nM) than the corresponding indole <b>99</b> (EC<sub>50</sub> = 7 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In line with all other 3-pyridyl ether analogues, these three compounds were not highly D3R > D2R-selective.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Analogues Exploring Concurrent 4-Methoxyphenyl Ether and 4-Methoxybenzamide Replacement</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0022.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0023.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">β-arrestin recruitment activity was assessed as described in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. <i>E</i><sub>max</sub> values are expressed as a percentage of the maximum dopamine response observed in the same assay. <i>I</i><sub>max</sub> values are expressed as a percentage of the maximum inhibition of a dopamine (EC<sub>80</sub> concentration) response observed with the antagonist sulpiride in the same assay.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">ND curve did not plateau.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Analogues Based on the 2-Indolyl Carboxamide Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0024.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0025.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">β-arrestin recruitment activity was assessed as described in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. <i>E</i><sub>max</sub> values are expressed as a percentage of the maximum dopamine response observed in the same assay. <i>I</i><sub>max</sub> values are expressed as a percentage of the maximum inhibition of a dopamine (EC<sub>80</sub> concentration) response observed with the antagonist sulpiride in the same assay.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">ND curve did not plateau.</p></div></div><div></div></div><div class="NLM_p">We hoped that the potency might be improved through further optimization of the 4-methoxyphenyl ether group. Of the 35 carboxamide analogues in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the 2-indolyl analogue <b>20</b> was found to be by far the most potent and selective and remained our lead compound. Keeping the 2-indole carboxamide in place, we systematically explored replacements for the 4-methoxyphenyl ether (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The unsubstituted phenyl ether <b>80</b> was indeed more potent (EC<sub>50</sub> = 9 nM); however, it possessed modest D2R agonist and antagonist activities. The 3,4-methylenedioxyphenyl analogue <b>81</b> was a competent D3R agonist, though with slight D2R antagonism. The 4-methoxyphenyl thioether <b>82</b> was completely inactive across all three SAR assays, while the 4-thiomethoxyphenyl ether <b>83</b> was a modestly potent (EC<sub>50</sub> = 630 nM) and a fully selective D3R agonist. The limited data on oxygen-to-sulfur replacement potentially suggest a steric requirement of the ether oxygen for effective interaction with the D3R. This contrasts with the data for the α-methyl ether analogue <b>47</b>, which possessed increased potency over the desmethyl hit compound <b>1</b>. Additional focused analogues and computational experiments would be necessary to further elucidate the contributions of steric bulk and hydrogen-bond acceptor ability to overall analogue potency. We prepared a set of other 4-substituted phenyl ether analogues <b>84</b>–<b>92</b>. The 4-(trifluoromethoxy)phenyl ether <b>85</b> was a weakly potent (EC<sub>50</sub> = 3800 nM) and a fully selective D3R agonist, whereas the corresponding 4-(trifluoromethoxy)phenyl ether on the 4-methoxyphenyl carboxamide scaffold (i.e., <b>6</b>) possessed no measurable activity. The 4-ethylphenyl ether analogue <b>87</b> possessed comparable D3R potency (EC<sub>50</sub> = 1600 nM) to its counterpart on the 4-methoxyphenyl carboxamide scaffold, <b>4</b>. However, the 4-chlorophenyl ether analogue <b>90</b> did display a significant improvement to potency (EC<sub>50</sub> = 114 nM) compared to its 4-methoxyphenyl carboxamide counterpart <b>5</b> (EC<sub>50</sub> = 1000 nM). Other 4-substituted phenyl ethers also afforded potent and selective D3R agonists, such as the methyl-, fluoro-, and bromo-phenyl ether analogues (<b>86</b>, <b>89</b>, and <b>91</b>, respectively). The 4-ethoxyphenyl ether <b>84</b> and the 4-<i>tert</i>-butylphenyl ether <b>88</b> were completely inactive, possibly revealing a limit to the tolerated substituent size. A limited set of disubstituted phenyl ether analogues were explored (<b>93</b>–<b>97</b>), with the 2-chloro-4-methoxyphenyl ether <b>97</b> being the most potent (EC<sub>50</sub> = 41 nM) and selective analogue among the group. Analogue <b>97</b> was only slightly less potent than the original 2-indolyl carboxamide <b>20</b>; however, the chlorine atom in <b>97</b> did not confer any additional benefit and we continued to focus on <b>20</b> for further evaluation. Other examples were notably less potent, including the 3-chloro-4-methylphenyl ether <b>95</b>. This is interesting in light of the potent D3R agonism of 4-methylphenyl analogue <b>86</b>, further suggesting size limitations of the aryl ether. A set of four pyridyl ether analogues were evaluated, ranging from the very potent 5-chloro-3-pyridyl ether <b>101</b> (EC<sub>50</sub> = 5 nM) to the weakly potent 2-pyridyl ether <b>98</b> (EC<sub>50</sub> = 3500 nM). While not an exhaustive set, the potent analogues identified (i.e., <b>99</b> and <b>100</b>) lacked full D3R > D2R selectivity and only the 4-pyridyl ether <b>100</b> was found to be a selective D3R agonist of modest potency (EC<sub>50</sub> = 472 nM).</div><div class="NLM_p">Having earlier noted a slight potency improvement from methyl incorporation adjacent to the aryl ether (i.e., <b>47</b>), we tested the effect on two such 2-indole carboxamide exemplars (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). We observed a contradictory effect between the two cases: while the effect was slightly detrimental in the 4-methoxyphenyl ether analogue <b>102</b>, it provided a 3-fold potency enhancement for the 4-chlorophenyl ether analogue <b>103</b>. In both examples, however, the analogues also exhibited D2R agonist activity. It may be worth noting that methyl incorporation onto the tether afforded analogues that were racemic mixtures. Separation and testing of the enantiopure analogues could markedly affect the potency and/or selectivity and may be pursued in future SAR investigations. Replacement of the ether with an <i>N</i>-methyl tertiary amine afforded the modestly potent (EC<sub>50</sub> = 1900 nM) though D3R-selective analogue <b>104</b>. The 5-indole ether <b>105</b> was found to be a potent D3R agonist (EC<sub>50</sub> = 61 nM) as well as a reasonably potent D2R antagonist (IC<sub>50</sub> = 440 nM). Although this particular compound does not meet the criteria of a selective D3R agonist sought in the current study, <b>105</b> may be of particular interest as a lead in complementary studies examining D3R stimulation and, simultaneously, D2R antagonism.</div><div class="NLM_p">Finally, within the context of the 2-indole carboxamide analogues, we made additional modifications to the linker between the 2-indole carboxamide and 4-methoxyphenyl moieties. Compounds <b>106</b> and <b>107</b> have one or two additional methylene groups, respectively, inserted between the piperazine and 4-methoxyphenyl ether (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). These modifications lead to a complete loss of D3R agonist activity, although both compounds retained low potency D2R antagonist activity. In <b>108</b>, the piperazine ring was converted to a piperidine ring (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), which, similar to that observed with compound <b>50</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), led to a complete loss in D3R and D2R activities, further highlighting the importance of this nitrogen for receptor activity. Finally, we made analogue <b>109</b> in which a methylene group was inserted between the 2-indoylcarboxaminde and piperazine moieties, which lead to a complete loss of both D3R agonist and D2R antagonist activities (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Taken together, these results highlight the importance of linker length, especially for D3R agonist potency and efficacy.</div><div class="NLM_p">In summary, we explored SAR trends for both termini of compound <b>1</b> and, to a lesser extent, modifications on the core piperazine and tether. We have identified a number of potent and selective D3R agonists with the greater challenge being to maintain the D3R receptor selectivity without gaining D2R activity. The most potent and selective D3R agonist identified was the 2-indole carboxamide analogue <b>20</b>, containing the 4-methoxyphenyl ether found in hit compound <b>1</b>. The closely related but slightly less potent 2-chloro-4-methoxyphenyl ether <b>97</b> supports the chemotype as a valid D3R agonist scaffold. Therefore, we chose to further investigate compound <b>20</b> as a D3R-selective agonist and have designated it as NIH Molecular Libraries Initiative probe molecule ML417 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A).</div><figure id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacological activity of compound 20 on all dopamine receptor subtypes. (A) Chemical structure of <b>20</b>. (B) Agonist concentration–response curves for stimulating β-arrestin recruitment in response to <b>20</b> for the indicated DA receptor subtypes. β-arrestin recruitment was assessed using the DiscoverX assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, and the data are expressed as a percentage of the maximum dopamine signal for each receptor (not shown) and represent means ± SEM of at least three experiments performed in triplicate. The EC<sub>50</sub> for <b>20</b> at the D3R is reported in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. (C) Antagonist concentration–response curves of <b>20</b> on cells expressing individual dopamine receptor subtypes as indicated. β-arrestin recruitment was stimulated with an ∼EC<sub>80</sub> concentration of dopamine for each receptor subtype and incubated with the indicated concentrations of <b>20</b>. Data are expressed as a percentage of the signal seen with the EC<sub>80</sub> concentration of dopamine and represent means ± SEM of at least three experiments performed in triplicate. The IC<sub>50</sub> for <b>20</b> at the D2R was estimated to be >10 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Pharmacological Characterization of Lead Compound <b>20</b></h3><div class="NLM_p">Our lead compound <b>20</b> was subjected to further characterization using a variety of pharmacological assays. We initially wanted to assess the selectivity of compound <b>20</b> among all dopamine receptor subtypes using the β-arrestin recruitment functional assay. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B, <b>20</b> is a full agonist at the D3R with an EC<sub>50</sub> of 38 nM while displaying minimal agonist efficacy at all other receptor subtypes. When tested as an antagonist, <b>20</b> displayed very limited activity (IC<sub>50</sub> > 50 μM) at all subtypes except for the D2R where it exhibited some weak partial antagonism (IC<sub>50</sub> > 10 μM; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). This is in contrast to the parent hit compound <b>1</b> that showed full antagonism at the D2R, indicating that our medicinal chemistry efforts increased the potency of the compound for the D3R and decreased its activity at the D2R resulting in a potent and highly selective agonist of the D3R.</div><div class="NLM_p">The activity of <b>20</b> on β-arrestin recruitment to the D3R was confirmed using an orthogonal assay that measures bioluminescence resonance energy transfer (BRET) when the D3R and β-arrestin, fused to complimentary biosensors (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>), are in close proximity. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A using the BRET-based β-arrestin recruitment assay, <b>20</b> displayed full agonist activity at the D3R with an EC<sub>50</sub> of 1.2 nM. These results confirm those obtained using the DiscoverX β-arrestin recruitment assay (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), although <b>20</b> exhibited an ∼30-fold greater potency using the BRET-based assay. The reason for this discrepancy is not clear but may be related to differing assay time courses, different cell types, and/or varying levels and types of G protein-coupled receptor kinases (GRKs) that can affect β-arrestin recruitment to GPCRs.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Regardless, these findings confirm that <b>20</b> is a full and potent agonist for β-arrestin recruitment. We next sought to characterize the effects of <b>20</b> on G protein-mediated signaling. Initially, we used another BRET-based assay to examine D3R coupling to Go, an inhibitory G protein that the D3R has previously been shown to activate.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B, <b>20</b> functioned as a full agonist in the D3R-mediated Go-BRET assay with an EC<sub>50</sub> of 0.18 nM. The higher potency of <b>20</b> in this assay is likely due to spare receptors resulting in signal amplification in contrast to the β-arrestin recruitment assays, which lack amplification.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> We next wished to examine G protein-mediated second messenger modulation and turned to a BRET-based cAMP assay using the Epac-based biosensor, CAMYEL.<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60−62)</a><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C shows that <b>20</b> potently inhibits cAMP accumulation with an EC<sub>50</sub> of 86 nM and an efficacy identical to that of dopamine. Finally, we examined the activity of <b>20</b> in an ERK1/2 phosphorylation (pERK) assay (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). GPCR-mediated phosphorylation of ERK1/2 has previously been shown to occur through G protein-dependent and -independent signaling pathways,<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> which may be related to the GPCR and/or cell type. However, we have found that the pretreatment of our cells with pertussis toxin, which inactivates G<sub>αi/o</sub> proteins,<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> completely ablates the D3R-mediated pERK response indicating that it is G protein-mediated (data not shown). Similar to the other signaling assays, we found that <b>20</b> functioned as a full agonist at the D3R with an EC<sub>50</sub> of 21 nM (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). Taken together, these data demonstrate that <b>20</b> is a full and potent agonist for multiple signaling pathways associated with D3R activation. Notably, in these signaling assays, there are small variances in the potencies of <b>20</b> relative to those for dopamine, suggesting that <b>20</b> may exhibit biased signaling properties; however, this will need to be evaluated in detail in future experiments.</div><figure id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacology of compound 20 on D3R-mediated signaling outputs. Agonist-mediated concentration–response curves of dopamine or <b>20</b> for stimulating a variety of D3R-mediated signaling pathways. (A) Cells were stimulated as indicated and analyzed using the BRET-based β-arrestin recruitment assay (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>), resulting in EC<sub>50</sub> values of 2.3 ± 0.9 and 1.2 ± 0.5 nM (mean ± SEM, <i>n</i> = 4) for dopamine and <b>20</b>, respectively. (B) Cells were stimulated as indicated and analyzed using the BRET-based Go activation assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, resulting in EC<sub>50</sub> values of 1.1 ± 0.04 and 0.18 ± 0.1 nM (mean ± SEM, <i>n</i> = 6) for dopamine and <b>20</b>, respectively. (C) Cells were incubated with the indicated concentrations of dopamine (DA) or <b>20</b>, and inhibition of forskolin-stimulated cAMP accumulation was determined using the CAMYEL biosensor as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data are presented as the percentage of maximum inhibition by DA. <b>20</b> displays a full agonist activity of D3R-mediated inhibition of cAMP production, exhibiting an EC<sub>50</sub> of 86 ± 26 nM (mean ± SEM, <i>n</i> = 4). Dopamine demonstrated an EC<sub>50</sub> value of 3.5 ± 0.7 nM (mean ± SEM, <i>n</i> = 4). (D) Cells were stimulated as indicated, and pERK was assessed using the Alphascreen SureFire assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. EC<sub>50</sub> values for dopamine and <b>20</b> are 2.9 ± 0.6 and 21 ± 6.6 nM (mean ± SEM, <i>n</i> = 4), respectively. All data were analyzed using nonlinear regression curve fits and expressed as a percentage of the maximum dopamine signal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further characterize the pharmacological selectivity of <b>20</b>, we evaluated its activity in large arrays of GPCRs and several transporters or ion channels. For comparison, we also evaluated the recently described D3R-selective agonist CJ-1639<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and its parent scaffold, the D3R-preferring agonist pramipexole. Initially, we screened the compounds using the NIMH Psychoactive Drug Screening Program (PDSP),<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> which uses radioligand binding assays to assess affinity values for ligands at 45 unique GPCRs, transporters, and ion channels. The results of this screen are shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. For the primary screen, a single high concentration (10 μM) of test compound was used to inhibit radioligand binding to the targets, and those compounds that exhibited >50% inhibition were rescreened in full concentration–response format to estimate their affinity (<i>K</i><sub>i</sub>) values. Notably, <b>20</b> exhibited submicromolar affinity for only three of the targets, the β<sub>1</sub>-adrenergic, 5-HT<sub>2B</sub> serotonergic, and σ-1 receptors. Pramipexole and CJ-1639 exhibited submicromolar affinity for 6 and 13 of the targets, respectively. Among the D2-like receptors, pramipexole was 826-fold D3R > D2R-selective and 32-fold D3R > D4R-selective. In parallel studies in our laboratory, we found that pramipexole inhibits [<sup>3</sup>H]-methylspiperone binding to the D3R with a <i>K</i><sub>i</sub> of 8.2 ± 2.0 nM (mean ± SEM, <i>n</i> = 3) and to the D2R with a <i>K</i><sub>i</sub> of 4.7 ± 1.3 μM (mean ± SEM, <i>n</i> = 3), exhibiting 573-fold D3R > D2R selectivity in good agreement with the PDSP data. In the PDSP screen, CJ-1639 exhibited 130-fold D3R > D2R selectivity and 1.5-fold D3R > D4R selectivity. In our laboratory, we found that CJ-1639 inhibits [<sup>3</sup>H]-methylspiperone binding to the D3R with a <i>K</i><sub>i</sub> of 5.6 ± 1.0 nM (mean ± SEM, <i>n</i> = 3) and to the D2R with a <i>K</i><sub>i</sub> of 21 ± 5.6 μM (mean ± SEM, <i>n</i> = 3), exhibiting 3750-fold D3R > D2R selectivity. Thus, in our hands, CJ-1639 is significantly more D3R > D2R-selective than was observed in the PDSP screen and closer to the D3R > D2R selectivity initially described by Chen et al.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Binding Affinities<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> of <b>20</b>, CJ-1639, and Pramipexole for Inhibiting Radioligand Binding to the Indicated Drug Targets as Determined in the PDSP Screen</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">compound</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">compound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">20 (<i>K</i><sub>i</sub>, nM)</th><th class="colsep0 rowsep0" align="center">CJ-1639 (<i>K</i><sub>i</sub>, nM)</th><th class="colsep0 rowsep0" align="center">Pramipexole (<i>K</i><sub>i</sub>, nM)</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">20 (<i>K</i><sub>i</sub>, nM)</th><th class="colsep0 rowsep0" align="center">CJ-1639 (<i>K</i><sub>i</sub>, nM)</th><th class="colsep0 rowsep0" align="center">Pramipexole (<i>K</i><sub>i</sub>, nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT1A</td><td class="colsep0 rowsep0" align="left">2108</td><td class="colsep0 rowsep0" align="left">708</td><td class="colsep0 rowsep0" align="left">6514</td><td class="colsep0 rowsep0" align="left">D3</td><td class="colsep0 rowsep0" align="left">1240</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT1B</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">3508</td><td class="colsep0 rowsep0" align="left">D4</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT1D</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">D5</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT1E</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">DAT</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">205</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT2A</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">2841</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">DOR</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT2B</td><td class="colsep0 rowsep0" align="left">674</td><td class="colsep0 rowsep0" align="left">1178</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">GABA<sub>A</sub></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT2C</td><td class="colsep0 rowsep0" align="left">5997</td><td class="colsep0 rowsep0" align="left">762</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">H1</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT3</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">H2</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">224</td><td class="colsep0 rowsep0" align="left">2683</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT5A</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">H3</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">893</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT6</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">H4</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5HT7</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">770</td><td class="colsep0 rowsep0" align="left">1188</td><td class="colsep0 rowsep0" align="left">KOR</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha1A</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">M1</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha1B</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">666</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">M2</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha1D</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">1184</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">M3</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha2A</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">75.7</td><td class="colsep0 rowsep0" align="left">M4</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">2279</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha2B</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">67.7</td><td class="colsep0 rowsep0" align="left">M5</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">2297</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha2C</td><td class="colsep0 rowsep0" align="left">2841</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">52.2</td><td class="colsep0 rowsep0" align="left">MOR</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">745</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Beta 1</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NET</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">436</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Beta 2</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">PBR</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Beta 3</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">SERT</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BZP site</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">Sigma 1</td><td class="colsep0 rowsep0" align="left">383</td><td class="colsep0 rowsep0" align="left">531</td><td class="colsep0 rowsep0" align="left">4446</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D1</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">Sigma 2</td><td class="colsep0 rowsep0" align="left">2750</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D2</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">3902</td><td class="colsep0 rowsep0" align="left">743.7</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> (nM) values for the indicated compounds were determined as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">NA indicates that the inhibition of binding was < 50% in the primary assay conducted using a single 10 μM concentration.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">ND indicates that the value was not determined.</p></div></div></div><div class="NLM_p">Notably, in the PDSP screen, <b>20</b> exhibited a <i>K</i><sub>i</sub> for the D3R of 1.24 μM. Thus, as was initially observed with compound <b>1</b>, when assessed using [<sup>3</sup>H]-methylspiperone binding in membrane preparations, <b>20</b> exhibits an affinity for the D3R that is much weaker than its potency observed using any of the functional assays, even those that lack amplification. In contrast, the agonists pramipexole and CJ-1639 both display similar D3R binding affinities and functional potencies. For instance, when we examined pramipexole and CJ-1639 in the D3R-mediated β-arrestin recruitment assay, we found EC<sub>50</sub> values of 5.4 ± 1.5 nM (mean ± SEM, <i>n</i> = 3) and 9.3 ± 1.5 nM (mean ± SEM, <i>n</i> = 3), respectively, in good agreement with their affinities observed in the binding assays (see above).</div><div class="NLM_p">Given the above observations, we decided to investigate the effects of assay buffer conditions on the radioligand binding results (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Our standard binding buffer is Earle’s balanced salt solution (EBSS), which is an isotonic bicarbonate–phosphate buffer containing 117 mM NaCl, 5.37 mM KCl, 1.8 mM CaCl<sub>2</sub>, 0.8 mM MgSO<sub>4</sub>, and 5.55 mM glucose. In addition to EBSS, we utilized Tris buffer with no additional salts, as well as Tris plus 140 mM NaCl, and performed [<sup>3</sup>H]-methylspiperone competition binding with <b>20</b> and pramipexole (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Interestingly, <b>20</b> was ∼10-fold more potent using the Tris buffer compared to EBSS, whereas <b>20</b>’s potency decreased by ∼4-fold when 140 mM NaCl was added to the Tris buffer (Tris + Na<sup>+</sup>). Notably, the [<sup>3</sup>H]-methylspiperone binding buffer used by the PDSP is 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) plus 50 mM NaCl and 5 mM MgCl<sub>2</sub>, more similar to that of EBSS with respect to the concentrations of Na<sup>+</sup> and divalent cations. Not surprisingly, the potency of <b>20</b> is similar when comparing the EBSS (<i>K</i><sub>i</sub> = 3.7 μM) and HEPES (<i>K</i><sub>i</sub> = 1.24 μM) buffer systems. In contrast to <b>20</b>, the potency of pramipexole appeared to be relatively unaffected by the assay buffer conditions (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), as is [<sup>3</sup>H]-methylspiperone (data not shown).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Affinities<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> of <b>20</b> and Pramipexole for Inhibiting Either [<sup>3</sup>H]-Methylspiperone or [<sup>3</sup>H]-7-OH-DPAT Binding to the D3R in Various Buffer Systems</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">[<sup>3</sup>H]-methylspiperone <i>K</i><sub>i</sub> (nM)</th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">[<sup>3</sup>H]-7-OH-DPAT <i>K</i><sub>i</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center" char="±">EBSS</th><th class="colsep0 rowsep0" align="center" char="±">Tris</th><th class="colsep0 rowsep0" align="center" char="±">Tris + Na<sup>+</sup></th><th class="colsep0 rowsep0" align="center" char="±">EBSS</th><th class="colsep0 rowsep0" align="center" char="±">Tris</th><th class="colsep0 rowsep0" align="center" char="±">Tris + Na<sup>+</sup></th><th class="colsep0 rowsep0" align="center">Tris + Mg<sup>2+</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">3700 ± 900</td><td class="colsep0 rowsep0" align="char" char="±">350 ± 130</td><td class="colsep0 rowsep0" align="char" char="±">1500 ± 370</td><td class="colsep0 rowsep0" align="char" char="±">720 ± 31</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">94 ± 11</td><td class="colsep0 rowsep0" align="left">12.5 ± 3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pramipexole</td><td class="colsep0 rowsep0" align="char" char="±">8.2 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.94 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">5.6 ± 1.3</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> (nM) values for the indicated compounds were determined as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Data are expressed as mean ± SEM of individual experiments performed 3–16 times.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">ND indicates that the value was not determined.</p></div></div></div><div class="NLM_p">Typically, agonist ligands appear more potent when competing for radiolabeled agonist binding as the binding sites represent the high-affinity active G protein-coupled state of the GPCR.<a onclick="showRef(event, 'ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70">(68−70)</a> As such, we repeated our competition binding experiments using [<sup>3</sup>H]-7-OH-DPAT, which is an agonist of the D3R (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). The same potency trends were observed with the various buffer systems, although both <b>20</b> and pramipexole appeared more potent using [<sup>3</sup>H]-7-OH-DPAT compared with [<sup>3</sup>H]-methylspiperone, as was expected. In addition, we noted that the addition of 5 mM MgCl<sub>2</sub> to Tris buffer (Tris + Mg<sup>2+</sup>) increased the potency of <b>20</b> by ∼2-fold. These observations are in line with previous results showing that Na<sup>+</sup> typically decreases agonist binding affinity, likely through stabilizing the inactive state of the GPCR,<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> while Mg<sup>2+</sup> increases agonist binding affinity through promoting GPCR−G protein interactions.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> Taken together, these results suggest that the apparent binding affinity of <b>20</b> for the D3R in membrane preparations can vary by as much as 300-fold depending on the buffer constituents and radioligand utilized. Moreover, the potency of <b>20</b> using intact cell functional assays (EC<sub>50</sub>s = 0.18–86 nM) is more closely aligned with its affinity for the active signaling state of the D3R as detected using [<sup>3</sup>H]-7-OH-DPAT membrane binding, as previously observed for multiple GPCRs.<a onclick="showRef(event, 'ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70">(68−70)</a></div><div class="NLM_p">We extended our selectivity screening to the DiscoverX gpcrMAX functional assay, which measures agonist-stimulated β-arrestin recruitment to 168 known GPCRs (<a href="http://www.DiscoverX.com" class="extLink">http://www.DiscoverX.com</a>). We chose to perform this screen using a high concentration (10 μM) of <b>20</b> to maximize the detection of off-target activities. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A shows the results of this screen performed in agonist mode where each GPCR is stimulated with <b>20</b>, and β-arrestin recruitment is then measured. Notably, the D3R is the only GPCR in this array that was fully activated, although small, but measurable agonist responses were observed with the short and long isoforms of the D2R. These latter activities were comparable to the low activity of <b>20</b> at the D2R observed in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B using 10 μM and higher concentrations. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B shows the results of this screen in antagonist mode and that <b>20</b> exhibits low potency partial antagonist activity at several GPCRs. These include the Epstein–Barr virus-induced GPCR 2 (EBI2), the sphingosine-1-phosphate 5 receptor (EDG8), the cholecystokinin A receptor (CCKAR), the alpha2C-adrenergic receptor (ADRA2C), and the 5HT2A serotonergic receptor (HTR2A). Antagonism of these receptors is not associated with any known clinical side effects and, in any case, such interactions would not occur at the nanomolar concentrations employed to selectively activate the D3R. Importantly, <b>20</b> was identified as exhibiting submicromolar affinity for the 5-HT<sub>2B</sub> receptor in the PDSP screen (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), which is a potential liability as drugs that activate the 5-HT<sub>2B</sub> receptor have been associated with cardiac valvulopathy.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> Unfortunately, the DiscoverX gpcrMAX panel does not include the 5-HT<sub>2B</sub> receptor, so this screen did not provide us with a functional profile of <b>20</b> at this receptor subtype. Thus, in separate experiments, we assessed the effects of <b>20</b> (10 μM) on 5-HT<sub>2B</sub> receptor stimulation of inositol 1-phosphate (IP1) accumulation (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Fortunately, no agonist activity was observed, but this concentration of <b>20</b> produced an 80% inhibition of the response elicited by 30 nM serotonin (data not shown), suggesting that <b>20</b> may be a low potency antagonist of the 5-HT<sub>2B</sub> receptor at high micromolar concentrations. Taken together, these findings indicate that <b>20</b> is a selective D3R agonist with very limited cross-reactivity at other GPCRs.</div><figure id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Functional profiling of compound 20 against an array of 168 known GPCRs. A single high concentration (10 μM) of <b>20</b> was screened against the DiscoverX gpcrMAX assay panel in both agonist (A) and antagonist (B) modes, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data represent the percent maximum stimulation observed by a reference agonist for each GPCR (agonist mode) or the percent inhibition of a response generated by an EC<sub>80</sub> concentration of a reference agonist (antagonist mode). A complete key to the GPCR array and numerical results are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Supplemental Table S1</a>. In (B), partial antagonist activity was observed at the ADRA2C (36%), CCKAR (63%), EDG8 (77%), EBI2 (88%), and HTR2A (37%) receptors using a 10 μM concentration of <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">For comparison with <b>20</b>, the D3R-preferring agonists CJ-1639 and pramipexole were also screened in the DiscoverX gpcrMAX panel. <a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Figure S1A</a> shows that, at 10 μM, CJ-1639 is a full agonist of both the D2R and D3R, with partial agonist activities at the D4R and the chemokine CXCR7 receptor. Conversely, at 10 μM, CJ-1639 displays >50% antagonist activity at the α<sub>1B</sub>-adrenergic receptor, H<sub>1</sub>, H<sub>2</sub>, and H<sub>3</sub> histamine receptors, and the μ opioid receptor (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Figure S1B</a>). Pramipexole also exhibits full agonist activity at the D2R and D3R, as well as partial agonist activity at the α<sub>2A</sub>- and α<sub>2B</sub>-adrenergic receptors (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Figure S2A</a>). Interestingly, pramipexole did not exhibit antagonist activity at any of the GPCRs tested, even at the 10 μM concentration (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Figure S2A</a>). Overall, using these assays, CJ-1639 and pramipexole appear less globally selective than <b>20</b>, although they may exhibit greater D3R selectivity if lower screening concentrations are employed.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Molecular Modeling Predicts Unique Interactions of Compound <b>20</b> with the D3R</h3><div class="NLM_p">To characterize the binding pose of <b>20</b>, we carried out a computational modeling and simulation study of a D3R model in complex with <b>20</b>. We first docked <b>20</b> into a D3R model that we have equilibrated previously<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> and found that the majority of the resulting poses of <b>20</b> are with the indole amide moiety pointing away from the orthosteric binding site (OBS, defined in ref <a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a>), similar to other indole amide D3R ligands that we have characterized previously.<a onclick="showRef(event, 'ref6 ref78'); return false;" href="javascript:void(0);" class="ref ref6 ref78">(6,78)</a> Using three subtly different poses in such an orientation with the lowest docking scores, we collected three molecular dynamics (MD) simulation trajectories. The simulations converged to a <b>20</b> pose, in which at one end its anisole moiety binds in the OBS and protrudes into the interface between TM5 and TM6 and interacts with Tyr198<sup>5.48</sup> (superscripts denote Ballesteros and Weinstein numbering),<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> while at the other end its indole amide moiety interacts with Tyr365<sup>7.35</sup> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). Further, the positively charged piperazine nitrogen of <b>20</b> closest to the anisole moiety was found to interact with Asp110<sup>3.32</sup> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B), the highly conserved aspartic acid residue found in TM3 of all biogenic amine GPCRs.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Given this observation, it is not surprising that compounds either lacking this nitrogen (<b>50</b>) or with immediately adjacent methyl groups (<b>46</b> and <b>48</b>) that could produce steric hindrance exhibited greatly reduced or no activity for interacting with the D3R (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><figure id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Molecular modeling identified residues that uniquely interact with 20. (A) Side view of a representative D3R model in complex with <b>20</b> resulting from our MD simulations. The model was based on the D3R crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (B) Zoom-in view of the ligand binding pocket showing that two Tyr residues, Tyr198<sup>5.48</sup> and Tyr365<sup>7.35</sup>, uniquely interact with the two ends of the ligand. The conserved TM3 aspartate residue, Asp110<sup>3.32</sup>, in contact with the basic piperazine nitrogen is also depicted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We noticed that the two tyrosine residues, Tyr198<sup>5.48</sup> and Tyr365<sup>7.35</sup>, in contact with <b>20</b> cannot directly interact with dopamine.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Thus, to validate the predicted binding pose of <b>20</b> at D3R, we mutated Tyr198<sup>5.48</sup> and Tyr365<sup>7.35</sup> to alanine residues either individually or in combination and compared the pharmacological profiles of dopamine and <b>20</b> at these mutants. The mutant D3R constructs were found to express similarly to D3R-WT as determined using [<sup>3</sup>H]-methylspiperone saturation binding assays (<i>B</i><sub>max</sub> values (fmol/mg): WT = 3700 ± 650, Y198A = 4300 ± 1000, Y365A = 3000 ± 500, Y198A/Y365A = 2700 ± 930; <i>K</i><sub>d</sub> values (nM): WT = 0.51 ± 0.08, Y198A = 0.53 ± 0.06, Y365A = 0.49 ± 0.11, Y198A/Y365A = 0.35 ± 0.1; mean ± SEM from three independent experiments). We then compared the ability of compound <b>20</b> and dopamine to stimulate β-arrestin recruitment to these constructs. <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A shows that they stimulate β-arrestin recruitment to the D3R-WT with similar potencies (EC<sub>50</sub> = 1.4 and 3.7 nM for <b>20</b> and dopamine, respectively). The Y198A mutation resulted in a reduction in efficacy (<i>E</i><sub>max</sub> = 38%) and a 13-fold reduction in the potency (EC<sub>50</sub> = 17 nM) of <b>20</b> for stimulating β-arrestin recruitment (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Because the mutation similarly reduced the potency of dopamine by 14-fold (EC<sub>50</sub> = 55 nM) but not its efficacy, the drastically reduced efficacy of <b>20</b> is a specific effect of the mutation on this ligand. The Y365A mutation resulted in a pronounced 400-fold reduction in the potency (EC<sub>50</sub> = 520 nM) and a decrease in efficacy (<i>E</i><sub>max</sub> = 26%) for <b>20</b>, whereas dopamine’s potency was reduced by only 9-fold (EC<sub>50</sub> = 33 nM) without any reduction of its efficacy (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). Notably, the double Y198A/Y365A mutation completely abolished the efficacy of <b>20</b> for stimulating β-arrestin recruitment to the D3R (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D), whereas the effects on dopamine’s potency (EC<sub>50</sub> = 820 nM) appeared to be additive (215-fold) compared to the effects of the single mutants. The unique dependence of <b>20</b> on these two residues for full activation of the receptor supports our computational results that show they are in direct contact with <b>20</b> but not dopamine. Interestingly, Tyr365<sup>7.35</sup> has previously been suggested as an interaction site for a dopamine receptor agonist with D3R > D2R selectivity.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><figure id="fig8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0008.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mutagenesis studies support the D3R binding site model for compound 20. HEK293 cells were transiently transfected with the following Rluc8-fused receptor constructs: D3R-WT (A), D3R-Y198A (B), D3R-Y365A (C), or D3R-Y198A/Y365A (D), as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Cells were stimulated as indicated and analyzed using the BRET-based β-arrestin recruitment assay (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Data are expressed as a percentage of the maximum dopamine (DA) response. (A) <b>20</b> is a full agonist at the D3R-WT; EC<sub>50</sub> = 1.4 ± 0.7 nM, <i>E</i><sub>max</sub> = 92 ± 10% (mean ± SEM, <i>n</i> = 8); DA EC<sub>50</sub> = 3.7 ± 1.2 nM, <i>E</i><sub>max</sub> = 100 ± 0.3% (mean ± SEM, <i>n</i> = 8). (B) <b>20</b> has a reduced potency and efficacy at the D3R-Y198A mutant; EC<sub>50</sub> = 17 ± 7.6 nM*, <i>E</i><sub>max</sub> = 38 ± 6.2%** (mean ± SEM, <i>n</i> = 4); DA EC<sub>50</sub> = 55 ± 16 nM***, <i>E</i><sub>max</sub> = 100 ± 0.2% (mean ± SEM, <i>n</i> = 4). (C) <b>20</b> has a reduced potency and efficacy at the D3R-Y365A; EC<sub>50</sub> = 520 ± 150 nM**; <i>E</i><sub>max</sub> 26 ± 11%** (mean ± SEM, <i>n</i> = 4); DA EC<sub>50</sub> = 33 ± 3.3 nM****; <i>E</i><sub>max</sub> = 100 ± 0.1% (mean ± SEM, <i>n</i> = 4). (D) D3R-Y198A/Y365A mutation abolishes the agonist activity of <b>20</b>. DA EC<sub>50</sub> = 820 ± 56 nM****; <i>E</i><sub>max</sub> = 100 ± 0.1% (mean ± SEM, <i>n</i> = 3). Statistical comparisons between WT and mutant parameters were made using a two-tailed t-test: *<i>p</i> < 0.05, **<i>p</i> < 0.005, ***<i>p</i> < 0.0.001, ****<i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We thought it would be of interest to also characterize and compare the effects of the Y198A and Y365A mutations on the signaling properties of pramipexole. <a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Figure S3A</a> shows that pramipexole and dopamine have similar potencies in stimulating β-arrestin recruitment to the D3R-WT. Introduction of the Y198A, Y365A, or double Y198A/Y365A mutations into the D3R decreased the potency of pramipexole to a similar extent as that seen with dopamine, while, in contrast to that seen with compound <b>20</b>, there was no effect on the efficacy of pramipexole for stimulating β-arrestin recruitment (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Figure S3</a>). These results suggest that different efficacy determinants exist for the activation of the D3R by pramipexole and <b>20</b>. Taken together, the mutational data lend support to the molecular modeling results that describe unique interactions of <b>20</b> with the D3R.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Neuroprotective Properties of Compound <b>20</b></h3><div class="NLM_p">As D3R-preferring agonists, such as pramipexole and related compounds, have shown neuroprotective properties in several models of neurodegeneration,<a onclick="showRef(event, 'ref11 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref13 ref14 ref15 ref16">(11,13−16)</a> we evaluated the effects of compound <b>20</b>, using pramipexole as a comparator, in a cellular model of neuroprotection. We genetically engineered a human iPSC cell line so that it stably expresses the human D3R (3–5 pmol/mg) and differentiated these cells into dopaminergic neurons in culture (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). The cells were then treated with the dopaminergic neurotoxin 6-OHDA to induce cell death. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, 6-OHDA treatment reduced cell viability by 62 ± 8% after 24 h. Both compound <b>20</b> and pramipexole demonstrated a dose-dependent reduction in 6-OHDA-induced cell death. This effect was significant at 50 nM of <b>20</b> and maximal at 500 nM. In contrast, pramipexole was somewhat less potent in not achieving a significant level of protection until a concentration of 500 nM was employed (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). These data indicate that compound <b>20</b> simulates the previously described neuroprotective properties of pramipexole and highlights the utility of pursuing this compound for <i>in vivo</i> development, including investigations of additional models of neurodegeneration and as a probe compound to understand the role of the D3R in neuroprotection.</div><figure id="fig9" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0009.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>20</b> protects D3R-expressing dopaminergic neurons from 6-OHDA-induced cell death. Human iPSCs expressing the D3R were differentiated into dopaminergic neurons, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Cells were treated with the indicated concentrations of vehicle, <b>20</b>, or pramipexole for 24 h and then incubated with 30 μM of 6-hydroxydopamine (6-OHDA) for 24 h to induce cell death (the control cell group did not receive 6-OHDA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assays were performed, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data represent the means ± SEM from six experiments performed in quadruplicate. In the absence of drugs (vehicle), 6-OHDA treatment reduced cell viability by 62 ± 8%. Pretreatment with <b>20</b> and pramipexole protected against 6-OHDA-induced cell death in a dose-dependent fashion. Statistical significance for differences between the drug- and vehicle-treated groups was assessed using two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison post hoc test: *<i>p</i> < 0.05, **<i>p</i> < 0.01, <sup>#</sup><i>p</i> < 0.001, <sup>&</sup><i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Pharmacokinetics and Toxicology</h3><div class="NLM_p last">As we are interested in the use of <b>20</b> as an <i>in vivo</i> probe and as a lead compound for therapeutics development, we performed a number of preliminary toxicology, ADME, and pharmacokinetics experiments. Compound <b>20</b> showed no liability (AC<sub>50</sub>s > 50 μM) using a cytotoxicity screening panel that measures changes in nuclear size, DNA structure, cell membrane permeability, mitochondrial mass, mitochondrial membrane potential, and cytochrome C release (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Further, no toxicity was observed in the AMES reverse mutation assay (data not shown). Compound <b>20</b> displays reasonable liver microsomal stability (<i>t</i><sub>1/2</sub> = 21.2 min) and excellent permeability using the PAMPA assay (541 (10<sup>–6</sup> cm/sec)); however, its aqueous solubility is low (1.1 μg/mL). <i>In vivo</i> pharmacokinetic experiments in mice (using 20 mg/kg IP) reveal that compound <b>20</b> is brain penetrant and exhibits a plasma half-life of 3.44 h and a brain half-life of 4.23 h (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Figure S4, Tables S2 and S3</a>). Further, compound <b>20</b> displays a plasma <i>T</i><sub>max</sub> of 0.5 h and a <i>C</i><sub>max</sub> of 6500 ng/mL, and a brain <i>T</i><sub>max</sub> of 0.25 h and a <i>C</i><sub>max</sub> of 28 000 ng/mL (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Tables S2 and S3</a>). Taken together, these findings are very encouraging for future <i>in vivo</i> studies using compound <b>20</b> and the potential therapeutic development of this scaffold.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17654" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17654" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have identified a novel and highly selective D3R agonist scaffold originating from a high-throughput screening campaign. Focused optimization led to the potent and uniquely selective D3R agonist, <b>20</b>. Its exquisite receptor selectivity suggests that <b>20</b> will prove to be a valuable pharmacological tool to interrogate the physiological functions of the D3R in normal and pathological conditions. Compound <b>20</b> demonstrated neuroprotective effects along with promising toxicology and pharmacokinetic profiles, further suggesting that it may show utility as a therapeutic lead for the treatment of neurodegenerative or other disorders.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Materials</h3><div class="NLM_p last">[<sup>3</sup>H]-Methylspiperone (80 Ci/mmol) was obtained from PerkinElmer Life Sciences (Waltham, MA). D1R, D2R, D3R, D4R, and D5R expressing CHO-K1 cells and CP2 media were purchased from DiscoverX (Fremont, CA). Other cell culture media and reagents were purchased from MediaTech/Cellgro (Manassas, VA). Cell culture flasks, materials, and all assay plates were purchased from ThermoFisher Scientific (Waltham, MA) and Greiner Bio-One (Monroe, NC). DNA constructs for the BRET assays were kind gifts from Dr. Jonathan A. Javitch. Compound CJ-1639 was a kind gift from Dr. Shaomeng Wang. Receptor mutants were prepared at Bioinnovatise (Rockville, MD), and all mutations were verified by DNA sequencing. Chemicals and buffer components were purchased from Sigma-Aldrich (St. Louis, MO), except where indicated. All tested analogues were synthesized as described below and were characterized as being >95% pure.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Synthesis and Analysis Experimental Details</h4><div class="NLM_p">All reagents were used as received from the following suppliers: Alfa Aesar, Sigma-Aldrich, Ark Pharm, Combi-Blocks, Fisher Scientific Oakwood, Matrix, and 1Click Chemistry. Acetonitrile and THF were purified using the Innovative Technology PureSolv solvent purification system using two alumina columns. The <sup>1</sup>H and <sup>13</sup>C spectra were recorded on a 400 MHz Bruker Avance spectrometer equipped with a broad-band observe probe and a 500 MHz Bruker AVIII spectrometer equipped with a dual cryoprobe, respectively. Chemical shifts are reported in parts per million and were referenced to residual proton solvent signals. <sup>13</sup>C multiplicities were determined with the aid of an APT pulse sequence, differentiating the signals for methyl (CH<sub>3</sub>) and methyne (CH) carbons as “d” from methylene (CH<sub>2</sub>) and quaternary (C) carbons as “u”. The infrared (IR) spectra were acquired as thin films using a universal ATR sampling accessory on a ThermoFisher Nicolet iS5 FTIR spectrometer, and the absorption frequencies are reported in cm<sup>–1</sup>. Melting points were determined on a Stanford Research Systems Optimelt automated melting point system interfaced through a PC and are uncorrected. Microwave syntheses were conducted in a Biotage Initiator constant temperature microwave synthesizer. Flash column chromatography separations were performed using the Teledyne Isco CombiFlash Rf using RediSep Rf silica gel columns. Thin-layer chromatography (TLC) was performed on Analtech UNIPLATE silica gel GHLF plates (gypsum inorganic hard layer with fluorescence). TLC plates were developed using iodine vapor or ceric ammonium molybdate stain, as required. Automated preparative RP HPLC purification was performed using an Agilent 1200 Mass-Directed Fractionation system (Prep Pump G1361 with gradient extension, make-up pump G1311A, pH modification pump G1311A, HTS PAL autosampler, UV-DAD detection G1315D, fraction collector G1364B, and Agilent 6120 quadrupole spectrometer G6120A). HRMS determinations for compounds <b>106</b>–<b>109</b> were analyzed with a ThermoFisher Q Exactive HF-X (ThermoFisher, Bremen, Germany) mass spectrometer coupled with a Waters Acquity H-class liquid chromatograph system. Samples were introduced via a heated electrospray ionization (HESI) source at a flow rate of 0.6 mL/min. Electrospray source conditions were set as follows: spray voltage 3.0 kV, sheath gas (nitrogen) 60 arb, auxiliary gas (nitrogen) 20 arb, sweep gas (nitrogen) 0 arb, nebulizer temperature 375 °C, capillary temperature 380 °C, and RF funnel 45 V. The mass range was set to 150–2000 <i>m</i>/<i>z</i>. All measurements were recorded at a resolution setting of 120 000. The preparative chromatography conditions included a Waters X-Bridge C<sub>18</sub> column (19 × 150 mm<sup>2</sup>, 5 μm, with 19 × 10 mm<sup>2</sup> guard column), elution with a water and acetonitrile gradient, which increases 20% in acetonitrile content over 4 min at a flow rate of 20 mL/min (modified to pH 9.8 through the addition of NH<sub>4</sub>OH by auxiliary pump), and sample dilution in dimethyl sulfoxide (DMSO). The preparative gradient, triggering thresholds, and UV wavelength were selected according to the analytical reverse-phase high-performance liquid chromatography (RP HPLC) analysis of each crude sample. The analytical method used an Agilent 1200 RRLC system with UV detection (Agilent 1200 DAD SL) and mass detection (Agilent 6224 TOF). The analytical method conditions included a Waters Acquity BEH C<sub>18</sub> column (2.1 × 50 mm<sup>2</sup>, 1.7 μm) and elution with a linear gradient of 5% acetonitrile in pH 9.8 buffered aqueous ammonium formate to 100% acetonitrile at a 0.4 mL/min flow rate. Compound purity was measured on the basis of peak integration (area under the curve) from UV/vis absorbance (at 214 nm), and compound identity was determined on the basis of mass analysis. All compounds used for assays or biological studies possessed HPLC purity >95%. The analytical HPLC system used is a dedicated instrument for assessing compound purity and routinely detects impurities as low as 0.1%. Any compounds with a measured HPLC purity of 100% were thus conservatively assigned a purity of “>99.5%”. Any compounds purified by automated preparative RP HPLC purification utilized the same solvent gradient and column material in the analytical conditions to minimize the possibility of undetected impurities carrying over from the purification run.</div><div class="NLM_p last">All final compounds were inspected for functional groups known to contribute PAINS liabilities, and none were found.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure A: Piperazine Coupling with Alkyl Bromides</h4><div class="NLM_p last">The monocarboxamide piperazine substrate, alkyl bromide (1.1–1.2 equiv), potassium carbonate (3.0 equiv), and potassium iodide (1.0 equiv) were charged in a reaction vial and slurried with MeCN (50 mL/mmol substrate) and stirred at 60 °C for 14–20 h. The reaction was filtered, and the solids were washed with CH<sub>2</sub>Cl<sub>2</sub> (2 × 5 mL). The combined filtrates were evaporated, and the residue was purified by silica gel chromatography to afford the alkylated piperazine product.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Procedure B: Piperazine Coupling with Alkyl Bromides: High-Throughput Synthesis Protocol</h4><div class="NLM_p last">The monocarboxamide piperazine substrate as a solution in DMF (0.2 M) and alkyl bromide (1.0 equiv) as a solution in DMF (0.2 M) were added to a reaction tube (Bohdan MiniBlock) containing potassium carbonate (3.0 equiv) and potassium iodide (0.1 equiv). The vial was sealed, and the reaction as stirred at 60 °C for 14–20 h. The reaction was filtered, and the solids were washed with CH<sub>2</sub>Cl<sub>2</sub> (2 × 5 mL). The combined filtrates were evaporated, and the residue was purified by mass-directed, reverse-phase HPLC to afford the alkylated piperazine product.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> General Procedure C: Mitsunobu Reaction Route to Aryl Ether Analogues</h4><div class="NLM_p last">A solution of (2-hydroxylethyl)piperazine substrate, phenol (1.0 equiv), and triphenyl phosphine (1.0 equiv) in THF or CH<sub>2</sub>Cl<sub>2</sub> (10 mL/mmol substrate) was cooled in an ice/water bath, and DIAD (1.25 equiv) was added in a single portion. After 1 min, the ice/water bath was removed, and the reaction was stirred at room temperature (rt) for an additional 5 min and then stirred at 60 °C for 16–40 h. The reaction was monitored for conversion by liquid chromatography/mass spectrometer (LC–MS) and declared complete when no further change was observed in the chromatogram. For reactions in THF, the solvent was removed in vacuo, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). For reactions in CH<sub>2</sub>Cl<sub>2</sub>, additional CH<sub>2</sub>Cl<sub>2</sub> was added to adjust the volume to 5 mL. The CH<sub>2</sub>Cl<sub>2</sub> solution was washed with aqueous 1 N NaOH (2 × 1 mL) and then water (1 mL), and the organic layer was purified by silica gel chromatography to afford the aryl ether product.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure D: Late-Stage Acylation Route to Disubstituted Piperazine Analogues</h4><div class="NLM_p last">A solution of piperazine <b>114</b> and triethylamine (1.5 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL/mmol substrate) was cooled in an ice/water bath, and the appropriate acid chloride (1.0–1.3 equiv) was added in a single portion. The reaction was capped and stirred for 16–20 h, slowly warming to rt. The reaction was washed with water (2 × 5 mL), then dried over Na<sub>2</sub>SO<sub>4</sub>, and the organic layer was purified by silica gel chromatography to afford the aryl ether product.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> General Procedure E: PyBOP-Mediated Coupling Route to Disubstituted Piperazine Analogues</h4><div class="NLM_p last">To a solution of arylcarboxylic acid (1.0–1.3 equiv) in DMF (10 mL/mmol substrate) was added PyBOP (1.2 equiv), and the reaction was stirred at rt for 10 min. A solution of 1-(2-(aryloxy)ethyl)piperazine <b>114</b> (1.0 equiv) and diisopropylethyl amine (3.0 equiv) in DMF (10 mL/mmol substrate) was added, and the reaction was stirred at rt for 16–20 h. The reaction solvent was removed in vacuo, and the residue was partitioned between saturated aqueous NaHCO<sub>3</sub> and CH<sub>2</sub>Cl<sub>2</sub> (2 × 5 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by silica gel chromatography or reverse-phase, mass-directed preparative HPLC to afford the disubstituted piperazine product.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Procedure F: Piperazine Alkyl Chloride Displacement Route to Aryl Ether Piperazine Analogues</h4><div class="NLM_p last">A solution of alkyl chloride substrate, phenol nucleophile (1.6–1.9 equiv), and potassium carbonate (2.5 equiv) in DMF (10 mL/mmol substrate) was heated at 60 °C for the stated reaction time and cooled to rt. The reaction was diluted with water (10 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 2 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by silica gel chromatography or reverse-phase, mass-directed preparative HPLC to afford the disubstituted piperazine product.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> General Procedure G: Piperazine Alkyl Chloride Displacement Route to Aryl Ether Piperazine Analogues, Parallel Synthesis Protocol</h4><div class="NLM_p last">A solution of piperazine alkyl chloride substrate in DMF (0.528 M, 1.0 equiv) was added to a 24-position Bohdan MiniBlock reaction tube containing a mixture of phenol, aniline, or thiol nucleophile (1.6–1.9 equiv) and potassium carbonate (3.9 equiv) in DMF (800 μL). The reaction was heated at 60 °C for 16 h and concentrated on a Genevac centrifugal evaporator for 3 h at 35 °C. The residue was partitioned between water (2 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 mL) and filtered through a Biotage phase separator tube into a 16 × 100 mm tube. The organic layer was concentrated on a Genevac centrifugal evaporator and purified by preparative, mass-directed, reverse-phase HPLC to afford the aryl ether product.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> General Procedure H: Alkylation of Phenols with 1,2-Dibromoethane</h4><div class="NLM_p">To a solution of phenol <b>112</b> and potassium hydroxide (2.0 equiv) in water (3 mL/mmol of phenol) were added sequentially tetrabutylammonium bromide (0.2 equiv) and then 1,2-dibromoethane (5 equiv). The reaction was heated at reflux for 19 h, cooled to rt, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 mL). The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified by silica chromatography to afford the bromide product <b>112</b>.</div><div id="sec4_2_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>1</b>)</h5><div class="NLM_p last">(4-Methoxyphenyl)(piperazin-1-yl)methanone (49 mg, 0.22 mmol) and 1-(2-bromoethoxy)-4-methoxybenzene (61 mg, 0.27 mmol, 1.2 equiv) were reacted according to General Procedure A to afford the alkylated piperazine as a white solid (66 mg, 0.18 mmol, 81% yield). <i>R</i><sub><i>f</i></sub> = 0.29 (EtOAc); mp = 87–89 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.51–2.68 (complex, 4H), 2.81 (t, <i>J</i> = 5.6 Hz, 2H), 3.51–3.74 (complex, 4H), 3.76 (s, 3H), 3.82 (s, 3H), 4.06 (t, <i>J</i> = 5.6 Hz, 2H), 6.80–6.86 (complex, 4H), 6.89–6.92 (m, 2H), 7.36–7.40 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.3, 55.7, 113.7, 114.6, 115.6, 129.1; u: 53.5, 53.7, 57.3, 66.5, 127.8, 152.8, 154.0, 160.7, 170.2; FTIR (neat): 1623, 1607, 1506 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 371.1965; found 371.1973; HPLC purity = 99.2%.</div></div><div id="sec4_2_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> (4-(2-(2-Methoxyphenoxy)ethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>2</b>)</h5><div class="NLM_p last">(4-Methoxyphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 1-(2-bromoethoxy)-2-methoxybenzene (46 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as a light yellow solid (28 mg, 0.076 mmol, 38% yield). <i>R</i><sub><i>f</i></sub> = 0.14 (EtOAc); mp = 119–121 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.52–2.68 (complex, 4H), 2.86 (t, <i>J</i> = 5.9 Hz, 2H), 3.45–3.88 (complex, 4H), 3.81 (s, 3H), 3.83 (s, 3H), 4.14 (t, <i>J</i> = 5.9 Hz, 2H), 6.85–6.94 (complex, 6H), 7.35–7.39 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.3, 55.9, 111.9, 113.7, 113.9, 120.8, 121.6, 129.1; u: 53.5, 53.7, 57.0, 67.0, 127.8, 148.1, 149.6, 160.7, 170.2; FTIR (neat): 1608, 1504 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 371.1965; found 371.1985; HPLC purity = 96%.</div></div><div id="sec4_2_9_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> (4-(2-(3-Methoxyphenoxy)ethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>3</b>)</h5><div class="NLM_p last">(4-Methoxyphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 1-(2-bromoethoxy)-3-methoxybenzene (46 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as a pale yellow oil (47 mg, 0.13 mmol, 63% yield). <i>R</i><sub><i>f</i></sub> = 0.24 (EtOAc). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.51–2.66 (complex, 4H), 2.81 (t, <i>J</i> = 5.6 Hz, 2H), 3.47–3.82 (complex, 4H), 3.76 (s, 3H), 3.80 (s, 3H), 4.08 (t, <i>J</i> = 5.6 Hz, 2H), 6.44–6.51 (complex, 3H), 6.87–6.91 (m, 2H), 7.17 (t, <i>J</i> = 8.2 Hz, 1H), 7.36–7.39 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.25, 55.32, 101.1, 106.5, 106.6, 113.7, 129.1, 129.9; u: 53.57, 53.63, 57.1, 65.8, 127.8, 159.8, 160.7, 160.8, 170.2; FTIR (neat): 1603, 1492 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 371.1965; found 371.1988; HPLC purity = 99%.</div></div><div id="sec4_2_9_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> (4-(2-(4-Ethylphenoxy)ethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>4</b>)</h5><div class="NLM_p last">(4-Methoxyphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 1-(2-bromoethoxy)-4-ethylbenzene (46 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as a waxy white solid (44 mg, 0.12 mmol, 59% yield). <i>R</i><sub><i>f</i></sub> = 0.19 (EtOAc); mp = 57–64 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.20 (t, <i>J</i> = 7.6 Hz, 3H), 2.52–2.65 (complex, 4H), 2.58 (q, <i>J</i> = 5.6 Hz, 2H), 2.82 (t, <i>J</i> = 5.6 Hz, 2H), 3.43–3.87 (complex, 4H), 3.81 (s, 3H), 4.08 (t, <i>J</i> = 5.6 Hz, 2H), 6.79–6.84 (m, 2H), 6.88–6.92 (m, 2H), 7.07–7.12 (m, 2H), 7.36–7.39 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 15.9, 55.3, 113.7, 114.4, 128.7, 129.1; u: 28.0, 53.5, 53.6, 57.2, 65.9, 127.8, 136.7, 156.6, 160.7, 170.2; FTIR (neat): 1625, 1607, 1510 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 369.2173; found 369.2195; HPLC purity = 98%.</div></div><div id="sec4_2_9_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (4-(2-(4-Chlorophenoxy)ethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>5</b>)</h5><div class="NLM_p last">(4-Methoxyphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 1-(2-bromoethoxy)-4-chlorobenzene (46 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as a white solid (28 mg, 0. 08 mmol, 38% yield). <i>R</i><sub><i>f</i></sub> = 0.18 (EtOAc); mp = 69–72 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.47–2.64 (complex, 4H), 2.81 (t, <i>J</i> = 5.6 Hz, 2H), 3.48–3.79 (complex, 4H), 3.81 (s, 3H), 4.06 (t, <i>J</i> = 5.6 Hz, 2H), 6.79–6.82 (m, 2H), 6.87–6.91 (m, 2H), 7.18–7.23 (m, 2H), 7.35–7.38 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.3, 113.7, 115.8, 129.1, 129.3; u: 53.6, 53.7, 57.0, 66.2, 125.8, 127.7, 157.2, 160.8, 170.2; FTIR (neat): 1623, 1607 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>24</sub>ClN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 375.1470; found 375.1501; HPLC purity = 99%.</div></div><div id="sec4_2_9_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (4-(2-(4-(Trifluoromethoxy)phenoxy)ethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>6</b>)</h5><div class="NLM_p last">(4-(2-Hydroxyethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (96 mg, 0.36 mmol) and 4-(trifluoromethoxy)phenol (65 mg, 0.36 mmol, 1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> were reacted according to General Procedure C for 46 h to afford the aryl ether as a light orange oil (56 mg, 0.13 mmol, 36% yield). <i>R</i><sub><i>f</i></sub> = 0.27 (EtOAc). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.50–2.68 (complex, 4H), 2.84 (t, <i>J</i> = 5.6 Hz, 2H), 3.47–3.82 (complex, 4H), 3.83 (s, 3H), 4.10 (t, <i>J</i> = 5.6 Hz, 2H), 6.86–6.92 (complex, 4H), 7.11–7.16 (m, 2H), 7.37–7.41 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.4, 114.0, 115.5, 122.7, 129.5; u: 52.7, 56.4, 63.26, 63.30, 120.4 (q, <i>J</i> = 257.9 Hz), 125.6, 143.6, 155.5, 161.6, 170.4; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −58.4; FTIR (neat): 1634, 1607, 1507 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>24</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 425.1683; found 425.1696; HPLC purity >99.5%.</div></div><div id="sec4_2_9_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (4-(2-(3,5-Dimethoxyphenoxy)ethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>7</b>)</h5><div class="NLM_p last">(4-Methoxyphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 1-(2-bromoethoxy)-3,5-dimethoxybenzene (52 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as a yellow oil (57 mg, 0.14 mmol, 71% yield). <i>R</i><sub><i>f</i></sub> = 0.17 (EtOAc). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.48–2.67 (complex, 4H), 2.81 (t, <i>J</i> = 5.5 Hz, 2H), 3.74 (s, 6H), 3.81 (s, 3H), 3.45–3.79 (complex, 4H), 4.05 (t, <i>J</i> = 5.5 Hz, 2H), 6.04–6.08 (complex, 3H), 6.89 (d, <i>J</i> = 8.7 Hz, 2H), 7.37 (d, <i>J</i> = 8.7 Hz, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.3, 93.1, 93.5, 113.7, 129.1; u: 53.5, 53.6, 57.0, 65.8, 127.8, 160.5, 160.7, 161.5, 170.2; FTIR (neat): 1592, 1456, 1425 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup> 401.2071; found 401.2102; HPLC purity = 98%.</div></div><div id="sec4_2_9_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (4-Methoxyphenyl)(4-(2-phenoxyethyl)piperazin-1-yl)methanone (<b>8</b>)</h5><div class="NLM_p last">(4-(2-Hydroxyethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (76 mg, 0.29 mmol) and phenol (27 mg, 0.29 mmol, 1.0 equiv) in THF were reacted according to General Procedure C for 22 h to afford the aryl ether as an orange oil (31 mg, 0.091 mmol, 32% yield). <i>R</i><sub><i>f</i></sub> = 0.17 (EtOAc). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.53–2.72 (complex, 4H), 2.85 (t, <i>J</i> = 5.6 Hz, 2H), 3.43–3.82 (complex, 4H), 3.83 (s, 3H), 4.12 (t, <i>J</i> = 5.6 Hz, 2H), 6.86–6.93 (complex, 4H), 6.95 (tt, <i>J</i> = 1.0, 7.4 Hz, 1H), 7.25–7.31 (m, 2H), 7.37–7.40 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.3, 113.7, 114.5, 120.9, 129.1, 129.4; u: 53.57, 53.60, 57.1, 65.7, 127.8, 158.5, 160.7, 170.2; FTIR (neat): 1622, 1599, 1456, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 341.1860; found 341.1872; HPLC purity = 99%.</div></div><div id="sec4_2_9_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (4-(2-(Benzo[<i>d</i>][1,3]dioxol-5-yloxy)ethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>9</b>)</h5><div class="NLM_p last">(4-Methoxyphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 5-(2-bromoethoxy)benzo[<i>d</i>][1,3]dioxole (49 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as a tan solid (50 mg, 0.13 mmol, 65% yield). <i>R</i><sub><i>f</i></sub> = 0.16 (EtOAc); mp = 97–101 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.48–2.64 (complex, 4H), 2.77 (t, <i>J</i> = 5.6 Hz, 2H), 3.44–3.86 (complex, 4H), 3.80 (s, 3H), 4.01 (t, <i>J</i> = 5.6 Hz, 2H), 5.87 (s, 2H), 6.29 (dd, <i>J</i> = 2.5, 8.5 Hz, 1H), 6.47 (d, <i>J</i> = 2.4 Hz, 1H), 6.67 (d, <i>J</i> = 8.4 Hz, 1H), 6.88 (d, <i>J</i> = 8.3 Hz, 1H), 7.36 (d, <i>J</i> = 8.8 Hz, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.3, 98.2, 105.7, 107.9, 113.7, 129.1; u: 53.5, 53.6, 57.1, 66.8, 127.8, 141.8, 148.2, 154.1, 160.7, 170.2; FTIR (neat): 1622, 1607, 1486 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup> 385.1758; found 385.1789; HPLC purity = 99%.</div></div><div id="sec4_2_9_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (4-Methoxyphenyl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>10</b>)</h5><div class="NLM_p last">(4-(2-Hydroxyethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (81 mg, 0.31 mmol) and 3-hydroxypyridine (29 mg, 0.31 mmol, 1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> were reacted according to General Procedure C for 22 h to afford the aryl ether as a colorless oil (16 mg, 0.047 mmol, 15% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.53–2.65 (complex, 4H), 2.86 (t, <i>J</i> = 5.6 Hz, 2H), 3.45–3.80 (complex, 4H), 3.83 (s, 3H), 4.16 (t, <i>J</i> = 5.6 Hz, 2H), 6.89–6.93 (m, 2H), 7.19–7.23 (m, 2H), 7.37–7.41 (m, 2H), 8.23 (dd, <i>J</i> = 2.0, 4.0 Hz, 1H), 8.32 (dd, <i>J</i> = 1.0, 2.4 Hz, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6, 53.7, 55.4, 57.0, 66.2, 113.7, 121.2, 123.8, 127.7, 129.2, 138.0, 142.4, 154.8, 160.8, 170.3; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 342.1812; found 342.1822; HPLC purity = 99%.</div></div><div id="sec4_2_9_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(phenyl)methanone (<b>11</b>)</h5><div class="NLM_p last">1-(2-(4-Methoxyphenoxy)ethyl)piperazine (107 mg, 0.45 mmol) and benzoyl chloride (83 mg, 0.59 mmol, 1.3 equiv) were reacted according to General Procedure D for 16 h to afford the acylated product as a viscous, pale yellow oil (106 mg, 0.31 mmol, 69% yield). <i>R</i><sub><i>f</i></sub> = 0.28 (EtOAc). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.49–2.70 (complex, 4H), 2.82 (t, <i>J</i> = 5.5 Hz, 2H), 3.39–3.50 (m, 2H), 3.75–3.86 (m, 2H), 3.77 (s, 3H), 4.07 (t, <i>J</i> = 5.6 Hz, 2H), 6.79–6.86 (complex, 4H), 7.37–7.44 (complex, 5H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.3, 53.9, 55.7, 57.2, 66.5, 114.6, 115.6, 127.0, 128.5, 129.7, 135.8, 152.7, 154.0, 170.3; FTIR (neat): 1626, 1506, 1431 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 341.1860; found 341.1874; HPLC purity = 98%.</div></div><div id="sec4_2_9_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(2-methoxyphenyl)methanone (<b>12</b>)</h5><div class="NLM_p last">(2-Methoxyphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 1-(2-bromoethoxy)-4-methoxybenzene (46 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as an orange oil (22 mg, 0.059 mmol, 30% yield). <i>R</i><sub><i>f</i></sub> = 0.21 (EtOAc). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.37–2.71 (complex, 4H), 2.79 (t, <i>J</i> = 5.6 Hz, 2H), 3.19–3.33 (m, 2H), 3.74 (s, 3H), 3.77–3.92 (m, 2H), 3.80 (s, 3H), 4.04 (t, <i>J</i> = 5.6 Hz, 2H), 6.78–6.84 (complex, 4H), 6.88 (d, <i>J</i> = 6.4 Hz, 1H), 6.96 (t, <i>J</i> = 7.5 Hz, 1H), 7.20–7.25 (m, 1H), 7.32 (tt, <i>J</i> = 1.1, 7.9 Hz, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.5, 55.7, 110.8, 114.6, 115.5, 120.9, 128.0, 130.3; u: 41.5, 46.7, 53.3, 53.8, 57.3, 66.5, 125.7, 152.8, 153.9, 155.3, 167.7; FTIR (neat): 1628, 1600, 1506 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 371.1965; found 371.1969; HPLC purity = 97%.</div></div><div id="sec4_2_9_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(3-methoxyphenyl)methanone (<b>13</b>)</h5><div class="NLM_p last">(3-Methoxyphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 1-(2-bromoethoxy)-4-methoxybenzene (46 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as an orange oil (44 mg, 0.12 mmol, 59% yield). <i>R</i><sub><i>f</i></sub> = 0.23 (EtOAc). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.45–2.66 (complex, 4H), 2.78 (t, <i>J</i> = 5.6 Hz, 2H), 3.36–3.49 (m, 2H), 3.71–3.84 (m, 2H), 3.73 (s, 3H), 3.79 (s, 3H), 4.03 (t, <i>J</i> = 5.6 Hz, 2H), 6.76–6.83 (complex, 4H), 6.89–6.95 (complex, 3H), 7.23–7.30 (m, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.3, 55.7, 112.4, 114.6, 115.5, 115.5, 119.0, 129.5; u: 53.2, 53.8, 57.2, 66.5, 137.0, 152.7, 153.9, 159.6, 170.0; FTIR (neat): 1628, 1578, 1506 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 371.1965; found 371.1987; HPLC purity = 99%.</div></div><div id="sec4_2_9_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (4-Chlorophenyl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>14</b>)</h5><div class="NLM_p last">(4-Chlorophenyl)(piperazin-1-yl)methanone (45 mg, 0.20 mmol) and 1-(2-bromoethoxy)-4-methoxybenzene (46 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as a light yellow solid (27 mg, 0.073 mmol, 37% yield). <i>R</i><sub><i>f</i></sub> = 0.29 (EtOAc); mp = 78–80 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.47–2.67 (complex, 4H), 2.80 (t, <i>J</i> = 5.6 Hz, 2H), 3.36–3.49 (m, 2H), 3.72–3.84 (m, 2H), 3.74 (s, 3H), 4.04 (t, <i>J</i> = 5.6 Hz, 2H), 6.78–6.85 (complex, 4H), 7.32–7.38 (complex, 4H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.7, 114.6, 115.5, 128.6, 128.7; u: 53.2, 53.8, 57.2, 66.5, 134.1, 135.7, 152.7, 154.0, 169.1; FTIR (neat): 1628, 1594, 1505 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>24</sub>ClN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 375.1470; found 375.1478; HPLC purity >99.5%.</div></div><div id="sec4_2_9_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (4-Ethylphenyl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>15</b>)</h5><div class="NLM_p last">(4-Ethylphenyl)(piperazin-1-yl)methanone (44 mg, 0.20 mmol) and 1-(2-bromoethoxy)-4-methoxybenzene (46 mg, 0.20 mmol, 1.0 equiv) were reacted according to General Procedure B to afford the alkylated piperazine as a light yellow oil (40 mg, 0.11 mmol, 54% yield). <i>R</i><sub><i>f</i></sub> = 0.29 (EtOAc). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.21 (t, <i>J</i> = 7.6 Hz, 3H), 2.46–2.68 (complex, 4H), 2.64 (q, <i>J</i> = 7.6 Hz, 2H), 2.79 (t, <i>J</i> = 5.6 Hz, 2H), 3.39–3.54 (m, 2H), 3.67–3.84 (m, 2H), 3.73 (s, 3H), 4.04 (t, <i>J</i> = 5.6 Hz, 2H), 6.77–6.84 (complex, 4H), 7.18–7.22 (m, 2H), 7.28–7.32 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 15.4, 55.7, 114.6, 115.5, 127.2, 127.9; u: 28.7, 53.7, 53.9, 57.2, 66.5, 133.0, 146.1, 152.7, 153.9, 170.5; FTIR (neat): 1627, 1506, 1426 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 369.2173; found 369.2196; HPLC purity = 99%.</div></div><div id="sec4_2_9_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(pyridine-4-yl)methanone (<b>16</b>)</h5><div class="NLM_p last">1-(2-(4-Methoxyphenoxy)ethyl)piperazine (108 mg, 0.46 mmol) and isonicotinoyl chloride hydrochloride (99 mg, 0.56 mmol, 1.2 equiv) were reacted according to General Procedure D for 16 h to afford the acylated product as an orange-brown oil (95 mg, 0.28 mmol, 61% yield). <i>R</i><sub><i>f</i></sub> = 0.11 (EtOAc). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.51–2.56 (m, 2H), 2.65–2.71 (m, 2H), 2.83 (t, <i>J</i> = 5.5 Hz, 2H), 3.36–3.41 (m, 4H), 3.77 (s, 3H), 3.79–3.85 (m, 2H), 4.06 (t, <i>J</i> = 5.5 Hz, 2H), 6.81–6.87 (complex, 4H), 7.28 (d, <i>J</i> = 6.0 Hz, 2H), 8.70 (d, <i>J</i> = 6.0 Hz, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 42.0, 47.4, 53.1, 53.7, 55.7, 57.2, 66.5, 114.6, 115.5, 121.2, 143.4, 150.3, 152.7, 154.0, 167.6; FTIR (neat): 1632, 1506, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 342.1812; found 342.1827; HPLC purity >99.5%.</div></div><div id="sec4_2_9_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(5-methoxypyridin-2-yl)methanone (<b>17</b>)</h5><div class="NLM_p last">5-Methoxypicolinic acid (19 mg, 0.12 mmol, 1.2 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a light yellow oil (38 mg, 0.10 mmol, 93% yield). <i>R</i><sub><i>f</i></sub> = 0.13 (EtOAc). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.42–2.51 (m, 2H), 2.52–2.58 (m, 2H), 2.70 (t, <i>J</i> = 5.8 Hz, 2H), 3.48–3.53 (m, 2H), 3.60–3.66 (m, 2H), 3.69 (s, 3H), 3.87 (s, 3H), 4.02 (t, <i>J</i> = 5.7 Hz, 2H), 6.82–6.89 (complex, 4H), 7.49 (dd, <i>J</i> = 2.9, 8.7 Hz, 1H), 7.59 (d, <i>J</i> = 8.6 Hz, 1H), 8.27 (dd, <i>J</i> = 0.6, 2.9 Hz, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 41.8, 46.7, 52.9, 53.4, 55.4, 55.8, 56.6, 65.8, 114.6, 115.4, 121.2, 124.8, 135.7, 146.0, 152.4, 153.4, 155.9, 166.3; FTIR (neat): 1628, 1507, 1458 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 372.1918; found 372.1926; HPLC purity >99.5%.</div></div><div id="sec4_2_9_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (1<i>H</i>-Indol-5-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>18</b>)</h5><div class="NLM_p last">1<i>H</i>-Indole-5-carboxylic acid (21 mg, 0.13 mmol, 1.2 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (29 mg, 0.08 mmol, 69% yield). <i>R</i><sub><i>f</i></sub> = 0.17 (EtOAc); mp = 123–127 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.50–2.69 (complex, 4H), 2.83 (t, <i>J</i> = 5.6 Hz, 2H), 3.50–3.85 (complex, 4H), 3.77 (s, 3H), 4.07 (t, <i>J</i> = 5.7 Hz, 2H), 6.57–6.60 (m, 1H), 6.81–6.85 (complex, 4H), 7.24–7.28 (m, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 1H), 7.73 (d, <i>J</i> = 1.6 Hz, 1H), 8.52 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 46.5, 53.8, 55.9, 57.4, 66.6, 103.3, 111.1, 114.8, 115.7, 120.4, 121.6, 125.5, 127.3, 127.5, 136.5, 152.9, 154.1, 171.9; FTIR (neat): 1599, 1506, 1431 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 380.1969; found 380.1971; HPLC purity = 96%.</div></div><div id="sec4_2_9_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> (1<i>H</i>-Indol-3-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>19</b>)</h5><div class="NLM_p last">1<i>H</i>-Indole-3-carboxylic acid (21 mg, 0.13 mmol, 1.2 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as an off-white solid (6.4 mg, 0.017 mmol, 15% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.59–2.66 (complex, 4H), 2.84 (t, <i>J</i> = 5.6 Hz, 2H), 3.72–3.81 (complex, 4H), 3.76 (s, 3H), 4.08 (t, <i>J</i> = 5.6 Hz, 2H), 6.79–6.86 (complex, 4H), 7.19–7.25 (m, 2H), 7.40–7.43 (m, 1H), 7.55 (d, <i>J</i> = 2.7 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 8.47 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 46.4, 54.0, 55.9, 57.5, 66.7, 111.7, 112.4, 114.8, 115.7, 120.6, 121.3, 123.1, 125.5, 127.0, 135.6, 152.9, 154.1, 166.6; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 380.1969; found 380.1973; HPLC purity = 99%.</div></div><div id="sec4_2_9_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> (1<i>H</i>-Indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>20</b>)</h5><div class="NLM_p last">To a mixture of 1-(2-(4-methoxyphenoxy)ethyl)piperazine (146 mg, 0.618 mmol), indole-2-carboxylic acid (119 mg, 0.741 mmol, 1.2 equiv), and DMAP (8 mg, 0.062 mmol, 0.1 equiv) in THF (10 mL) was added diisopropylcarbodiimide (0.29 mL, 234 mg, 1.85 mmol, 3.0 equiv). The reaction was stirred at rt for 15 h, and the solvents were removed under vacuum. The residue was purified via silica gel chromatography to afford the acylated product as an off-white solid (172 mg, 0.453 mmol, 73% yield). <i>R</i><sub><i>f</i></sub> = 0.54 (MeOH (10%) and NH<sub>4</sub>OH (2%) in CH<sub>2</sub>Cl<sub>2</sub>); mp = 163–165 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.68 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.90–4.05 (m, 4H), 4.10 (t, <i>J</i> = 5.5 Hz, 2H), 6.78 (dd, <i>J</i> = 1.0, 2.1 Hz, 1H), 6.82–6.89 (complex, 4H), 7.13 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.24–7.32 (m, 1H), 7.43 (dd, <i>J</i> = 1.1, 8.3 Hz, 1H), 7.65 (dd, <i>J</i> = 1.2, 8.0 Hz, 1H), 9.65 (br s, 1H) <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.7, 105.2, 111.8, 114.7, 115.6, 120.5, 121.8, 124.4; u: 53.6, 57.3, 66.6, 127.4, 129.2, 135.7, 152.8, 154.0, 162.3; FTIR (neat): 3258, 1597, 1506, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 380.1969; found 380.1995; HPLC purity = 96% (for LC/MS chromatogram and spectrum, see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Figures S5 and S6</a>).</div></div><div id="sec4_2_9_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (7-Methoxy-1<i>H</i>-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>21</b>)</h5><div class="NLM_p last">7-Methoxy-1<i>H</i>-indole-2-carboxylic acid (22 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a tan solid (31.6 mg, 0.077 mmol, 71% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.67 (t, <i>J</i> = 5.1 Hz, 4H), 2.84 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.89–4.01 (complex, 4H), 3.96 (s, 3H), 4.09 (t, <i>J</i> = 5.6 Hz, 2H), 6.69 (dd, <i>J</i> = 0.8, 7.7 Hz, 1H), 6.74 (d, <i>J</i> = 2.3 Hz, 1H), 6.82–6.87 (complex, 4H), 7.05 (t, <i>J</i> = 7.9 Hz, 1H), 7.21–7.25 (m, 1H), 9.22 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.1, 53.7, 55.6, 55.9, 57.4, 66.6, 103.6, 105.5, 114.2, 114.8, 115.7, 121.2, 126.8, 128.7, 129.1, 146.6, 152.9, 154.1, 162.3; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 410.2074; found 410.2073; HPLC purity = 99%.</div></div><div id="sec4_2_9_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (6-Methoxy-1<i>H</i>-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>22</b>)</h5><div class="NLM_p last">6-Methoxy-1<i>H</i>-indole-2-carboxylic acid (22 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as an off-white solid (30 mg, 0.073 mmol, 67% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.67 (t, <i>J</i> = 5.1 Hz, 4H), 2.84 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.86 (s, 3H), 3.90–4.01 (complex, 4H), 4.09 (t, <i>J</i> = 5.6 Hz, 2H), 6.72 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.81 (dd, <i>J</i> = 2.3, 8.7 Hz, 1H), 6.82–6.88 (complex, 5H), 7.44–7.62 (m, 1H), 9.10 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.7, 55.7, 55.9, 57.4, 66.7, 93.8, 105.8, 112.1, 114.8, 115.7, 122.0, 122.8, 128.3, 136.7, 152.9, 154.1, 158.4, 162.3; FTIR (neat): 1596, 1505 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 410.2074; found 410.2074; HPLC purity = 98%.</div></div><div id="sec4_2_9_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (5-Methoxy-1<i>H</i>-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>23</b>)</h5><div class="NLM_p last">5-Methoxy-1<i>H</i>-indole-2-carboxylic acid (22 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (32 mg, 0.078 mmol, 72% yield). <i>R</i><sub><i>f</i></sub> = 0.20 (EtOAc); mp = 154–155 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.67 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.84 (s, 3H), 3.89–4.04 (complex, 4H), 4.09 (t, <i>J</i> = 5.6 Hz, 2H), 6.70 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.82–6.89 (complex, 4H), 6.95 (dd, <i>J</i> = 2.4, 8.9 Hz, 1H), 7.05 (d, <i>J</i> = 2.4 Hz, 1H), 7.32 (td, <i>J</i> = 0.8, 9.1 Hz, 1H), 9.22 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.1, 53.7, 55.9, 57.4, 66.7, 102.4, 105.1, 112.8, 114.8, 115.7, 115.8, 127.9, 129.8, 131.1, 152.9, 154.1, 154.7, 162.4; FTIR (neat): 1595, 1525, 1506, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 410.2074; found 410.2076; HPLC purity >99.5%.</div></div><div id="sec4_2_9_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (4-Methoxy-1<i>H</i>-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>24</b>)</h5><div class="NLM_p last">4-Methoxy-1<i>H</i>-indole-2-carboxylic acid (22 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (30 mg, 0.072 mmol, 67% yield). <i>R</i><sub><i>f</i></sub> = 0.64 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 127–129 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.67 (t, <i>J</i> = 5.1 Hz, 4H), 2.84 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.90–4.05 (complex, 4H), 3.96 (s, 3H), 4.09 (t, <i>J</i> = 5.6 Hz, 2H), 6.51 (dd, <i>J</i> = 0.6, 7.8 Hz, 1H), 6.90 (dd, <i>J</i> = 0.9, 2.3 Hz, 1H), 7.04 (ddd, <i>J</i> = 1.8, 8.0, 79.5 Hz, 1H), 7.20 (t, <i>J</i> = 7.9 Hz, 1H), 9.29 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.1, 53.7, 55.4, 55.9, 57.4, 66.7, 99.7, 102.8, 105.0, 114.8, 115.7, 118.8, 125.5, 128.1, 137.1, 152.9, 154.1, 154.2, 162.2; FTIR (neat): 1595, 1580, 1505, 1433 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 410.2074; found 410.2076; HPLC purity >99.5%.</div></div><div id="sec4_2_9_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(7-methyl-1<i>H</i>-indol-2-yl)methanone (<b>25</b>)</h5><div class="NLM_p last">7-Methyl-1<i>H</i>-indole-2-carboxylic acid (20 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as an off-white solid (28.0 mg, 0.071 mmol, 66% yield). <i>R</i><sub><i>f</i></sub> = 0.64 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 134–138 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.50 (s, 3H), 2.68 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.87–4.05 (complex, 4H), 4.10 (t, <i>J</i> = 5.5 Hz, 2H), 6.78 (d, <i>J</i> = 2.1 Hz, 1H), 6.82–6.91 (complex, 4H), 7.01–7.11 (m, 2H), 7.49 (dd, <i>J</i> = 2.2, 6.7 Hz, 1H), 9.12 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 16.9, 41.1, 53.7, 55.4, 57.2, 66.0, 101.2, 105.9, 106.7, 106.8, 119.6, 121.0, 121.2, 124.8, 127.1, 129.0, 130.1, 135.5, 160.0, 161.0, 162.5; FTIR (neat): 1598, 1534, 1505, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.2125; found 394.2124; HPLC purity >99.5%.</div></div><div id="sec4_2_9_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(6-methyl-1<i>H</i>-indol-2-yl)methanone (<b>26</b>)</h5><div class="NLM_p last">6-Methyl-1<i>H</i>-indole-2-carboxylic acid (19 mg, 0.11 mmol, 1.0 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (26.7 mg, 0.068 mmol, 63% yield). <i>R</i><sub><i>f</i></sub> = 0.60 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 130–131 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.46 (s, 3H), 2.67 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.90–4.03 (complex, 4H), 4.09 (t, <i>J</i> = 5.6 Hz, 2H), 6.73 (dd, <i>J</i> = 0.9, 2.1 Hz, 1H), 6.81–6.89 (complex, 4H), 6.97 (ddd, <i>J</i> = 0.6, 1.4, 8.2 Hz, 1H), 7.21 (m, 1H), 7.52 (dd, <i>J</i> = 0.9, 8.2 Hz, 1H), 9.08 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 22.1, 53.7, 55.9, 57.4, 66.7, 105.4, 111.6, 114.8, 115.7, 121.6, 122.8, 125.5, 128.8, 134.6, 136.2, 152.9, 154.1, 162.5; FTIR (neat): 1596, 1523, 1507, 1438 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 394.2125; found 394.2128; HPLC purity = 99%.</div></div><div id="sec4_2_9_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(5-methyl-1<i>H</i>-indol-2-yl)methanone (<b>27</b>)</h5><div class="NLM_p last">5-Methyl-1<i>H</i>-indole-2-carboxylic acid (20 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (29 mg, 0.074 mmol, 68% yield). <i>R</i><sub><i>f</i></sub> = 0.60 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 175–179 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.44 (s, 3H), 2.67 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.91–4.02 (complex, 4H), 4.09 (t, <i>J</i> = 5.5 Hz, 2H), 6.69 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.81–6.89 (complex, 4H), 7.11 (dd, <i>J</i> = 1.3, 8.4 Hz, 1H), 7.31 (dt, <i>J</i> = 0.8, 8.4 Hz, 1H), 7.41 (dd, <i>J</i> = 0.8, 1.7 Hz, 1H), 9.10 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.7, 55.7, 55.9, 57.4, 66.7, 93.8, 105.8, 112.1, 114.8, 115.7, 122.0, 122.8, 128.3, 136.7, 152.9, 154.1, 158.4, 162.3; FTIR (neat): 1592, 1536, 1506, 1434 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 394.2125; found 394.2127; HPLC purity = 99%.</div></div><div id="sec4_2_9_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(4-methyl-1<i>H</i>-indol-2-yl)methanone (<b>28</b>)</h5><div class="NLM_p last">4-Methyl-1<i>H</i>-indole-2-carboxylic acid (21 mg, 0.12 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as an off-white solid (31.3 mg, 0.080 mmol, 74% yield). <i>R</i><sub><i>f</i></sub> = 0.68 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 134–136 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.56 (s, 2H), 2.69 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.77 (s, 3H), 3.91–4.06 (complex, 4H), 4.10 (t, <i>J</i> = 5.5 Hz, 2H), 6.78 (dd, <i>J</i> = 1.0, 2.2 Hz, 1H), 6.81–6.89 (complex, 4H), 6.93 (td, <i>J</i> = 0.9, 7.1 Hz, 1H), 7.19 (dd, <i>J</i> = 7.0, 8.3 Hz, 1H), 7.24–7.27 (m, 1H), 9.20 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 18.9, 41.1, 53.7, 55.9, 57.4, 66.7, 103.9, 109.4, 114.8, 115.7, 120.7, 124.7, 127.7, 128.8, 131.6, 135.5, 152.9, 154.1, 162.4; FTIR (neat): 1597, 1506, 1456, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 394.2125; found 394.2125; HPLC purity = 99%.</div></div><div id="sec4_2_9_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> (7-Chloro-1<i>H</i>-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>29</b>)</h5><div class="NLM_p last">7-Chloro-1<i>H</i>-indole-2-carboxylic acid (23 mg, 0.12 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a yellow solid (31.8 mg, 0.077 mmol, 71% yield). <i>R</i><sub><i>f</i></sub> = 0.68 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 125–130 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.68 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.77 (s, 3H), 3.87–4.04 (complex, 4H), 4.09 (t, <i>J</i> = 5.5 Hz, 2H), 6.79 (d, <i>J</i> = 2.2 Hz, 1H), 6.83–6.90 (m, 4H), 7.08 (t, <i>J</i> = 7.8 Hz, 1H), 7.28 (dd, <i>J</i> = 0.9, 7.6 Hz, 1H), 7.54 (td, <i>J</i> = 0.9, 8.0 Hz, 1H), 9.23 (br s, 1H) <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.1, 53.7, 55.9, 57.4, 66.7, 105.9, 114.8, 115.7, 117.3, 120.6, 121.5, 123.7, 128.8, 130.1, 133.2, 152.9, 154.1, 161.8; FTIR (neat): 1604, 1505, 1435 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 414.1579; found 414.1578; HPLC purity >99.5%.</div></div><div id="sec4_2_9_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> (6-Chloro-1<i>H</i>-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>30</b>)</h5><div class="NLM_p last">6-Chloro-1<i>H</i>-indole-2-carboxylic acid (24 mg, 0.12 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (31.2 mg, 0.075 mmol, 70% yield). <i>R</i><sub><i>f</i></sub> = 0.61 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 165–168 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.69 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.77 (s, 3H), 3.89–4.04 (m, 4H), 4.10 (t, <i>J</i> = 5.5 Hz, 2H), 6.75 (dd, <i>J</i> = 1.0, 2.1 Hz, 1H), 6.82–6.88 (complex, 4H), 7.10 (dd, <i>J</i> = 1.8, 8.5 Hz, 1H), 7.40–7.44 (m, 1H), 7.55 (d, <i>J</i> = 8.7 Hz, 1H), 9.46 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.7 (×2 C), 55.9, 57.4, 66.7, 105.4, 111.7, 114.8, 115.7, 121.7, 122.9, 126.1, 130.1, 130.4, 136.0, 152.9, 154.1, 162.0; FTIR (neat): 1591, 1506, 1456, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 414.1579; found 414.1575; HPLC purity = 95%.</div></div><div id="sec4_2_9_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> (5-Chloro-1<i>H</i>-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>31</b>)</h5><div class="NLM_p last">5-Chloro-1<i>H</i>-indole-2-carboxylic acid (22 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as an off-white solid (30.6 mg, 0.074 mmol, 68% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.68 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.77 (s, 3H), 3.88–4.02 (m, 4H), 4.09 (t, <i>J</i> = 5.5 Hz, 2H), 6.70 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.81–6.88 (complex, 4H), 7.23 (dd, <i>J</i> = 2.0, 8.8 Hz, 1H), 7.35 (d, <i>J</i> = 8.7 Hz, 1H), 7.60 (d, <i>J</i> = 2.0 Hz, 1H), 9.41 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.7 (×2 C), 55.9, 57.4, 66.7, 104.7, 113.0, 114.8, 115.7, 121.2, 125.0, 126.3, 128.5, 130.6, 134.1, 152.9, 154.1, 162.0; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 414.1579; found 414.1578; HPLC purity = 99.5%.</div></div><div id="sec4_2_9_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (4-Chloro-1<i>H</i>-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>32</b>)</h5><div class="NLM_p last">4-Chloro-1<i>H</i>-indole-2-carboxylic acid (21 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (29.9 mg, 0.072 mmol, 67% yield). <i>R</i><sub><i>f</i></sub> = 0.64 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 139–141 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.57 (t, <i>J</i> = 5.1 Hz, 4H), 2.73 (t, <i>J</i> = 5.7 Hz, 2H), 3.69 (s, 3H), 3.71–3.82 (m, 4H), 4.04 (t, <i>J</i> = 5.7 Hz, 2H), 6.76 (s, 1H), 6.82–6.91 (complex, 4H), 7.13 (dd, <i>J</i> = 1.0, 7.6 Hz, 1H), 7.16–7.23 (m, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 11.97 (s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.1 (×2 C), 55.4, 56.6, 65.9, 101.6, 111.3, 114.6, 115.4, 119.4, 124.0, 125.2, 125.4, 131.0, 136.6, 152.5, 153.4, 161.3; FTIR (neat): 1599, 1505, 1458, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 414.1579; found 414.1581; HPLC purity >99.5%.</div></div><div id="sec4_2_9_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(1-methyl-1<i>H</i>-indol-2-yl)methanone (<b>33</b>)</h5><div class="NLM_p last">1-(2-(4-Methoxyphenoxy)ethyl)piperazine (109 mg, 0.461 mmol) and 1-methyl-1<i>H</i>-indole-2-carbonyl chloride (107 mg, 0.554 mmol, 1.2 equiv) were reacted according to General Procedure D to afford the acylated piperazine product as a tan oil (117 mg, 0.297 mmol, 65% yield). <i>R</i><sub><i>f</i></sub> = 0.81 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>c). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.53–2.72 (m, 4H), 2.84 (t, <i>J</i> = 5.5 Hz, 2H), 3.77 (s, 3H), 3.84 (s, 3H), 3.74–3.87 (m, 4H), 4.08 (t, <i>J</i> = 5.5 Hz, 2H), 6.60 (d, <i>J</i> = 0.9 Hz, 1H), 6.80–6.88 (complex, 4H), 7.14 (ddd, <i>J</i> = 1.0, 6.9, 8.0 Hz, 1H), 7.30 (ddd, <i>J</i> = 1.2, 6.9, 8.3 Hz, 1H), 7.36 (td, <i>J</i> = 0.9, 8.4 Hz, 1H), 7.62 (d, <i>J</i> = 8.0 Hz, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 31.1, 53.7 (×2 C), 55.7, 57.2, 66.5, 103.6, 109.8, 114.7, 115.6, 120.3, 121.5, 123.3, 126.4, 131.6, 137.9, 152.7, 154.0, 163.0; FTIR (neat): 1624, 1506, 1462, 1438 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.2125; found 394.2146; HPLC purity = 98.2%.</div></div><div id="sec4_2_9_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(3-methyl-1<i>H</i>-indol-2-yl)methanone (<b>34</b>)</h5><div class="NLM_p last">3-Methyl-1<i>H</i>-indole-2-carboxylic acid (19 mg, 0.11 mmol, 1.0 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a light yellow solid (20.4 mg, 0.052 mmol, 48% yield). <i>R</i><sub><i>f</i></sub> = 0.73 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 105–123 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.26 (s, 3H), 2.48–2.55 (m, 4H), 2.72 (t, <i>J</i> = 5.7 Hz, 2H), 3.52–3.61 (m, 4H), 3.69 (s, 3H), 4.02 (t, <i>J</i> = 5.7 Hz, 2H), 6.84–6.89 (complex, 4H), 7.03 (ddd, <i>J</i> = 1.0, 6.9, 7.9 Hz, 1H), 7.16 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.33 (d, <i>J</i> = 8.2 Hz, 1H), 7.51–7.58 (m, 1H), 11.19 (s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.3, 53.2 (×2 C), 55.3, 56.5, 65.8, 109.9, 111.6, 114.5, 115.3, 118.9, 119.2, 122.8, 127.4, 127.7, 135.6, 152.4, 153.3, 163.3; FTIR (neat): 1603, 1506, 1451, 1440 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.2125; found 394.2126; HPLC purity = 99.2%.</div></div><div id="sec4_2_9_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methanone (<b>35</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid (20 mg, 0.12 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (27.3 mg, 0.072 mmol, 66% yield). <i>R</i><sub><i>f</i></sub> = 0.71 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 167–176 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.69 (t, <i>J</i> = 5.1 Hz, 4H), 2.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.77 (s, 3H), 3.90–4.03 (m, 4H), 4.09 (t, <i>J</i> = 5.5 Hz, 2H), 6.72 (d, <i>J</i> = 1.4 Hz, 1H), 6.81–6.92 (complex, 4H), 7.13 (dd, <i>J</i> = 4.7, 7.9 Hz, 1H), 7.98 (dd, <i>J</i> = 1.6, 7.9 Hz, 1H), 8.50 (dd, <i>J</i> = 1.6, 4.7 Hz, 1H), 10.73 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6, 55.7, 57.2, 66.5, 103.4, 114.7, 115.6, 116.9, 119.8, 129.9, 130.3, 146.0, 147.7, 152.8, 154.0, 162.0; FTIR (neat): 1618, 1579, 1506, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1921; HPLC purity >99.5%.</div></div><div id="sec4_2_9_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-2-yl)methanone (<b>36</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[2,3-<i>c</i>]pyridine-2-carboxylic acid (20 mg, 0.12 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (30.5 mg, 0.080 mmol, 74% yield). <i>R</i><sub><i>f</i></sub> = 0.28 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 163–165 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.69–2.74 (m, 4H), 2.86 (t, <i>J</i> = 5.4 Hz, 2H), 3.77 (s, 3H), 3.90–4.03 (m, 4H), 4.10 (t, <i>J</i> = 5.5 Hz, 2H), 6.70–6.97 (complex, 5H), 7.34 (d, <i>J</i> = 5.8 Hz, 1H), 8.37 (d, <i>J</i> = 5.8 Hz, 1H), 8.99 (d, <i>J</i> = 1.1 Hz, 1H), 10.02 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6, 55.7, 57.2, 66.5, 104.3, 106.8, 114.7, 115.6, 124.6, 130.3, 139.1, 142.7, 145.5, 152.7, 154.0, 161.7; FTIR (neat): 1609, 1578, 1506 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1926; HPLC purity = 99.5%.</div></div><div id="sec4_2_9_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2-yl)methanone (<b>37</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine-2-carboxylic acid (23 mg, 0.14 mmol, 1.3 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a light yellow solid (30.3 mg, 0.080 mmol, 74% yield). <i>R</i><sub><i>f</i></sub> = 0.28 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 160–164 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.57 (t, <i>J</i> = 5.1 Hz, 4H), 2.74 (t, <i>J</i> = 5.7 Hz, 2H), 3.69 (s, 3H), 3.70–3.83 (m, 4H), 4.04 (t, <i>J</i> = 5.7 Hz, 2H), 6.82–6.91 (complex, 4H), 6.92–7.01 (m, 1H), 7.36 (d, <i>J</i> = 5.8 Hz, 1H), 8.22 (d, <i>J</i> = 5.8 Hz, 1H), 8.90 (d, <i>J</i> = 1.2 Hz, 1H), 11.99 (s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.1, 55.3, 56.5, 65.8, 103.1, 107.0, 114.5, 115.3, 124.0, 131.0, 138.9, 141.5, 144.7, 152.4, 153.3, 161.3; FTIR (neat): 1608, 1575, 1505 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1926; HPLC purity = 99.7%.</div></div><div id="sec4_2_9_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> (4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-2-yl)methanone (<b>38</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[3,2-<i>b</i>]pyridine-2-carboxylic acid (19 mg, 0.12 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (26.9 mg, 0.071 mmol, 65% yield). <i>R</i><sub><i>f</i></sub> = 0.34 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 165–166 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.70 (t, <i>J</i> = 5.1 Hz, 4H), 2.86 (t, <i>J</i> = 5.5 Hz, 2H), 3.77 (s, 3H), 3.85–4.14 (m, 4H), 4.10 (t, <i>J</i> = 5.6 Hz, 2H), 6.75–6.92 (complex, 4H), 6.98 (d, <i>J</i> = 1.1 Hz, 1H), 7.20 (dd, <i>J</i> = 4.6, 8.3 Hz, 1H), 7.74 (d, <i>J</i> = 8.2 Hz, 1H), 8.53 (dd, <i>J</i> = 1.4, 4.6 Hz, 1H), 9.69 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6, 55.7, 57.2, 66.5, 105.7, 114.7, 115.6, 119.1, 119.2, 128.8, 131.7, 144.9, 145.3, 152.7, 154.0, 161.9; FTIR (neat): 1601, 1505, 1437, 1407 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1929; HPLC purity = 99.0%.</div></div><div id="sec4_2_9_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> (1<i>H</i>-Benzo[<i>d</i>]imidazol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>39</b>)</h5><div class="NLM_p last">1<i>H</i>-Benzo[<i>d</i>]imidazole-2-carboxylic acid (20 mg, 0.12 mmol, 1.1 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (26 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (29.3 mg, 0.077 mmol, 71% yield). <i>R</i><sub><i>f</i></sub> = 0.78 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 139–141 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.70–2.81 (m, 4H), 2.86 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.94 (t, <i>J</i> = 5.0 Hz, 2H), 4.11 (t, <i>J</i> = 5.6 Hz, 2H), 4.82 (t, <i>J</i> = 5.2 Hz, 2H), 6.75–6.95 (complex, 4H), 7.30–7.43 (m, 2H), 7.48–7.58 (m, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 11.00 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 43.2, 46.7, 53.4, 54.2, 55.7, 57.2, 66.5, 111.7, 114.6, 115.6, 121.0, 123.1, 125.1, 132.5, 143.2, 145.3, 152.8, 154.0, 158.2; FTIR (neat): 1608, 1506, 1440, 1406 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1919; HPLC purity = 99.8%.</div></div><div id="sec4_2_9_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Benzofuran-2-yl(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>40</b>)</h5><div class="NLM_p last">Benzofuran-2-carboxylic acid (21.0 mg, 0.13 mmol, 1.2 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (25.7 mg, 0.11 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (25.3 mg, 0.067 mmol, 61% yield). <i>R</i><sub><i>f</i></sub> = 0.68 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 113–116 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.70–2.81 (m, 4H), 2.86 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (s, 3H), 3.94 (t, <i>J</i> = 5.0 Hz, 2H), 4.11 (t, <i>J</i> = 5.6 Hz, 2H), 4.82 (t, <i>J</i> = 5.2 Hz, 2H), 6.75–6.95 (complex, 4H), 7.30–7.43 (m, 2H), 7.48–7.58 (m, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 11.00 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.4, 54.0, 55.7, 57.2, 66.5, 111.9, 112.0, 114.6, 115.6, 122.2, 123.6, 126.4, 127.0, 149.0, 152.8, 154.0, 154.6, 159.7; FTIR (neat): 1630, 1561, 1506, 1433 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 381.1809; found 381.1814; HPLC purity = 98.6%.</div></div><div id="sec4_2_9_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> Benzo[<i>b</i>]thiophen-2-yl(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>41</b>)</h5><div class="NLM_p last">Benzo[<i>b</i>]thiophen-2-carboxylic acid (25 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (30 mg, 0.13 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a white solid (27.0 mg, 0.077 mmol, 60% yield). <i>R</i><sub><i>f</i></sub> = 0.68 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 57–59 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.62–2.69 (m, 4H), 2.84 (t, <i>J</i> = 5.5 Hz, 2H), 3.77 (s, 3H), 3.78–3.88 (m, 4H), 4.08 (t, <i>J</i> = 5.6 Hz, 2H), 6.80–6.89 (m, 4H), 7.37–7.42 (m, 2H), 7.48 (d, <i>J</i> = 0.8 Hz, 1H), 7.79–7.83 (m, 1H), 7.84–7.87 (m, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 55.7, 57.2, 66.5, 114.6, 115.6, 122.4, 124.6, 124.8, 125.2, 125.8, 136.6, 138.6, 140.2, 152.7, 154.0, 163.8; FTIR (neat): 1619, 1505, 1458, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 397.1580; found 397.1587; HPLC purity = 99.5%.</div></div><div id="sec4_2_9_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Cyclohexyl(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>42</b>)</h5><div class="NLM_p last">Cyclohexanecarbonyl chloride (75 μL, 0.56 mmol, 1.2 equiv) and 1-(2-(4-methoxyphenoxy)ethyl)piperazine (110 mg, 0.47 mmol) were reacted according to General Procedure D to afford the acylated piperazine product as a yellow solid (101.3 mg, 0.293 mmol, 63% yield); <i>R</i><sub><i>f</i></sub> = 0.58 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>); mp = 54–58 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.17–1.32 (m, 4H), 1.44–1.59 (m, 2H), 1.69–1.87 (m, 4H), 2.39–2.61 (m, 5H), 2.80 (t, <i>J</i> = 5.6 Hz, 2H), 3.58 (dt, <i>J</i> = 5.2, 60.8 Hz, 4H), 3.77 (s, 3H), 4.07 (t, <i>J</i> = 5.6 Hz, 2H), 6.78–6.88 (m, 4H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 25.8, 25.9, 29.4, 40.4, 41.5, 45.3, 53.4, 54.1, 55.7, 57.3, 66.5, 114.6, 115.6, 152.8, 154.0, 174.5; FTIR (neat): 1634, 1506, 1433 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>31</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 347.2329; found 347.2349; HPLC purity = 99.2%.</div></div><div id="sec4_2_9_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 1-(4-(2-(4-Methoxyphenoxy)ethyl)piperazin-1-yl)ethan-1-one (<b>43</b>)</h5><div class="NLM_p last">Acetyl chloride (32.8 μL, 0.461 mmol, 1.0 equiv), 1-(2-(4-methoxyphenoxy)ethyl)piperazine (109 mg, 0.461 mmol), and triethylamine (100 μL, 0.717 mmol, 1.5 equiv) were reacted according to General Procedure D to afford the acylated piperazine product as a brown oil (79.6 mg, 0.287 mmol, 62% yield). <i>R</i><sub><i>f</i></sub> = 0.57 (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.09 (s, 3H), 2.54 (t, <i>J</i> = 5.2 Hz, 2H), 2.58 (t, <i>J</i> = 5.0 Hz, 2H), 2.81 (t, <i>J</i> = 5.6 Hz, 2H), 3.49 (t, <i>J</i> = 5.3 Hz, 2H), 3.64 (t, <i>J</i> = 4.6 Hz, 2H), 3.77 (s, 3H), 4.06 (t, <i>J</i> = 5.6 Hz, 2H), 6.77–6.87 (m, 4H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 21.3, 41.4, 46.3, 53.2, 53.7, 55.7, 57.2, 66.5, 114.6, 115.6, 152.8, 154.0, 168.9; FTIR (neat): 1637, 1505, 1461, 1426 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>15</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 279.1703; found 279.1716; HPLC purity >99.5%.</div></div><div id="sec4_2_9_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 1-(2-(4-Methoxyphenoxy)ethyl)-4-((4-methoxyphenyl)sulfonyl)piperazine (<b>44</b>)</h5><div class="NLM_p last">To a solution of 1-(2-(4-methoxyphenoxy)ethyl)piperazine (76 mg, 0.32 mmol) and triethylamine (90 μL, 0.64 mmol, 2.0 equiv) in toluene (25 mL) at rt was added 4-methoxybenzene-1-sulfonyl chloride (67 mg, 0.32 mmol, 1.0 equiv). The reaction was capped and stirred for 19 h at rt. The reaction solvents were removed in vacuo, and the residue was partitioned between saturated aqueous NaHCO<sub>3</sub> (40 mL) and CH<sub>2</sub>Cl<sub>2</sub> (2 × 20 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and purified by silica gel chromatography to afford the sulfonamide product as an off-white solid (71.4 mg, 0.176 mmol, 55% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.65 (t, <i>J</i> = 5.0 Hz, 4H), 2.76 (t, <i>J</i> = 5.5 Hz, 2H), 3.03 (t, <i>J</i> = 4.9 Hz, 2H), 3.75 (s, 3H), 3.86 (s, 3H), 3.98 (t, <i>J</i> = 5.5 Hz, 2H), 6.77–6.81 (m, 4H), 6.98 (d, <i>J</i> = 8.9 Hz, 2H), 7.68 (d, <i>J</i> = 9.0 Hz, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d: 55.7, 55.8, 114.3, 114.7, 115.7, 130.1; u: 46.1, 52.7, 57.0, 66.6, 127.0, 152.8, 154.1; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>27</sub>N<sub>2</sub>O<sub>5</sub>S [M + H]<sup>+</sup> 407.1635; found 407.1635; HPLC purity >99.5%.</div></div><div id="sec4_2_9_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 1-(2-(4-Methoxyphenoxy)ethyl)-4-(4-methoxyphenyl)piperazine (<b>45</b>)</h5><div class="NLM_p last">To a solution of 1-(4-methoxyphenyl)piperazine (39 mg, 0.20 mmol) and 1-(2-bromoethoxy)-4-methoxybenzene (52 mg, 0.22 mmol, 1.1 equiv) in MeCN (10 mL) was added triethylamine (40 μL, 0.29 mmol, 1.4 equiv), and the reaction was stirred at 60 °C for 18 h. The reaction was filtered, and the solids were washed with CH<sub>2</sub>Cl<sub>2</sub> (2 × 5 mL). The combined filtrates were evaporated, and the residue was purified by silica gel chromatography to afford the alkylated piperazine product as a tan solid (47.5 mg, 0.139 mmol, 68% yield). <i>R</i><sub><i>f</i></sub> = 0.45 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 156–159 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.72–2.78 (m, 4H), 2.85 (t, <i>J</i> = 5.8 Hz, 2H), 3.08–3.16 (m, 4H), 3.76 (s, 3H), 3.78 (s, 3H), 4.10 (t, <i>J</i> = 5.8 Hz, 2H), 6.81–6.88 (m, 6H), 6.89–6.92 (m, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 50.6, 53.8, 55.6, 55.7, 57.4, 66.6, 114.4, 114.6, 115.6, 118.2, 145.7, 152.9, 153.8, 153.9; FTIR (neat): 1508, 1457, 1441 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>27</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 343.2016; found 343.2032; HPLC purity = 97.1%.</div></div><div id="sec4_2_9_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> (4-(1-(4-Methoxyphenoxy)propan-2-yl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>46</b>)</h5><div class="NLM_p last">A solution of (4-methoxyphenyl)(piperazin-1-yl)methanone2,2,2-trifluoroacetate (78 mg, 0.23 mmol, 1.0 equiv), 1-(4-methoxyphenoxy)propan-2-one (44 mg, 0.24 mmol, 1.0 equiv), acetic acid (4 μL, 0.07 mmol, 0.3 equiv), and sodium triacetoxyborohydride (76 mg, 0.36 mmol, 1.5 equiv) in dichloroethane (2 mL) was heated at 50 °C for 7 days and cooled to rt. The reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub> (4 mL) and washed with saturated aqueous NaHCO<sub>3</sub> (2 × 2 mL) and water (1 × 2 mL). The combined organic layers were dried over MgSO<sub>4</sub>, concentrated in vacuo, and purified by silica gel chromatography to afford the reductive amination product as a tan solid (51.1 mg, 0.132 mmol, 57% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.17 (d, <i>J</i> = 6.8 Hz, 3H), 2.54–2.75 (m, 4H), 3.03 (dtd, <i>J</i> = 5.6, 6.8, 12.4 Hz, 1H), 3.41–3.75 (br m, 4H), 3.77 (s, 3H), 3.83 (s, 3H), 3.83–3.86 (m, 1H), 4.00 (dd, <i>J</i> = 5.6, 9.6 Hz, 1H), 6.83 (m, 4H), 6.87–6.95 (m, 2H), 7.35–7.42 (m, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 13.3, 55.3, 55.7, 58.4, 70.6, 113.7, 114.6, 115.5, 127.9, 129.2, 152.9, 153.9, 160.7, 170.2; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 385.2122; found 385.2135; HPLC purity = 99.6%.</div></div><div id="sec4_2_9_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> (4-(2-(4-Methoxyphenoxy)propyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>47</b>)</h5><div class="NLM_p last">4-Methoxybenzoic acid (22 mg, 0.14 mmol, 1.2 equiv) and 1-(2-(4-methoxyphenoxy)propyl)piperazine <b>114d</b> (29 mg, 0.12 mmol, 1.0 equiv) were reacted according to General Procedure E to afford the acylated piperazine product <b>47</b> as a yellow oil (30.3 mg, 0.0789 mmol, 68% yield). <i>R</i><sub><i>f</i></sub> = 0.41 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.28 (d, <i>J</i> = 6.1 Hz, 3H), 2.50 (dd, <i>J</i> = 4.5, 13.3 Hz, 1H), 2.53–2.63 (m, 4H), 2.71 (dd, <i>J</i> = 6.8, 13.3 Hz, 1H), 3.28–3.74 (m, 4H), 3.77 (s, 3H), 3.83 (s, 3H), 4.42 (td, <i>J</i> = 4.6, 6.5 Hz, 1H), 6.83 (qt, <i>J</i> = 2.8, 9.4 Hz, 4H), 6.88–6.92 (m, 2H), 7.34–7.39 (m, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 18.6, 55.3, 55.7, 63.5, 73.3, 113.7, 114.6, 117.6, 127.9, 129.1, 151.7, 154.1, 160.7, 170.2; FTIR (neat): 1625, 1606, 1503, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 385.2122; found 385.2121; HPLC purity = 98.4%.</div></div><div id="sec4_2_9_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> (4-(2-(4-Methoxyphenoxy)ethyl)-3-methylpiperazin-1-yl)(4-methoxyphenyl)methanone (<b>48</b>)</h5><div class="NLM_p last">(4-Methoxyphenyl)(3-methylpiperazin-1-yl)methanone (45.0 mg, 0.19 mmol) and 1-(2-bromoethoxy)-4-methoxybenzene (48.8 mg, 0.21 mmol, 1.1 equiv) were reacted according to General Procedure A and then purified by preparative, reverse-phase HPLC to afford the alkylated piperazine as a sticky, golden solid (20.1 mg, 0.052 mmol, 27% yield). <i>R</i><sub><i>f</i></sub> = 0.38 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.01–1.19 (m, 3H), 2.44–2.64 (m, 4H), 2.78 (dt, <i>J</i> = 5.8, 13.9 Hz, 1H), 2.90–3.02 (m, 2H), 3.10 (dt, <i>J</i> = 5.9, 12.7 Hz, 1H), 3.32 (ddd, <i>J</i> = 3.1, 9.9, 13.0 Hz, 1H), 3.76 (s, 3H), 3.83 (s, 3H), 4.03 (t, <i>J</i> = 5.9 Hz, 2H), 6.80–6.83 (m, 4H), 6.90 (d, <i>J</i> = 8.7 Hz, 2H), 7.37 (d, <i>J</i> = 8.7 Hz, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 52.4, 55.1, 55.3, 55.7, 66.4, 113.7, 114.6, 115.5, 127.8, 129.1, 152.8, 153.9, 160.7, 170.2; FTIR (neat): 1627, 1608, 1507, 1429 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 385.2122; found 385.2140; HPLC purity = 95.1%.</div></div><div id="sec4_2_9_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> (4-(2-(4-Methoxyphenoxy)ethyl)-2-methylpiperazin-1-yl)(4-methoxyphenyl)methanone (<b>49</b>)</h5><div class="NLM_p last">A mixture of 1-(2-bromoethoxy)-4-methoxybenzene (51.0 mg, 0.221 mmol, 1.1 equiv), (4-methoxyphenyl)(2-methylpiperazin-1-yl)methanone <b>111f</b> (47.0 mg, 0.201 mmol, 1.0 equiv), and potassium carbonate (56.0 mg, 0.405 mmol, 2.0 equiv) in DMF (1 mL) was heated at 100 °C for 5 h and cooled to rt. The reaction was diluted with water (10 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 × 2 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by silica gel chromatography to afford the aryl ether product as a light yellow oil (28.4 mg, 0.0741 mmol, 37% yield). <i>R</i><sub><i>f</i></sub> = 0.48 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 2.14–2.24 (m, 1H), 2.34 (dd, <i>J</i> = 3.8, 11.3 Hz, 1H), 2.67–2.84 (m, 3H), 2.90 (d, <i>J</i> = 11.3 Hz, 1H), 3.29 (t, <i>J</i> = 12.5 Hz, 1H), 3.77 (s, 3H), 3.83 (s, 3H), 3.93–4.15 (m, 3H), 4.24–4.60 (m, 1H), 6.80–6.87 (m, 4H), 6.88–6.94 (m, 2H), 7.31–7.38 (m, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 16.6, 54.1, 55.3, 55.7, 57.2, 58.1, 66.8, 113.7, 114.6, 115.6, 128.5, 128.7, 152.8, 153.9, 160.5, 170.3; FTIR (neat): 1624, 1607, 1506, 1421 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 385.2122; found 385.2121; HPLC purity = 99.7%.</div></div><div id="sec4_2_9_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> (4-(2-(4-Methoxyphenoxy)ethyl)piperidin-1-yl)(4-methoxyphenyl)methanone (<b>50</b>)</h5><div class="NLM_p last">A mixture of (4-(2-chloroethyl)piperidin-1-yl)(4-methoxyphenyl)methanone (64.9 mg, 0.230 mmol, 1.0 equiv), 4-methoxyphenol (32.0 mg, 0.258 mmol, 1.1 equiv), and potassium carbonate (57.0 mg, 0.412 mmol, 1.8 equiv) in DMF (1 mL) was heated at 55 °C for 19 h, followed by 80 °C for 45 h and then cooled to rt. The reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and washed with 1 M NaOH (3 × 2 mL) and water (4 × 2 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by silica gel chromatography to afford the aryl ether product as an off-white solid (12.2 mg, 0.033 mmol, 14% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.12–1.35 (br m, 3H), 1.74 (q, <i>J</i> = 6.3 Hz, 3H), 1.78–1.90 (m, 2H), 2.69–3.07 (br m, 2H), 3.77 (s, 3H), 3.83 (s, 3H), 3.97 (t, <i>J</i> = 6.2 Hz, 2H), 4.47–4.79 (m, 1H), 6.79–6.85 (m, 4H), 6.88–6.93 (m, 2H), 7.35–7.40 (m, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 33.2, 35.8, 55.3, 55.7, 65.8, 113.6, 114.7, 115.3, 128.4, 128.9, 153.0, 153.8, 160.6, 170.3; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>28</sub>NO<sub>4</sub> [M + H]<sup>+</sup> 370.2013; found 370.2004; HPLC purity = 98.1%.</div></div><div id="sec4_2_9_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 4-Methoxy-<i>N</i>-(2-((2-(4-methoxyphenoxy)ethyl)(methyl)amino)ethyl)-<i>N</i>-methylbenzamide (<b>51</b>)</h5><div class="NLM_p last"><i>N</i>-(2-((2-Chloroethyl)(methyl)amino)ethyl)-4-methoxy-<i>N</i>-methylbenzamide hydrochloride (70.7 mg, 0.220 mmol, 1.0 equiv), 4-methoxyphenol (38.0 mg, 0.306 mmol, 1.4 equiv), and potassium carbonate (101 mg, 0.731 mmol, 3.3 equiv) in DMF (1 mL) was heated at 50 °C for 7 h and cooled to rt. The reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and washed with water (4 × 2 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by silica gel chromatography to afford the aryl ether product as a colorless oil (56.5 mg, 0.161 mmol, 73% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.11–2.52 (br m, 3H), 2.58–2.92 (br m, 4H), 3.05 (s, 3H), 3.36–3.69 (br m, 2H), 3.77 (s, 3H), 3.81 (s, 3H), 3.97 (d, <i>J</i> = 17.9 Hz, 2H), 6.78–6.84 (m, 4H), 6.84–6.90 (m, 2H), 7.32–7.41 (m, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 43.0, 55.3, 55.7, 56.7, 66.8, 113.6, 114.6, 115.4, 128.8, 128.9, 152.9, 153.8, 160.4; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 373.2122; found 373.2132; HPLC purity = 97.9%.</div></div><div id="sec4_2_9_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> (4-(2-(3-Methoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methanone (<b>52</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid (19 mg, 0.12 mmol, 1.2 equiv) and 1-(2-(3-methoxyphenoxy)ethyl)piperazine (200 μL, 0.488 M, 0.0980 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a white solid (24.8 mg, 0.0653 mmol, 67% yield). <i>R</i><sub><i>f</i></sub> = 0.54 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 136–139 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.68 (t, <i>J</i> = 5.1 Hz, 4H), 2.86 (t, <i>J</i> = 5.5 Hz, 2H), 3.78 (s, 3H), 3.85–4.03 (m, 4H), 4.12 (t, <i>J</i> = 5.5 Hz, 2H), 6.43–6.55 (m, 3H), 6.68–6.74 (m, 1H), 7.09–7.22 (m, 2H), 7.98 (dd, <i>J</i> = 1.5, 7.9 Hz, 1H), 8.54 (dd, <i>J</i> = 1.5, 4.7 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 26.4, 26.5, 46.3, 46.3, 55.3, 57.1, 65.8, 101.1, 105.7, 106.58, 106.63, 119.1, 119.2, 128.8, 129.9, 131.7, 144.9, 145.3, 159.8, 160.9, 161.9; FTIR (neat): 1602, 1530, 1492 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1928; HPLC purity = 99.4%.</div></div><div id="sec4_2_9_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> (4-(2-(3-Methoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2-yl)methanone (<b>53</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine-2-carboxylic acid (18 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(3-methoxyphenoxy)ethyl)piperazine (200 μL, 0.488 M, 0.0980 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a sticky, off-white solid (22.9 mg, 0.0598 mmol, 61% yield); <i>R</i><sub><i>f</i></sub> = 0.11 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.70 (t, <i>J</i> = 5.1 Hz, 4H), 2.87 (t, <i>J</i> = 5.4 Hz, 2H), 3.78 (s, 3H), 3.85–4.06 (m, 4H), 4.12 (t, <i>J</i> = 5.4 Hz, 2H), 6.45–6.56 (m, 3H), 6.82–6.89 (m, 1H), 7.18 (t, <i>J</i> = 8.2 Hz, 1H), 7.31–7.37 (m, 1H), 8.36 (d, <i>J</i> = 5.9 Hz, 1H), 8.96–9.02 (m, 1H), 10.32 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 55.3, 57.0, 65.9, 101.2, 104.3, 106.5, 106.7, 106.9, 124.5, 129.9, 130.4, 139.2, 142.5, 145.4, 159.8, 160.9, 161.8; FTIR (neat): 1603, 1534, 1492, 1451, 1435 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1928; HPLC purity = 96.4%.</div></div><div id="sec4_2_9_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> (1<i>H</i>-Indol-2-yl)(4-(2-(3-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>54</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-methoxyphenol (19 μL, 0.17 mmol, 1.6 equiv) were reacted according to General Procedure G to afford the aryl ether product as a light yellow solid (24.1 mg, 0.0638 mmol, 60% yield). <i>R</i><sub><i>f</i></sub> = 0.59 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 99–102 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.64–2.71 (m, 4H), 2.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.79 (s, 3H), 3.88–4.04 (m, 4H), 4.13 (t, <i>J</i> = 5.5 Hz, 2H), 6.49 (t, <i>J</i> = 2.4 Hz, 1H), 6.50–6.54 (m, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.1 Hz, 1H), 7.14 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.19 (t, <i>J</i> = 8.2 Hz, 1H), 7.28 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.43 (dq, <i>J</i> = 0.9, 8.2 Hz, 1H), 7.65 (dq, <i>J</i> = 0.9, 8.1 Hz, 1H), 9.25 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.0, 53.6, 55.3, 57.1, 65.8, 101.1, 105.3, 106.5, 106.7, 111.7, 120.6, 121.9, 124.4, 127.5, 129.2, 129.9, 135.6, 159.9, 160.8, 162.2; FTIR (neat): 1592, 1526, 1491 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 380.1969; found 380.1980; HPLC purity = 99.2%.</div></div><div id="sec4_2_9_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> (5-Methoxy-1<i>H</i>-indol-2-yl)(4-(2-(3-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>55</b>)</h5><div class="NLM_p last">5-Methoxy-1H-indole-2-carboxylic acid (20 mg, 0.10 mmol, 1.0 equiv) and 1-(2-(3-methoxyphenoxy)ethyl)piperazine (200 μL, 0.488 M, 0.0980 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as an off-white solid (24.0 mg, 0.0588 mmol, 60% yield). <i>R</i><sub><i>f</i></sub> = 0.64 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 116–118 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.63–2.73 (m, 4H), 2.86 (t, <i>J</i> = 5.6 Hz, 2H), 3.79 (s, 3H), 3.85 (s, 3H), 3.90–4.02 (m, 4H), 4.13 (t, <i>J</i> = 5.5 Hz, 2H), 6.48 (t, <i>J</i> = 2.4 Hz, 1H), 6.50–6.55 (m, 2H), 6.70 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.96 (dd, <i>J</i> = 2.5, 8.9 Hz, 1H), 7.05 (d, <i>J</i> = 2.5 Hz, 1H), 7.19 (t, <i>J</i> = 8.2 Hz, 1H), 7.32 (dt, <i>J</i> = 0.8, 8.9 Hz, 1H), 9.21 (br s, 1H); 13C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6, 55.3, 55.7, 57.1, 65.8, 101.1, 102.2, 104.9, 106.5, 106.7, 112.6, 115.7, 127.8, 129.7, 129.9, 130.9, 154.6, 159.9, 160.8, 162.2; FTIR (neat): 1591, 1525, 1492 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 410.2074; found 410.2071; HPLC purity >99.5%.</div></div><div id="sec4_2_9_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> (1<i>H</i>-Benzo[<i>d</i>]imidazol-2-yl)(4-(2-(3-methoxyphenoxy)ethyl)piperazin-1-yl)methanone (<b>56</b>)</h5><div class="NLM_p last">1<i>H</i>-Benzo[<i>d</i>]imidazole-2-carboxylic acid (17 mg, 0.11 mmol, 1.1 equiv) and 1-(2-(3-methoxyphenoxy)ethyl)piperazine (200 μL, 0.488 M, 0.0980 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a white solid (22.7 mg, 0.0598 mmol, 61% yield). <i>R</i><sub><i>f</i></sub> = 0.38 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) mp = 50–65 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.75 (q, <i>J</i> = 4.6 Hz, 4H), 2.88 (t, <i>J</i> = 5.6 Hz, 2H), 3.79 (s, 3H), 3.96 (t, <i>J</i> = 5.1 Hz, 2H), 4.14 (t, <i>J</i> = 5.6 Hz, 2H), 4.82 (t, <i>J</i> = 5.1 Hz, 2H), 6.46–6.55 (m, 3H), 7.18 (t, <i>J</i> = 8.2 Hz, 1H), 7.27–7.39 (m, 2H), 7.52 (d, <i>J</i> = 7.6 Hz, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 11.53 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 43.1, 46.6, 53.3, 54.1, 55.2, 57.0, 65.7, 101.0, 106.4, 106.5, 111.6, 121.0, 123.0, 125.0, 129.8, 132.5, 143.1, 145.2, 158.2, 159.8, 160.7; FTIR (neat): 1604, 1588, 1491, 1447 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1924; HPLC purity = 99.4%.</div></div><div id="sec4_2_9_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> (4-Methoxy-2-methylphenyl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>57</b>)</h5><div class="NLM_p last">4-Methoxy-2-methyl-benzoic acid (26 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (545 μL, 0.235 M, 0.128 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a light yellow solid (29.5 mg, 0.083 mmol, 65% yield). <i>R</i><sub><i>f</i></sub> = 0.29 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 91–93 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.30 (s, 3H), 2.48 (t, <i>J</i> = 5.1 Hz, 2H), 2.65 (t, <i>J</i> = 5.2 Hz, 2H), 2.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.26–3.34 (m, 2H), 3.78–3.89 (m, 2H), 3.80 (s, 3H), 4.15 (t, <i>J</i> = 5.5 Hz, 2H), 6.71–6.75 (m, 2H), 7.08–7.13 (m, 1H), 7.17–7.24 (m, 2H), 8.23 (dd, <i>J</i> = 1.7, 4.3 Hz, 1H), 8.31–8.34 (m, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 19.4, 41.5, 46.9, 53.4, 54.1, 55.3, 57.0, 66.3, 111.2, 115.8, 121.2, 123.8, 127.4, 128.5, 136.3, 138.0, 142.4, 154.8, 159.8, 170.1; FTIR (neat): 1625, 1606, 1574, 1459 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 356.1969; found 356.1970; HPLC purity = 98.6%.</div></div><div id="sec4_2_9_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> (6-Methoxy-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>58</b>)</h5><div class="NLM_p last">6-Methoxy-1<i>H</i>-indole-2-carboxylic acid (26 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a white solid (42.2 mg, 0.111 mmol, 86% yield). <i>R</i><sub><i>f</i></sub> = 0.40 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 142–144 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.67 (t, <i>J</i> = 5.1 Hz, 4H), 2.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.83 (s, 3H), 3.88–4.04 (m, 4H), 4.17 (t, <i>J</i> = 5.5 Hz, 2H), 6.68–6.75 (m, 1H), 6.79 (dd, <i>J</i> = 1.4, 8.8 Hz, 1H), 6.83–6.88 (m, 1H), 7.17–7.24 (m, 2H), 7.49 (d, <i>J</i> = 8.7 Hz, 1H), 8.19–8.28 (m, 1H), 8.30–8.37 (m, 1H), 9.44 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 26.4, 26.5, 46.2, 46.3, 55.7, 57.1, 66.3, 93.7, 106.1, 111.9, 121.3, 121.8, 122.6, 123.9, 128.1, 136.6, 138.0, 142.4, 154.8, 158.3, 162.2; FTIR (neat): 1623, 1607, 1506 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1905; HPLC purity = 95%.</div></div><div id="sec4_2_9_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> (5-Methoxy-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>59</b>)</h5><div class="NLM_p last">5-Methoxy-1<i>H</i>-indole-2-carboxylic acid (26 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a pale yellow solid (36.6 mg, 0.0963 mmol, 75% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.67 (t, <i>J</i> = 5.1 Hz, 4H), 2.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.83 (s, 3H), 3.88–4.03 (m, 4H), 4.17 (t, <i>J</i> = 5.5 Hz, 2H), 6.67–6.72 (m, 1H), 6.94 (dd, <i>J</i> = 2.4, 8.9 Hz, 1H), 7.04 (d, <i>J</i> = 2.4 Hz, 1H), 7.19–7.23 (m, 2H), 7.31 (d, <i>J</i> = 8.9 Hz, 1H), 8.23 (dd, <i>J</i> = 2.2, 3.7 Hz, 1H), 8.30–8.37 (m, 1H), 9.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.7, 55.7, 57.1, 66.3, 102.3, 104.9, 112.7, 115.7, 121.3, 123.9, 127.8, 129.7, 131.1, 138.0, 142.4, 154.6, 154.9, 162.4; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 381.1921; found 381.1922; HPLC purity = 98.7%.</div></div><div id="sec4_2_9_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> (7-Methyl-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>60</b>)</h5><div class="NLM_p last">7-Methyl-1<i>H</i>-indole-2-carboxylic acid (24 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as an orange solid (33.5 mg, 0.0919 mmol, 71% yield). <i>R</i><sub><i>f</i></sub> = 0.26 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 49–60 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.49 (s, 3H), 2.67 (t, <i>J</i> = 4.8 Hz, 4H), 2.88 (t, <i>J</i> = 5.5 Hz, 2H), 3.83–4.06 (m, 4H), 4.18 (t, <i>J</i> = 5.5 Hz, 2H), 6.78 (d, <i>J</i> = 2.0 Hz, 1H), 6.99–7.10 (m, 2H), 7.18–7.24 (m, 2H), 7.44–7.51 (m, 1H), 8.24 (q, <i>J</i> = 2.5, 3.7 Hz, 1H), 8.29–8.36 (m, 1H), 9.24 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 16.7, 53.7, 57.1, 66.3, 105.8, 119.5, 120.9, 121.2, 121.4, 123.9, 124.7, 127.0, 128.9, 135.4, 138.0, 142.4, 154.9, 162.5; FTIR (neat): 1601, 1574, 1536, 1429 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 365.1972; found 365.1974; HPLC purity = 98.2%.</div></div><div id="sec4_2_9_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> (6-Methyl-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>61</b>)</h5><div class="NLM_p last">6-Methyl-1<i>H</i>-indole-2-carboxylic acid (24 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a white solid (31.8 mg, 0.0872 mmol, 68% yield). <i>R</i><sub><i>f</i></sub> = 0.29 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 163–166 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.47 (s, 3H), 2.62–2.72 (m, 4H), 2.89 (t, <i>J</i> = 5.5 Hz, 2H), 3.85–4.02 (m, 4H), 4.19 (t, <i>J</i> = 5.5 Hz, 2H), 6.74 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.86–7.01 (m, 1H), 7.19–7.24 (m, 3H), 7.46–7.64 (m, 1H), 8.23–8.25 (m, 1H), 8.33–8.35 (m, 1H), 9.07 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 21.9, 53.6, 57.1, 66.3, 105.3, 111.4, 121.3, 121.5, 122.7, 123.9, 125.3, 128.6, 134.6, 136.0, 138.0, 142.4, 154.8, 162.3; FTIR (neat): 1596, 1573, 1522, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 365.1972; found 365.1974; HPLC purity >99.5%.</div></div><div id="sec4_2_9_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> (5-Methyl-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>62</b>)</h5><div class="NLM_p last">5-Methyl-1<i>H</i>-indole-2-carboxylic acid (24 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as an off-white solid (38.2 mg, 0.105 mmol, 81% yield). <i>R</i><sub><i>f</i></sub> = 0.29 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 145–147 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.44 (s, 3H), 2.64–2.73 (m, 4H), 2.89 (t, <i>J</i> = 5.5 Hz, 2H), 3.82–4.02 (m, 4H), 4.19 (t, <i>J</i> = 5.5 Hz, 2H), 6.69 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 7.11 (dd, <i>J</i> = 1.6, 7.1 Hz, 1H), 7.21–7.24 (m, 2H), 7.29–7.33 (m, 1H), 7.40–7.42 (m, 1H), 8.22–8.26 (m, 1H), 8.33–8.35 (m, 1H), 9.14 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 21.5, 53.6, 57.0, 66.2, 104.8, 111.4, 121.2, 121.3, 123.9, 126.4, 127.7, 129.2, 129.9, 134.0, 138.0, 142.4, 154.8, 162.4; FTIR (neat): 1597, 1574, 1529, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 365.1972; found 365.1977; HPLC purity = 99.5%.</div></div><div id="sec4_2_9_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> (4-Methyl-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>63</b>)</h5><div class="NLM_p last">4-Methyl-1<i>H</i>-indole-2-carboxylic acid (24 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a tan solid (38.4 mg, 0.105 mmol, 82% yield). <i>R</i><sub><i>f</i></sub> = 0.28 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 52–58 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.55 (s, 3H), 2.68 (t, <i>J</i> = 5.3 Hz, 4H), 2.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.91–4.09 (m, 4H), 4.17 (t, <i>J</i> = 5.5 Hz, 2H), 6.77 (d, <i>J</i> = 1.4 Hz, 1H), 6.91 (d, <i>J</i> = 7.0 Hz, 1H), 7.13–7.22 (m, 3H), 7.24–7.29 (m, 1H), 8.21–8.26 (m, 1H), 8.32–8.37 (m, 1H), 9.99 (s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 18.7, 53.6, 57.0, 66.3, 103.7, 109.4, 120.5, 121.3, 123.9, 124.4, 127.5, 128.6, 131.3, 135.7, 138.0, 142.4, 154.8, 162.6; FTIR (neat): 1600, 1585, 1519, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 365.1972; found 365.1976; HPLC purity = 98.1%.</div></div><div id="sec4_2_9_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> (3-Methyl-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>64</b>)</h5><div class="NLM_p last">3-Methyl-1<i>H</i>-indole-2-carboxylic acid (24 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a golden oil (40.9 mg, 0.112 mmol, 87% yield). <i>R</i><sub><i>f</i></sub> = 0.17 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.37 (s, 3H), 2.57–2.69 (m, 4H), 2.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.69–3.81 (m, 4H), 4.15 (t, <i>J</i> = 5.5 Hz, 2H), 7.10–7.16 (m, 1H), 7.17–7.28 (m, 3H), 7.36 (d, <i>J</i> = 8.2 Hz, 1H), 7.59 (d, <i>J</i> = 7.9 Hz, 1H), 8.23 (dd, <i>J</i> = 1.8, 4.1 Hz, 1H), 8.32 (d, <i>J</i> = 2.5 Hz, 1H), 8.86 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 10.2, 53.8, 57.0, 66.2, 111.5, 112.1, 119.8, 119.8, 121.3, 123.9, 124.0, 127.0, 128.2, 135.9, 138.0, 142.4, 154.8, 164.7; FTIR (neat): 1607, 1574, 1472, 1450, 1424 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 365.1972; found 365.1973; HPLC purity = 98.1%.</div></div><div id="sec4_2_9_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> (1-Methyl-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>65</b>)</h5><div class="NLM_p last">1-Methyl-1<i>H</i>-indole-2-carboxylic acid (24 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a yellow oil (41.6 mg, 0.114 mmol, 88% yield). <i>R</i><sub><i>f</i></sub> = 0.34 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.54–2.72 (m, 4H), 2.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.77–3.82 (m, 4H), 3.83 (s, 3H), 4.16 (t, <i>J</i> = 5.5 Hz, 2H), 6.60 (d, <i>J</i> = 0.7 Hz, 1H), 7.10–7.17 (m, 1H), 7.20–7.22 (m, 1H), 7.24–7.39 (m, 3H), 7.62 (d, <i>J</i> = 7.9 Hz, 1H), 8.23 (dd, <i>J</i> = 2.1, 3.8 Hz, 1H), 8.28–8.35 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 26.4, 31.1, 46.3, 57.0, 66.3, 103.7, 109.8, 120.3, 121.4, 121.5, 123.4, 123.9, 126.4, 131.5, 137.9, 142.3, 154.8, 163.1; FTIR (neat): 1625, 1574, 1522, 1463, 1422 cm<sup>–1</sup> HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 365.1972; found 365.1972; HPLC purity = 98.7%.</div></div><div id="sec4_2_9_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> (1-Methyl-1<i>H</i>-indol-3-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>66</b>)</h5><div class="NLM_p last">1-Methyl-1<i>H</i>-indole-3-carboxylic acid (27 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (545 μL, 0.235 M, 0.128 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a golden oil (29.5 mg, 0.0803 mmol, 63% yield). <i>R</i><sub><i>f</i></sub> = 0.23 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.63 (t, <i>J</i> = 5.1 Hz, 4H), 2.87 (t, <i>J</i> = 5.6 Hz, 2H), 3.77 (t, <i>J</i> = 4.9 Hz, 4H), 3.82 (s, 3H), 4.17 (t, <i>J</i> = 5.6 Hz, 2H), 7.18–7.24 (m, 3H), 7.27–7.31 (m, 1H), 7.35 (dt, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.43 (s, 1H), 7.69 (dt, <i>J</i> = 1.0, 7.9 Hz, 1H), 8.23 (dd, <i>J</i> = 2.0, 4.0 Hz, 1H), 8.32 (dd, <i>J</i> = 1.1, 2.5 Hz, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 33.2, 41.0, 53.9, 57.1, 66.2, 109.8, 110.4, 120.5, 120.9, 121.2, 122.4, 123.8, 125.9, 131.7, 136.4, 138.0, 142.4, 154.8, 166.6; FTIR (neat): 1604, 1532, 1472, 1424 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 365.1972; found 365.1972; HPLC purity = 99.0%.</div></div><div id="sec4_2_9_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> (7-Chloro-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>67</b>)</h5><div class="NLM_p last">7-Chloro-1<i>H</i>-indole-2-carboxylic acid (27 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a golden oil (37.9 mg, 0.0978 mmol, 76% yield). <i>R</i><sub><i>f</i></sub> = 0.29 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.69 (t, <i>J</i> = 5.1 Hz, 4H), 2.89 (t, <i>J</i> = 5.5 Hz, 2H), 3.87–4.03 (m, 4H), 4.19 (t, <i>J</i> = 5.5 Hz, 2H), 6.80 (d, <i>J</i> = 2.2 Hz, 1H), 7.08 (t, <i>J</i> = 7.8 Hz, 1H), 7.20–7.24 (m, 2H), 7.28 (dd, <i>J</i> = 0.9, 7.6 Hz, 1H), 7.55 (dt, <i>J</i> = 0.9, 8.0 Hz, 1H), 8.24 (dd, <i>J</i> = 2.3, 3.7 Hz, 1H), 8.34 (dd, <i>J</i> = 1.3, 2.4 Hz, 1H), 9.24 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.0, 57.0, 66.3, 105.8, 117.2, 120.4, 121.3, 121.4, 123.6, 123.9, 128.7, 129.9, 133.0, 138.0, 142.4, 154.8, 161.7; FTIR (neat): 1614, 1574, 1532, 1430 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 386.1426; found 386.1431; HPLC purity = 98.7%.</div></div><div id="sec4_2_9_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> (6-Chloro-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>68</b>)</h5><div class="NLM_p last">6-Chloro-1<i>H</i>-indole-2-carboxylic acid (28 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as an off-white solid (39.1 mg, 0.101 mmol, 78% yield). <i>R</i><sub><i>f</i></sub> = 0.25 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 161–163 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.70 (t, <i>J</i> = 5.2 Hz, 4H), 2.89 (t, <i>J</i> = 5.5 Hz, 2H), 3.83–4.09 (m, 4H), 4.19 (t, <i>J</i> = 5.5 Hz, 2H), 6.75 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 7.10 (dd, <i>J</i> = 1.8, 8.5 Hz, 1H), 7.19–7.24 (m, 2H), 7.42 (dt, <i>J</i> = 0.8, 1.7 Hz, 1H), 7.55 (dt, <i>J</i> = 0.7, 8.5 Hz, 1H), 8.25 (dd, <i>J</i> = 2.3, 3.7 Hz, 1H), 8.34 (dd, <i>J</i> = 1.2, 2.5 Hz, 1H), 9.52 (br s, 1H).; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.0, 53.6, 57.0, 66.3, 105.3, 111.6, 121.3, 121.6, 122.8, 123.9, 126.0, 129.9, 130.3, 136.0, 138.0, 142.4, 154.8, 162.0; FTIR (neat): 1606, 1574, 1522, 1430 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 386.1426; found 386.1423; HPLC purity = 99.7%.</div></div><div id="sec4_2_9_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> (5-Chloro-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>69</b>)</h5><div class="NLM_p last">5-Chloro-1<i>H</i>-indole-2-carboxylic acid (25.2 mg, 0.129 mmol, 1.0 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E and purified by mass-directed, preparative HPLC to afford the acylated product as a white solid (33.6 mg, 0.087 mmol, 67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.69 (t, <i>J</i> = 5.1 Hz, 4H), 2.89 (t, <i>J</i> = 5.5 Hz, 2H), 3.89–4.04 (m, 4H), 4.19 (t, <i>J</i> = 5.5 Hz, 2H), 6.71 (dd, <i>J</i> = 0.8, 2.1 Hz, 1H), 7.21–7.24 (m, 3H), 7.35 (td, <i>J</i> = 0.6, 8.8 Hz, 1H),7.60–7.62 (m, 1H), 8.24–8.25 (m, 1H), 8.32–8.35 (m, 1H), 9.39 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6 (br, 2C), 57.0, 66.2, 104.6, 112.8, 121.0, 121.3, 123.9, 124.9, 126.1, 128.4, 130.4, 133.9, 138.0, 142.4, 154.8, 161.9; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.1426; found 385.1418; HPLC purity = 98.8%.</div></div><div id="sec4_2_9_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> (4-Chloro-1<i>H</i>-indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>70</b>)</h5><div class="NLM_p last">4-Chloro-1<i>H</i>-indole-2-carboxylic acid (27 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as an off-white solid (36.4 mg, 0.0939 mmol, 73% yield). <i>R</i><sub><i>f</i></sub> = 0.22 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 155–158 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.65–2.76 (m, 4H), 2.90 (t, <i>J</i> = 5.5 Hz, 2H), 3.81–4.10 (m, 4H), 4.19 (t, <i>J</i> = 5.5 Hz, 2H), 6.86 (dd, <i>J</i> = 0.9, 2.4 Hz, 1H), 7.11–7.25 (m, 4H), 7.33 (dt, <i>J</i> = 1.0, 8.0 Hz, 1H), 8.20–8.28 (m, 1H), 8.35 (dd, <i>J</i> = 1.3, 2.4 Hz, 1H), 9.61 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.0, 53.6, 57.0, 66.3, 103.6, 110.4, 120.2, 121.3, 123.9, 124.9, 126.4, 127.0, 129.7, 136.2, 138.0, 142.4, 154.8, 161.8; FTIR (neat): 1604, 1572, 1527, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 386.1426; found 386.1424; HPLC purity = 99.4%.</div></div><div id="sec4_2_9_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> (4-(2-(Pyridin-3-yloxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-2-yl)methanone (<b>71</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine-2-carboxylic acid (25 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a white solid (39.9 mg, 0.113 mmol, 88% yield). <i>R</i><sub><i>f</i></sub> = 0.13 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 133–135 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.70 (t, <i>J</i> = 5.1 Hz, 4H), 2.90 (t, <i>J</i> = 5.4 Hz, 2H), 3.85–4.08 (m, 4H), 4.19 (t, <i>J</i> = 5.5 Hz, 2H), 6.73 (d, <i>J</i> = 1.7 Hz, 1H), 7.14 (dd, <i>J</i> = 4.7, 7.9 Hz, 1H), 7.22 (dt, <i>J</i> = 1.5, 4.5 Hz, 2H), 7.99 (dd, <i>J</i> = 1.6, 7.9 Hz, 1H), 8.24 (dd, <i>J</i> = 2.0, 3.9 Hz, 1H), 8.34 (dd, <i>J</i> = 1.2, 2.5 Hz, 1H), 8.51 (dd, <i>J</i> = 1.6, 4.7 Hz, 1H), 10.81 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.0, 53.6, 57.0, 66.3, 103.4, 116.9, 119.8, 121.3, 123.9, 129.9, 130.4, 138.0, 142.4, 146.0, 147.7, 154.8, 162.0; FTIR (neat): 1618, 1575, 1521, 1430 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 352.1768; found 352.1769; HPLC purity >99.5%.</div></div><div id="sec4_2_9_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> (4-(2-(Pyridin-3-yloxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-2-yl)methanone (<b>72</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[2,3-<i>c</i>]pyridine-2-carboxylic acid (24 mg, 0.15 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a light yellow solid (35.7 mg, 0.101 mmol, 79% yield). <i>R</i><sub><i>f</i></sub> = 0.07 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 166–172 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.71 (t, <i>J</i> = 5.2 Hz, 4H), 2.90 (t, <i>J</i> = 5.4 Hz, 2H), 3.86–4.07 (m, 4H), 4.20 (t, <i>J</i> = 5.4 Hz, 2H), 6.87 (dd, <i>J</i> = 1.0, 1.9 Hz, 1H), 7.20–7.25 (m, 2H), 7.34 (dt, <i>J</i> = 1.1, 5.8 Hz, 1H), 8.24–8.26 (m, 1H), 8.35 (dd, <i>J</i> = 1.4, 2.3 Hz, 1H), 8.38 (d, <i>J</i> = 5.8 Hz, 1H), 8.96–9.01 (m, 1H), 9.75 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.0, 53.6, 57.0, 66.3, 104.3, 106.8, 121.3, 123.9, 124.6, 130.3, 138.0, 139.0, 142.5, 142.8, 145.5, 154.8, 161.6; FTIR (neat): 1611, 1573, 1534, 1428 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 352.1768; found 352.1766; HPLC purity >99.5%.</div></div><div id="sec4_2_9_73" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> (4-(2-(Pyridin-3-yloxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-2-yl)methanone (<b>73</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine-2-carboxylic acid (22 mg, 0.14 mmol, 1.0 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as an off-white solid (35.9 mg, 0.103 mmol, 80% yield). <i>R</i><sub><i>f</i></sub> = 0.07 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 163–170 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.71 (t, <i>J</i> = 5.1 Hz, 4H), 2.91 (t, <i>J</i> = 5.5 Hz, 2H), 3.80–4.13 (m, 4H), 4.20 (t, <i>J</i> = 5.5 Hz, 2H), 6.87 (d, <i>J</i> = 1.4 Hz, 1H), 7.20–7.26 (m, 2H), 7.34 (dt, <i>J</i> = 1.1, 5.9 Hz, 1H), 8.24 (dd, <i>J</i> = 1.2, 1.7 Hz, 1H), 8.35 (dd, <i>J</i> = 1.2, 2.5 Hz, 1H), 8.38 (d, <i>J</i> = 5.8 Hz, 1H), 8.99 (d, <i>J</i> = 1.1 Hz, 1H), 9.90 (s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.0, 53.6, 57.0, 66.3, 104.3, 106.8, 121.3, 123.9, 124.6, 130.3, 138.0, 139.0, 142.5, 142.8, 145.5, 154.8, 161.7; FTIR (neat): 1610, 1573, 1534, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 352.1768; found 352.1768; HPLC purity >99.5%.</div></div><div id="sec4_2_9_74" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> (4-(2-(Pyridin-3-yloxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-2-yl)methanone (<b>74</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrolo[3,2-<i>b</i>]pyridine-2-carboxylic acid (25 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a white solid (35.8 mg, 0.102 mmol, 79% yield). <i>R</i><sub><i>f</i></sub> = 0.11 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 173–177 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.71 (t, <i>J</i> = 5.1 Hz, 4H), 2.90 (t, <i>J</i> = 5.5 Hz, 2H), 3.76–4.13 (m, 4H), 4.19 (t, <i>J</i> = 5.5 Hz, 2H), 6.98 (dd, <i>J</i> = 0.9, 2.1 Hz, 1H), 7.18–7.25 (m, 3H), 7.74 (dt, <i>J</i> = 1.2, 8.2 Hz, 1H), 8.24 (dd, <i>J</i> = 1.9, 4.2 Hz, 1H), 8.35 (dd, <i>J</i> = 1.1, 2.5 Hz, 1H), 8.53 (dd, <i>J</i> = 1.4, 4.6 Hz, 1H), 9.72–9.82 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.5, 57.0, 66.2, 105.7, 119.1, 119.2, 121.3, 123.9, 128.8, 131.7, 137.9, 142.4, 145.0, 145.2, 154.8, 161.9; FTIR (neat): 1617, 1574, 1526, 1428 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 352.1768; found 352.1766; HPLC purity = 99.5%.</div></div><div id="sec4_2_9_75" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> (1<i>H</i>-Benzo[<i>d</i>]imidazol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>75</b>)</h5><div class="NLM_p last">1<i>H</i>-Benzo[<i>d</i>]imidazole-2-carboxylic acid (23 mg, 0.14 mmol, 1.1 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (200 μL, 0.645 M, 0.129 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as an off-white solid (34.2 mg, 0.0972 mmol, 75% yield). <i>R</i><sub><i>f</i></sub> = 0.14 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 163–164 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.75 (dt, <i>J</i> = 5.1, 10.1 Hz, 4H), 2.90 (t, <i>J</i> = 5.5 Hz, 2H), 3.93 (t, <i>J</i> = 5.1 Hz, 2H), 4.20 (t, <i>J</i> = 5.5 Hz, 2H), 4.82 (t, <i>J</i> = 5.1 Hz, 2H), 7.23 (dd, <i>J</i> = 1.5, 3.5 Hz, 2H), 7.29–7.40 (m, 2H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.82 (d, <i>J</i> = 8.0 Hz, 1H), 8.25 (dd, <i>J</i> = 2.5, 3.6 Hz, 1H), 8.35 (dd, <i>J</i> = 1.4, 2.3 Hz, 1H), 10.84 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 41.0, 43.2, 46.6, 53.4, 54.2, 57.0, 66.2, 111.7, 121.1, 121.3, 123.2, 123.9, 125.1, 132.5, 138.0, 142.4, 143.2, 145.3, 154.8, 158.2; FTIR (neat): 1618, 1574, 1489, 1428 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 352.1768; found 352.1764; HPLC purity = 99.6%.</div></div><div id="sec4_2_9_76" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> (1<i>H</i>-Indazol-3-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>76</b>)</h5><div class="NLM_p last">1<i>H</i>-Indazole-3-carboxylic acid (25 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (545 μL, 0.235 M, 0.128 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a tan solid (25.8 mg, 0.0739 mmol, 57% yield). <i>R</i><sub><i>f</i></sub> = 0.11 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). mp = 121–123 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.64–2.76 (m, 4H), 2.89 (t, <i>J</i> = 5.6 Hz, 2H), 3.86–4.15 (m, 4H), 4.19 (t, <i>J</i> = 5.6 Hz, 2H), 7.20–7.23 (m, 2H), 7.25 (dd, <i>J</i> = 1.1, 6.9 Hz, 1H), 7.39–7.44 (m, 1H), 7.49 (dt, <i>J</i> = 0.9, 8.5 Hz, 1H), 8.13 (dt, <i>J</i> = 1.0, 8.2 Hz, 1H), 8.24 (dd, <i>J</i> = 1.9, 4.1 Hz, 1H), 8.34 (dd, <i>J</i> = 1.2, 2.5 Hz, 1H), 10.86 (br s, 1H).; <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 42.4, 46.9, 53.5, 54.2, 57.0, 66.2, 109.7, 121.3, 122.2, 122.4, 123.4, 123.9, 127.3, 138.0, 140.0, 140.5, 142.3, 154.9, 162.7; FTIR (neat): 1613, 1574, 1486, 1429 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 352.1768; found 352.1768; HPLC purity = 97.5%.</div></div><div id="sec4_2_9_77" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> Benzofuran-2-yl(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>77</b>)</h5><div class="NLM_p last">Benzofuran-2-carboxylic acid (25 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (545 μL, 0.235 M, 0.128 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a sticky yellow solid (40.1 mg, 0.114 mmol, 89% yield). <i>R</i><sub><i>f</i></sub> = 0.27 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.63–2.70 (m, 4H), 2.86 (t, <i>J</i> = 5.5 Hz, 2H), 3.76–3.96 (m, 4H), 4.16 (t, <i>J</i> = 5.5 Hz, 2H), 7.18–7.21 (m, 2H), 7.24–7.28 (m, 1H), 7.34–7.41 (m, 1H), 7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.63 (d, <i>J</i> = 7.8 Hz, 1H), 8.17–8.24 (m, 1H), 8.31 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 26.3, 26.4, 46.2, 46.3, 57.0, 66.2, 111.8, 112.1, 121.3, 122.2, 123.6, 123.8, 126.5, 126.9, 138.0, 142.4, 148.9, 154.6, 154.8, 159.7; FTIR (neat): 1630, 1573, 1475, 1428 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 352.1656; found 352.1663; HPLC purity = 99.2%.</div></div><div id="sec4_2_9_78" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> Benzo[<i>b</i>]thiophen-2-yl(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>78</b>)</h5><div class="NLM_p last">Benzo[<i>b</i>]thiophene-2-carboxylic acid (27 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (545 μL, 0.235 M, 0.128 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as a light yellow oil (31.4 mg, 0.0855 mmol, 67% yield). <i>R</i><sub><i>f</i></sub> = 0.38 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.59–2.73 (m, 4H), 2.86 (t, <i>J</i> = 5.5 Hz, 2H), 3.75–3.86 (m, 4H), 4.15 (t, <i>J</i> = 5.5 Hz, 2H), 7.20 (d, <i>J</i> = 2.7 Hz, 2H), 7.34–7.41 (m, 2H), 7.45–7.49 (m, 1H), 7.76–7.87 (m, 2H), 8.18–8.26 (m, 1H), 8.27–8.36 (m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 46.26, 46.30, 53.6, 57.0, 66.3, 121.3, 122.4, 123.8, 124.6, 124.8, 125.2, 125.8, 136.5, 138.0, 138.6, 140.1, 142.4, 154.8, 163.8; FTIR (neat): 1617, 1573, 1521, 1421 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 368.1427; found 368.1427; HPLC purity = 99.0%.</div></div><div id="sec4_2_9_79" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> (4-(2-(Pyridin-3-yloxy)ethyl)piperazin-1-yl)(1<i>H</i>-pyrrol-2-yl)methanone (<b>79</b>)</h5><div class="NLM_p last">1<i>H</i>-Pyrrole-2-carboxylic acid (17 mg, 0.15 mmol, 1.2 equiv) and 1-(2-(pyridin-3-yloxy)ethyl)piperazine (545 μL, 0.235 M, 0.128 mmol) were reacted according to General Procedure E to afford the acylated piperazine product as an off-white solid (19.7 mg, 0.0646 mmol, 50% yield). <i>R</i><sub><i>f</i></sub> = 0.17 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 131–133 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.64 (t, <i>J</i> = 5.2 Hz, 4H), 2.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.80–3.97 (m, 4H), 4.18 (t, <i>J</i> = 5.6 Hz, 2H), 6.25 (dt, <i>J</i> = 2.7, 3.8 Hz, 1H), 6.52 (ddd, <i>J</i> = 1.3, 2.5, 3.8 Hz, 1H), 6.92 (td, <i>J</i> = 1.2, 2.7 Hz, 1H), 7.16–7.25 (m, 2H), 8.24 (dd, <i>J</i> = 2.1, 3.7 Hz, 1H), 8.34 (dd, <i>J</i> = 1.3, 2.3 Hz, 1H), 9.53 (br s, 1H);<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6, 57.1, 66.2, 109.6, 112.1, 120.9, 121.3, 123.8, 124.5, 138.0, 142.4, 154.8, 161.6; FTIR (neat): 1584, 1573, 1465, 1426 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>16</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 301.1659; found 301.1667; HPLC purity = 98.3%.</div></div><div id="sec4_2_9_80" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> (1<i>H</i>-Indol-2-yl)(4-(2-phenoxyethyl)piperazin-1-yl)methanone (<b>80</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (37.1 mg, 0.128 mmol) and phenol (19.3 mg, 0.205 mmol, 1.6 equiv) were reacted according to General Procedure F and purified by silica gel chromatography to afford the aryl ether product as a light yellow solid (26.3 mg, 0.075 mmol, 59% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.69 (t, <i>J</i> = 5.1 Hz, 4H), 2.88 (t, <i>J</i> = 5.6 Hz, 2H), 3.89–4.04 (m, 4H), 4.15 (t, <i>J</i> = 5.6 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.1 Hz, 1H), 6.90–6.98 (m, 3H), 7.12–7.15 (m, 1H), 7.25–7.32 (m, 3H), 7.43 (dd, <i>J</i> = 0.8, 8.3 Hz, 1H), 7.65 (dd, <i>J</i> = 0.9, 8.0 Hz, 1H), 9.22 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6 (br, 2C), 57.2, 65.8, 105.3, 111.7, 114.6, 120.6, 121.0, 121.8, 124.4, 127.4, 129.2, 129.5, 135.5, 158.6, 162.2; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 350.1863; found 350.1860; HPLC purity = 99.0%.</div></div><div id="sec4_2_9_81" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> (4-(2-(Benzo[<i>d</i>][1,3]dioxol-5-yloxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>81</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and benzo[<i>d</i>][1,3]dioxol-5-ol (25 mg, 0.18 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white solid (20.5 mg, 0.052 mmol, 49% yield). <i>R</i><sub><i>f</i></sub> = 0.34 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 142–146 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.56 (t, <i>J</i> = 5.0 Hz, 4H), 2.72 (t, <i>J</i> = 5.7 Hz, 2H), 3.69–3.83 (m, 4H), 4.03 (t, <i>J</i> = 5.7 Hz, 2H), 5.95 (s, 2H), 6.38 (dd, <i>J</i> = 2.5, 8.5 Hz, 1H), 6.65 (d, <i>J</i> = 2.5 Hz, 1H), 6.76–6.85 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.41 (dd, <i>J</i> = 0.9, 8.2 Hz, 1H), 7.60 (dd, <i>J</i> = 1.0, 8.0 Hz, 1H), 11.56 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.11, 53.13, 56.4, 66.1, 97.8, 100.9, 103.9, 105.7, 108.0, 112.0, 119.7, 121.3, 123.1, 126.7, 129.8, 135.8, 141.1, 147.9, 153.8, 161.9; FTIR 1600, 1527, 1487, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 394.1761; found 394.1782; HPLC purity = 99.4%.</div></div><div id="sec4_2_9_82" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> (1<i>H</i>-Indol-2-yl)(4-(2-((4-methoxyphenyl)thio)ethyl)piperazin-1-yl)methanone (<b>82</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-methoxybenzenethiol (21 μL, 0.17 mmol, 1.6 equiv) were reacted according to General Procedure G to afford the aryl thioether product as a tan solid (19.3 mg, 0.0487 mmol, 46% yield). <i>R</i><sub><i>f</i></sub> = 0.39 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 114–122 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.46 (t, <i>J</i> = 5.1 Hz, 4H), 2.51–2.56 (m, 2H), 2.96–3.03 (m, 2H), 3.62–3.81 (m, 7H), 6.76 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.88–6.94 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.30–7.37 (m, 2H), 7.41 (dq, <i>J</i> = 1.0, 8.3 Hz, 1H), 7.59 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 11.55 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 30.3, 51.4, 54.0, 55.9, 102.8, 110.9, 113.6, 118.6, 120.1, 122.0, 124.8, 125.6, 128.7, 130.8, 134.7, 157.1, 160.7; FTIR (neat) 1595, 1526, 1492, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 396.1740; found 396.1739; HPLC purity >99.5%.</div></div><div id="sec4_2_9_83" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> (1<i>H</i>-Indol-2-yl)(4-(2-(4-(methylthio)phenoxy)ethyl)piperazin-1-yl)methanone (<b>83</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-(methylthio)phenol (24 mg, 0.17 mmol, 1.6 equiv) were reacted according to General Procedure G to afford the aryl ether product as a tan residue (10.3 mg, 0.0265 mmol, 25% yield). <i>R</i><sub><i>f</i></sub> = 0.38 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.40–2.42 (s, 3H), 2.57 (t, <i>J</i> = 5.1 Hz, 4H), 2.75 (t, <i>J</i> = 5.7 Hz, 2H), 3.72–3.82 (m, 4H), 4.09 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J J</i> = 0.9, 2.2 Hz, 1H), 6.92–6.96 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 7.9 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 6.9, 8.2 Hz, 1H), 7.22–7.25 (m, 2H), 7.41 (dq, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 11.57 (br s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 16.5, 53.1, 56.4, 65.5, 103.9, 112.0, 115.3, 119.7, 121.3, 123.1, 126.7, 128.3, 129.0, 129.8, 135.8, 156.7, 161.9; FTIR (neat) 3247, 1598, 1574, 1525, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 396.1740; found 396.1754; HPLC purity = 98%.</div></div><div id="sec4_2_9_84" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> (4-(2-(4-Ethoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>84</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-ethoxyphenol (25 mg, 0.18 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white residue (18.6 mg, 0.0477 mmol, 45% yield). <i>R</i><sub><i>f</i></sub> = 0.35 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.29 (t, <i>J</i> = 7.0 Hz, 3H), 2.56 (t, <i>J</i> = 5.1 Hz, 4H), 2.73 (t, <i>J</i> = 5.7 Hz, 2H), 3.67–3.82 (m, 4H), 3.94 (q, <i>J</i> = 7.0 Hz, 2H), 4.04 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.80–6.90 (m, 4H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.41 (dq, <i>J</i> = 1.0, 8.3 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 11.56 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.6, 53.1, 56.4, 63.2, 65.7, 103.8, 111.9, 115.1, 115.2, 119.6, 121.2, 123.1, 126.7, 129.8, 135.8, 152.2, 152.5, 161.8; FTIR (neat) 1598, 1526, 1506, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.2125; found 394.2139; HPLC purity >99.5%.</div></div><div id="sec4_2_9_85" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> (1<i>H</i>-Indol-2-yl)(4-(2-(4-(trifluoromethoxy)phenoxy)ethyl)piperazin-1-yl)methanone (<b>85</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-(trifluoromethoxy)phenol (30.3 mg, 0.170 mmol, 1.6 equiv) were reacted according to General Procedure G to afford the aryl ether product as an off-white solid (27.7 mg, 0.0647 mmol, 61% yield). <i>R</i><sub><i>f</i></sub> = 0.35 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 147–150 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 2.65–2.70 (m, 4H), 2.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.85–4.02 (m, 4H), 4.13 (t, <i>J</i> = 5.5 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.88–6.93 (m, 2H), 7.12–7.17 (m, 3H), 7.29 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.43 (dq, <i>J</i> = 0.9, 8.2 Hz, 1H), 7.65 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 9.23 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.6, 57.0, 66.4, 105.3, 111.7, 115.3, 117.5, 119.5, 120.6, 121.6, 121.9, 122.5, 123.6, 124.5, 127.5, 129.2, 135.6, 142.9 (q, <i>J</i> = 1.6, 2.5 Hz), 157.1, 162.2; FTIR (neat) 1598, 1526, 1506, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 434.1686; found 434.1685; HPLC purity >99.5%.</div></div><div id="sec4_2_9_86" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> (1<i>H</i>-Indol-2-yl)(4-(2-(p-tolyloxy)ethyl)piperazin-1-yl)methanone (<b>86</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-methylphenol (18.6 mg, 0.172 mmol, 1.6 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white solid (19.3 mg, 0.0535 mmol, 50% yield). <i>R</i><sub><i>f</i></sub> = 0.36 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 151–153 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.29 (s, 3H), 2.65–2.71 (m, 4H), 2.86 (t, <i>J</i> = 5.6 Hz, 2H), 3.85–4.04 (m, 4H), 4.12 (t, <i>J</i> = 5.6 Hz, 2H), 6.78 (dd, <i>J</i> = 1.0, 2.2 Hz, 1H), 6.79–6.84 (m, 2H), 7.06–7.11 (m, 2H), 7.14 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.26–7.31 (m, 1H), 7.42 (dq, <i>J</i> = 0.9, 8.2 Hz, 1H), 7.65 (dq, <i>J</i> = 1.0, 8.0 Hz, 1H), 9.20 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 20.5, 41.0, 53.6, 57.2, 65.9, 105.3, 111.7, 114.4, 120.6, 121.9, 124.4, 127.5, 129.2, 129.9, 130.2, 135.5, 156.5, 162.2; FTIR (neat) 1599, 1527, 1510, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 364.2020; found 364.2038; HPLC purity = 99.5%.</div></div><div id="sec4_2_9_87" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> (4-(2-(4-Ethylphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>87</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-ethylphenol (22 mg, 0.18 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white solid (20.1 mg, 0.0535 mmol, 50% yield). <i>R</i><sub><i>f</i></sub> = 0.32 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 135–138 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.14 (t, <i>J</i> = 7.6 Hz, 3H), 2.52–2.59 (m, 6H), 2.75 (t, <i>J</i> = 5.7 Hz, 2H), 3.70–3.82 (m, 4H), 4.07 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.84–6.88 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 7.9 Hz, 1H), 7.07–7.13 (m, 2H), 7.18 (ddd, <i>J</i> = 1.2, 6.9, 8.2 Hz, 1H), 7.42 (dq, <i>J</i> = 0.9, 8.3 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 7.8 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.9, 27.2, 53.1, 56.5, 65.3, 103.9, 112.0, 114.3, 119.7, 121.3, 123.1, 126.7, 128.6, 129.8, 135.7, 135.8, 156.4, 161.9; FTIR (neat) 1598, 1526, 1510, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 378.2176; found 378.2183; HPLC purity = 99.6%.</div></div><div id="sec4_2_9_88" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> (4-(2-(4-(<i>tert</i>-Butyl)phenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>88</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-(<i>tert</i>-butyl)phenol (27 mg, 0.18 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white solid (18.2 mg, 0.0477 mmol, 45% yield). <i>R</i><sub><i>f</i></sub> = 0.34 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 171–175 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.25 (s, 9H), 2.57 (t, <i>J</i> = 5.1 Hz, 4H), 2.75 (t, <i>J</i> = 5.7 Hz, 2H), 3.70–3.83 (m, 4H), 4.08 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.84–6.90 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 7.0, 8.3 Hz, 1H), 7.25–7.30 (m, 2H), 7.41 (dq, <i>J</i> = 0.9, 8.3 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 8.1 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 31.2, 33.6, 53.0, 56.4, 65.2, 103.8, 111.9, 113.8, 119.6, 121.2, 123.1, 125.9, 126.7, 129.8, 135.8, 142.6, 156.0, 161.8; FTIR (neat) 1599, 1512, 1459, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 406.2489; found 406.2488; HPLC purity = 99.6%.</div></div><div id="sec4_2_9_89" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> (4-(2-(4-Fluorophenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>89</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-fluorophenol (22 mg, 0.19 mmol, 1.8 equiv) were reacted according to General Procedure G to afford the aryl ether product as an off-white solid (24.3 mg, 0.0668 mmol, 63% yield). <i>R</i><sub><i>f</i></sub> = 0.44 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 162–164 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.57 (t, <i>J</i> = 5.1 Hz, 4H), 2.75 (t, <i>J</i> = 5.7 Hz, 2H), 3.72–3.80 (m, 4H), 4.09 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.95–6.99 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.09–7.13 (m, 2H), 7.18 (ddd, <i>J</i> = 1.2, 6.9, 8.2 Hz, 1H), 7.42 (dq, <i>J</i> = 0.9, 8.3 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 11.58 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 52.8, 56.4, 65.9, 103.9, 112.0, 115.7 (d, <i>J</i> = 7.3 Hz), 115.9, 119.7, 121.3, 123.1, 126.7, 129.8, 135.8, 154.7 (d, <i>J</i> = 1.6 Hz), 161.9; FTIR (neat): 1596, 1527, 1504, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 368.1769; found 368.1780; HPLC purity = 99.7%.</div></div><div id="sec4_2_9_90" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> (4-(2-(4-Chlorophenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>90</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-chlorophenol (25 mg, 0.19 mmol, 1.8 equiv) were reacted according to General Procedure G to afford the aryl ether product as a light yellow solid (24.1 mg, 0.0625 mmol, 59% yield). <i>R</i><sub><i>f</i></sub> = 0.43 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 170–173 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.56 (t, <i>J</i> = 5.1 Hz, 4H), 2.75 (t, <i>J</i> = 5.6 Hz, 2H), 3.64–3.86 (m, 4H), 4.11 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.96–7.01 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 7.0, 8.3 Hz, 1H), 7.30–7.34 (m, 2H), 7.41 (dq, <i>J</i> = 0.9, 8.2 Hz, 1H), 7.60 (dq, <i>J</i> = 1.0, 8.0 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.0, 56.2, 65.6, 103.8, 111.9, 116.2, 119.6, 121.2, 123.1, 124.1, 126.6, 129.1, 129.7, 135.8, 157.2, 161.8; FTIR (neat) 1596, 1526, 1490, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>23</sub>ClN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 384.1473; found 384.1474; HPLC purity = 99.7%.</div></div><div id="sec4_2_9_91" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> (4-(2-(4-Bromophenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>91</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-bromophenol (31 mg, 0.18 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as a light yellow solid (27.4 mg, 0.0646 mmol, 61% yield). <i>R</i><sub><i>f</i></sub> = 0.41 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 165–168 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.56 (q, <i>J</i> = 5.2 Hz, 4H), 2.75 (t, <i>J</i> = 5.7 Hz, 2H), 3.68–3.82 (m, 4H), 4.10 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.92–6.96 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 7.9 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 6.9, 8.2 Hz, 1H), 7.40–7.46 (m, 3H), 7.60 (dq, <i>J</i> = 0.9, 8.1 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.1, 56.3, 65.7, 103.9, 111.9, 112.0, 116.8, 119.7, 121.3, 123.1, 126.7, 129.8, 132.1, 135.8.; FTIR (neat) 1597, 1526, 1487, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>23</sub>BrN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 429.0968; found 430.0954; HPLC purity = 99.6%.</div></div><div id="sec4_2_9_92" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> (1<i>H</i>-Indol-2-yl)(4-(2-(4-nitrophenoxy)ethyl)piperazin-1-yl)methanone (<b>92</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-nitrophenol (25 mg, 0.18 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as an off-white solid (5.3 mg, 0.0138 mmol, 13% yield). <i>R</i><sub><i>f</i></sub> = 0.40 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 188–204 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.55–2.60 (m, 4H), 2.81 (t, <i>J</i> = 5.6 Hz, 2H), 3.68–3.82 (m, 4H), 4.28 (t, <i>J</i> = 5.6 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 7.9 Hz, 1H), 7.16–7.21 (m, 3H), 7.42 (dq, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 8.19–8.24 (m, 2H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.0, 56.1, 66.4, 103.9, 112.0, 115.1, 119.7, 121.3, 123.2, 125.9, 126.7, 129.8, 135.8, 140.8, 161.9, 163.8; FTIR (neat) 1592, 1509, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 395.1714; found 395.1712; HPLC purity >99.5%.</div></div><div id="sec4_2_9_93" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> (4-(2-(3,4-Dimethoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>93</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 3,4-dimethoxyphenol (28 mg, 0.18 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as a colorless, sticky solid (25.5 mg, 0.0625 mmol, 59% yield). <i>R</i><sub><i>f</i></sub> = 0.36 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.63–2.73 (m, 4H), 2.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.84 (s, 3H), 3.85 (s, 3H), 3.92–4.05 (m, 4H), 4.09 (t, <i>J</i> = 5.5 Hz, 2H), 6.40 (td, <i>J</i> = 2.8, 7.2, 8.0 Hz, 1H), 6.54 (d, <i>J</i> = 2.8 Hz, 1H), 6.75–6.81 (m, 2H), 7.13 (t, <i>J</i> = 7.5 Hz, 1H), 7.27 (t, <i>J</i> = 7.6 Hz, 1H), 7.43 (d, <i>J</i> = 8.3 Hz, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 9.59 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 53.6, 55.9, 56.40, 56.44, 57.2, 66.3, 69.4, 101.0, 101.4, 103.7, 104.4, 105.2, 111.7, 111.8, 120.5, 121.8, 124.3, 127.4, 129.2, 143.7, 149.9, 153.2; FTIR (neat) 1596, 1510, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 410.2074; found 410.2088; HPLC purity >99.5%.</div></div><div id="sec4_2_9_94" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> (4-(2-(3,4-Dimethylphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>94</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 3,4-dimethylphenol (24 mg, 0.20 mmol, 1.9 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white solid (20.7 mg, 0.0548 mmol, 52% yield). <i>R</i><sub><i>f</i></sub> = 0.42 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 129–137 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.13 (s, 3H), 2.18 (s, 3H), 2.56 (t, <i>J</i> = 5.0 Hz, 4H), 2.73 (t, <i>J</i> = 5.7 Hz, 2H), 3.65–3.85 (m, 4H), 4.05 (t, <i>J</i> = 5.7 Hz, 2H), 6.66 (dd, <i>J</i> = 2.7, 8.3 Hz, 1H), 6.74–6.81 (m, 2H), 6.98–7.09 (m, 2H), 7.18 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.41 (dd, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.56–7.70 (m, 1H), 11.56 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 18.4, 19.6, 53.1, 56.5, 65.2, 103.9, 111.4, 112.0, 115.8, 119.7, 121.3, 123.1, 126.7, 127.9, 129.8, 130.1, 135.8, 137.2, 156.5, 161.9; FTIR (neat) 1600, 1526, 1502, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 378.2176; found 378.2181; HPLC purity = 99.2%.</div></div><div id="sec4_2_9_95" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> (4-(2-(3-Chloro-4-methylphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>95</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 3-chloro-4-methylphenol (25 mg, 0.17 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white solid (25.0 mg, 0.0636 mmol, 60% yield). <i>R</i><sub><i>f</i></sub> = 0.53 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 156–158 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.24 (s, 3H), 2.26 (t, <i>J</i> = 5.1 Hz, 4H), 2.74 (t, <i>J</i> = 5.6 Hz, 2H), 3.68–3.83 (m, 4H), 4.10 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.86 (dd, <i>J</i> = 2.6, 8.4 Hz, 1H), 7.02–7.06 (m, 2H), 7.18 (ddd, <i>J</i> = 1.2, 6.9, 8.2 Hz, 1H), 7.24 (dd, <i>J</i> = 0.8, 8.4 Hz, 1H), 7.41 (dq, <i>J</i> = 0.9, 8.2 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 18.6, 53.1, 56.3, 65.8, 103.9, 112.0, 113.8, 114.7, 119.7, 121.3, 123.1, 126.7, 127.0, 129.8, 131.6, 133.5, 135.8, 157.3, 161.9; FTIR (neat) 1599, 1526, 1495, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 398.1630; found 398.1640; HPLC purity = 99.3%.</div></div><div id="sec4_2_9_96" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> (4-(2-(4-Chloro-3-methylphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>96</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 4-chloro-3-methylphenol (26 mg, 0.18 mmol, 1.7 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white solid (25.1 mg, 0.0636 mmol, 60% yield). <i>R</i><sub><i>f</i></sub> = 0.49 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 146–148 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.29 (s, 3H), 2.56 (t, <i>J</i> = 5.1 Hz, 4H), 2.75 (t, <i>J</i> = 5.7 Hz, 2H), 3.68–3.83 (m, 4H), 4.09 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.79–6.83 (m, 1H), 6.98 (dd, <i>J</i> = 0.8, 3.1 Hz, 1H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.1, 6.9, 8.2 Hz, 1H), 7.29 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (dq, <i>J</i> = 1.0, 8.4 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 19.7, 53.1, 56.3, 65.6, 103.9, 112.0, 113.6, 117.2, 119.7, 121.3, 123.1, 124.5, 126.7, 129.4, 129.8, 135.8, 136.4, 157.2, 161.9; FTIR (neat) 1597, 1526, 1480, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 398.1630; found 398.1630; HPLC purity >99.5%.</div></div><div id="sec4_2_9_97" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> (4-(2-(2-Chloro-4-methoxyphenoxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>97</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 2-chloro-4-methoxyphenol (30 mg, 0.19 mmol, 1.8 equiv) were reacted according to General Procedure G to afford the aryl ether product as a white solid (26.6 mg, 0.0647 mmol, 61% yield). <i>R</i><sub><i>f</i></sub> = 0.46 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 157–159 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.60 (t, <i>J</i> = 5.1 Hz, 4H), 2.78 (t, <i>J</i> = 5.7 Hz, 2H), 3.72 (s, 3H) 3.73–3.82 (m, 4H), 4.13 (t, <i>J</i> = 5.7 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.87 (dd, <i>J</i> = 3.0, 9.0 Hz, 1H), 7.01–7.07 (m, 2H), 7.12 (d, <i>J</i> = 9.1 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.41 (dq, <i>J</i> = 0.9, 8.3 Hz, 1H), 7.60 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 11.56 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 52.8, 55.7, 56.3, 67.5, 103.9, 112.0, 113.4, 115.3, 115.5, 119.7, 121.3, 122.0, 123.1, 126.7, 129.8, 135.8, 148.0, 153.5, 161.9; FTIR (neat) 1596, 1526, 1496, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 414.1579; found 414.1594; HPLC purity = 99.5%.</div></div><div id="sec4_2_9_98" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> (1<i>H</i>-Indol-2-yl)(4-(2-(pyridin-2-yloxy)ethyl)piperazin-1-yl)methanone (<b>98</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and pyridine-2-ol (16 mg, 0.17 mmol, 1.6 equiv) were reacted according to General Procedure G to afford the pyridyl ether product as a light yellow, sticky solid (21.4 mg, 0.0615 mmol, 58% yield). <i>R</i><sub><i>f</i></sub> = 0.27 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.49–2.54 (m, 4H), 2.61 (t, <i>J</i> = 6.4 Hz, 2H), 3.68–3.78 (m, 4H), 4.01 (t, <i>J</i> = 6.4 Hz, 2H), 6.21 (td, <i>J</i> = 1.4, 6.6 Hz, 1H), 6.37 (ddd, <i>J</i> = 0.6, 1.4, 9.1 Hz, 1H), 6.77 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 7.04 (ddd, <i>J</i> = 1.1, 6.9, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 6.9, 8.2 Hz, 1H), 7.37–7.43 (m, 2H), 7.59 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 7.67 (ddd, <i>J</i> = 0.7, 2.1, 6.8 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 45.5, 52.8, 55.9, 103.9, 104.8, 112.0, 119.3, 119.7, 121.3, 123.2, 126.7, 129.8, 135.8, 139.7, 139.9, 161.4, 161.9; FTIR (neat) 1652, 1572, 1538, 1435 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 351.1816; found 351.1844; HPLC purity = 99.4%.</div></div><div id="sec4_2_9_99" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> (1<i>H</i>-Indol-2-yl)(4-(2-(pyridin-3-yloxy)ethyl)piperazin-1-yl)methanone (<b>99</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and pyridine-2-ol (19 mg, 0.20 mmol, 1.9 equiv) were reacted according to General Procedure G to afford the pyridyl ether product as a tan solid (18.1 mg, 0.0517 mmol, 49% yield). <i>R</i><sub><i>f</i></sub> = 0.50 (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 129–132 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.58 (t, <i>J</i> = 5.1 Hz, 5H), 2.78 (t, <i>J</i> = 5.6 Hz, 2H), 3.69–3.85 (m, 4H), 4.19 (t, <i>J</i> = 5.6 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 7.9 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 6.9, 8.2 Hz, 1H), 7.33 (ddd, <i>J</i> = 0.7, 4.6, 8.4 Hz, 1H), 7.41 (dd, <i>J</i> = 1.2, 2.8 Hz, 1H), 7.43 (dd, <i>J</i> = 1.2, 2.9 Hz, 1H), 7.60 (dd, <i>J</i> = 1.0, 8.0 Hz, 1H), 8.17 (dd, <i>J</i> = 1.3, 4.6 Hz, 1H), 8.31 (dd, <i>J</i> = 0.7, 3.0 Hz, 1H), 11.58 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.1, 56.3, 65.6, 103.9, 112.0, 119.7, 121.0, 121.3, 123.1, 124.1, 126.7, 129.8, 135.8, 137.8, 141.7, 154.7, 161.9; FTIR (neat) 1598, 1574, 1525, 1427 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 351.1816; found 351.1815; HPLC purity >99.5%.</div></div><div id="sec4_2_9_100" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> (1<i>H</i>-Indol-2-yl)(4-(2-(pyridin-4-yloxy)ethyl)piperazin-1-yl)methanone (<b>100</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and pyridin-4-ol (19 mg, 0.20 mmol, 1.9 equiv) were reacted according to General Procedure G to afford the pyridyl ether product as an off-white residue (9.0 mg, 0.025 mmol, 24% yield). <i>R</i><sub><i>f</i></sub> = 0.29 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.57 (t, <i>J</i> = 5.1 Hz, 4H), 2.78 (t, <i>J</i> = 5.6 Hz, 2H), 3.67–3.85 (m, 4H), 4.20 (t, <i>J</i> = 5.6 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.96–7.01 (m, 2H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 6.9, 8.2 Hz, 1H), 7.41 (dq, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.58–7.62 (m, 1H), 8.34–8.41 (m, 2H), 11.56 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.0, 56.1, 65.3, 103.9, 110.4, 112.0, 119.7, 121.3, 123.1, 126.7, 129.8, 135.8, 150.9, 161.9, 164.2; FTIR (neat) 1638, 1608, 1549, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 351.1816; found 351.1808; HPLC purity >99.5%.</div></div><div id="sec4_2_9_101" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> (4-(2-((5-Chloropyridin-3-yl)oxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>101</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.9 mg, 0.106 mmol) and 5-chloropyridin-3-ol (26 mg, 0.20 mmol, 1.9 equiv) were reacted according to General Procedure G to afford the pyridyl ether product as a white solid (23.1 mg, 0.0604 mmol, 57% yield). <i>R</i><sub><i>f</i></sub> = 0.38 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 184–186 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.57 (t, <i>J</i> = 5.0 Hz, 4H), 2.78 (t, <i>J</i> = 5.6 Hz, 2H), 3.68–3.83 (m, 4H), 4.24 (t, <i>J</i> = 5.6 Hz, 2H), 6.78 (dd, <i>J</i> = 0.9, 2.3 Hz, 1H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 8.0 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.1, 6.9, 8.2 Hz, 1H), 7.42 (dq, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.59–7.62 (m, 1H), 7.64–7.67 (m, 1H), 8.22 (d, <i>J</i> = 1.9 Hz, 1H), 8.29 (d, <i>J</i> = 2.5 Hz, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 51.9, 55.0, 65.1, 102.8, 110.9, 118.6, 119.9, 120.2, 122.0, 125.6, 128.7, 130.0, 134.7, 135.7, 138.8, 154.1, 160.7; FTIR (neat) 1611, 1576, 1535, 1429 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.1426; found 385.1422; HPLC purity >99.5%.</div></div><div id="sec4_2_9_102" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> (1<i>H</i>-Indol-2-yl)(4-(2-(4-methoxyphenoxy)propyl)piperazin-1-yl)methanone (<b>102</b>)</h5><div class="NLM_p last">1<i>H</i>-Indole-2-carboxylic acid (24 mg, 0.15 mmol, 1.3 equiv) and 1-(2-(4-methoxyphenoxy)propyl)piperazine <b>114d</b> (29 mg, 0.11 mmol, 1.0 equiv) were reacted according to General Procedure E to afford the aryl ether product as an off-white solid (27.1 mg, 0.0684 mmol, 59% yield). <i>R</i><sub><i>f</i></sub> = 0.54 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 136–138 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.30 (d, <i>J</i> = 6.1 Hz, 3H), 2.53 (dd, <i>J</i> = 4.4, 13.3 Hz, 1H), 2.65 (tq, <i>J</i> = 5.6, 6.3, 11.5 Hz, 4H), 2.74 (dd, <i>J</i> = 6.9, 13.3 Hz, 1H), 3.77 (s, 3H), 3.86–3.98 (m, 4H), 4.45 (pd, <i>J</i> = 4.3, 6.2 Hz, 1H), 6.76 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.81–6.90 (m, 4H), 7.13 (ddd, <i>J</i> = 0.9, 6.9, 7.9 Hz, 1H), 7.26–7.30 (m, 1H), 7.42 (dq, <i>J</i> = 0.9, 8.4 Hz, 1H), 7.64 (dq, <i>J</i> = 0.9, 8.1 Hz, 1H), 9.23 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 18.6, 29.7, 53.8, 55.7, 63.5, 73.4, 105.2, 111.7, 114.7, 117.6, 120.6, 121.8, 124.4, 127.5, 129.3, 135.5, 151.8, 154.1, 162.2; FTIR (neat) 1597, 1526, 1504, 1438 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.2125; found 394.2124; HPLC purity >99.5%.</div></div><div id="sec4_2_9_103" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> (4-(2-(4-Chlorophenoxy)propyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>103</b>)</h5><div class="NLM_p last">1<i>H</i>-Indole-2-carboxylic acid (22.0 mg, 0.137 mmol, 1.2 equiv) and 1-(2-(4-chlorophenoxy)propyl)piperazine <b>114e</b> (29.0 mg, 0.116 mmol, 1.0 equiv) were reacted according to General Procedure E to afford the acylated product <b>103</b> as a white solid (22.3 mg, 0.0558 mmol, 49% yield). <i>R</i><sub><i>f</i></sub> = 0.46 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 149–151 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.32 (d, <i>J</i> = 6.2 Hz, 3H), 2.55 (dd, <i>J</i> = 4.4, 13.4 Hz, 1H), 2.64 (tq, <i>J</i> = 5.6, 6.4, 11.5 Hz, 4H), 2.74 (dd, <i>J</i> = 6.8, 13.4 Hz, 1H), 3.82–4.01 (m, 4H), 4.53 (pd, <i>J</i> = 4.3, 6.2 Hz, 1H), 6.76 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 6.83–6.87 (m, 2H), 7.13 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.21–7.25 (m, 2H), 7.26–7.30 (m, 1H), 7.42 (dq, <i>J</i> = 0.9, 8.3 Hz, 1H), 7.64 (dq, <i>J</i> = 0.9, 8.0 Hz, 1H), 9.26 (br s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 18.4, 29.7, 53.8, 63.3, 72.8, 105.2, 111.7, 117.3, 120.6, 121.8, 124.4, 125.7, 127.4, 129.2, 129.4, 135.5, 156.4, 162.2; FTIR (neat) 1595, 1526, 1487, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 398.1630; found 398.1633; HPLC purity = 99.7%.</div></div><div id="sec4_2_9_104" class="NLM_sec NLM_sec_level_4"><div id="ac_i142" class="anchor-spacer"></div><h5 class="article-section__title" id="_i142"> (1<i>H</i>-Indol-2-yl)(4-(2-((4-methoxyphenyl)(methyl)amino)ethyl)piperazin-1-yl)methanone (<b>104</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone in DMF (200 μL, 0.528 M, 0.106 mmol) and 4-methoxy-<i>N</i>-methylaniline (24 mg, 0.18 mmol, 1.6 equiv) were reacted according to General Procedure G to afford the tertiary aniline product as a white solid (1.9 mg, 0.0048 mmol, 5% yield). HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 393.2285; found 393.2283; HPLC purity >99.5%.</div></div><div id="sec4_2_9_105" class="NLM_sec NLM_sec_level_4"><div id="ac_i143" class="anchor-spacer"></div><h5 class="article-section__title" id="_i143"> (4-(2-((1<i>H</i>-Indol-5-yl)oxy)ethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>105</b>)</h5><div class="NLM_p last">(4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (30.8 mg, 0.106 mmol) and 5-hydroxyindole (22.6 mg, 0.170 mmol, 1.6 equiv) were reacted according to General Procedure F and purified by mass-directed, preparative HPLC to afford the aryl ether product as a colorless oil (9.8 mg, 0.025 mmol, 24% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.59 (t, <i>J</i> = 5.1 Hz, 4H), 2.77 (t, <i>J</i> = 5.8 Hz, 2H), 3.70–3.85 (m, 4H), 4.10 (t, <i>J</i> = 5.7 Hz, 2H), 6.31–6.33 (m, 1H), 6.74 (dd, <i>J</i> = 2.4, 8.7 Hz, 1H), 6.79 (dd, <i>J</i> = 0.8, 2.2 Hz, 1H), 7.03–7.07 (m, 2H), 7.16–7.20 (m, 1H), 7.26–7.28 (m, 2H), 7.41 (dd, <i>J</i> = 0.9, 8.3 Hz, 1H), 7.61 (dd, <i>J</i> = 0.6, 8.0 Hz, 1H), 10.90 (br s, 1H), 11.57 (br s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 53.17, 53.19, 56.7, 65.9, 100.8, 102.8, 103.9, 111.6, 111.9, 112.0, 119.7, 121.3, 123.1, 125.7, 126.7, 127.9, 129.8, 131.0, 135.8, 152.2, 161.9; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 389.1972; found 389.1971; HPLC purity = 96.8%.</div></div><div id="sec4_2_9_106" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> (1<i>H</i>-Indol-2-yl)(4-(3-(4-methoxyphenoxy)propyl)piperazin-1-yl)methanone (<b>106</b>)</h5><div class="NLM_p last">(1<i>H</i>-Indol-2-yl)(piperazin-1-yl)methanone (43 mg, 0.19 mmol) and 1-(3-bromopropoxy)-4-methoxybenzene (55 mg, 0.23 mmol, 1.2 equiv) were reacted according to General Procedure A to afford the alkylated piperazine as a tan solid (61 mg, 0.16 mmol, 83% yield). <i>R</i><sub><i>f</i></sub> = 0.36 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 122–127 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.95–2.02 (m, 2H), 2.53–2.61 (complex, 6H), 3.77 (s, 3H), 3.94–4.09 (complex, 6H), 6.78 (d, <i>J</i> = 1.9 Hz, 1H), 6.83–6.88 (complex, 4H), 7.13 (t, <i>J</i> = 7.5 Hz, 1H), 7.25–7.29 (m, 1H), 7.45 (d, <i>J</i> = 8.3 Hz, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 10.02 (br s, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 55.7, 105.2, 111.9, 114.7, 115.5, 120.4, 121.7, 124.2; u 26.8, 53.19, 53.23, 55.0, 66.6, 127.4, 129.3, 135.9, 153.1, 153.8, 162.5; FTIR (neat) 1595, 1526, 1505, 1436 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.2125; found 394.2117; HPLC purity = 97.2%.</div></div><div id="sec4_2_9_107" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> (1<i>H</i>-Indol-2-yl)(4-(4-(4-methoxyphenoxy)butyl)piperazin-1-yl)methanone (<b>107</b>)</h5><div class="NLM_p last">(1<i>H</i>-Indol-2-yl)(piperazin-1-yl)methanone (38 mg, 0.17 mmol) and 1-(4-bromobutoxy)-4-methoxybenzene (52 mg, 0.20 mmol, 1.2 equiv) were reacted according to General Procedure A to afford the alkylated piperazine as a tan solid (51 mg, 0.13 mmol, 76% yield). <i>R</i><sub><i>f</i></sub> = 0.36 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 111–113 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.64–1.72 (m, 2H), 1.77–1.84 (m, 2H), 2.44 (t, <i>J</i> = 7.4 Hz, 2H), 2.53 (t, <i>J</i> = 5.0 Hz, 4H), 3.75 (s, 3H), 3.91–3.99 (complex, 6H), 6.75–6.77 (m, 1H), 6.80–6.85 (m, 1H), 7.09–7.13 (m, 1H), 7.23–7.27 (m, 1H), 7.42 (dd, <i>J</i> = 0.7, 8.3 Hz, 1H), 7.63 (dd, <i>J</i> = 0.6, 7.4 Hz, 1H), 9.92 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 23.3, 27.3, 53.2 (br, 2 C), 55.7, 58.1, 68.2, 105.2, 111.9, 114.6, 115.4, 120.4, 121.7, 124.2, 127.4, 129.3, 135.8, 153.1, 153.7, 162.5; FTIR (neat) 1593, 1506, 1463, 1437 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 408.2282; found 408.2265; HPLC purity = 98.1%.</div></div><div id="sec4_2_9_108" class="NLM_sec NLM_sec_level_4"><div id="ac_i146" class="anchor-spacer"></div><h5 class="article-section__title" id="_i146"> (1<i>H</i>-Indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperidin-1-yl)methanone (<b>108</b>)</h5><div class="NLM_p last">To a mixture of 2-(1-(1<i>H</i>-indole-2-carbonyl)piperidin-4-yl)ethyl 4-methylbenzenesulfonate <b>122</b> (82 mg, 0.19 mmol) and potassium carbonate (80 mg, 0.58 mmol, 3.0 equiv) in MeCN (3 mL) was added 4-methoxyphenol (72 mg, 0.58 mmol, 3 equiv) in THF (5 mL), and the reaction was stirred at 60 °C for 17 h. After cooling to rt, the reaction was filtered and the solids washed with CH<sub>2</sub>Cl<sub>2</sub> (2 × 5 mL). The combined filtrates were evaporated, and the residue was purified by silica gel chromatography to afford the aryl ether product <b>108</b> as an off-white solid (51 mg, 0.14 mmol, 70% yield). <i>R</i><sub><i>f</i></sub> = 0.58 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); mp = 176–179 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.29–1.41 (m, 2H), 1.74–1.80 (m, 2H), 1.87–1.95 (complex, 3H), 2.97–3.17 (br m, 2H), 3.78 (s, 3H), 4.00 (t, <i>J</i> = 6.2 Hz, 2H), 4.70–4.4.76 (m, 2H), 6.77–6.79 (m, 1H), 6.84–6.85 (m, 4H), 7.11–7.15 (m, 1H), 7.25–7.30 (m, 1H), 7.43 (dd, <i>J</i> = 0.7, 8.3 Hz, 1H), 7.65 (dd, <i>J</i> = 0.6, 8.0 Hz, 1H), 9.35 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 32.4 (br, 2 C), 33.2, 35.8, 55.7, 65.8, 104.9, 111.7, 114.7, 115.4, 120.5, 121.8, 124.2, 127.5, 129.6, 135.6, 153.0, 153.8, 162.2; FTIR (neat) 1596, 1534, 1505, 1440 cm<sup>–1</sup>; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>27</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 379.2016; found 379.2020; HPLC purity = 97.8%.</div></div><div id="sec4_2_9_109" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147"> 1-(1<i>H</i>-Indol-2-yl)-2-(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)ethan-1-one (<b>109</b>)</h5><div class="NLM_p last">1-(2-(4-Methoxyphenoxy)ethyl)piperazine (60 mg, 0.25 mmol), 2-chloro-1-(1<i>H</i>-indol-2-yl)ethan-1-one (49 mg, 0.25 mmol, 1.0 equiv), potassium carbonate (140 mg, 1.02 mmol, 4.0 equiv), and potassium iodide (42 mg, 0.25 mmol, 1.0 equiv) were charged in a reaction vial, slurried with MeCN (4 mL), and stirred at 65 °C for 18 h. The reaction was filtered and the solids washed with CH<sub>2</sub>Cl<sub>2</sub> (2 × 5 mL). The combined filtrates were evaporated, and the residue was purified by silica gel chromatography to afford the aryl ether product as a tan residue (51 mg, 0.13 mmol, 51% yield). <i>R</i><sub><i>f</i></sub> = 0.30 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.64–2.75 (complex, 8H), 2.82 (t, <i>J</i> = 5.8 Hz, 2H), 3.75–3.77 (complex, 5H), 4.06 (t, <i>J</i> = 5.8 Hz, 2H), 6.79–6.85 (complex, 4H), 7.12–7.17 (m, 1H), 7.32–7.38 (m, 2H), 7.43 (d, <i>J</i> = 8.3 Hz, 1H), 7.71 (d, <i>J</i> = 8.1 Hz, 1H), 9.78 (br s, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 55.7, 109.4, 112.3, 114.6, 115.6, 121.0, 123.1, 126.4; u 53.4, 53.6, 57.3, 64.8, 66.5, 127.4, 134.4, 137.1, 152.9, 153.9, 189.6; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 394.2125; found 394.2132; HPLC purity = 96.9%.</div></div><div id="sec4_2_9_110" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> (4-Methoxyphenyl)(piperazin-1-yl)methanone (<b>111a</b>)</h5><div class="NLM_p last">This material was purchased from Oakwood Chemical.</div></div><div id="sec4_2_9_111" class="NLM_sec NLM_sec_level_4"><div id="ac_i149" class="anchor-spacer"></div><h5 class="article-section__title" id="_i149"> (2-Methoxyphenyl)(piperazin-1-yl)methanone (<b>111b</b>)</h5><div class="NLM_p last">This material was purchased from 1Click Chemistry Inc.</div></div><div id="sec4_2_9_112" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> (3-Methoxyphenyl)(piperazin-1-yl)methanone (<b>111c</b>)</h5><div class="NLM_p last">This material was purchased from Combi-Blocks Inc.</div></div><div id="sec4_2_9_113" class="NLM_sec NLM_sec_level_4"><div id="ac_i151" class="anchor-spacer"></div><h5 class="article-section__title" id="_i151"> (4-Chlorophenyl)(piperazin-1-yl)methanone (<b>111d</b>)</h5><div class="NLM_p last">This material was synthesized according to the protocol of Wang and co-workers.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Thus, a solution of piperazine (1.26 g, 14.6 mmol) in THF (100 ml) was cooled in an rt water bath, and butyllithium (13.8 ml, 30.7 mmol) was added. The reaction was stirred at rt for 30 min, and 4-chlorobenzoyl chloride (1.9 ml, 14.6 mmol) was added as a solution in THF (10 mL). The reaction was stirred for 10 additional min and quenched with MeOH (10 mL). All solvents were removed in vacuo, and the residue was partitioned between saturated aqueous NaHCO<sub>3</sub> (50 mL) and EtOAc (25 mL). The aqueous layer was extracted with EtOAc (2 × 25 mL), and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated in vacuo, and purified by silica chromatography to afford the previously reported acylated product.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> (818 mg, 2.72 mmol, 68% yield). <sup>1</sup>H NMR (400 MHz, MeOD-<i>d</i><sub>4</sub>) δ 2.68–2.96 (m, 4H), 3.34–3.78 (m, 4H), 7.36–7.44 (m, 2H), 7.44–7.51 (m, 2H); <sup>13</sup>C NMR (101 MHz, MeOD-<i>d</i><sub>4</sub>) δ 42.1, 45.6, 128.4, 128.5, 134.0, 135.6, 169.9.</div></div><div id="sec4_2_9_114" class="NLM_sec NLM_sec_level_4"><div id="ac_i152" class="anchor-spacer"></div><h5 class="article-section__title" id="_i152"> (4-Ethylphenyl)(piperazin-1-yl)methanone (<b>111e</b>)</h5><div class="NLM_p">To a solution of <i>tert</i>-butyl piperazine-1-carboxylate (1.44 g, 7.73 mmol) and triethylamine (2.69 mL, 19.33 mmol, 2.5 equiv) in THF (120 mL) at 0 °C was added 4-ethylbenzoyl chloride (1.25 mL, 8.50 mmol, 1.1 equiv). The reaction was stirred overnight (19 h), slowly warming to rt. The reaction was quenched with saturated aqueous NaHCO<sub>3</sub>, and the aqueous layer was extracted with EtOAc (2 × 30 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), evaporated, and purified by silica chromatography to afford the acylated product, <i>tert</i>-butyl 4-(4-ethylbenzoyl)piperazine-1-carboxylate, as a white solid (2.14 g, 6.72 mmol, 87% yield) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.23 (t, <i>J</i> = 7.6 Hz, 3H), 1.45 (s, 9H), 2.66 (q, <i>J</i> = 7.6 Hz, 2H), 3.31–3.74 (m, 8H), 7.19–7.27 (m, 2H), 7.31 (d, <i>J</i> = 8.1 Hz, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 15.2, 15.4, 28.4, 28.7, 29.0, 80.3, 127.2, 127.8, 128.0, 130.2, 132.7, 146.4, 154.6, 170.9.</div><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(4-ethylbenzoyl)piperazine-1-carboxylate (1.90 g, 5.97 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (60 mL) was added trifluoroacetic acid (9.19 mL, 119 mmol, 20 equiv). The reaction was stirred at rt for 4 h and concentrated under vacuum. The residue was partitioned between aqueous saturated sodium bicarbonate (100 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 30 mL). The combined organic layers were concentrated under vacuum to afford the piperazine product <b>111e</b> as a white solid (1.87 g, 5.63 mmol, 94% yield). <sup>1</sup>H NMR (400 MHz, MeOD-<i>d</i><sub>4</sub>) δ 1.24 (t, <i>J</i> = 7.6 Hz, 3H), 2.68 (q, <i>J</i> = 7.6 Hz, 2H), 2.72–2.94 (m, 4H), 3.35–3.78 (m, 4H), 7.25–7.35 (m, 4H); <sup>13</sup>C NMR (101 MHz, MeOD-<i>d</i><sub>4</sub>) δ 14.5, 28.3, 42.3, 45.4, 126.8, 127.7, 132.6, 146.5, 171.3.</div></div><div id="sec4_2_9_115" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153"> (4-Methoxyphenyl)(2-methylpiperazin-1-yl)methanone (<b>111f</b>)</h5><div class="NLM_p last">To a solution of 2-methylpiperazine (0.99 g, 9.88 mmol) in THF (100 mL) was added butyllithium (2.22 M in hexanes, 9.35 mL, 20.76 mmol, 2.1 equiv), and the reaction was stirred at rt for 30 min. This preformed anion solution was cooled to 0 °C, and a solution of 4-methoxybenzoyl chloride (1.68 g, 9.88 mmol, 1.0 equiv) in THF (10 mL) was added. After stirring at 0 °C for 10 min, the reaction was quenched by the addition of MeOH (10 mL), and the solvents were removed in vacuo. The residue was partitioned between saturated aqueous NaHCO<sub>3</sub> (50 mL) and EtOAc (3 × 25 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated in vacuo, and purified on C18-functionalized silica gel chromatography to afford the acylated product <b>111f</b> as a tan solid (427.9 mg, 1.83 mmol, 18% yield).</div></div><div id="sec4_2_9_116" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> (4-Methoxyphenyl)(2-methylpiperazin-1-yl)methanone (<b>111g</b>)</h5><div class="NLM_p">To a solution of <i>tert</i>-butyl 3-methylpiperazine-1-carboxylate (1.20 g, 6.01 mmol) and triethylamine (1.0 mL, 7.17 mmol, 1.2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (25 mL) was added 4-methoxybenzoyl chloride (1.12 g, 6.54 mmol, 1.1 equiv). The reaction was stirred at rt for 4 h and quenched with aqueous citric acid (1 M, 15 mL). The organic layer was washed with water (5 mL) and then aqueous NaOH (1 M, 5 mL) and dried with MgSO<sub>4</sub>. The solvent was removed in vacuo, and the residue was purified by silica chromatography to afford the acylated product, <i>tert</i>-butyl 4-(4-methoxybenzoyl)-3-methylpiperazine-1-carboxylate, as a colorless oil (1.98 g, 5.92 mmol, 98% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.25 (d, <i>J</i> = 6.7 Hz, 3H), 1.47 (s, 9H), 2.69–3.27 (complex, 5H), 3.84 (s, 3H), 3.96–4.15 (m, 2H), 6.92 (d, <i>J</i> = 8.8 Hz, 2H), 7.35 (d, <i>J</i> = 8.8 Hz, 2H).</div><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(4-methoxybenzoyl)-3-methylpiperazine-1-carboxylate (1.98 g, 5.91 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added trifluoroacetic acid (10 mL, 129 mmol, 22 equiv). The reaction was stirred at rt for 5 h and concentrated under vacuum. The residue was partitioned between aqueous sodium hydroxide (1 M, 50 mL) and CH<sub>2</sub>Cl<sub>2</sub> (4 × 10 mL). The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum, and purified by silica chromatography to afford the piperazine product <b>111g</b> as a viscous, tan oil (1.30 g, 5.56 mmol, 94% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.36 (d, <i>J</i> = 6.9 Hz, 3H), 2.76 (dt, <i>J</i> = 3.5, 12.3 Hz, 1H), 2.82–2.87 (m, 1H), 2.97 (dd, <i>J</i> = 4.0, 12.4 Hz, 1H), 3.00–3.05 (m, 1H), 3.16–3.27 (m, 1H), 3.83 (s, 3H), 3.91–4.05 (m, 1H), 4.34–4.48 (m, 1H), 6.88–6.96 (m, 2H), 7.32–7.38 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.5, 40.7, 46.1, 47.6, 50.2, 55.4, 113.8, 128.3, 128.6, 160.6, 170.6.</div></div><div id="sec4_2_9_117" class="NLM_sec NLM_sec_level_4"><div id="ac_i155" class="anchor-spacer"></div><h5 class="article-section__title" id="_i155"> (1<i>H</i>-Indol-2-yl)(piperazin-1-yl)methanone (<b>111h</b>)</h5><div class="NLM_p">1<i>H</i>-Indole-2-carboxylic acid (1.55 g, 9.62 mmol) and HATU (4.39 g, 11.55 mmol, 1.2 equiv) were dissolved in EtOAc (80 mL) and stirred at rt for 10 min followed by the addition of a <i>tert</i>-butyl piperazine-1-carboxylate (1.79 g, 9.62 mmol, 1.0 equiv) solution in THF (80 mL). After stirring at rt for an additional 10 min, Et<sub>3</sub>N (4.0 mL, 28.87 mmol, 3.0 equiv) was added, and the reaction was stirred at rt for 43 h. The solvents were removed in vacuo, and the residue was washed with water (4 × 50 mL). The crude solid product was further purified by silica chromatography to afford the amide piperazine product, <i>tert</i>-butyl 4-(1<i>H</i>-indole-2-carbonyl)piperazine-1-carboxylate, as a white solid (2.65 g, 9.62 mmol, 84% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.49 (s, 9H), 3.56 (dd, <i>J</i> = 4.2, 6.4 Hz, 4H), 3.91 (s, 4H), 6.76–6.81 (m, 1H), 7.14 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.25–7.34 (m, 1H), 7.43 (dd, <i>J</i> = 1.0, 8.4 Hz, 1H), 7.62–7.69 (m, 1H), 9.29 (br s, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 28.4, 105.4, 111.7, 120.7, 121.9, 124.6; u 37.2, 41.9, 80.4, 127.4, 128.9, 135.6, 154.6, 162.6.</div><div class="NLM_p last">A solution of <i>tert</i>-butyl 4-(1<i>H</i>-indole-2-carbonyl)piperazine-1-carboxylate (1.66 g, 5.03 mmol) in hexafluoroisopropanol (15 mL) was heated under microwave irradiation at 145 °C for 2.5 h and cooled to rt. The solvent was removed in vacuo, and the residue was recrystallized from methyl <i>tert</i>-butyl ether to afford the free base piperazine product <b>111h</b> as a white solid (998 mg, 4.35 mmol, 87% yield). Mp 185–187 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.49 (s, 9H), 3.56 (dd, <i>J</i> = 4.2, 6.4 Hz, 4H), 3.91 (s, 4H), 6.76–6.81 (m, 1H), 7.14 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.25–7.34 (m, 1H), 7.43 (dd, <i>J</i> = 1.0, 8.4 Hz, 1H), 7.62–7.69 (m, 1H), 9.29 (br s, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 105.1, 111.7, 120.2, 121.5, 124.0; u 45.5 (2C), 127.0, 128.7, 136.0, 163.1.</div></div><div id="sec4_2_9_118" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156"> 1-(2-Bromoethoxy)-4-methoxybenzene (<b>112a</b>)</h5><div class="NLM_p last">This material was synthesized as previously described.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div></div><div id="sec4_2_9_119" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157"> 1-(2-Bromoethoxy)-2-methoxybenzene (<b>112b</b>)</h5><div class="NLM_p last">2-Methoxyphenol (2.84 g, 22.88 mmol) was reacted according to General Procedure H to afford bromide as a white solid (2.0 g, 8.65 mmol, 38% yield). <i>R</i><sub><i>f</i></sub> = 0.70 (25% EtOAc in hexanes); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.62 (t, <i>J</i> = 6.6 Hz, 2H), 3.87 (s, 3H), 4.33 (t, <i>J</i> = 6.9 Hz, 2H), 6.88–7.03 (complex, 4H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 56.0, 112.3, 115.0, 120.9, 122.4; u 28.9, 69.3, 147.5, 149.9. These data are in agreement with those previously reported.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div></div><div id="sec4_2_9_120" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> 1-(2-Bromoethoxy)-3-methoxybenzene (<b>112c</b>)</h5><div class="NLM_p last">3-Methoxyphenol (2.05 g, 16.51 mmol) was reacted according to General Procedure H to afford bromide as a colorless oil (1.90 g, 8.22 mmol, 50% yield). <i>R</i><sub><i>f</i></sub> = 0.71 (25% EtOAc in hexanes); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.62 (t, <i>J</i> = 6.3 Hz, 2H), 3.78 (s, 3H), 4.26 (t, <i>J</i> = 6.3 Hz, 2H), 6.47–6.55 (complex, 3H), 7.16–7.21 (m, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 55.3, 101.3, 106.7, 107.1, 130.0; u 29.2, 67.9, 159.3, 160.9; IR (thin film): 1589, 1491, 1450 cm<sup>–1</sup>.</div></div><div id="sec4_2_9_121" class="NLM_sec NLM_sec_level_4"><div id="ac_i159" class="anchor-spacer"></div><h5 class="article-section__title" id="_i159"> 1-(2-Bromoethoxy)-4-ethylbenzene (<b>112d</b>)</h5><div class="NLM_p last">4-Ethylphenol (3.55 g, 29.10 mmol) was reacted according to General Procedure H to afford bromide as a dark golden oil (2.10 g, 9.17 mmol, 31% yield). <i>R</i><sub><i>f</i></sub> = 0.79 (25% EtOAc in hexanes); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.19 (t, <i>J</i> = 7.6 Hz, 3H), 2.57 (q, <i>J</i> = 7.6 Hz, 2H), 3.56 (t, <i>J</i> = 6.3 Hz, 2H), 4.20 (t, <i>J</i> = 6.3 Hz, 2H), 6.78–6.86 (m, 2H), 7.07–7.10 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 16.0, 114.8, 128.9; u 28.1, 29.4, 68.1, 137.3, 156.2. These data are in agreement with those previously reported.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div></div><div id="sec4_2_9_122" class="NLM_sec NLM_sec_level_4"><div id="ac_i160" class="anchor-spacer"></div><h5 class="article-section__title" id="_i160"> 1-(2-Bromoethoxy)-4-chlorobenzene (<b>112e</b>)</h5><div class="NLM_p last">4-Chlorophenol (3.18 g, 24.74 mmol) was reacted according to General Procedure H to afford bromide as a white solid (2.80 g, 11.89 mmol, 48% yield). <i>R</i><sub><i>f</i></sub> = 0.73 (25% EtOAc in hexanes); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.61 (t, <i>J</i> = 6.2 Hz, 2H), 4.23 (t, <i>J</i> = 6.2 Hz, 2H), 6.80–6.87 (m, 2H), 7.21–7.25 (m, 2H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 116.1, 129.5; u 29.0, 68.2, 126.4, 156.7; IR (neat): 1594, 1581, 1488, 1457 cm<sup>–1</sup>. These data are in agreement with those previously reported.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div></div><div id="sec4_2_9_123" class="NLM_sec NLM_sec_level_4"><div id="ac_i161" class="anchor-spacer"></div><h5 class="article-section__title" id="_i161"> 1-(2-Bromoethoxy)-3,5-dimethoxybenzene (<b>112f</b>)</h5><div class="NLM_p last">3,5-Dimethoxyphenol (3.02 g, 19.6 mmol) was reacted according to General Procedure H to afford bromide as a colorless oil (2.70 g, 10.3 mmol, 53% yield). R<sub><i>f</i></sub> = 0.43 (25% EtOAc in hexanes); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 3.61 (t, <i>J</i> = 6.2 Hz, 2H), 3.76 (s, 6H), 4.24 (t, <i>J</i> = 6.2 Hz, 2H), 6.08 (d, <i>J</i> = 2.1 Hz, 2H), 6.10–6.12 (m, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 55.4, 93.61, 93.62; u 29.1, 67.9, 160.0, 161.6; IR (thin film): 1590, 1474, 1456 cm<sup>–1</sup>. These data are in agreement with those previously reported.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div></div><div id="sec4_2_9_124" class="NLM_sec NLM_sec_level_4"><div id="ac_i162" class="anchor-spacer"></div><h5 class="article-section__title" id="_i162"> 5-(2-Bromoethoxy)benzo[<i>d</i>][1,3]dioxole (<b>112g</b>)</h5><div class="NLM_p last">3,4-(Methylenedioxy)phenol (2.31 g, 16.72 mmol) was reacted according to General Procedure H to afford bromide as a faintly purple solid (2.70 g, 11.0 mmol, 66% yield). R<sub><i>f</i></sub> = 0.55 (25% EtOAc in hexanes); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.50 (t, <i>J</i> = 6.3 Hz, 2H), 4.11 (t, <i>J</i> = 6.2 Hz, 2H), 5.82 (s, 2H), 6.24 (dd, <i>J</i> = 2.5, 8.4 Hz, 1H), 6.42 (d, <i>J</i> = 2.5 Hz, 1H), 6.61 (d, <i>J</i> = 8.4 Hz, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 98.6, 106.3, 108.0; u 29.3, 69.0, 101.3, 142.3, 148.4, 153.5; IR (thin film): 1632, 1494, 1481 cm<sup>–1</sup>.</div></div><div id="sec4_2_9_125" class="NLM_sec NLM_sec_level_4"><div id="ac_i163" class="anchor-spacer"></div><h5 class="article-section__title" id="_i163"> 3-(2-Chloroethoxy)pyridine (<b>112h</b>)</h5><div class="NLM_p last">To a mixture of 3-hydroxypyridine (872 mg, 9.17 mmol) and potassium carbonate (2.54 mg, 18.35 mmol, 2.0 equiv) in DMF (15 mL) was added 1-dibromo-2-chloroethane (3.0 mL, 5.19 g, 36.2 mmol, 4.0 equiv). The reaction was heated at 60 °C for 22 h, cooled to rt, and partitioned between water (150 mL) and CH<sub>2</sub>Cl<sub>2</sub> (5 × 10 mL). The combined organic layers were washed with aqueous sodium hydroxide (1 M, 2 × 10 mL) and then water (2 × 10 mL) and dried with Na<sub>2</sub>SO<sub>4</sub>. The organic layer was adsorbed onto silica and purified by silica chromatography to afford the ether product as a dark orange oil (284 mg, 1.80 mmol, 20% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.84 (t, <i>J</i> = 5.8 Hz, 2H), 4.29 (t, <i>J</i> = 5.8 Hz, 2H), 7.22–7.25 (m, 2H), 8.27 (dd, <i>J</i> = 2.2, 3.8 Hz, 1H), 8.34 (dd, <i>J</i> = 1.3, 2.4 Hz, 1H).</div></div><div id="sec4_2_9_126" class="NLM_sec NLM_sec_level_4"><div id="ac_i164" class="anchor-spacer"></div><h5 class="article-section__title" id="_i164"> 1-(3-Bromopropoxy)-4-methoxybenzene (<b>112i</b>)</h5><div class="NLM_p last">This material was purchased from 1Click Chemistry Inc.</div></div><div id="sec4_2_9_127" class="NLM_sec NLM_sec_level_4"><div id="ac_i165" class="anchor-spacer"></div><h5 class="article-section__title" id="_i165"> 1-(4-Bromobutoxy)-4-methoxybenzene (<b>112j</b>)</h5><div class="NLM_p last">This material was purchased from 1Click Chemistry Inc.</div></div><div id="sec4_2_9_128" class="NLM_sec NLM_sec_level_4"><div id="ac_i166" class="anchor-spacer"></div><h5 class="article-section__title" id="_i166"> 1-(4-Methoxyphenyl)piperazine (<b>113</b>)</h5><div class="NLM_p last">This material was purchased from Combi-Blocks Inc.</div></div><div id="sec4_2_9_129" class="NLM_sec NLM_sec_level_4"><div id="ac_i167" class="anchor-spacer"></div><h5 class="article-section__title" id="_i167"> 1-(2-(4-Methoxyphenoxy)ethyl)piperazine (<b>114a</b>)</h5><div class="NLM_p">A mixture of <i>tert</i>-butyl piperazine-1-carboxylate (490 mg, 2.63 mmol), 1-(2-bromoethoxy)-4-methoxybenzene <b>112a</b> (608 mg, 2.63 mmol), potassium carbonate (727 mg, 5.26 mmol, 2.0 equiv), and potassium iodide (44 mg, 0.263 mmol) in acetonitrile (35 mL) was heated at 70 °C for 16 h. The reaction was cooled to rt, filtered, and the solids were washed with acetonitrile (2 × 15 mL). The combined organics were adsorbed onto celite and purified by silica chromatography to afford the ether product, <i>tert</i>-butyl 4-(2-(4-methoxyphenoxy)ethyl)piperazine-1-carboxylate, as a colorless oil (622 mg, 1.85 mmol, 70% yield). R<sub><i>f</i></sub> = 0.57 (EtOAc); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.46 (s, 9 H), 2.51 (t, <i>J</i> = 4.8 Hz, 4 H), 2.79 (t, <i>J</i> = 6.0 Hz, 2 H), 3.45 (t, <i>J</i> = 4.8 Hz, 4 H), 3.76 (s, 3 H), 4.05 (t, <i>J</i> = 6.0 Hz, 2 H), 6.83 (d, <i>J</i> = 2.4 Hz, 4 H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 28.5, 55.8, 114.7, 115.7; u 53.5, 57.5, 66.7, 79.6, 153.0, 154.1, 154.8; HRMS (m/z): calcd for C<sub>18</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> ([M]<sup>+</sup> + H) 337.2122; found 337.2122; HPLC purity = 99.0%.</div><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(2-(4-methoxyphenoxy)ethyl)piperazine-1-carboxylate (185 mg, 0.55 mmol) and triethylsilane (96 mg, 0.825 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added trifluoroacetic acid (0.85 mL, 1,254 mg, 11.00 mmol). The reaction was stirred at rt for 4 h and concentrated under vacuum. The residue was partitioned between aqueous sodium bicarbonate (10 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were concentrated under vacuum to afford the piperazine product <b>114a</b> as a colorless oil (118 mg, 0.499 mmol, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.54–2.60 (m, 4 H), 2.78 (t, <i>J</i> = 6.0 Hz, 2 H), 2.94 (t, <i>J</i> = 4.8 Hz, 4 H), 3.76 (s, 3 H), 4.05 (t, <i>J</i> = 6.0 Hz, 2 H), 6.83 (d, <i>J</i> = 2.8 Hz, 4 H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 55.8, 114.8, 115.7; u 45.9, 54.6, 58.0, 66.6, 153.0, 154.0; HRMS (m/z): calcd for C<sub>13</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub> ([M]<sup>+</sup> + H) 237.1598; found 237.1573; HPLC purity = 94.1%.</div></div><div id="sec4_2_9_130" class="NLM_sec NLM_sec_level_4"><div id="ac_i168" class="anchor-spacer"></div><h5 class="article-section__title" id="_i168"> 1-(2-(3-Methoxyphenoxy)ethyl)piperazine (<b>114b</b>)</h5><div class="NLM_p last">This material was purchased from 1Click Chemistry Inc.</div></div><div id="sec4_2_9_131" class="NLM_sec NLM_sec_level_4"><div id="ac_i169" class="anchor-spacer"></div><h5 class="article-section__title" id="_i169"> 1-(2-(Pyridin-3-yloxy)ethyl)piperazine (<b>114c</b>)</h5><div class="NLM_p">A slurry of <i>tert</i>-butyl piperazine-1-carboxylate (699 mg, 3.59 mmol), 3-(2-chloroethoxy)pyridine <b>112h</b> (283 mg, 1.80 mmol), and potassium carbonate (499 mg, 3.61 mmol, 2.0 equiv) in DMF (2 mL) was heated at 90 °C for 21 h. The reaction was cooled to rt, diluted with water (20 mL), and extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 × 5 mL). The combined organics were dried with Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum, and purified by silica chromatography to afford the alkylated product, <i>tert</i>-butyl 4-(2-(4 pyridin-3-yloxy)ethyl)piperazine-1-carboxylate, as a golden oil (434 mg, 1.41 mmol, 79% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.53 (t, <i>J</i> = 5.0 Hz, 4H), 2.83 (t, <i>J</i> = 5.6 Hz, 2H), 3.46 (t, <i>J</i> = 5.1 Hz, 4H), 4.15 (t, <i>J</i> = 5.7 Hz, 2H), 7.19–7.23 (m, 2H), 8.20–8.26 (m, 1H), 8.32–8.34 (m, 1H).</div><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(2-(4 pyridin-3-yloxy)ethyl)piperazine-1-carboxylate (1.54 g, 5.02 mmol) and triethylsilane (0.874 g, 7.51 mmol, 1.5 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL) was added trifluoroacetic acid (6.0 mL, 8.94 g, 78.4 mmol). The reaction was stirred at rt for 19 h and concentrated under vacuum. The residue was partitioned between aqueous sodium hydroxide (5 M, 11 mL) and CH<sub>2</sub>Cl<sub>2</sub> (5 × 10 mL). The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum, and purified by chromatography on basic alumina (50 g) to afford the piperazine product <b>114c</b> as a light orange oil (915 mg, 4.41 mmol, 88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.49–2.61 (m, 4H), 2.81 (t, <i>J</i> = 5.8 Hz, 2H), 2.92 (t, <i>J</i> = 4.9 Hz, 4H), 4.15 (t, <i>J</i> = 5.8 Hz, 2H), 7.18–7.24 (m, 2H), 8.22 (dd, <i>J</i> = 2.4, 3.6 Hz, 1H), 8.32 (dd, <i>J</i> = 1.4, 2.3 Hz, 1H).</div></div><div id="sec4_2_9_132" class="NLM_sec NLM_sec_level_4"><div id="ac_i170" class="anchor-spacer"></div><h5 class="article-section__title" id="_i170"> 1-(2-(4-Methoxyphenoxy)propyl)piperazine (<b>114d</b>)</h5><div class="NLM_p">To a mixture of <i>tert</i>-butyl piperazine-1-carboxylate (931 mg, 5.00 mmol) and potassium carbonate (1.73 g, 12.5 mmol, 2.5 equiv) in DMF (5 mL) was added 2-chloropropanoyl chloride (698 mg, 5.50 mmol, 1.1 equiv), and the reaction was stirred at rt for 20 min. 4-Methoxyphenol (746 mg, 6.01 mmol, 1.2 equiv) was added, and the reaction was stirred at rt for 5 min and then at 80 °C for 4 h. The reaction was partitioned between water (50 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were sequentially washed with saturated aqueous NaHCO<sub>3</sub> (3 mL), water (3 mL), aqueous citric acid (1 M, 3 mL), and water (2 × 3 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, adsorbed onto silica gel (4 g), and purified by silica gel chromatography to afford the acylated ether product, <i>tert</i>-butyl 4-(2-(4-methoxyphenoxy)propyl)piperazine-1-carboxylate, as a colorless oil (430 mg, 1.18 mmol, 24% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.44 (s, 9H), 1.54–1.64 (complex, 5H), 3.06–3.27 (m, 2H), 3.39–3.69 (m, 4H), 3.76 (s, 3H), 4.88 (q, <i>J</i> = 6.8 Hz, 1H), 6.72–6.93 (m, 4H); HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup> 365.2071; found 365.2082.</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 4-(2-(4-methoxyphenoxy)propyl)piperazine-1-carboxylate (376 mg, 1.03 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) was added sequentially triethylsilane (240 mg, 2.07 mmol, 2.0 equiv) and then trifluoroacetic acid (4 mL), and the reaction was stirred at rt for 26 h. The reaction was concentrated in vacuo and partitioned between aqueous NaOH (2 M, 6 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The combined organic layers were washed with water (2 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated, and purified by silica gel chromatography to afford the deprotected product, 2-(4-methoxyphenoxy)-1-(piperazin-1-yl)propan-1-one, as a colorless oil (219 mg, 0.829 mmol, 80% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.59 (d, <i>J</i> = 6.9 Hz, 3H), 2.58–2.91 (m, 4H), 3.47–3.73 (m, 4H), 3.76 (s, 3H), 4.88 (q, <i>J</i> = 6.8 Hz, 1H), 6.77–6.88 (m, 4H).</div><div class="NLM_p last">To a solution of 2-(4-methoxyphenoxy)-1-(piperazin-1-yl)propan-1-one (219 mg, 0.829 mmol) in THF (2 mL) at 0 °C was added a THF solution of borane (2.8 mL, 2.8 mmol, 3.2 equiv). After bubbling had ceased (6 min), the reaction was stirred at 65 °C for 4 h. MeOH (2 mL) was added, and the reaction was concentrated in vacuo. The residue was dissolved in MeOH (3 mL), and concentrated HCl (0.25 mL) was added, and the solution was stirred at 65 °C for 30 min. The solution was concentrated in vacuo, and the residue was partitioned between aqueous HCl (1 M, 4 mL) and CH<sub>2</sub>Cl<sub>2</sub> (4 mL). Aqueous sodium hydroxide (10 M, 3 mL) was added to increase the pH to >9, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 × 2 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated, and purified by silica gel chromatography to afford the reduced product <b>114d</b> as a colorless oil (178 mg, 0.711 mmol, 86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.27 (d, <i>J</i> = 6.2 Hz, 3H), 2.38–2.57 (complex, 5H), 2.68 (dd, <i>J</i> = 6.7, 13.1 Hz, 1H), 2.88 (t, <i>J</i> = 4.9 Hz, 4H), 3.77 (s, 3H), 4.35–4.48 (m, 1H), 6.75–6.92 (m, 4H).</div></div><div id="sec4_2_9_133" class="NLM_sec NLM_sec_level_4"><div id="ac_i171" class="anchor-spacer"></div><h5 class="article-section__title" id="_i171"> 1-(2-(4-Chlorophenoxy)propyl)piperazine (<b>114e</b>)</h5><div class="NLM_p">To a mixture of <i>tert</i>-butyl piperazine-1-carboxylate (931 mg, 5.00 mmol) and potassium carbonate (1.73 g, 12.5 mmol, 2.5 equiv) in DMF (5 mL) was added 2-chloropropanoyl chloride (698 mg, 5.50 mmol, 1.1 equiv), and the reaction was stirred at rt for 20 min. 4-Chlorophenol (771 mg, 6.00 mmol, 1.2 equiv) was added, and the reaction was stirred at rt for 5 min and then at 80 °C for 4 h. The reaction was partitioned between water (50 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were sequentially washed with saturated aqueous NaHCO<sub>3</sub> (3 mL), water (3 mL), aqueous citric acid (1 M, 3 mL) and water (2 × 3 mL). The organic layer was dried over MgSO<sub>4</sub>, adsorbed onto silica gel (4 g), and purified by silica gel chromatography to afford the acylated ether product, <i>tert</i>-butyl 4-(2-(4-chlorophenoxy)propyl)piperazine-1-carboxylate, as a white solid (515 mg, 1.40 mmol, 28% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.45 (s, 9H), 1.62 (d, <i>J</i> = 6.9 Hz, 3H), 3.09–3.26 (m, 3H), 3.41–3.79 (m, 5H), 4.91 (q, <i>J</i> = 6.8 Hz, 1H), 6.83 (d, <i>J</i> = 9.1 Hz, 2H), 7.23 (d, <i>J</i> = 9.0 Hz, 2H); HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>14</sub>H<sub>18</sub>ClN<sub>2</sub>O<sub>4</sub> [M – <i>tert</i>-butyl + 2H]<sup>+</sup> 313.0950; found 313.0944.</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 4-(2-(4-chlorophenoxy)propyl)piperazine-1-carboxylate (458 mg, 1.24 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) was added sequentially triethylsilane (291 mg, 2.50 mmol, 2.0 equiv) and then trifluoroacetic acid (4 mL), and the reaction was stirred at rt for 19 h. The reaction was concentrated in vacuo and partitioned between aqueous NaOH (2 M, 6 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The combined organic layers were washed with water (2 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated, and purified by silica gel chromatography to afford the deprotected product, 2-(4-chlorophenoxy)-1-(piperazin-1-yl)propan-1-one, as a colorless oil (299 mg, 1.11 mmol, 90% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.61 (d, <i>J</i> = 6.8 Hz, 3H), 2.56–2.91 (m, 5H), 3.45–3.76 (m, 3H), 4.91 (q, <i>J</i> = 6.8 Hz, 1H), 6.83 (d, <i>J</i> = 9.0 Hz, 2H), 7.23 (d, <i>J</i> = 9.1 Hz, 2H).</div><div class="NLM_p last">To a solution of 2-(4-chlorophenoxy)-1-(piperazin-1-yl)propan-1-one (308 mg, 1.15 mmol) in THF (2 mL) at 0 °C was added a THF solution of borane (1 M, 3.5 mL, 3.5 mmol, 3.1 equiv). After bubbling had ceased (6 min), the reaction was stirred at 65 °C for 4 h. MeOH (2 mL) was added, and the reaction was concentrated in vacuo. The residue was dissolved in MeOH (3 mL), and concentrated HCl (0.25 mL) was added, and the solution was stirred at 65 °C for 30 min. The solution was concentrated in vacuo, and the residue was partitioned between aqueous HCl (1 M, 4 mL) and CH<sub>2</sub>Cl<sub>2</sub> (4 mL). Aqueous sodium hydroxide (10 M, 3 mL) was added to increase the pH to >9, and the aqueous was extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 × 2 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated, and purified by silica gel chromatography to afford the amide reduction product <b>114e</b> as a colorless oil (257 mg, 1.10 mmol, 88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.29 (d, <i>J</i> = 6.2 Hz, 3H), 2.39–2.55 (complex, 5H), 2.68 (dd, <i>J</i> = 6.6, 13.2 Hz, 1H), 2.86 (t, <i>J</i> = 4.9 Hz, 4H), 4.49 (td, <i>J</i> = 4.8, 6.3 Hz, 1H), 6.84 (d, <i>J</i> = 9.0 Hz, 2H), 7.21 (d, <i>J</i> = 9.0 Hz, 2H).</div></div><div id="sec4_2_9_134" class="NLM_sec NLM_sec_level_4"><div id="ac_i172" class="anchor-spacer"></div><h5 class="article-section__title" id="_i172"> (4-(2-Chloroethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (<b>116</b>)</h5><div class="NLM_p">To a solution of 2-(piperazin-1-yl)ethanol (904 mg, 6.94 mmol) and triethylamine (843 mg, 8.33 mmol, 1.2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (18 mL) was added 1<i>H</i>-indole-2-carbonyl chloride (1,367 mg, 7.61 mmol, 1.1 equiv) while cooling the reaction solution in an ice/water bath. The reaction was stirred for 20 h, slowly warming to rt. The reaction was concentrated in vacuo, and the residue was suspended in 50% saturated aqueous NaHCO<sub>3</sub> (40 mL). The solids were collected by filtration, washed with water (2 × 20 mL), and dried under vacuum to afford the acylated product, (4-(2-hydroxyethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone, as a tan solid (1.41 g, 5.17 mmol, 75% yield), which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.59 (t, <i>J</i> = 5.3 Hz, 2H), 3.65 (t, <i>J</i> = 5.4 Hz, 2H), 3.84 (s, 3H), 6.91 (d, <i>J</i> = 8.7 Hz, 2H), 7.39 (d, <i>J</i> = 8.8 Hz, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.0 (br), 55.4, 57.8, 59.3, 113.7, 127.7, 129.2, 160.8, 170.3; HRMS (m/z): calcd for C<sub>14</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 265.1547; found 265.1575.</div><div class="NLM_p last">Chlorination of the primary alcohol was accomplished utilizing the protocol of Kartika and co-workers.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Thus, a solution of (4-(2-hydroxyethyl)piperazin-1-yl)(1<i>H</i>-indol-2-yl)methanone (1.96 g, 7.18 mmol) and triethylamine (2.50 mL, 1.82 g, 17.94 mmol, 2.5 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (65 mL) was cooled to 0 °C. Triphosgene (1.07 g, 3.60 mmol, 0.5 equiv) was added as a solid, and the reaction was stirred for 5 min at 0 °C and then at rt for 3 h. The reaction was quenched with saturated aqueous NaHCO<sub>3</sub> (50 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 10 mL). The combined organic layers were washed sequentially with saturated aqueous NaHCO<sub>3</sub> (25 mL) and then water (25 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica chromatography to afford chloride <b>116</b> as a tan solid (1.10 g, 3.77 mmol, 53% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.44 (t, <i>J</i> = 6.2 Hz, 2H), 2.46–2.53 (m, 4H), 3.53 (q, <i>J</i> = 6.1 Hz, 2H), 3.64–3.83 (m, 4H), 4.47 (t, <i>J</i> = 5.3 Hz, 1H), 6.77 (dd, <i>J</i> = 0.9, 2.2 Hz, 1H), 7.04 (ddd, <i>J</i> = 1.0, 6.9, 7.9 Hz, 1H), 7.18 (ddd, <i>J</i> = 1.2, 7.0, 8.2 Hz, 1H), 7.41 (dd, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.60 (dd, <i>J</i> = 1.0, 8.0 Hz, 1H), 11.56 (br s, 1H).</div></div><div id="sec4_2_9_135" class="NLM_sec NLM_sec_level_4"><div id="ac_i173" class="anchor-spacer"></div><h5 class="article-section__title" id="_i173"> (4-(2-Chloroxyethyl)piperidin-1-yl)(4-methoxyphenyl)methanone (<b>118</b>)</h5><div class="NLM_p">To a solution of 2-(piperidin-4-yl)ethanol (518 mg, 4.01 mmol) and triethylamine (508 mg, 5.02 mmol, 1.25 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added 4-methoxybenzoyl chloride (0.60 mL, 4.36 mmol, 1.1 equiv) while cooling the solution in an ice/water bath. The reaction was stirred for 16 h, slowly warming to rt, and then washed sequentially with aqueous HCl (1 M, 2 × 5 mL), water (1 × 5 mL), and aqueous NaHCO<sub>3</sub> (1 × 4 mL). The organic layer was adsorbed onto silica gel (1.5 g) and purified by silica chromatography to afford the acylated product, (4-(2-hydroxyethyl)piperidin-1-yl)(4-methoxyphenyl)methanone, as a colorless oil (845 mg, 3.21 mmol, 80% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.12–1.30 (m, 1H), 1.50–1.59 (m, 2H), 1.64–1.86 (m, 4H), 2.69–3.06 (m, 4H), 3.71 (t, <i>J</i> = 6.5 Hz, 3H), 3.83 (s, 5H), 6.90 (d, <i>J</i> = 8.7 Hz, 2H), 7.37 (d, <i>J</i> = 8.8 Hz, 2H); HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>15</sub>H<sub>22</sub>NO<sub>3</sub> [M + H]<sup>+</sup> 264.1594; found 264.1605.</div><div class="NLM_p last">To a solution of (4-(2-hydroxyethyl)piperidin-1-yl)(4-methoxyphenyl)methanone (144 mg, 0.547 mmol) in CHCl<sub>3</sub> (3 mL) at 0 °C was added thionyl chloride (65.1 mg, 0.547 mmol, 1.0 equiv). The reaction was stirred at 0 °C for 18 min, rt for 2 h, heated at 50 °C for 46 h, and then cooled to rt. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (4 mL) and washed sequentially with aqueous NaHCO<sub>3</sub> (2 × 2 mL) and then water (1 × 2 mL). The organic layer was dried with MgSO<sub>4</sub> and purified by silica gel chromatography to afford the chlorinated product <b>118</b> as a beige oil (141 mg, 0.470 mmol, 86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.10–1.29 (m, 1H), 1.68–1.88 (complex, 6H), 2.72–3.09 (m, 4H), 3.59 (t, <i>J</i> = 6.6 Hz, 2H), 3.83 (s, 3H), 6.90 (d, <i>J</i> = 8.7 Hz, 2H), 7.37 (d, <i>J</i> = 8.7 Hz, 2H).</div></div><div id="sec4_2_9_136" class="NLM_sec NLM_sec_level_4"><div id="ac_i174" class="anchor-spacer"></div><h5 class="article-section__title" id="_i174"> <i>N</i>-(2-((2-Chloroethyl)(methyl)amino)ethyl)-4-methoxy-<i>N</i>-methylbenzamide Hydrochloride (<b>120</b>)</h5><div class="NLM_p">To a solution of <i>N</i>-(2-hydroxyethyl)-4-methoxy-<i>N</i>-methylbenzamide<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a><b>119</b> (572 mg, 2.73 mmol) in CHCl<sub>3</sub> (6 mL) at 0 °C was added thionyl chloride (489 mg, 4.11 mmol, 1.5 equiv). The reaction was stirred at 0 °C for 3 min, heated at 55 °C for 35 min, and then cooled to rt. The reaction mixture was adsorbed onto silica gel (1.0 g) and purified by silica gel chromatography to afford the chlorinated product, <i>N</i>-(2-chloroethyl)-4-methoxy-<i>N</i>-methylbenzamide, as a colorless oil (336 mg, 1.48 mmol, 54% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.53–1.69 (m, 2H), 3.12 (s, 3H), 3.68–3.88 (m, 2H), 3.84 (s, 3H), 6.92 (d, <i>J</i> = 8.7 Hz, 2H), 7.41 (d, <i>J</i> = 8.2 Hz, 2H).</div><div class="NLM_p">To a solution of <i>N</i>-(2-chloroethyl)-4-methoxy-<i>N</i>-methylbenzamide (332 mg, 1.45 mmol) in MeCN (6 mL) was added 2-(methylamino)ethanol (563 mg, 7.50 mmol, 5.1 equiv). The reaction was stirred at 80 °C for 25 h and then cooled to rt. The reaction mixture was adsorbed onto silica gel (1.4 g) and purified by silica gel chromatography to afford the alkylated product, <i>N</i>-(2-((2-hydroxyethyl)(methyl)amino)ethyl)-4-methoxy-<i>N</i>-methylbenzamide, as a colorless oil (259 mg, 0.972 mmol, 67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.29–2.74 (complex, 7H), 3.04 (s, 3H), 3.39–3.68 (m, 4H), 3.83 (s, 3H), 6.90 (d, <i>J</i> = 8.7 Hz, 2H), 7.39 (d, <i>J</i> = 8.7 Hz, 2H); HRMS (m/z): calcd for C<sub>14</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 267.1703; found 267.1726.</div><div class="NLM_p last">To a solution of <i>N</i>-(2-((2-hydroxyethyl)(methyl)amino)ethyl)-4-methoxy-<i>N</i>-methylbenzamide (121 mg, 0.454 mmol) in CHCl<sub>3</sub> (3 mL) at 0 °C was added thionyl chloride (82.0 mg, 0.685 mmol, 1.5 equiv). The reaction was stirred at 0 °C for 3 min, rt for 30 min, heated at 50 °C for 25 min, then cooled to rt, and concentrated in vacuo. The residue was partitioned between aqueous sodium hydroxide (1 M, 3 mL) and CH<sub>2</sub>Cl<sub>2</sub> (2 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated, and purified by silica gel chromatography to afford the hydroxy product <b>120</b> as a beige oil (109 mg, 0.38 mmol, 84% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.00 (s, 3H), 3.17 (s, 3H), 3.38–3.54 (m, 2H), 3.60–3.71 (m, 2H), 3.84 (s, 3H), 3.92–4.23 (m, 4H), 6.93 (d, <i>J</i> = 8.8 Hz, 2H), 7.47 (d, <i>J</i> = 8.7 Hz, 2H).</div></div><div id="sec4_2_9_137" class="NLM_sec NLM_sec_level_4"><div id="ac_i175" class="anchor-spacer"></div><h5 class="article-section__title" id="_i175"> (4-(2-Hydroxyethyl)piperazin-1-yl)(4-methoxyphenyl)methanone (<b>121</b>)</h5><div class="NLM_p last">To a solution of 2-(piperazin-1-yl)ethanol (521 mg, 4.00 mmol) and triethylamine (508 mg, 5.02 mmol, 1.3 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added 4-methoxybenzoyl chloride (0.60 mL, 4.36 mmol, 1.1 equiv) while cooling the solution in an ice/water bath. The reaction was stirred for 24 h, slowly warming to rt. The reaction was adsorbed onto silica gel (2 g) and purified by silica chromatography to afford the previously reported acylated product<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> as a white solid (818 mg, 2.72 mmol, 68% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.42–2.66 (m, 4H), 2.59 (t, <i>J</i> = 5.3 Hz, 2H), 3.46–3.79 (m, 4H), 3.65 (t, <i>J</i> = 5.4 Hz, 2H), 3.84 (s, 3H), 6.91 (d, <i>J</i> = 8.7 Hz, 2H), 7.39 (d, <i>J</i> = 8.8 Hz, 2H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 53.0 (br), 55.4, 57.8, 59.3, 113.7, 127.7, 129.2, 160.8, 170.3; HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>14</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 265.1547; found 265.1575.</div></div><div id="sec4_2_9_138" class="NLM_sec NLM_sec_level_4"><div id="ac_i176" class="anchor-spacer"></div><h5 class="article-section__title" id="_i176"> 2-(1-(1<i>H</i>-Indole-2-carbonyl)piperidin-4-yl)ethyl 4-methylbenzenesulfonate (<b>122</b>)</h5><div class="NLM_p">To a solution of 1<i>H</i>-indole-2-carboxylic acid (374 mg, 2.32 mmol, 1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) were added HOBt (314 mg, 2.32 mmol, 1.0 equiv) and EDC·HCl (445 mg, 2.32 mmol, 1.0 equiv), and the reaction was stirred at rt for 10 min. 2-(Piperidin-4-yl)ethan-1-ol (300 mg, 2.32 mmol) was added, and the reaction was stirred at rt for 18 h. The reaction was partitioned between water (40 mL) and CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated, and the residue was purified by silica gel chromatography to afford the previously reported amide product, (4-(2-hydroxyethyl)piperidin-1-yl)(1<i>H</i>-indol-2-yl)methanone, as a white solid (310 mg, 1.14 mmol, 49% yield).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.13–1.32 (m, 2H), 1.45–1.52 (m, 2H), 1.67–1.85 (m, 3H), 2.68–3.21 (complex, 4H), 3.60 (t, <i>J</i> = 6.6 Hz, 2H), 4.56 (d, <i>J</i> = 13.4 Hz, 1H), 6.68 (s, 1H), 7.05 (t, <i>J</i> = 7.5 Hz, 1H), 7.19 (t, <i>J</i> = 7.7 Hz, 1H), 7.37 (d, <i>J</i> = 8.3 Hz, 1H), 7.56 (d, <i>J</i> = 8.0 Hz, 1H), 10.00 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 32.2, 32.7, 38.7, 43.5, 59.5, 104.9, 111.8, 120.3, 121.5, 124.0, 127.1, 129.2, 135.8, 162.9.</div><div class="NLM_p last">To (4-(2-hydroxyethyl)piperidin-1-yl)(1<i>H</i>-indol-2-yl)methanone (166 mg, 0.61 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (13 mL) were added Et<sub>3</sub>N (0.34 mL, 2.44 mmol, 4.0 equiv) and then <i>p</i>-toluenesulfonyl chloride (232 mg, 1.22 mmol, 2.0 equiv). The reaction was stirred at rt until TLC indicated the conversion of alcohol (2 h). The reaction was quenched with saturated aqueous ammonium chloride (10 mL), and the layers were separated. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 10 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>and evaporated, and the residue was purified by silica gel chromatography to afford tosylate <b>122</b> as a white solid (120 mg, 0.28 mmol, 46% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.16–1.28 (m, 2H), 1.61–1.66 (m, 2H), 1.70–1.83 (complex, 3H), 2.45 (s, 3H), 2.86–3.12 (m, 2H), 4.10 (t, <i>J</i> = 6.2 Hz, 2H), 4.66–4.73 (m, 2H), 6.73–6.75 (m, 1H), 7.10–7.14 (m, 1H), 7.24–7.28 (m, 1H), 7.36(d, <i>J</i> = 8.0 Hz, 2H), 7.42 (dd, <i>J</i> = 0.8, 8.3 Hz, 1H), 7.64 (dd, <i>J</i> = 0.7, 8.0 Hz, 1H), 7.81 (d, <i>J</i> = 8.3 Hz, 1H), 9.66 (s, 1H); <sup>13</sup>C NMR (101 MHz, APT pulse sequence, CDCl<sub>3</sub>) δ d 21.7, 32.4, 104.9, 111.8, 120.4, 121.7, 124.2, 127.9, 129.9; u 32.1, 35.1, 67.8, 127.4, 129.5, 132.9, 135.7, 144.9, 162.3.</div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i177" class="anchor-spacer"></div><h3 class="article-section__title" id="_i177"> Transient Transfections</h3><div class="NLM_p last">HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and maintained at 37 °C in a humidified incubator containing 5% CO<sub>2</sub>. The day before transfection, cells were plated in 100 mm tissue culture dishes at 4 × 10<sup>6</sup> cells/dish in serum-free DMEM. The cells were transfected with the indicated DNA constructs using polyethylenimine (PEI) as the transfection reagent at a ratio of 3:1 (μL PEI: μg DNA). Twenty-four hours after transfection, the media was changed to DMEM supplemented with 10% fetal bovine serum, and cells were used for experiments the next day.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i178" class="anchor-spacer"></div><h3 class="article-section__title" id="_i178"> Radioligand Binding Assays</h3><div class="NLM_p last">HEK293 cells that were stably transfected with the human D2RL or D3R (Codex Biosolutions, Inc., Gaithersburg, MD) or parental HEK293 cells that were transiently transfected with either the D2RL, D3R, or indicated point mutants, as described above, were removed mechanically using calcium-free Earle’s balanced salt solution (EBSS-). Intact cells were collected by centrifugation and then lysed with 5 mM Tris–HCl and 5 mM MgCl<sub>2</sub> at pH 7.4. Homogenates were centrifuged at 30 000<i>g</i> for 30 min. The membranes were resuspended in EBSS pH 7.4. For competition binding studies, membrane preparations were incubated for 90 min at room temperature with various concentrations of compound and a single or various concentration(s) of [<sup>3</sup>H]-methylspiperone in a reaction volume of 250 μL. Nonspecific binding was determined in the presence of 4 μM (+)-butaclamol. Bound ligand was separated from unbound by filtration through GF/C filters using a PerkinElmer cell harvester and quantified using a TopCount instrument (PerkinElmer). <i>K</i><sub>i</sub> values were calculated using the Cheng–Prusoff equation<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> from the observed IC<sub>50</sub> values and the radioligand <i>K</i><sub>d</sub> value determined from separate saturation binding experiments.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i179" class="anchor-spacer"></div><h3 class="article-section__title" id="_i179"> β-Arrestin Recruitment DiscoverX PathHunter Assay</h3><div class="NLM_p last">In this assay, a CHO-K1 cell line expressing the human D3R fused with a small 42 amino acid fragment of β-galactosidase called ProLink and also expressing a fusion protein consisting of β-arrestin and a larger N-terminal deletion mutant of β-galactosidase was employed. Upon receptor activation, β-arrestin is recruited to the ProLink-tagged D3R, resulting in complementation of β-galactosidase to form a functional enzyme; addition of the substrate (PathHunter Detection Reagent) generates a chemiluminescent signal. Assays were conducted as previously described by our laboratory.<a onclick="showRef(event, 'ref53 ref92'); return false;" href="javascript:void(0);" class="ref ref53 ref92">(53,92)</a> Briefly, CHO-K1 DiscoverX cells stably expressing various dopamine receptors were plated in CP2 media (DiscoverX, Fremont, CA) in 384-well black, clear-bottom plates at a density of 2625 cells/well and incubated overnight at 37 °C. Cells were then incubated with indicated compounds for 90 min at 37 °C for agonist mode or for 120 min in the presence of an EC<sub>80</sub> concentration of dopamine for antagonist mode. Cells were then incubated with a DiscoverX detection reagent for 30 min at room temperature, and luminescence was read on an FDSS μCell (Hamamatsu, Bridgewater, NJ). Data were collected as relative luminescence units (RLUs) and normalized as a percentage of the luminescence produced by a maximum concentration of dopamine.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i180" class="anchor-spacer"></div><h3 class="article-section__title" id="_i180"> β-Arrestin Recruitment BRET Assay</h3><div class="NLM_p last">HEK293 cells were transiently transfected with D3R-Rluc8, β-arrestin2-mVenus, and G protein-coupled receptor kinase 3. GRK3 was used because it provides the greatest enhancement of β-arrestin recruitment for the D3R compared to other GRKs (unpublished observations). This GRK preference has also been noted by other labs.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Cells were harvested with EBSS-, plated in 96-well white plates at 20 000 cells/well in Dulbecco’s phosphate-buffered saline (DPBS) and incubated at room temperature for 45 min. Cells were incubated with 5 μM coelenterazine h (Nanolight Technology, Pinetop, AZ) for 5 min and then stimulated with the indicated concentrations of the test compound for 5 min. The BRET signal was determined by quantifying and calculating the ratio of the light emitted by mVenus (525 nm) over that emitted by Rluc8 (485 nm) using a PHERAstar FSX Microplate Reader (BMG Labtech, Cary, NC).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i181" class="anchor-spacer"></div><h3 class="article-section__title" id="_i181"> Go-BRET Activation Assay</h3><div class="NLM_p last">HEK293 cells transiently expressing the D3R and Gα<sub>oA</sub>-Rluc8, untagged-β<sub>1</sub>, and mVenus-γ<sub>2</sub> were harvested with EBSS-, plated in 96-well white plates at 20,000 cells/well in DPBS and incubated at room temperature for 45 min. Cells were incubated with 5 μM coelenterazine h (Nanolight Technology, Pinetop, AZ) for 5 min and then stimulated with the indicated concentrations of the test compound for 5 min. The BRET signal was determined by quantifying and calculating the ratio of the light emitted by mVenus (525 nm) over that emitted by RLuc8 (485 nm) using a PHERAstar FSX Microplate Reader (BMG Labtech, Cary, NC).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i182" class="anchor-spacer"></div><h3 class="article-section__title" id="_i182"> ERK1/2 Phosphorylation Assay</h3><div class="NLM_p last">ERK1/2 phosphorylation was measured using the AlphaScreen SureFire Ultra ERK kit (PerkinElmer, Waltham, USA). CHO-K1 DiscoverX cells stably expressing the D3R were seeded into 384-well small volume white plates at a density of 40,000 cells/well in serum-free Ham’s F12 media overnight. Cells were stimulated with the indicated concentration of the test compound for 15 min, followed by cell lysis as specified by the manufacturer’s protocol. The plate was shaken for 10 min at room temperature, followed by the addition of Surefire activation buffer, Surefire reaction buffer, AlphaScreen acceptor beads, and AlphaScreen donor beads in ratios specified by the manufacturer. The plate was incubated in the dark for 2 h and then read using a PHERAstar FSX Microplate Reader (BMG Labtech, Cary, NC).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i183" class="anchor-spacer"></div><h3 class="article-section__title" id="_i183"> cAMP CAMYEL Biosensor Assay</h3><div class="NLM_p last">HEK293 cells transiently expressing the D3R and the CAMYEL cAMP biosensor (yellow fluorescence protein-Epac-Rluc)<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> were harvested with EBSS-, plated in 96-well white plates at 20 000 cells/well in DPBS and incubated at room temperature for 45 min. Cells were pretreated for 5 min with 10 μM forskolin and 10 μM propranolol (to block endogenous β-adrenergic receptors) and then incubated with 5 μM coelenterazine h (Nanolight Technology, Pinetop, AZ) for 5 min, followed by stimulation with the indicated concentrations of the test compound for 5 min. The BRET signal was determined by quantifying and calculating the ratio of the light emitted by mVenus (525 nm) over that emitted by Rluc8 (485 nm) using a PHERAstar FSX Microplate Reader (BMG Labtech, Cary, NC).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i184" class="anchor-spacer"></div><h3 class="article-section__title" id="_i184"> DiscoverX gpcrMAX GPCR Panel</h3><div class="NLM_p last">To determine the selectivity profiles of ML417, CJ-1639, and pramipexole, these compounds were screened using the DiscoverX gpcrMAX GPCR panel, which measures the GPCR activation of β-arrestin recruitment to different GPCRs in either agonist or antagonist modes using a single high concentration (10 μM) of the test compound. This study was conducted by DiscoverX, Inc. (Fremont, CA). Reference standards were run for each GPCR in the panel as an integral part of each assay to ensure the validity of the results. Assay results are presented as the mean percent activation or inhibition of the indicated GPCRs (for n = 2 replicates) for each compound tested. For a full description of the DiscoverX gpcrMAX GPCR panel and the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, see <a href="http://www.DiscoverX.com" class="extLink">http://www.DiscoverX.com</a>.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i185" class="anchor-spacer"></div><h3 class="article-section__title" id="_i185"> Psychoactive Drug Screening Program (PDSP) Radioligand Binding Panel</h3><div class="NLM_p last"><b>20</b>, CJ-1639, and pramipexole were screened using the National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program (PDSP) directed by Dr. Bryan L. Roth (University of North Carolina, Chapel Hill, NC). For experimental details, including radioligands used and associated <i>K</i><sub>d</sub> values for each individual target, please refer to the PDSP website <a href="http://pdsp.med.unc.edu/" class="extLink">http://pdsp.med.unc.edu/</a>. Primary screening is performed using 10 μM of the test compound, and, if >50% inhibition of radioligand binding is observed, then secondary screening is performed in full concentration–response format to derive affinity values.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i186" class="anchor-spacer"></div><h3 class="article-section__title" id="_i186"> Inositol 1-Phosphate (IP1) Accumulation Assay</h3><div class="NLM_p last">Compound <b>20</b> was tested as both an agonist and antagonist of the 5-HT<sub>2B</sub> receptor using the Eurofins Cerep service (Celle l’Evescault, France). Briefly, recombinant CHO cells expressing the human 5-HT<sub>2B</sub> were used to measure IP1 accumulation in response to an agonist. Serotonin was used as the control agonist, while SB206553<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> was used as the control antagonist. In these assays, serotonin had an EC<sub>50</sub> of 4.5 nM, while SB206553 had an IC<sub>50</sub> of 13 nM. Antagonist assays were conducted in the presence of an EC<sub>80</sub> concentration (30 nM) of serotonin. The results obtained were the means of two separate assays.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i187" class="anchor-spacer"></div><h3 class="article-section__title" id="_i187"> Molecular Dynamics Simulations</h3><div class="NLM_p">The binding mode of <b>20</b> at the D3R was predicted by computational docking and molecular dynamics (MD) simulations. The ligand was docked to an equilibrated model of the D3R, which was built<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> based on the D3R crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Briefly, the missing N terminus was predicted <i>de novo</i>, and a truncated poly-Gly segment was used in place of the ICL3.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> The initial poses of the ligand were acquired by using an induced-fit docking protocol<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> in the Schrodinger software (release 2015-3; Schrodinger Inc., New York, NY). The MD simulations were performed in the explicit water–POPC lipid bilayer environment using Desmond MD System (version 3.8; D. E. Shaw Research, New York, NY) with the CHARMM36 protein and lipid force field<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> and the TIP3P water model. The ligand parameters were acquired from the GAAMP server.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div class="NLM_p last">As the predicted pKa of <b>20</b> is ambiguous using both empirical and quantum mechanics approaches, we experimentally titrated the molecule using a Sirius T3 instrument with a pH electrode and onboard titration tubes (Sirius Analytical Inc., Beverly, MA). Reference spectra without a compound and with controls containing either piroxicam or sulfathiazole were collected prior to the assays (data not shown). Samples were titrated using onboard robotics via the addition of HCl or KOH to generate the spectra, and pKa values were calculated using the onboard Sirius T3 software. The pKa of <b>20</b> was determined to be 8.62, and thus the basic piperazine nitrogen is predicted to be largely protonated at physiological pH. Consequently, we used the protonated, i.e., the charged form of the ligand in our simulations. The system charges were neutralized, and a solvent concentration of 0.15 M NaCl was added. The system was initially minimized and equilibrated with restraints on the ligand heavy atoms and protein backbone atoms, followed by a production stage in an isothermal–isobaric (NPT) ensemble at 310 K and 1 atm with all atoms unrestrained, as described previously.<a onclick="showRef(event, 'ref71 ref76'); return false;" href="javascript:void(0);" class="ref ref71 ref76">(71,76)</a> We used the Langevin constant pressure and temperature dynamical system<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> to maintain the pressure and the temperature, on an anisotropic flexible periodic cell with a constant-ratio constraint applied on the lipid bilayer in the X–Y plane.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i188" class="anchor-spacer"></div><h3 class="article-section__title" id="_i188"> Insertion of Human D3R into NSCs</h3><div class="NLM_p last">The human D3R open reading frame (ORF) was cloned into a donor vector containing homologous arms for the CLYBL safe harbor site and a neomycin resistance selection cassette. The ORF was synthesized as a codon-optimized gBlock (Integrated DNA Technologies) and inserted into the BsrGI site of the donor vector via Gibson assembly. The donor vector with the DRD3 knock-in and two TALEN pairs targeting the CLYBL locus were delivered by nucleofection (2 μg of each vector) into the human neural stem cells (NSCs) derived from the NCRM-1 iPSC line. Forty-eight hours after transfection, the drug selection was initiated in media containing 600 μg/mL of G418. Selection was continued for 7 days at which point the surviving NSCs were expanded in media without G418. Details about the TALEN-based safe harbor targeting approach are described by Cerbini et al. (2015).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Targeted cell lines were characterized for D3R expression by [<sup>3</sup>H]-methylspiperone binding assays.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i189" class="anchor-spacer"></div><h3 class="article-section__title" id="_i189"> iPSC Cell Culture and Differentiation into Dopaminergic Neurons</h3><div class="NLM_p last">Neural stem cells (NSCs) were maintained in a growth medium composed of neurobasal medium (Gibco), B-27 (Gibco), nonessential amino acid (Sigma-Aldrich), GlutaMAX (Gibco), and 10 ng/mL of fibroblast growth factor (FGF). Differentiation into a dopaminergic phenotype was carried out over 10 days in a medium composed of neurobasal medium, 1X B-27 supplements, 1X nonessential amino acids, 20 ng/mL brain-derived neurotrophic factor (BDNF), 20 ng/mL glial-derived neurotrophic factor (GDNF), and 20 ng/mL TGFb3.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> All growth factors were purchased from Peprotech (Rocky Hill, NJ). NSCs were grown in plates/flasks coated with Geltrex (ThermoFisher Scientific, Carlsbad, CA). Fifty percent of the differentiation media was replaced with fresh media every 72 h.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i190" class="anchor-spacer"></div><h3 class="article-section__title" id="_i190"> MTT Assay</h3><div class="NLM_p last">3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from ThermoFisher Scientific (Carlsbad, CA) (catalog number: M6494). MTT was dissolved in PBS at a concentration of 5 mg/mL (12 mM) and filtered. NSCs were plated at 10,000 cells per well in a 96-well plate and differentiation as described above for 10 days. On day 10 of the differentiation protocol, the cells were treated with the indicated concentrations of DMSO vehicle, <b>20</b>, or pramipexole. Twenty-four hours later, the cells were treated with 30 μM of 6-hydroxydopamine (6-OHDA). MTT assays were performed 24 h after 6-OHDA treatment. Each dilution was done in quadruplicates, and the experiments were performed at least 6 times. MTT assays were performed per the manufacturer’s protocol (ThermoFisher Scientific, Waltham, MA). Briefly, all media were pipetted out of the wells and fresh 100 μL of media was added. Ten percent (10 μL) of 5 mg/mL MTT solution was added to each well and incubated at 37 °C for 4 h. All but 25 μL of the MTT/media solution was pipetted out of each well. Fifty microliters of DMSO was added to dissolve the resultant formazan crystals. The plate was agitated on a shaker for 10 min. Optical density (OD) was read at a 540 nm wavelength on PHERAstar FX (BMG Labtech, Cary, NC) with a reference wavelength at 650 nm.</div></div><div id="sec4_16_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i191" class="anchor-spacer"></div><h3 class="article-section__title" id="_i191"> Ames Assay</h3><div class="NLM_p last">The mutagenicity potential of <b>20</b> was tested using the Ames reverse mutation assay by Cyprotex Inc. (Watertown, MA). Briefly, 10 million bacteria were exposed in triplicate to <b>20</b> for 90 min in a medium containing a low concentration of histidine. The cultures were then diluted into an indicator medium lacking histidine, dispensed into a 384-well plate, and incubated for 48 h at 37 °C. Cells that have undergone a reversion will grow, resulting in a color change. The number of wells showing growth were counted and compared to the vehicle control. An increase in the number of colonies of at least 2-fold over baseline and a dose–response indicated a positive response. Data were analyzed using an unpaired, one-sided Student’s <i>t</i> test.</div></div><div id="sec4_16_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i192" class="anchor-spacer"></div><h3 class="article-section__title" id="_i192"> Cytotoxicity Screening Panel</h3><div class="NLM_p last">HepG2 cells were plated on 384-well tissue culture-treated black-walled clear-bottomed polystyrene plates. The cells were treated with the test compound using a range of concentrations. At the end of the incubation period, the cells were loaded with the relevant dye/antibody for each cell health marker. The plates were then scanned using an automated fluorescent cellular imager, ArrayScan (Thermo Scientific Cellomics, Waltham, MA). Cytotoxicity was assessed using a multiparametric approach using high content screening (HCS).</div></div><div id="sec4_16_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i193" class="anchor-spacer"></div><h3 class="article-section__title" id="_i193"> Mouse Plasma and Brain Tissue Sampling</h3><div class="NLM_p last">All animal studies were conducted by Cyprotex Inc. (Watertown, MA). The levels of <b>20</b> in mouse plasma and brain tissue samples were assessed as follows. A single IP dose (20 mg/kg) of <b>20</b> was administered to 6–8 week old male C57BL/6 mice. The formulation consisted of 10% dimethylacetamide (DMA) and 60% PEG400, balanced with 30% saline. Plasma and brain samples were collected across eight time points (5, 15, 30, 60, 120, 240, 480, and 1440 min). Brain samples were homogenized in 2 volumes (1:2 w/v dilution) of phosphate buffer solution (PBS). Once homogenized, the samples were precipitated with 3 volumes of acetonitrile containing an analytical internal standard (bucetin). Samples were then centrifuged to remove the precipitated protein, and the supernatant was analyzed by LC–MS/MS. All brain samples were compared to a calibration curve prepared from a control mouse brain. Plasma samples (5, 15, 30, 60, and 120 min time points) were diluted 10-fold with the control plasma. No dilutions were made for the 240, 480, and 1440 min plasma samples. All plasma samples were precipitated with 3 volumes of acetonitrile containing an analytical internal standard (bucetin). Samples were then centrifuged to remove the precipitated protein, and the supernatant was analyzed by LC–MS/MS. All plasma samples were compared to a calibration curve prepared from control mouse plasma. Samples were analyzed by LC–MS/MS using a Waters Xevo TQ mass spectrometer coupled with an Acquity UPLC and a CTC PAL chilled autosampler, all controlled by MassLynx software (Waters). After separation on a C18 reverse-phase HPLC column (Waters Acquity HSS T3 2.1 × 50 mm<sup>2</sup> 1.8 μM) using an acetonitrile–water gradient system, peaks were analyzed by mass spectrometry (MS) using ESI ionization in MRM mode. All work was performed with appropriate local health regulations and ethical approval. Three mice were used for each time point collected, and the data represent means ± SEM.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i194" class="anchor-spacer"></div><h3 class="article-section__title" id="_i194"> Statistical Analyses</h3><div class="NLM_p last">Nonlinear regression analyses were conducted using GraphPad Prism version 8.0.1 (GraphPad Software, Inc., La Jolla, CA). Results are expressed as means ± SEM. EC<sub>50</sub>, IC<sub>50</sub>, <i>E</i><sub>max</sub>, and <i>I</i><sub>max</sub> values were calculated from individual concentration–response curves and then averaged to generate means and SEM values. Other statistical tests were performed as described in the legends.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i195"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00424" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88575" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88575" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00424?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00424</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Bioanalysis of compound <b>20</b> in samples from mouse plasma and brain; functional profiling of CJ-1639 and pramipexole against an array of 168 known GPCRs; MS analysis for key analog <b>20</b>; HPLC and NMR spectra; and images of <sup>1</sup>H and <sup>13</sup>C NMR spectra for final analog compounds <b>1</b>–<b>109</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and SAR data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Protein data bank for D3R homology model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf">jm0c00424_si_001.pdf (7.16 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_002.csv">jm0c00424_si_002.csv (12.26 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_003.pdb">jm0c00424_si_003.pdb (399.89 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00424" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin J. Frankowski</span> - <span class="hlFld-Affiliation affiliation">University
of Kansas Specialized Chemistry Center, University of Kansas, Lawrence, Kansas 66047, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel
Hill, North Carolina 27599, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5b303e2d32353d1b2e3538753e3f2e"><span class="__cf_email__" data-cfemail="244f41524d4a4264514a470a414051">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David R. Sibley</span> - <span class="hlFld-Affiliation affiliation">Molecular
Neuropharmacology Section, National Institute of Neurological Disorders
and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0624-962X" title="Orcid link">http://orcid.org/0000-0002-0624-962X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f2819b909e978b96b29c9b9c9681dc9c9b9adc959d84"><span class="__cf_email__" data-cfemail="c3b0aaa1afa6baa783adaaada7b0edadaaabeda4acb5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy E. Moritz</span> - <span class="hlFld-Affiliation affiliation">Molecular
Neuropharmacology Section, National Institute of Neurological Disorders
and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Benjamin Free</span> - <span class="hlFld-Affiliation affiliation">Molecular
Neuropharmacology Section, National Institute of Neurological Disorders
and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2428-0487" title="Orcid link">http://orcid.org/0000-0002-2428-0487</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Warren S. Weiner</span> - <span class="hlFld-Affiliation affiliation">University
of Kansas Specialized Chemistry Center, University of Kansas, Lawrence, Kansas 66047, United States</span>; 
    <span>Present Address:
                        (W.S.W.) University of Arizona Health Sciences, College of Medicine, 1501 N. Campbell Avenue, Tucson, Arizona 85724</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emmanuel O. Akano</span> - <span class="hlFld-Affiliation affiliation">Molecular
Neuropharmacology Section, National Institute of Neurological Disorders
and Stroke, Intramural Research Program, National Institutes of Health, 35 Convent Drive, MSC-3723, Bethesda, Maryland 20892-3723, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Disha Gandhi</span> - <span class="hlFld-Affiliation affiliation">Center
for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel
Hill, North Carolina 27599, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ara Abramyan</span> - <span class="hlFld-Affiliation affiliation">Computational
Chemistry and Molecular Biophysics Unit, Molecular Targets and Medications
Discovery Branch, National Institute on Drug Abuse, Intramural Research
Program, National Institutes of Health, Baltimore, Maryland, 333 Cassell
Drive, Baltimore, Maryland 21224, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas M. Keck</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry & Biochemistry, Department of Molecular & Cellular
Biosciences, College of Science and Mathematics, Rowan University, 201 Mullica Hill Road, Glassboro, New Jersey 08028, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1845-9373" title="Orcid link">http://orcid.org/0000-0003-1845-9373</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marc Ferrer</span> - <span class="hlFld-Affiliation affiliation">NIH Chemical
Genomics Center, Division of Preclinical Innovation, National Center
for Advancing Translational Sciences, National
Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Hu</span> - <span class="hlFld-Affiliation affiliation">NIH Chemical
Genomics Center, Division of Preclinical Innovation, National Center
for Advancing Translational Sciences, National
Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noel Southall</span> - <span class="hlFld-Affiliation affiliation">NIH Chemical
Genomics Center, Division of Preclinical Innovation, National Center
for Advancing Translational Sciences, National
Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph Steiner</span> - <span class="hlFld-Affiliation affiliation">NeuroTherapeutics
Development Unit, National Institute for Neurological Disorders and
Stroke, Intramural Research Program, National
Institutes of Health, Bethesda, Maryland 20892, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Aubé</span> - <span class="hlFld-Affiliation affiliation">University
of Kansas Specialized Chemistry Center, University of Kansas, Lawrence, Kansas 66047, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel
Hill, North Carolina 27599, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1049-5767" title="Orcid link">http://orcid.org/0000-0003-1049-5767</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Shi</span> - <span class="hlFld-Affiliation affiliation">Computational
Chemistry and Molecular Biophysics Unit, Molecular Targets and Medications
Discovery Branch, National Institute on Drug Abuse, Intramural Research
Program, National Institutes of Health, Baltimore, Maryland, 333 Cassell
Drive, Baltimore, Maryland 21224, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e15268-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i198">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20157" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20157" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Benjamin Neuenswander for preparative and analytical HPLC and Patrick Porubsky for compound management. The authors thank the University of North Carolina’s Department of Chemistry Mass Spectrometry Core Laboratory for their assistance with mass spectrometry analysis. Q Exactive HF-X system HRMS determinations were supported by the National Science Foundation under Grant No. (CHE-1726291). The authors thank Shaomeng Wang, Ph.D. at the University of Michigan, for the kind gift of Compound CJ-1639. Receptor binding profiles were generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program, contract # HHSN-271-2018-00023-C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, Ph.D. at the University of North Carolina at Chapel Hill, and Project Officer Jamie Driscoll at NIMH, Bethesda, MD. Support for this research was provided by the National Institute of Neurological Disorders and Stroke-Intramural Research Program, the National Institute on Drug Abuse-Intramural Research Program (Z1A DA000609), and Molecular Libraries Initiative funding to the University of Kansas Specialized Chemistry Center (U54HG005031), and generous support was provided by the Eshelman Institute for Innovation at the UNC Eshelman School of Pharmacy.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">(MPTP)</td><td class="NLM_def"><p class="first last">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p></td></tr><tr><td class="NLM_term">(HTR2A)</td><td class="NLM_def"><p class="first last">5HT2A serotonergic receptor</p></td></tr><tr><td class="NLM_term">(6-OHDA)</td><td class="NLM_def"><p class="first last">6-hydroxydopamine</p></td></tr><tr><td class="NLM_term">(ADRA2C)</td><td class="NLM_def"><p class="first last">alpha2C-adrenergic receptor</p></td></tr><tr><td class="NLM_term">(BRET)</td><td class="NLM_def"><p class="first last">bioluminescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">(BDNF)</td><td class="NLM_def"><p class="first last">brain-derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">(CCKAR)</td><td class="NLM_def"><p class="first last">cholecystokinin A receptor</p></td></tr><tr><td class="NLM_term">(DA)</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">(DAR)</td><td class="NLM_def"><p class="first last">dopamine receptor</p></td></tr><tr><td class="NLM_term">(DPBS)</td><td class="NLM_def"><p class="first last">Dulbecco’s phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">(EBSS)</td><td class="NLM_def"><p class="first last">Earle’s balanced salt solution</p></td></tr><tr><td class="NLM_term">(EBI2)</td><td class="NLM_def"><p class="first last">Epstein–Barr virus-induced GPCR 2</p></td></tr><tr><td class="NLM_term">(pERK)</td><td class="NLM_def"><p class="first last">ERK1/2 phosphorylation</p></td></tr><tr><td class="NLM_term">(FGF)</td><td class="NLM_def"><p class="first last">fibroblast growth factor</p></td></tr><tr><td class="NLM_term">(GRKs)</td><td class="NLM_def"><p class="first last">G protein-coupled receptor kinases</p></td></tr><tr><td class="NLM_term">(GDNF)</td><td class="NLM_def"><p class="first last">glial-derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">(GPCR)</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">(HTS)</td><td class="NLM_def"><p class="first last">high-throughput screen</p></td></tr><tr><td class="NLM_term">(IP1)</td><td class="NLM_def"><p class="first last">inositol 1-phosphate</p></td></tr><tr><td class="NLM_term">(MD)</td><td class="NLM_def"><p class="first last">molecular dynamics</p></td></tr><tr><td class="NLM_term">(MLPCN)</td><td class="NLM_def"><p class="first last">Molecular Libraries Probe Production Centers Network</p></td></tr><tr><td class="NLM_term">(OBS)</td><td class="NLM_def"><p class="first last">orthosteric binding site</p></td></tr><tr><td class="NLM_term">(PD)</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">(PEI)</td><td class="NLM_def"><p class="first last">polyethylenimine</p></td></tr><tr><td class="NLM_term">(PTGER2)</td><td class="NLM_def"><p class="first last">prostaglandin E receptor 2</p></td></tr><tr><td class="NLM_term">(PDSP)</td><td class="NLM_def"><p class="first last">Psychoactive Drug Screening Program</p></td></tr><tr><td class="NLM_term">(RLU)</td><td class="NLM_def"><p class="first last">relative luminescence unit</p></td></tr><tr><td class="NLM_term">(RLS)</td><td class="NLM_def"><p class="first last">restless legs syndrome</p></td></tr><tr><td class="NLM_term">(EDG8)</td><td class="NLM_def"><p class="first last">sphingosine-1-phosphate 5 receptor</p></td></tr><tr><td class="NLM_term">(SAR)</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">(TM)</td><td class="NLM_def"><p class="first last">transmembrane domain</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i200">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 101 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsma, F. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Molecular biology of dopamine receptors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/0165-6147(92)90025-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2F0165-6147%2892%2990025-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1561715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK38XhsVCjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1992&pages=61-69&author=D.+R.+Sibleyauthor=F.+J.+Monsma&title=Molecular+biology+of+dopamine+receptors&doi=10.1016%2F0165-6147%2892%2990025-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biology of dopamine receptors</span></div><div class="casAuthors">Sibley, David R.; Monsma, Frederick J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-9</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    </div><div class="casAbstract">A review, with 58 refs., of the mol. characteristics of the recently cloned dopamine receptors.  The prospects for the cloning and identification of addnl. subtypes in this receptor family are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2MT0wXZx0J7Vg90H21EOLACvtfcHk0lhcgej-VsPwsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsVCjs74%253D&md5=6ca0cd0927c4ea79da78f3f48dfacaa3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0165-6147%2892%2990025-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-6147%252892%252990025-2%26sid%3Dliteratum%253Aachs%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMonsma%26aufirst%3DF.%2BJ.%26atitle%3DMolecular%2520biology%2520of%2520dopamine%2520receptors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1992%26volume%3D13%26spage%3D61%26epage%3D69%26doi%3D10.1016%2F0165-6147%2892%2990025-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Money, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanwood, G. D.</span></span> <span> </span><span class="NLM_article-title">Developmental origins of brain disorders: roles for dopamine</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">260</span>, <span class="refDoi"> DOI: 10.3389/fncel.2013.00260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.3389%2Ffncel.2013.00260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24391541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCit7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=260&author=K.+M.+Moneyauthor=G.+D.+Stanwood&title=Developmental+origins+of+brain+disorders%3A+roles+for+dopamine&doi=10.3389%2Ffncel.2013.00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Developmental origins of brain disorders: roles for dopamine</span></div><div class="casAuthors">Money, Kelli M.; Stanwood, Gregg D.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">260/1-260/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Neurotransmitters and neuromodulators, such as dopamine, participate in a wide range of behavioral and cognitive functions in the adult brain, including movement, cognition and reward.  Dopamine-mediated signaling plays a fundamental neurodevelopmental role in forebrain differentiation and circuit formation.  These developmental effects, such as modulation of neuronal migration and dendritic growth, occur before synaptogenesis and demonstrate novel roles for dopaminergic signaling beyond neuromodulation at the synapse.  Pharmacol. and genetic disruptions demonstrate that these effects are brain region- and receptor subtype-specific.  For example, the striatum and frontal cortex exhibit abnormal neuronal structure and function following prenatal disruption of dopamine receptor signaling.  Alterations in these processes are implicated in the pathophysiol. of neuropsychiatric disorders and emerging studies of neurodevelopmental disruptions may shed light on the pathophysiol. of abnormal neuronal circuitry in neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEMjXRriak9bVg90H21EOLACvtfcHk0lgC7_MtBtYGdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCit7zN&md5=68a87dee0dc7b8767e63e20f24abcf1b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2013.00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2013.00260%26sid%3Dliteratum%253Aachs%26aulast%3DMoney%26aufirst%3DK.%2BM.%26aulast%3DStanwood%26aufirst%3DG.%2BD.%26atitle%3DDevelopmental%2520origins%2520of%2520brain%2520disorders%253A%2520roles%2520for%2520dopamine%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2013%26volume%3D7%26spage%3D260%26doi%3D10.3389%2Ffncel.2013.00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">Dopamine receptors - IUPHAR Review 13</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1111/bph.12906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fbph.12906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25671228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1-23&author=J.+M.+Beaulieuauthor=S.+Espinozaauthor=R.+R.+Gainetdinov&title=Dopamine+receptors+-+IUPHAR+Review+13&doi=10.1111%2Fbph.12906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors - IUPHAR Review 13</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Espinoza, Stefano; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The variety of physiol. functions controlled by dopamine in the brain and periphery is mediated by the D1, D2, D3, D4 and D5 dopamine GPCRs.  Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease.  Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-assocd. behaviors and functions.  Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as β-arrestins that are classically involved in GPCR desensitization.  Another level of complexity is the growing appreciation of the physiol. roles played by dopamine receptor heteromers.  Applications of new in vivo techniques have significantly furthered the understanding of the physiol. functions played by dopamine receptors.  Here we provide an update of the current knowledge regarding the complex biol., signalling, physiol. and pharmacol. of dopamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fpdKAWrR5rVg90H21EOLACvtfcHk0lgC7_MtBtYGdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ&md5=7f15533abc8fb6aa76a4ec41072b6219</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fbph.12906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12906%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DDopamine%2520receptors%2520-%2520IUPHAR%2520Review%252013%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1%26epage%3D23%26doi%3D10.1111%2Fbph.12906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaar, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natesan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutcheon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O. D.</span></span> <span> </span><span class="NLM_article-title">Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="NLM_elocation-id">107704</span> <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.107704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.neuropharm.2019.107704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=31299229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BB3Mzmslagsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+J.+Kaarauthor=S.+Natesanauthor=R.+McCutcheonauthor=O.+D.+Howes&title=Antipsychotics%3A+mechanisms+underlying+clinical+response+and+side-effects+and+novel+treatment+approaches+based+on+pathophysiology&doi=10.1016%2Fj.neuropharm.2019.107704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology</span></div><div class="casAuthors">Kaar Stephen J; Howes Oliver D; Natesan Sridhar; McCutcheon Robert</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107704</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic disorders but are ineffective for some patients and associated with side-effects and nonadherence in others.  We review the in vitro, pre-clinical, clinical and molecular imaging evidence on the mode of action of antipsychotics and their side-effects.  This identifies the key role of striatal dopamine D2 receptor blockade for clinical response, but also for endocrine and motor side-effects, indicating a therapeutic window for D2 blockade.  We consider how partial D2/3 receptor agonists fit within this framework, and the role of off-target effects of antipsychotics, particularly at serotonergic, histaminergic, cholinergic, and adrenergic receptors for efficacy and side-effects such as weight gain, sedation and dysphoria.  We review the neurobiology of schizophrenia relevant to the mode of action of antipsychotics, and for the identification of new treatment targets.  This shows elevated striatal dopamine synthesis and release capacity in dorsal regions of the striatum underlies the positive symptoms of psychosis and suggests reduced dopamine release in cortical regions contributes to cognitive and negative symptoms.  Current drugs act downstream of the major dopamine abnormalities in schizophrenia, and potentially worsen cortical dopamine function.  We consider new approaches including targeting dopamine synthesis and storage, autoreceptors, and trace amine receptors, and the cannabinoid, muscarinic, GABAergic and glutamatergic regulation of dopamine neurons, as well as post-synaptic modulation through phosphodiesterase inhibitors.  Finally, we consider treatments for cognitive and negative symptoms such dopamine agonists, nicotinic agents and AMPA modulators before discussing immunological approaches which may be disease modifying.  This article is part of the issue entitled 'Special Issue on Antipsychotics'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_8nvOYm_yGkloaUqgkFHkfW6udTcc2eYhyC8dPCyWHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mzmslagsw%253D%253D&md5=06ca3f300890d137860206a6bd3b0b99</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.107704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.107704%26sid%3Dliteratum%253Aachs%26aulast%3DKaar%26aufirst%3DS.%2BJ.%26aulast%3DNatesan%26aufirst%3DS.%26aulast%3DMcCutcheon%26aufirst%3DR.%26aulast%3DHowes%26aufirst%3DO.%2BD.%26atitle%3DAntipsychotics%253A%2520mechanisms%2520underlying%2520clinical%2520response%2520and%2520side-effects%2520and%2520novel%2520treatment%2520approaches%2520based%2520on%2520pathophysiology%26jtitle%3DNeuropharmacology%26date%3D2019%26doi%3D10.1016%2Fj.neuropharm.2019.107704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battagello, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittencourt, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, R. G.</span></span> <span> </span><span class="NLM_article-title">Dopamine: functions, signaling, and association with neurological diseases</span>. <i>Cell. Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1007/s10571-018-0632-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs10571-018-0632-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30446950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BB3crhvVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=31-59&author=M.+O.+Kleinauthor=D.+S.+Battagelloauthor=A.+R.+Cardosoauthor=D.+N.+Hauserauthor=J.+C.+Bittencourtauthor=R.+G.+Correa&title=Dopamine%3A+functions%2C+signaling%2C+and+association+with+neurological+diseases&doi=10.1007%2Fs10571-018-0632-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine: Functions, Signaling, and Association with Neurological Diseases</span></div><div class="casAuthors">Klein Marianne O; Battagello Daniella S; Cardoso Ariel R; Bittencourt Jackson C; Hauser David N; Correa Ricardo G; Bittencourt Jackson C</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular neurobiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The dopaminergic system plays important roles in neuromodulation, such as motor control, motivation, reward, cognitive function, maternal, and reproductive behaviors.  Dopamine is a neurotransmitter, synthesized in both central nervous system and the periphery, that exerts its actions upon binding to G protein-coupled receptors.  Dopamine receptors are widely expressed in the body and function in both the peripheral and the central nervous systems.  Dopaminergic signaling pathways are crucial to the maintenance of physiological processes and an unbalanced activity may lead to dysfunctions that are related to neurodegenerative diseases.  Unveiling the neurobiology and the molecular mechanisms that underlie these illnesses may contribute to the development of new therapies that could promote a better quality of life for patients worldwide.  In this review, we summarize the aspects of dopamine as a catecholaminergic neurotransmitter and discuss dopamine signaling pathways elicited through dopamine receptor activation in normal brain function.  Furthermore, we describe the potential involvement of these signaling pathways in evoking the onset and progression of some diseases in the nervous system, such as Parkinson's, Schizophrenia, Huntington's, Attention Deficit and Hyperactivity Disorder, and Addiction.  A brief description of new dopaminergic drugs recently approved and under development treatments for these ailments is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuNldawXYWK-3MPKNEWB5RfW6udTcc2eYhyC8dPCyWHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crhvVKjsw%253D%253D&md5=a92f053e46bf4358f18571f34b3ea81d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs10571-018-0632-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10571-018-0632-3%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DM.%2BO.%26aulast%3DBattagello%26aufirst%3DD.%2BS.%26aulast%3DCardoso%26aufirst%3DA.%2BR.%26aulast%3DHauser%26aufirst%3DD.%2BN.%26aulast%3DBittencourt%26aufirst%3DJ.%2BC.%26aulast%3DCorrea%26aufirst%3DR.%2BG.%26atitle%3DDopamine%253A%2520functions%252C%2520signaling%252C%2520and%2520association%2520with%2520neurological%2520diseases%26jtitle%3DCell.%2520Mol.%2520Neurobiol.%26date%3D2019%26volume%3D39%26spage%3D31%26epage%3D59%26doi%3D10.1007%2Fs10571-018-0632-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+Won+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lgQwB4iWcI8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWon%2BHan%26aufirst%3DG.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-M.</span></span> <span> </span><span class="NLM_article-title">Current perspectives on the selective regulation of dopamine D2 and D3 receptors</span>. <i>Arch. Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1521</span>– <span class="NLM_lpage">1538</span>, <span class="refDoi"> DOI: 10.1007/s12272-010-1005-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs12272-010-1005-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21052931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlOqtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=1521-1538&author=D.+I.+Choauthor=M.+Zhengauthor=K.-M.+Kim&title=Current+perspectives+on+the+selective+regulation+of+dopamine+D2+and+D3+receptors&doi=10.1007%2Fs12272-010-1005-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspectives on the selective regulation of dopamine D2 and D3 receptors</span></div><div class="casAuthors">Cho, Dong Im; Zheng, Mei; Kim, Kyeong-Man</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1521-1538</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Among the characterized dopamine receptor subtypes, D2 receptor (D2R) and D3 receptor (D3R) are the main targets of neuroleptics that are currently in use.  In particular, D3R is closely related to the etiol. of schizophrenia and drug addiction.  The spatial expression patterns of D2R and D3R are distinct in certain areas of the brain.  D2R are heavily expressed in the regions responsible for motor functions, whereas D3R are more selectively expressed in the limbic regions, which are assocd. with cognitive and emotional functions.  Therefore, disturbances in the motor and endocrine functions, which are the most serious problems caused by the current neuroleptics, are likely to result from the non-selective blockade of D2R.  Selective regulation of D3R is needed to sep. the desired therapeutic activities from unwanted side effects that result from promiscuous blockade of other receptors.  D2R and D3R possess high sequence homol. and employ similar signaling pathways, and it is difficult to selectively regulate them.  In this review, we discuss the signaling mechanisms, intracellular trafficking, and desensitization properties of D2R and D3R.  In addn., the proteins interacting with D2R or D3R are discussed in relation to their roles in the regulation of receptor functions, followed by the current status of the development of selective D3R ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4cCMB-iwXjLVg90H21EOLACvtfcHk0lgQwB4iWcI8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlOqtr3K&md5=7dd5bae45a4c7f356f33523f999dafe6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs12272-010-1005-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-010-1005-8%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DD.%2BI.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DK.-M.%26atitle%3DCurrent%2520perspectives%2520on%2520the%2520selective%2520regulation%2520of%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2010%26volume%3D33%26spage%3D1521%26epage%3D1538%26doi%3D10.1007%2Fs12272-010-1005-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin Free, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2017.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.cellsig.2017.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=28716664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtF2qu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=75-81&author=A.+E.+Moritzauthor=R.+Benjamin+Freeauthor=D.+R.+Sibley&title=Advances+and+challenges+in+the+search+for+D2+and+D3+dopamine+receptor-selective+compounds&doi=10.1016%2Fj.cellsig.2017.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds</span></div><div class="casAuthors">Moritz, Amy E.; Benjamin Free, R.; Sibley, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Compds. that target D2-like dopamine receptors (DRs) are currently used as therapeutics for several neuropsychiatric disorders including schizophrenia (antagonists) and Parkinson's disease (agonists).  However, as the D2R and D3R subtypes are highly homologous, creating compds. with sufficient subtype-selectivity as well as drug-like properties for therapeutic use has proved challenging.  This review summarizes the progress that has been made in developing D2R- or D3R-selective antagonists and agonists, and also describes the exptl. conditions that need to be considered when detg. the selectivity of a given compd., as apparent selectivity can vary widely depending on assay conditions.  Future advances in this field may take advantage of currently available structural data to target alternative secondary binding sites through creating bivalent or bitopic chem. structures.  Alternatively, the use of high-throughput screening techniques to identify novel scaffolds that might bind to the D2R or D3R in areas other than the highly conserved orthosteric site, such as allosteric sites, followed by iterative medicinal chem. will likely lead to exceptionally selective compds. in the future.  More selective compds. will provide a better understanding of the normal and pathol. functioning of each receptor subtype, as well as offer the potential for improved therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprWt_AnCx4BbVg90H21EOLACvtfcHk0lgQwB4iWcI8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtF2qu7jI&md5=da8fe4b2437f67f0451f8c14412a8182</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2017.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DBenjamin%2BFree%26aufirst%3DR.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DAdvances%2520and%2520challenges%2520in%2520the%2520search%2520for%2520D2%2520and%2520D3%2520dopamine%2520receptor-selective%2520compounds%26jtitle%3DCell.%2520Signalling%26date%3D2018%26volume%3D41%26spage%3D75%26epage%3D81%26doi%3D10.1016%2Fj.cellsig.2017.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(01)00139-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FS0163-7258%2801%2900139-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=11578658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntV2hur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2001&pages=231-259&author=J.+N.+Joyce&title=Dopamine+D3+receptor+as+a+therapeutic+target+for+antipsychotic+and+antiparkinsonian+drugs&doi=10.1016%2FS0163-7258%2801%2900139-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs</span></div><div class="casAuthors">Joyce, J. N.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">231-259</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The cloning of the gene for the D3 receptor and subsequent identification of its distribution in brain and pharmacol. allowed for serious consideration of the possibility that it might be a target for drugs used to treat schizophrenia and Parkinson's disease (PD).  That is because it is highly expressed in limbic regions of the brain, exhibits low expression in motor divisions, and has pharmacol. similarity to the D2 receptor.  Thus, antipsychotics that were presumed to block D2 receptors also had high affinity for the D3 receptor.  Dopamine agonists used to treat the clin. symptoms of PD also have high affinity for the D3 receptor, and two D3 receptor-preferring agonists were effective for treatment of PD.  Many compds. achieving high potency and selectivity are now available, but few have reached clin. testing.  Recent findings with respect to the anatomy of this receptor in human brain, altered expression in schizophrenia and PD, and biol. models to study its function support the proposal that it is a target for development of drugs to alleviate symptoms in neuropsychiatric and neurol. disorders.  Because of distinct aspects of regulation of the D3 receptor, it represents a unique target for therapeutic intervention in schizophrenia without high potential for unintended side effects such as tardive dyskinesia.  It may also be that D3 receptor agonists can provide neuroprotective effects in PD and can modify clin. symptoms that D2 receptor-preferring agonists cannot provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAzYJRgnl5LVg90H21EOLACvtfcHk0lgQwB4iWcI8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntV2hur8%253D&md5=70af1ac4de6b531b5b3b13f0fe179d0f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2801%2900139-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252801%252900139-5%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26atitle%3DDopamine%2520D3%2520receptor%2520as%2520a%2520therapeutic%2520target%2520for%2520antipsychotic%2520and%2520antiparkinsonian%2520drugs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2001%26volume%3D90%26spage%3D231%26epage%3D259%26doi%3D10.1016%2FS0163-7258%2801%2900139-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Parkinson
Study Group, C. C. I.</span> <span> </span><span class="NLM_article-title">Long-term
effect of initiating pramipexole vs levodopa in early Parkinson disease</span>. <i>Arch. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1001/archneurol.2009.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1001%2Farchneurol.2009.32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=19433655" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=563-570&author=Parkinson%0AStudy+Group%2C+C.+C.+I.&title=Long-term%0Aeffect+of+initiating+pramipexole+vs+levodopa+in+early+Parkinson+disease&doi=10.1001%2Farchneurol.2009.32"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1001%2Farchneurol.2009.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneurol.2009.32%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DLong-term%250Aeffect%2520of%2520initiating%2520pramipexole%2520vs%2520levodopa%2520in%2520early%2520Parkinson%2520disease%26jtitle%3DArch.%2520Neurol.%26date%3D2009%26volume%3D66%26spage%3D563%26epage%3D570%26doi%3D10.1001%2Farchneurol.2009.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presgraves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borwege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osredkar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Replogle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PazSoldan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1016/S0014-4886(03)00353-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FS0014-4886%2803%2900353-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=14637109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVekt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2003&pages=393-407&author=J.+N.+Joyceauthor=S.+Presgravesauthor=L.+Renishauthor=S.+Borwegeauthor=T.+Osredkarauthor=D.+Hagnerauthor=M.+Replogleauthor=M.+PazSoldanauthor=M.+J.+Millan&title=Neuroprotective+effects+of+the+novel+D3%2FD2+receptor+agonist+and+antiparkinson+agent%2C+S32504%2C+in+vitro+against+1-methyl-4-phenylpyridinium+%28MPP%2B%29+and+in+vivo+against+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine+%28MPTP%29%3A+a+comparison+to+ropinirole&doi=10.1016%2FS0014-4886%2803%2900353-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole</span></div><div class="casAuthors">Joyce, Jeffrey N.; Presgraves, Steve; Renish, Lynn; Borwege, Sabinne; Osredkar, Tracy; Hagner, Diane; Replogle, Maria; PazSoldan, Mateo; Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">393-407</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The novel naphtoxazine deriv. and preferential D3 vs. D2 receptor agonist, S32504, restores perturbed motor function in rodent and primate models of antiparkinsonian activity with a potency superior to those of two further, preferential D3 receptor agonists, pramipexole and ropinirole.  However, potential neuroprotective properties of S32054 have not, to date, been evaluated.  Herein, employing several measures of cellular integrity, we demonstrate that S32504 robustly, concn.-dependently and completely protects terminally differentiated SH-SY5Y cells against 1-methyl-4-phenylpyridinium (MPP+)-induced cell death in vitro.  Further, S32504 was substantially more potent than pramipexole and ropinirole, the latter of which was neurotoxic at high concns.  In vivo, subchronic treatment with low (0.25 mg/kg) and high (2.5 mg/kg) doses of S32504 prior to and during treatment of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP, provided complete protection against MPTP-induced tyrosine hydroxylase immunoreactive (TH-IR) neuronal death in the substantia nigra pars compacta and ventral tegmental area.  A high dose of ropinirole (2.5 mg/kg) provided some protection but statistical significance was not attained, and a low dose (0.25 mg/kg) was ineffective.  Neither drug afforded protection against the MPTP-induced loss of DA fibers in the striatum, as measured by TH-IR and dopamine transporter immunoreactive fiber counts.  In conclusion, the novel naphotoxazine and dopaminergic agonist, S32504, robustly protects dopaminergic neurons against the neurotoxic effects of MPP+ and MPTP in in vitro and in vivo models, resp.  The underlying mechanisms and therapeutic pertinence of these actions will be of interest to further evaluate in view of its potent actions in behavioral models of antiparkinson activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDej4-H1TCE7Vg90H21EOLACvtfcHk0lgGzVpL10AjFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVekt7w%253D&md5=b63b7542a3897800ae31c602d6bb5eb0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0014-4886%2803%2900353-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4886%252803%252900353-4%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26aulast%3DPresgraves%26aufirst%3DS.%26aulast%3DRenish%26aufirst%3DL.%26aulast%3DBorwege%26aufirst%3DS.%26aulast%3DOsredkar%26aufirst%3DT.%26aulast%3DHagner%26aufirst%3DD.%26aulast%3DReplogle%26aufirst%3DM.%26aulast%3DPazSoldan%26aufirst%3DM.%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DNeuroprotective%2520effects%2520of%2520the%2520novel%2520D3%252FD2%2520receptor%2520agonist%2520and%2520antiparkinson%2520agent%252C%2520S32504%252C%2520in%2520vitro%2520against%25201-methyl-4-phenylpyridinium%2520%2528MPP%252B%2529%2520and%2520in%2520vivo%2520against%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine%2520%2528MPTP%2529%253A%2520a%2520comparison%2520to%2520ropinirole%26jtitle%3DExp.%2520Neurol.%26date%3D2003%26volume%3D184%26spage%3D393%26epage%3D407%26doi%3D10.1016%2FS0014-4886%2803%2900353-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osredkar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reploge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakakibara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span> <span> </span><span class="NLM_article-title">Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2004.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.expneurol.2004.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=15081599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVCht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2004&pages=178-189&author=J.+N.+Joyceauthor=T.+C.+Derauthor=L.+Renishauthor=T.+Osredkarauthor=D.+Hagnerauthor=M.+Replogeauthor=S.+Sakakibaraauthor=S.+Ueda&title=Loss+of+D3+receptors+in+the+zitter+mutant+rat+is+not+reversed+by+L-dopa+treatment&doi=10.1016%2Fj.expneurol.2004.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment</span></div><div class="casAuthors">Joyce, Jeffrey N.; Der, T. C.; Renish, Lynn; Osredkar, Tracy; Hagner, Diane; Reploge, Maria; Sakakibara, Shinichi; Ueda, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">In Parkinson's disease (PD) and animal models of parkinsonism the destruction of nigrostriatal (NSB) system results in a marked loss of the dopamine D3 receptor and mRNA in the islands of Calleja (ICj) and the nucleus accumbens shell (NAS).  In animal models, it has been reported that both measures are elevated by repeated intermittent administration of L-dopa.  However, a large proportion of PD cases are resistant to l-dopa-induced elevation of D3 receptor no.  The zitter mutant (Zi/Zi) rat replicates the slow progressive degeneration of the NSB obsd. in PD and also exhibits a loss of D3 receptor no. in the NAS or ICj.  To test if this could be reversed with subchronic L-dopa treatment, injections of carbidopa (10 mg/kg i.p.) were followed an hour later with injection of L-dopa (100 mg/kg i.p.) twice a day for 10 days.  In control Sprague-Dawley (SD) and zitter heterozygote (Zi/-) rats that do not show a loss of D3 receptors with vehicle treatment, l-dopa produced no change in D3 receptor no. or in DA terminal d. as measured by dopamine transporter (DAT) binding and tyrosine hydroxylase immunoautoradiog. (TH-IR).  There was a marked loss of DAT and TH-IR in caudate-putamen (CPu) and NA, as well as D3 receptors in NAS and ICj in Zi/Zi rats but no further change with L-dopa treatment.  To det. if the resistance to L-dopa-induced increase in D3 receptor was due to a deficiency in expression of cortical BDNF or its receptor, TrkB, in CPu and NAS, we examd. BDNF mRNA by ISHH in frontal cortex and TrkB mRNA in frontal cortex, CPu, and NA.  The loss of the NSB in the Zi/Zi did not alter levels of BDNF or TrkB mRNA, nor did L-dopa administration alter levels BDNF or TrkB mRNA.  Thus, unlike in 6-hydroxydopamine-treated rats, in Zi/Zi rats administered L-dopa does not reverse the loss of BDNF mRNA or lead to an elevation of D3 receptor no.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNXHY6AxSivbVg90H21EOLACvtfcHk0lgGzVpL10AjFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVCht7k%253D&md5=39ec32bf5bc734e05f8afd45f6d5337d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2004.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2004.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26aulast%3DDer%26aufirst%3DT.%2BC.%26aulast%3DRenish%26aufirst%3DL.%26aulast%3DOsredkar%26aufirst%3DT.%26aulast%3DHagner%26aufirst%3DD.%26aulast%3DReploge%26aufirst%3DM.%26aulast%3DSakakibara%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DS.%26atitle%3DLoss%2520of%2520D3%2520receptors%2520in%2520the%2520zitter%2520mutant%2520rat%2520is%2520not%2520reversed%2520by%2520L-dopa%2520treatment%26jtitle%3DExp.%2520Neurol.%26date%3D2004%26volume%3D187%26spage%3D178%26epage%3D189%26doi%3D10.1016%2Fj.expneurol.2004.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, W.</span></span> <span> </span><span class="NLM_article-title">Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson’s disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">2513</span>– <span class="NLM_lpage">2523</span>, <span class="refDoi"> DOI: 10.1002/jnr.22405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fjnr.22405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=20623619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1GmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2010&pages=2513-2523&author=C.+Liauthor=S.+Biswasauthor=X.+Liauthor=A.+K.+Duttaauthor=W.+Le&title=Novel+D3+dopamine+receptor-preferring+agonist+D-264%3A+evidence+of+neuroprotective+property+in+Parkinson%E2%80%99s+disease+animal+models+induced+by+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine+and+lactacystin&doi=10.1002%2Fjnr.22405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin</span></div><div class="casAuthors">Li, Chao; Biswas, S.; Li, Xingang; Dutta, A. K.; Le, Weidong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2513-2523</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD), a progressive neurodegenerative movement disorder, is known to be caused by diverse pathol. conditions resulting from dysfunction of the ubiquitin-proteasome system (UPS), mitochondria, and oxidative stress leading to preferential nigral dopamine (DA) neuron degeneration in the substantia nigra.  In the present study, we evaluated the novel D3 receptor-preferring agonist D-264 in a mouse model of PD to evaluate its neuroprotective properties against both the nigrostriatal dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and the proteasome inhibitor lactacystin-induced dopaminergic degeneration.  C57BL/6 male mice either were given MPTP by i.p. injection twice per day for 2 successive days at a dose 20 mg/kg or were microinjected with lactacystin bilaterally (1.25 μg/side) into the medial forebrain bundle (MFB).  Pretreatment with D-264 (1 mg/kg and 5 mg/kg, i.p., once per day), started 7 days before administration of MPTP or lactacystin.  We found that D-264 significantly improved behavioral performance, attenuated both MPTP- and lactacystin-induced DA neuron loss, and blocked proteasomal inhibition and microglial activation in the substantia nigra (SN).  Furthermore, D-264 treatment was shown to increase the levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived factor (GDNF) in MPTP- and lactacystin-treated mice, possibly indicating, at least in part, the mechanism of neuroprotection by D-264.  Furthermore, pretreatment with the D3 receptor antagonist U99194 significantly altered the effect of neuroprotection conferred by D-264.  Collectively, our study demonstrates that D-264 can prevent neurodegeneration induced by the selective neurotoxin MPTP and the UPS inhibitor lactacystin.  The results indicate that D-264 could potentially serve as a symptomatic and neuroprotective treatment agent for PD. © 2010 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5cBGfbUSM67Vg90H21EOLACvtfcHk0li54-w6ruSeug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1GmtLY%253D&md5=32d866170d2ac26eafa98608393881c1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fjnr.22405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.22405%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DLe%26aufirst%3DW.%26atitle%3DNovel%2520D3%2520dopamine%2520receptor-preferring%2520agonist%2520D-264%253A%2520evidence%2520of%2520neuroprotective%2520property%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520animal%2520models%2520induced%2520by%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine%2520and%2520lactacystin%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2010%26volume%3D88%26spage%3D2513%26epage%3D2523%26doi%3D10.1002%2Fjnr.22405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolsey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borwege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagner, D.</span></span> <span> </span><span class="NLM_article-title">Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson’s disease, and downregulates the dopamine transporter via the D3 receptor</span>. <i>BMC Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1186/1741-7007-2-22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1186%2F1741-7007-2-22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=15473914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BD2M7lsVKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=22&author=J.+N.+Joyceauthor=C.+Woolseyauthor=H.+Ryooauthor=S.+Borwegeauthor=D.+Hagner&title=Low+dose+pramipexole+is+neuroprotective+in+the+MPTP+mouse+model+of+Parkinson%E2%80%99s+disease%2C+and+downregulates+the+dopamine+transporter+via+the+D3+receptor&doi=10.1186%2F1741-7007-2-22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor</span></div><div class="casAuthors">Joyce Jeffrey N; Woolsey Cheryl; Ryoo Han; Borwege Sabine; Hagner Diane</div><div class="citationInfo"><span class="NLM_cas:title">BMC biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Our aim was to determine if pramipexole, a D3 preferring agonist, effectively reduced dopamine neuron and fiber loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model when given at intraperitoneal doses corresponding to clinical doses.  We also determined whether subchronic treatment with pramipexole regulates dopamine transporter function, thereby reducing intracellular transport of the active metabolite of MPTP, 1-methyl-4-phenylpyridinium (MPP+).  METHODS:  Ten 12-month old C57BL/6 mice were treated with MPTP (or saline) twice per day at 20 mg/kg s.c. (4 injections over 48 h).  Mice were pretreated for 3 days and during the 2-day MPTP regimen with pramipexole (0.1 mg/kg/day) or saline.  Stereological quantification of dopamine neuron number and optical density measurement of dopamine fiber loss were carried out at 1 week after treatment, using immunostaining for dopamine transporter (DAT) and tyrosine hydroxylase (TH).  Additional wild-type (WT) and D3 receptor knockout (KO) mice were treated for 5 days with pramipexole (0.1 mg/kg/day) or vehicle.  The kinetics of [3H]MPP+ and [3H]DA uptake (Vmax and Km) were determined 24 h later; and at 24 h and 14 days dopamine transporter density was measured by quantitative autoradiography.  RESULTS:  Pramipexole treatment completely antagonized the neurotoxic effects of MPTP, as measured by substantia nigra and ventral tegmental area TH-immunoreactive cell counts.  MPTP- induced loss of striatal innervation, as measured by DAT-immunoreactivity, was partially prevented by pramipexole, but not with regard to TH-IR.  Pramipexole also reduced DAT- immunoreactivity in non-MPTP treated mice.  Subchronic treatment with pramipexole lowered the Vmax for [3H]DA and [3H]MPP+ uptake into striatal synaptosomes of WT mice.  Pramipexole treatment lowered Vmax in WT but not D3 KO mice; however, D3 KO mice had lower Vmax for [3H]DA uptake.  There was no change in DAT number in WT with pramipexole treatment or D3 KO mice at 24 h post-treatment, but there was a reduction in WT-pramipexole treated and not in D3 KO mice at 14 days post-treatment.  CONCLUSION:  These results suggest that protection occurs at clinically suitable doses of pramipexole.  Protection could be due to a reduced amount of MPP+ taken up into DA terminals via DAT.  D3 receptor plays an important role in this regulation of transporter uptake and availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTvj5p-QMRX8SzjBFCN0BJfW6udTcc2eaOCgtsLtyo-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7lsVKitw%253D%253D&md5=a046e050141ec6fa787105912c3433d6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2F1741-7007-2-22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7007-2-22%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26aulast%3DWoolsey%26aufirst%3DC.%26aulast%3DRyoo%26aufirst%3DH.%26aulast%3DBorwege%26aufirst%3DS.%26aulast%3DHagner%26aufirst%3DD.%26atitle%3DLow%2520dose%2520pramipexole%2520is%2520neuroprotective%2520in%2520the%2520MPTP%2520mouse%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%252C%2520and%2520downregulates%2520the%2520dopamine%2520transporter%2520via%2520the%2520D3%2520receptor%26jtitle%3DBMC%2520Biol.%26date%3D2004%26volume%3D2%26spage%3D22%26doi%3D10.1186%2F1741-7007-2-22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iravani, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddon, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, A. H.</span></span> <span> </span><span class="NLM_article-title">Pramipexole protects against MPTP toxicity in non-human primates</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2005.03625.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fj.1471-4159.2005.03625.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=16464239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD28XivFSrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2006&pages=1315-1321&author=M.+M.+Iravaniauthor=C.+O.+Haddonauthor=J.+M.+Cooperauthor=P.+Jennerauthor=A.+H.+Schapira&title=Pramipexole+protects+against+MPTP+toxicity+in+non-human+primates&doi=10.1111%2Fj.1471-4159.2005.03625.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole protects against MPTP toxicity in non-human primates</span></div><div class="casAuthors">Iravani, Mahmoud M.; Haddon, Claire O.; Cooper, J. Mark; Jenner, Peter; Schapira, Anthony H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1315-1321</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The neurotoxin MPTP induces nigral dopaminergic cell death in primates and produces a partial model of Parkinson's disease (PD).  Pramipexole is a D2/D3 dopamine receptor agonist used in the symptomatic treatment of PD, and which also protects neuronal cells against dopaminergic toxins in vitro.  We now demonstrate that pramipexole partially prevents MPTP toxicity in vivo in a primate species.  Common marmosets were repeatedly treated with pramipexole either before, coincidentally with, or after low-dose MPTP treatment designed to induce a partial lesion of the substantia nigra.  Animals pretreated with pramipexole had a significantly greater no. of surviving tyrosine hydroxylase (TH) pos. neurons in the pars compacta of the substantia nigra.  Pramipexole pretreatment also prevented degeneration of striatal dopamine terminals.  Treatment with pramipexole concurrently with MPTP or following MPTP did not prevent TH-pos. cell loss.  Pramipexole pretreatment appears to induce adaptive changes that protect against dopaminergic cell loss in primates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuDu72oalI4LVg90H21EOLACvtfcHk0limfmImQyljbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivFSrur0%253D&md5=3b068af73bbcfd395b34387960fdff12</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2005.03625.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2005.03625.x%26sid%3Dliteratum%253Aachs%26aulast%3DIravani%26aufirst%3DM.%2BM.%26aulast%3DHaddon%26aufirst%3DC.%2BO.%26aulast%3DCooper%26aufirst%3DJ.%2BM.%26aulast%3DJenner%26aufirst%3DP.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%26atitle%3DPramipexole%2520protects%2520against%2520MPTP%2520toxicity%2520in%2520non-human%2520primates%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D96%26spage%3D1315%26epage%3D1321%26doi%3D10.1111%2Fj.1471-4159.2005.03625.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vu, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robie, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvey, P. M.</span></span> <span> </span><span class="NLM_article-title">Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine</span>. <i>J. Neural Transm.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1007/s007020050014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs007020050014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10847557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFeqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2000&pages=159-176&author=T.+Q.+Vuauthor=Z.+D.+Lingauthor=S.+Y.+Maauthor=H.+C.+Robieauthor=C.+W.+Tongauthor=E.+Y.+Chenauthor=J.+W.+Liptonauthor=P.+M.+Carvey&title=Pramipexole+attenuates+the+dopaminergic+cell+loss+induced+by+intraventricular+6-hydroxydopamine&doi=10.1007%2Fs007020050014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine</span></div><div class="casAuthors">Vu, T. Q.; Ling, Z. D.; Ma, S. Y.; Robie, H. C.; Tong, C. W.; Chen, E. Y.; Lipton, J. W.; Carvey, P. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-176</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">1435-1463</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Wien</span>)
        </div><div class="casAbstract">The D3 preferring dopamine agonist pramipexole has been shown to attenuate the cell loss induced by levodopa in vitro.  Pramipexole was herein evaluated in the 6-hydroxydopamine lesion model to det. its in vivo effect.  Rats were treated with pramipexole or saline before and after an intracerebroventricular 6-hydroxydopamine injection.  In the preliminary study, 6-hydroxydopamine produced a 68% redn. in striatal dopamine and a 62% loss in tyrosine hydroxylase immunoreactive (THir) cell counts in the substantia nigra.  Pramipexole treated animals exhibited a 29% and a 27% redn. in striatal dopamine and THir cell counts, resp.  THir cell counts and striatal dopamine were significantly correlated.  In the stereol. study, 6-hydroxydopamine reduced THir cell counts by 47% in saline treated animals and 26% in pramipexole treated animals.  These data demonstrate that pramipexole attenuates the biochem. and THir cell changes normally produced by 6-hydroxydopamine consistent with its neuroprotective actions in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyiX_1PSvUNbVg90H21EOLACvtfcHk0limfmImQyljbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFeqtLw%253D&md5=482f372bb740d3fe2e8d8016a4584bdc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs007020050014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs007020050014%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DT.%2BQ.%26aulast%3DLing%26aufirst%3DZ.%2BD.%26aulast%3DMa%26aufirst%3DS.%2BY.%26aulast%3DRobie%26aufirst%3DH.%2BC.%26aulast%3DTong%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DE.%2BY.%26aulast%3DLipton%26aufirst%3DJ.%2BW.%26aulast%3DCarvey%26aufirst%3DP.%2BM.%26atitle%3DPramipexole%2520attenuates%2520the%2520dopaminergic%2520cell%2520loss%2520induced%2520by%2520intraventricular%25206-hydroxydopamine%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2000%26volume%3D107%26spage%3D159%26epage%3D176%26doi%3D10.1007%2Fs007020050014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F. S.</span></span> <span> </span><span class="NLM_article-title">Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>475</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(03)02087-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FS0014-2999%2803%2902087-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=12954356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFSjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=475&publication_year=2003&pages=29-35&author=A.+D.+Ramirezauthor=S.+K.+Wongauthor=F.+S.+Menniti&title=Pramipexole+inhibits+MPTP+toxicity+in+mice+by+dopamine+D3+receptor+dependent+and+independent+mechanisms&doi=10.1016%2FS0014-2999%2803%2902087-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms</span></div><div class="casAuthors">Ramirez, Andres D.; Wong, Stephen K.-F.; Menniti, Frank S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">475</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The role of dopamine D3 receptors was investigated in mediating the neuroprotective effect of the dopamine D2/D3 receptor agonist (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminebenzothiazole (pramipexole) in vivo.  Pramipexole retained the ability to inhibit 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopamine depletion in mice in which the dopamine D3 receptor had been deleted.  However, the neuroprotective efficacy was reduced in the dopamine D3 receptor-deleted mice compared to that in littermates expressing the wildtype receptor.  Furthermore, the dopamine D3 receptor selective antagonist 2-{3-[4-(2-tert-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol (A-437203) partially inhibited the neuroprotective effect of pramipexole in dopamine D3 receptor expressing mice but not in receptor-deleted mice.  These results indicate that pramipexole protects dopamine neurons from MPTP-induced toxicity by mechanisms that are both dependent and independent of an interaction with dopamine D3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow_ATcma1GUbVg90H21EOLACvtfcHk0lht1UqxeekYMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFSjs7g%253D&md5=2c52641e3d4b7a8abdb1b56092704c9d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2902087-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252902087-9%26sid%3Dliteratum%253Aachs%26aulast%3DRamirez%26aufirst%3DA.%2BD.%26aulast%3DWong%26aufirst%3DS.%2BK.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26atitle%3DPramipexole%2520inhibits%2520MPTP%2520toxicity%2520in%2520mice%2520by%2520dopamine%2520D3%2520receptor%2520dependent%2520and%2520independent%2520mechanisms%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D475%26spage%3D29%26epage%3D35%26doi%3D10.1016%2FS0014-2999%2803%2902087-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lao, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. C.</span></span> <span> </span><span class="NLM_article-title">Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice</span>. <i>Neurotoxic. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1007/s12640-013-9408-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs12640-013-9408-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=23820985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKqsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=523-531&author=C.+L.+Laoauthor=Y.+H.+Kuoauthor=Y.+T.+Hsiehauthor=J.+C.+Chen&title=Intranasal+and+subcutaneous+administration+of+dopamine+D3+receptor+agonists+functionally+restores+nigrostriatal+dopamine+in+MPTP-treated+mice&doi=10.1007%2Fs12640-013-9408-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Intranasal and Subcutaneous Administration of Dopamine D3 Receptor Agonists Functionally Restores Nigrostriatal Dopamine in MPTP-Treated Mice</span></div><div class="casAuthors">Lao, Chu Lan; Kuo, Yen-Hsi; Hsieh, Yueh-Ting; Chen, Jin-Chung</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-531</span>CODEN:
                <span class="NLM_cas:coden">NURRFI</span>;
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a neurodegenerative disease with a hallmark motor defect caused by the death of dopaminergic neurons in the substantia nigra.  Intranasal drug administration may be useful for Parkinson's treatment because this route avoids first-pass metab. and increases bioavailability in the brain.  In this study, we investigated the neuroprotection/neurorestoration effect of dopamine D3 receptor (D3R) agonists administered via both intranasal and s.c. routes in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced PD mouse model.  Furthermore, we employed D3R knock-out mice to validate the dependence on D3R signaling.  We found that in wild-type mice, but not D3 receptor knockout mice, both intranasal and s.c. administration of D3R agonists rescue dopamine (DA) depletion in the striatum as well as DA neuronal death in the substantia nigra after MPTP treatment.  Moreover, s.c. 7-OH-DPAT administration significantly improved gait performance (stride length and overall running speed) of MPTP-lesioned mice after 7 and 14 days of recovery.  In addn., the distribution of D3 agonist 7-OH-DPAT was measured in designated brain areas by mass spectrometry anal. after s.c. and intranasal administration.  Our data suggest that intranasal administration of D3R agonist would be a practical approach to treat PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBAxJ7TfReC7Vg90H21EOLACvtfcHk0lht1UqxeekYMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKqsLbP&md5=345a2be3df95964dc94fbb289b33f369</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs12640-013-9408-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12640-013-9408-1%26sid%3Dliteratum%253Aachs%26aulast%3DLao%26aufirst%3DC.%2BL.%26aulast%3DKuo%26aufirst%3DY.%2BH.%26aulast%3DHsieh%26aufirst%3DY.%2BT.%26aulast%3DChen%26aufirst%3DJ.%2BC.%26atitle%3DIntranasal%2520and%2520subcutaneous%2520administration%2520of%2520dopamine%2520D3%2520receptor%2520agonists%2520functionally%2520restores%2520nigrostriatal%2520dopamine%2520in%2520MPTP-treated%2520mice%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2013%26volume%3D24%26spage%3D523%26epage%3D531%26doi%3D10.1007%2Fs12640-013-9408-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weintraub, D.</span></span> <span> </span><span class="NLM_article-title">Dopamine and impulse control disorders in Parkinson’s disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">S93</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1002/ana.21454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fana.21454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=19127573" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=S93-100&author=D.+Weintraub&title=Dopamine+and+impulse+control+disorders+in+Parkinson%E2%80%99s+disease&doi=10.1002%2Fana.21454"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fana.21454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.21454%26sid%3Dliteratum%253Aachs%26aulast%3DWeintraub%26aufirst%3DD.%26atitle%3DDopamine%2520and%2520impulse%2520control%2520disorders%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2008%26volume%3D64%26spage%3DS93%26epage%3D100%26doi%3D10.1002%2Fana.21454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balarajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanna, A. E.</span></span> <span> </span><span class="NLM_article-title">The pathophysiology of impulse control disorders in Parkinson disease</span>. <i>Behav. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1155/2013/579092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1155%2F2013%2F579092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22713408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BC38jjtFejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=237-244&author=S.+Balarajahauthor=A.+E.+Cavanna&title=The+pathophysiology+of+impulse+control+disorders+in+Parkinson+disease&doi=10.1155%2F2013%2F579092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The pathophysiology of impulse control disorders in Parkinson disease</span></div><div class="casAuthors">Balarajah Sharmili; Cavanna Andrea Eugenio</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">237-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  This review aims to evaluate the most recent evidence on the pathophysiology of impulse control disorders (ICDs) in Parkinson disease (PD).  METHODS:  Computerised searches of Medline, Embase and PsycInfo, along with manual searches for grey literature, were conducted and resulted in a total of 16 studies suitable for review.  RESULTS:  Evidence was divided into four categories: medication used in PD management, imaging studies, genetic analysis and subthalamic deep brain stimulation (STN-DBS).  Analysis of the literature reveals that both intrinsic and extrinsic factors may play a role in the pathophysiology of ICDs in PD.  Dysfunction of the mesocorticolimbic pathway and polymorphisms of the dopamine D3 and D4 receptors may increase an individual's susceptibility to the development of ICDs.  DISCUSSION:  Dopaminergic medication, particularly dopamine agonists (DAs), increases the risk of developing impulsive behaviours in a PD patient.  Further evidence, particularly in the form of prospective studies and randomised controlled trials is required to better establish the pathophysiology of ICDs in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTexXVCbB7JbrqxQ2mb9Pu8fW6udTcc2ebTeoleNx1agLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jjtFejsQ%253D%253D&md5=84e4e207c021c8bd8c2c44cf7a9af3bb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1155%2F2013%2F579092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F579092%26sid%3Dliteratum%253Aachs%26aulast%3DBalarajah%26aufirst%3DS.%26aulast%3DCavanna%26aufirst%3DA.%2BE.%26atitle%3DThe%2520pathophysiology%2520of%2520impulse%2520control%2520disorders%2520in%2520Parkinson%2520disease%26jtitle%3DBehav.%2520Neurol.%26date%3D2013%26volume%3D26%26spage%3D237%26epage%3D244%26doi%3D10.1155%2F2013%2F579092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaylock, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span> <span> </span><span class="NLM_article-title">Medication discovery for addiction: translating the dopamine D3 receptor hypothesis</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">882</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2012.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bcp.2012.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22781742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOqu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=882-890&author=A.+H.+Newmanauthor=B.+L.+Blaylockauthor=M.+A.+Naderauthor=J.+Bergmanauthor=D.+R.+Sibleyauthor=P.+Skolnick&title=Medication+discovery+for+addiction%3A+translating+the+dopamine+D3+receptor+hypothesis&doi=10.1016%2Fj.bcp.2012.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis</span></div><div class="casAuthors">Newman, Amy Hauck; Blaylock, Brandi L.; Nader, Michael A.; Bergman, Jack; Sibley, David R.; Skolnick, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">882-890</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor (D3R) has been investigated as a potential target for medication development to treat substance use disorders (SUDs) with a particular focus on cocaine and methamphetamine.  Currently, there are no approved medications to treat cocaine and methamphetamine addiction and thus developing pharmacotherapeutics to complement existing behavioral strategies is a fundamental goal.  Novel compds. with high affinity and D3R selectivity have been evaluated in numerous animal models of drug abuse and favorable outcomes in nonhuman primate models of self-administration and relapse have provided compelling evidence to advance these agents into the clinic.  One approach is to repurpose drugs that share the D3R mechanism and already have clin. utility, and to this end buspirone has been identified as a viable candidate for clin. trials.  A second, but substantially more resource intensive and risky approach involves the development of compds. that exclusively target D3R, such as GSK598809 and PG 619.  Clin. investigation of these drugs or other novel D3R-selective agents will provide a better understanding of the role D3R plays in addiction and whether or not antagonists or partial agonists that are D3R selective are effective in achieving abstinence in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_waGudfGt4LVg90H21EOLACvtfcHk0lhifgy6QZ4ddA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOqu73O&md5=820f1ddd46c9888c687bc0cc8cd3aa96</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBlaylock%26aufirst%3DB.%2BL.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DSkolnick%26aufirst%3DP.%26atitle%3DMedication%2520discovery%2520for%2520addiction%253A%2520translating%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D882%26epage%3D890%26doi%3D10.1016%2Fj.bcp.2012.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 agonists in the treatment of Parkinson’s disease</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.2174/156802661510150328223428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.2174%2F156802661510150328223428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25832718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=908-926&author=B.+Dasauthor=G.+Modiauthor=A.+Dutta&title=Dopamine+D3+agonists+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.2174%2F156802661510150328223428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Agonists in the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Das, Banibrata; Modi, Gyan; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">908-926</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is t he second most common form of neurodegenerative disorders that results from the progressive loss of dopaminergic neurons in the midbrain substantia nigra pars compacta (SNpc) triggering profound motor perturbation, as well as cognitive, sensory and mood deficits.  Although these symptoms can be improved using currently available dopamine replacement strategies, they are not able to slow the neurodegenerative process that underlies PD progression.  Following the discovery of the D3 receptor from mol. cloning, it has gained much attention as a potential therapeutic target for the treatment of PD due to their localization in the limbic regions of the brain as well as pharmacol. similarity to the D2 receptor subtype.  Of particular interest, D3 receptor- selective agonists appear to have neuroprotective effects apart from their ability to relieve PD symptoms.  Owing to the distinct significance of D3 receptor in mediating diverse neurol. effects, it represents a unique target for therapeutic intervention in PD with much less undesirable side effects.  Herein, we review progress in the development of D3 receptor selective agonist mols. having a broad spectrum of affinities, selectivities as well as unique pharmacol. properties directed at slowing the neurodegeneration process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1vO7t50SK9rVg90H21EOLACvtfcHk0lhifgy6QZ4ddA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D&md5=46885592d050d099cbad73ba7ef8e61b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F156802661510150328223428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661510150328223428%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DDopamine%2520D3%2520agonists%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D908%26epage%3D926%26doi%3D10.2174%2F156802661510150328223428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design</span>. <i>Adv. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-420118-7.00007-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FB978-0-12-420118-7.00007-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24484980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFCitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=267-300&author=T.+M.+Keckauthor=C.+Burzynskiauthor=L.+Shiauthor=A.+H.+Newman&title=Beyond+small-molecule+SAR%3A+using+the+dopamine+D3+receptor+crystal+structure+to+guide+drug+design&doi=10.1016%2FB978-0-12-420118-7.00007-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design</span></div><div class="casAuthors">Keck, Thomas M.; Burzynski, Caitlin; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Pharmacology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse</span>),
    <span class="NLM_cas:pages">267-300</span>CODEN:
                <span class="NLM_cas:coden">ADPHEL</span>;
        ISSN:<span class="NLM_cas:issn">1054-3589</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor is a target of pharmacotherapeutic interest in a variety of neurol. disorders including schizophrenia, restless leg syndrome, and drug addiction.  The high protein sequence homol. between the D3 and D2 receptors has posed a challenge to developing D3 receptor-selective ligands whose behavioral actions can be attributed to D3 receptor engagement, in vivo.  However, through primarily small-mol. structure-activity relationship (SAR) studies, a variety of chem. scaffolds have been discovered over the past two decades that have resulted in several D3 receptor-selective ligands with high affinity and in vivo activity.  Nevertheless, viable clin. candidates remain limited.  The recent detn. of the high-resoln. crystal structure of the D3 receptor has invigorated structure-based drug design, providing refinements to the mol. dynamic models and testable predictions about receptor-ligand interactions.  This chapter will highlight recent preclin. and clin. studies demonstrating potential utility of D3 receptor-selective ligands in the treatment of addiction.  In addn., new structure-based rational drug design strategies for D3 receptor-selective ligands that complement traditional small-mol. SAR to improve the selectivity and directed efficacy profiles are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbH7VLMIagF7Vg90H21EOLACvtfcHk0liN98Cygg-AZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFCitb8%253D&md5=d266814a068e4528c70e200a860fab64</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-420118-7.00007-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-420118-7.00007-X%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DBeyond%2520small-molecule%2520SAR%253A%2520using%2520the%2520dopamine%2520D3%2520receptor%2520crystal%2520structure%2520to%2520guide%2520drug%2520design%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2014%26volume%3D69%26spage%3D267%26epage%3D300%26doi%3D10.1016%2FB978-0-12-420118-7.00007-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangel-Barajas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Bitropic D3 dopamine receptor selective compounds as potential antipsychotics</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3700</span>– <span class="NLM_lpage">3724</span>, <span class="refDoi"> DOI: 10.2174/1381612821666150724100830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.2174%2F1381612821666150724100830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26205291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFagu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3700-3724&author=R.+R.+Luedtkeauthor=C.+Rangel-Barajasauthor=M.+Malikauthor=D.+E.+Reichertauthor=R.+H.+Mach&title=Bitropic+D3+dopamine+receptor+selective+compounds+as+potential+antipsychotics&doi=10.2174%2F1381612821666150724100830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics</span></div><div class="casAuthors">Luedtke, Robert R.; Rangel-Barajas, Claudia; Malik, Mahinder; Reichert, David E.; Mach, R. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3700-3724</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Neuropsychiatric disorders represent a substantial social and health care issue.  The National Institutes of Health ests. that greater than 2 million adults suffer from neuropsychiatric disorders in the USA.  These individuals experience symptoms that can include auditory hallucinations, delusions, unrealistic beliefs and cognitive dysfunction.  Although antipsychotic medications are available, suboptimal therapeutic responses are obsd. for approx. one-third of patients.  Therefore, there is still a need to explore new pharmacotherapeutic strategies for the treatment of neuropsychiatric disorders.  Many of the medications that are used clin. to treat neuropsychiatric disorders have a pharmacol. profile that includes being an antagonist at D2-like (D2, D3 and D4) dopamine receptor subtypes.  However, dopamine receptor subtypes are involved in a variety of neuronal circuits that include movement coordination, cognition, emotion, affect, memory and the regulation of prolactin.  Consequently, antagonism at D2-like receptors can also contribute to some of the adverse side effects assocd. with the long-term use of antipsychotics including the a) adverse extrapyramidal symptoms assocd. with the use of typical antipsychotics and b) metabolic side effects (wt. gain, hyperglycemia, increased risk of diabetes mellitus, dyslipidemia and gynecomastia) assocd. with atypical antipsychotic use.  Preclin. studies suggest that D3 vs. D2 dopamine receptor selective compds. might represent an alternative strategy for the treatment of the symptoms of schizophrenia.  In this review we discuss a) how bitropic Nphenylpiperazine D3 dopamine receptor selective compds. have been developed by modification of the primary (orthosteric) and secondary (allosteric or modulatory) pharmacophores to optimize D3 receptor affinity and D2/D3 binding selectivity ratios and b) the functional selectivity of these compds.  Examples of how these compds. might be modified to develop bivalent ligands capable of interacting with receptor dimers or oligomers are also provided.  Preclin. studies using bitropic D3 dopamine receptor selective ligands are also discussed as strategy to pharmacol. dissect the role of the D2 and D3 dopamine receptor subtypes in animal models of neuropsychiatric, neurol. and substance abuse disorders.  This research has the potential to a) advance the understanding of the role of the D2 and D3 dopamine receptor subtypes in neuropsychiatric disorders and b) lead to new treatment strategies for neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpDfir_TtCtbVg90H21EOLACvtfcHk0liN98Cygg-AZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFagu7bJ&md5=f7e1b836218171fb2f43f417ac2ff784</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1381612821666150724100830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612821666150724100830%26sid%3Dliteratum%253Aachs%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DRangel-Barajas%26aufirst%3DC.%26aulast%3DMalik%26aufirst%3DM.%26aulast%3DReichert%26aufirst%3DD.%2BE.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DBitropic%2520D3%2520dopamine%2520receptor%2520selective%2520compounds%2520as%2520potential%2520antipsychotics%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D3700%26epage%3D3724%26doi%3D10.2174%2F1381612821666150724100830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElveen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1021/jm049465g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049465g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=839-848&author=P.+Grundtauthor=E.+E.+Carlsonauthor=J.+Caoauthor=C.+J.+Bennettauthor=E.+McElveenauthor=M.+Taylorauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=Novel+heterocyclic+trans+olefin+analogues+of+N-%7B4-%5B4-%282%2C3-dichlorophenyl%29piperazin-1-yl%5Dbutyl%7Darylcarboxamides+as+selective+probes+with+high+affinity+for+the+dopamine+D3+receptor&doi=10.1021%2Fjm049465g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor</span></div><div class="casAuthors">Grundt, Peter; Carlson, Erin E.; Cao, Jianjing; Bennett, Christina J.; McElveen, Elizabeth; Taylor, Michelle; Luedtke, Robert R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-848</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine.  However, definitive pharmacol. investigations have been hampered by the lack of highly D3 receptor selective compds. that can be used in vivo.  To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluorene-2-carboxylic acid {4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl}-amide, Ki (hD3) = 2.0 nM, Ki (hD2L) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chem. modification in an attempt to reduce its high lipophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity.  A series of >30 novel analogs were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2L, D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist 125I-IABN.  Structural diversity in the aryl amide end of the mol. was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine.  Several analogs demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand.  Compd. 29 (N-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine-2-yl-benzamide) displayed the most promising pharmacol. profile (Ki (hD3) = 0.7 nM, Ki (hD2L) = 93.3 nM, D2/D3 selectivity ratio of 133).  In addn., this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM.  Compd. 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM).  Moreover, a decrease in c log D value of ∼2 orders of magnitude was detd. for this novel D3-receptor-preferring ligand, compared to 1.  In summary, chem. modification of 1 has resulted in compds. with high affinity and selectivity for D3 receptors.  The most promising candidate, compd. 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofDgtp4SPuC7Vg90H21EOLACvtfcHk0ljDDP4R3KN5BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D&md5=080af9d0e167912621f35c40020c534b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm049465g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049465g%26sid%3Dliteratum%253Aachs%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DCarlson%26aufirst%3DE.%2BE.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DC.%2BJ.%26aulast%3DMcElveen%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520heterocyclic%2520trans%2520olefin%2520analogues%2520of%2520N-%257B4-%255B4-%25282%252C3-dichlorophenyl%2529piperazin-1-yl%255Dbutyl%257Darylcarboxamides%2520as%2520selective%2520probes%2520with%2520high%2520affinity%2520for%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D839%26epage%3D848%26doi%3D10.1021%2Fjm049465g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D(3) receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4962</span>– <span class="NLM_lpage">4968</span>, <span class="refDoi"> DOI: 10.1021/jm401798r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401798r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOnurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4962-4968&author=J.+Chenauthor=B.+Levantauthor=C.+Jiangauthor=T.+M.+Keckauthor=A.+H.+Newmanauthor=S.+Wang&title=Tranylcypromine+substituted+cis-hydroxycyclobutylnaphthamides+as+potent+and+selective+dopamine+D%283%29+receptor+antagonists&doi=10.1021%2Fjm401798r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists</span></div><div class="casAuthors">Chen, Jianyong; Levant, Beth; Jiang, Cheng; Keck, Thomas M.; Newman, Amy Hauck; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4962-4968</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report a class of potent and selective dopamine D3 receptor antagonists based upon tranylcypromine.  Although tranylcypromine has a low affinity for the rat D3 receptor (Ki = 12.8 μM), our efforts have yielded (1R,2S)-11 (CJ-1882), which has Ki values of 2.7 and 2.8 nM at the rat and human dopamine D3 receptors, resp., and displays resp. selectivities of >10000-fold and 223-fold over the rat and human D2 receptors.  Evaluation in a β-arrestin functional assay showed that (1R,2S)-11 is a potent and competitive antagonist at the human D3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWudWdAfWgLVg90H21EOLACvtfcHk0ljDDP4R3KN5BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOnurg%253D&md5=e2ddf0711d00103be281cb043b19ec3a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm401798r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401798r%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTranylcypromine%2520substituted%2520cis-hydroxycyclobutylnaphthamides%2520as%2520potent%2520and%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4962%26epage%3D4968%26doi%3D10.1021%2Fjm401798r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Chiral resolution and serendipitous fluorination reaction for the selective dopamine D3 receptor antagonist BAK2-66</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1021/ml500006v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500006v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=647-651&author=V.+Kumarauthor=A.+K.+Banalaauthor=E.+G.+Garciaauthor=J.+Caoauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=J.+R.+Deschampsauthor=A.+H.+Newman&title=Chiral+resolution+and+serendipitous+fluorination+reaction+for+the+selective+dopamine+D3+receptor+antagonist+BAK2-66&doi=10.1021%2Fml500006v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66</span></div><div class="casAuthors">Kumar, Vivek; Banala, Ashwini K.; Garcia, Erick G.; Cao, Jianjing; Keck, Thomas M.; Bonifazi, Alessandro; Deschamps, Jeffery R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-651</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The improved chiral synthesis of the selective dopamine D3 receptor (D3R) antagonist (R)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)1H-indole-2-carboxamide ((R)-PG648) is described.  The same chiral secondary alc. intermediate was used to prep. the enantiomers of a 3-F-benzofuranyl analog, BAK 2-66 (I).  The abs. configurations of the 3-F enantiomers were assigned from their X-ray crystal structures that confirmed retention of configuration during fluorination with N,N-diethylaminosulfur trifluoride (DAST).  (R)-I showed higher D3R affinity and selectivity than its (S)-enantiomer; however, it had lower D3R affinity and enantioselectivity than (R)-PG648.  Further, importance of the 4-atom linker length between the aryl amide and 4-phenylpiperazine was demonstrated with the 4-fluorobutyl-product (II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTRVSlrPS4ybVg90H21EOLACvtfcHk0lha7m0UtWMNHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamuro%253D&md5=17ddfb3b45b6630f53c917281d76b620</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml500006v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500006v%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DGarcia%26aufirst%3DE.%2BG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DChiral%2520resolution%2520and%2520serendipitous%2520fluorination%2520reaction%2520for%2520the%2520selective%2520dopamine%2520D3%2520receptor%2520antagonist%2520BAK2-66%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D647%26epage%3D651%26doi%3D10.1021%2Fml500006v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">High affinity dopamine D3 receptor (D3R)-selective antagonists attenuate heroin self-administration in wild-type but not D3R knockout mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6213</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00776</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00776" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1alur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6195-6213&author=C.+A.+Boatengauthor=O.+M.+Bakareauthor=J.+Zhanauthor=A.+K.+Banalaauthor=C.+Burzynskiauthor=E.+Pommierauthor=T.+M.+Keckauthor=P.+Donthamsettiauthor=J.+A.+Javitchauthor=R.+Raisauthor=B.+S.+Slusherauthor=Z.+X.+Xiauthor=A.+H.+Newman&title=High+affinity+dopamine+D3+receptor+%28D3R%29-selective+antagonists+attenuate+heroin+self-administration+in+wild-type+but+not+D3R+knockout+mice&doi=10.1021%2Facs.jmedchem.5b00776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice</span></div><div class="casAuthors">Boateng, Comfort A.; Bakare, Oluyomi M.; Zhan, Jia; Banala, Ashwini K.; Burzynski, Caitlin; Pommier, Elie; Keck, Thomas M.; Donthamsetti, Prashant; Javitch, Jonathan A.; Rais, Rana; Slusher, Barbara S.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6195-6213</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders.  Several D3R-selective antagonists are effective in animal models of drug abuse, esp. in models of relapse.  Nevertheless, poor bioavailability, metabolic instability, and/or predicted toxicity have impeded success in translating these drug candidates to clin. use.  Herein, the authors report a series of D3R-selective 4-phenylpiperazines with improved metabolic stability.  A subset of these compds. was evaluated for D3R functional efficacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR with D3R has been obsd.  Several high affinity D3R antagonists, including compds. I (Ki = 0.12 nM) and II (Ki = 0.35 nM), showed improved metabolic stability compared to the parent compd., PG648.  Notably, I and the classic D3R antagonist SB277011A were effective in reducing self-administration of heroin in wild-type but not D3R knockout mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagzWQU_gPV7Vg90H21EOLACvtfcHk0lhpxI1gNR0PTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1alur%252FK&md5=1724065cac8ac51295cf4660a20ed734</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00776%26sid%3Dliteratum%253Aachs%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DZhan%26aufirst%3DJ.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHigh%2520affinity%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529-selective%2520antagonists%2520attenuate%2520heroin%2520self-administration%2520in%2520wild-type%2520but%2520not%2520D3R%2520knockout%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6195%26epage%3D6213%26doi%3D10.1021%2Facs.jmedchem.5b00776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7650</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00860</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00860" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7634-7650&author=V.+Kumarauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=E.+Pommierauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+Gardnerauthor=Z.+B.+Youauthor=Z.+X.+Xiauthor=A.+H.+Newman&title=Highly+selective+dopamine+D3+receptor+%28D3R%29+antagonists+and+partial+agonists+based+on+eticlopride+and+the+D3R+crystal+structure%3A+new+leads+for+opioid+dependence+treatment&doi=10.1021%2Facs.jmedchem.6b00860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment</span></div><div class="casAuthors">Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Pommier, Elie; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot; You, Zhi-Bing; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7634-7650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention.  Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clin. use for cocaine abuse.  Herein, the authors report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies.  Lead compd. I was selected based on its in vitro profile: D3R Ki = 6.84 nM, 1700-fold D3R vs. D2R binding selectivity, and its metabolic stability in mouse microsomes.  Compd. I inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization.  In addn., pretreatment with I also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats.  These findings support the D3R as a target for opioid dependence treatment and compd. I as a new lead mol. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyb_lyL223q7Vg90H21EOLACvtfcHk0lgeuFw0-iZsrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN&md5=c352556630974f4205a8684b4fd29226</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00860%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%26aulast%3DYou%26aufirst%3DZ.%2BB.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%2520antagonists%2520and%2520partial%2520agonists%2520based%2520on%2520eticlopride%2520and%2520the%2520D3R%2520crystal%2520structure%253A%2520new%2520leads%2520for%2520opioid%2520dependence%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7634%26epage%3D7650%26doi%3D10.1021%2Facs.jmedchem.6b00860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Investigation of novel primary and secondary pharmacophores and 3-substitution in the linking chain of a series of highly selective and bitopic dopamine D3 receptor antagonists and partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9061</span>– <span class="NLM_lpage">9077</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00607</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00607" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVShtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9061-9077&author=A.+B.+Shaikauthor=V.+Kumarauthor=A.+Bonifaziauthor=A.+M.+Guerreroauthor=S.+L.+Cemajauthor=A.+Gadianoauthor=J.+Lamauthor=Z.+X.+Xiauthor=R.+Raisauthor=B.+S.+Slusherauthor=A.+H.+Newman&title=Investigation+of+novel+primary+and+secondary+pharmacophores+and+3-substitution+in+the+linking+chain+of+a+series+of+highly+selective+and+bitopic+dopamine+D3+receptor+antagonists+and+partial+agonists&doi=10.1021%2Facs.jmedchem.9b00607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D3 Receptor Antagonists and Partial Agonists</span></div><div class="casAuthors">Shaik, Anver Basha; Kumar, Vivek; Bonifazi, Alessandro; Guerrero, Adrian M.; Cemaj, Sophie L.; Gadiano, Alexandra; Lam, Jenny; Xi, Zheng-Xiong; Rais, Rana; Slusher, Barbara S.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9061-9077</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptors (D3R) play a crit. role in neuropsychiatric conditions including substance use disorders (SUD).  Recently, we reported a series of N-(3-hydroxy-4-(4-phenylpiperazin-1-yl)butyl)-1H-indole-2-carboxamide analogs as high affinity and selective D3R lead mols. for the treatment of opioid use disorders (OUD).  Further optimization led to a series of analogs that replaced the 3-OH with a 3-F in the linker between the primary pharmacophore (PP) and secondary pharmacophore (SP).  Among the 3-F-compds., 9b demonstrated the highest D3R binding affinity (Ki = 0.756 nM) and was 327-fold selective for D3R over D2R.  In addn., modification of the PP or SP with a 3,4-(methylenedioxy)phenyl group was also examd.  Further, an enantioselective synthesis as well as chiral HPLC methods were developed to give enantiopure R- and S-enantiomers of the four lead compds.  Off-target binding affinities, functional efficacies, and metabolic profiles revealed crit. structural components for D3R selectivity as well as drug-like features required for development as pharmacotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR79XdHJXFkbVg90H21EOLACvtfcHk0lgeuFw0-iZsrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVShtLfO&md5=0b8b1d8d76d17164a4ab7ba0e17ea2c2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00607%26sid%3Dliteratum%253Aachs%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DInvestigation%2520of%2520novel%2520primary%2520and%2520secondary%2520pharmacophores%2520and%25203-substitution%2520in%2520the%2520linking%2520chain%2520of%2520a%2520series%2520of%2520highly%2520selective%2520and%2520bitopic%2520dopamine%2520D3%2520receptor%2520antagonists%2520and%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9061%26epage%3D9077%26doi%3D10.1021%2Facs.jmedchem.9b00607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert Lane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010611-134514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1146%2Fannurev-pharmtox-010611-134514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21910627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2ntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=153-178&author=C.+Valantauthor=J.+Robert+Laneauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=The+best+of+both+worlds%3F+Bitopic+orthosteric%2Fallosteric+ligands+of+g+protein-coupled+receptors&doi=10.1146%2Fannurev-pharmtox-010611-134514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors</span></div><div class="casAuthors">Valant, Celine; Lane, J. Robert; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-178</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  It is now acknowledged that G protein-coupled receptors, the largest class of drug targets, adopt multiple active states that can be preferentially stabilized by orthosteric ligands or allosteric modulators, thus giving rise to the phenomenon of pathway-biased signaling.  In the past few years, researchers have begun to explore the potential of linking orthosteric and allosteric pharmacophores to yield bitopic hybrid ligands.  This approach is an extension of the more traditional bivalent ligand concept and shares some of the same challenges, including the choice and role of the linker between the two pharmacophores and the validation of mechanism of action.  Nonetheless, the promise of bitopic ligands is the generation of novel chem. tools that have improved affinity and/or selectivity profiles.  Previously identified functionally selective compds. (and medicines) also may act via a bitopic mechanism, suggesting that the phenomenon is more widespread than currently appreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQs4WlX5wY8LVg90H21EOLACvtfcHk0lgeuFw0-iZsrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2ntrc%253D&md5=334839005a548a9739df466e3d09e1ae</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010611-134514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010611-134514%26sid%3Dliteratum%253Aachs%26aulast%3DValant%26aufirst%3DC.%26aulast%3DRobert%2BLane%26aufirst%3DJ.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DThe%2520best%2520of%2520both%2520worlds%253F%2520Bitopic%2520orthosteric%252Fallosteric%2520ligands%2520of%2520g%2520protein-coupled%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2012%26volume%3D52%26spage%3D153%26epage%3D178%26doi%3D10.1146%2Fannurev-pharmtox-010611-134514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Bridging the gap: bitopic ligands of G-protein-coupled receptors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2012.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.tips.2012.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=23177916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslejsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=59-66&author=J.+R.+Laneauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Bridging+the+gap%3A+bitopic+ligands+of+G-protein-coupled+receptors&doi=10.1016%2Fj.tips.2012.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Bridging the gap: bitopic ligands of G-protein-coupled receptors</span></div><div class="casAuthors">Lane, J. Robert; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-66</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Although classical approaches to G-protein-coupled receptor (GPCR) drug design have targeted the orthosteric binding site, potentially all GPCRs possess druggable allosteric sites.  In addn., it is clear that GPCRs can adopt multiple active states linked to distinct functional outcomes that can be stabilized by both allosteric and orthosteric ligands.  Recent studies have begun to explore the possibilities of linking orthosteric and allosteric pharmacophores to yield 'bitopic' ligands as an approach to achieve improved receptor affinity or selectivity.  Furthermore, it is possible that previously identified functionally selective drugs may represent unappreciated bitopic ligands at this important class of drug targets.  Here we discuss both the potential of bitopic ligands in GPCR drug discovery and the challenges assocd. with the design of such ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorsAmJef7SRbVg90H21EOLACvtfcHk0lgCCKjHLFy2Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslejsrbE&md5=bd5a180e7eda47a59073fef0f48124f6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DBridging%2520the%2520gap%253A%2520bitopic%2520ligands%2520of%2520G-protein-coupled%2520receptors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2013%26volume%3D34%26spage%3D59%26epage%3D66%26doi%3D10.1016%2Fj.tips.2012.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01688</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01688" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1478-1494&author=V.+Kumarauthor=A.+E.+Moritzauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=C.+D.+Sibleyauthor=R.+B.+Freeauthor=L.+Shiauthor=J.+R.+Laneauthor=D.+R.+Sibleyauthor=A.+H.+Newman&title=Synthesis+and+pharmacological+characterization+of+novel+trans-cyclopropylmethyl-linked+bivalent+ligands+that+exhibit+selectivity+and+allosteric+pharmacology+at+the+dopamine+D3+receptor+%28D3R%29&doi=10.1021%2Facs.jmedchem.6b01688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)</span></div><div class="casAuthors">Kumar, Vivek; Moritz, Amy E.; Keck, Thomas M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Sibley, Christopher D.; Free, R. Benjamin; Shi, Lei; Lane, J. Robert; Sibley, David R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1478-1494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bitopic ligands directed toward D2-like receptors has proven to be of particular interest to improve the selectivity and/or affinity of these ligands and as an approach to modulate and bias their efficacies.  The structural similarities between dopamine D3 receptor (D3R)-selective mols. that display bitopic or allosteric pharmacol. and those that are simply competitive antagonists are subtle and intriguing.  Herein the authors synthesized a series of mols. in which the primary and secondary pharmacophores were derived from the D3R-selective antagonists SB269,652 and SB277011A whose structural similarity and pharmacol. disparity provided the perfect templates for SAR investigation.  Incorporating a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, I and II, which further delineates SAR assocd. with allosterism at D3R and provides leads toward novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PUM_XBYBsLVg90H21EOLACvtfcHk0lgCCKjHLFy2Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D&md5=de385d8d9699e2d37a56974382989a19</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01688%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DSibley%26aufirst%3DC.%2BD.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DSynthesis%2520and%2520pharmacological%2520characterization%2520of%2520novel%2520trans-cyclopropylmethyl-linked%2520bivalent%2520ligands%2520that%2520exhibit%2520selectivity%2520and%2520allosteric%2520pharmacology%2520at%2520the%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1478%26epage%3D1494%26doi%3D10.1021%2Facs.jmedchem.6b01688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imler, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">The significance of chirality in drug design and synthesis of bitopic ligands as D3 receptor (D3R) selective agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6287</span>– <span class="NLM_lpage">6314</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00702</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00702" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6287-6314&author=F.+O.+Battitiauthor=S.+L.+Cemajauthor=A.+M.+Guerreroauthor=A.+B.+Shaikauthor=J.+Lamauthor=R.+Raisauthor=B.+S.+Slusherauthor=J.+R.+Deschampsauthor=G.+H.+Imlerauthor=A.+H.+Newmanauthor=A.+Bonifazi&title=The+significance+of+chirality+in+drug+design+and+synthesis+of+bitopic+ligands+as+D3+receptor+%28D3R%29+selective+agonists&doi=10.1021%2Facs.jmedchem.9b00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists</span></div><div class="casAuthors">Battiti, Francisco O.; Cemaj, Sophie L.; Guerrero, Adrian M.; Shaik, Anver Basha; Lam, Jenny; Rais, Rana; Slusher, Barbara S.; Deschamps, Jeffery R.; Imler, Greg H.; Newman, Amy Hauck; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6287-6314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the large degree of homol. among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge.  Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike.  Inspired by the potential for chem. modification of the D3 preferential agonists (+)-PD128,907 (1) and PF592,379 (2), we synthesized bitopic structures to further improve their D3R selectivity.  We found that the (2S,5S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D3R.  In addn., a cyclopropyl moiety incorporated into the linker and full resoln. of the chiral centers resulted in lead compd. 53 and eutomer 53a that demonstrate significantly higher D3R binding selectivities than the ref. compds.  Moreover, the favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of dopamine system dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnvIdaD7juX7Vg90H21EOLACvtfcHk0lgCCKjHLFy2Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N&md5=6c2be1149f915f639a42a99f6acdc062</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00702%26sid%3Dliteratum%253Aachs%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DImler%26aufirst%3DG.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3DThe%2520significance%2520of%2520chirality%2520in%2520drug%2520design%2520and%2520synthesis%2520of%2520bitopic%2520ligands%2520as%2520D3%2520receptor%2520%2528D3R%2529%2520selective%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6287%26epage%3D6314%26doi%3D10.1021%2Facs.jmedchem.9b00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">2016 Philip S. Portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1797</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1779-1797&author=A.+H.+Newmanauthor=F.+O.+Battitiauthor=A.+Bonifazi&title=2016+Philip+S.+Portoghese+medicinal+chemistry+lectureship%3A+designing+bivalent+or+bitopic+molecules+for+G-protein+coupled+receptors.+The+whole+is+greater+than+the+sum+of+its+parts&doi=10.1021%2Facs.jmedchem.9b01105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts</span></div><div class="casAuthors">Newman, Amy Hauck; Battiti, Francisco O.; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1779-1797</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The genesis of designing bivalent or bitopic mols. that engender unique pharmacol. properties began with Portoghese's work directed toward opioid receptors, in the early 1980s.  This strategy has evolved as an attractive way to engineer highly selective compds. for targeted G-protein coupled receptors (GPCRs) with optimized efficacies and/or signaling bias.  The emergence of X-ray crystal structures of many GPCRs and the identification of both orthosteric and allosteric binding sites have provided further guidance to ligand drug design that includes a primary pharmacophore (PP), a secondary pharmacophore (SP), and a linker between them.  It is crit. to note the synergistic relationship among all three of these components as they contribute to the overall interaction of these mols. with their receptor proteins and that strategically designed combinations have and will continue to provide the GPCR mol. tools of the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo84RXs5E3FQbVg90H21EOLACvtfcHk0liAM76CYfaG5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE&md5=d63fe27924f25354b10b2f01f44461a5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3D2016%2520Philip%2520S.%2520Portoghese%2520medicinal%2520chemistry%2520lectureship%253A%2520designing%2520bivalent%2520or%2520bitopic%2520molecules%2520for%2520G-protein%2520coupled%2520receptors.%2520The%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520its%2520parts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1779%26epage%3D1797%26doi%3D10.1021%2Facs.jmedchem.9b01105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestor, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGonigle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyapati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ersche, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flechais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchibatla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metastasio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suckling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingford-Hughes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span> <span> </span><span class="NLM_article-title">Acute D3 antagonist GSK598809 selectively enhances neural response during monetary reward anticipation in drug and alcohol dependence</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1038/npp.2016.289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fnpp.2016.289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=28042871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=1049-1057&author=A.+Murphyauthor=L.+J.+Nestorauthor=J.+McGonigleauthor=L.+Patersonauthor=V.+Boyapatiauthor=K.+D.+Erscheauthor=R.+Flechaisauthor=S.+Kuchibatlaauthor=A.+Metastasioauthor=C.+Orbanauthor=F.+Passettiauthor=L.+Reedauthor=D.+Smithauthor=J.+Sucklingauthor=E.+Taylorauthor=T.+W.+Robbinsauthor=A.+Lingford-Hughesauthor=D.+J.+Nuttauthor=J.+F.+Deakinauthor=R.+Elliott&title=Acute+D3+antagonist+GSK598809+selectively+enhances+neural+response+during+monetary+reward+anticipation+in+drug+and+alcohol+dependence&doi=10.1038%2Fnpp.2016.289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence</span></div><div class="casAuthors">Murphy, Anna; Nestor, Liam J.; McGonigle, John; Paterson, Louise; Boyapati, Venkataramana; Ersche, Karen D.; Flechais, Remy; Kuchibatla, Shankar; Metastasio, Antonio; Orban, Csaba; Passetti, Filippo; Reed, Laurence; Smith, Dana; Suckling, John; Taylor, Eleanor; Robbins, Trevor W.; Lingford-Hughes, Anne; Nutt, David J.; Deakin, John F. W.; Elliott, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1049-1057</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Evidence suggests that disturbances in neurobiol. mechanisms of reward and inhibitory control maintain addiction and provoke relapse during abstinence.  Abnormalities within the dopamine system may contribute to these disturbances and pharmacol. targeting the D3 dopamine receptor (DRD3) is therefore of significant clin. interest.  We used functional magnetic resonance imaging to investigate the acute effects of the DRD3 antagonist GSK598809 on anticipatory reward processing, using the monetary incentive delay task (MIDT), and response inhibition using the Go/No-Go task (GNGT).  A double-blind, placebo-controlled, crossover design approach was used in abstinent alc. dependent, abstinent poly-drug dependent and healthy control volunteers.  For the MIDT, there was evidence of blunted ventral striatal response to reward in the poly-drug-dependent group under placebo.  GSK598809 normalized ventral striatal reward response and enhanced response in the DRD3-rich regions of the ventral pallidum and substantia nigra.  Exploratory investigations suggested that the effects of GSK598809 were mainly driven by those with primary dependence on alc. but not on opiates.  Taken together, these findings suggest that GSK598809 may remediate reward deficits in substance dependence.  For the GNGT, enhanced response in the inferior frontal cortex of the poly-drug group was found.  However, there were no effects of GSK598809 on the neural network underlying response inhibition nor were there any behavioral drug effects on response inhibition.  GSK598809 modulated the neural network underlying reward anticipation but not response inhibition, suggesting that DRD3 antagonists may restore reward deficits in addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeqsfPKqdH27Vg90H21EOLACvtfcHk0liAM76CYfaG5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGltLk%253D&md5=56dbd2ce52bc763fdc3eb92dd407150b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.289%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DA.%26aulast%3DNestor%26aufirst%3DL.%2BJ.%26aulast%3DMcGonigle%26aufirst%3DJ.%26aulast%3DPaterson%26aufirst%3DL.%26aulast%3DBoyapati%26aufirst%3DV.%26aulast%3DErsche%26aufirst%3DK.%2BD.%26aulast%3DFlechais%26aufirst%3DR.%26aulast%3DKuchibatla%26aufirst%3DS.%26aulast%3DMetastasio%26aufirst%3DA.%26aulast%3DOrban%26aufirst%3DC.%26aulast%3DPassetti%26aufirst%3DF.%26aulast%3DReed%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DSuckling%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DRobbins%26aufirst%3DT.%2BW.%26aulast%3DLingford-Hughes%26aufirst%3DA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26aulast%3DDeakin%26aufirst%3DJ.%2BF.%26aulast%3DElliott%26aufirst%3DR.%26atitle%3DAcute%2520D3%2520antagonist%2520GSK598809%2520selectively%2520enhances%2520neural%2520response%2520during%2520monetary%2520reward%2520anticipation%2520in%2520drug%2520and%2520alcohol%2520dependence%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D1049%26epage%3D1057%26doi%3D10.1038%2Fnpp.2016.289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Ciano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvauchelle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span> <span> </span><span class="NLM_article-title">Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [(11)C]-(+)-PHNO PET study in humans</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1284</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0285-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fs41386-018-0285-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30659274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrtr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1284-1290&author=P.+Di%0ACianoauthor=E.+Mansouriauthor=J.+Tongauthor=A.+A.+Wilsonauthor=S.+Houleauthor=I.+Boileauauthor=T.+Duvauchelleauthor=P.+Robertauthor=J.+C.+Schwartzauthor=B.+Le+Foll&title=Occupancy+of+dopamine+D2+and+D3+receptors+by+a+novel+D3+partial+agonist+BP1.4979%3A+a+%5B%2811%29C%5D-%28%2B%29-PHNO+PET+study+in+humans&doi=10.1038%2Fs41386-018-0285-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans</span></div><div class="casAuthors">Di Ciano, Patricia; Mansouri, Esmaeil; Tong, Junchao; Wilson, Alan A.; Houle, Sylvain; Boileau, Isabelle; Duvauchelle, Thierry; Robert, Philippe; Schwartz, Jean Charles; Le Foll, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1284-1290</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">There has been considerable interest in the development of dopamine D3 receptor (DRD3) partial agonists and antagonists for the treatment of substance use disorders.  Pre-clin. evidence overwhelmingly supports the use of these drugs, but translation to humans has remained elusive due to the lack of selective compds. that are suitable for use in humans.  Although it has been established for full antagonists, little in vivo occupancy data are available with DRD3 partial agonists.  Here we investigate for the first time in healthy controls, the in vivo occupancy of a novel D3 partial agonist (BP1.4979) at the DRD3 and DRD2.  Participants received either a single dose (1, 3, 10 or 30 mg) or a subchronic regimen (5-7 days, q.d. or b.i.d) of BP1.4979, with the last dose given at 1, 12 or 24 h prior to scanning with [11C]-(+)-PHNO.  Single and subchronic administration of BP1.4979 dose-dependently occupied the DRD3 and DRD2, and this occupancy was preferential for the DRD3, notably at longer time points after administration of BP1.4979.  Also consistent with preference for the DRD3, prolactin levels were minimally increased, and no subjective effects of BP1.4979 were reported.  Serum levels of BP1.4979 were higher than its active metabolite, BP1.6239, while no notable increases in the inactive metabolite, BP1.6197, were found.  These findings indicate the range of doses that can be used to occupy selectively the DRD3 over the DRD2 with BP1.4979 and speak to the use of in vivo imaging approaches in dose finding studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFpJzOngtkErVg90H21EOLACvtfcHk0ljBxfdLtcAHpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrtr7O&md5=4fe2612458efa661aa06b90ae7ccb805</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0285-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0285-4%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BCiano%26aufirst%3DP.%26aulast%3DMansouri%26aufirst%3DE.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DDuvauchelle%26aufirst%3DT.%26aulast%3DRobert%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26atitle%3DOccupancy%2520of%2520dopamine%2520D2%2520and%2520D3%2520receptors%2520by%2520a%2520novel%2520D3%2520partial%2520agonist%2520BP1.4979%253A%2520a%2520%255B%252811%2529C%255D-%2528%252B%2529-PHNO%2520PET%2520study%2520in%2520humans%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1284%26epage%3D1290%26doi%3D10.1038%2Fs41386-018-0285-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span> <span> </span><span class="NLM_article-title">The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.neuropharm.2017.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=28888944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=190-199&author=Z.+B.+Youauthor=J.+T.+Gaoauthor=G.+H.+Biauthor=Y.+Heauthor=C.+Boatengauthor=J.+Caoauthor=E.+L.+Gardnerauthor=A.+H.+Newmanauthor=Z.+X.+Xi&title=The+novel+dopamine+D3+receptor+antagonists%2Fpartial+agonists+CAB2-015+and+BAK4-54+inhibit+oxycodone-taking+and+oxycodone-seeking+behavior+in+rats&doi=10.1016%2Fj.neuropharm.2017.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats</span></div><div class="casAuthors">You, Zhi-Bing; Gao, Jun-Tao; Bi, Guo-Hua; He, Yi; Boateng, Comfort; Cao, Jianjing; Gardner, Eliot L.; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190-199</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of prescription opioid analgesics, particularly oxycodone, has dramatically increased, and parallels escalated opioid abuse and drug-related deaths worldwide.  Understanding the mol. mechanisms underlying the development of opioid dependence and expanding treatment options to counter prescription opioid abuse has become a crit. public health matter.  In the present study, we first evaluated the reinforcing effects of oxycodone in a rat model of self-administration and then explored the potential utility of two novel high affinity dopamine D3 receptor (D3R) antagonists/partial agonists, CAB2-015 and BAK4-54, for treatment of prescription opioid abuse and dependence.  We found that rats acquired oxycodone self-administration rapidly within a range of unit doses that was similar to that for heroin, confirming that oxycodone has significant abuse potential.  Strikingly, pretreatment with either CAB2-015 or BAK4-54 (0.4-10 mg/kg, i.p.) dose-dependently decreased oxycodone self-administration, and shifted the oxycodone dose-response curve downward.  Repeated pretreatment with CAB2-015 or BAK4-54 (0.4-4 mg/kg) facilitated extinction and inhibited oxycodone-induced reinstatement of drug-seeking behavior.  In addn., pretreatment with CAB2-015 or BAK4-54 (4-10 mg/kg) also dose-dependently decreased oxycodone-enhanced locomotor activity, but only CAB2-015 decreased oral sucrose self-administration.  These data suggest that D3R antagonists may be suitable alternatives or adjunctive to opioid-based medications currently used clin. in treating opioid addiction and that the D3R-selective ligands (CAB2-015 or BAK4-54) provide new lead mols. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2yL76pWO8Z7Vg90H21EOLACvtfcHk0ljBxfdLtcAHpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsrfF&md5=a046de2818f1daf7029be110c5c0cc9b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.%2BB.%26aulast%3DGao%26aufirst%3DJ.%2BT.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBoateng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26atitle%3DThe%2520novel%2520dopamine%2520D3%2520receptor%2520antagonists%252Fpartial%2520agonists%2520CAB2-015%2520and%2520BAK4-54%2520inhibit%2520oxycodone-taking%2520and%2520oxycodone-seeking%2520behavior%2520in%2520rats%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D126%26spage%3D190%26epage%3D199%26doi%3D10.1016%2Fj.neuropharm.2017.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0284-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fs41386-018-0284-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30555159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1415-1424&author=Z.+B.+Youauthor=G.+H.+Biauthor=E.+Galajauthor=V.+Kumarauthor=J.+Caoauthor=A.+Gadianoauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+L.+Gardnerauthor=Z.+X.+Xiauthor=A.+H.+Newman&title=Dopamine+D3R+antagonist+VK4-116+attenuates+oxycodone+self-administration+and+reinstatement+without+compromising+its+antinociceptive+effects&doi=10.1038%2Fs41386-018-0284-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span></div><div class="casAuthors">You, Zhi-Bing; Bi, Guo-Hua; Galaj, Ewa; Kumar, Vivek; Cao, Jianjing; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot L.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1415-1424</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prescription opioids such as oxycodone are highly effective analgesics for clin. pain management, but their misuse and abuse have led to the current opioid epidemic in the United States.  In order to ameliorate this public health crisis, the development of effective pharmacotherapies for the prevention and treatment of opioid abuse and addiction is essential and urgently required.  In this study, we evaluated-in lab. rats-the potential utility of VK4-116, a novel and highly selective dopamine D3 receptor (D3R) antagonist, for the prevention and treatment of prescription opioid use disorders.  Pretreatment with VK4-116 (5-25 mg/kg, i.p.) dose-dependently inhibited the acquisition and maintenance of oxycodone self-administration.  VK4-116 also lowered the break-point (BP) for oxycodone self-administration under a progressive-ratio schedule of reinforcement, shifted the oxycodone dose-response curve downward, and inhibited oxycodone extinction responding and reinstatement of oxycodone-seeking behavior.  In addn., VK4-116 pretreatment dose-dependently enhanced the antinociceptive effects of oxycodone and reduced naloxone-pptd. conditioned place aversion in rats chronically treated with oxycodone.  In contrast, VK4-116 had little effect on oral sucrose self-administration.  Taken together, these findings indicate a central role for D3Rs in opioid reward and support further development of VK4-116 as an effective agent for mitigating the development of opioid addiction, reducing the severity of withdrawal and preventing relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3PmmEMo-frVg90H21EOLACvtfcHk0ljBxfdLtcAHpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN&md5=dac3d9cbb6c0594cd06d3ec328aa519f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0284-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0284-5%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.%2BB.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DGalaj%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520D3R%2520antagonist%2520VK4-116%2520attenuates%2520oxycodone%2520self-administration%2520and%2520reinstatement%2520without%2520compromising%2520its%2520antinociceptive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1415%26epage%3D1424%26doi%3D10.1038%2Fs41386-018-0284-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humburg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorndike, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, C. W.</span></span> <span> </span><span class="NLM_article-title">Newly developed dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1124/jpet.119.259390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fjpet.119.259390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=31562201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1WltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2019&pages=602-614&author=C.+J.+Jordanauthor=B.+A.+Humburgauthor=E.+B.+Thorndikeauthor=A.+B.+Shaikauthor=Z.+X.+Xiauthor=M.+H.+Baumannauthor=A.+H.+Newmanauthor=C.+W.+Schindler&title=Newly+developed+dopamine+D3+receptor+antagonists%2C+R-VK4-40+and+R-VK4-116%2C+do+not+potentiate+cardiovascular+effects+of+cocaine+or+oxycodone+in+rats&doi=10.1124%2Fjpet.119.259390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Newly developed Dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats</span></div><div class="casAuthors">Jordan, Chloe J.; Humburg, Bree A.; Thorndike, Eric B.; Shaik, Anver Basha; Xi, Zheng-Xiong; Baumann, Michael H.; Newman, Amy Hauck; Schindler, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">602-618</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Opioid and cocaine abuse are major public health burdens.  Existing medications for opioid use disorder are limited by abuse liability and side effects, whereas no treatments are currently approved in the United States for cocaine use disorder.  Dopamine D3 receptor (D3R) antagonists have shown promise in attenuating opioid and cocaine reward and mitigating relapse in preclin. models.  However, translation of D3R antagonists to the clinic has been hampered by reports that the D3R antagonists GSK598,809 (5-(5-((3-((1S,5R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole) and SB-277,011A (2-(2-((1r,4r)-4-(2-oxo-2-(quinolin-4-yl)ethyl)cyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile) have adverse cardiovascular effects in the presence of cocaine.  Recently, we developed two structurally novel D3R antagonists, R-VK4-40 and R-VK4-116, which are highly selective for D3R and display translational potential for treatment of opioid use disorder.  Here, we tested whether R-VK4-40 ((R)-N-(4-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide) and R-VK4-116 ((R)-N-(4-(4-(3-Chloro-5-ethyl-2-methoxyphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide) have unwanted cardiovascular effects in the presence of oxycodone, a prescription opioid, or cocaine in freely moving rats fitted with surgically implanted telemetry transmitters.  We also examd. cardiovascular effects of the D3R antagonist, SB-277,011A, and L-741,626 (1-((1H-indol-3-yl)methyl)-4-(4-chlorophenyl)piperidin-4-ol), a dopamine D2 receptor-selective antagonist, for comparison.  Consistent with prior reports, SB-277,011A increased blood pressure, heart rate, and locomotor activity alone and in the presence of cocaine.  L-741,626 increased blood pressure and heart rate.  In contrast, R-VK4-40 alone dose-dependently reduced blood pressure and heart rate and attenuated oxycodone-induced increases in blood pressure and oxycodone or cocaine-induced increases in heart rate.  Similarly, R-VK4-116 alone dose-dependently reduced cocaine-induced increases in blood pressure and heart rate.  These results highlight the safety of new D3R antagonists and support the continued development of R-VK4-40 and R-VK4-116 for the treatment of opioid and cocaine use disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvUfnNpZtkLVg90H21EOLACvtfcHk0ljoudk6rDU1Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1WltLo%253D&md5=5fe7b8a11ae2083e6d78b2123bdd6fde</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fjpet.119.259390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.119.259390%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DHumburg%26aufirst%3DB.%2BA.%26aulast%3DThorndike%26aufirst%3DE.%2BB.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DSchindler%26aufirst%3DC.%2BW.%26atitle%3DNewly%2520developed%2520dopamine%2520D3%2520receptor%2520antagonists%252C%2520R-VK4-40%2520and%2520R-VK4-116%252C%2520do%2520not%2520potentiate%2520cardiovascular%2520effects%2520of%2520cocaine%2520or%2520oxycodone%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D371%26spage%3D602%26epage%3D614%26doi%3D10.1124%2Fjpet.119.259390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humburg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span> <span> </span><span class="NLM_article-title">The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>158</i></span>, <span class="NLM_elocation-id">107597</span> <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.neuropharm.2019.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30974107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVegt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2019&author=C.+J.+Jordanauthor=B.+Humburgauthor=M.+Riceauthor=G.+H.+Biauthor=Z.+B.+Youauthor=A.+B.+Shaikauthor=J.+Caoauthor=A.+Bonifaziauthor=A.+Gadianoauthor=R.+Raisauthor=B.+Slusherauthor=A.+H.+Newmanauthor=Z.+X.+Xi&title=The+highly+selective+dopamine+D3R+antagonist%2C+R-VK4-40+attenuates+oxycodone+reward+and+augments+analgesia+in+rodents&doi=10.1016%2Fj.neuropharm.2019.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents</span></div><div class="casAuthors">Jordan, Chloe J.; Humburg, Bree; Rice, Myra; Bi, Guo-Hua; You, Zhi-Bing; Shaik, Anver Basha; Cao, Jianjing; Bonifazi, Alessandro; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107597</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the effects of R-VK4-40, a highly selective D3R receptor antagonist, on the rewarding and analgesic effects of oxycodone, the most commonly abused prescription opioid, in rats and mice.  Systemic administration of R-VK4-40 dose-dependently inhibited oxycodone self-administration and shifted oxycodone dose-response curves downward in rats.  Pretreatment with R-VK4-40 also dose-dependently lowered break-points for oxycodone under a progressive-ratio schedule.  To det. whether a DA-dependent mechanism underlies the impact of D3 antagonism in reducing opioid reward, we used optogenetic approaches to examine intracranial self-stimulation (ICSS) maintained by optical activation of ventral tegmental area (VTA) DA neurons in DAT-Cre mice.  Pretreatment with R-VK4-40 blocked oxycodone-enhanced brain-stimulation reward.  By itself, R-VK4-40 produced a modest dose-dependent redn. in optical ICSS.  Pretreatment with R-VK4-40 did not compromise the antinociceptive effects of oxycodone in rats, and R-VK4-40 alone produced mild antinociceptive effects without altering open-field locomotion or rotarod locomotor performance.  Together, these findings suggest R-VK4-40 may permit a lower dose of prescription opioids for pain management, potentially mitigating tolerance and dependence, while diminishing reward potency.  Hence, development of R-VK4-40 as a therapy for the treatment of opioid use disorders and/or pain is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoec47hB7NVR7Vg90H21EOLACvtfcHk0lhfcDxNPGWBjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVegt7vI&md5=2619b493c3addad36e8ec504f41b25c7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DHumburg%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DM.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DYou%26aufirst%3DZ.%2BB.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26atitle%3DThe%2520highly%2520selective%2520dopamine%2520D3R%2520antagonist%252C%2520R-VK4-40%2520attenuates%2520oxycodone%2520reward%2520and%2520augments%2520analgesia%2520in%2520rodents%26jtitle%3DNeuropharmacology%26date%3D2019%26volume%3D158%26doi%3D10.1016%2Fj.neuropharm.2019.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Ligand discovery from a dopamine D3 receptor homology model and crystal structure</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1038/nchembio.662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fnchembio.662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21926995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFylsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=769-778&author=J.+Carlssonauthor=R.+G.+Colemanauthor=V.+Setolaauthor=J.+J.+Irwinauthor=H.+Fanauthor=A.+Schlessingerauthor=A.+Saliauthor=B.+L.+Rothauthor=B.+K.+Shoichet&title=Ligand+discovery+from+a+dopamine+D3+receptor+homology+model+and+crystal+structure&doi=10.1038%2Fnchembio.662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand discovery from a dopamine D3 receptor homology model and crystal structure</span></div><div class="casAuthors">Carlsson, Jens; Coleman, Ryan G.; Setola, Vincent; Irwin, John J.; Fan, Hao; Schlessinger, Avner; Sali, Andrej; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">769-778</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are intensely studied as drug targets and for their role in signaling.  With the detn. of the first crystal structures, interest in structure-based ligand discovery increased.  Unfortunately, for most GPCRs no exptl. structures are available.  The detn. of the D3 receptor structure and the challenge to the community to predict it enabled a fully prospective comparison of ligand discovery from a modeled structure vs. that of the subsequently released crystal structure.  Over 3.3 million mols. were docked against a homol. model, and 26 of the highest ranking were tested for binding.  Six had affinities ranging from 0.2 to 3.1 μM.  Subsequently, the crystal structure was released and the docking screen repeated.  Of the 25 compds. selected, five had affinities ranging from 0.3 to 3.0 μM.  One of the new ligands from the homol. model screen was optimized for affinity to 81 nM.  The feasibility of docking screens against modeled GPCRs more generally is considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz6gBx3Olbn7Vg90H21EOLACvtfcHk0lhfcDxNPGWBjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFylsLvP&md5=7242aa512079a348678b309d352ecdb9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.662%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DR.%2BG.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DLigand%2520discovery%2520from%2520a%2520dopamine%2520D3%2520receptor%2520homology%2520model%2520and%2520crystal%2520structure%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D769%26epage%3D778%26doi%3D10.1038%2Fnchembio.662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubukov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span> <span> </span><span class="NLM_article-title">Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">794</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1124/mol.113.088054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fmol.113.088054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24021214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyitLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=794-807&author=J.+R.+Laneauthor=P.+Chubukovauthor=W.+Liuauthor=M.+Canalsauthor=V.+Cherezovauthor=R.+Abagyanauthor=R.+C.+Stevensauthor=V.+Katritch&title=Structure-based+ligand+discovery+targeting+orthosteric+and+allosteric+pockets+of+dopamine+receptors&doi=10.1124%2Fmol.113.088054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors</span></div><div class="casAuthors">Lane, J. Robert; Chubukov, Pavel; Liu, Wei; Canals, Meritxell; Cherezov, Vadim; Abagyan, Ruben; Stevens, Raymond C.; Katritch, Vsevolod</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">794-807</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Small mols. targeting allosteric pockets of G protein-coupled receptors (GPCRs) have a great therapeutic potential for the treatment of neurol. and other chronic disorders.  Here we performed virtual screening for orthosteric and putative allosteric ligands of the human dopamine D3 receptor (D3R) using two optimized crystal-structure-based models: the receptor with an empty binding pocket (D3RAPO), and the receptor complex with dopamine (D3RDopa).  Subsequent biochem. and functional characterization revealed 14 novel ligands with a binding affinity of better than 10 μM in the D3RAPO candidate list (56% hit rate), and 8 novel ligands in the D3RDopa list (32% hit rate).  Most ligands in the D3RAPO model span both orthosteric and extended pockets and behave as antagonists at D3R, with compd. 7 showing the highest potency of dopamine inhibition (IC50 = 7 nM).  In contrast, compds. identified by the D3RDopa model are predicted to occupy an allosteric site at the extracellular extension of the pocket, and they all lack the anchoring amino group.  Compds. targeting the allosteric site display a variety of functional activity profiles, where behavior of at least two compds. (23 and 26) is consistent with noncompetitive allosteric modulation of dopamine signaling in the extracellular signal-regulated kinase 1 and 2 phosphorylation and β-arrestin recruitment assays.  The high affinity and ligand efficiency of the chem. diverse hits identified in this study suggest utility of structure-based screening targeting allosteric sites of GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5wO8LtvA7YbVg90H21EOLACvtfcHk0lgt3VcM9b1yrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyitLvO&md5=c0efe2cb7bb1ce9708826aea36de2043</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.088054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.088054%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DChubukov%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DKatritch%26aufirst%3DV.%26atitle%3DStructure-based%2520ligand%2520discovery%2520targeting%2520orthosteric%2520and%2520allosteric%2520pockets%2520of%2520dopamine%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D794%26epage%3D807%26doi%3D10.1124%2Fmol.113.088054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">High-affinity and selective dopamine D(3) receptor full agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5612</span>– <span class="NLM_lpage">5617</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bmcl.2012.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22871578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGht73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5612-5617&author=J.+Chenauthor=B.+Levantauthor=S.+Wang&title=High-affinity+and+selective+dopamine+D%283%29+receptor+full+agonists&doi=10.1016%2Fj.bmcl.2012.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity and selective dopamine D3 receptor full agonists</span></div><div class="casAuthors">Chen, Jianyong; Levant, Beth; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5612-5617</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have designed, synthesized and evaluated a series of new compds. with the goal to identify potent and selective D3 ligands.  The two most potent and selective new D3 ligands are compds. 38 and 52, which bind to the D3 receptors with a Ki value of <1 nM and display a selectivity of 450-494 times over the D2 receptors and >10,000 times over the D1 receptors.  Both 38 and 52 are full agonists with high potency at the D3 receptor in a D3 functional assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEFcieGKEBo7Vg90H21EOLACvtfcHk0lgt3VcM9b1yrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGht73J&md5=6585606ab267fe77cd960eba6629faff</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DHigh-affinity%2520and%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520full%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5612%26epage%3D5617%26doi%3D10.1016%2Fj.bmcl.2012.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">CJ-1639: a potent and highly selective dopamine D3 receptor full agonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1021/ml200100t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200100t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=620-625&author=J.+Chenauthor=G.+T.+Collinsauthor=B.+Levantauthor=J.+Woodsauthor=J.+R.+Deschampsauthor=S.+Wang&title=CJ-1639%3A+a+potent+and+highly+selective+dopamine+D3+receptor+full+agonist&doi=10.1021%2Fml200100t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist</span></div><div class="casAuthors">Chen, Jianyong; Collins, Gregory T.; Levant, Beth; Woods, James; Deschamps, Jeffrey R.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">620-625</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have identified several ligands with high binding affinities to the dopamine D3 receptor and excellent selectivity over the D2 and D1 receptors.  CJ-1639 (17) binds to the D3 receptor with a Ki value of 0.50 nM and displays a selectivity of >5000 times over D2 and D1 receptors in binding assays using dopamine receptors expressed in the native rat brain tissues.  CJ-1639 binds to human D3 receptor with a Ki value of 3.61 nM and displays over >1000-fold selectivity over human D1 and D2 receptors.  CJ-1639 is active at 0.01 mg/kg at the dopamine D3 receptor in the rat and only starts to show a modest D2 activity at doses as high as 10 mg/kg.  CJ-1639 is the most potent and selective D3 full agonist reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1_j_DTOKv47Vg90H21EOLACvtfcHk0lg7piQwxZMNqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLs%253D&md5=563e24bd67062d01a456b6f03429329a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fml200100t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200100t%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DG.%2BT.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DCJ-1639%253A%2520a%2520potent%2520and%2520highly%2520selective%2520dopamine%2520D3%2520receptor%2520full%2520agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D620%26epage%3D625%26doi%3D10.1021%2Fml200100t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2653</span>– <span class="NLM_lpage">2660</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fcmdc.201402398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25338762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaksbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2653-2660&author=J.+Chenauthor=C.+Jiangauthor=B.+Levantauthor=X.+Liauthor=T.+Zhaoauthor=B.+Wenauthor=R.+Luoauthor=D.+Sunauthor=S.+Wang&title=Pramipexole+derivatives+as+potent+and+selective+dopamine+D%283%29+receptor+agonists+with+improved+human+microsomal+stability&doi=10.1002%2Fcmdc.201402398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole Derivatives as Potent and Selective Dopamine D3 Receptor Agonists with Improved Human Microsomal Stability</span></div><div class="casAuthors">Chen, Jianyong; Jiang, Cheng; Levant, Beth; Li, Xiaoqin; Zhao, Ting; Wen, Bo; Luo, Ruijuan; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2653-2660</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the synthesis and evaluation of a series of new pramipexole derivs. as highly potent and selective agonists of the dopamine-3 (D3) receptor.  A no. of these new compds. bind to the D3 receptor with sub-nanomolar affinity and show excellent selectivity (>10 000) for the D3 receptor over the D1 and D2 receptors.  For example, compd. 23 (N-(cis-3-(2-(((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)benzamide) binds to the D3 receptor with a Ki value of 0.53 nΜ and shows a selectivity of >20 000 over the D2 and D1 receptors in the binding assays using a rat brain prepn.  It has excellent stability in human liver microsomes.  Moreover, in vitro functional assays showed it to be a full agonist for the human D3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxr67n6Ksdj7Vg90H21EOLACvtfcHk0lg7piQwxZMNqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaksbfL&md5=57dd5129b272187e10c83651a3aa42db</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402398%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DPramipexole%2520derivatives%2520as%2520potent%2520and%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520agonists%2520with%2520improved%2520human%2520microsomal%2520stability%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D2653%26epage%3D2660%26doi%3D10.1002%2Fcmdc.201402398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazeldine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrington, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzhikandathil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2- ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3005</span>– <span class="NLM_lpage">3019</span>, <span class="refDoi"> DOI: 10.1021/jm701524h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701524h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFyksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3005-3019&author=S.+Biswasauthor=S.+Hazeldineauthor=B.+Ghoshauthor=I.+Parringtonauthor=E.+Kuzhikandathilauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Bioisosteric+heterocyclic+versions+of+7-%7B%5B2-%284-phenyl-piperazin-1-yl%29ethyl%5Dpropylamino%7D-5%2C6%2C7%2C8-tetrahydronaphthalen-2-+ol%3A+identification+of+highly+potent+and+selective+agonists+for+dopamine+D3+receptor+with+potent+in+vivo+activity&doi=10.1021%2Fjm701524h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric Heterocyclic Versions of 7-{[2-(4-Phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: Identification of Highly Potent and Selective Agonists for Dopamine D3 Receptor with Potent in Vivo Activity</span></div><div class="casAuthors">Biswas, Swati; Hazeldine, Stuart; Ghosh, Balaram; Parrington, Ingrid; Kuzhikandathil, Eldo; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3005-3019</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the current report, the authors extend the SAR study on the hybrid structure 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol further to include heterocyclic bioisosteric analogs.  Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptors with tritiated spiperone to evaluate inhibition consts. (Ki).  Functional activity of selected compds. in stimulating GTPγS binding was assessed with CHO cells expressing human D2 receptors and AtT-20 cells expressing human D3 receptors.  The highest binding affinity and selectivity for D3 receptors were exhibited by compd. (I) (Ki = 0.92 nM and D2/D3=253).  In the functional GTPγS binding assay, I exhibited full agonist activity with picomolar affinity for D3 receptor with high selectivity (EC50 = 0.08 nM and D2/D3=248).  In the in vivo rotational study, I exhibited potent rotational activity in 6-OH-DA unilaterally lesioned rats with long duration of action, which indicates its potential application in neuroprotective treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6yNJ94snDg7Vg90H21EOLACvtfcHk0ljQQae55Dq8Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFyksbk%253D&md5=6c649b6077843039c49dab02128df139</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm701524h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701524h%26sid%3Dliteratum%253Aachs%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DHazeldine%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DParrington%26aufirst%3DI.%26aulast%3DKuzhikandathil%26aufirst%3DE.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DBioisosteric%2520heterocyclic%2520versions%2520of%25207-%257B%255B2-%25284-phenyl-piperazin-1-yl%2529ethyl%255Dpropylamino%257D-5%252C6%252C7%252C8-tetrahydronaphthalen-2-%2520ol%253A%2520identification%2520of%2520highly%2520potent%2520and%2520selective%2520agonists%2520for%2520dopamine%2520D3%2520receptor%2520with%2520potent%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3005%26epage%3D3019%26doi%3D10.1021%2Fjm701524h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydro benzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson’s disease animal models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1037</span>, <span class="refDoi"> DOI: 10.1021/jm901184n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901184n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WjsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1023-1037&author=B.+Ghoshauthor=T.+Antonioauthor=J.+Zhenauthor=P.+Kharkarauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Development+of+%28S%29-N6-%282-%284-%28isoquinolin-1-yl%29piperazin-1-yl%29ethyl%29-N6-propyl-4%2C5%2C6%2C7-tetrahydro+benzo%5Bd%5D-thiazole-2%2C6-diamine+and+its+analogue+as+a+D3+receptor+preferring+agonist%3A+potent+in+vivo+activity+in+Parkinson%E2%80%99s+disease+animal+models&doi=10.1021%2Fjm901184n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Development of (S)-N6-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: Potent in vivo activity in Parkinson's disease animal models</span></div><div class="casAuthors">Ghosh, Balaram; Antonio, Tamara; Zhen, Juan; Kharkar, Prashant; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1023-1037</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here we report structure-activity relationship study of a novel hybrid series of compds. where structural alteration of arom. hydrophobic moieties connected to the piperazine ring and bioisosteric replacement of the arom. tetralin moieties were carried out.  Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptors with tritiated spiperone to evaluate inhibition consts. (Ki).  Functional activity of selected compds. in stimulating GTPγS binding was assessed with CHO cells expressing human D2 receptors and AtT-20 cells expressing human D3 receptors.  SAR results identified compd. (-)-24c (D-301, I) as one of the lead mols. with preferential agonist activity for D3 receptor (EC50 (GTPγS); D3 = 0.52 nM; D2/D3 (EC50): 223).  Compds. (-)-24b and (-)-24c exhibited potent radical scavenging activity.  The two lead compds., (-)-24b and (-)-24c, exhibited high in vivo activity in two Parkinson's disease (PD) animal models, reserpinized rat model and 6-OHDA induced unilaterally lesioned rat model.  Future studies will explore potential use of these compds. in the neuroprotective therapy for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9rYWZ-mha0rVg90H21EOLACvtfcHk0ljQQae55Dq8Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WjsLnO&md5=ae4d8fb18fd9607e1508ee936f88b7bd</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm901184n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901184n%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DKharkar%26aufirst%3DP.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DDevelopment%2520of%2520%2528S%2529-N6-%25282-%25284-%2528isoquinolin-1-yl%2529piperazin-1-yl%2529ethyl%2529-N6-propyl-4%252C5%252C6%252C7-tetrahydro%2520benzo%255Bd%255D-thiazole-2%252C6-diamine%2520and%2520its%2520analogue%2520as%2520a%2520D3%2520receptor%2520preferring%2520agonist%253A%2520potent%2520in%2520vivo%2520activity%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520animal%2520models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1023%26epage%3D1037%26doi%3D10.1021%2Fjm901184n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydroben zo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5826</span>– <span class="NLM_lpage">5840</span>, <span class="refDoi"> DOI: 10.1021/jm300268s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300268s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsF2gurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5826-5840&author=M.+Johnsonauthor=T.+Antonioauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Structure-activity+relationship+study+of+N%286%29-%282-%284-%281H-Indol-5-yl%29piperazin-1-yl%29ethyl%29-N%286%29-propyl-4%2C5%2C6%2C7-tetrahydroben+zo%5Bd%5Dthiazole-2%2C6-diamine+analogues%3A+development+of+highly+selective+D3+dopamine+receptor+agonists+along+with+a+highly+potent+D2%2FD3+agonist+and+their+pharmacological+characterization&doi=10.1021%2Fjm300268s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization</span></div><div class="casAuthors">Johnson, Mark; Antonio, Tamara; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5826-5840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our effort to develop multifunctional drugs against Parkinson's disease, a structure-activity-relationship study was carried out based on our hybrid mol. template targeting D2/D3 receptors.  Competitive binding with [3H]spiroperidol was used to evaluate affinity (Ki) of test compds.  Functional activity of selected compds. in stimulating [35S]GTPγS binding was assessed in CHO cells expressing either human D2 or D3 receptors.  Our results demonstrated development of highly selective compds. for D3 receptor (for (-)-40 (I) Ki, D3 = 1.84 nM, D2/D3 = 583.2; for (-)-45Ki, D3 = 1.09 nM, D2/D3 = 827.5).  Functional data identified (-)-40 (EC50, D2 = 114 nM, D3 = 0.26 nM, D2/D3 = 438) as one of the highest D3 selective agonists known to date.  In addn., high affinity, nonselective D3 agonist (-)-19 (EC50, D2 = 2.96 nM and D3 = 1.26 nM) was also developed.  Lead compds. with antioxidant activity were evaluated using an in vivo PD animal model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6RjEg-1KqXbVg90H21EOLACvtfcHk0lgcF7bU_H9pSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsF2gurk%253D&md5=3b8cfcd3f1e19da405875c342ba3abdc</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm300268s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300268s%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520N%25286%2529-%25282-%25284-%25281H-Indol-5-yl%2529piperazin-1-yl%2529ethyl%2529-N%25286%2529-propyl-4%252C5%252C6%252C7-tetrahydroben%2520zo%255Bd%255Dthiazole-2%252C6-diamine%2520analogues%253A%2520development%2520of%2520highly%2520selective%2520D3%2520dopamine%2520receptor%2520agonists%2520along%2520with%2520a%2520highly%2520potent%2520D2%252FD3%2520agonist%2520and%2520their%2520pharmacological%2520characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5826%26epage%3D5840%26doi%3D10.1021%2Fjm300268s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandy, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selley, D. E.</span></span> <span> </span><span class="NLM_article-title">Efficacy of hybrid tetrahydrobenzo[d]thiazole based aryl piperazines D-264 and D-301 at D(2) and D(3) receptors</span>. <i>Neurochem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1007/s11064-015-1808-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs11064-015-1808-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26718829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslSi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=328-339&author=J.+Zhenauthor=T.+Antonioauthor=J.+C.+Jacobauthor=D.+K.+Grandyauthor=M.+E.+Reithauthor=A.+K.+Duttaauthor=D.+E.+Selley&title=Efficacy+of+hybrid+tetrahydrobenzo%5Bd%5Dthiazole+based+aryl+piperazines+D-264+and+D-301+at+D%282%29+and+D%283%29+receptors&doi=10.1007%2Fs11064-015-1808-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D2 and D3 Receptors</span></div><div class="casAuthors">Zhen, Juan; Antonio, Tamara; Jacob, Joanna C.; Grandy, David K.; Reith, Maarten E. A.; Dutta, Aloke K.; Selley, Dana E.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">328-339</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In elucidating the role of pharmacodynamic efficacy at D3 receptors in therapeutic effectiveness of dopamine receptor agonists, the influence of study system must be understood.  Here two compds. with D3 over D2 selectivity developed in our earlier work, D-264 and D-301, are compared in dopamine receptor-mediated G-protein activation in striatal regions of wild-type and D2 receptor knockout mice and in CHO cells expressing D2 or D3 receptors.  In caudate-putamen of D2 knockout mice, D-301 was ∼3-fold more efficacious than D-264 in activating G-proteins as assessed by [35S]GTPγS binding; in nucleus accumbens, D-301 stimulated G-protein activation whereas D-264 did not.  In contrast, the two ligands exerted similar efficacy in both regions of wild-type mice, suggesting both ligands activate D2 receptors with similar efficacy.  In D2 and D3 receptor-expressing CHO cells, D-264 and D-301 appeared to act in the [35S]GTPγS assay as full agonists because they produced maximal stimulation equal to dopamine.  Competition for [3H]spiperone binding was then performed to det. Ki/EC50 ratios as an index of receptor reserve for each ligand.  Action of D-301, but not D-264, showed receptor reserve in D3 but not in D2 receptor-expressing cells, whereas dopamine showed receptor reserve in both cell lines.  Gαo1 is highly expressed in brain and is important in D2-like receptor-G protein coupling.  Transfection of Gαo1 in D3- but not D2-expressing CHO cells led to receptor reserve for D-264 without altering receptor expression levels.  D-301 and dopamine exhibited receptor reserve in D3-expressing cells both with and without transfection of Gαo1.  Altogether, these results indicate that D-301 has greater intrinsic efficacy to activate D3 receptors than D-264, whereas the two compds. act on D2 receptors with similar intrinsic efficacy.  These findings also suggest caution in interpreting Emax values from functional assays in receptor-transfected cell models without accounting for receptor reserve.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyXeh7TIhgVbVg90H21EOLACvtfcHk0ljSZEtXEwgPGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslSi&md5=5ff4c70588902e082d93aaa329f832d6</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs11064-015-1808-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11064-015-1808-6%26sid%3Dliteratum%253Aachs%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DJacob%26aufirst%3DJ.%2BC.%26aulast%3DGrandy%26aufirst%3DD.%2BK.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DSelley%26aufirst%3DD.%2BE.%26atitle%3DEfficacy%2520of%2520hybrid%2520tetrahydrobenzo%255Bd%255Dthiazole%2520based%2520aryl%2520piperazines%2520D-264%2520and%2520D-301%2520at%2520D%25282%2529%2520and%2520D%25283%2529%2520receptors%26jtitle%3DNeurochem.%2520Res.%26date%3D2016%26volume%3D41%26spage%3D328%26epage%3D339%26doi%3D10.1007%2Fs11064-015-1808-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, S. H.</span></span> <span> </span><span class="NLM_article-title">Correction: design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists</span>. <i>Medchemcomm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1565</span>, <span class="refDoi"> DOI: 10.1039/C8MD90042F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1039%2FC8MD90042F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30289124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ynt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1565&author=Y.+Caoauthor=N.+Sunauthor=J.+Zhangauthor=Z.+Liuauthor=Y.+Z.+Tangauthor=Z.+Wuauthor=K.+M.+Kimauthor=S.+H.+Cheon&title=Correction%3A+design%2C+synthesis%2C+and+evaluation+of+bitopic+arylpiperazine-phthalimides+as+selective+dopamine+D3+receptor+agonists&doi=10.1039%2FC8MD90042F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Correction: Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists [Erratum to document cited in CA172:154797]</span></div><div class="casAuthors">Cao, Yongkai; Sun, Ningning; Zhang, Jiumei; Liu, Zhiguo; Tang, Yi-zhe; Wu, Zhengzhi; Kim, Kyeong-Man; Cheon, Seung Hoon</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1565</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Correction for 'Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists' by Yongkai Cao et al., Med.  Chem. Commun., 2018, DOI: 10.1039/c8md00237a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_cgUcuLVmL7Vg90H21EOLACvtfcHk0ljSZEtXEwgPGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ynt7vM&md5=df74f0d3550f358e19c2408dcc7f76e4</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC8MD90042F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8MD90042F%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DY.%2BZ.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DCheon%26aufirst%3DS.%2BH.%26atitle%3DCorrection%253A%2520design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520bitopic%2520arylpiperazine-phthalimides%2520as%2520selective%2520dopamine%2520D3%2520receptor%2520agonists%26jtitle%3DMedchemcomm%26date%3D2018%26volume%3D9%26spage%3D1565%26doi%3D10.1039%2FC8MD90042F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aube, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamji, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roush, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noah, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severson, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Advancing biological understanding and therapeutics discovery with small-molecule probes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.cell.2015.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26046436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVehsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2015&pages=1252-1265&author=S.+L.+Schreiberauthor=J.+D.+Kotzauthor=M.+Liauthor=J.+Aubeauthor=C.+P.+Austinauthor=J.+C.+Reedauthor=H.+Rosenauthor=E.+L.+Whiteauthor=L.+A.+Sklarauthor=C.+W.+Lindsleyauthor=B.+R.+Alexanderauthor=J.+A.+Bittkerauthor=P.+A.+Clemonsauthor=A.+de+Souzaauthor=M.+A.+Foleyauthor=M.+Palmerauthor=A.+F.+Shamjiauthor=M.+J.+Wawerauthor=O.+McManusauthor=M.+Wuauthor=B.+Zouauthor=H.+Yuauthor=J.+E.+Goldenauthor=F.+J.+Schoenenauthor=A.+Simeonovauthor=A.+Jadhavauthor=M.+R.+Jacksonauthor=A.+B.+Pinkertonauthor=T.+D.+Chungauthor=P.+R.+Griffinauthor=B.+F.+Cravattauthor=P.+S.+Hodderauthor=W.+R.+Roushauthor=E.+Robertsauthor=D.+H.+Chungauthor=C.+B.+Jonssonauthor=J.+W.+Noahauthor=W.+E.+Seversonauthor=S.+Ananthanauthor=B.+Edwardsauthor=T.+I.+Opreaauthor=P.+J.+Connauthor=C.+R.+Hopkinsauthor=M.+R.+Woodauthor=S.+R.+Staufferauthor=K.+A.+Emmitte&title=Advancing+biological+understanding+and+therapeutics+discovery+with+small-molecule+probes&doi=10.1016%2Fj.cell.2015.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes</span></div><div class="casAuthors">Schreiber, Stuart L.; Kotz, Joanne D.; Li, Min; Aube, Jeffrey; Austin, Christopher P.; Reed, John C.; Rosen, Hugh; White, E. Lucile; Sklar, Larry A.; Lindsley, Craig W.; Alexander, Benjamin R.; Bittker, Joshua A.; Clemons, Paul A.; de Souza, Andrea; Foley, Michael A.; Palmer, Michelle; Shamji, Alykhan F.; Wawer, Mathias J.; McManus, Owen; Wu, Meng; Zou, Beiyan; Yu, Haibo; Golden, Jennifer E.; Schoenen, Frank J.; Simeonov, Anton; Jadhav, Ajit; Jackson, Michael R.; Pinkerton, Anthony B.; Chung, Thomas D. Y.; Griffin, Patrick R.; Cravatt, Benjamin F.; Hodder, Peter S.; Roush, William R.; Roberts, Edward; Chung, Dong-Hoon; Jonsson, Colleen B.; Noah, James W.; Severson, William E.; Ananthan, Subramaniam; Edwards, Bruce; Oprea, Tudor I.; Conn, P. Jeffrey; Hopkins, Corey R.; Wood, Michael R.; Stauffer, Shaun R.; Emmitte, Kyle A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1252-1265</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Small-mol. probes can illuminate biol. processes and aid in the assessment of emerging therapeutic targets by perturbing biol. systems in a manner distinct from other exptl. approaches.  Despite the tremendous promise of chem. tools for studying biol. and disease, small-mol. probes were unavailable for most targets and pathways as recently as a decade ago.  In 2005, the NIH launched the decade-long Mol. Libraries Program with the intent of innovating in and broadening access to small-mol. science.  This Perspective describes how novel small-mol. probes identified through the program are enabling the exploration of biol. pathways and therapeutic hypotheses not otherwise testable.  These experiences illustrate how small-mol. probes can help bridge the chasm between biol. research and the development of medicines but also highlight the need to innovate the science of therapeutic discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfjCbrl4SObLVg90H21EOLACvtfcHk0ljV8oe1nPXhXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVehsr%252FO&md5=067b42ffe9e77c0e0e83f29126d7afd7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DKotz%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DAube%26aufirst%3DJ.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DAlexander%26aufirst%3DB.%2BR.%26aulast%3DBittker%26aufirst%3DJ.%2BA.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3Dde%2BSouza%26aufirst%3DA.%26aulast%3DFoley%26aufirst%3DM.%2BA.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DShamji%26aufirst%3DA.%2BF.%26aulast%3DWawer%26aufirst%3DM.%2BJ.%26aulast%3DMcManus%26aufirst%3DO.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DGolden%26aufirst%3DJ.%2BE.%26aulast%3DSchoenen%26aufirst%3DF.%2BJ.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DJackson%26aufirst%3DM.%2BR.%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DChung%26aufirst%3DT.%2BD.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DHodder%26aufirst%3DP.%2BS.%26aulast%3DRoush%26aufirst%3DW.%2BR.%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DJonsson%26aufirst%3DC.%2BB.%26aulast%3DNoah%26aufirst%3DJ.%2BW.%26aulast%3DSeverson%26aufirst%3DW.%2BE.%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DEdwards%26aufirst%3DB.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26atitle%3DAdvancing%2520biological%2520understanding%2520and%2520therapeutics%2520discovery%2520with%2520small-molecule%2520probes%26jtitle%3DCell%26date%3D2015%26volume%3D161%26spage%3D1252%26epage%3D1265%26doi%3D10.1016%2Fj.cell.2015.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meade, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulcey, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant-Genevier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnaeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marugan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of a G protein–biased agonist that inhibits ß-arrestin recruitment to the D2 dopamine receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1124/mol.113.090563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fmol.113.090563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24755247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=96-105&author=R.+B.+Freeauthor=L.+S.+Chunauthor=A.+E.+Moritzauthor=B.+N.+Millerauthor=T.+B.+Doyleauthor=J.+L.+Conroyauthor=A.+Padronauthor=J.+A.+Meadeauthor=J.+Xiaoauthor=X.+Huauthor=A.+E.+Dulceyauthor=Y.+Hanauthor=L.+Duanauthor=S.+Titusauthor=M.+Bryant-Genevierauthor=E.+Barnaevaauthor=M.+Ferrerauthor=J.+A.+Javitchauthor=T.+Beumingauthor=L.+Shiauthor=N.+T.+Southallauthor=J.+J.+Maruganauthor=D.+R.+Sibley&title=Discovery+and+characterization+of+a+G+protein%E2%80%93biased+agonist+that+inhibits+%C3%9F-arrestin+recruitment+to+the+D2+dopamine+receptor&doi=10.1124%2Fmol.113.090563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor</span></div><div class="casAuthors">Free, R. Benjamin; Chun, Lani S.; Moritz, Amy E.; Miller, Brittney N.; Doyle, Trevor B.; Conroy, Jennie L.; Padron, Adrian; Meade, Julie A.; Xiao, Jingbo; Hu, Xin; Dulcey, Andres E.; Han, Yang; Duan, Lihua; Titus, Steve; Bryant-Genevier, Melanie; Barnaeva, Elena; Ferrer, Marc; Javitch, Jonathan A.; Beuming, Thijs; Shi, Lei; Southall, Noel T.; Marugan, Juan J.; Sibley, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-105, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A high-throughput screening campaign was conducted to interrogate a 380,000+ small-mol. library for novel D2 dopamine receptor modulators using a calcium mobilization assay.  Active agonist compds. from the primary screen were examd. for orthogonal D2 dopamine receptor signaling activities including cAMP modulation and β-arrestin recruitment.  Although the majority of the subsequently confirmed hits activated all signaling pathways tested, several compds. showed a diminished ability to stimulate β-arrestin recruitment.  One such compd. (MLS1547; 5-chloro-7-[(4-pyridin-2-ylpiperazin-1-yl)methyl]quinolin-8-ol) is a highly efficacious agonist at D2 receptor-mediated G protein-linked signaling, but does not recruit β-arrestin as demonstrated using two different assays.  This compd. does, however, antagonize dopamine-stimulated β-arrestin recruitment to the D2 receptor.  In an effort to investigate the chem. scaffold of MLS1547 further, we characterized a set of 24 analogs of MLS1547 with respect to their ability to inhibit cAMP accumulation or stimulate β-arrestin recruitment.  A no. of the analogs were similar to MLS1547 in that they displayed agonist activity for inhibiting cAMP accumulation, but did not stimulate β-arrestin recruitment (i.e., they were highly biased).  In contrast, other analogs displayed various degrees of G protein signaling bias.  These results provided the basis to use pharmacophore modeling and mol. docking analyses to build a preliminary structure-activity relationship of the functionally selective properties of this series of compds.  In summary, we have identified and characterized a novel G protein-biased agonist of the D2 dopamine receptor and identified structural features that may contribute to its biased signaling properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUnTQyiZvZxrVg90H21EOLACvtfcHk0ljV8oe1nPXhXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksrvF&md5=7a3412858a3d780d8f90ca4535d485fc</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.090563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.090563%26sid%3Dliteratum%253Aachs%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DChun%26aufirst%3DL.%2BS.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DMiller%26aufirst%3DB.%2BN.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DPadron%26aufirst%3DA.%26aulast%3DMeade%26aufirst%3DJ.%2BA.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDulcey%26aufirst%3DA.%2BE.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DL.%26aulast%3DTitus%26aufirst%3DS.%26aulast%3DBryant-Genevier%26aufirst%3DM.%26aulast%3DBarnaeva%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DSouthall%26aufirst%3DN.%2BT.%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520G%2520protein%25E2%2580%2593biased%2520agonist%2520that%2520inhibits%2520%25C3%259F-arrestin%2520recruitment%2520to%2520the%2520D2%2520dopamine%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D86%26spage%3D96%26epage%3D105%26doi%3D10.1124%2Fmol.113.090563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnaeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant-Genevier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulcey, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marugan, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3450</span>– <span class="NLM_lpage">3463</span>, <span class="refDoi"> DOI: 10.1021/jm500126s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500126s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVCrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3450-3463&author=J.+Xiaoauthor=R.+B.+Freeauthor=E.+Barnaevaauthor=J.+L.+Conroyauthor=T.+Doyleauthor=B.+Millerauthor=M.+Bryant-Genevierauthor=M.+K.+Taylorauthor=X.+Huauthor=A.+E.+Dulceyauthor=N.+Southallauthor=M.+Ferrerauthor=S.+Titusauthor=W.+Zhengauthor=D.+R.+Sibleyauthor=J.+J.+Marugan&title=Discovery%2C+optimization%2C+and+characterization+of+novel+D2+dopamine+receptor+selective+antagonists&doi=10.1021%2Fjm500126s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists</span></div><div class="casAuthors">Xiao, Jingbo; Free, R. Benjamin; Barnaeva, Elena; Conroy, Jennie L.; Doyle, Trevor; Miller, Brittney; Bryant-Genevier, Marthe; Taylor, Mercedes K.; Hu, Xin; Dulcey, Andres E.; Southall, Noel; Ferrer, Marc; Titus, Steve; Zheng, Wei; Sibley, David R.; Marugan, Juan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3450-3463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The D2 dopamine receptor (D2 DAR) is one of the most validated drug targets for neuropsychiatric and endocrine disorders.  However, clin. approved drugs targeting D2 DAR display poor selectivity between the D2 and other receptors, esp. the D3 DAR.  This lack of selectivity may lead to undesirable side effects.  Described are chem. and pharmacol. characterizations of a novel D2 DAR antagonist series with excellent D2 vs. D1, D3, D4, and D5 receptor selectivity.  The final probe, 10-Methyl-11-oxo-N-(2-(thiophen-2-yl)ethyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5-(S)-oxide, was obtained through a quant. high-throughput screening campaign, followed by medicinal chem. optimization, to yield a selective mol. with good in vitro phys. properties, metabolic stability, and in vivo pharmacokinetics.  The optimized mol. may be a useful in vivo probe for studying D2 DAR signal modulation and could also serve as a lead compd. for the development of D2 DAR-selective drug-like mols. for the treatment of multiple neuropsychiatric and endocrine disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpR_vjtd6k47Vg90H21EOLACvtfcHk0lg8qnRaATmFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVCrsLk%253D&md5=29a129e52d18b35637390618096fc4d8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm500126s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500126s%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DBarnaeva%26aufirst%3DE.%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DDoyle%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DB.%26aulast%3DBryant-Genevier%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DM.%2BK.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDulcey%26aufirst%3DA.%2BE.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DTitus%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%252C%2520optimization%252C%2520and%2520characterization%2520of%2520novel%2520D2%2520dopamine%2520receptor%2520selective%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3450%26epage%3D3463%26doi%3D10.1021%2Fjm500126s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span> <span> </span><span class="NLM_article-title">Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">708</span>, <span class="refDoi"> DOI: 10.1038/nrd4308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fnrd4308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25176435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=692-708&author=P.+J.+Connauthor=C.+W.+Lindsleyauthor=J.+Meilerauthor=C.+M.+Niswender&title=Opportunities+and+challenges+in+the+discovery+of+allosteric+modulators+of+GPCRs+for+treating+CNS+disorders&doi=10.1038%2Fnrd4308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders</span></div><div class="casAuthors">Conn, P. Jeffrey; Lindsley, Craig W.; Meiler, Jens; Niswender, Colleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">692-708</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Novel allosteric modulators of G protein-coupled receptors (GPCRs) are providing fundamental advances in the development of GPCR ligands with high subtype selectivity and novel modes of efficacy that have not been possible with traditional approaches.  As new allosteric modulators are advancing as drug candidates, we are developing an increased understanding of the major advantages and broad range of activities that can be achieved with these agents through selective modulation of specific signalling pathways, differential effects on GPCR homodimers vs. heterodimers, and other properties.  This understanding creates exciting opportunities, as well as unique challenges, in the optimization of novel therapeutic agents for disorders of the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS1YQIo2v0lLVg90H21EOLACvtfcHk0lg8qnRaATmFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtbzL&md5=07571da612fc9344e5d6af86aa3eaf83</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd4308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4308%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26atitle%3DOpportunities%2520and%2520challenges%2520in%2520the%2520discovery%2520of%2520allosteric%2520modulators%2520of%2520GPCRs%2520for%2520treating%2520CNS%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D692%26epage%3D708%26doi%3D10.1038%2Fnrd4308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span> <span> </span><span class="NLM_article-title">Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">37409</span>– <span class="NLM_lpage">37414</span>, <span class="refDoi"> DOI: 10.1074/jbc.M106728200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1074%2Fjbc.M106728200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=11473130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3MXns1eksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=37409-37414&author=K.+M.+Kimauthor=K.+J.+Valenzanoauthor=S.+R.+Robinsonauthor=W.+D.+Yaoauthor=L.+S.+Barakauthor=M.+G.+Caron&title=Differential+regulation+of+the+dopamine+D2+and+D3+receptors+by+G+protein-coupled+receptor+kinases+and+beta-arrestins&doi=10.1074%2Fjbc.M106728200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and β-arrestins</span></div><div class="casAuthors">Kim, Kyeong-Man; Valenzano, Kenneth J.; Robinson, Susan R.; Yao, Wei Dong; Barak, Larry S.; Caron, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">37409-37414</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The D2 and D3 receptors (D2R and D3R), which are potential targets for antipsychotic drugs, have a similar structural architecture and signaling pathway.  Furthermore, in some brain regions they are expressed in the same cells, suggesting that differences between the two receptors might lie in other properties such as their regulation.  In this study the authors investigated, using COS-7 and HEK-293 cells, the mechanism underlying the intracellular trafficking of the D2R and D3R.  Activation of D2R caused G protein-coupled receptor kinase-dependent receptor phosphorylation, a robust translocation of β-arrestin to the cell membrane, and profound receptor internalization.  The internalization of the D2R was dynamin-dependent, suggesting that a clathrin-coated endocytic pathway is involved.  In addn., the D2R, upon agonist-mediated internalization, localized to intracellular compartments distinct from those utilized by the β2-adrenergic receptor.  However, in the case of the D3R, only subtle agonist-mediated receptor phosphorylation, β-arrestin translocation to the plasma membrane, and receptor internalization were obsd.  Interchange of the second and third intracellular loops of the D2R and D3R reversed their phenotypes, implicating these regions in the regulatory properties of the two receptors.  Thus, the authors' studies indicate that functional distinctions between the D2R and D3R may be found in their desensitization and cellular trafficking properties.  The differences in their regulatory properties suggest that they have distinct physiol. roles in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOhqTknhrd_LVg90H21EOLACvtfcHk0lg8qnRaATmFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXns1eksrc%253D&md5=c94706df9516d391398753cc64a17fc5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M106728200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M106728200%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DValenzano%26aufirst%3DK.%2BJ.%26aulast%3DRobinson%26aufirst%3DS.%2BR.%26aulast%3DYao%26aufirst%3DW.%2BD.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DDifferential%2520regulation%2520of%2520the%2520dopamine%2520D2%2520and%2520D3%2520receptors%2520by%2520G%2520protein-coupled%2520receptor%2520kinases%2520and%2520beta-arrestins%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D37409%26epage%3D37414%26doi%3D10.1074%2Fjbc.M106728200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongetti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBounty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of selectivity and efficacy at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6699</span>, <span class="refDoi"> DOI: 10.1021/jm300482h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300482h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6689-6699&author=A.+H.+Newmanauthor=T.+Beumingauthor=A.+K.+Banalaauthor=P.+Donthamsettiauthor=K.+Pongettiauthor=A.+LaBountyauthor=B.+Levyauthor=J.+Caoauthor=M.+Michinoauthor=R.+R.+Luedtkeauthor=J.+A.+Javitchauthor=L.+Shi&title=Molecular+determinants+of+selectivity+and+efficacy+at+the+dopamine+D3+receptor&doi=10.1021%2Fjm300482h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span></div><div class="casAuthors">Newman, Amy Hauck; Beuming, Thijs; Banala, Ashwini K.; Donthamsetti, Prashant; Pongetti, Katherine; LaBounty, Alex; Levy, Benjamin; Cao, Jianjing; Michino, Mayako; Luedtke, Robert R.; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6689-6699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.  The high sequence homol. between the D3R and D2R, esp. within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compds. challenging.  Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compds. and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy.  We find that selectivity arises from divergent interactions within a second binding pocket (SBP) sep. from the OBS, whereas efficacy depends on the binding mode in the OBS.  Our findings reveal structural features of the receptor that are crit. to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies.  These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmBJU7uyvVg7Vg90H21EOLACvtfcHk0lj6us7hibSpBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D&md5=033dd49282723650828a3ec0a31211e5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm300482h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300482h%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DPongetti%26aufirst%3DK.%26aulast%3DLaBounty%26aufirst%3DA.%26aulast%3DLevy%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DMolecular%2520determinants%2520of%2520selectivity%2520and%2520efficacy%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6689%26epage%3D6699%26doi%3D10.1021%2Fjm300482h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweppe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel analogues of (R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (sumanirole) provide clues to dopamine D2/D3 receptor agonist selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2973</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01612</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01612" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2973-2988&author=M.+F.+Zouauthor=T.+M.+Keckauthor=V.+Kumarauthor=P.+Donthamsettiauthor=M.+Michinoauthor=C.+Burzynskiauthor=C.+Schweppeauthor=A.+Bonifaziauthor=R.+B.+Freeauthor=D.+R.+Sibleyauthor=A.+Janowskyauthor=L.+Shiauthor=J.+A.+Javitchauthor=A.+H.+Newman&title=Novel+analogues+of+%28R%29-5-%28methylamino%29-5%2C6-dihydro-4H-imidazo%5B4%2C5%2C1-ij%5Dquinolin-2%281H%29-one+%28sumanirole%29+provide+clues+to+dopamine+D2%2FD3+receptor+agonist+selectivity&doi=10.1021%2Facs.jmedchem.5b01612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity</span></div><div class="casAuthors">Zou, Mu-Fa; Keck, Thomas M.; Kumar, Vivek; Donthamsetti, Prashant; Michino, Mayako; Burzynski, Caitlin; Schweppe, Catherine; Bonifazi, Alessandro; Free, R. Benjamin; Sibley, David R.; Janowsky, Aaron; Shi, Lei; Javitch, Jonathan A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2973-2988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 1-, 5-, and 8-substituted analogs of sumanirole (I), a dopamine D2/D3 receptor (D2R/D3R) agonist, were synthesized.  Binding affinities at both D2R and D3R were higher when detd. in competition with the agonist radioligand [3H]7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT) than with the antagonist radioligand [3H]N-methylspiperone.  Although I was confirmed as a D2R-preferential agonist, its selectivity in binding and functional studies was lower than previously reported.  All analogs were detd. to be D2R/D3R agonists in both GoBRET and mitogenesis functional assays.  Loss of efficacy was detected for the N-1-substituted analogs at D3R.  In contrast, the N-5-alkyl-substituted analogs, and notably the n-butyl-arylamides (II and III), all showed improved affinity at D2R over I with neither a loss of efficacy nor an increase in selectivity.  Computational modeling provided a structural basis for the D2R selectivity of I, illustrating how subtle differences in the highly homologous orthosteric binding site (OBS) differentially affect D2R/D3R affinity and functional efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCYS7hdbWljrVg90H21EOLACvtfcHk0lj6us7hibSpBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yqs70%253D&md5=504e9fde86b9cef1a3b52fa4a3ef2063</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01612%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DSchweppe%26aufirst%3DC.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DJanowsky%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520analogues%2520of%2520%2528R%2529-5-%2528methylamino%2529-5%252C6-dihydro-4H-imidazo%255B4%252C5%252C1-ij%255Dquinolin-2%25281H%2529-one%2520%2528sumanirole%2529%2520provide%2520clues%2520to%2520dopamine%2520D2%252FD3%2520receptor%2520agonist%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2973%26epage%3D2988%26doi%3D10.1021%2Facs.jmedchem.5b01612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Soto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, B. K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonye, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">aaw5885</span> <span class="refDoi"> DOI: 10.1126/scisignal.aaw5885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1126%2Fscisignal.aaw5885" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&author=M.+Sanchez-Sotoauthor=R.+K.+Vermaauthor=B.+K.+A.+Willetteauthor=E.+C.+Gonyeauthor=A.+M.+Mooreauthor=A.+E.+Moritzauthor=C.+A.+Boatengauthor=H.+Yanoauthor=R.+B.+Freeauthor=L.+Shiauthor=D.+R.+Sibley&title=A+structural+basis+for+how+ligand+binding+site+changes+can+allosterically+regulate+GPCR+signaling+and+engender+functional+selectivity&doi=10.1126%2Fscisignal.aaw5885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aaw5885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aaw5885%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Soto%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DWillette%26aufirst%3DB.%2BK.%2BA.%26aulast%3DGonye%26aufirst%3DE.%2BC.%26aulast%3DMoore%26aufirst%3DA.%2BM.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DA%2520structural%2520basis%2520for%2520how%2520ligand%2520binding%2520site%2520changes%2520can%2520allosterically%2520regulate%2520GPCR%2520signaling%2520and%2520engender%2520functional%2520selectivity%26jtitle%3DSci.%2520Signaling%26date%3D2020%26volume%3D13%26doi%3D10.1126%2Fscisignal.aaw5885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salahpour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">BRET biosensors to study GPCR biology, pharmacology, and signal transduction</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.3389/fendo.2012.00105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.3389%2Ffendo.2012.00105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22952466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BC38bksV2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=105&author=A.+Salahpourauthor=S.+Espinozaauthor=B.+Masriauthor=V.+Lamauthor=L.+S.+Barakauthor=R.+R.+Gainetdinov&title=BRET+biosensors+to+study+GPCR+biology%2C+pharmacology%2C+and+signal+transduction&doi=10.3389%2Ffendo.2012.00105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">BRET biosensors to study GPCR biology, pharmacology, and signal transduction</span></div><div class="casAuthors">Salahpour Ali; Espinoza Stefano; Masri Bernard; Lam Vincent; Barak Larry S; Gainetdinov Raul R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bioluminescence resonance energy transfer (BRET)-based biosensors have been extensively used over the last decade to study protein-protein interactions and intracellular signal transduction in living cells.  In this review, we discuss the various BRET biosensors that have been developed to investigate biology, pharmacology, and signaling of G protein-coupled receptors (GPCRs).  GPCRs form two distinct types of multiprotein signal transduction complexes based upon their inclusion of G proteins or β-arrestins that can be differentially affected by drugs that exhibit functional selectivity toward G protein or β-arrestin signaling.  BRET has been especially adept at illuminating the dynamics of protein-protein interactions between receptors, G proteins, β-arrestins, and their many binding partners in living cells; as well as measuring the formation and accumulation of second messengers following receptor activation.  Specifically, we discuss in detail the application of BRET to study dopamine and trace amine receptors signaling, presenting examples of an exchange protein activated by cAMP biosensor to measure cAMP, β-arrestin biosensors to determine β-arrestin recruitment to the receptor, and dopamine D2 receptor and trace amine-associated receptor 1 biosensors to investigate heterodimerization between them.  As the biochemical spectrum of BRET biosensors expands, the number of signaling pathways that can be measured will concomitantly increase.  This will be particularly useful for the evaluation of functional selectivity in which the real-time BRET capability to measure distinct signaling modalities will dramatically shorten the time to characterize new generation of biased drugs.  These emerging approaches will further expand the growing application of BRET in the screening for novel pharmacologically active compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI8fyvdZc3H-IHSmpohpd0fW6udTcc2eZQPF1looLIsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bksV2qtw%253D%253D&md5=cf710c8ff571036e36f0f28603ba9817</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2012.00105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2012.00105%26sid%3Dliteratum%253Aachs%26aulast%3DSalahpour%26aufirst%3DA.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DMasri%26aufirst%3DB.%26aulast%3DLam%26aufirst%3DV.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DBRET%2520biosensors%2520to%2520study%2520GPCR%2520biology%252C%2520pharmacology%252C%2520and%2520signal%2520transduction%26jtitle%3DFront.%2520Endocrinol.%26date%3D2012%26volume%3D3%26spage%3D105%26doi%3D10.3389%2Ffendo.2012.00105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Soto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span> <span> </span><span class="NLM_article-title">Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1124/mol.115.101808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fmol.115.101808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26843180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWntrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=457-466&author=M.+S%C3%A1nchez-Sotoauthor=A.+Bonifaziauthor=N.+S.+Caiauthor=M.+P.+Ellenbergerauthor=A.+H.+Newmanauthor=S.+Ferreauthor=H.+Yano&title=Evidence+for+noncanonical+neurotransmitter+activation%3A+norepinephrine+as+a+dopamine+D2-like+receptor+agonist&doi=10.1124%2Fmol.115.101808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist</span></div><div class="casAuthors">Sanchez-Soto, Marta; Bonifazi, Alessandro; Cai, Ning Sheng; Ellenberger, Michael P.; Newman, Amy Hauck; Ferre, Sergi; Yano, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-466</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Gαi/o-coupled dopamine D2-like receptor family comprises three subtypes: the D2 receptor (D2R), with short and long isoform variants (D2SR and D2LR), D3 receptor (D3R), and D4 receptor (D4R), with several polymorphic variants.  The common overlap of norepinephrine innervation and D2-like receptor expression patterns prompts the question of a possible noncanonical action by norepinephrine.  In fact, previous studies have suggested that norepinephrine can functionally interact with D4R.  To our knowledge, significant interactions between norepinephrine and D2R or D3R receptors have not been demonstrated.  By using radioligand binding and bioluminescent resonance energy transfer (BRET) assays in transfected cells, the present study attempted a careful comparison between dopamine and norepinephrine in their possible activation of all D2-like receptors, including the two D2R isoforms and the most common D4R polymorphic variants.  Functional BRET assays included activation of G proteins with all Gαi/o subunits, adenylyl cyclase inhibition, and β arrestin recruitment.  Norepinephrine acted as a potent agonist for all D2-like receptor subtypes, with the general rank order of potency of D3R > D4R ≥ D2SR ≥ D2L.  However, for both dopamine and norepinephrine, differences depended on the Gαi/o protein subunit involved.  The most striking differenceswere obsd. with Gαi2, where the rank order of potencies for both dopamine and norepinephrine were D4R > D2SR = D2LR >> D3R.  Furthermore the results do not support the existence of differences in the ability of dopamine and norepinephrine to activate different human D4R variants.  The potency of norepinephrine for adrenergic α2A receptor was only about 20-fold higher compared with D3R and D4R across the three functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbXqWDRdlAsrVg90H21EOLACvtfcHk0lhQgy3Tv0yY_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWntrbN&md5=df11300a8c0bb71ef35b5d2917bee471</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101808%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Soto%26aufirst%3DM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DH.%26atitle%3DEvidence%2520for%2520noncanonical%2520neurotransmitter%2520activation%253A%2520norepinephrine%2520as%2520a%2520dopamine%2520D2-like%2520receptor%2520agonist%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D457%26epage%3D466%26doi%3D10.1124%2Fmol.115.101808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel bivalent ligands based on the sumanirole pharmacophore reveal dopamine D2 receptor (D2R) biased agonism</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2890</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2890-2907&author=A.+Bonifaziauthor=H.+Yanoauthor=M.+P.+Ellenbergerauthor=L.+Mullerauthor=V.+Kumarauthor=M.+F.+Zouauthor=N.+S.+Caiauthor=A.+M.+Guerreroauthor=A.+S.+Woodsauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+bivalent+ligands+based+on+the+sumanirole+pharmacophore+reveal+dopamine+D2+receptor+%28D2R%29+biased+agonism&doi=10.1021%2Facs.jmedchem.6b01875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Ellenberger, Michael P.; Muller, Ludovic; Kumar, Vivek; Zou, Mu-Fa; Cai, Ning Sheng; Guerrero, Adrian M.; Woods, Amina S.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2890-2907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bivalent ligands has attracted interest as a way to potentially improve the selectivity and/or affinity for a specific receptor subtype.  The ability to bind two distinct receptor binding sites simultaneously can allow the selective activation of specific G-protein dependent or β-arrestin-mediated cascade pathways.  Herein, we developed an extended SAR study using sumanirole (1) as the primary pharmacophore.  We found that substitutions in the N-1- and/or N-5-positions, physiochem. properties of those substituents, and secondary arom. pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by Gi/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment.  Compd. 19 was identified as a new lead for its selective D2 G-protein biased agonism with an EC50 in the subnanomolar range.  Structure-activity correlations were obsd. between substitutions in positions N-1 and/or N-5 of 1 and the capacity of the new bivalent compds. to selectively activate G-proteins vs. β-arrestin recruitment in D2R-BRET functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprfScHokUgP7Vg90H21EOLACvtfcHk0lhQgy3Tv0yY_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D&md5=24bf22a101756e44fbc8f8345d2c1fe4</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01875%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DWoods%26aufirst%3DA.%2BS.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520bivalent%2520ligands%2520based%2520on%2520the%2520sumanirole%2520pharmacophore%2520reveal%2520dopamine%2520D2%2520receptor%2520%2528D2R%2529%2520biased%2520agonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2890%26epage%3D2907%26doi%3D10.1021%2Facs.jmedchem.6b01875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudevan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, D. K.</span></span> <span> </span><span class="NLM_article-title">ERK activation pathways downstream of GPCRs</span>. <i>Int. Rev. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/bs.ircmb.2018.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fbs.ircmb.2018.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=29699693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslOqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2018&pages=79-109&author=R.+Jainauthor=U.+Watsonauthor=L.+Vasudevanauthor=D.+K.+Saini&title=ERK+activation+pathways+downstream+of+GPCRs&doi=10.1016%2Fbs.ircmb.2018.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">ERK activation pathways downstream of GPCRs</span></div><div class="casAuthors">Jain, Ruchi; Watson, Uchenna; Vasudevan, Lakshmi; Saini, Deepak K.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">G Protein-Coupled Receptors: Emerging Paradigms in Activation, Signaling and Regulation, Part A</span>),
    <span class="NLM_cas:pages">79-109</span>CODEN:
                <span class="NLM_cas:coden">IRCMAH</span>;
        ISSN:<span class="NLM_cas:issn">1937-6448</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">GPCRs, the 7-TM receptors, represent a class of cell surface receptors which modulate a variety of physiol. responses.  The serpentine structure in addn. to contributing the diversity of stimuli these receptors can sense also provides flexibility to the extracellular and intracellular regions where other proteins can interact with and can form functionally active multimeric entities.  The range in signaling and physiol. responses generated by these receptors can be attributed to a large repertoire of the receptor subtypes as well as their differential coupling to various classes of G-protein subunits and other proteins which facilitate multistate activation.  A multistate GPCR can engage diverse signaling mols., thereby modulating not only the canonical cellular responses but also noncanonical responses typically assocd. with activation of other cascades such as RTK and MAPK/ERK signaling.  Given the crucial involvement of MAP kinase/ERK signaling in cell fate detn. specially with respect to regulating cell proliferation, cellular apoptosis, and survival, GPCR-mediated cross-activation of MAPK has been explored in various systems and shown to involve functional integration of multiple pathways.  This review describes the present knowledge of the different mechanisms of ERK activation downstream of GPCRs and our present understanding of receptor-dependent and -independent MAPK activation cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5AuLkT6t3LVg90H21EOLACvtfcHk0lihoIqCxPdXUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslOqsbk%253D&md5=bd2cd11ef1314ed8933018602fd45d0d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fbs.ircmb.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.ircmb.2018.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%26aulast%3DWatson%26aufirst%3DU.%26aulast%3DVasudevan%26aufirst%3DL.%26aulast%3DSaini%26aufirst%3DD.%2BK.%26atitle%3DERK%2520activation%2520pathways%2520downstream%2520of%2520GPCRs%26jtitle%3DInt.%2520Rev.%2520Cell%2520Mol.%2520Biol.%26date%3D2018%26volume%3D338%26spage%3D79%26epage%3D109%26doi%3D10.1016%2Fbs.ircmb.2018.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E. V.</span></span> <span> </span><span class="NLM_article-title">Arrestin-mediated signaling: is there a controversy?</span>. <i>World J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.4331/wjbc.v9.i3.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.4331%2Fwjbc.v9.i3.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30595812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BB3cnms12gsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=25-35&author=V.+V.+Gurevichauthor=E.+V.+Gurevich&title=Arrestin-mediated+signaling%3A+is+there+a+controversy%3F&doi=10.4331%2Fwjbc.v9.i3.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Arrestin-mediated signaling: Is there a controversy?</span></div><div class="casAuthors">Gurevich Vsevolod V; Gurevich Eugenia V</div><div class="citationInfo"><span class="NLM_cas:title">World journal of biological chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">25-35</span>
        ISSN:<span class="NLM_cas:issn">1949-8454</span>.
    </div><div class="casAbstract">The activation of the mitogen-activated protein (MAP) kinases extracellular signal-regulated kinase (ERK)1/2 was traditionally used as a readout of signaling of G protein-coupled receptors (GPCRs) via arrestins, as opposed to conventional GPCR signaling via G proteins.  Several recent studies using HEK293 cells where all G proteins were genetically ablated or inactivated, or both non-visual arrestins were knocked out, demonstrated that ERK1/2 phosphorylation requires G protein activity, but does not necessarily require the presence of non-visual arrestins.  This appears to contradict the prevailing paradigm.  Here we discuss these results along with the recent data on gene edited cells and arrestin-mediated signaling.  We suggest that there is no real controversy.  G proteins might be involved in the activation of the upstream-most MAP3Ks, although in vivo most MAP3K activation is independent of heterotrimeric G proteins, being initiated by receptor tyrosine kinases and/or integrins.  As far as MAP kinases are concerned, the best-established role of arrestins is scaffolding of the three-tiered cascades (MAP3K-MAP2K-MAPK).  Thus, it seems likely that arrestins, GPCR-bound and free, facilitate the propagation of signals in these cascades, whereas signal initiation via MAP3K activation may be independent of arrestins.  Different MAP3Ks are activated by various inputs, some of which are mediated by G proteins, particularly in cell culture, where we artificially prevent signaling by receptor tyrosine kinases and integrins, thereby favoring GPCR-induced signaling.  Thus, there is no reason to change the paradigm: Arrestins and G proteins play distinct non-overlapping roles in cell signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXFg0b3lPWBEQ0lWbKiCflfW6udTcc2eadNttTh1F0-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnms12gsQ%253D%253D&md5=59b4f08141238f64410faa5b42181714</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.4331%2Fwjbc.v9.i3.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4331%252Fwjbc.v9.i3.25%26sid%3Dliteratum%253Aachs%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DGurevich%26aufirst%3DE.%2BV.%26atitle%3DArrestin-mediated%2520signaling%253A%2520is%2520there%2520a%2520controversy%253F%26jtitle%3DWorld%2520J.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D9%26spage%3D25%26epage%3D35%26doi%3D10.4331%2Fwjbc.v9.i3.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielcarek, N.</span></span> <span> </span><span class="NLM_article-title">The ins and outs of pertussis toxin</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">4668</span>– <span class="NLM_lpage">4682</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2011.08237.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fj.1742-4658.2011.08237.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21740523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFygsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=4668-4682&author=C.+Lochtauthor=L.+Coutteauthor=N.+Mielcarek&title=The+ins+and+outs+of+pertussis+toxin&doi=10.1111%2Fj.1742-4658.2011.08237.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of pertussis toxin</span></div><div class="casAuthors">Locht, Camille; Coutte, Loic; Mielcarek, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4668-4682</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Pertussis toxin, produced and secreted by the whooping cough agent Bordetella pertussis, is one of the most complex sol. bacterial proteins.  It is actively secreted through the B. pertussis cell invelope by the Ptl secretion system, a member of the widespread type IV secretion systems.  The toxin is composed of 5 subunits (named S1 to S5 according to their decreasing mol. wts.) arranged in an A-B structure.  The A protomer is composed of the enzymically active S1 subunit, which catalyzes ADP-ribosylation of the α subunit of trimeric G proteins, thereby disturbing the metabolic functions of the target cells, leading to a variety of biol. activities.  The B oligomer is composed of 1S2:1S3:2S4:1S5 and is responsible for binding of the toxin to the target cell receptors and for intracellular trafficking via receptor-mediated endocytosis and retrograde transport.  The toxin is one of the most important virulence factors of B. pertussis and is a component of all current vaccines against whooping cough.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJhofih3mT-rVg90H21EOLACvtfcHk0lh41WTU6MWQTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFygsrs%253D&md5=c114959565a9049773f64adf64bf697a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2011.08237.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2011.08237.x%26sid%3Dliteratum%253Aachs%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DCoutte%26aufirst%3DL.%26aulast%3DMielcarek%26aufirst%3DN.%26atitle%3DThe%2520ins%2520and%2520outs%2520of%2520pertussis%2520toxin%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D4668%26epage%3D4682%26doi%3D10.1111%2Fj.1742-4658.2011.08237.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangmool, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, H.</span></span> <span> </span><span class="NLM_article-title">G(i/o) protein-dependent and -independent actions of pertussis toxin (PTX)</span>. <i>Toxins</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.3390/toxins3070884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.3390%2Ftoxins3070884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22069745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGqsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=884-899&author=S.+Mangmoolauthor=H.+Kurose&title=G%28i%2Fo%29+protein-dependent+and+-independent+actions+of+pertussis+toxin+%28PTX%29&doi=10.3390%2Ftoxins3070884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Gi/o protein-dependent and -independent actions of pertussis toxin (PTX)</span></div><div class="casAuthors">Mangmool, Supachoke; Kurose, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Toxins</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">884-899</span>CODEN:
                <span class="NLM_cas:coden">TOXIB7</span>;
        ISSN:<span class="NLM_cas:issn">2072-6651</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Pertussis toxin (PTX) is a typical A-B toxin.  The A-protomer (S1 subunit) exhibits ADP-ribosyltransferase activity.  The B-oligomer consists of four subunits (S2 to S5) and binds extracellular mols. that allow the toxin to enter the cells.  The A-protomer ADP-ribosylates the α subunits of heterotrimeric Gi/o proteins, resulting in the receptors being uncoupled from the Gi/o proteins.  The B-oligomer binds proteins expressed on the cell surface, such as Toll-like receptor 4 and activates an intracellular signal transduction cascade.  Thus, PTX modifies cellular responses by at least two different signaling pathways; ADP-ribosylation of the Gαi/o proteins by the A-protomer (Gi/o protein-dependent action) and the interaction of the B-oligomer with cell surface proteins (Gi/o protein-independent action).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpAETCXrweT7Vg90H21EOLACvtfcHk0lh41WTU6MWQTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGqsrnI&md5=5db2f7f113457f3e4e1fb6198c530d93</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3390%2Ftoxins3070884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftoxins3070884%26sid%3Dliteratum%253Aachs%26aulast%3DMangmool%26aufirst%3DS.%26aulast%3DKurose%26aufirst%3DH.%26atitle%3DG%2528i%252Fo%2529%2520protein-dependent%2520and%2520-independent%2520actions%2520of%2520pertussis%2520toxin%2520%2528PTX%2529%26jtitle%3DToxins%26date%3D2011%26volume%3D3%26spage%3D884%26epage%3D899%26doi%3D10.3390%2Ftoxins3070884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.+P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0lh41WTU6MWQTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creese, I.</span></span> <span> </span><span class="NLM_article-title">Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">6351</span>– <span class="NLM_lpage">6361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=6176582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaL38XktFyjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=6351-6361&author=D.+R.+Sibleyauthor=A.+De+Leanauthor=I.+Creese&title=Anterior+pituitary+dopamine+receptors.+Demonstration+of+interconvertible+high+and+low+affinity+states+of+the+D-2+dopamine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Anterior pituitary dopamine receptors.  Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor</span></div><div class="casAuthors">Sibley, David R.; De Lean, Andre; Creese, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6351-61</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The interactions of dopaminergic agonists and antagonists with binding sites in bovine anterior pituitary membranes have been investigated with radioligand-binding techniques and computer-modeling procedures.  3H-labeled agonist (3H-agonist) binding is stereospecific, reversible, saturable, and of high affinity.  The rank order of catecholamines, phenothiazines, and related drugs in competing for 3H-agonist binding is indicative of interactions with a D-2 dopamine receptor.  Both agonist/3H-agonist and antagonist/3H-agonist competition curves are monophasic and noncooperative, with computer anal. indicating a single class of binding sites.  Sp. 3H-agonist binding can be completely inhibited by guanine nucleotides.  guanyl-5'-yl imidodiphosphate  [34273-04-6] Is the most potent nucleotide, followed by GTP  [86-01-1] and GDP  [146-91-8] which are equipotent.  The equil. binding capacity for 3H-labeled antagonists (3H-antagonists) is twice that for 3H-agonists.  Unlabeled antagonists inhibit 3H-antagonist binding competitively and exhibit antagonist/3H-antagonist competition curves which model best to a state of homogeneous affinity.  In contrast, unlabeled agonists inhibit 3H-antagonist binding in a heterogeneous fashion displaying multiphasic competition curves which can be resolved into high- and low-affinity binding sites.  In the presence of satg. concns. of guanine nucleotides, however, the agonist/3H-antagonist curves model best to a single affinity state which is identical with the low-affinity state seen in control curves.  The binding data can be explained by postulating 2 states of the D-2 dopamine receptor, inducible by agonists but not antagonists and modulated by guanine nucleotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPIbAAeUc1SLVg90H21EOLACvtfcHk0ljcIsKF--SILA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XktFyjs7Y%253D&md5=a5474a2efe8c5e0c50e9bd939f759c9d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DDe%2BLean%26aufirst%3DA.%26aulast%3DCreese%26aufirst%3DI.%26atitle%3DAnterior%2520pituitary%2520dopamine%2520receptors.%2520Demonstration%2520of%2520interconvertible%2520high%2520and%2520low%2520affinity%2520states%2520of%2520the%2520D-2%2520dopamine%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D6351%26epage%3D6361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creese, I.</span></span> <span> </span><span class="NLM_article-title">Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=6835198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaL3sXhsFGmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=295-302&author=D.+R.+Sibleyauthor=L.+C.+Mahanauthor=I.+Creese&title=Dopamine+receptor+binding+on+intact+cells.+Absence+of+a+high-affinity+agonist-receptor+binding+state"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptor binding on intact cells:  absence of a high-affinity agonist-receptor binding state</span></div><div class="casAuthors">Sibley, David R.; Mahan, Lawrence C.; Creese, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The ligand binding characteristics of D-2 dopaminergic receptors on dispersed bovine anterior pituitary cells were investigated.  The binding of the radiolabeled butyrophenone antagonist, spiroperidol  [749-02-0], to intact cells was reversible, of high-affinity, and saturable, with an apparent dissocn. const. (KD) of 0.21 nM and a maximal binding capacity of 9.0 fmoles/106 cells.  The stereospecificity and rank order of neuroleptic antagonists, catecholamines, and related drugs in competing for [3H]spiroperidol binding were indicative of interactions with a dopamine  [51-61-6] receptor.  There was no high-affinity, stereospecific, or saturable binding of the radiolabeled dopamine agonist, N-propylnorapomorphine (NPA)  [18426-20-5] to these dispersed cells.  In contrast, washed membranes prepd. from these cells exhibited high-affinity [3H]NPA binding, with a KD of 0.25 nM.  Similarly, in membranes prepd. from dispersed cells, agonist/[3H]spiroperidol competition curves were heterogeneous, exhibiting high- and low-affinity displacement phases.  In the presence of exogenous guanine nucleotides, these curves were shifted to the right and became uniphasic.  Computer anal. indicated that agonist/[3H]spiroperidol curves in membranes are best explained by assuming a 2-state binding model, whereas in the presence of guanine nucleotides a 1-state model is sufficient to fit the data.  In intact cells, however, agonist/[3H]spiroperidol curves were monophasic and exhibited affinities similar to the corresponding low-affinity agonist binding state seen in membranes.  Addn. of guanine nucleotides did not alter the agonist/[3H]spiroperidol curves in intact cells.  Apparently, high-affinity dopamine agonist binding in pituitary membranes does not represent a distinct receptor subtype but rather a guanine nucleotide-sensitive, agonist-specific binding state of a single D-2 receptor.  In this model, endogenous or exogenous guanine nucleotides in intact cells or membranes, resp., mediate an interconversion from the high- to the low-affinity agonist binding state, thus effectively eliminating high-affinity agonist binding as measured directly with [3H]NPA or indirectly with agonist/[3H]spiroperidol competition expts.  Nonequil. binding expts. indicated that in the presence of guanine nucleotides the high-affinity agonist binding state is undetectable throughout the approach to equil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwiqpEQxW97Vg90H21EOLACvtfcHk0ljcIsKF--SILA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhsFGmt74%253D&md5=177ecd033a8717307b895d3d68986662</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMahan%26aufirst%3DL.%2BC.%26aulast%3DCreese%26aufirst%3DI.%26atitle%3DDopamine%2520receptor%2520binding%2520on%2520intact%2520cells.%2520Absence%2520of%2520a%2520high-affinity%2520agonist-receptor%2520binding%2520state%26jtitle%3DMol.%2520Pharmacol.%26date%3D1983%26volume%3D23%26spage%3D295%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narendran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slifstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erritzoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kegeles, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abi-Dargham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laruelle, M.</span></span> <span> </span><span class="NLM_article-title">In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1002/syn.20013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fsyn.20013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=15065219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslGgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=188-208&author=R.+Narendranauthor=D.+R.+Hwangauthor=M.+Slifsteinauthor=P.+S.+Talbotauthor=D.+Erritzoeauthor=Y.+Huangauthor=T.+B.+Cooperauthor=D.+Martinezauthor=L.+S.+Kegelesauthor=A.+Abi-Darghamauthor=M.+Laruelle&title=In+vivo+vulnerability+to+competition+by+endogenous+dopamine%3A+comparison+of+the+D2+receptor+agonist+radiotracer+%28-%29-N-%5B11C%5Dpropyl-norapomorphine+%28%5B11C%5DNPA%29+with+the+D2+receptor+antagonist+radiotracer+%5B11C%5D-raclopride&doi=10.1002%2Fsyn.20013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride</span></div><div class="casAuthors">Narendran, Rajesh; Hwang, Dah-Ren; Slifstein, Mark; Talbot, Peter S.; Erritzoe, David; Huang, Yiyun; Cooper, Thomas B.; Martinez, Diana; Kegeles, Lawrence S.; Abi-Dargham, Anissa; Laruelle, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">188-208</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">(-)-N-Propyl-norapomorphine (NPA) is a full dopamine (DA) D2 receptor agonist and [11C]NPA is a suitable radiotracer to image D2 receptors configured in a state of high affinity for agonists with positron emission tomog. (PET).  In this study the vulnerability of the in vivo binding of [11C]NPA to acute fluctuation in synaptic DA was assessed with PET in baboons and compared to that of the ref. D2 receptor antagonist radiotracer [11C]raclopride.  Three male baboons were studied with [11C]raclopride and [11C]NPA under baseline conditions and following administration of the potent DA releaser amphetamine (0.3, 0.5, and 1.0 mg kg-1 i.v.).  Kinetic modeling with an arterial input function was used to derive the striatal specific-to-nonspecific equil. partition coeff. (V3'').  [11C]Raclopride V3'' was reduced by 24 ± 10%, 32 ± 6%, and 44 ± 9% following amphetamine doses of 0.3, 0.5, and 1.0 mg kg-1, resp.  [11C]NPA V3'' was reduced by 32 ± 2%, 45 ± 3%, and 53 ± 9% following amphetamine doses of 0.3, 0.5, and 1.0 mg kg-1, resp.  Thus, endogenous DA was more effective at competing with [11C]NPA binding compared to [11C]raclopride binding, a finding consistent with the pharmacol. of these tracers (agonist vs. antagonist).  These results also suggest that 71% of D2 receptors are configured in a state of high affinity for agonists in vivo.  In conclusion, [11C]NPA might provide a superior radiotracer to probe presynaptic DA function with PET in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpopfT4WzpIyLVg90H21EOLACvtfcHk0ljcIsKF--SILA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslGgt7g%253D&md5=1c61e44d1b32a62b3178a06e24a9f170</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20013%26sid%3Dliteratum%253Aachs%26aulast%3DNarendran%26aufirst%3DR.%26aulast%3DHwang%26aufirst%3DD.%2BR.%26aulast%3DSlifstein%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DP.%2BS.%26aulast%3DErritzoe%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DT.%2BB.%26aulast%3DMartinez%26aufirst%3DD.%26aulast%3DKegeles%26aufirst%3DL.%2BS.%26aulast%3DAbi-Dargham%26aufirst%3DA.%26aulast%3DLaruelle%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520vulnerability%2520to%2520competition%2520by%2520endogenous%2520dopamine%253A%2520comparison%2520of%2520the%2520D2%2520receptor%2520agonist%2520radiotracer%2520%2528-%2529-N-%255B11C%255Dpropyl-norapomorphine%2520%2528%255B11C%255DNPA%2529%2520with%2520the%2520D2%2520receptor%2520antagonist%2520radiotracer%2520%255B11C%255D-raclopride%26jtitle%3DSynapse%26date%3D2004%26volume%3D52%26spage%3D188%26epage%3D208%26doi%3D10.1002%2Fsyn.20013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8618</span>– <span class="NLM_lpage">8621</span>, <span class="refDoi"> DOI: 10.1039/C5CC02204E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1039%2FC5CC02204E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25896577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1Wnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=8618-8621&author=M.+Michinoauthor=R.+B.+Freeauthor=T.+B.+Doyleauthor=D.+R.+Sibleyauthor=L.+Shi&title=Structural+basis+for+Na%28%2B%29-sensitivity+in+dopamine+D2+and+D3+receptors&doi=10.1039%2FC5CC02204E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for Na+-sensitivity in dopamine D2 and D3 receptors</span></div><div class="casAuthors">Michino, Mayako; Free, R. Benjamin; Doyle, Trevor B.; Sibley, David R.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">8618-8621</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">To understand the structural basis for the Na+-sensitivity of ligand binding to dopamine D2-like receptors, using computational anal. in combination with binding assays, the authors identified interactions crit. in propagating the impact of Na+ on receptor conformations and on the ligand-binding site.  The authors' findings expand the pharmacol.-relevant conformational spectrum of these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonu0n6gq5E2bVg90H21EOLACvtfcHk0ljdn_fU2BYpwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1Wnuro%253D&md5=750d293936c4215a96a5deb95f6271d6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1039%2FC5CC02204E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC02204E%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DStructural%2520basis%2520for%2520Na%2528%252B%2529-sensitivity%2520in%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D8618%26epage%3D8621%26doi%3D10.1039%2FC5CC02204E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarzycka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span> <span> </span><span class="NLM_article-title">Harnessing ion-binding sites for GPCR pharmacology</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1124/pr.119.017863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fpr.119.017863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=31551350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhslOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=571-595&author=B.+Zarzyckaauthor=S.+A.+Zaidiauthor=B.+L.+Rothauthor=V.+Katritch&title=Harnessing+ion-binding+sites+for+GPCR+pharmacology&doi=10.1124%2Fpr.119.017863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Ion-Binding Sites for GPCR Pharmacology</span></div><div class="casAuthors">Zarzycka Barbara; Zaidi Saheem A; Roth Bryan L; Katritch Vsevolod</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-595</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endogenous ions play important roles in the function and pharmacology of G-protein coupled receptors (GPCRs).  Historically the evidence for ionic modulation of GPCR function dates to 1973 with studies of opioid receptors, where it was demonstrated that physiologic concentrations of sodium allosterically attenuated agonist binding.  This Na(+)-selective effect was distinct from effects of other monovalent and divalent cations, with the latter usually counteracting sodium's negative allosteric modulation of binding.  Since then, numerous studies documenting the effects of mono- and divalent ions on GPCR function have been published.  While ions can act selectively and nonselectively at many sites in different receptors, the discovery of the conserved sodium ion site in class A GPCR structures in 2012 revealed the unique nature of Na(+) site, which has emerged as a near-universal site for allosteric modulation of class A GPCR structure and function.  In this review, we synthesize and highlight recent advances in the functional, biophysical, and structural characterization of ions bound to GPCRs.  Taken together, these findings provide a molecular understanding of the unique roles of Na(+) and other ions as GPCR allosteric modulators.  We will also discuss how this knowledge can be applied to the redesign of receptors and ligand probes for desired functional and pharmacological profiles.  SIGNIFICANCE STATEMENT: The function and pharmacology of GPCRs strongly depend on the presence of mono and divalent ions in experimental assays and in living organisms.  Recent insights into the molecular mechanism of this ion-dependent allosterism from structural, biophysical, biochemical, and computational studies provide quantitative understandings of the pharmacological effects of drugs in vitro and in vivo and open new avenues for the rational design of chemical probes and drug candidates with improved properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5AH-E4H-sd4McDoIzZtNkfW6udTcc2eaH_V0Xhvqtlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhslOrsQ%253D%253D&md5=59b4c3be0c835ca26f9c2cb5d8b60142</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fpr.119.017863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.119.017863%26sid%3Dliteratum%253Aachs%26aulast%3DZarzycka%26aufirst%3DB.%26aulast%3DZaidi%26aufirst%3DS.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKatritch%26aufirst%3DV.%26atitle%3DHarnessing%2520ion-binding%2520sites%2520for%2520GPCR%2520pharmacology%26jtitle%3DPharmacol.%2520Rev.%26date%3D2019%26volume%3D71%26spage%3D571%26epage%3D595%26doi%3D10.1124%2Fpr.119.017863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Regulation of anterior pituitary D2 dopamine receptors by magnesium and sodium ions</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1842</span>– <span class="NLM_lpage">1849</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1985.tb10542.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fj.1471-4159.1985.tb10542.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=2932536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaL28XhtlWr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1985&pages=1842-1849&author=M.+Watanabeauthor=S.+R.+Georgeauthor=P.+Seeman&title=Regulation+of+anterior+pituitary+D2+dopamine+receptors+by+magnesium+and+sodium+ions&doi=10.1111%2Fj.1471-4159.1985.tb10542.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of anterior pituitary D2 dopamine receptors by magnesium and sodium ions</span></div><div class="casAuthors">Watanabe, Masayuki; George, Susan R.; Seeman, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1842-9</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">At D2 dopamine receptors in porcine anterior pituitary tissue, Mg2+ shifted receptors to agonist high-affinity states, but decreased the affinity of the antagonist [3H]spiperone.  Conversely, Na+ shifted the receptors to agonist low-affinity states, but increased the affinity of [3H]spiperone.  Mg is proposed to stabilize the hormone-receptor-guanine nucleotide regulatory protein complex, whereas Na appears to destabilize this ternary complex.  Thus, Mg and Na appear to mediate their regulatory effects via a common component at the D2 dopamine-receptor ternary complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHpRHyaW1tFrVg90H21EOLACvtfcHk0lh0bh9uvPOLXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhtlWr&md5=5f8b07cf6e45c1aa216acbba5c10b0c9</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1985.tb10542.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1985.tb10542.x%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DRegulation%2520of%2520anterior%2520pituitary%2520D2%2520dopamine%2520receptors%2520by%2520magnesium%2520and%2520sodium%2520ions%26jtitle%3DJ.%2520Neurochem.%26date%3D1985%26volume%3D45%26spage%3D1842%26epage%3D1849%26doi%3D10.1111%2Fj.1471-4159.1985.tb10542.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Drugs and valvular heart disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1056/NEJMp068265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1056%2FNEJMp068265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=17202450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=6-9&author=B.+L.+Roth&title=Drugs+and+valvular+heart+disease&doi=10.1056%2FNEJMp068265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and valvular heart disease</span></div><div class="casAuthors">Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-9</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaFEwabTP8rVg90H21EOLACvtfcHk0lh0bh9uvPOLXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D&md5=e5161a25f1a2596cef68030f0f8a7b61</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1056%2FNEJMp068265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp068265%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DDrugs%2520and%2520valvular%2520heart%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D6%26epage%3D9%26doi%3D10.1056%2FNEJMp068265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanettini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzoli, G.</span></span> <span> </span><span class="NLM_article-title">Valvular heart disease and the use of dopamine agonists for Parkinson’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa054830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1056%2FNEJMoa054830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=17202454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlCgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=39-46&author=R.+Zanettiniauthor=A.+Antoniniauthor=G.+Gattoauthor=R.+Gentileauthor=S.+Teseiauthor=G.+Pezzoli&title=Valvular+heart+disease+and+the+use+of+dopamine+agonists+for+Parkinson%E2%80%99s+disease&doi=10.1056%2FNEJMoa054830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Valvular heart disease and the use of dopamine agonists for Parkinson's disease</span></div><div class="casAuthors">Zanettini, Renzo; Antonini, Angelo; Gatto, Gemma; Gentile, Rosa; Tesei, Silvana; Pezzoli, Gianni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ergot-derived dopamine receptor agonists, often used in the treatment of Parkinson's disease, have been assocd. with an increased risk of valvular heart disease.  We performed an echocardiog. prevalence study in 155 patients taking dopamine agonists for Parkinson's disease (pergolide, 64 patients; cabergoline, 49; and non-ergot-derived dopamine agonists, 42) and 90 control subjects.  Valve regurgitation was assessed according to American Society of Echocardiog. recommendations.  The mitral-valve tenting area was also measured and used as a quant. index for leaflet stiffening and apical displacement of leaflet coaptation.  Clin. important regurgitation (moderate to severe, grade 3 to 4) in any valve was found with significantly greater frequency in patients taking pergolide (23.4%) or cabergoline (28.6%) but not in patients taking non-ergot-derived dopamine agonists (0%), as compared with control subjects (5.6%).  The relative risk for moderate or severe valve regurgitation in the pergolide group was 6.3 for mitral regurgitation (P = 0.008), 4.2 for aortic regurgitation (P = 0.01), and 5.6 for tricuspid regurgitation (P = 0.16); corresponding relative risks in the cabergoline group were 4.6 (P = 0.09), 7.3 (P < 0.001), and 5.5 (P = 0.12).  The mean mitral tenting area was significantly greater in ergot-treated patients and showed a linear relationship with the severity of mitral regurgitation.  Patients treated with ergot derivs. who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades.  The frequency of clin. important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non-ergot-derived dopamine agonists, as compared with control subjects.  These findings should be considered in evaluating the risk-benefit ratio of treatment with ergot derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBEYayXrLZ37Vg90H21EOLACvtfcHk0liA86Qj2a4vXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlCgsQ%253D%253D&md5=b41c2061f5deabc517e33a51ea15d1a7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa054830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa054830%26sid%3Dliteratum%253Aachs%26aulast%3DZanettini%26aufirst%3DR.%26aulast%3DAntonini%26aufirst%3DA.%26aulast%3DGatto%26aufirst%3DG.%26aulast%3DGentile%26aufirst%3DR.%26aulast%3DTesei%26aufirst%3DS.%26aulast%3DPezzoli%26aufirst%3DG.%26atitle%3DValvular%2520heart%2520disease%2520and%2520the%2520use%2520of%2520dopamine%2520agonists%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D39%26epage%3D46%26doi%3D10.1056%2FNEJMoa054830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Toward understanding the structural basis of partial agonism at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=580-593&author=M.+Michinoauthor=C.+A.+Boatengauthor=P.+Donthamsettiauthor=H.+Yanoauthor=O.+M.+Bakareauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=V.+Kumarauthor=C.+Zhuauthor=R.+Vermaauthor=J.+R.+Deschampsauthor=J.+A.+Javitchauthor=A.+H.+Newmanauthor=L.+Shi&title=Toward+understanding+the+structural+basis+of+partial+agonism+at+the+dopamine+D3+receptor&doi=10.1021%2Facs.jmedchem.6b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor</span></div><div class="casAuthors">Michino, Mayako; Boateng, Comfort A.; Donthamsetti, Prashant; Yano, Hideaki; Bakare, Oluyomi M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Kumar, Vivek; Zhu, Clare; Verma, Ravi; Deschamps, Jeffrey R.; Javitch, Jonathan A.; Newman, Amy Hauck; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">580-593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders.  In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions.  Here, the authors report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious.  To investigate the structural basis of partial agonism, the authors performed comparative microsecond-scale mol. dynamics simulations starting from the inactive state of D3R in complex with these enantiomers.  Anal. of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations.  These receptor models bound with partial agonists may be useful for structure-based design of compds. with tailored efficacy profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELFqc0pAf8LVg90H21EOLACvtfcHk0liA86Qj2a4vXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK&md5=91e378048c5dfd4c44fb54746a2e1df2</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01148%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DVerma%26aufirst%3DR.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520partial%2520agonism%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D580%26epage%3D593%26doi%3D10.1021%2Facs.jmedchem.6b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1124/pr.114.009944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fpr.114.009944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25527701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVWqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=198-213&author=M.+Michinoauthor=T.+Beumingauthor=P.+Donthamsettiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=L.+Shi&title=What+can+crystal+structures+of+aminergic+receptors+tell+us+about+designing+subtype-selective+ligands%3F&doi=10.1124%2Fpr.114.009944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?</span></div><div class="casAuthors">Michino, Mayako; Beuming, Thijs; Donthamsetti, Prashant; Newman, Amy Hauck; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">198-213</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are integral membrane proteins that represent an important class of drug targets.  In particular, aminergic GPCRs interact with a significant portion of drugs currently on the market.  However, most drugs that target these receptors are assocd. with undesirable side effects, which are due in part to promiscuous interactions with close homologs of the intended target receptors.  Here, based on a systematic anal. of all 37 of the currently available high-resoln. crystal structures of aminergic GPCRs, we review structural elements that contribute to and can be exploited for designing subtype-selective compds.  We describe the roles of secondary binding pockets (SBPs), as well as differences in ligand entry pathways to the orthosteric binding site, in detg. selectivity.  In addn., using the available crystal structures, we have identified conformational changes in the SBPs that are assocd. with receptor activation and explore the implications of these changes for the rational development of selective ligands with tailored efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp88D-c63Tm3LVg90H21EOLACvtfcHk0liA86Qj2a4vXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVWqu7s%253D&md5=7ed6698fae95a5e045a8d4e12b18fef5</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009944%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DWhat%2520can%2520crystal%2520structures%2520of%2520aminergic%2520receptors%2520tell%2520us%2520about%2520designing%2520subtype-selective%2520ligands%253F%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D198%26epage%3D213%26doi%3D10.1124%2Fpr.114.009944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinquet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1124/mol.113.087833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fmol.113.087833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24061855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyitLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=854-864&author=M.+Michinoauthor=P.+Donthamsettiauthor=T.+Beumingauthor=A.+Banalaauthor=L.+Duanauthor=T.+Rouxauthor=Y.+Hanauthor=E.+Trinquetauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=L.+Shi&title=A+single+glycine+in+extracellular+loop+1+is+the+critical+determinant+for+pharmacological+specificity+of+dopamine+D2+and+D3+receptors&doi=10.1124%2Fmol.113.087833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors</span></div><div class="casAuthors">Michino, Mayako; Donthamsetti, Prashant; Beuming, Thijs; Banala, Ashwini; Duan, Lihua; Roux, Thomas; Han, Yang; Trinquet, Eric; Newman, Amy Hauck; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">854-864</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Subtype-selective agents for the dopamine D3 receptor (D3R) have been considered as potential medications for drug addiction and other neuropsychiatric disorders.  Medicinal chem. efforts have led to the discovery of 4-phenylpiperazine derivs. that are >100-fold selective for the dopamine D3 receptor over dopamine D2 receptor (D2R), despite high sequence identity (78% in the transmembrane domain).  Based on the recent crystal structure of D3R, we demonstrated that the 4-phenylpiperazine moiety in this class of D3R-selective compds. binds to the conserved orthosteric binding site, whereas the extended aryl amide moiety is oriented toward a divergent secondary binding pocket (SBP).  In an effort to further characterize mol. determinants of the selectivity of these compds., we modeled their binding modes in D3R and D2R by comparative ligand docking and mol. dynamics simulations.  We found that the aryl amide moiety in the SBP differentially induces conformational changes in transmembrane segment 2 and extracellular loop 1 (EL1), which amplify the divergence of the SBP in D3R and D2R.  Receptor chimera and site-directed mutagenesis studies were used to validate these binding modes and to identify a divergent glycine in EL1 as crit. to D3R over D2R subtype selectivity.  A better understanding of drug-dependent receptor conformations such as these is key to the rational design of compds. targeting a specific receptor among closely related homologs, and may also lead to discovery of novel chemotypes that exploit subtle differences in protein conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHm99ZIZbabVg90H21EOLACvtfcHk0lhKged_wQlTTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyitLvK&md5=225a4cfc272ec9897eeb010dd551c3b9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.087833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.087833%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DL.%26aulast%3DRoux%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DTrinquet%26aufirst%3DE.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DA%2520single%2520glycine%2520in%2520extracellular%2520loop%25201%2520is%2520the%2520critical%2520determinant%2520for%2520pharmacological%2520specificity%2520of%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D854%26epage%3D864%26doi%3D10.1124%2Fmol.113.087833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span> <span> </span><span class="NLM_article-title">Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors</span>. <i>Methods Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FS1043-9471%2805%2980049-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1Kmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1995&pages=366-428&author=J.+A.+Ballesterosauthor=H.+Weinstein&title=Integrated+methods+for+the+construction+of+three-dimensional+models+and+computational+probing+of+structure-function+relations+in+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors</span></div><div class="casAuthors">Ballesteros, Juan A.; Weinstein, Harel</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Neurosciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">366-428</span>CODEN:
                <span class="NLM_cas:coden">MENEE5</span>;
        ISSN:<span class="NLM_cas:issn">1043-9471</span>.
    </div><div class="casAbstract">A review, with 135 refs., on approaches that can be used to resolve the apparent ambiguities that burden the pharmacol. testing of G protein-coupled receptor (GPCR) models, based on the integration of structural information about the receptor, about mutants, and about the changes induced by ligand binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfENoRspqa7LVg90H21EOLACvtfcHk0lhKged_wQlTTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1Kmtrk%253D&md5=d3f99e9d07cea245a770f3f099bc8cc7</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS1043-9471%2805%2980049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1043-9471%252805%252980049-7%26sid%3Dliteratum%253Aachs%26aulast%3DBallesteros%26aufirst%3DJ.%2BA.%26aulast%3DWeinstein%26aufirst%3DH.%26atitle%3DIntegrated%2520methods%2520for%2520the%2520construction%2520of%2520three-dimensional%2520models%2520and%2520computational%2520probing%2520of%2520structure-function%2520relations%2520in%2520G%2520protein-coupled%2520receptors%26jtitle%3DMethods%2520Neurosci.%26date%3D1995%26volume%3D25%26spage%3D366%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Benzoylation of dianions: preparation of monobenzoylated derivatives of symmetrical secondary diamines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7661</span>– <span class="NLM_lpage">7662</span>, <span class="refDoi"> DOI: 10.1021/jo9908501</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9908501" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK1MXls1Ojtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=7661-7662&author=T.+Wangauthor=Z.+Zhangauthor=N.+A.+Meanwell&title=Benzoylation+of+dianions%3A+preparation+of+monobenzoylated+derivatives+of+symmetrical+secondary+diamines&doi=10.1021%2Fjo9908501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoylation of Dianions: Preparation of Monobenzoylated Derivatives of Symmetrical Secondary Diamines</span></div><div class="casAuthors">Wang, Tao; Zhang, Zhongxing; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7661-7662</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Methodol. is presented for efficient monoarylation of sym. secondary diamines.  The problem of diaroylation being predominant was overcome by making the mono- or dilithium salt of the amine first, which is more reactive toward aroyl chlorides than the diamine, affording the monoacylated product under kinetic control.  When piperazine was treated with 2 equiv of n-butyllithium and 1 equiv of benzoyl chloride at room temp., the monobenzoylated product was found to predominate (35:1 mono/di).  The sequential, nonsym. functionalization of piperazine and homopiperazine via this methodol. was also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBK3IT93jOlrVg90H21EOLACvtfcHk0lhKged_wQlTTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXls1Ojtrs%253D&md5=74f64965dbacbf9d60b2b62613de9063</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjo9908501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9908501%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DBenzoylation%2520of%2520dianions%253A%2520preparation%2520of%2520monobenzoylated%2520derivatives%2520of%2520symmetrical%2520secondary%2520diamines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D7661%26epage%3D7662%26doi%3D10.1021%2Fjo9908501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3739</span>– <span class="NLM_lpage">3743</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bmcl.2014.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25086680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKktLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3739-3743&author=L.+X.+Wangauthor=X.+B.+Zhouauthor=M.+L.+Xiaoauthor=N.+Jiangauthor=F.+Liuauthor=W.+X.+Zhouauthor=X.+K.+Wangauthor=Z.+B.+Zhengauthor=S.+Li&title=Synthesis+and+biological+evaluation+of+substituted+4-%28thiophen-2-ylmethyl%29-2H-phthalazin-1-ones+as+potent+PARP-1+inhibitors&doi=10.1016%2Fj.bmcl.2014.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors</span></div><div class="casAuthors">Wang, Ling-xiao; Zhou, Xin-bo; Xiao, Meng-liang; Jiang, Ning; Liu, Feng; Zhou, Wen-xia; Wang, Xiao-kui; Zheng, Zhi-bing; Li, Song</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3739-3743</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have developed a series of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors.  Preliminary biol. evaluation indicated that most compds. possessed inhibitory potencies comparable to, or higher than AZD-2281.  Among these compds., I appeared to be the most notable one, which displayed an 8-fold improvement in enzymic activity compared to AZD-2281.  These efforts lay the foundation for our further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn-zjG4BtXnbVg90H21EOLACvtfcHk0lh96RoLRRrA9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKktLfN&md5=e5399d0975fa5c4b09a658c5fb985438</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%2BX.%26aulast%3DZhou%26aufirst%3DX.%2BB.%26aulast%3DXiao%26aufirst%3DM.%2BL.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DW.%2BX.%26aulast%3DWang%26aufirst%3DX.%2BK.%26aulast%3DZheng%26aufirst%3DZ.%2BB.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520substituted%25204-%2528thiophen-2-ylmethyl%2529-2H-phthalazin-1-ones%2520as%2520potent%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3739%26epage%3D3743%26doi%3D10.1016%2Fj.bmcl.2014.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marona-Lewicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monte, A.</span></span> <span> </span><span class="NLM_article-title">‘Hybrid’ benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6242</span>– <span class="NLM_lpage">6251</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bmc.2008.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=18467103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFegur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=6242-6251&author=D.+M.+Schultzauthor=J.+A.+Prescherauthor=S.+Kiddauthor=D.+Marona-Lewickaauthor=D.+E.+Nicholsauthor=A.+Monte&title=%E2%80%98Hybrid%E2%80%99+benzofuran-benzopyran+congeners+as+rigid+analogs+of+hallucinogenic+phenethylamines&doi=10.1016%2Fj.bmc.2008.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines</span></div><div class="casAuthors">Schultz, Danielle M.; Prescher, Jennifer A.; Kidd, Stephanie; Marona-Lewicka, Danuta; Nichols, David E.; Monte, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6242-6251</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phenylalkylamines that possess conformationally rigidified furanyl moieties in place of alkoxy arene ring substituents have been shown previously to possess the highest affinities and agonist functional potencies at the serotonin 5-HT2A receptor among this chem. class.  Further, affinity declines when both furanyl rings are expanded to the larger dipyranyl ring system.  The present paper reports the synthesis and pharmacol. evaluation of a series of hybrid' benzofuranyl-benzopyranyl phenylalkylamines to probe further the sizes of the binding pockets within the serotonin 5-HT2A agonist binding site.  Thus, five compds. were prepd. as homologs of the parent compd., 8-bromo-1-(2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminopropane 2, and their affinity, functional potency, and intrinsic activity were assessed using cells stably expressing the rat 5-HT2A receptor.  The behavioral pharmacol. of these new analogs was also evaluated in the two-lever drug discrimination paradigm.  Although all of the hybrid isomers had similar, nanomolar range receptor affinities, those with the smaller furanyl ring at the arene 2-position (I, II) displayed a 4- to 15-fold greater functional potency than those with the larger pyranyl ring at that position (III, IV).  When the furan ring of the more potent agonist II was aromatized to give 6, a receptor affinity similar to the parent difuranyl compd. 2 was attained, along with a functional potency equiv. to 2, I, and II.  In drug discrimination expts. using rats trained to discriminate LSD from saline, II was more than two times more potent than IV, with the latter having a potency similar to the classic hallucinogenic amphetamine 1 (DOB).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqplYj7r_9BLLVg90H21EOLACvtfcHk0lh96RoLRRrA9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFegur4%253D&md5=9dee4f8d37c074a7631715750cf65703</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DSchultz%26aufirst%3DD.%2BM.%26aulast%3DPrescher%26aufirst%3DJ.%2BA.%26aulast%3DKidd%26aufirst%3DS.%26aulast%3DMarona-Lewicka%26aufirst%3DD.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMonte%26aufirst%3DA.%26atitle%3D%25E2%2580%2598Hybrid%25E2%2580%2599%2520benzofuran-benzopyran%2520congeners%2520as%2520rigid%2520analogs%2520of%2520hallucinogenic%2520phenethylamines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D6242%26epage%3D6251%26doi%3D10.1016%2Fj.bmc.2008.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurczab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jastrzebska-Wiesek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojarski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajdel, P.</span></span> <span> </span><span class="NLM_article-title">Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: multiobjective based design, synthesis, and antidepressant and anxiolytic properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.ejmech.2015.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26698537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWis7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=334-346&author=V.+Canaleauthor=R.+Kurczabauthor=A.+Partykaauthor=G.+Satalaauthor=T.+Lendaauthor=M.+Jastrzebska-Wiesekauthor=A.+Wesolowskaauthor=A.+J.+Bojarskiauthor=P.+Zajdel&title=Towards+new+5-HT7+antagonists+among+arylsulfonamide+derivatives+of+%28aryloxy%29ethyl-alkyl+amines%3A+multiobjective+based+design%2C+synthesis%2C+and+antidepressant+and+anxiolytic+properties&doi=10.1016%2Fj.ejmech.2015.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties</span></div><div class="casAuthors">Canale, Vittorio; Kurczab, Rafal; Partyka, Anna; Satala, Grzegorz; Ledna, Tomasz; Jastrzebska-Wiesek, Magdalena; Wesolowska, Anna; Bojarski, Andrzej J.; Zajdel, Pawel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">334-346</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 39 arylsulfonamide/amide derivs. of (aryloxy)ethyl alkyl amines, was designed with the support of the Virtual Combinatorial Library-Virtual Screening protocol, and synthesized using solid-phase methodologies.  Representative compds. were biol. evaluated for their affinity for 5-HT7Rs and for their selectivity over related 5-HTRs (5-HT1ARs, 5-HT2ARs, 5-HT6Rs), dopamine D2Rs and adrenergic α1Rs.  The study identified two compds. 3-fluoro-N-[1-[2-(2-cyclopentylphenoxy)ethyl]piperidin-4-yl]benzenesulfonamide (PZ-1417) and 4-fluoro-N-[1-[2-[(propan-2-yl)phenoxy]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzenesulfonamide (PZ-1150) as being potent 5-HT7R antagonists with antidepressant and anxiolytic properties in the forced swim test (0.625-5 mg/kg and 0.625 mg/kg, resp.), the tail suspension test (0.625 mg/kg and 0.625 mg/kg, resp.), and in four plate test (0.625 mg/kg and 1.25-2.5 mg/kg, resp.) in mice.  It has to be stressed that new compds. displayed higher activity than that of SB-269970, a ref. 5-HT7R antagonist.  Finally, the study provided valuable insight into the development of potential therapeutic agents for the treatment of CNS disorders.  The synthesis of the target compds. was achieved using a BAL-MBHA-PS (backbone-amide-linker polystyrene resin) as solid phase support.  The title compds. thus formed included 4-fluoro-N-[1-(2-phenoxyethyl)-4-piperidinyl]benzenesulfonamide and azetidine analogs, 8-azabicyclo[3.2.1]octane analogs, 2,5-diazabicyclo[2.2.1]heptane analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4A7DvF2HXkLVg90H21EOLACvtfcHk0lgsTqdfAweSbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWis7jL&md5=e7a8d356d230e2ffa60f7a3a39220fae</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DCanale%26aufirst%3DV.%26aulast%3DKurczab%26aufirst%3DR.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DSatala%26aufirst%3DG.%26aulast%3DLenda%26aufirst%3DT.%26aulast%3DJastrzebska-Wiesek%26aufirst%3DM.%26aulast%3DWesolowska%26aufirst%3DA.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26aulast%3DZajdel%26aufirst%3DP.%26atitle%3DTowards%2520new%25205-HT7%2520antagonists%2520among%2520arylsulfonamide%2520derivatives%2520of%2520%2528aryloxy%2529ethyl-alkyl%2520amines%253A%2520multiobjective%2520based%2520design%252C%2520synthesis%252C%2520and%2520antidepressant%2520and%2520anxiolytic%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D334%26epage%3D346%26doi%3D10.1016%2Fj.ejmech.2015.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valhondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fontecha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Villa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauterbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhamu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Rodriguez, M. L.</span></span> <span> </span><span class="NLM_article-title">New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7851</span>– <span class="NLM_lpage">7861</span>, <span class="refDoi"> DOI: 10.1021/jm400766k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400766k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVynsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7851-7861&author=M.+Valhondoauthor=I.+Marcoauthor=M.+Martin-Fontechaauthor=H.+Vazquez-Villaauthor=J.+A.+Ramosauthor=R.+Berkelsauthor=T.+Lauterbachauthor=B.+Benhamuauthor=M.+L.+Lopez-Rodriguez&title=New+serotonin+5-HT1A+receptor+agonists+endowed+with+antinociceptive+activity+in+vivo&doi=10.1021%2Fjm400766k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">New Serotonin 5-HT1A Receptor Agonists Endowed with Antinociceptive Activity in Vivo</span></div><div class="casAuthors">Valhondo, Margarita; Marco, Isabel; Martin-Fontecha, Mar; Vazquez-Villa, Henar; Ramos, Jose A.; Berkels, Reinhard; Lauterbach, Thomas; Benhamu, Bellinda; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7851-7861</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis of 32 new compds. based on two different openings (A and B) of the chromane ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand I.  The synthesized compds. were assessed for binding affinity, selectivity, and functional activity at the 5-HT1AR.  Selected candidates resulting from B opening were also evaluated for their potential antinociceptive effect in vivo and pharmacokinetic properties in vitro.  Analog II [2-(4-{[2-(2-ethoxyphenoxy)ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)dione, tested as HCl salt] has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 2.3 nM; EC50 = 19 nM).  Pharmacokinetic studies indicated that compd. II displays a good metabolic stability in human liver microsomes (t1/2 ∼ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM).  Interestingly, II (3 mg/kg, i.p., and 30 mg/kg, po) caused significant attenuation of formalin-induced behavior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was reversed by the selective 5-HT1AR antagonist WAY-100635.  Thus, the new 5-HT1AR agonist identified in this work, II, exhibits oral analgesic activity, and the results herein represent a step toward identifying new therapeutics for the control of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvXewqtJFSrVg90H21EOLACvtfcHk0lgsTqdfAweSbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVynsrvO&md5=a13618fbc4ab81f159b66839539a1cc6</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm400766k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400766k%26sid%3Dliteratum%253Aachs%26aulast%3DValhondo%26aufirst%3DM.%26aulast%3DMarco%26aufirst%3DI.%26aulast%3DMartin-Fontecha%26aufirst%3DM.%26aulast%3DVazquez-Villa%26aufirst%3DH.%26aulast%3DRamos%26aufirst%3DJ.%2BA.%26aulast%3DBerkels%26aufirst%3DR.%26aulast%3DLauterbach%26aufirst%3DT.%26aulast%3DBenhamu%26aufirst%3DB.%26aulast%3DLopez-Rodriguez%26aufirst%3DM.%2BL.%26atitle%3DNew%2520serotonin%25205-HT1A%2520receptor%2520agonists%2520endowed%2520with%2520antinociceptive%2520activity%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7851%26epage%3D7861%26doi%3D10.1021%2Fjm400766k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buisson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braddock, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton-Rickardt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span> <span> </span><span class="NLM_article-title">Approaches to design non-covalent inhibitors for human granzyme B (hGrB)</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">8952</span>– <span class="NLM_lpage">8965</span>, <span class="refDoi"> DOI: 10.1039/C4OB01874E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1039%2FC4OB01874E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25277547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyqsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=8952-8965&author=M.+S.+Kimauthor=L.+A.+Buissonauthor=D.+A.+Heathcoteauthor=H.+Huauthor=D.+C.+Braddockauthor=A.+G.+Barrettauthor=P.+G.+Ashton-Rickardtauthor=J.+P.+Snyder&title=Approaches+to+design+non-covalent+inhibitors+for+human+granzyme+B+%28hGrB%29&doi=10.1039%2FC4OB01874E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to design non-covalent inhibitors for human granzyme B (hGrB)</span></div><div class="casAuthors">Kim, Mi-Sun; Buisson, Lauriane A.; Heathcote, Dean A.; Hu, Haipeng; Braddock, D. Christopher; Barrett, Anthony G. M.; Ashton-Rickardt, Philip G.; Snyder, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">8952-8965</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A structure-based design campaign for non-covalent small mol. inhibitors of human granzyme B was carried out by means of a virtual screening strategy employing three constraints and probe site-mapping with FTMAP to identify ligand "hot spots".  In addn., new scaffolds of diverse structures were subsequently explored with ROCS shape-based superposition methods, following by Glide SP docking, induced fit docking and anal. of QikProp mol. properties.  Novel classes of moderately active small mol. blockers (≥25 μM IC50 values) from com. available libraries were identified, and three novel scaffolds have been synthesized by multi-step procedures.  Furthermore, we provide an example of a comprehensive structure-based drug discovery approach to non-covalent inhibitors that relies on the X-ray structure of a covalently bound ligand and suggest that the design path may be compromised by alternative and unknown binding poses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPUyBeYdwLLVg90H21EOLACvtfcHk0lgUuccAzTnfkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyqsL%252FM&md5=c8c016e007f9fdb60524533692010009</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1039%2FC4OB01874E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB01874E%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DBuisson%26aufirst%3DL.%2BA.%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DBraddock%26aufirst%3DD.%2BC.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAshton-Rickardt%26aufirst%3DP.%2BG.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26atitle%3DApproaches%2520to%2520design%2520non-covalent%2520inhibitors%2520for%2520human%2520granzyme%2520B%2520%2528hGrB%2529%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26spage%3D8952%26epage%3D8965%26doi%3D10.1039%2FC4OB01874E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boos, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, R. R.</span></span> <span> </span><span class="NLM_article-title">Maltose and maltotriose derivatives as potential inhibitors of the maltose-binding protein</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_fpage">2084</span>– <span class="NLM_lpage">2099</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200701139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fejoc.200701139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlOktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=2084-2099&author=H.+Malikauthor=W.+Boosauthor=R.+R.+Schmidt&title=Maltose+and+maltotriose+derivatives+as+potential+inhibitors+of+the+maltose-binding+protein&doi=10.1002%2Fejoc.200701139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Maltose and maltotriose derivatives as potential inhibitors of the maltose-binding protein</span></div><div class="casAuthors">Malik, Heinz; Boos, Winfried; Schmidt, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2084-2099</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1434-193X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Inhibition of substrate binding to maltose-binding protein (MBP) was investigated with structurally modified maltose and maltotriose derivs. that were designed based on the X-ray anal. of maltose and maltotriose bound to MBP.  In maltose, positions 1a, 2a, 2b, 4b and 6b were modified to produce maltose derivs., e.g. I, of which only two trivalent maltose derivs. exhibited high affinity to MBP.  Maltotriose modifications were carried out at position to produce maltotriose derivs., e.g. II.  Among them, one deriv. possessing a 6a-O-Pr group, and another deriv. where the 6c-hydroxy group is replaced by bromide, showed higher affinity to MBP than the parent maltotriose.  Hence, three structurally quite different compds. are important lead compds. for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr47meI-qeKZrVg90H21EOLACvtfcHk0lgUuccAzTnfkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlOktb4%253D&md5=35bc6e41ddd2277793d9655000483844</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200701139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200701139%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DH.%26aulast%3DBoos%26aufirst%3DW.%26aulast%3DSchmidt%26aufirst%3DR.%2BR.%26atitle%3DMaltose%2520and%2520maltotriose%2520derivatives%2520as%2520potential%2520inhibitors%2520of%2520the%2520maltose-binding%2520protein%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2008%26spage%3D2084%26epage%3D2099%26doi%3D10.1002%2Fejoc.200701139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalpando, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCandless, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartika, R.</span></span> <span> </span><span class="NLM_article-title">Chlorination of aliphatic primary alcohols via triphosgene-triethylamine activation</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3676</span>– <span class="NLM_lpage">3679</span>, <span class="refDoi"> DOI: 10.1021/ol301520d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol301520d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=3676-3679&author=C.+E.+Ayalaauthor=A.+Villalpandoauthor=A.+L.+Nguyenauthor=G.+T.+McCandlessauthor=R.+Kartika&title=Chlorination+of+aliphatic+primary+alcohols+via+triphosgene-triethylamine+activation&doi=10.1021%2Fol301520d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Chlorination of Aliphatic Primary Alcohols via Triphosgene-Triethylamine Activation</span></div><div class="casAuthors">Ayala, Caitlan E.; Villalpando, Andres; Nguyen, Alex L.; McCandless, Gregory T.; Kartika, Rendy</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3676-3679</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of primary aliph. alcs. with triphosgene and triethylamine mixts. afforded either alkyl chloride or diethylcarbamate products, and the switch in selectivity appeared to be driven by sterics.  The reaction conditions to achieve this highly useful transformation were unexceptionally mild and readily tolerated by a wide range of sensitive functionalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNrFDUtZsUirVg90H21EOLACvtfcHk0lgB8KY27g5YHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtLzF&md5=cd8101dc8031daaa02bbf4dfd78309a0</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fol301520d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol301520d%26sid%3Dliteratum%253Aachs%26aulast%3DAyala%26aufirst%3DC.%2BE.%26aulast%3DVillalpando%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DA.%2BL.%26aulast%3DMcCandless%26aufirst%3DG.%2BT.%26aulast%3DKartika%26aufirst%3DR.%26atitle%3DChlorination%2520of%2520aliphatic%2520primary%2520alcohols%2520via%2520triphosgene-triethylamine%2520activation%26jtitle%3DOrg.%2520Lett.%26date%3D2012%26volume%3D14%26spage%3D3676%26epage%3D3679%26doi%3D10.1021%2Fol301520d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knochel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashima, K.</span></span> <span> </span><span class="NLM_article-title">Zinc-catalyzed esterification of N-β-hydroxyethylamides: removal of directing groups under mild conditions</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_fpage">5010</span>– <span class="NLM_lpage">5014</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201700748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fejoc.201700748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOjsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=5010-5014&author=Y.+Nishiiauthor=T.+Hiraiauthor=S.+Fernandezauthor=P.+Knochelauthor=K.+Mashima&title=Zinc-catalyzed+esterification+of+N-%CE%B2-hydroxyethylamides%3A+removal+of+directing+groups+under+mild+conditions&doi=10.1002%2Fejoc.201700748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc-Catalyzed Esterification of N-β-Hydroxyethylamides: Removal of Directing Groups under Mild Conditions</span></div><div class="casAuthors">Nishii, Yuji; Hirai, Takahiro; Fernandez, Sarah; Knochel, Paul; Mashima, Kazushi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2017</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">5010-5014</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Amide transformations involving C-N bond cleavage are recognized as difficult reactions owing to the inert nature of amides resulting from resonance.  Accordingly, a strong inductive effect and geometrical distortion reasonably decrease the resonance stabilization to attenuate the C-N linkage.  Although the conversion of such activated amides has been studied intensively, reaction systems for "unactivated" amides are underdeveloped.  We herein report that a zinc(II) trifluoromethanesulfonate [Zn(OTf)2] catalyst achieves the esterification of a wide range of unactivated tertiary amides with the assistance of intramol. acyl rearrangement.  The reaction was applied to the one-pot removal of various amide-based directing groups under mild reaction conditions to afford the corresponding esters in high yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcUBNF3GL4l7Vg90H21EOLACvtfcHk0lgB8KY27g5YHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOjsb%252FJ&md5=2bca305ddda3f1535a18b53d7a0cd98e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201700748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201700748%26sid%3Dliteratum%253Aachs%26aulast%3DNishii%26aufirst%3DY.%26aulast%3DHirai%26aufirst%3DT.%26aulast%3DFernandez%26aufirst%3DS.%26aulast%3DKnochel%26aufirst%3DP.%26aulast%3DMashima%26aufirst%3DK.%26atitle%3DZinc-catalyzed%2520esterification%2520of%2520N-%25CE%25B2-hydroxyethylamides%253A%2520removal%2520of%2520directing%2520groups%2520under%2520mild%2520conditions%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2017%26spage%3D5010%26epage%3D5014%26doi%3D10.1002%2Fejoc.201700748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuder, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiec-Kononowicz, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel nead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.2174/15734064113096660050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.2174%2F15734064113096660050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24047214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKgs7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=588-599&author=K.+J.+Kuderauthor=M.+Stachnikauthor=W.+Schunackauthor=E.+Szymanskaauthor=K.+Kiec-Kononowicz&title=Discovery+of+novel+nead+in+the+group+of+N-substituted+piperazine+ether+derivatives+with+potential+histamine+H3+receptor+activity&doi=10.2174%2F15734064113096660050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Lead in the Group of N-substituted Piperazine Ether Derivatives with Potential Histamine H3 Receptor Activity</span></div><div class="casAuthors">Kuder, Kamil J.; Stachnik, Marta; Schunack, Walter; Szymanska, Ewa; Kiec-Kononowicz, Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">588-599</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The search for novel lead from the group of various substituted N-piperazine ether derivs. was performed.  Acyl- and pyridylpiperazine ethyl/propyl ethers were obtained via three different synthetic pathways.  Affinity to histamine H3 receptor was established, as well as, for selected compds., selectivity towards histamine H4R.  Docking studies to the histamine H3R homol. model strengthened the position of (4-(3-(4-(3-chlorobenzoyl)piperazin-1- yl)propoxy)phenyl)(cyclopropyl)methanone as a novel lead for further studies on histamine H3 receptor antagonist/inverse agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozKIeMkzFmSLVg90H21EOLACvtfcHk0liPZxzdNhA8ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKgs7rM&md5=6fc18fe715423d987e871c18674b78d6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.2174%2F15734064113096660050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15734064113096660050%26sid%3Dliteratum%253Aachs%26aulast%3DKuder%26aufirst%3DK.%2BJ.%26aulast%3DStachnik%26aufirst%3DM.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DSzymanska%26aufirst%3DE.%26aulast%3DKiec-Kononowicz%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520novel%2520nead%2520in%2520the%2520group%2520of%2520N-substituted%2520piperazine%2520ether%2520derivatives%2520with%2520potential%2520histamine%2520H3%2520receptor%2520activity%26jtitle%3DMed.%2520Chem.%26date%3D2014%26volume%3D10%26spage%3D588%26epage%3D599%26doi%3D10.2174%2F15734064113096660050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakefuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naritomi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17beta-hydroxysteroid dehydrogenase inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5261</span>– <span class="NLM_lpage">5270</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bmc.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=23845281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOrt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=5261-5270&author=K.+Watanabeauthor=A.+Kakefudaauthor=M.+Yasudaauthor=K.+Enjoauthor=A.+Kikuchiauthor=T.+Furutaniauthor=Y.+Naritomiauthor=Y.+Otsukaauthor=M.+Okadaauthor=M.+Ohta&title=Discovery+of+2-methyl-1-%7B1-%5B%285-methyl-1H-indol-2-yl%29carbonyl%5Dpiperidin-4-yl%7Dpropan-2-ol%3A+a+novel%2C+potent+and+selective+type+5+17beta-hydroxysteroid+dehydrogenase+inhibitor&doi=10.1016%2Fj.bmc.2013.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: A novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor</span></div><div class="casAuthors">Watanabe, Kazushi; Kakefuda, Akio; Yasuda, Minoru; Enjo, Kentaro; Kikuchi, Aya; Furutani, Takashi; Naritomi, Yoichi; Otsuka, Yukio; Okada, Minoru; Ohta, Mitsuaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5261-5270</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Type 5 17β-hydroxysteroid dehydrogenase (17β-HSD5), also known as aldo-keto reductase 1C3 (AKR1C3), is a member of the aldo-keto reductase superfamily of enzymes and is expressed in the human prostate.  One of the main functions of 17β-HSD5 is to catalyze the conversion of the weak androgen, androstenedione, to the potent androgen, testosterone.  The concn. of intraprostatic 5α-dihydrotestosterone (DHT) in patients following chem. or surgical castration has been reported to remain as high as 39% of that of healthy men, with 17β-HSD5 shown to be involved in this androgen synthesis.  Inhibition of 17β-HSD5 therefore represents a promising target for the treatment of castration-resistant prostate cancer (CRPC).  To investigate this, we conducted high-throughput screening (HTS) and identified compd. (I), which displayed a structure distinct from known 17β-HSD5 inhibitors.  To optimize the inhibitory activity of compd. (I), we first introduced a primary alc. group.  We then converted the primary alc. group to a tertiary alc., which further enhanced the inhibitory activity, improved metabolic stability, and led to the identification of compd. (II).  Oral administration of compd. II to castrated nude mice bearing the CWR22R xenograft resulted in the suppression of androstenedione (AD)-induced intratumoral testosterone prodn.  Compd. II also demonstrated good isoform selectivity, minimal inhibitory activity against either CYP or hERG, and enhanced pharmacokinetic and physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1xQk8Ntpn7LVg90H21EOLACvtfcHk0liPZxzdNhA8ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOrt7fE&md5=dcad39e26020f35400d19ba2e0670726</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DKakefuda%26aufirst%3DA.%26aulast%3DYasuda%26aufirst%3DM.%26aulast%3DEnjo%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DNaritomi%26aufirst%3DY.%26aulast%3DOtsuka%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-methyl-1-%257B1-%255B%25285-methyl-1H-indol-2-yl%2529carbonyl%255Dpiperidin-4-yl%257Dpropan-2-ol%253A%2520a%2520novel%252C%2520potent%2520and%2520selective%2520type%25205%252017beta-hydroxysteroid%2520dehydrogenase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D5261%26epage%3D5270%26doi%3D10.1016%2Fj.bmc.2013.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yung-Chi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=4202581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khatri, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roof, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">3581</span>– <span class="NLM_lpage">3594</span>, <span class="refDoi"> DOI: 10.1021/jm200288r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200288r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVyhsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3581-3594&author=A.+K.+Banalaauthor=B.+A.+Levyauthor=S.+S.+Khatriauthor=C.+A.+Furmanauthor=R.+A.+Roofauthor=Y.+Mishraauthor=S.+A.+Griffinauthor=D.+R.+Sibleyauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=N-%283-fluoro-4-%284-%282-methoxy+or+2%2C3-dichlorophenyl%29piperazine-1-yl%29butyl%29arylcarboxamides+as+selective+dopamine+D3+receptor+ligands%3A+critical+role+of+the+carboxamide+linker+for+D3+receptor+selectivity&doi=10.1021%2Fjm200288r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as Selective Dopamine D3 Receptor Ligands: Critical Role of the Carboxamide Linker for D3 Receptor Selectivity</span></div><div class="casAuthors">Banala, Ashwini K.; Levy, Benjamin A.; Khatri, Sameer S.; Furman, Cheryse A.; Roof, Rebecca A.; Mishra, Yogesh; Griffin, Suzy A.; Sibley, David R.; Luedtke, Robert R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3581-3594</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-(3-Fluoro-4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)arylcarboxamides were prepd. and evaluated for binding and function at dopamine D3 receptors (D3Rs) and dopamine D2 receptors (D2Rs).  In this series, we discovered some of the most D3R selective compds. reported to date (e.g., I, >1000-fold D3R-selective over D2R).  In addn., chimeric receptor studies further identified the second extracellular (E2) loop as an important contributor to D3R binding selectivity.  Further, compds. lacking the carbonyl group in the amide linker were synthesized, and while these amine-linked analogs bound with similar affinities to the amides at D2R, this modification dramatically reduced binding affinities at D3R by >100-fold, resulting in compds. with significantly reduced D3R selectivity.  This study supports a pivotal role for the D3R E2 loop and the carbonyl group in the 4-phenylpiperazine class of compds. and further reveals a point of sepn. between structure-activity relationships at D3R and D2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLX7c82j9-5bVg90H21EOLACvtfcHk0lgnmeyMDEPa6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVyhsbw%253D&md5=4fecff363e5628b365e7aeba6a824f9d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm200288r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200288r%26sid%3Dliteratum%253Aachs%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DLevy%26aufirst%3DB.%2BA.%26aulast%3DKhatri%26aufirst%3DS.%2BS.%26aulast%3DFurman%26aufirst%3DC.%2BA.%26aulast%3DRoof%26aufirst%3DR.%2BA.%26aulast%3DMishra%26aufirst%3DY.%26aulast%3DGriffin%26aufirst%3DS.%2BA.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DN-%25283-fluoro-4-%25284-%25282-methoxy%2520or%25202%252C3-dichlorophenyl%2529piperazine-1-yl%2529butyl%2529arylcarboxamides%2520as%2520selective%2520dopamine%2520D3%2520receptor%2520ligands%253A%2520critical%2520role%2520of%2520the%2520carboxamide%2520linker%2520for%2520D3%2520receptor%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3581%26epage%3D3594%26doi%3D10.1021%2Fjm200288r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebres, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taussig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternweis, P. C.</span></span> <span> </span><span class="NLM_article-title">Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">10576</span>– <span class="NLM_lpage">10584</span>, <span class="refDoi"> DOI: 10.1074/jbc.M609695200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1074%2Fjbc.M609695200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=17283075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Shsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=10576-10584&author=L.+I.+Jiangauthor=J.+Collinsauthor=R.+Davisauthor=K.+M.+Linauthor=D.+DeCampauthor=T.+Roachauthor=R.+Hsuehauthor=R.+A.+Rebresauthor=E.+M.+Rossauthor=R.+Taussigauthor=I.+Fraserauthor=P.+C.+Sternweis&title=Use+of+a+cAMP+BRET+sensor+to+characterize+a+novel+regulation+of+cAMP+by+the+sphingosine+1-phosphate%2FG13+pathway&doi=10.1074%2Fjbc.M609695200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate/G13 Pathway</span></div><div class="casAuthors">Jiang, Lily I.; Collins, Julie; Davis, Richard; Lin, Keng-Mean; DeCamp, Dianne; Roach, Tamara; Hsueh, Robert; Rebres, Robert A.; Ross, Elliott M.; Taussig, Ronald; Fraser, Iain; Sternweis, Paul C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">10576-10584</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Regulation of intracellular cAMP is integral in mediating cell growth, cell differentiation, and immune responses in hematopoietic cells.  To facilitate studies of cAMP regulation we developed a BRET (bioluminescence resonance energy transfer) sensor for cAMP, CAMYEL (cAMP sensor using YFP-Epac-RLuc), which can quant. and rapidly monitor intracellular concns. of cAMP in vivo.  This sensor was used to characterize three distinct pathways for modulation of cAMP synthesis stimulated by presumed Gs-dependent receptors for isoproterenol and prostaglandin E2.  Whereas two ligands, UDP and complement C5a, appear to use known mechanisms for augmentation of cAMP via Gq/calcium and Gi, the action of sphingosine 1-phosphate (S1P) is novel.  In these cells, S1P, a biol. active lysophospholipid, greatly enhances increases in intracellular cAMP triggered by the ligands for Gs-coupled receptors while having only a minimal effect by itself.  The enhancement of cAMP by S1P is resistant to pertussis toxin and independent of intracellular calcium.  Studies with RNAi and chem. perturbations demonstrate that the effect of S1P is mediated by the S1P2 receptor and the heterotrimeric G13 protein.  Thus in these macrophage cells, all four major classes of G proteins can regulate intracellular cAMP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEgBftC6CUb7Vg90H21EOLACvtfcHk0lgnmeyMDEPa6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Shsr4%253D&md5=4a6f1e5dc8ae6dc23d80ac234ee91179</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M609695200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M609695200%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%2BI.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DK.%2BM.%26aulast%3DDeCamp%26aufirst%3DD.%26aulast%3DRoach%26aufirst%3DT.%26aulast%3DHsueh%26aufirst%3DR.%26aulast%3DRebres%26aufirst%3DR.%2BA.%26aulast%3DRoss%26aufirst%3DE.%2BM.%26aulast%3DTaussig%26aufirst%3DR.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DSternweis%26aufirst%3DP.%2BC.%26atitle%3DUse%2520of%2520a%2520cAMP%2520BRET%2520sensor%2520to%2520characterize%2520a%2520novel%2520regulation%2520of%2520cAMP%2520by%2520the%2520sphingosine%25201-phosphate%252FG13%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D10576%26epage%3D10584%26doi%3D10.1074%2Fjbc.M609695200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennett, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, T. P.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1996.tb15208.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fj.1476-5381.1996.tb15208.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=8821530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK28XpsVGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1996&pages=427-434&author=G.+A.+Kennettauthor=M.+D.+Woodauthor=F.+Brightauthor=J.+Ciliaauthor=D.+C.+Piperauthor=T.+Gagerauthor=D.+Thomasauthor=G.+S.+Baxterauthor=I.+T.+Forbesauthor=P.+Hamauthor=T.+P.+Blackburn&title=In+vitro+and+in+vivo+profile+of+SB+206553%2C+a+potent+5-HT2C%2F5-HT2B+receptor+antagonist+with+anxiolytic-like+properties&doi=10.1111%2Fj.1476-5381.1996.tb15208.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties</span></div><div class="casAuthors">Kennett, G. a.; Wood, M. D.; Bright, F.; Cilia, J.; Piper, D. C.; Gager, T.; Thomas, D.; Baxter, G. S.; Forbes, I. T.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-34</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole) displays a high affinity (pKI 7.9) for the cloned human 5-HT2C receptor expressed in HEK 293 cells and the 5-HT2B receptor (pA2 8.9) as measured in the rat stomach fundus prepn.  SB 206553 has low affinity for cloned human 5-HT2A receptors expressed in HEK 293 cells (pK1 5.8) and (pKI <6) for a wide variety of other neurotransmitter receptors.  SB 206553 appears to be a surmountable antagonist of 5-HT-stimulated phosphinositide hydrolysis in HEK 293 cells expressing the human 5-HT2C receptor (pKB 9.0).  The compd. potently (ID50 5.5 mg kg-1, p.o., 0.27 mg kg-1, i.v.) inhibited the hypolocomotor response to m-chlorophenylpiperazine (mCPP), a putative model of 5-HT2C/5-HT2B receptor function in vivo.  At similar doses (2-20 mg kg-1, p.o.) SB 206553 increased total interaction scores in a rat social interaction test and increased punished responding in a rat Geller-Seifter conflict test.  These effects are consistent with the possession of anxiolytic properties.  SB 206553 also increased suppressed responding in a marmoset conflict model of anxiety at somewhat higher doses (15 and 20 mg kg-1, p.o.) but also reduced unsuppressed responding.  These results suggest that SB 206553 is a potent mixed 5-HT2C/5-HT2B receptor antagonist with selectivity over the 5-HT2A and all other sites studied and possesses anxiolytic-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGhOi9PL6P5bVg90H21EOLACvtfcHk0lggaE-VSuHO7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XpsVGgsg%253D%253D&md5=f6faa809154f400759171bfdedb17460</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1996.tb15208.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1996.tb15208.x%26sid%3Dliteratum%253Aachs%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DBright%26aufirst%3DF.%26aulast%3DCilia%26aufirst%3DJ.%26aulast%3DPiper%26aufirst%3DD.%2BC.%26aulast%3DGager%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DBaxter%26aufirst%3DG.%2BS.%26aulast%3DForbes%26aufirst%3DI.%2BT.%26aulast%3DHam%26aufirst%3DP.%26aulast%3DBlackburn%26aufirst%3DT.%2BP.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520profile%2520of%2520SB%2520206553%252C%2520a%2520potent%25205-HT2C%252F5-HT2B%2520receptor%2520antagonist%2520with%2520anxiolytic-like%2520properties%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D117%26spage%3D427%26epage%3D434%26doi%3D10.1111%2Fj.1476-5381.1996.tb15208.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span> <span> </span><span class="NLM_article-title">Novel procedure for modeling ligand/receptor induced fit effects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1021/jm050540c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+procedure+for+modeling+ligand%2Freceptor+induced+fit+effects&doi=10.1021%2Fjm050540c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0lggaE-VSuHO7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520procedure%2520for%2520modeling%2520ligand%252Freceptor%2520induced%2520fit%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553%26doi%3D10.1021%2Fjm050540c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Development of the CHARMM Force Field for Lipids</span>. <i>J. Phys. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1532</span>, <span class="refDoi"> DOI: 10.1021/jz200167q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jz200167q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFSlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=1526-1532&author=R.+W.+Pastorauthor=A.+D.+Mackerell&title=Development+of+the+CHARMM+Force+Field+for+Lipids&doi=10.1021%2Fjz200167q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the CHARMM Force Field for Lipids</span></div><div class="casAuthors">Pastor, R. W.; MacKerell, A. D., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1526-1532</span>CODEN:
                <span class="NLM_cas:coden">JPCLCD</span>;
        ISSN:<span class="NLM_cas:issn">1948-7185</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of the CHARMM additive all-atom lipid force field (FF) is traced from the early 1990s to the most recent version (C36) published in 2010.  Though simulations with early versions yielded useful results, they failed to reproduce two important quantities, a zero surface tension at the exptl. bilayer surface area and the signature splitting of the deuterium order parameters in the glycerol and upper chain carbons.  Systematic optimization of parameters based on high-level quantum mech. data and free-energy simulations have resolved these issues, and bilayers with a wide range of lipids can be simulated in tensionless ensembles using C36.  Issues assocd. with other all-atom lipid FFs, success and limitations in the C36 FF, and ongoing developments are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxTy0osyr8LVg90H21EOLACvtfcHk0lgd6-iqLZ6pZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFSlsLg%253D&md5=41920c7e6fbd1aae3b1b7ae8e8234ec8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjz200167q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjz200167q%26sid%3Dliteratum%253Aachs%26aulast%3DPastor%26aufirst%3DR.%2BW.%26aulast%3DMackerell%26aufirst%3DA.%2BD.%26atitle%3DDevelopment%2520of%2520the%2520CHARMM%2520Force%2520Field%2520for%2520Lipids%26jtitle%3DJ.%2520Phys.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D1526%26epage%3D1532%26doi%3D10.1021%2Fjz200167q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3257</span>– <span class="NLM_lpage">3273</span>, <span class="refDoi"> DOI: 10.1021/ct300400x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct300400x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKqurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=3257-3273&author=R.+B.+Bestauthor=X.+Zhuauthor=J.+Shimauthor=P.+E.+Lopesauthor=J.+Mittalauthor=M.+Feigauthor=A.+D.+Mackerell&title=Optimization+of+the+additive+CHARMM+all-atom+protein+force+field+targeting+improved+sampling+of+the+backbone+phi%2C+psi+and+side-chain+chi%281%29+and+chi%282%29+dihedral+angles&doi=10.1021%2Fct300400x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone .vphi., ψ and Side-Chain χ1 and χ2 Dihedral Angles</span></div><div class="casAuthors">Best, Robert B.; Zhu, Xiao; Shim, Jihyun; Lopes, Pedro E. M.; Mittal, Jeetain; Feig, Michael; MacKerell, Alexander D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3257-3273</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">While the quality of the current CHARMM22/CMAP additive force field for proteins has been demonstrated in a large no. of applications, limitations in the model with respect to the equil. between the sampling of helical and extended conformations in folding simulations have been noted.  To overcome this, as well as make other improvements in the model, we present a combination of refinements that should result in enhanced accuracy in simulations of proteins.  The common (non-Gly, -Pro) backbone CMAP potential has been refined against exptl. soln. NMR data for weakly structured peptides, resulting in a rebalancing of the energies of the α-helix and extended regions of the Ramachandran map, correcting the α-helical bias of CHARMM22/CMAP.  The Gly and Pro CMAPs have been refitted to more accurate quantum-mech. energy surfaces.  Side-chain torsion parameters have been optimized by fitting to backbone-dependent quantum-mech. energy surfaces, followed by addnl. empirical optimization targeting NMR scalar couplings for unfolded proteins.  A comprehensive validation of the revised force field was then performed against a collection of exptl. data: (i) comparison of simulations of eight proteins in their crystal environments with crystal structures; (ii) comparison with backbone scalar couplings for weakly structured peptides; (iii) comparison with NMR residual dipolar couplings and scalar couplings for both backbone and side-chains in folded proteins; (iv) equil. folding of mini-proteins.  The results indicate that the revised CHARMM 36 parameters represent an improved model for modeling and simulation studies of proteins, including studies of protein folding, assembly, and functionally relevant conformational changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGnwGJMAMFvLVg90H21EOLACvtfcHk0lgd6-iqLZ6pZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKqurfP&md5=9a48a0c5770fb1e887c3bb34d45b1354</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fct300400x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct300400x%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DR.%2BB.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DLopes%26aufirst%3DP.%2BE.%26aulast%3DMittal%26aufirst%3DJ.%26aulast%3DFeig%26aufirst%3DM.%26aulast%3DMackerell%26aufirst%3DA.%2BD.%26atitle%3DOptimization%2520of%2520the%2520additive%2520CHARMM%2520all-atom%2520protein%2520force%2520field%2520targeting%2520improved%2520sampling%2520of%2520the%2520backbone%2520phi%252C%2520psi%2520and%2520side-chain%2520chi%25281%2529%2520and%2520chi%25282%2529%2520dihedral%2520angles%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2012%26volume%3D8%26spage%3D3257%26epage%3D3273%26doi%3D10.1021%2Fct300400x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span> <span> </span><span class="NLM_article-title">Automated force field parameterization for non-polarizable and polarizable atomic models based on ab initio target data</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3543</span>– <span class="NLM_lpage">3556</span>, <span class="refDoi"> DOI: 10.1021/ct4003477</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct4003477" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSns7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=3543-3556&author=L.+Huangauthor=B.+Roux&title=Automated+force+field+parameterization+for+non-polarizable+and+polarizable+atomic+models+based+on+ab+initio+target+data&doi=10.1021%2Fct4003477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Automated Force Field Parameterization for Nonpolarizable and Polarizable Atomic Models Based on Ab Initio Target Data</span></div><div class="casAuthors">Huang, Lei; Roux, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3543-3556</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Classical mol. dynamics (MD) simulations based on atomistic models are increasingly used to study a wide range of biol. systems.  A prerequisite for meaningful results from such simulations is an accurate mol. mech. force field.  Most biomol. simulations are currently based on the widely used AMBER and CHARMM force fields, which were parametrized and optimized to cover a small set of basic compds. corresponding to the natural amino acids and nucleic acid bases.  Atomic models of addnl. compds. are commonly generated by analogy to the parameter set of a given force field.  While this procedure yields models that are internally consistent, the accuracy of the resulting models can be limited.  The authors propose a method, general automated at. model parameterization (GAAMP), for generating automatically the parameters of at. models of small mols. using the results from ab initio quantum mech. (QM) calcns. as target data.  Force fields that were previously developed for a wide range of model compds. serve as initial guesses, although any of the final parameter can be optimized.  The electrostatic parameters (partial charges, polarizabilities, and shielding) are optimized on the basis of QM electrostatic potential (ESP) and, if applicable, the interaction energies between the compd. and water mols.  The soft dihedrals are automatically identified and parametrized by targeting QM dihedral scans as well as the energies of stable conformers.  To validate the approach, the solvation free energy is calcd. for >200 small mols. and MD simulations of three different proteins were carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjMGhS8IcFx7Vg90H21EOLACvtfcHk0lgga45A8FfSgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSns7rP&md5=8f7c3d2fd1e29afe685a4e94a5e0943a</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fct4003477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct4003477%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DRoux%26aufirst%3DB.%26atitle%3DAutomated%2520force%2520field%2520parameterization%2520for%2520non-polarizable%2520and%2520polarizable%2520atomic%2520models%2520based%2520on%2520ab%2520initio%2520target%2520data%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2013%26volume%3D9%26spage%3D3543%26epage%3D3556%26doi%3D10.1021%2Fct4003477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feller, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, B. R.</span></span> <span> </span><span class="NLM_article-title">Constant pressure molecular dynamics simulation: the langevin piston method</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">4613</span>– <span class="NLM_lpage">4621</span>, <span class="refDoi"> DOI: 10.1063/1.470648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1063%2F1.470648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK2MXotVentLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1995&pages=4613-4621&author=S.+E.+Fellerauthor=Y.+Zhangauthor=R.+W.+Pastorauthor=B.+R.+Brooks&title=Constant+pressure+molecular+dynamics+simulation%3A+the+langevin+piston+method&doi=10.1063%2F1.470648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Constant pressure molecular dynamics simulation: the Langevin piston method</span></div><div class="casAuthors">Feller, Scott E.; Zhang, Yuhong; Pastor, Richard W.; Brooks, Bernard R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4613-21</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    
            (<span class="NLM_cas:orgname">American Institute of Physics</span>)
        </div><div class="casAbstract">A new method for performing mol. dynamics simulations under const. pressure is presented.  In the method, which is based on the extended system formalism introduced by Andersen, the deterministic equations of motion for the piston degree of freedom are replaced by a Langevin equation; a suitable choice of collision frequency then eliminates the unphys. "ringing" of the vol. assocd. with the piston mass.  In this way it is similar to the "weak coupling algorithm" developed by Berendsen and co-workers to perform mol. dynamics simulation without piston mass effects.  It is shown, however, that the weak coupling algorithm induces artifacts into the simulation which can be quite severe for inhomogeneous systems such as aq. biopolymers or liq./liq. interfaces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZp5NIYiFpuLVg90H21EOLACvtfcHk0lgga45A8FfSgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotVentLo%253D&md5=219a4e0a48397a35fa2c62cf99bf225a</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1063%2F1.470648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.470648%26sid%3Dliteratum%253Aachs%26aulast%3DFeller%26aufirst%3DS.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPastor%26aufirst%3DR.%2BW.%26aulast%3DBrooks%26aufirst%3DB.%2BR.%26atitle%3DConstant%2520pressure%2520molecular%2520dynamics%2520simulation%253A%2520the%2520langevin%2520piston%2520method%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1995%26volume%3D103%26spage%3D4613%26epage%3D4621%26doi%3D10.1063%2F1.470648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerbini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span> <span> </span><span class="NLM_article-title">Transfection, selection, and colony-picking of human induced pluripotent stem cells TALEN-targeted with a GFP gene into the AAVS1 safe harbor</span>. <i>J. Visualized Exp.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>, <span class="NLM_elocation-id">e52504</span> <span class="refDoi"> DOI: 10.3791/52504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.3791%2F52504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvV2ntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+Cerbiniauthor=Y.+Luoauthor=M.+S.+Raoauthor=J.+Zou&title=Transfection%2C+selection%2C+and+colony-picking+of+human+induced+pluripotent+stem+cells+TALEN-targeted+with+a+GFP+gene+into+the+AAVS1+safe+harbor&doi=10.3791%2F52504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Transfection, selection, and colony-picking of human induced pluripotent stem cells TALEN-targeted with a GFP gene into the AAVS1 safe harbor</span></div><div class="casAuthors">Cerbini, Trevor; Luo, Yongquan; Rao, Mahendra S.; Zou, Jizhong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Visualized Experiments</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">96</span>),
    <span class="NLM_cas:pages">e52504/1-e52504/9</span>CODEN:
                <span class="NLM_cas:coden">JVEOA4</span>;
        ISSN:<span class="NLM_cas:issn">1940-087X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Visualized Experiments</span>)
        </div><div class="casAbstract">A review.  Targeted transgene addn. can provide persistent gene expression while circumventing the gene silencing and insertional mutagenesis caused by viral vector mediated random integration.  This protocol describes a universal and efficient transgene targeted addn. platform in human iPSCs based on utilization of validated open-source TALENs and a gene-trap-like donor to deliver transgenes into a safe harbor locus.  Importantly, effective gene editing is rate-limited by the delivery efficiency of gene editing vectors.  Therefore, this protocol first focuses on prepn. of iPSCs for transfection to achieve high nuclear delivery efficiency.  When iPSCs are dissocd. into single cells using a gentle-cell dissocn. reagent and transfected using an optimized program, >50% cells can be induced to take up the large gene editing vectors.  Because the AAVS1 locus is located in the intron of an active gene (PPP1R12C), a splicing acceptor (SA)-linked puromycin resistant gene (PAC) was used to select targeted iPSCs while excluding random integration-only and untransfected cells.  This strategy greatly increases the chance of obtaining targeted clones, and can be used in other active gene targeting expts. as well.  Two weeks after puromycin selection at the dose adjusted for the specific iPSC line, clones are ready to be picked by manual dissection of large, isolated colonies into smaller pieces that are transferred to fresh medium in a smaller well for further expansion and genetic and functional screening.  One can follow this protocol to readily obtain multiple GFP reporter iPSC lines that are useful for in vivo and in vitro imaging and cell isolation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpreUnjkiWc-bVg90H21EOLACvtfcHk0lhdmI9LHPL_hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvV2ntb4%253D&md5=efef34580fcb534a231403a371bde2c0</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.3791%2F52504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3791%252F52504%26sid%3Dliteratum%253Aachs%26aulast%3DCerbini%26aufirst%3DT.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DM.%2BS.%26aulast%3DZou%26aufirst%3DJ.%26atitle%3DTransfection%252C%2520selection%252C%2520and%2520colony-picking%2520of%2520human%2520induced%2520pluripotent%2520stem%2520cells%2520TALEN-targeted%2520with%2520a%2520GFP%2520gene%2520into%2520the%2520AAVS1%2520safe%2520harbor%26jtitle%3DJ.%2520Visualized%2520Exp.%26date%3D2015%26doi%3D10.3791%2F52504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swistowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swistowska, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X.</span></span> <span> </span><span class="NLM_article-title">Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e6233</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0006233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1371%2Fjournal.pone.0006233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=19597550" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&author=A.+Swistowskiauthor=J.+Pengauthor=Y.+Hanauthor=A.+M.+Swistowskaauthor=M.+S.+Raoauthor=X.+Zeng&title=Xeno-free+defined+conditions+for+culture+of+human+embryonic+stem+cells%2C+neural+stem+cells+and+dopaminergic+neurons+derived+from+them&doi=10.1371%2Fjournal.pone.0006233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0006233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0006233%26sid%3Dliteratum%253Aachs%26aulast%3DSwistowski%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DSwistowska%26aufirst%3DA.%2BM.%26aulast%3DRao%26aufirst%3DM.%2BS.%26aulast%3DZeng%26aufirst%3DX.%26atitle%3DXeno-free%2520defined%2520conditions%2520for%2520culture%2520of%2520human%2520embryonic%2520stem%2520cells%252C%2520neural%2520stem%2520cells%2520and%2520dopaminergic%2520neurons%2520derived%2520from%2520them%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26doi%3D10.1371%2Fjournal.pone.0006233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Amy E. Moritz, Alessandro Bonifazi, Adrian M. Guerrero, Vivek Kumar, R. Benjamin Free, J. Robert Lane, Ravi Kumar Verma, Lei Shi, Amy Hauck Newman, <span class="NLM_string-name hlFld-ContribAuthor">David R. Sibley</span>. </span><span class="cited-content_cbyCitation_article-title">Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D3 Dopamine Receptor. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (20)
                                     , 3309-3320. <a href="https://doi.org/10.1021/acschemneuro.0c00425" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00425%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DEvidence%252Bfor%252Ba%252BStereoselective%252BMechanism%252Bfor%252BBitopic%252BActivity%252Bby%252BExtended-Length%252BAntagonists%252Bof%252Bthe%252BD3%252BDopamine%252BReceptor%26aulast%3DMoritz%26aufirst%3DAmy%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09072020%26date%3D24092020%26date%3D05102020%26date%3D24092020%26volume%3D11%26issue%3D20%26spage%3D3309%26epage%3D3320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Mancuso</span>, <span class="hlFld-ContribAuthor ">Anna  Di Fiore</span>, <span class="hlFld-ContribAuthor ">Laura  De Luca</span>, <span class="hlFld-ContribAuthor ">Andrea  Angeli</span>, <span class="hlFld-ContribAuthor ">Giuseppina  De Simone</span>, <span class="hlFld-ContribAuthor ">Claudiu T.  Supuran</span>, <span class="hlFld-ContribAuthor ">Rosaria  Gitto</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biochemical evaluation of novel carbonic anhydrase inhibitors triggered by structural knowledge on hCA VII. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>44 </em>, 116279. <a href="https://doi.org/10.1016/j.bmc.2021.116279" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116279%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiochemical%252Bevaluation%252Bof%252Bnovel%252Bcarbonic%252Banhydrase%252Binhibitors%252Btriggered%252Bby%252Bstructural%252Bknowledge%252Bon%252BhCA%252BVII%26aulast%3DMancuso%26aufirst%3DFrancesca%26date%3D2021%26volume%3D44%26spage%3D116279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Béla  Kiss</span>, <span class="hlFld-ContribAuthor ">István  Laszlovszky</span>, <span class="hlFld-ContribAuthor ">Balázs  Krámos</span>, <span class="hlFld-ContribAuthor ">András  Visegrády</span>, <span class="hlFld-ContribAuthor ">Amrita  Bobok</span>, <span class="hlFld-ContribAuthor ">György  Lévay</span>, <span class="hlFld-ContribAuthor ">Balázs  Lendvai</span>, <span class="hlFld-ContribAuthor ">Viktor  Román</span>. </span><span class="cited-content_cbyCitation_article-title">Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 104. <a href="https://doi.org/10.3390/biom11010104" title="DOI URL">https://doi.org/10.3390/biom11010104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11010104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11010104%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DNeuronal%252BDopamine%252BD3%252BReceptors%25253A%252BTranslational%252BImplications%252Bfor%252BPreclinical%252BResearch%252Band%252BCNS%252BDisorders%26aulast%3DKiss%26aufirst%3DB%25C3%25A9la%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1%26spage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of the HTS lead, compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pharmacological activity of lead compound <b>1</b> on the D3R and D2R. (A, B) Agonist concentration–response curves for stimulating β-arrestin recruitment in response to either dopamine (DA) or <b>1</b> using cells expressing either the D3R (A) or D2R (B). Cells were stimulated as indicated, and β-arrestin recruitment was assessed using the DiscoverX assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data are expressed as a percentage of the maximum dopamine (DA) signal and are shown as means ± standard error of the mean (SEM) of at least three experiments performed in triplicate. In (A), the EC<sub>50</sub> value for DA is 6.4 ± 0.6 nM (mean ± SEM, <i>n</i> = 12) and of <b>1</b> is 710 ± 150 nM (mean ± SEM, <i>n</i> = 13). In (B), the EC<sub>50</sub> value for DA is 140 ± 23 nM (mean ± SEM, <i>n</i> = 13). (C) Antagonist concentration–response curves of either sulpiride or <b>1</b> for inhibiting β-arrestin recruitment to the D2R. Cells were incubated with the indicated concentrations of the compound in the presence of an EC<sub>80</sub> concentration of DA (1 μM). Data are expressed as a percentage of signal seen in the absence of test compounds and are shown as means ± SEM of at least three experiments performed in triplicate. The IC<sub>50</sub> value of sulpiride is 42 ± 4.9 nM (mean ± SEM, <i>n</i> = 8) and of <b>1</b> is 16 ± 3.0 μM (mean ± SEM, <i>n</i> = 10). (D) Radioligand binding assays using [<sup>3</sup>H]-methylspiperone were performed as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data are representative of six independent experiments and expressed as a percentage of the specific binding. The IC<sub>50</sub> values of <b>1</b> were determined to be >100 μM for the D3R and D2R.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Summary of Alkylation Routes to SAR Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) potassium iodide (0.1 or 1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), MeCN or DMF, 60 °C, 14–20 h, 27–81% yield; (b) <b>112a</b> (1.1 equiv), Et<sub>3</sub>N (1.4 equiv), MeCN, 60 °C, 18 h, 68% yield; (c) <b>112a</b> (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), <i>N</i>,<i>N</i>-dimethylformamide (DMF), 100 °C, 5 h, 37% yield; and (d) 1-(3-bromopropoxy)-4-methoxybenzene or 1-(4-bromobutoxy)-4-methoxybenzene, potassium iodide (1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), MeCN, 60 °C, 19 h, 76–83% yield.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Summary of Late-Stage Acylation Routes to SAR Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), potassium iodide (0.1 equiv), MeCN or DMF, 70 or 90 °C, 16–21 h, 70–79% yield; (b) Et<sub>3</sub>SiH (1.5–2.0 equiv), trifluoroacetic acid (15–20 equiv), CH<sub>2</sub>Cl<sub>2</sub>, room temperature (rt), 4–26 h, 80–91% yield; (c) Ar<sup>1</sup>C(O)Cl (1.0–1.3 equiv), Et<sub>3</sub>N (1.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 16–20 h, 61–69% yield; (d) Ar<sup>1</sup>CO<sub>2</sub>H (1.0–1.3 equiv), PyBOP (1.2 equiv), <i>i</i>-Pr<sub>2</sub>EtN (3.0 equiv), DMF, rt, 16–20 h, 15–93% yield; (e) 1<i>H</i>-indole-2-carboxylic acid (1.2 equiv), diisopropylcarbodiimide (3.0 equiv), 4-dimethylaminopyridine (DMAP, 0.1 equiv), tetrahydrofuran (THF), rt, 15 h, 73% yield; (f) 2-chloroproponyl chloride (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.5 equiv), 4-methoxyphenol or 4-chlorophenol (1.2 equiv), DMF, 80 °C, 4 h, 24–28% yield; and (g) BH<sub>3</sub>·THF (3.1–3.2 equiv), THF, 65 °C, 0.5–4 h, 86–88% yield.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the Sulfonamide Analogue <b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-methoxybenzene-1-sulfonyl chloride (1.0 equiv), Et<sub>3</sub>N (2.0 equiv), toluene, rt, 19 h, 55% yield.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Reductive Amination Protocol for the Synthesis of the Methyl-Substituted Analogue <b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-(4-methoxyphenoxy)propan-2-one (1.0 equiv), NaBH(OAc)<sub>3</sub> (1.5 equiv), ClCH<sub>2</sub>CH<sub>2</sub>Cl, AcOH (0.3 equiv), 50 °C, 7 d, 57% yield.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0014.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Summary of Alkyl Chloride Displacement Routes to SAR Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1<i>H</i>-indole-2-carbonyl chloride (1.1 equiv), Et<sub>3</sub>N (1.2 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 20 h, 75% yield; (b) triphosgene (0.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 3 h, 53% yield; (c) Ar<sup>2</sup>OH (1.1–1.9 equiv), Ar<sup>2</sup>SH (1.6 equiv) or Ar<sup>2</sup>NHMe (1.6 equiv), K<sub>2</sub>CO<sub>3</sub> (1.8–3.3 equiv), DMF, 50–80 °C, 7–19 h, 5–73% yield; (d) 4-methoxybenzoyl chloride (1.1 equiv), Et<sub>3</sub>N (1.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 80% yield; (e) thionyl chloride (1.0–1.5 equiv), CHCl<sub>3</sub>, 50–55 °C, 0.5 or 46 h, 54–86% yield; and (f) 2-(methylamino)ethanol (5.1 equiv), MeCN, 80 °C, 25 h, 67% yield.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0015.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Mitsunobu Reaction Route to SAR Analogues <b>6</b>, <b>8</b>, and <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-methoxybenzoyl chloride (1.1 equiv), Et<sub>3</sub>N (1.3 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 24 h, 68% yield; and (b) Ar<sup>2</sup>OH (1.0 equiv), Ph<sub>3</sub>P (1.0 equiv), diisopropyl azodicarboxylate (DIAD, 1.3 equiv), CH<sub>2</sub>Cl<sub>2</sub> or THF, 60 °C, 16–40 h, 15–46% yield.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0016.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of the Piperidine Analogue <b>108</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) indole-2-carboxylic acid (1.0 equiv), HOBt (1.0 equiv), EDC·HCl (1.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 18 h, 49% yield; (b) TsCl (2.0 equiv), Et<sub>3</sub>N (4.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 46% yield; and (c) 4-methoxyphenol (3.0 equiv), K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), MeCN, 60 °C, 17 h, 70% yield.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0017.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of the Dibasic Piperazine Analogue <b>109</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-chloro-1-(1<i>H</i>-indol-2-yl)ethan-1-one (1.0 equiv), KI (1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (4.0 equiv), MeCN, 65 °C, 18 h, 51% yield.</p></p></figure><figure data-id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Illustration of structural modifications to compound <b>1</b> to investigate structure–activity relationships.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacological activity of compound 20 on all dopamine receptor subtypes. (A) Chemical structure of <b>20</b>. (B) Agonist concentration–response curves for stimulating β-arrestin recruitment in response to <b>20</b> for the indicated DA receptor subtypes. β-arrestin recruitment was assessed using the DiscoverX assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, and the data are expressed as a percentage of the maximum dopamine signal for each receptor (not shown) and represent means ± SEM of at least three experiments performed in triplicate. The EC<sub>50</sub> for <b>20</b> at the D3R is reported in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. (C) Antagonist concentration–response curves of <b>20</b> on cells expressing individual dopamine receptor subtypes as indicated. β-arrestin recruitment was stimulated with an ∼EC<sub>80</sub> concentration of dopamine for each receptor subtype and incubated with the indicated concentrations of <b>20</b>. Data are expressed as a percentage of the signal seen with the EC<sub>80</sub> concentration of dopamine and represent means ± SEM of at least three experiments performed in triplicate. The IC<sub>50</sub> for <b>20</b> at the D2R was estimated to be >10 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacology of compound 20 on D3R-mediated signaling outputs. Agonist-mediated concentration–response curves of dopamine or <b>20</b> for stimulating a variety of D3R-mediated signaling pathways. (A) Cells were stimulated as indicated and analyzed using the BRET-based β-arrestin recruitment assay (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>), resulting in EC<sub>50</sub> values of 2.3 ± 0.9 and 1.2 ± 0.5 nM (mean ± SEM, <i>n</i> = 4) for dopamine and <b>20</b>, respectively. (B) Cells were stimulated as indicated and analyzed using the BRET-based Go activation assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, resulting in EC<sub>50</sub> values of 1.1 ± 0.04 and 0.18 ± 0.1 nM (mean ± SEM, <i>n</i> = 6) for dopamine and <b>20</b>, respectively. (C) Cells were incubated with the indicated concentrations of dopamine (DA) or <b>20</b>, and inhibition of forskolin-stimulated cAMP accumulation was determined using the CAMYEL biosensor as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data are presented as the percentage of maximum inhibition by DA. <b>20</b> displays a full agonist activity of D3R-mediated inhibition of cAMP production, exhibiting an EC<sub>50</sub> of 86 ± 26 nM (mean ± SEM, <i>n</i> = 4). Dopamine demonstrated an EC<sub>50</sub> value of 3.5 ± 0.7 nM (mean ± SEM, <i>n</i> = 4). (D) Cells were stimulated as indicated, and pERK was assessed using the Alphascreen SureFire assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. EC<sub>50</sub> values for dopamine and <b>20</b> are 2.9 ± 0.6 and 21 ± 6.6 nM (mean ± SEM, <i>n</i> = 4), respectively. All data were analyzed using nonlinear regression curve fits and expressed as a percentage of the maximum dopamine signal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Functional profiling of compound 20 against an array of 168 known GPCRs. A single high concentration (10 μM) of <b>20</b> was screened against the DiscoverX gpcrMAX assay panel in both agonist (A) and antagonist (B) modes, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data represent the percent maximum stimulation observed by a reference agonist for each GPCR (agonist mode) or the percent inhibition of a response generated by an EC<sub>80</sub> concentration of a reference agonist (antagonist mode). A complete key to the GPCR array and numerical results are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf" class="ext-link">Supplemental Table S1</a>. In (B), partial antagonist activity was observed at the ADRA2C (36%), CCKAR (63%), EDG8 (77%), EBI2 (88%), and HTR2A (37%) receptors using a 10 μM concentration of <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Molecular modeling identified residues that uniquely interact with 20. (A) Side view of a representative D3R model in complex with <b>20</b> resulting from our MD simulations. The model was based on the D3R crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL">3PBL</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (B) Zoom-in view of the ligand binding pocket showing that two Tyr residues, Tyr198<sup>5.48</sup> and Tyr365<sup>7.35</sup>, uniquely interact with the two ends of the ligand. The conserved TM3 aspartate residue, Asp110<sup>3.32</sup>, in contact with the basic piperazine nitrogen is also depicted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0008.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mutagenesis studies support the D3R binding site model for compound 20. HEK293 cells were transiently transfected with the following Rluc8-fused receptor constructs: D3R-WT (A), D3R-Y198A (B), D3R-Y365A (C), or D3R-Y198A/Y365A (D), as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Cells were stimulated as indicated and analyzed using the BRET-based β-arrestin recruitment assay (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Data are expressed as a percentage of the maximum dopamine (DA) response. (A) <b>20</b> is a full agonist at the D3R-WT; EC<sub>50</sub> = 1.4 ± 0.7 nM, <i>E</i><sub>max</sub> = 92 ± 10% (mean ± SEM, <i>n</i> = 8); DA EC<sub>50</sub> = 3.7 ± 1.2 nM, <i>E</i><sub>max</sub> = 100 ± 0.3% (mean ± SEM, <i>n</i> = 8). (B) <b>20</b> has a reduced potency and efficacy at the D3R-Y198A mutant; EC<sub>50</sub> = 17 ± 7.6 nM*, <i>E</i><sub>max</sub> = 38 ± 6.2%** (mean ± SEM, <i>n</i> = 4); DA EC<sub>50</sub> = 55 ± 16 nM***, <i>E</i><sub>max</sub> = 100 ± 0.2% (mean ± SEM, <i>n</i> = 4). (C) <b>20</b> has a reduced potency and efficacy at the D3R-Y365A; EC<sub>50</sub> = 520 ± 150 nM**; <i>E</i><sub>max</sub> 26 ± 11%** (mean ± SEM, <i>n</i> = 4); DA EC<sub>50</sub> = 33 ± 3.3 nM****; <i>E</i><sub>max</sub> = 100 ± 0.1% (mean ± SEM, <i>n</i> = 4). (D) D3R-Y198A/Y365A mutation abolishes the agonist activity of <b>20</b>. DA EC<sub>50</sub> = 820 ± 56 nM****; <i>E</i><sub>max</sub> = 100 ± 0.1% (mean ± SEM, <i>n</i> = 3). Statistical comparisons between WT and mutant parameters were made using a two-tailed t-test: *<i>p</i> < 0.05, **<i>p</i> < 0.005, ***<i>p</i> < 0.0.001, ****<i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/medium/jm0c00424_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0009.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>20</b> protects D3R-expressing dopaminergic neurons from 6-OHDA-induced cell death. Human iPSCs expressing the D3R were differentiated into dopaminergic neurons, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Cells were treated with the indicated concentrations of vehicle, <b>20</b>, or pramipexole for 24 h and then incubated with 30 μM of 6-hydroxydopamine (6-OHDA) for 24 h to induce cell death (the control cell group did not receive 6-OHDA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assays were performed, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Data represent the means ± SEM from six experiments performed in quadruplicate. In the absence of drugs (vehicle), 6-OHDA treatment reduced cell viability by 62 ± 8%. Pretreatment with <b>20</b> and pramipexole protected against 6-OHDA-induced cell death in a dose-dependent fashion. Statistical significance for differences between the drug- and vehicle-treated groups was assessed using two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison post hoc test: *<i>p</i> < 0.05, **<i>p</i> < 0.01, <sup>#</sup><i>p</i> < 0.001, <sup>&</sup><i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00424/20200520/images/large/jm0c00424_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00424&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i200">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 101 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsma, F. J.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Molecular biology of dopamine receptors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/0165-6147(92)90025-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2F0165-6147%2892%2990025-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1561715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK38XhsVCjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1992&pages=61-69&author=D.+R.+Sibleyauthor=F.+J.+Monsma&title=Molecular+biology+of+dopamine+receptors&doi=10.1016%2F0165-6147%2892%2990025-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biology of dopamine receptors</span></div><div class="casAuthors">Sibley, David R.; Monsma, Frederick J., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-9</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    </div><div class="casAbstract">A review, with 58 refs., of the mol. characteristics of the recently cloned dopamine receptors.  The prospects for the cloning and identification of addnl. subtypes in this receptor family are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2MT0wXZx0J7Vg90H21EOLACvtfcHk0liN3TiBb_lQNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsVCjs74%253D&md5=6ca0cd0927c4ea79da78f3f48dfacaa3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0165-6147%2892%2990025-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-6147%252892%252990025-2%26sid%3Dliteratum%253Aachs%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMonsma%26aufirst%3DF.%2BJ.%26atitle%3DMolecular%2520biology%2520of%2520dopamine%2520receptors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1992%26volume%3D13%26spage%3D61%26epage%3D69%26doi%3D10.1016%2F0165-6147%2892%2990025-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Money, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanwood, G. D.</span></span> <span> </span><span class="NLM_article-title">Developmental origins of brain disorders: roles for dopamine</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">260</span>, <span class="refDoi"> DOI: 10.3389/fncel.2013.00260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.3389%2Ffncel.2013.00260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24391541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCit7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=260&author=K.+M.+Moneyauthor=G.+D.+Stanwood&title=Developmental+origins+of+brain+disorders%3A+roles+for+dopamine&doi=10.3389%2Ffncel.2013.00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Developmental origins of brain disorders: roles for dopamine</span></div><div class="casAuthors">Money, Kelli M.; Stanwood, Gregg D.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">260/1-260/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Neurotransmitters and neuromodulators, such as dopamine, participate in a wide range of behavioral and cognitive functions in the adult brain, including movement, cognition and reward.  Dopamine-mediated signaling plays a fundamental neurodevelopmental role in forebrain differentiation and circuit formation.  These developmental effects, such as modulation of neuronal migration and dendritic growth, occur before synaptogenesis and demonstrate novel roles for dopaminergic signaling beyond neuromodulation at the synapse.  Pharmacol. and genetic disruptions demonstrate that these effects are brain region- and receptor subtype-specific.  For example, the striatum and frontal cortex exhibit abnormal neuronal structure and function following prenatal disruption of dopamine receptor signaling.  Alterations in these processes are implicated in the pathophysiol. of neuropsychiatric disorders and emerging studies of neurodevelopmental disruptions may shed light on the pathophysiol. of abnormal neuronal circuitry in neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEMjXRriak9bVg90H21EOLACvtfcHk0lj04Nx8ppKATA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCit7zN&md5=68a87dee0dc7b8767e63e20f24abcf1b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2013.00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2013.00260%26sid%3Dliteratum%253Aachs%26aulast%3DMoney%26aufirst%3DK.%2BM.%26aulast%3DStanwood%26aufirst%3DG.%2BD.%26atitle%3DDevelopmental%2520origins%2520of%2520brain%2520disorders%253A%2520roles%2520for%2520dopamine%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2013%26volume%3D7%26spage%3D260%26doi%3D10.3389%2Ffncel.2013.00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">Dopamine receptors - IUPHAR Review 13</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1111/bph.12906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fbph.12906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25671228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1-23&author=J.+M.+Beaulieuauthor=S.+Espinozaauthor=R.+R.+Gainetdinov&title=Dopamine+receptors+-+IUPHAR+Review+13&doi=10.1111%2Fbph.12906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors - IUPHAR Review 13</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Espinoza, Stefano; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The variety of physiol. functions controlled by dopamine in the brain and periphery is mediated by the D1, D2, D3, D4 and D5 dopamine GPCRs.  Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease.  Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-assocd. behaviors and functions.  Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as β-arrestins that are classically involved in GPCR desensitization.  Another level of complexity is the growing appreciation of the physiol. roles played by dopamine receptor heteromers.  Applications of new in vivo techniques have significantly furthered the understanding of the physiol. functions played by dopamine receptors.  Here we provide an update of the current knowledge regarding the complex biol., signalling, physiol. and pharmacol. of dopamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fpdKAWrR5rVg90H21EOLACvtfcHk0lj04Nx8ppKATA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ&md5=7f15533abc8fb6aa76a4ec41072b6219</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fbph.12906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12906%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DDopamine%2520receptors%2520-%2520IUPHAR%2520Review%252013%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1%26epage%3D23%26doi%3D10.1111%2Fbph.12906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaar, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natesan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutcheon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, O. D.</span></span> <span> </span><span class="NLM_article-title">Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="NLM_elocation-id">107704</span> <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.107704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.neuropharm.2019.107704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=31299229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BB3Mzmslagsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+J.+Kaarauthor=S.+Natesanauthor=R.+McCutcheonauthor=O.+D.+Howes&title=Antipsychotics%3A+mechanisms+underlying+clinical+response+and+side-effects+and+novel+treatment+approaches+based+on+pathophysiology&doi=10.1016%2Fj.neuropharm.2019.107704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology</span></div><div class="casAuthors">Kaar Stephen J; Howes Oliver D; Natesan Sridhar; McCutcheon Robert</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107704</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic disorders but are ineffective for some patients and associated with side-effects and nonadherence in others.  We review the in vitro, pre-clinical, clinical and molecular imaging evidence on the mode of action of antipsychotics and their side-effects.  This identifies the key role of striatal dopamine D2 receptor blockade for clinical response, but also for endocrine and motor side-effects, indicating a therapeutic window for D2 blockade.  We consider how partial D2/3 receptor agonists fit within this framework, and the role of off-target effects of antipsychotics, particularly at serotonergic, histaminergic, cholinergic, and adrenergic receptors for efficacy and side-effects such as weight gain, sedation and dysphoria.  We review the neurobiology of schizophrenia relevant to the mode of action of antipsychotics, and for the identification of new treatment targets.  This shows elevated striatal dopamine synthesis and release capacity in dorsal regions of the striatum underlies the positive symptoms of psychosis and suggests reduced dopamine release in cortical regions contributes to cognitive and negative symptoms.  Current drugs act downstream of the major dopamine abnormalities in schizophrenia, and potentially worsen cortical dopamine function.  We consider new approaches including targeting dopamine synthesis and storage, autoreceptors, and trace amine receptors, and the cannabinoid, muscarinic, GABAergic and glutamatergic regulation of dopamine neurons, as well as post-synaptic modulation through phosphodiesterase inhibitors.  Finally, we consider treatments for cognitive and negative symptoms such dopamine agonists, nicotinic agents and AMPA modulators before discussing immunological approaches which may be disease modifying.  This article is part of the issue entitled 'Special Issue on Antipsychotics'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_8nvOYm_yGkloaUqgkFHkfW6udTcc2eZ1JoEAcWMEvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mzmslagsw%253D%253D&md5=06ca3f300890d137860206a6bd3b0b99</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.107704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.107704%26sid%3Dliteratum%253Aachs%26aulast%3DKaar%26aufirst%3DS.%2BJ.%26aulast%3DNatesan%26aufirst%3DS.%26aulast%3DMcCutcheon%26aufirst%3DR.%26aulast%3DHowes%26aufirst%3DO.%2BD.%26atitle%3DAntipsychotics%253A%2520mechanisms%2520underlying%2520clinical%2520response%2520and%2520side-effects%2520and%2520novel%2520treatment%2520approaches%2520based%2520on%2520pathophysiology%26jtitle%3DNeuropharmacology%26date%3D2019%26doi%3D10.1016%2Fj.neuropharm.2019.107704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battagello, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittencourt, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, R. G.</span></span> <span> </span><span class="NLM_article-title">Dopamine: functions, signaling, and association with neurological diseases</span>. <i>Cell. Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1007/s10571-018-0632-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs10571-018-0632-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30446950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BB3crhvVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=31-59&author=M.+O.+Kleinauthor=D.+S.+Battagelloauthor=A.+R.+Cardosoauthor=D.+N.+Hauserauthor=J.+C.+Bittencourtauthor=R.+G.+Correa&title=Dopamine%3A+functions%2C+signaling%2C+and+association+with+neurological+diseases&doi=10.1007%2Fs10571-018-0632-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine: Functions, Signaling, and Association with Neurological Diseases</span></div><div class="casAuthors">Klein Marianne O; Battagello Daniella S; Cardoso Ariel R; Bittencourt Jackson C; Hauser David N; Correa Ricardo G; Bittencourt Jackson C</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular neurobiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The dopaminergic system plays important roles in neuromodulation, such as motor control, motivation, reward, cognitive function, maternal, and reproductive behaviors.  Dopamine is a neurotransmitter, synthesized in both central nervous system and the periphery, that exerts its actions upon binding to G protein-coupled receptors.  Dopamine receptors are widely expressed in the body and function in both the peripheral and the central nervous systems.  Dopaminergic signaling pathways are crucial to the maintenance of physiological processes and an unbalanced activity may lead to dysfunctions that are related to neurodegenerative diseases.  Unveiling the neurobiology and the molecular mechanisms that underlie these illnesses may contribute to the development of new therapies that could promote a better quality of life for patients worldwide.  In this review, we summarize the aspects of dopamine as a catecholaminergic neurotransmitter and discuss dopamine signaling pathways elicited through dopamine receptor activation in normal brain function.  Furthermore, we describe the potential involvement of these signaling pathways in evoking the onset and progression of some diseases in the nervous system, such as Parkinson's, Schizophrenia, Huntington's, Attention Deficit and Hyperactivity Disorder, and Addiction.  A brief description of new dopaminergic drugs recently approved and under development treatments for these ailments is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuNldawXYWK-3MPKNEWB5RfW6udTcc2eZ1JoEAcWMEvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crhvVKjsw%253D%253D&md5=a92f053e46bf4358f18571f34b3ea81d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs10571-018-0632-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10571-018-0632-3%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DM.%2BO.%26aulast%3DBattagello%26aufirst%3DD.%2BS.%26aulast%3DCardoso%26aufirst%3DA.%2BR.%26aulast%3DHauser%26aufirst%3DD.%2BN.%26aulast%3DBittencourt%26aufirst%3DJ.%2BC.%26aulast%3DCorrea%26aufirst%3DR.%2BG.%26atitle%3DDopamine%253A%2520functions%252C%2520signaling%252C%2520and%2520association%2520with%2520neurological%2520diseases%26jtitle%3DCell.%2520Mol.%2520Neurobiol.%26date%3D2019%26volume%3D39%26spage%3D31%26epage%3D59%26doi%3D10.1007%2Fs10571-018-0632-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won Han, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+T.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+Won+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0liMmq8IeVOv6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWon%2BHan%26aufirst%3DG.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-M.</span></span> <span> </span><span class="NLM_article-title">Current perspectives on the selective regulation of dopamine D2 and D3 receptors</span>. <i>Arch. Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1521</span>– <span class="NLM_lpage">1538</span>, <span class="refDoi"> DOI: 10.1007/s12272-010-1005-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs12272-010-1005-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21052931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlOqtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=1521-1538&author=D.+I.+Choauthor=M.+Zhengauthor=K.-M.+Kim&title=Current+perspectives+on+the+selective+regulation+of+dopamine+D2+and+D3+receptors&doi=10.1007%2Fs12272-010-1005-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspectives on the selective regulation of dopamine D2 and D3 receptors</span></div><div class="casAuthors">Cho, Dong Im; Zheng, Mei; Kim, Kyeong-Man</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1521-1538</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Among the characterized dopamine receptor subtypes, D2 receptor (D2R) and D3 receptor (D3R) are the main targets of neuroleptics that are currently in use.  In particular, D3R is closely related to the etiol. of schizophrenia and drug addiction.  The spatial expression patterns of D2R and D3R are distinct in certain areas of the brain.  D2R are heavily expressed in the regions responsible for motor functions, whereas D3R are more selectively expressed in the limbic regions, which are assocd. with cognitive and emotional functions.  Therefore, disturbances in the motor and endocrine functions, which are the most serious problems caused by the current neuroleptics, are likely to result from the non-selective blockade of D2R.  Selective regulation of D3R is needed to sep. the desired therapeutic activities from unwanted side effects that result from promiscuous blockade of other receptors.  D2R and D3R possess high sequence homol. and employ similar signaling pathways, and it is difficult to selectively regulate them.  In this review, we discuss the signaling mechanisms, intracellular trafficking, and desensitization properties of D2R and D3R.  In addn., the proteins interacting with D2R or D3R are discussed in relation to their roles in the regulation of receptor functions, followed by the current status of the development of selective D3R ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4cCMB-iwXjLVg90H21EOLACvtfcHk0liMmq8IeVOv6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlOqtr3K&md5=7dd5bae45a4c7f356f33523f999dafe6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs12272-010-1005-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-010-1005-8%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DD.%2BI.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DK.-M.%26atitle%3DCurrent%2520perspectives%2520on%2520the%2520selective%2520regulation%2520of%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2010%26volume%3D33%26spage%3D1521%26epage%3D1538%26doi%3D10.1007%2Fs12272-010-1005-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin Free, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2017.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.cellsig.2017.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=28716664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtF2qu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=75-81&author=A.+E.+Moritzauthor=R.+Benjamin+Freeauthor=D.+R.+Sibley&title=Advances+and+challenges+in+the+search+for+D2+and+D3+dopamine+receptor-selective+compounds&doi=10.1016%2Fj.cellsig.2017.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds</span></div><div class="casAuthors">Moritz, Amy E.; Benjamin Free, R.; Sibley, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Compds. that target D2-like dopamine receptors (DRs) are currently used as therapeutics for several neuropsychiatric disorders including schizophrenia (antagonists) and Parkinson's disease (agonists).  However, as the D2R and D3R subtypes are highly homologous, creating compds. with sufficient subtype-selectivity as well as drug-like properties for therapeutic use has proved challenging.  This review summarizes the progress that has been made in developing D2R- or D3R-selective antagonists and agonists, and also describes the exptl. conditions that need to be considered when detg. the selectivity of a given compd., as apparent selectivity can vary widely depending on assay conditions.  Future advances in this field may take advantage of currently available structural data to target alternative secondary binding sites through creating bivalent or bitopic chem. structures.  Alternatively, the use of high-throughput screening techniques to identify novel scaffolds that might bind to the D2R or D3R in areas other than the highly conserved orthosteric site, such as allosteric sites, followed by iterative medicinal chem. will likely lead to exceptionally selective compds. in the future.  More selective compds. will provide a better understanding of the normal and pathol. functioning of each receptor subtype, as well as offer the potential for improved therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprWt_AnCx4BbVg90H21EOLACvtfcHk0ljP8XEypCMLlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtF2qu7jI&md5=da8fe4b2437f67f0451f8c14412a8182</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2017.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DBenjamin%2BFree%26aufirst%3DR.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DAdvances%2520and%2520challenges%2520in%2520the%2520search%2520for%2520D2%2520and%2520D3%2520dopamine%2520receptor-selective%2520compounds%26jtitle%3DCell.%2520Signalling%26date%3D2018%26volume%3D41%26spage%3D75%26epage%3D81%26doi%3D10.1016%2Fj.cellsig.2017.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(01)00139-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FS0163-7258%2801%2900139-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=11578658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntV2hur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2001&pages=231-259&author=J.+N.+Joyce&title=Dopamine+D3+receptor+as+a+therapeutic+target+for+antipsychotic+and+antiparkinsonian+drugs&doi=10.1016%2FS0163-7258%2801%2900139-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs</span></div><div class="casAuthors">Joyce, J. N.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">231-259</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The cloning of the gene for the D3 receptor and subsequent identification of its distribution in brain and pharmacol. allowed for serious consideration of the possibility that it might be a target for drugs used to treat schizophrenia and Parkinson's disease (PD).  That is because it is highly expressed in limbic regions of the brain, exhibits low expression in motor divisions, and has pharmacol. similarity to the D2 receptor.  Thus, antipsychotics that were presumed to block D2 receptors also had high affinity for the D3 receptor.  Dopamine agonists used to treat the clin. symptoms of PD also have high affinity for the D3 receptor, and two D3 receptor-preferring agonists were effective for treatment of PD.  Many compds. achieving high potency and selectivity are now available, but few have reached clin. testing.  Recent findings with respect to the anatomy of this receptor in human brain, altered expression in schizophrenia and PD, and biol. models to study its function support the proposal that it is a target for development of drugs to alleviate symptoms in neuropsychiatric and neurol. disorders.  Because of distinct aspects of regulation of the D3 receptor, it represents a unique target for therapeutic intervention in schizophrenia without high potential for unintended side effects such as tardive dyskinesia.  It may also be that D3 receptor agonists can provide neuroprotective effects in PD and can modify clin. symptoms that D2 receptor-preferring agonists cannot provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAzYJRgnl5LVg90H21EOLACvtfcHk0ljP8XEypCMLlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntV2hur8%253D&md5=70af1ac4de6b531b5b3b13f0fe179d0f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2801%2900139-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252801%252900139-5%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26atitle%3DDopamine%2520D3%2520receptor%2520as%2520a%2520therapeutic%2520target%2520for%2520antipsychotic%2520and%2520antiparkinsonian%2520drugs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2001%26volume%3D90%26spage%3D231%26epage%3D259%26doi%3D10.1016%2FS0163-7258%2801%2900139-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Parkinson
Study Group, C. C. I.</span> <span> </span><span class="NLM_article-title">Long-term
effect of initiating pramipexole vs levodopa in early Parkinson disease</span>. <i>Arch. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1001/archneurol.2009.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1001%2Farchneurol.2009.32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=19433655" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=563-570&author=Parkinson%0AStudy+Group%2C+C.+C.+I.&title=Long-term%0Aeffect+of+initiating+pramipexole+vs+levodopa+in+early+Parkinson+disease&doi=10.1001%2Farchneurol.2009.32"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1001%2Farchneurol.2009.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneurol.2009.32%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DLong-term%250Aeffect%2520of%2520initiating%2520pramipexole%2520vs%2520levodopa%2520in%2520early%2520Parkinson%2520disease%26jtitle%3DArch.%2520Neurol.%26date%3D2009%26volume%3D66%26spage%3D563%26epage%3D570%26doi%3D10.1001%2Farchneurol.2009.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presgraves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borwege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osredkar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Replogle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PazSoldan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1016/S0014-4886(03)00353-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FS0014-4886%2803%2900353-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=14637109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVekt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2003&pages=393-407&author=J.+N.+Joyceauthor=S.+Presgravesauthor=L.+Renishauthor=S.+Borwegeauthor=T.+Osredkarauthor=D.+Hagnerauthor=M.+Replogleauthor=M.+PazSoldanauthor=M.+J.+Millan&title=Neuroprotective+effects+of+the+novel+D3%2FD2+receptor+agonist+and+antiparkinson+agent%2C+S32504%2C+in+vitro+against+1-methyl-4-phenylpyridinium+%28MPP%2B%29+and+in+vivo+against+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine+%28MPTP%29%3A+a+comparison+to+ropinirole&doi=10.1016%2FS0014-4886%2803%2900353-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole</span></div><div class="casAuthors">Joyce, Jeffrey N.; Presgraves, Steve; Renish, Lynn; Borwege, Sabinne; Osredkar, Tracy; Hagner, Diane; Replogle, Maria; PazSoldan, Mateo; Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">393-407</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The novel naphtoxazine deriv. and preferential D3 vs. D2 receptor agonist, S32504, restores perturbed motor function in rodent and primate models of antiparkinsonian activity with a potency superior to those of two further, preferential D3 receptor agonists, pramipexole and ropinirole.  However, potential neuroprotective properties of S32054 have not, to date, been evaluated.  Herein, employing several measures of cellular integrity, we demonstrate that S32504 robustly, concn.-dependently and completely protects terminally differentiated SH-SY5Y cells against 1-methyl-4-phenylpyridinium (MPP+)-induced cell death in vitro.  Further, S32504 was substantially more potent than pramipexole and ropinirole, the latter of which was neurotoxic at high concns.  In vivo, subchronic treatment with low (0.25 mg/kg) and high (2.5 mg/kg) doses of S32504 prior to and during treatment of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP, provided complete protection against MPTP-induced tyrosine hydroxylase immunoreactive (TH-IR) neuronal death in the substantia nigra pars compacta and ventral tegmental area.  A high dose of ropinirole (2.5 mg/kg) provided some protection but statistical significance was not attained, and a low dose (0.25 mg/kg) was ineffective.  Neither drug afforded protection against the MPTP-induced loss of DA fibers in the striatum, as measured by TH-IR and dopamine transporter immunoreactive fiber counts.  In conclusion, the novel naphotoxazine and dopaminergic agonist, S32504, robustly protects dopaminergic neurons against the neurotoxic effects of MPP+ and MPTP in in vitro and in vivo models, resp.  The underlying mechanisms and therapeutic pertinence of these actions will be of interest to further evaluate in view of its potent actions in behavioral models of antiparkinson activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDej4-H1TCE7Vg90H21EOLACvtfcHk0lgNlX3H8i-WUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVekt7w%253D&md5=b63b7542a3897800ae31c602d6bb5eb0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0014-4886%2803%2900353-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4886%252803%252900353-4%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26aulast%3DPresgraves%26aufirst%3DS.%26aulast%3DRenish%26aufirst%3DL.%26aulast%3DBorwege%26aufirst%3DS.%26aulast%3DOsredkar%26aufirst%3DT.%26aulast%3DHagner%26aufirst%3DD.%26aulast%3DReplogle%26aufirst%3DM.%26aulast%3DPazSoldan%26aufirst%3DM.%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DNeuroprotective%2520effects%2520of%2520the%2520novel%2520D3%252FD2%2520receptor%2520agonist%2520and%2520antiparkinson%2520agent%252C%2520S32504%252C%2520in%2520vitro%2520against%25201-methyl-4-phenylpyridinium%2520%2528MPP%252B%2529%2520and%2520in%2520vivo%2520against%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine%2520%2528MPTP%2529%253A%2520a%2520comparison%2520to%2520ropinirole%26jtitle%3DExp.%2520Neurol.%26date%3D2003%26volume%3D184%26spage%3D393%26epage%3D407%26doi%3D10.1016%2FS0014-4886%2803%2900353-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osredkar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reploge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakakibara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span> <span> </span><span class="NLM_article-title">Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2004.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.expneurol.2004.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=15081599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVCht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2004&pages=178-189&author=J.+N.+Joyceauthor=T.+C.+Derauthor=L.+Renishauthor=T.+Osredkarauthor=D.+Hagnerauthor=M.+Replogeauthor=S.+Sakakibaraauthor=S.+Ueda&title=Loss+of+D3+receptors+in+the+zitter+mutant+rat+is+not+reversed+by+L-dopa+treatment&doi=10.1016%2Fj.expneurol.2004.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment</span></div><div class="casAuthors">Joyce, Jeffrey N.; Der, T. C.; Renish, Lynn; Osredkar, Tracy; Hagner, Diane; Reploge, Maria; Sakakibara, Shinichi; Ueda, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">In Parkinson's disease (PD) and animal models of parkinsonism the destruction of nigrostriatal (NSB) system results in a marked loss of the dopamine D3 receptor and mRNA in the islands of Calleja (ICj) and the nucleus accumbens shell (NAS).  In animal models, it has been reported that both measures are elevated by repeated intermittent administration of L-dopa.  However, a large proportion of PD cases are resistant to l-dopa-induced elevation of D3 receptor no.  The zitter mutant (Zi/Zi) rat replicates the slow progressive degeneration of the NSB obsd. in PD and also exhibits a loss of D3 receptor no. in the NAS or ICj.  To test if this could be reversed with subchronic L-dopa treatment, injections of carbidopa (10 mg/kg i.p.) were followed an hour later with injection of L-dopa (100 mg/kg i.p.) twice a day for 10 days.  In control Sprague-Dawley (SD) and zitter heterozygote (Zi/-) rats that do not show a loss of D3 receptors with vehicle treatment, l-dopa produced no change in D3 receptor no. or in DA terminal d. as measured by dopamine transporter (DAT) binding and tyrosine hydroxylase immunoautoradiog. (TH-IR).  There was a marked loss of DAT and TH-IR in caudate-putamen (CPu) and NA, as well as D3 receptors in NAS and ICj in Zi/Zi rats but no further change with L-dopa treatment.  To det. if the resistance to L-dopa-induced increase in D3 receptor was due to a deficiency in expression of cortical BDNF or its receptor, TrkB, in CPu and NAS, we examd. BDNF mRNA by ISHH in frontal cortex and TrkB mRNA in frontal cortex, CPu, and NA.  The loss of the NSB in the Zi/Zi did not alter levels of BDNF or TrkB mRNA, nor did L-dopa administration alter levels BDNF or TrkB mRNA.  Thus, unlike in 6-hydroxydopamine-treated rats, in Zi/Zi rats administered L-dopa does not reverse the loss of BDNF mRNA or lead to an elevation of D3 receptor no.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNXHY6AxSivbVg90H21EOLACvtfcHk0ljyOYu2YqzX9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVCht7k%253D&md5=39ec32bf5bc734e05f8afd45f6d5337d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2004.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2004.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26aulast%3DDer%26aufirst%3DT.%2BC.%26aulast%3DRenish%26aufirst%3DL.%26aulast%3DOsredkar%26aufirst%3DT.%26aulast%3DHagner%26aufirst%3DD.%26aulast%3DReploge%26aufirst%3DM.%26aulast%3DSakakibara%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DS.%26atitle%3DLoss%2520of%2520D3%2520receptors%2520in%2520the%2520zitter%2520mutant%2520rat%2520is%2520not%2520reversed%2520by%2520L-dopa%2520treatment%26jtitle%3DExp.%2520Neurol.%26date%3D2004%26volume%3D187%26spage%3D178%26epage%3D189%26doi%3D10.1016%2Fj.expneurol.2004.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, W.</span></span> <span> </span><span class="NLM_article-title">Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson’s disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">2513</span>– <span class="NLM_lpage">2523</span>, <span class="refDoi"> DOI: 10.1002/jnr.22405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fjnr.22405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=20623619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1GmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2010&pages=2513-2523&author=C.+Liauthor=S.+Biswasauthor=X.+Liauthor=A.+K.+Duttaauthor=W.+Le&title=Novel+D3+dopamine+receptor-preferring+agonist+D-264%3A+evidence+of+neuroprotective+property+in+Parkinson%E2%80%99s+disease+animal+models+induced+by+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine+and+lactacystin&doi=10.1002%2Fjnr.22405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin</span></div><div class="casAuthors">Li, Chao; Biswas, S.; Li, Xingang; Dutta, A. K.; Le, Weidong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2513-2523</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD), a progressive neurodegenerative movement disorder, is known to be caused by diverse pathol. conditions resulting from dysfunction of the ubiquitin-proteasome system (UPS), mitochondria, and oxidative stress leading to preferential nigral dopamine (DA) neuron degeneration in the substantia nigra.  In the present study, we evaluated the novel D3 receptor-preferring agonist D-264 in a mouse model of PD to evaluate its neuroprotective properties against both the nigrostriatal dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and the proteasome inhibitor lactacystin-induced dopaminergic degeneration.  C57BL/6 male mice either were given MPTP by i.p. injection twice per day for 2 successive days at a dose 20 mg/kg or were microinjected with lactacystin bilaterally (1.25 μg/side) into the medial forebrain bundle (MFB).  Pretreatment with D-264 (1 mg/kg and 5 mg/kg, i.p., once per day), started 7 days before administration of MPTP or lactacystin.  We found that D-264 significantly improved behavioral performance, attenuated both MPTP- and lactacystin-induced DA neuron loss, and blocked proteasomal inhibition and microglial activation in the substantia nigra (SN).  Furthermore, D-264 treatment was shown to increase the levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived factor (GDNF) in MPTP- and lactacystin-treated mice, possibly indicating, at least in part, the mechanism of neuroprotection by D-264.  Furthermore, pretreatment with the D3 receptor antagonist U99194 significantly altered the effect of neuroprotection conferred by D-264.  Collectively, our study demonstrates that D-264 can prevent neurodegeneration induced by the selective neurotoxin MPTP and the UPS inhibitor lactacystin.  The results indicate that D-264 could potentially serve as a symptomatic and neuroprotective treatment agent for PD. © 2010 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5cBGfbUSM67Vg90H21EOLACvtfcHk0ljyOYu2YqzX9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1GmtLY%253D&md5=32d866170d2ac26eafa98608393881c1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fjnr.22405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.22405%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DLe%26aufirst%3DW.%26atitle%3DNovel%2520D3%2520dopamine%2520receptor-preferring%2520agonist%2520D-264%253A%2520evidence%2520of%2520neuroprotective%2520property%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520animal%2520models%2520induced%2520by%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine%2520and%2520lactacystin%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2010%26volume%3D88%26spage%3D2513%26epage%3D2523%26doi%3D10.1002%2Fjnr.22405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolsey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borwege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagner, D.</span></span> <span> </span><span class="NLM_article-title">Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson’s disease, and downregulates the dopamine transporter via the D3 receptor</span>. <i>BMC Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1186/1741-7007-2-22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1186%2F1741-7007-2-22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=15473914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BD2M7lsVKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=22&author=J.+N.+Joyceauthor=C.+Woolseyauthor=H.+Ryooauthor=S.+Borwegeauthor=D.+Hagner&title=Low+dose+pramipexole+is+neuroprotective+in+the+MPTP+mouse+model+of+Parkinson%E2%80%99s+disease%2C+and+downregulates+the+dopamine+transporter+via+the+D3+receptor&doi=10.1186%2F1741-7007-2-22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor</span></div><div class="casAuthors">Joyce Jeffrey N; Woolsey Cheryl; Ryoo Han; Borwege Sabine; Hagner Diane</div><div class="citationInfo"><span class="NLM_cas:title">BMC biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Our aim was to determine if pramipexole, a D3 preferring agonist, effectively reduced dopamine neuron and fiber loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model when given at intraperitoneal doses corresponding to clinical doses.  We also determined whether subchronic treatment with pramipexole regulates dopamine transporter function, thereby reducing intracellular transport of the active metabolite of MPTP, 1-methyl-4-phenylpyridinium (MPP+).  METHODS:  Ten 12-month old C57BL/6 mice were treated with MPTP (or saline) twice per day at 20 mg/kg s.c. (4 injections over 48 h).  Mice were pretreated for 3 days and during the 2-day MPTP regimen with pramipexole (0.1 mg/kg/day) or saline.  Stereological quantification of dopamine neuron number and optical density measurement of dopamine fiber loss were carried out at 1 week after treatment, using immunostaining for dopamine transporter (DAT) and tyrosine hydroxylase (TH).  Additional wild-type (WT) and D3 receptor knockout (KO) mice were treated for 5 days with pramipexole (0.1 mg/kg/day) or vehicle.  The kinetics of [3H]MPP+ and [3H]DA uptake (Vmax and Km) were determined 24 h later; and at 24 h and 14 days dopamine transporter density was measured by quantitative autoradiography.  RESULTS:  Pramipexole treatment completely antagonized the neurotoxic effects of MPTP, as measured by substantia nigra and ventral tegmental area TH-immunoreactive cell counts.  MPTP- induced loss of striatal innervation, as measured by DAT-immunoreactivity, was partially prevented by pramipexole, but not with regard to TH-IR.  Pramipexole also reduced DAT- immunoreactivity in non-MPTP treated mice.  Subchronic treatment with pramipexole lowered the Vmax for [3H]DA and [3H]MPP+ uptake into striatal synaptosomes of WT mice.  Pramipexole treatment lowered Vmax in WT but not D3 KO mice; however, D3 KO mice had lower Vmax for [3H]DA uptake.  There was no change in DAT number in WT with pramipexole treatment or D3 KO mice at 24 h post-treatment, but there was a reduction in WT-pramipexole treated and not in D3 KO mice at 14 days post-treatment.  CONCLUSION:  These results suggest that protection occurs at clinically suitable doses of pramipexole.  Protection could be due to a reduced amount of MPP+ taken up into DA terminals via DAT.  D3 receptor plays an important role in this regulation of transporter uptake and availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTvj5p-QMRX8SzjBFCN0BJfW6udTcc2ebediu1guqtw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7lsVKitw%253D%253D&md5=a046e050141ec6fa787105912c3433d6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2F1741-7007-2-22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7007-2-22%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DJ.%2BN.%26aulast%3DWoolsey%26aufirst%3DC.%26aulast%3DRyoo%26aufirst%3DH.%26aulast%3DBorwege%26aufirst%3DS.%26aulast%3DHagner%26aufirst%3DD.%26atitle%3DLow%2520dose%2520pramipexole%2520is%2520neuroprotective%2520in%2520the%2520MPTP%2520mouse%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%252C%2520and%2520downregulates%2520the%2520dopamine%2520transporter%2520via%2520the%2520D3%2520receptor%26jtitle%3DBMC%2520Biol.%26date%3D2004%26volume%3D2%26spage%3D22%26doi%3D10.1186%2F1741-7007-2-22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iravani, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddon, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, A. H.</span></span> <span> </span><span class="NLM_article-title">Pramipexole protects against MPTP toxicity in non-human primates</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2005.03625.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fj.1471-4159.2005.03625.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=16464239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD28XivFSrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2006&pages=1315-1321&author=M.+M.+Iravaniauthor=C.+O.+Haddonauthor=J.+M.+Cooperauthor=P.+Jennerauthor=A.+H.+Schapira&title=Pramipexole+protects+against+MPTP+toxicity+in+non-human+primates&doi=10.1111%2Fj.1471-4159.2005.03625.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole protects against MPTP toxicity in non-human primates</span></div><div class="casAuthors">Iravani, Mahmoud M.; Haddon, Claire O.; Cooper, J. Mark; Jenner, Peter; Schapira, Anthony H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1315-1321</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The neurotoxin MPTP induces nigral dopaminergic cell death in primates and produces a partial model of Parkinson's disease (PD).  Pramipexole is a D2/D3 dopamine receptor agonist used in the symptomatic treatment of PD, and which also protects neuronal cells against dopaminergic toxins in vitro.  We now demonstrate that pramipexole partially prevents MPTP toxicity in vivo in a primate species.  Common marmosets were repeatedly treated with pramipexole either before, coincidentally with, or after low-dose MPTP treatment designed to induce a partial lesion of the substantia nigra.  Animals pretreated with pramipexole had a significantly greater no. of surviving tyrosine hydroxylase (TH) pos. neurons in the pars compacta of the substantia nigra.  Pramipexole pretreatment also prevented degeneration of striatal dopamine terminals.  Treatment with pramipexole concurrently with MPTP or following MPTP did not prevent TH-pos. cell loss.  Pramipexole pretreatment appears to induce adaptive changes that protect against dopaminergic cell loss in primates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuDu72oalI4LVg90H21EOLACvtfcHk0ljiu7V8c2lUsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivFSrur0%253D&md5=3b068af73bbcfd395b34387960fdff12</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2005.03625.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2005.03625.x%26sid%3Dliteratum%253Aachs%26aulast%3DIravani%26aufirst%3DM.%2BM.%26aulast%3DHaddon%26aufirst%3DC.%2BO.%26aulast%3DCooper%26aufirst%3DJ.%2BM.%26aulast%3DJenner%26aufirst%3DP.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%26atitle%3DPramipexole%2520protects%2520against%2520MPTP%2520toxicity%2520in%2520non-human%2520primates%26jtitle%3DJ.%2520Neurochem.%26date%3D2006%26volume%3D96%26spage%3D1315%26epage%3D1321%26doi%3D10.1111%2Fj.1471-4159.2005.03625.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vu, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robie, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvey, P. M.</span></span> <span> </span><span class="NLM_article-title">Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine</span>. <i>J. Neural Transm.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1007/s007020050014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs007020050014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10847557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFeqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2000&pages=159-176&author=T.+Q.+Vuauthor=Z.+D.+Lingauthor=S.+Y.+Maauthor=H.+C.+Robieauthor=C.+W.+Tongauthor=E.+Y.+Chenauthor=J.+W.+Liptonauthor=P.+M.+Carvey&title=Pramipexole+attenuates+the+dopaminergic+cell+loss+induced+by+intraventricular+6-hydroxydopamine&doi=10.1007%2Fs007020050014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine</span></div><div class="casAuthors">Vu, T. Q.; Ling, Z. D.; Ma, S. Y.; Robie, H. C.; Tong, C. W.; Chen, E. Y.; Lipton, J. W.; Carvey, P. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-176</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">1435-1463</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Wien</span>)
        </div><div class="casAbstract">The D3 preferring dopamine agonist pramipexole has been shown to attenuate the cell loss induced by levodopa in vitro.  Pramipexole was herein evaluated in the 6-hydroxydopamine lesion model to det. its in vivo effect.  Rats were treated with pramipexole or saline before and after an intracerebroventricular 6-hydroxydopamine injection.  In the preliminary study, 6-hydroxydopamine produced a 68% redn. in striatal dopamine and a 62% loss in tyrosine hydroxylase immunoreactive (THir) cell counts in the substantia nigra.  Pramipexole treated animals exhibited a 29% and a 27% redn. in striatal dopamine and THir cell counts, resp.  THir cell counts and striatal dopamine were significantly correlated.  In the stereol. study, 6-hydroxydopamine reduced THir cell counts by 47% in saline treated animals and 26% in pramipexole treated animals.  These data demonstrate that pramipexole attenuates the biochem. and THir cell changes normally produced by 6-hydroxydopamine consistent with its neuroprotective actions in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyiX_1PSvUNbVg90H21EOLACvtfcHk0lh59qc0y56gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFeqtLw%253D&md5=482f372bb740d3fe2e8d8016a4584bdc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs007020050014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs007020050014%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DT.%2BQ.%26aulast%3DLing%26aufirst%3DZ.%2BD.%26aulast%3DMa%26aufirst%3DS.%2BY.%26aulast%3DRobie%26aufirst%3DH.%2BC.%26aulast%3DTong%26aufirst%3DC.%2BW.%26aulast%3DChen%26aufirst%3DE.%2BY.%26aulast%3DLipton%26aufirst%3DJ.%2BW.%26aulast%3DCarvey%26aufirst%3DP.%2BM.%26atitle%3DPramipexole%2520attenuates%2520the%2520dopaminergic%2520cell%2520loss%2520induced%2520by%2520intraventricular%25206-hydroxydopamine%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2000%26volume%3D107%26spage%3D159%26epage%3D176%26doi%3D10.1007%2Fs007020050014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menniti, F. S.</span></span> <span> </span><span class="NLM_article-title">Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>475</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(03)02087-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FS0014-2999%2803%2902087-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=12954356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFSjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=475&publication_year=2003&pages=29-35&author=A.+D.+Ramirezauthor=S.+K.+Wongauthor=F.+S.+Menniti&title=Pramipexole+inhibits+MPTP+toxicity+in+mice+by+dopamine+D3+receptor+dependent+and+independent+mechanisms&doi=10.1016%2FS0014-2999%2803%2902087-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms</span></div><div class="casAuthors">Ramirez, Andres D.; Wong, Stephen K.-F.; Menniti, Frank S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">475</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The role of dopamine D3 receptors was investigated in mediating the neuroprotective effect of the dopamine D2/D3 receptor agonist (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminebenzothiazole (pramipexole) in vivo.  Pramipexole retained the ability to inhibit 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopamine depletion in mice in which the dopamine D3 receptor had been deleted.  However, the neuroprotective efficacy was reduced in the dopamine D3 receptor-deleted mice compared to that in littermates expressing the wildtype receptor.  Furthermore, the dopamine D3 receptor selective antagonist 2-{3-[4-(2-tert-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol (A-437203) partially inhibited the neuroprotective effect of pramipexole in dopamine D3 receptor expressing mice but not in receptor-deleted mice.  These results indicate that pramipexole protects dopamine neurons from MPTP-induced toxicity by mechanisms that are both dependent and independent of an interaction with dopamine D3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow_ATcma1GUbVg90H21EOLACvtfcHk0lh59qc0y56gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFSjs7g%253D&md5=2c52641e3d4b7a8abdb1b56092704c9d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2902087-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252902087-9%26sid%3Dliteratum%253Aachs%26aulast%3DRamirez%26aufirst%3DA.%2BD.%26aulast%3DWong%26aufirst%3DS.%2BK.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26atitle%3DPramipexole%2520inhibits%2520MPTP%2520toxicity%2520in%2520mice%2520by%2520dopamine%2520D3%2520receptor%2520dependent%2520and%2520independent%2520mechanisms%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D475%26spage%3D29%26epage%3D35%26doi%3D10.1016%2FS0014-2999%2803%2902087-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lao, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. C.</span></span> <span> </span><span class="NLM_article-title">Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice</span>. <i>Neurotoxic. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1007/s12640-013-9408-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs12640-013-9408-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=23820985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKqsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=523-531&author=C.+L.+Laoauthor=Y.+H.+Kuoauthor=Y.+T.+Hsiehauthor=J.+C.+Chen&title=Intranasal+and+subcutaneous+administration+of+dopamine+D3+receptor+agonists+functionally+restores+nigrostriatal+dopamine+in+MPTP-treated+mice&doi=10.1007%2Fs12640-013-9408-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Intranasal and Subcutaneous Administration of Dopamine D3 Receptor Agonists Functionally Restores Nigrostriatal Dopamine in MPTP-Treated Mice</span></div><div class="casAuthors">Lao, Chu Lan; Kuo, Yen-Hsi; Hsieh, Yueh-Ting; Chen, Jin-Chung</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-531</span>CODEN:
                <span class="NLM_cas:coden">NURRFI</span>;
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a neurodegenerative disease with a hallmark motor defect caused by the death of dopaminergic neurons in the substantia nigra.  Intranasal drug administration may be useful for Parkinson's treatment because this route avoids first-pass metab. and increases bioavailability in the brain.  In this study, we investigated the neuroprotection/neurorestoration effect of dopamine D3 receptor (D3R) agonists administered via both intranasal and s.c. routes in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced PD mouse model.  Furthermore, we employed D3R knock-out mice to validate the dependence on D3R signaling.  We found that in wild-type mice, but not D3 receptor knockout mice, both intranasal and s.c. administration of D3R agonists rescue dopamine (DA) depletion in the striatum as well as DA neuronal death in the substantia nigra after MPTP treatment.  Moreover, s.c. 7-OH-DPAT administration significantly improved gait performance (stride length and overall running speed) of MPTP-lesioned mice after 7 and 14 days of recovery.  In addn., the distribution of D3 agonist 7-OH-DPAT was measured in designated brain areas by mass spectrometry anal. after s.c. and intranasal administration.  Our data suggest that intranasal administration of D3R agonist would be a practical approach to treat PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBAxJ7TfReC7Vg90H21EOLACvtfcHk0lgubTh856kOLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKqsLbP&md5=345a2be3df95964dc94fbb289b33f369</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs12640-013-9408-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12640-013-9408-1%26sid%3Dliteratum%253Aachs%26aulast%3DLao%26aufirst%3DC.%2BL.%26aulast%3DKuo%26aufirst%3DY.%2BH.%26aulast%3DHsieh%26aufirst%3DY.%2BT.%26aulast%3DChen%26aufirst%3DJ.%2BC.%26atitle%3DIntranasal%2520and%2520subcutaneous%2520administration%2520of%2520dopamine%2520D3%2520receptor%2520agonists%2520functionally%2520restores%2520nigrostriatal%2520dopamine%2520in%2520MPTP-treated%2520mice%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2013%26volume%3D24%26spage%3D523%26epage%3D531%26doi%3D10.1007%2Fs12640-013-9408-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weintraub, D.</span></span> <span> </span><span class="NLM_article-title">Dopamine and impulse control disorders in Parkinson’s disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">S93</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1002/ana.21454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fana.21454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=19127573" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=S93-100&author=D.+Weintraub&title=Dopamine+and+impulse+control+disorders+in+Parkinson%E2%80%99s+disease&doi=10.1002%2Fana.21454"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fana.21454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.21454%26sid%3Dliteratum%253Aachs%26aulast%3DWeintraub%26aufirst%3DD.%26atitle%3DDopamine%2520and%2520impulse%2520control%2520disorders%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2008%26volume%3D64%26spage%3DS93%26epage%3D100%26doi%3D10.1002%2Fana.21454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balarajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanna, A. E.</span></span> <span> </span><span class="NLM_article-title">The pathophysiology of impulse control disorders in Parkinson disease</span>. <i>Behav. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1155/2013/579092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1155%2F2013%2F579092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22713408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BC38jjtFejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=237-244&author=S.+Balarajahauthor=A.+E.+Cavanna&title=The+pathophysiology+of+impulse+control+disorders+in+Parkinson+disease&doi=10.1155%2F2013%2F579092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The pathophysiology of impulse control disorders in Parkinson disease</span></div><div class="casAuthors">Balarajah Sharmili; Cavanna Andrea Eugenio</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">237-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  This review aims to evaluate the most recent evidence on the pathophysiology of impulse control disorders (ICDs) in Parkinson disease (PD).  METHODS:  Computerised searches of Medline, Embase and PsycInfo, along with manual searches for grey literature, were conducted and resulted in a total of 16 studies suitable for review.  RESULTS:  Evidence was divided into four categories: medication used in PD management, imaging studies, genetic analysis and subthalamic deep brain stimulation (STN-DBS).  Analysis of the literature reveals that both intrinsic and extrinsic factors may play a role in the pathophysiology of ICDs in PD.  Dysfunction of the mesocorticolimbic pathway and polymorphisms of the dopamine D3 and D4 receptors may increase an individual's susceptibility to the development of ICDs.  DISCUSSION:  Dopaminergic medication, particularly dopamine agonists (DAs), increases the risk of developing impulsive behaviours in a PD patient.  Further evidence, particularly in the form of prospective studies and randomised controlled trials is required to better establish the pathophysiology of ICDs in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTexXVCbB7JbrqxQ2mb9Pu8fW6udTcc2eZ_Mhj6sA8H1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jjtFejsQ%253D%253D&md5=84e4e207c021c8bd8c2c44cf7a9af3bb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1155%2F2013%2F579092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F579092%26sid%3Dliteratum%253Aachs%26aulast%3DBalarajah%26aufirst%3DS.%26aulast%3DCavanna%26aufirst%3DA.%2BE.%26atitle%3DThe%2520pathophysiology%2520of%2520impulse%2520control%2520disorders%2520in%2520Parkinson%2520disease%26jtitle%3DBehav.%2520Neurol.%26date%3D2013%26volume%3D26%26spage%3D237%26epage%3D244%26doi%3D10.1155%2F2013%2F579092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaylock, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span> <span> </span><span class="NLM_article-title">Medication discovery for addiction: translating the dopamine D3 receptor hypothesis</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">882</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2012.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bcp.2012.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22781742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOqu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=882-890&author=A.+H.+Newmanauthor=B.+L.+Blaylockauthor=M.+A.+Naderauthor=J.+Bergmanauthor=D.+R.+Sibleyauthor=P.+Skolnick&title=Medication+discovery+for+addiction%3A+translating+the+dopamine+D3+receptor+hypothesis&doi=10.1016%2Fj.bcp.2012.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis</span></div><div class="casAuthors">Newman, Amy Hauck; Blaylock, Brandi L.; Nader, Michael A.; Bergman, Jack; Sibley, David R.; Skolnick, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">882-890</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor (D3R) has been investigated as a potential target for medication development to treat substance use disorders (SUDs) with a particular focus on cocaine and methamphetamine.  Currently, there are no approved medications to treat cocaine and methamphetamine addiction and thus developing pharmacotherapeutics to complement existing behavioral strategies is a fundamental goal.  Novel compds. with high affinity and D3R selectivity have been evaluated in numerous animal models of drug abuse and favorable outcomes in nonhuman primate models of self-administration and relapse have provided compelling evidence to advance these agents into the clinic.  One approach is to repurpose drugs that share the D3R mechanism and already have clin. utility, and to this end buspirone has been identified as a viable candidate for clin. trials.  A second, but substantially more resource intensive and risky approach involves the development of compds. that exclusively target D3R, such as GSK598809 and PG 619.  Clin. investigation of these drugs or other novel D3R-selective agents will provide a better understanding of the role D3R plays in addiction and whether or not antagonists or partial agonists that are D3R selective are effective in achieving abstinence in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_waGudfGt4LVg90H21EOLACvtfcHk0lhKENDlWm1Ohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOqu73O&md5=820f1ddd46c9888c687bc0cc8cd3aa96</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBlaylock%26aufirst%3DB.%2BL.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DSkolnick%26aufirst%3DP.%26atitle%3DMedication%2520discovery%2520for%2520addiction%253A%2520translating%2520the%2520dopamine%2520D3%2520receptor%2520hypothesis%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D882%26epage%3D890%26doi%3D10.1016%2Fj.bcp.2012.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3 agonists in the treatment of Parkinson’s disease</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.2174/156802661510150328223428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.2174%2F156802661510150328223428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25832718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=908-926&author=B.+Dasauthor=G.+Modiauthor=A.+Dutta&title=Dopamine+D3+agonists+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.2174%2F156802661510150328223428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3 Agonists in the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Das, Banibrata; Modi, Gyan; Dutta, Aloke</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">908-926</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is t he second most common form of neurodegenerative disorders that results from the progressive loss of dopaminergic neurons in the midbrain substantia nigra pars compacta (SNpc) triggering profound motor perturbation, as well as cognitive, sensory and mood deficits.  Although these symptoms can be improved using currently available dopamine replacement strategies, they are not able to slow the neurodegenerative process that underlies PD progression.  Following the discovery of the D3 receptor from mol. cloning, it has gained much attention as a potential therapeutic target for the treatment of PD due to their localization in the limbic regions of the brain as well as pharmacol. similarity to the D2 receptor subtype.  Of particular interest, D3 receptor- selective agonists appear to have neuroprotective effects apart from their ability to relieve PD symptoms.  Owing to the distinct significance of D3 receptor in mediating diverse neurol. effects, it represents a unique target for therapeutic intervention in PD with much less undesirable side effects.  Herein, we review progress in the development of D3 receptor selective agonist mols. having a broad spectrum of affinities, selectivities as well as unique pharmacol. properties directed at slowing the neurodegeneration process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1vO7t50SK9rVg90H21EOLACvtfcHk0lhKENDlWm1Ohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1akt7w%253D&md5=46885592d050d099cbad73ba7ef8e61b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2174%2F156802661510150328223428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661510150328223428%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DDutta%26aufirst%3DA.%26atitle%3DDopamine%2520D3%2520agonists%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D908%26epage%3D926%26doi%3D10.2174%2F156802661510150328223428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design</span>. <i>Adv. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-420118-7.00007-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FB978-0-12-420118-7.00007-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24484980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFCitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=267-300&author=T.+M.+Keckauthor=C.+Burzynskiauthor=L.+Shiauthor=A.+H.+Newman&title=Beyond+small-molecule+SAR%3A+using+the+dopamine+D3+receptor+crystal+structure+to+guide+drug+design&doi=10.1016%2FB978-0-12-420118-7.00007-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design</span></div><div class="casAuthors">Keck, Thomas M.; Burzynski, Caitlin; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Pharmacology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse</span>),
    <span class="NLM_cas:pages">267-300</span>CODEN:
                <span class="NLM_cas:coden">ADPHEL</span>;
        ISSN:<span class="NLM_cas:issn">1054-3589</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The dopamine D3 receptor is a target of pharmacotherapeutic interest in a variety of neurol. disorders including schizophrenia, restless leg syndrome, and drug addiction.  The high protein sequence homol. between the D3 and D2 receptors has posed a challenge to developing D3 receptor-selective ligands whose behavioral actions can be attributed to D3 receptor engagement, in vivo.  However, through primarily small-mol. structure-activity relationship (SAR) studies, a variety of chem. scaffolds have been discovered over the past two decades that have resulted in several D3 receptor-selective ligands with high affinity and in vivo activity.  Nevertheless, viable clin. candidates remain limited.  The recent detn. of the high-resoln. crystal structure of the D3 receptor has invigorated structure-based drug design, providing refinements to the mol. dynamic models and testable predictions about receptor-ligand interactions.  This chapter will highlight recent preclin. and clin. studies demonstrating potential utility of D3 receptor-selective ligands in the treatment of addiction.  In addn., new structure-based rational drug design strategies for D3 receptor-selective ligands that complement traditional small-mol. SAR to improve the selectivity and directed efficacy profiles are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbH7VLMIagF7Vg90H21EOLACvtfcHk0lhKKlCRwsOHeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFCitb8%253D&md5=d266814a068e4528c70e200a860fab64</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-420118-7.00007-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-420118-7.00007-X%26sid%3Dliteratum%253Aachs%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DBeyond%2520small-molecule%2520SAR%253A%2520using%2520the%2520dopamine%2520D3%2520receptor%2520crystal%2520structure%2520to%2520guide%2520drug%2520design%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2014%26volume%3D69%26spage%3D267%26epage%3D300%26doi%3D10.1016%2FB978-0-12-420118-7.00007-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangel-Barajas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Bitropic D3 dopamine receptor selective compounds as potential antipsychotics</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3700</span>– <span class="NLM_lpage">3724</span>, <span class="refDoi"> DOI: 10.2174/1381612821666150724100830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.2174%2F1381612821666150724100830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26205291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFagu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3700-3724&author=R.+R.+Luedtkeauthor=C.+Rangel-Barajasauthor=M.+Malikauthor=D.+E.+Reichertauthor=R.+H.+Mach&title=Bitropic+D3+dopamine+receptor+selective+compounds+as+potential+antipsychotics&doi=10.2174%2F1381612821666150724100830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics</span></div><div class="casAuthors">Luedtke, Robert R.; Rangel-Barajas, Claudia; Malik, Mahinder; Reichert, David E.; Mach, R. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3700-3724</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Neuropsychiatric disorders represent a substantial social and health care issue.  The National Institutes of Health ests. that greater than 2 million adults suffer from neuropsychiatric disorders in the USA.  These individuals experience symptoms that can include auditory hallucinations, delusions, unrealistic beliefs and cognitive dysfunction.  Although antipsychotic medications are available, suboptimal therapeutic responses are obsd. for approx. one-third of patients.  Therefore, there is still a need to explore new pharmacotherapeutic strategies for the treatment of neuropsychiatric disorders.  Many of the medications that are used clin. to treat neuropsychiatric disorders have a pharmacol. profile that includes being an antagonist at D2-like (D2, D3 and D4) dopamine receptor subtypes.  However, dopamine receptor subtypes are involved in a variety of neuronal circuits that include movement coordination, cognition, emotion, affect, memory and the regulation of prolactin.  Consequently, antagonism at D2-like receptors can also contribute to some of the adverse side effects assocd. with the long-term use of antipsychotics including the a) adverse extrapyramidal symptoms assocd. with the use of typical antipsychotics and b) metabolic side effects (wt. gain, hyperglycemia, increased risk of diabetes mellitus, dyslipidemia and gynecomastia) assocd. with atypical antipsychotic use.  Preclin. studies suggest that D3 vs. D2 dopamine receptor selective compds. might represent an alternative strategy for the treatment of the symptoms of schizophrenia.  In this review we discuss a) how bitropic Nphenylpiperazine D3 dopamine receptor selective compds. have been developed by modification of the primary (orthosteric) and secondary (allosteric or modulatory) pharmacophores to optimize D3 receptor affinity and D2/D3 binding selectivity ratios and b) the functional selectivity of these compds.  Examples of how these compds. might be modified to develop bivalent ligands capable of interacting with receptor dimers or oligomers are also provided.  Preclin. studies using bitropic D3 dopamine receptor selective ligands are also discussed as strategy to pharmacol. dissect the role of the D2 and D3 dopamine receptor subtypes in animal models of neuropsychiatric, neurol. and substance abuse disorders.  This research has the potential to a) advance the understanding of the role of the D2 and D3 dopamine receptor subtypes in neuropsychiatric disorders and b) lead to new treatment strategies for neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpDfir_TtCtbVg90H21EOLACvtfcHk0lhKKlCRwsOHeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFagu7bJ&md5=f7e1b836218171fb2f43f417ac2ff784</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1381612821666150724100830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612821666150724100830%26sid%3Dliteratum%253Aachs%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DRangel-Barajas%26aufirst%3DC.%26aulast%3DMalik%26aufirst%3DM.%26aulast%3DReichert%26aufirst%3DD.%2BE.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DBitropic%2520D3%2520dopamine%2520receptor%2520selective%2520compounds%2520as%2520potential%2520antipsychotics%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D3700%26epage%3D3724%26doi%3D10.2174%2F1381612821666150724100830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElveen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1021/jm049465g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049465g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=839-848&author=P.+Grundtauthor=E.+E.+Carlsonauthor=J.+Caoauthor=C.+J.+Bennettauthor=E.+McElveenauthor=M.+Taylorauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=Novel+heterocyclic+trans+olefin+analogues+of+N-%7B4-%5B4-%282%2C3-dichlorophenyl%29piperazin-1-yl%5Dbutyl%7Darylcarboxamides+as+selective+probes+with+high+affinity+for+the+dopamine+D3+receptor&doi=10.1021%2Fjm049465g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor</span></div><div class="casAuthors">Grundt, Peter; Carlson, Erin E.; Cao, Jianjing; Bennett, Christina J.; McElveen, Elizabeth; Taylor, Michelle; Luedtke, Robert R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-848</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine.  However, definitive pharmacol. investigations have been hampered by the lack of highly D3 receptor selective compds. that can be used in vivo.  To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluorene-2-carboxylic acid {4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl}-amide, Ki (hD3) = 2.0 nM, Ki (hD2L) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chem. modification in an attempt to reduce its high lipophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity.  A series of >30 novel analogs were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2L, D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist 125I-IABN.  Structural diversity in the aryl amide end of the mol. was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine.  Several analogs demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand.  Compd. 29 (N-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine-2-yl-benzamide) displayed the most promising pharmacol. profile (Ki (hD3) = 0.7 nM, Ki (hD2L) = 93.3 nM, D2/D3 selectivity ratio of 133).  In addn., this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM.  Compd. 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM).  Moreover, a decrease in c log D value of ∼2 orders of magnitude was detd. for this novel D3-receptor-preferring ligand, compared to 1.  In summary, chem. modification of 1 has resulted in compds. with high affinity and selectivity for D3 receptors.  The most promising candidate, compd. 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofDgtp4SPuC7Vg90H21EOLACvtfcHk0liOJ4ZBL1SI1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFGisA%253D%253D&md5=080af9d0e167912621f35c40020c534b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm049465g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049465g%26sid%3Dliteratum%253Aachs%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DCarlson%26aufirst%3DE.%2BE.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DC.%2BJ.%26aulast%3DMcElveen%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520heterocyclic%2520trans%2520olefin%2520analogues%2520of%2520N-%257B4-%255B4-%25282%252C3-dichlorophenyl%2529piperazin-1-yl%255Dbutyl%257Darylcarboxamides%2520as%2520selective%2520probes%2520with%2520high%2520affinity%2520for%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D839%26epage%3D848%26doi%3D10.1021%2Fjm049465g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D(3) receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4962</span>– <span class="NLM_lpage">4968</span>, <span class="refDoi"> DOI: 10.1021/jm401798r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401798r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOnurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4962-4968&author=J.+Chenauthor=B.+Levantauthor=C.+Jiangauthor=T.+M.+Keckauthor=A.+H.+Newmanauthor=S.+Wang&title=Tranylcypromine+substituted+cis-hydroxycyclobutylnaphthamides+as+potent+and+selective+dopamine+D%283%29+receptor+antagonists&doi=10.1021%2Fjm401798r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists</span></div><div class="casAuthors">Chen, Jianyong; Levant, Beth; Jiang, Cheng; Keck, Thomas M.; Newman, Amy Hauck; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4962-4968</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report a class of potent and selective dopamine D3 receptor antagonists based upon tranylcypromine.  Although tranylcypromine has a low affinity for the rat D3 receptor (Ki = 12.8 μM), our efforts have yielded (1R,2S)-11 (CJ-1882), which has Ki values of 2.7 and 2.8 nM at the rat and human dopamine D3 receptors, resp., and displays resp. selectivities of >10000-fold and 223-fold over the rat and human D2 receptors.  Evaluation in a β-arrestin functional assay showed that (1R,2S)-11 is a potent and competitive antagonist at the human D3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWudWdAfWgLVg90H21EOLACvtfcHk0liOJ4ZBL1SI1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOnurg%253D&md5=e2ddf0711d00103be281cb043b19ec3a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm401798r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401798r%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTranylcypromine%2520substituted%2520cis-hydroxycyclobutylnaphthamides%2520as%2520potent%2520and%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4962%26epage%3D4968%26doi%3D10.1021%2Fjm401798r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Chiral resolution and serendipitous fluorination reaction for the selective dopamine D3 receptor antagonist BAK2-66</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1021/ml500006v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500006v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslamuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=647-651&author=V.+Kumarauthor=A.+K.+Banalaauthor=E.+G.+Garciaauthor=J.+Caoauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=J.+R.+Deschampsauthor=A.+H.+Newman&title=Chiral+resolution+and+serendipitous+fluorination+reaction+for+the+selective+dopamine+D3+receptor+antagonist+BAK2-66&doi=10.1021%2Fml500006v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66</span></div><div class="casAuthors">Kumar, Vivek; Banala, Ashwini K.; Garcia, Erick G.; Cao, Jianjing; Keck, Thomas M.; Bonifazi, Alessandro; Deschamps, Jeffery R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-651</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The improved chiral synthesis of the selective dopamine D3 receptor (D3R) antagonist (R)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)1H-indole-2-carboxamide ((R)-PG648) is described.  The same chiral secondary alc. intermediate was used to prep. the enantiomers of a 3-F-benzofuranyl analog, BAK 2-66 (I).  The abs. configurations of the 3-F enantiomers were assigned from their X-ray crystal structures that confirmed retention of configuration during fluorination with N,N-diethylaminosulfur trifluoride (DAST).  (R)-I showed higher D3R affinity and selectivity than its (S)-enantiomer; however, it had lower D3R affinity and enantioselectivity than (R)-PG648.  Further, importance of the 4-atom linker length between the aryl amide and 4-phenylpiperazine was demonstrated with the 4-fluorobutyl-product (II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTRVSlrPS4ybVg90H21EOLACvtfcHk0ljtUzoxpJoZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslamuro%253D&md5=17ddfb3b45b6630f53c917281d76b620</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml500006v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500006v%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DGarcia%26aufirst%3DE.%2BG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DChiral%2520resolution%2520and%2520serendipitous%2520fluorination%2520reaction%2520for%2520the%2520selective%2520dopamine%2520D3%2520receptor%2520antagonist%2520BAK2-66%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D647%26epage%3D651%26doi%3D10.1021%2Fml500006v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">High affinity dopamine D3 receptor (D3R)-selective antagonists attenuate heroin self-administration in wild-type but not D3R knockout mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6213</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00776</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00776" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1alur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6195-6213&author=C.+A.+Boatengauthor=O.+M.+Bakareauthor=J.+Zhanauthor=A.+K.+Banalaauthor=C.+Burzynskiauthor=E.+Pommierauthor=T.+M.+Keckauthor=P.+Donthamsettiauthor=J.+A.+Javitchauthor=R.+Raisauthor=B.+S.+Slusherauthor=Z.+X.+Xiauthor=A.+H.+Newman&title=High+affinity+dopamine+D3+receptor+%28D3R%29-selective+antagonists+attenuate+heroin+self-administration+in+wild-type+but+not+D3R+knockout+mice&doi=10.1021%2Facs.jmedchem.5b00776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice</span></div><div class="casAuthors">Boateng, Comfort A.; Bakare, Oluyomi M.; Zhan, Jia; Banala, Ashwini K.; Burzynski, Caitlin; Pommier, Elie; Keck, Thomas M.; Donthamsetti, Prashant; Javitch, Jonathan A.; Rais, Rana; Slusher, Barbara S.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6195-6213</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders.  Several D3R-selective antagonists are effective in animal models of drug abuse, esp. in models of relapse.  Nevertheless, poor bioavailability, metabolic instability, and/or predicted toxicity have impeded success in translating these drug candidates to clin. use.  Herein, the authors report a series of D3R-selective 4-phenylpiperazines with improved metabolic stability.  A subset of these compds. was evaluated for D3R functional efficacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR with D3R has been obsd.  Several high affinity D3R antagonists, including compds. I (Ki = 0.12 nM) and II (Ki = 0.35 nM), showed improved metabolic stability compared to the parent compd., PG648.  Notably, I and the classic D3R antagonist SB277011A were effective in reducing self-administration of heroin in wild-type but not D3R knockout mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagzWQU_gPV7Vg90H21EOLACvtfcHk0ljtUzoxpJoZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1alur%252FK&md5=1724065cac8ac51295cf4660a20ed734</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00776%26sid%3Dliteratum%253Aachs%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DZhan%26aufirst%3DJ.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHigh%2520affinity%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529-selective%2520antagonists%2520attenuate%2520heroin%2520self-administration%2520in%2520wild-type%2520but%2520not%2520D3R%2520knockout%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6195%26epage%3D6213%26doi%3D10.1021%2Facs.jmedchem.5b00776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Highly selective dopamine D3 receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7650</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00860</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00860" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7634-7650&author=V.+Kumarauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=E.+Pommierauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+Gardnerauthor=Z.+B.+Youauthor=Z.+X.+Xiauthor=A.+H.+Newman&title=Highly+selective+dopamine+D3+receptor+%28D3R%29+antagonists+and+partial+agonists+based+on+eticlopride+and+the+D3R+crystal+structure%3A+new+leads+for+opioid+dependence+treatment&doi=10.1021%2Facs.jmedchem.6b00860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment</span></div><div class="casAuthors">Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Pommier, Elie; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot; You, Zhi-Bing; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7634-7650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention.  Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clin. use for cocaine abuse.  Herein, the authors report a series of novel and D3R crystal structure-guided 4-phenylpiperazines with exceptionally high D3R affinities and/or selectivities with varying efficacies.  Lead compd. I was selected based on its in vitro profile: D3R Ki = 6.84 nM, 1700-fold D3R vs. D2R binding selectivity, and its metabolic stability in mouse microsomes.  Compd. I inhibited oxycodone-induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization.  In addn., pretreatment with I also dose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in rats.  These findings support the D3R as a target for opioid dependence treatment and compd. I as a new lead mol. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyb_lyL223q7Vg90H21EOLACvtfcHk0lgC5cLaP1fgTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSltbrN&md5=c352556630974f4205a8684b4fd29226</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00860%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DPommier%26aufirst%3DE.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%26aulast%3DYou%26aufirst%3DZ.%2BB.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DHighly%2520selective%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%2520antagonists%2520and%2520partial%2520agonists%2520based%2520on%2520eticlopride%2520and%2520the%2520D3R%2520crystal%2520structure%253A%2520new%2520leads%2520for%2520opioid%2520dependence%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7634%26epage%3D7650%26doi%3D10.1021%2Facs.jmedchem.6b00860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Investigation of novel primary and secondary pharmacophores and 3-substitution in the linking chain of a series of highly selective and bitopic dopamine D3 receptor antagonists and partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9061</span>– <span class="NLM_lpage">9077</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00607</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00607" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVShtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9061-9077&author=A.+B.+Shaikauthor=V.+Kumarauthor=A.+Bonifaziauthor=A.+M.+Guerreroauthor=S.+L.+Cemajauthor=A.+Gadianoauthor=J.+Lamauthor=Z.+X.+Xiauthor=R.+Raisauthor=B.+S.+Slusherauthor=A.+H.+Newman&title=Investigation+of+novel+primary+and+secondary+pharmacophores+and+3-substitution+in+the+linking+chain+of+a+series+of+highly+selective+and+bitopic+dopamine+D3+receptor+antagonists+and+partial+agonists&doi=10.1021%2Facs.jmedchem.9b00607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D3 Receptor Antagonists and Partial Agonists</span></div><div class="casAuthors">Shaik, Anver Basha; Kumar, Vivek; Bonifazi, Alessandro; Guerrero, Adrian M.; Cemaj, Sophie L.; Gadiano, Alexandra; Lam, Jenny; Xi, Zheng-Xiong; Rais, Rana; Slusher, Barbara S.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9061-9077</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dopamine D3 receptors (D3R) play a crit. role in neuropsychiatric conditions including substance use disorders (SUD).  Recently, we reported a series of N-(3-hydroxy-4-(4-phenylpiperazin-1-yl)butyl)-1H-indole-2-carboxamide analogs as high affinity and selective D3R lead mols. for the treatment of opioid use disorders (OUD).  Further optimization led to a series of analogs that replaced the 3-OH with a 3-F in the linker between the primary pharmacophore (PP) and secondary pharmacophore (SP).  Among the 3-F-compds., 9b demonstrated the highest D3R binding affinity (Ki = 0.756 nM) and was 327-fold selective for D3R over D2R.  In addn., modification of the PP or SP with a 3,4-(methylenedioxy)phenyl group was also examd.  Further, an enantioselective synthesis as well as chiral HPLC methods were developed to give enantiopure R- and S-enantiomers of the four lead compds.  Off-target binding affinities, functional efficacies, and metabolic profiles revealed crit. structural components for D3R selectivity as well as drug-like features required for development as pharmacotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR79XdHJXFkbVg90H21EOLACvtfcHk0lgC5cLaP1fgTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVShtLfO&md5=0b8b1d8d76d17164a4ab7ba0e17ea2c2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00607%26sid%3Dliteratum%253Aachs%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DInvestigation%2520of%2520novel%2520primary%2520and%2520secondary%2520pharmacophores%2520and%25203-substitution%2520in%2520the%2520linking%2520chain%2520of%2520a%2520series%2520of%2520highly%2520selective%2520and%2520bitopic%2520dopamine%2520D3%2520receptor%2520antagonists%2520and%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9061%26epage%3D9077%26doi%3D10.1021%2Facs.jmedchem.9b00607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert Lane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010611-134514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1146%2Fannurev-pharmtox-010611-134514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21910627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2ntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=153-178&author=C.+Valantauthor=J.+Robert+Laneauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=The+best+of+both+worlds%3F+Bitopic+orthosteric%2Fallosteric+ligands+of+g+protein-coupled+receptors&doi=10.1146%2Fannurev-pharmtox-010611-134514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors</span></div><div class="casAuthors">Valant, Celine; Lane, J. Robert; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-178</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  It is now acknowledged that G protein-coupled receptors, the largest class of drug targets, adopt multiple active states that can be preferentially stabilized by orthosteric ligands or allosteric modulators, thus giving rise to the phenomenon of pathway-biased signaling.  In the past few years, researchers have begun to explore the potential of linking orthosteric and allosteric pharmacophores to yield bitopic hybrid ligands.  This approach is an extension of the more traditional bivalent ligand concept and shares some of the same challenges, including the choice and role of the linker between the two pharmacophores and the validation of mechanism of action.  Nonetheless, the promise of bitopic ligands is the generation of novel chem. tools that have improved affinity and/or selectivity profiles.  Previously identified functionally selective compds. (and medicines) also may act via a bitopic mechanism, suggesting that the phenomenon is more widespread than currently appreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQs4WlX5wY8LVg90H21EOLACvtfcHk0lhcMXTtMQk46Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2ntrc%253D&md5=334839005a548a9739df466e3d09e1ae</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010611-134514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010611-134514%26sid%3Dliteratum%253Aachs%26aulast%3DValant%26aufirst%3DC.%26aulast%3DRobert%2BLane%26aufirst%3DJ.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DThe%2520best%2520of%2520both%2520worlds%253F%2520Bitopic%2520orthosteric%252Fallosteric%2520ligands%2520of%2520g%2520protein-coupled%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2012%26volume%3D52%26spage%3D153%26epage%3D178%26doi%3D10.1146%2Fannurev-pharmtox-010611-134514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Bridging the gap: bitopic ligands of G-protein-coupled receptors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2012.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.tips.2012.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=23177916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslejsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=59-66&author=J.+R.+Laneauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Bridging+the+gap%3A+bitopic+ligands+of+G-protein-coupled+receptors&doi=10.1016%2Fj.tips.2012.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Bridging the gap: bitopic ligands of G-protein-coupled receptors</span></div><div class="casAuthors">Lane, J. Robert; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-66</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Although classical approaches to G-protein-coupled receptor (GPCR) drug design have targeted the orthosteric binding site, potentially all GPCRs possess druggable allosteric sites.  In addn., it is clear that GPCRs can adopt multiple active states linked to distinct functional outcomes that can be stabilized by both allosteric and orthosteric ligands.  Recent studies have begun to explore the possibilities of linking orthosteric and allosteric pharmacophores to yield 'bitopic' ligands as an approach to achieve improved receptor affinity or selectivity.  Furthermore, it is possible that previously identified functionally selective drugs may represent unappreciated bitopic ligands at this important class of drug targets.  Here we discuss both the potential of bitopic ligands in GPCR drug discovery and the challenges assocd. with the design of such ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorsAmJef7SRbVg90H21EOLACvtfcHk0lhcMXTtMQk46Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslejsrbE&md5=bd5a180e7eda47a59073fef0f48124f6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DBridging%2520the%2520gap%253A%2520bitopic%2520ligands%2520of%2520G-protein-coupled%2520receptors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2013%26volume%3D34%26spage%3D59%26epage%3D66%26doi%3D10.1016%2Fj.tips.2012.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1494</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01688</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01688" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1478-1494&author=V.+Kumarauthor=A.+E.+Moritzauthor=T.+M.+Keckauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=C.+D.+Sibleyauthor=R.+B.+Freeauthor=L.+Shiauthor=J.+R.+Laneauthor=D.+R.+Sibleyauthor=A.+H.+Newman&title=Synthesis+and+pharmacological+characterization+of+novel+trans-cyclopropylmethyl-linked+bivalent+ligands+that+exhibit+selectivity+and+allosteric+pharmacology+at+the+dopamine+D3+receptor+%28D3R%29&doi=10.1021%2Facs.jmedchem.6b01688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)</span></div><div class="casAuthors">Kumar, Vivek; Moritz, Amy E.; Keck, Thomas M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Sibley, Christopher D.; Free, R. Benjamin; Shi, Lei; Lane, J. Robert; Sibley, David R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1478-1494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bitopic ligands directed toward D2-like receptors has proven to be of particular interest to improve the selectivity and/or affinity of these ligands and as an approach to modulate and bias their efficacies.  The structural similarities between dopamine D3 receptor (D3R)-selective mols. that display bitopic or allosteric pharmacol. and those that are simply competitive antagonists are subtle and intriguing.  Herein the authors synthesized a series of mols. in which the primary and secondary pharmacophores were derived from the D3R-selective antagonists SB269,652 and SB277011A whose structural similarity and pharmacol. disparity provided the perfect templates for SAR investigation.  Incorporating a trans-cyclopropylmethyl linker between pharmacophores and manipulating linker length resulted in the identification of two bivalent noncompetitive D3R-selective antagonists, I and II, which further delineates SAR assocd. with allosterism at D3R and provides leads toward novel drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PUM_XBYBsLVg90H21EOLACvtfcHk0lhjp_Z5gd-nlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlyhsLs%253D&md5=de385d8d9699e2d37a56974382989a19</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01688%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DSibley%26aufirst%3DC.%2BD.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DSynthesis%2520and%2520pharmacological%2520characterization%2520of%2520novel%2520trans-cyclopropylmethyl-linked%2520bivalent%2520ligands%2520that%2520exhibit%2520selectivity%2520and%2520allosteric%2520pharmacology%2520at%2520the%2520dopamine%2520D3%2520receptor%2520%2528D3R%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1478%26epage%3D1494%26doi%3D10.1021%2Facs.jmedchem.6b01688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cemaj, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imler, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">The significance of chirality in drug design and synthesis of bitopic ligands as D3 receptor (D3R) selective agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6287</span>– <span class="NLM_lpage">6314</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00702</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00702" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6287-6314&author=F.+O.+Battitiauthor=S.+L.+Cemajauthor=A.+M.+Guerreroauthor=A.+B.+Shaikauthor=J.+Lamauthor=R.+Raisauthor=B.+S.+Slusherauthor=J.+R.+Deschampsauthor=G.+H.+Imlerauthor=A.+H.+Newmanauthor=A.+Bonifazi&title=The+significance+of+chirality+in+drug+design+and+synthesis+of+bitopic+ligands+as+D3+receptor+%28D3R%29+selective+agonists&doi=10.1021%2Facs.jmedchem.9b00702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists</span></div><div class="casAuthors">Battiti, Francisco O.; Cemaj, Sophie L.; Guerrero, Adrian M.; Shaik, Anver Basha; Lam, Jenny; Rais, Rana; Slusher, Barbara S.; Deschamps, Jeffery R.; Imler, Greg H.; Newman, Amy Hauck; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6287-6314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the large degree of homol. among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge.  Previous work has exemplified the use of bitopic ligands as a powerful strategy in achieving subtype selectivity for agonists and antagonists alike.  Inspired by the potential for chem. modification of the D3 preferential agonists (+)-PD128,907 (1) and PF592,379 (2), we synthesized bitopic structures to further improve their D3R selectivity.  We found that the (2S,5S) conformation of scaffold 2 resulted in a privileged architecture with increased affinity and selectivity for the D3R.  In addn., a cyclopropyl moiety incorporated into the linker and full resoln. of the chiral centers resulted in lead compd. 53 and eutomer 53a that demonstrate significantly higher D3R binding selectivities than the ref. compds.  Moreover, the favorable metabolic stability in rat liver microsomes supports future studies in in vivo models of dopamine system dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnvIdaD7juX7Vg90H21EOLACvtfcHk0ljGN14MrVa-sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1WmsL3N&md5=6c2be1149f915f639a42a99f6acdc062</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00702%26sid%3Dliteratum%253Aachs%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DCemaj%26aufirst%3DS.%2BL.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DImler%26aufirst%3DG.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3DThe%2520significance%2520of%2520chirality%2520in%2520drug%2520design%2520and%2520synthesis%2520of%2520bitopic%2520ligands%2520as%2520D3%2520receptor%2520%2528D3R%2529%2520selective%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6287%26epage%3D6314%26doi%3D10.1021%2Facs.jmedchem.9b00702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span> <span> </span><span class="NLM_article-title">2016 Philip S. Portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1797</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1779-1797&author=A.+H.+Newmanauthor=F.+O.+Battitiauthor=A.+Bonifazi&title=2016+Philip+S.+Portoghese+medicinal+chemistry+lectureship%3A+designing+bivalent+or+bitopic+molecules+for+G-protein+coupled+receptors.+The+whole+is+greater+than+the+sum+of+its+parts&doi=10.1021%2Facs.jmedchem.9b01105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts</span></div><div class="casAuthors">Newman, Amy Hauck; Battiti, Francisco O.; Bonifazi, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1779-1797</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The genesis of designing bivalent or bitopic mols. that engender unique pharmacol. properties began with Portoghese's work directed toward opioid receptors, in the early 1980s.  This strategy has evolved as an attractive way to engineer highly selective compds. for targeted G-protein coupled receptors (GPCRs) with optimized efficacies and/or signaling bias.  The emergence of X-ray crystal structures of many GPCRs and the identification of both orthosteric and allosteric binding sites have provided further guidance to ligand drug design that includes a primary pharmacophore (PP), a secondary pharmacophore (SP), and a linker between them.  It is crit. to note the synergistic relationship among all three of these components as they contribute to the overall interaction of these mols. with their receptor proteins and that strategically designed combinations have and will continue to provide the GPCR mol. tools of the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo84RXs5E3FQbVg90H21EOLACvtfcHk0ljGN14MrVa-sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegtLrE&md5=d63fe27924f25354b10b2f01f44461a5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DBonifazi%26aufirst%3DA.%26atitle%3D2016%2520Philip%2520S.%2520Portoghese%2520medicinal%2520chemistry%2520lectureship%253A%2520designing%2520bivalent%2520or%2520bitopic%2520molecules%2520for%2520G-protein%2520coupled%2520receptors.%2520The%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520its%2520parts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1779%26epage%3D1797%26doi%3D10.1021%2Facs.jmedchem.9b01105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestor, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGonigle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyapati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ersche, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flechais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuchibatla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metastasio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suckling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingford-Hughes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span> <span> </span><span class="NLM_article-title">Acute D3 antagonist GSK598809 selectively enhances neural response during monetary reward anticipation in drug and alcohol dependence</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1049</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1038/npp.2016.289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fnpp.2016.289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=28042871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=1049-1057&author=A.+Murphyauthor=L.+J.+Nestorauthor=J.+McGonigleauthor=L.+Patersonauthor=V.+Boyapatiauthor=K.+D.+Erscheauthor=R.+Flechaisauthor=S.+Kuchibatlaauthor=A.+Metastasioauthor=C.+Orbanauthor=F.+Passettiauthor=L.+Reedauthor=D.+Smithauthor=J.+Sucklingauthor=E.+Taylorauthor=T.+W.+Robbinsauthor=A.+Lingford-Hughesauthor=D.+J.+Nuttauthor=J.+F.+Deakinauthor=R.+Elliott&title=Acute+D3+antagonist+GSK598809+selectively+enhances+neural+response+during+monetary+reward+anticipation+in+drug+and+alcohol+dependence&doi=10.1038%2Fnpp.2016.289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence</span></div><div class="casAuthors">Murphy, Anna; Nestor, Liam J.; McGonigle, John; Paterson, Louise; Boyapati, Venkataramana; Ersche, Karen D.; Flechais, Remy; Kuchibatla, Shankar; Metastasio, Antonio; Orban, Csaba; Passetti, Filippo; Reed, Laurence; Smith, Dana; Suckling, John; Taylor, Eleanor; Robbins, Trevor W.; Lingford-Hughes, Anne; Nutt, David J.; Deakin, John F. W.; Elliott, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1049-1057</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Evidence suggests that disturbances in neurobiol. mechanisms of reward and inhibitory control maintain addiction and provoke relapse during abstinence.  Abnormalities within the dopamine system may contribute to these disturbances and pharmacol. targeting the D3 dopamine receptor (DRD3) is therefore of significant clin. interest.  We used functional magnetic resonance imaging to investigate the acute effects of the DRD3 antagonist GSK598809 on anticipatory reward processing, using the monetary incentive delay task (MIDT), and response inhibition using the Go/No-Go task (GNGT).  A double-blind, placebo-controlled, crossover design approach was used in abstinent alc. dependent, abstinent poly-drug dependent and healthy control volunteers.  For the MIDT, there was evidence of blunted ventral striatal response to reward in the poly-drug-dependent group under placebo.  GSK598809 normalized ventral striatal reward response and enhanced response in the DRD3-rich regions of the ventral pallidum and substantia nigra.  Exploratory investigations suggested that the effects of GSK598809 were mainly driven by those with primary dependence on alc. but not on opiates.  Taken together, these findings suggest that GSK598809 may remediate reward deficits in substance dependence.  For the GNGT, enhanced response in the inferior frontal cortex of the poly-drug group was found.  However, there were no effects of GSK598809 on the neural network underlying response inhibition nor were there any behavioral drug effects on response inhibition.  GSK598809 modulated the neural network underlying reward anticipation but not response inhibition, suggesting that DRD3 antagonists may restore reward deficits in addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeqsfPKqdH27Vg90H21EOLACvtfcHk0li4_AhfGYq90Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGltLk%253D&md5=56dbd2ce52bc763fdc3eb92dd407150b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.289%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DA.%26aulast%3DNestor%26aufirst%3DL.%2BJ.%26aulast%3DMcGonigle%26aufirst%3DJ.%26aulast%3DPaterson%26aufirst%3DL.%26aulast%3DBoyapati%26aufirst%3DV.%26aulast%3DErsche%26aufirst%3DK.%2BD.%26aulast%3DFlechais%26aufirst%3DR.%26aulast%3DKuchibatla%26aufirst%3DS.%26aulast%3DMetastasio%26aufirst%3DA.%26aulast%3DOrban%26aufirst%3DC.%26aulast%3DPassetti%26aufirst%3DF.%26aulast%3DReed%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DSuckling%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DRobbins%26aufirst%3DT.%2BW.%26aulast%3DLingford-Hughes%26aufirst%3DA.%26aulast%3DNutt%26aufirst%3DD.%2BJ.%26aulast%3DDeakin%26aufirst%3DJ.%2BF.%26aulast%3DElliott%26aufirst%3DR.%26atitle%3DAcute%2520D3%2520antagonist%2520GSK598809%2520selectively%2520enhances%2520neural%2520response%2520during%2520monetary%2520reward%2520anticipation%2520in%2520drug%2520and%2520alcohol%2520dependence%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D1049%26epage%3D1057%26doi%3D10.1038%2Fnpp.2016.289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Ciano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boileau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvauchelle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span> <span> </span><span class="NLM_article-title">Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [(11)C]-(+)-PHNO PET study in humans</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1284</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0285-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fs41386-018-0285-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30659274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrtr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1284-1290&author=P.+Di%0ACianoauthor=E.+Mansouriauthor=J.+Tongauthor=A.+A.+Wilsonauthor=S.+Houleauthor=I.+Boileauauthor=T.+Duvauchelleauthor=P.+Robertauthor=J.+C.+Schwartzauthor=B.+Le+Foll&title=Occupancy+of+dopamine+D2+and+D3+receptors+by+a+novel+D3+partial+agonist+BP1.4979%3A+a+%5B%2811%29C%5D-%28%2B%29-PHNO+PET+study+in+humans&doi=10.1038%2Fs41386-018-0285-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans</span></div><div class="casAuthors">Di Ciano, Patricia; Mansouri, Esmaeil; Tong, Junchao; Wilson, Alan A.; Houle, Sylvain; Boileau, Isabelle; Duvauchelle, Thierry; Robert, Philippe; Schwartz, Jean Charles; Le Foll, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1284-1290</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">There has been considerable interest in the development of dopamine D3 receptor (DRD3) partial agonists and antagonists for the treatment of substance use disorders.  Pre-clin. evidence overwhelmingly supports the use of these drugs, but translation to humans has remained elusive due to the lack of selective compds. that are suitable for use in humans.  Although it has been established for full antagonists, little in vivo occupancy data are available with DRD3 partial agonists.  Here we investigate for the first time in healthy controls, the in vivo occupancy of a novel D3 partial agonist (BP1.4979) at the DRD3 and DRD2.  Participants received either a single dose (1, 3, 10 or 30 mg) or a subchronic regimen (5-7 days, q.d. or b.i.d) of BP1.4979, with the last dose given at 1, 12 or 24 h prior to scanning with [11C]-(+)-PHNO.  Single and subchronic administration of BP1.4979 dose-dependently occupied the DRD3 and DRD2, and this occupancy was preferential for the DRD3, notably at longer time points after administration of BP1.4979.  Also consistent with preference for the DRD3, prolactin levels were minimally increased, and no subjective effects of BP1.4979 were reported.  Serum levels of BP1.4979 were higher than its active metabolite, BP1.6239, while no notable increases in the inactive metabolite, BP1.6197, were found.  These findings indicate the range of doses that can be used to occupy selectively the DRD3 over the DRD2 with BP1.4979 and speak to the use of in vivo imaging approaches in dose finding studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFpJzOngtkErVg90H21EOLACvtfcHk0li4_AhfGYq90Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrtr7O&md5=4fe2612458efa661aa06b90ae7ccb805</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0285-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0285-4%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BCiano%26aufirst%3DP.%26aulast%3DMansouri%26aufirst%3DE.%26aulast%3DTong%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DBoileau%26aufirst%3DI.%26aulast%3DDuvauchelle%26aufirst%3DT.%26aulast%3DRobert%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26atitle%3DOccupancy%2520of%2520dopamine%2520D2%2520and%2520D3%2520receptors%2520by%2520a%2520novel%2520D3%2520partial%2520agonist%2520BP1.4979%253A%2520a%2520%255B%252811%2529C%255D-%2528%252B%2529-PHNO%2520PET%2520study%2520in%2520humans%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1284%26epage%3D1290%26doi%3D10.1038%2Fs41386-018-0285-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span> <span> </span><span class="NLM_article-title">The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.neuropharm.2017.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=28888944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2017&pages=190-199&author=Z.+B.+Youauthor=J.+T.+Gaoauthor=G.+H.+Biauthor=Y.+Heauthor=C.+Boatengauthor=J.+Caoauthor=E.+L.+Gardnerauthor=A.+H.+Newmanauthor=Z.+X.+Xi&title=The+novel+dopamine+D3+receptor+antagonists%2Fpartial+agonists+CAB2-015+and+BAK4-54+inhibit+oxycodone-taking+and+oxycodone-seeking+behavior+in+rats&doi=10.1016%2Fj.neuropharm.2017.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats</span></div><div class="casAuthors">You, Zhi-Bing; Gao, Jun-Tao; Bi, Guo-Hua; He, Yi; Boateng, Comfort; Cao, Jianjing; Gardner, Eliot L.; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190-199</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of prescription opioid analgesics, particularly oxycodone, has dramatically increased, and parallels escalated opioid abuse and drug-related deaths worldwide.  Understanding the mol. mechanisms underlying the development of opioid dependence and expanding treatment options to counter prescription opioid abuse has become a crit. public health matter.  In the present study, we first evaluated the reinforcing effects of oxycodone in a rat model of self-administration and then explored the potential utility of two novel high affinity dopamine D3 receptor (D3R) antagonists/partial agonists, CAB2-015 and BAK4-54, for treatment of prescription opioid abuse and dependence.  We found that rats acquired oxycodone self-administration rapidly within a range of unit doses that was similar to that for heroin, confirming that oxycodone has significant abuse potential.  Strikingly, pretreatment with either CAB2-015 or BAK4-54 (0.4-10 mg/kg, i.p.) dose-dependently decreased oxycodone self-administration, and shifted the oxycodone dose-response curve downward.  Repeated pretreatment with CAB2-015 or BAK4-54 (0.4-4 mg/kg) facilitated extinction and inhibited oxycodone-induced reinstatement of drug-seeking behavior.  In addn., pretreatment with CAB2-015 or BAK4-54 (4-10 mg/kg) also dose-dependently decreased oxycodone-enhanced locomotor activity, but only CAB2-015 decreased oral sucrose self-administration.  These data suggest that D3R antagonists may be suitable alternatives or adjunctive to opioid-based medications currently used clin. in treating opioid addiction and that the D3R-selective ligands (CAB2-015 or BAK4-54) provide new lead mols. for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2yL76pWO8Z7Vg90H21EOLACvtfcHk0lgTil1o7h-9Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsrfF&md5=a046de2818f1daf7029be110c5c0cc9b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.%2BB.%26aulast%3DGao%26aufirst%3DJ.%2BT.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBoateng%26aufirst%3DC.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26atitle%3DThe%2520novel%2520dopamine%2520D3%2520receptor%2520antagonists%252Fpartial%2520agonists%2520CAB2-015%2520and%2520BAK4-54%2520inhibit%2520oxycodone-taking%2520and%2520oxycodone-seeking%2520behavior%2520in%2520rats%26jtitle%3DNeuropharmacology%26date%3D2017%26volume%3D126%26spage%3D190%26epage%3D199%26doi%3D10.1016%2Fj.neuropharm.2017.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">You, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0284-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fs41386-018-0284-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30555159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=1415-1424&author=Z.+B.+Youauthor=G.+H.+Biauthor=E.+Galajauthor=V.+Kumarauthor=J.+Caoauthor=A.+Gadianoauthor=R.+Raisauthor=B.+S.+Slusherauthor=E.+L.+Gardnerauthor=Z.+X.+Xiauthor=A.+H.+Newman&title=Dopamine+D3R+antagonist+VK4-116+attenuates+oxycodone+self-administration+and+reinstatement+without+compromising+its+antinociceptive+effects&doi=10.1038%2Fs41386-018-0284-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects</span></div><div class="casAuthors">You, Zhi-Bing; Bi, Guo-Hua; Galaj, Ewa; Kumar, Vivek; Cao, Jianjing; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara S.; Gardner, Eliot L.; Xi, Zheng-Xiong; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1415-1424</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Prescription opioids such as oxycodone are highly effective analgesics for clin. pain management, but their misuse and abuse have led to the current opioid epidemic in the United States.  In order to ameliorate this public health crisis, the development of effective pharmacotherapies for the prevention and treatment of opioid abuse and addiction is essential and urgently required.  In this study, we evaluated-in lab. rats-the potential utility of VK4-116, a novel and highly selective dopamine D3 receptor (D3R) antagonist, for the prevention and treatment of prescription opioid use disorders.  Pretreatment with VK4-116 (5-25 mg/kg, i.p.) dose-dependently inhibited the acquisition and maintenance of oxycodone self-administration.  VK4-116 also lowered the break-point (BP) for oxycodone self-administration under a progressive-ratio schedule of reinforcement, shifted the oxycodone dose-response curve downward, and inhibited oxycodone extinction responding and reinstatement of oxycodone-seeking behavior.  In addn., VK4-116 pretreatment dose-dependently enhanced the antinociceptive effects of oxycodone and reduced naloxone-pptd. conditioned place aversion in rats chronically treated with oxycodone.  In contrast, VK4-116 had little effect on oral sucrose self-administration.  Taken together, these findings indicate a central role for D3Rs in opioid reward and support further development of VK4-116 as an effective agent for mitigating the development of opioid addiction, reducing the severity of withdrawal and preventing relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3PmmEMo-frVg90H21EOLACvtfcHk0li_gI-RG4KWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLvN&md5=dac3d9cbb6c0594cd06d3ec328aa519f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0284-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0284-5%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.%2BB.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DGalaj%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DGardner%26aufirst%3DE.%2BL.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DDopamine%2520D3R%2520antagonist%2520VK4-116%2520attenuates%2520oxycodone%2520self-administration%2520and%2520reinstatement%2520without%2520compromising%2520its%2520antinociceptive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D1415%26epage%3D1424%26doi%3D10.1038%2Fs41386-018-0284-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humburg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorndike, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, C. W.</span></span> <span> </span><span class="NLM_article-title">Newly developed dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1124/jpet.119.259390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fjpet.119.259390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=31562201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1WltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2019&pages=602-614&author=C.+J.+Jordanauthor=B.+A.+Humburgauthor=E.+B.+Thorndikeauthor=A.+B.+Shaikauthor=Z.+X.+Xiauthor=M.+H.+Baumannauthor=A.+H.+Newmanauthor=C.+W.+Schindler&title=Newly+developed+dopamine+D3+receptor+antagonists%2C+R-VK4-40+and+R-VK4-116%2C+do+not+potentiate+cardiovascular+effects+of+cocaine+or+oxycodone+in+rats&doi=10.1124%2Fjpet.119.259390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Newly developed Dopamine D3 receptor antagonists, R-VK4-40 and R-VK4-116, do not potentiate cardiovascular effects of cocaine or oxycodone in rats</span></div><div class="casAuthors">Jordan, Chloe J.; Humburg, Bree A.; Thorndike, Eric B.; Shaik, Anver Basha; Xi, Zheng-Xiong; Baumann, Michael H.; Newman, Amy Hauck; Schindler, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">602-618</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Opioid and cocaine abuse are major public health burdens.  Existing medications for opioid use disorder are limited by abuse liability and side effects, whereas no treatments are currently approved in the United States for cocaine use disorder.  Dopamine D3 receptor (D3R) antagonists have shown promise in attenuating opioid and cocaine reward and mitigating relapse in preclin. models.  However, translation of D3R antagonists to the clinic has been hampered by reports that the D3R antagonists GSK598,809 (5-(5-((3-((1S,5R)-1-(2-fluoro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole) and SB-277,011A (2-(2-((1r,4r)-4-(2-oxo-2-(quinolin-4-yl)ethyl)cyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile) have adverse cardiovascular effects in the presence of cocaine.  Recently, we developed two structurally novel D3R antagonists, R-VK4-40 and R-VK4-116, which are highly selective for D3R and display translational potential for treatment of opioid use disorder.  Here, we tested whether R-VK4-40 ((R)-N-(4-(4-(2-Chloro-3-ethylphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide) and R-VK4-116 ((R)-N-(4-(4-(3-Chloro-5-ethyl-2-methoxyphenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide) have unwanted cardiovascular effects in the presence of oxycodone, a prescription opioid, or cocaine in freely moving rats fitted with surgically implanted telemetry transmitters.  We also examd. cardiovascular effects of the D3R antagonist, SB-277,011A, and L-741,626 (1-((1H-indol-3-yl)methyl)-4-(4-chlorophenyl)piperidin-4-ol), a dopamine D2 receptor-selective antagonist, for comparison.  Consistent with prior reports, SB-277,011A increased blood pressure, heart rate, and locomotor activity alone and in the presence of cocaine.  L-741,626 increased blood pressure and heart rate.  In contrast, R-VK4-40 alone dose-dependently reduced blood pressure and heart rate and attenuated oxycodone-induced increases in blood pressure and oxycodone or cocaine-induced increases in heart rate.  Similarly, R-VK4-116 alone dose-dependently reduced cocaine-induced increases in blood pressure and heart rate.  These results highlight the safety of new D3R antagonists and support the continued development of R-VK4-40 and R-VK4-116 for the treatment of opioid and cocaine use disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvUfnNpZtkLVg90H21EOLACvtfcHk0li_gI-RG4KWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1WltLo%253D&md5=5fe7b8a11ae2083e6d78b2123bdd6fde</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fjpet.119.259390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.119.259390%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DHumburg%26aufirst%3DB.%2BA.%26aulast%3DThorndike%26aufirst%3DE.%2BB.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DSchindler%26aufirst%3DC.%2BW.%26atitle%3DNewly%2520developed%2520dopamine%2520D3%2520receptor%2520antagonists%252C%2520R-VK4-40%2520and%2520R-VK4-116%252C%2520do%2520not%2520potentiate%2520cardiovascular%2520effects%2520of%2520cocaine%2520or%2520oxycodone%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D371%26spage%3D602%26epage%3D614%26doi%3D10.1124%2Fjpet.119.259390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humburg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span> <span> </span><span class="NLM_article-title">The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>158</i></span>, <span class="NLM_elocation-id">107597</span> <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.neuropharm.2019.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30974107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVegt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2019&author=C.+J.+Jordanauthor=B.+Humburgauthor=M.+Riceauthor=G.+H.+Biauthor=Z.+B.+Youauthor=A.+B.+Shaikauthor=J.+Caoauthor=A.+Bonifaziauthor=A.+Gadianoauthor=R.+Raisauthor=B.+Slusherauthor=A.+H.+Newmanauthor=Z.+X.+Xi&title=The+highly+selective+dopamine+D3R+antagonist%2C+R-VK4-40+attenuates+oxycodone+reward+and+augments+analgesia+in+rodents&doi=10.1016%2Fj.neuropharm.2019.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents</span></div><div class="casAuthors">Jordan, Chloe J.; Humburg, Bree; Rice, Myra; Bi, Guo-Hua; You, Zhi-Bing; Shaik, Anver Basha; Cao, Jianjing; Bonifazi, Alessandro; Gadiano, Alexandra; Rais, Rana; Slusher, Barbara; Newman, Amy Hauck; Xi, Zheng-Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107597</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We evaluated the effects of R-VK4-40, a highly selective D3R receptor antagonist, on the rewarding and analgesic effects of oxycodone, the most commonly abused prescription opioid, in rats and mice.  Systemic administration of R-VK4-40 dose-dependently inhibited oxycodone self-administration and shifted oxycodone dose-response curves downward in rats.  Pretreatment with R-VK4-40 also dose-dependently lowered break-points for oxycodone under a progressive-ratio schedule.  To det. whether a DA-dependent mechanism underlies the impact of D3 antagonism in reducing opioid reward, we used optogenetic approaches to examine intracranial self-stimulation (ICSS) maintained by optical activation of ventral tegmental area (VTA) DA neurons in DAT-Cre mice.  Pretreatment with R-VK4-40 blocked oxycodone-enhanced brain-stimulation reward.  By itself, R-VK4-40 produced a modest dose-dependent redn. in optical ICSS.  Pretreatment with R-VK4-40 did not compromise the antinociceptive effects of oxycodone in rats, and R-VK4-40 alone produced mild antinociceptive effects without altering open-field locomotion or rotarod locomotor performance.  Together, these findings suggest R-VK4-40 may permit a lower dose of prescription opioids for pain management, potentially mitigating tolerance and dependence, while diminishing reward potency.  Hence, development of R-VK4-40 as a therapy for the treatment of opioid use disorders and/or pain is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoec47hB7NVR7Vg90H21EOLACvtfcHk0li_gI-RG4KWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVegt7vI&md5=2619b493c3addad36e8ec504f41b25c7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DC.%2BJ.%26aulast%3DHumburg%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DM.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DYou%26aufirst%3DZ.%2BB.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DGadiano%26aufirst%3DA.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26atitle%3DThe%2520highly%2520selective%2520dopamine%2520D3R%2520antagonist%252C%2520R-VK4-40%2520attenuates%2520oxycodone%2520reward%2520and%2520augments%2520analgesia%2520in%2520rodents%26jtitle%3DNeuropharmacology%26date%3D2019%26volume%3D158%26doi%3D10.1016%2Fj.neuropharm.2019.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Ligand discovery from a dopamine D3 receptor homology model and crystal structure</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1038/nchembio.662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fnchembio.662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21926995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFylsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=769-778&author=J.+Carlssonauthor=R.+G.+Colemanauthor=V.+Setolaauthor=J.+J.+Irwinauthor=H.+Fanauthor=A.+Schlessingerauthor=A.+Saliauthor=B.+L.+Rothauthor=B.+K.+Shoichet&title=Ligand+discovery+from+a+dopamine+D3+receptor+homology+model+and+crystal+structure&doi=10.1038%2Fnchembio.662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand discovery from a dopamine D3 receptor homology model and crystal structure</span></div><div class="casAuthors">Carlsson, Jens; Coleman, Ryan G.; Setola, Vincent; Irwin, John J.; Fan, Hao; Schlessinger, Avner; Sali, Andrej; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">769-778</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are intensely studied as drug targets and for their role in signaling.  With the detn. of the first crystal structures, interest in structure-based ligand discovery increased.  Unfortunately, for most GPCRs no exptl. structures are available.  The detn. of the D3 receptor structure and the challenge to the community to predict it enabled a fully prospective comparison of ligand discovery from a modeled structure vs. that of the subsequently released crystal structure.  Over 3.3 million mols. were docked against a homol. model, and 26 of the highest ranking were tested for binding.  Six had affinities ranging from 0.2 to 3.1 μM.  Subsequently, the crystal structure was released and the docking screen repeated.  Of the 25 compds. selected, five had affinities ranging from 0.3 to 3.0 μM.  One of the new ligands from the homol. model screen was optimized for affinity to 81 nM.  The feasibility of docking screens against modeled GPCRs more generally is considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz6gBx3Olbn7Vg90H21EOLACvtfcHk0lgpH2xvh2A0Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFylsLvP&md5=7242aa512079a348678b309d352ecdb9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.662%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DR.%2BG.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DLigand%2520discovery%2520from%2520a%2520dopamine%2520D3%2520receptor%2520homology%2520model%2520and%2520crystal%2520structure%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D769%26epage%3D778%26doi%3D10.1038%2Fnchembio.662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubukov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span> <span> </span><span class="NLM_article-title">Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">794</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1124/mol.113.088054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fmol.113.088054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24021214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyitLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=794-807&author=J.+R.+Laneauthor=P.+Chubukovauthor=W.+Liuauthor=M.+Canalsauthor=V.+Cherezovauthor=R.+Abagyanauthor=R.+C.+Stevensauthor=V.+Katritch&title=Structure-based+ligand+discovery+targeting+orthosteric+and+allosteric+pockets+of+dopamine+receptors&doi=10.1124%2Fmol.113.088054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors</span></div><div class="casAuthors">Lane, J. Robert; Chubukov, Pavel; Liu, Wei; Canals, Meritxell; Cherezov, Vadim; Abagyan, Ruben; Stevens, Raymond C.; Katritch, Vsevolod</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">794-807</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Small mols. targeting allosteric pockets of G protein-coupled receptors (GPCRs) have a great therapeutic potential for the treatment of neurol. and other chronic disorders.  Here we performed virtual screening for orthosteric and putative allosteric ligands of the human dopamine D3 receptor (D3R) using two optimized crystal-structure-based models: the receptor with an empty binding pocket (D3RAPO), and the receptor complex with dopamine (D3RDopa).  Subsequent biochem. and functional characterization revealed 14 novel ligands with a binding affinity of better than 10 μM in the D3RAPO candidate list (56% hit rate), and 8 novel ligands in the D3RDopa list (32% hit rate).  Most ligands in the D3RAPO model span both orthosteric and extended pockets and behave as antagonists at D3R, with compd. 7 showing the highest potency of dopamine inhibition (IC50 = 7 nM).  In contrast, compds. identified by the D3RDopa model are predicted to occupy an allosteric site at the extracellular extension of the pocket, and they all lack the anchoring amino group.  Compds. targeting the allosteric site display a variety of functional activity profiles, where behavior of at least two compds. (23 and 26) is consistent with noncompetitive allosteric modulation of dopamine signaling in the extracellular signal-regulated kinase 1 and 2 phosphorylation and β-arrestin recruitment assays.  The high affinity and ligand efficiency of the chem. diverse hits identified in this study suggest utility of structure-based screening targeting allosteric sites of GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5wO8LtvA7YbVg90H21EOLACvtfcHk0lgpH2xvh2A0Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyitLvO&md5=c0efe2cb7bb1ce9708826aea36de2043</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.088054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.088054%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DChubukov%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DKatritch%26aufirst%3DV.%26atitle%3DStructure-based%2520ligand%2520discovery%2520targeting%2520orthosteric%2520and%2520allosteric%2520pockets%2520of%2520dopamine%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D794%26epage%3D807%26doi%3D10.1124%2Fmol.113.088054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">High-affinity and selective dopamine D(3) receptor full agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5612</span>– <span class="NLM_lpage">5617</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bmcl.2012.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22871578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGht73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5612-5617&author=J.+Chenauthor=B.+Levantauthor=S.+Wang&title=High-affinity+and+selective+dopamine+D%283%29+receptor+full+agonists&doi=10.1016%2Fj.bmcl.2012.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity and selective dopamine D3 receptor full agonists</span></div><div class="casAuthors">Chen, Jianyong; Levant, Beth; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5612-5617</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have designed, synthesized and evaluated a series of new compds. with the goal to identify potent and selective D3 ligands.  The two most potent and selective new D3 ligands are compds. 38 and 52, which bind to the D3 receptors with a Ki value of <1 nM and display a selectivity of 450-494 times over the D2 receptors and >10,000 times over the D1 receptors.  Both 38 and 52 are full agonists with high potency at the D3 receptor in a D3 functional assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEFcieGKEBo7Vg90H21EOLACvtfcHk0lgTgxEomLZmMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGht73J&md5=6585606ab267fe77cd960eba6629faff</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DHigh-affinity%2520and%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520full%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5612%26epage%3D5617%26doi%3D10.1016%2Fj.bmcl.2012.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">CJ-1639: a potent and highly selective dopamine D3 receptor full agonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1021/ml200100t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200100t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=620-625&author=J.+Chenauthor=G.+T.+Collinsauthor=B.+Levantauthor=J.+Woodsauthor=J.+R.+Deschampsauthor=S.+Wang&title=CJ-1639%3A+a+potent+and+highly+selective+dopamine+D3+receptor+full+agonist&doi=10.1021%2Fml200100t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist</span></div><div class="casAuthors">Chen, Jianyong; Collins, Gregory T.; Levant, Beth; Woods, James; Deschamps, Jeffrey R.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">620-625</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have identified several ligands with high binding affinities to the dopamine D3 receptor and excellent selectivity over the D2 and D1 receptors.  CJ-1639 (17) binds to the D3 receptor with a Ki value of 0.50 nM and displays a selectivity of >5000 times over D2 and D1 receptors in binding assays using dopamine receptors expressed in the native rat brain tissues.  CJ-1639 binds to human D3 receptor with a Ki value of 3.61 nM and displays over >1000-fold selectivity over human D1 and D2 receptors.  CJ-1639 is active at 0.01 mg/kg at the dopamine D3 receptor in the rat and only starts to show a modest D2 activity at doses as high as 10 mg/kg.  CJ-1639 is the most potent and selective D3 full agonist reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1_j_DTOKv47Vg90H21EOLACvtfcHk0lgTgxEomLZmMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLs%253D&md5=563e24bd67062d01a456b6f03429329a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fml200100t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200100t%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DG.%2BT.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DCJ-1639%253A%2520a%2520potent%2520and%2520highly%2520selective%2520dopamine%2520D3%2520receptor%2520full%2520agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D620%26epage%3D625%26doi%3D10.1021%2Fml200100t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2653</span>– <span class="NLM_lpage">2660</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fcmdc.201402398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25338762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaksbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2653-2660&author=J.+Chenauthor=C.+Jiangauthor=B.+Levantauthor=X.+Liauthor=T.+Zhaoauthor=B.+Wenauthor=R.+Luoauthor=D.+Sunauthor=S.+Wang&title=Pramipexole+derivatives+as+potent+and+selective+dopamine+D%283%29+receptor+agonists+with+improved+human+microsomal+stability&doi=10.1002%2Fcmdc.201402398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Pramipexole Derivatives as Potent and Selective Dopamine D3 Receptor Agonists with Improved Human Microsomal Stability</span></div><div class="casAuthors">Chen, Jianyong; Jiang, Cheng; Levant, Beth; Li, Xiaoqin; Zhao, Ting; Wen, Bo; Luo, Ruijuan; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2653-2660</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the synthesis and evaluation of a series of new pramipexole derivs. as highly potent and selective agonists of the dopamine-3 (D3) receptor.  A no. of these new compds. bind to the D3 receptor with sub-nanomolar affinity and show excellent selectivity (>10 000) for the D3 receptor over the D1 and D2 receptors.  For example, compd. 23 (N-(cis-3-(2-(((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)benzamide) binds to the D3 receptor with a Ki value of 0.53 nΜ and shows a selectivity of >20 000 over the D2 and D1 receptors in the binding assays using a rat brain prepn.  It has excellent stability in human liver microsomes.  Moreover, in vitro functional assays showed it to be a full agonist for the human D3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxr67n6Ksdj7Vg90H21EOLACvtfcHk0lgTgxEomLZmMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaksbfL&md5=57dd5129b272187e10c83651a3aa42db</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402398%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DLevant%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DPramipexole%2520derivatives%2520as%2520potent%2520and%2520selective%2520dopamine%2520D%25283%2529%2520receptor%2520agonists%2520with%2520improved%2520human%2520microsomal%2520stability%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D2653%26epage%3D2660%26doi%3D10.1002%2Fcmdc.201402398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazeldine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrington, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzhikandathil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2- ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3005</span>– <span class="NLM_lpage">3019</span>, <span class="refDoi"> DOI: 10.1021/jm701524h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701524h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFyksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3005-3019&author=S.+Biswasauthor=S.+Hazeldineauthor=B.+Ghoshauthor=I.+Parringtonauthor=E.+Kuzhikandathilauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Bioisosteric+heterocyclic+versions+of+7-%7B%5B2-%284-phenyl-piperazin-1-yl%29ethyl%5Dpropylamino%7D-5%2C6%2C7%2C8-tetrahydronaphthalen-2-+ol%3A+identification+of+highly+potent+and+selective+agonists+for+dopamine+D3+receptor+with+potent+in+vivo+activity&doi=10.1021%2Fjm701524h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric Heterocyclic Versions of 7-{[2-(4-Phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: Identification of Highly Potent and Selective Agonists for Dopamine D3 Receptor with Potent in Vivo Activity</span></div><div class="casAuthors">Biswas, Swati; Hazeldine, Stuart; Ghosh, Balaram; Parrington, Ingrid; Kuzhikandathil, Eldo; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3005-3019</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the current report, the authors extend the SAR study on the hybrid structure 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol further to include heterocyclic bioisosteric analogs.  Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptors with tritiated spiperone to evaluate inhibition consts. (Ki).  Functional activity of selected compds. in stimulating GTPγS binding was assessed with CHO cells expressing human D2 receptors and AtT-20 cells expressing human D3 receptors.  The highest binding affinity and selectivity for D3 receptors were exhibited by compd. (I) (Ki = 0.92 nM and D2/D3=253).  In the functional GTPγS binding assay, I exhibited full agonist activity with picomolar affinity for D3 receptor with high selectivity (EC50 = 0.08 nM and D2/D3=248).  In the in vivo rotational study, I exhibited potent rotational activity in 6-OH-DA unilaterally lesioned rats with long duration of action, which indicates its potential application in neuroprotective treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6yNJ94snDg7Vg90H21EOLACvtfcHk0lg4AVfOx8Wk2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFyksbk%253D&md5=6c649b6077843039c49dab02128df139</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm701524h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701524h%26sid%3Dliteratum%253Aachs%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DHazeldine%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DParrington%26aufirst%3DI.%26aulast%3DKuzhikandathil%26aufirst%3DE.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DBioisosteric%2520heterocyclic%2520versions%2520of%25207-%257B%255B2-%25284-phenyl-piperazin-1-yl%2529ethyl%255Dpropylamino%257D-5%252C6%252C7%252C8-tetrahydronaphthalen-2-%2520ol%253A%2520identification%2520of%2520highly%2520potent%2520and%2520selective%2520agonists%2520for%2520dopamine%2520D3%2520receptor%2520with%2520potent%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3005%26epage%3D3019%26doi%3D10.1021%2Fjm701524h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydro benzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson’s disease animal models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1037</span>, <span class="refDoi"> DOI: 10.1021/jm901184n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901184n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WjsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1023-1037&author=B.+Ghoshauthor=T.+Antonioauthor=J.+Zhenauthor=P.+Kharkarauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Development+of+%28S%29-N6-%282-%284-%28isoquinolin-1-yl%29piperazin-1-yl%29ethyl%29-N6-propyl-4%2C5%2C6%2C7-tetrahydro+benzo%5Bd%5D-thiazole-2%2C6-diamine+and+its+analogue+as+a+D3+receptor+preferring+agonist%3A+potent+in+vivo+activity+in+Parkinson%E2%80%99s+disease+animal+models&doi=10.1021%2Fjm901184n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Development of (S)-N6-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: Potent in vivo activity in Parkinson's disease animal models</span></div><div class="casAuthors">Ghosh, Balaram; Antonio, Tamara; Zhen, Juan; Kharkar, Prashant; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1023-1037</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here we report structure-activity relationship study of a novel hybrid series of compds. where structural alteration of arom. hydrophobic moieties connected to the piperazine ring and bioisosteric replacement of the arom. tetralin moieties were carried out.  Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptors with tritiated spiperone to evaluate inhibition consts. (Ki).  Functional activity of selected compds. in stimulating GTPγS binding was assessed with CHO cells expressing human D2 receptors and AtT-20 cells expressing human D3 receptors.  SAR results identified compd. (-)-24c (D-301, I) as one of the lead mols. with preferential agonist activity for D3 receptor (EC50 (GTPγS); D3 = 0.52 nM; D2/D3 (EC50): 223).  Compds. (-)-24b and (-)-24c exhibited potent radical scavenging activity.  The two lead compds., (-)-24b and (-)-24c, exhibited high in vivo activity in two Parkinson's disease (PD) animal models, reserpinized rat model and 6-OHDA induced unilaterally lesioned rat model.  Future studies will explore potential use of these compds. in the neuroprotective therapy for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9rYWZ-mha0rVg90H21EOLACvtfcHk0lg4AVfOx8Wk2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WjsLnO&md5=ae4d8fb18fd9607e1508ee936f88b7bd</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm901184n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901184n%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DKharkar%26aufirst%3DP.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DDevelopment%2520of%2520%2528S%2529-N6-%25282-%25284-%2528isoquinolin-1-yl%2529piperazin-1-yl%2529ethyl%2529-N6-propyl-4%252C5%252C6%252C7-tetrahydro%2520benzo%255Bd%255D-thiazole-2%252C6-diamine%2520and%2520its%2520analogue%2520as%2520a%2520D3%2520receptor%2520preferring%2520agonist%253A%2520potent%2520in%2520vivo%2520activity%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520animal%2520models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1023%26epage%3D1037%26doi%3D10.1021%2Fjm901184n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydroben zo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5826</span>– <span class="NLM_lpage">5840</span>, <span class="refDoi"> DOI: 10.1021/jm300268s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300268s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsF2gurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5826-5840&author=M.+Johnsonauthor=T.+Antonioauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Structure-activity+relationship+study+of+N%286%29-%282-%284-%281H-Indol-5-yl%29piperazin-1-yl%29ethyl%29-N%286%29-propyl-4%2C5%2C6%2C7-tetrahydroben+zo%5Bd%5Dthiazole-2%2C6-diamine+analogues%3A+development+of+highly+selective+D3+dopamine+receptor+agonists+along+with+a+highly+potent+D2%2FD3+agonist+and+their+pharmacological+characterization&doi=10.1021%2Fjm300268s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization</span></div><div class="casAuthors">Johnson, Mark; Antonio, Tamara; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5826-5840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our effort to develop multifunctional drugs against Parkinson's disease, a structure-activity-relationship study was carried out based on our hybrid mol. template targeting D2/D3 receptors.  Competitive binding with [3H]spiroperidol was used to evaluate affinity (Ki) of test compds.  Functional activity of selected compds. in stimulating [35S]GTPγS binding was assessed in CHO cells expressing either human D2 or D3 receptors.  Our results demonstrated development of highly selective compds. for D3 receptor (for (-)-40 (I) Ki, D3 = 1.84 nM, D2/D3 = 583.2; for (-)-45Ki, D3 = 1.09 nM, D2/D3 = 827.5).  Functional data identified (-)-40 (EC50, D2 = 114 nM, D3 = 0.26 nM, D2/D3 = 438) as one of the highest D3 selective agonists known to date.  In addn., high affinity, nonselective D3 agonist (-)-19 (EC50, D2 = 2.96 nM and D3 = 1.26 nM) was also developed.  Lead compds. with antioxidant activity were evaluated using an in vivo PD animal model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6RjEg-1KqXbVg90H21EOLACvtfcHk0ljPJvcuJ8KOkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsF2gurk%253D&md5=3b8cfcd3f1e19da405875c342ba3abdc</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm300268s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300268s%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520N%25286%2529-%25282-%25284-%25281H-Indol-5-yl%2529piperazin-1-yl%2529ethyl%2529-N%25286%2529-propyl-4%252C5%252C6%252C7-tetrahydroben%2520zo%255Bd%255Dthiazole-2%252C6-diamine%2520analogues%253A%2520development%2520of%2520highly%2520selective%2520D3%2520dopamine%2520receptor%2520agonists%2520along%2520with%2520a%2520highly%2520potent%2520D2%252FD3%2520agonist%2520and%2520their%2520pharmacological%2520characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5826%26epage%3D5840%26doi%3D10.1021%2Fjm300268s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandy, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selley, D. E.</span></span> <span> </span><span class="NLM_article-title">Efficacy of hybrid tetrahydrobenzo[d]thiazole based aryl piperazines D-264 and D-301 at D(2) and D(3) receptors</span>. <i>Neurochem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1007/s11064-015-1808-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1007%2Fs11064-015-1808-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26718829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslSi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=328-339&author=J.+Zhenauthor=T.+Antonioauthor=J.+C.+Jacobauthor=D.+K.+Grandyauthor=M.+E.+Reithauthor=A.+K.+Duttaauthor=D.+E.+Selley&title=Efficacy+of+hybrid+tetrahydrobenzo%5Bd%5Dthiazole+based+aryl+piperazines+D-264+and+D-301+at+D%282%29+and+D%283%29+receptors&doi=10.1007%2Fs11064-015-1808-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D2 and D3 Receptors</span></div><div class="casAuthors">Zhen, Juan; Antonio, Tamara; Jacob, Joanna C.; Grandy, David K.; Reith, Maarten E. A.; Dutta, Aloke K.; Selley, Dana E.</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">328-339</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In elucidating the role of pharmacodynamic efficacy at D3 receptors in therapeutic effectiveness of dopamine receptor agonists, the influence of study system must be understood.  Here two compds. with D3 over D2 selectivity developed in our earlier work, D-264 and D-301, are compared in dopamine receptor-mediated G-protein activation in striatal regions of wild-type and D2 receptor knockout mice and in CHO cells expressing D2 or D3 receptors.  In caudate-putamen of D2 knockout mice, D-301 was ∼3-fold more efficacious than D-264 in activating G-proteins as assessed by [35S]GTPγS binding; in nucleus accumbens, D-301 stimulated G-protein activation whereas D-264 did not.  In contrast, the two ligands exerted similar efficacy in both regions of wild-type mice, suggesting both ligands activate D2 receptors with similar efficacy.  In D2 and D3 receptor-expressing CHO cells, D-264 and D-301 appeared to act in the [35S]GTPγS assay as full agonists because they produced maximal stimulation equal to dopamine.  Competition for [3H]spiperone binding was then performed to det. Ki/EC50 ratios as an index of receptor reserve for each ligand.  Action of D-301, but not D-264, showed receptor reserve in D3 but not in D2 receptor-expressing cells, whereas dopamine showed receptor reserve in both cell lines.  Gαo1 is highly expressed in brain and is important in D2-like receptor-G protein coupling.  Transfection of Gαo1 in D3- but not D2-expressing CHO cells led to receptor reserve for D-264 without altering receptor expression levels.  D-301 and dopamine exhibited receptor reserve in D3-expressing cells both with and without transfection of Gαo1.  Altogether, these results indicate that D-301 has greater intrinsic efficacy to activate D3 receptors than D-264, whereas the two compds. act on D2 receptors with similar intrinsic efficacy.  These findings also suggest caution in interpreting Emax values from functional assays in receptor-transfected cell models without accounting for receptor reserve.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyXeh7TIhgVbVg90H21EOLACvtfcHk0ljPJvcuJ8KOkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslSi&md5=5ff4c70588902e082d93aaa329f832d6</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs11064-015-1808-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11064-015-1808-6%26sid%3Dliteratum%253Aachs%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DJacob%26aufirst%3DJ.%2BC.%26aulast%3DGrandy%26aufirst%3DD.%2BK.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26aulast%3DSelley%26aufirst%3DD.%2BE.%26atitle%3DEfficacy%2520of%2520hybrid%2520tetrahydrobenzo%255Bd%255Dthiazole%2520based%2520aryl%2520piperazines%2520D-264%2520and%2520D-301%2520at%2520D%25282%2529%2520and%2520D%25283%2529%2520receptors%26jtitle%3DNeurochem.%2520Res.%26date%3D2016%26volume%3D41%26spage%3D328%26epage%3D339%26doi%3D10.1007%2Fs11064-015-1808-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, S. H.</span></span> <span> </span><span class="NLM_article-title">Correction: design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists</span>. <i>Medchemcomm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1565</span>, <span class="refDoi"> DOI: 10.1039/C8MD90042F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1039%2FC8MD90042F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30289124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ynt7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1565&author=Y.+Caoauthor=N.+Sunauthor=J.+Zhangauthor=Z.+Liuauthor=Y.+Z.+Tangauthor=Z.+Wuauthor=K.+M.+Kimauthor=S.+H.+Cheon&title=Correction%3A+design%2C+synthesis%2C+and+evaluation+of+bitopic+arylpiperazine-phthalimides+as+selective+dopamine+D3+receptor+agonists&doi=10.1039%2FC8MD90042F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Correction: Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists [Erratum to document cited in CA172:154797]</span></div><div class="casAuthors">Cao, Yongkai; Sun, Ningning; Zhang, Jiumei; Liu, Zhiguo; Tang, Yi-zhe; Wu, Zhengzhi; Kim, Kyeong-Man; Cheon, Seung Hoon</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1565</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Correction for 'Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists' by Yongkai Cao et al., Med.  Chem. Commun., 2018, DOI: 10.1039/c8md00237a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_cgUcuLVmL7Vg90H21EOLACvtfcHk0lh_Aa_eobheFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ynt7vM&md5=df74f0d3550f358e19c2408dcc7f76e4</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC8MD90042F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8MD90042F%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DY.%2BZ.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DCheon%26aufirst%3DS.%2BH.%26atitle%3DCorrection%253A%2520design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520bitopic%2520arylpiperazine-phthalimides%2520as%2520selective%2520dopamine%2520D3%2520receptor%2520agonists%26jtitle%3DMedchemcomm%26date%3D2018%26volume%3D9%26spage%3D1565%26doi%3D10.1039%2FC8MD90042F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aube, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamji, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McManus, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roush, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noah, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severson, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmitte, K. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Advancing biological understanding and therapeutics discovery with small-molecule probes</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1252</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.cell.2015.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26046436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVehsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2015&pages=1252-1265&author=S.+L.+Schreiberauthor=J.+D.+Kotzauthor=M.+Liauthor=J.+Aubeauthor=C.+P.+Austinauthor=J.+C.+Reedauthor=H.+Rosenauthor=E.+L.+Whiteauthor=L.+A.+Sklarauthor=C.+W.+Lindsleyauthor=B.+R.+Alexanderauthor=J.+A.+Bittkerauthor=P.+A.+Clemonsauthor=A.+de+Souzaauthor=M.+A.+Foleyauthor=M.+Palmerauthor=A.+F.+Shamjiauthor=M.+J.+Wawerauthor=O.+McManusauthor=M.+Wuauthor=B.+Zouauthor=H.+Yuauthor=J.+E.+Goldenauthor=F.+J.+Schoenenauthor=A.+Simeonovauthor=A.+Jadhavauthor=M.+R.+Jacksonauthor=A.+B.+Pinkertonauthor=T.+D.+Chungauthor=P.+R.+Griffinauthor=B.+F.+Cravattauthor=P.+S.+Hodderauthor=W.+R.+Roushauthor=E.+Robertsauthor=D.+H.+Chungauthor=C.+B.+Jonssonauthor=J.+W.+Noahauthor=W.+E.+Seversonauthor=S.+Ananthanauthor=B.+Edwardsauthor=T.+I.+Opreaauthor=P.+J.+Connauthor=C.+R.+Hopkinsauthor=M.+R.+Woodauthor=S.+R.+Staufferauthor=K.+A.+Emmitte&title=Advancing+biological+understanding+and+therapeutics+discovery+with+small-molecule+probes&doi=10.1016%2Fj.cell.2015.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes</span></div><div class="casAuthors">Schreiber, Stuart L.; Kotz, Joanne D.; Li, Min; Aube, Jeffrey; Austin, Christopher P.; Reed, John C.; Rosen, Hugh; White, E. Lucile; Sklar, Larry A.; Lindsley, Craig W.; Alexander, Benjamin R.; Bittker, Joshua A.; Clemons, Paul A.; de Souza, Andrea; Foley, Michael A.; Palmer, Michelle; Shamji, Alykhan F.; Wawer, Mathias J.; McManus, Owen; Wu, Meng; Zou, Beiyan; Yu, Haibo; Golden, Jennifer E.; Schoenen, Frank J.; Simeonov, Anton; Jadhav, Ajit; Jackson, Michael R.; Pinkerton, Anthony B.; Chung, Thomas D. Y.; Griffin, Patrick R.; Cravatt, Benjamin F.; Hodder, Peter S.; Roush, William R.; Roberts, Edward; Chung, Dong-Hoon; Jonsson, Colleen B.; Noah, James W.; Severson, William E.; Ananthan, Subramaniam; Edwards, Bruce; Oprea, Tudor I.; Conn, P. Jeffrey; Hopkins, Corey R.; Wood, Michael R.; Stauffer, Shaun R.; Emmitte, Kyle A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1252-1265</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Small-mol. probes can illuminate biol. processes and aid in the assessment of emerging therapeutic targets by perturbing biol. systems in a manner distinct from other exptl. approaches.  Despite the tremendous promise of chem. tools for studying biol. and disease, small-mol. probes were unavailable for most targets and pathways as recently as a decade ago.  In 2005, the NIH launched the decade-long Mol. Libraries Program with the intent of innovating in and broadening access to small-mol. science.  This Perspective describes how novel small-mol. probes identified through the program are enabling the exploration of biol. pathways and therapeutic hypotheses not otherwise testable.  These experiences illustrate how small-mol. probes can help bridge the chasm between biol. research and the development of medicines but also highlight the need to innovate the science of therapeutic discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfjCbrl4SObLVg90H21EOLACvtfcHk0lh_Aa_eobheFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVehsr%252FO&md5=067b42ffe9e77c0e0e83f29126d7afd7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DKotz%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DAube%26aufirst%3DJ.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DAlexander%26aufirst%3DB.%2BR.%26aulast%3DBittker%26aufirst%3DJ.%2BA.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3Dde%2BSouza%26aufirst%3DA.%26aulast%3DFoley%26aufirst%3DM.%2BA.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DShamji%26aufirst%3DA.%2BF.%26aulast%3DWawer%26aufirst%3DM.%2BJ.%26aulast%3DMcManus%26aufirst%3DO.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DGolden%26aufirst%3DJ.%2BE.%26aulast%3DSchoenen%26aufirst%3DF.%2BJ.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DJackson%26aufirst%3DM.%2BR.%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DChung%26aufirst%3DT.%2BD.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DHodder%26aufirst%3DP.%2BS.%26aulast%3DRoush%26aufirst%3DW.%2BR.%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DJonsson%26aufirst%3DC.%2BB.%26aulast%3DNoah%26aufirst%3DJ.%2BW.%26aulast%3DSeverson%26aufirst%3DW.%2BE.%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DEdwards%26aufirst%3DB.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26atitle%3DAdvancing%2520biological%2520understanding%2520and%2520therapeutics%2520discovery%2520with%2520small-molecule%2520probes%26jtitle%3DCell%26date%3D2015%26volume%3D161%26spage%3D1252%26epage%3D1265%26doi%3D10.1016%2Fj.cell.2015.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meade, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulcey, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant-Genevier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnaeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marugan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of a G protein–biased agonist that inhibits ß-arrestin recruitment to the D2 dopamine receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1124/mol.113.090563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fmol.113.090563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24755247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=96-105&author=R.+B.+Freeauthor=L.+S.+Chunauthor=A.+E.+Moritzauthor=B.+N.+Millerauthor=T.+B.+Doyleauthor=J.+L.+Conroyauthor=A.+Padronauthor=J.+A.+Meadeauthor=J.+Xiaoauthor=X.+Huauthor=A.+E.+Dulceyauthor=Y.+Hanauthor=L.+Duanauthor=S.+Titusauthor=M.+Bryant-Genevierauthor=E.+Barnaevaauthor=M.+Ferrerauthor=J.+A.+Javitchauthor=T.+Beumingauthor=L.+Shiauthor=N.+T.+Southallauthor=J.+J.+Maruganauthor=D.+R.+Sibley&title=Discovery+and+characterization+of+a+G+protein%E2%80%93biased+agonist+that+inhibits+%C3%9F-arrestin+recruitment+to+the+D2+dopamine+receptor&doi=10.1124%2Fmol.113.090563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor</span></div><div class="casAuthors">Free, R. Benjamin; Chun, Lani S.; Moritz, Amy E.; Miller, Brittney N.; Doyle, Trevor B.; Conroy, Jennie L.; Padron, Adrian; Meade, Julie A.; Xiao, Jingbo; Hu, Xin; Dulcey, Andres E.; Han, Yang; Duan, Lihua; Titus, Steve; Bryant-Genevier, Melanie; Barnaeva, Elena; Ferrer, Marc; Javitch, Jonathan A.; Beuming, Thijs; Shi, Lei; Southall, Noel T.; Marugan, Juan J.; Sibley, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-105, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A high-throughput screening campaign was conducted to interrogate a 380,000+ small-mol. library for novel D2 dopamine receptor modulators using a calcium mobilization assay.  Active agonist compds. from the primary screen were examd. for orthogonal D2 dopamine receptor signaling activities including cAMP modulation and β-arrestin recruitment.  Although the majority of the subsequently confirmed hits activated all signaling pathways tested, several compds. showed a diminished ability to stimulate β-arrestin recruitment.  One such compd. (MLS1547; 5-chloro-7-[(4-pyridin-2-ylpiperazin-1-yl)methyl]quinolin-8-ol) is a highly efficacious agonist at D2 receptor-mediated G protein-linked signaling, but does not recruit β-arrestin as demonstrated using two different assays.  This compd. does, however, antagonize dopamine-stimulated β-arrestin recruitment to the D2 receptor.  In an effort to investigate the chem. scaffold of MLS1547 further, we characterized a set of 24 analogs of MLS1547 with respect to their ability to inhibit cAMP accumulation or stimulate β-arrestin recruitment.  A no. of the analogs were similar to MLS1547 in that they displayed agonist activity for inhibiting cAMP accumulation, but did not stimulate β-arrestin recruitment (i.e., they were highly biased).  In contrast, other analogs displayed various degrees of G protein signaling bias.  These results provided the basis to use pharmacophore modeling and mol. docking analyses to build a preliminary structure-activity relationship of the functionally selective properties of this series of compds.  In summary, we have identified and characterized a novel G protein-biased agonist of the D2 dopamine receptor and identified structural features that may contribute to its biased signaling properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUnTQyiZvZxrVg90H21EOLACvtfcHk0lghlMQYPj2OuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksrvF&md5=7a3412858a3d780d8f90ca4535d485fc</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.090563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.090563%26sid%3Dliteratum%253Aachs%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DChun%26aufirst%3DL.%2BS.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DMiller%26aufirst%3DB.%2BN.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DPadron%26aufirst%3DA.%26aulast%3DMeade%26aufirst%3DJ.%2BA.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDulcey%26aufirst%3DA.%2BE.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DL.%26aulast%3DTitus%26aufirst%3DS.%26aulast%3DBryant-Genevier%26aufirst%3DM.%26aulast%3DBarnaeva%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DSouthall%26aufirst%3DN.%2BT.%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520G%2520protein%25E2%2580%2593biased%2520agonist%2520that%2520inhibits%2520%25C3%259F-arrestin%2520recruitment%2520to%2520the%2520D2%2520dopamine%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D86%26spage%3D96%26epage%3D105%26doi%3D10.1124%2Fmol.113.090563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnaeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant-Genevier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulcey, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marugan, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3450</span>– <span class="NLM_lpage">3463</span>, <span class="refDoi"> DOI: 10.1021/jm500126s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500126s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVCrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3450-3463&author=J.+Xiaoauthor=R.+B.+Freeauthor=E.+Barnaevaauthor=J.+L.+Conroyauthor=T.+Doyleauthor=B.+Millerauthor=M.+Bryant-Genevierauthor=M.+K.+Taylorauthor=X.+Huauthor=A.+E.+Dulceyauthor=N.+Southallauthor=M.+Ferrerauthor=S.+Titusauthor=W.+Zhengauthor=D.+R.+Sibleyauthor=J.+J.+Marugan&title=Discovery%2C+optimization%2C+and+characterization+of+novel+D2+dopamine+receptor+selective+antagonists&doi=10.1021%2Fjm500126s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists</span></div><div class="casAuthors">Xiao, Jingbo; Free, R. Benjamin; Barnaeva, Elena; Conroy, Jennie L.; Doyle, Trevor; Miller, Brittney; Bryant-Genevier, Marthe; Taylor, Mercedes K.; Hu, Xin; Dulcey, Andres E.; Southall, Noel; Ferrer, Marc; Titus, Steve; Zheng, Wei; Sibley, David R.; Marugan, Juan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3450-3463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The D2 dopamine receptor (D2 DAR) is one of the most validated drug targets for neuropsychiatric and endocrine disorders.  However, clin. approved drugs targeting D2 DAR display poor selectivity between the D2 and other receptors, esp. the D3 DAR.  This lack of selectivity may lead to undesirable side effects.  Described are chem. and pharmacol. characterizations of a novel D2 DAR antagonist series with excellent D2 vs. D1, D3, D4, and D5 receptor selectivity.  The final probe, 10-Methyl-11-oxo-N-(2-(thiophen-2-yl)ethyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5-(S)-oxide, was obtained through a quant. high-throughput screening campaign, followed by medicinal chem. optimization, to yield a selective mol. with good in vitro phys. properties, metabolic stability, and in vivo pharmacokinetics.  The optimized mol. may be a useful in vivo probe for studying D2 DAR signal modulation and could also serve as a lead compd. for the development of D2 DAR-selective drug-like mols. for the treatment of multiple neuropsychiatric and endocrine disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpR_vjtd6k47Vg90H21EOLACvtfcHk0lhB-VKNpB_tbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVCrsLk%253D&md5=29a129e52d18b35637390618096fc4d8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm500126s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500126s%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DBarnaeva%26aufirst%3DE.%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DDoyle%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DB.%26aulast%3DBryant-Genevier%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DM.%2BK.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDulcey%26aufirst%3DA.%2BE.%26aulast%3DSouthall%26aufirst%3DN.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DTitus%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%252C%2520optimization%252C%2520and%2520characterization%2520of%2520novel%2520D2%2520dopamine%2520receptor%2520selective%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3450%26epage%3D3463%26doi%3D10.1021%2Fjm500126s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span> <span> </span><span class="NLM_article-title">Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">708</span>, <span class="refDoi"> DOI: 10.1038/nrd4308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fnrd4308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25176435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=692-708&author=P.+J.+Connauthor=C.+W.+Lindsleyauthor=J.+Meilerauthor=C.+M.+Niswender&title=Opportunities+and+challenges+in+the+discovery+of+allosteric+modulators+of+GPCRs+for+treating+CNS+disorders&doi=10.1038%2Fnrd4308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders</span></div><div class="casAuthors">Conn, P. Jeffrey; Lindsley, Craig W.; Meiler, Jens; Niswender, Colleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">692-708</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Novel allosteric modulators of G protein-coupled receptors (GPCRs) are providing fundamental advances in the development of GPCR ligands with high subtype selectivity and novel modes of efficacy that have not been possible with traditional approaches.  As new allosteric modulators are advancing as drug candidates, we are developing an increased understanding of the major advantages and broad range of activities that can be achieved with these agents through selective modulation of specific signalling pathways, differential effects on GPCR homodimers vs. heterodimers, and other properties.  This understanding creates exciting opportunities, as well as unique challenges, in the optimization of novel therapeutic agents for disorders of the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS1YQIo2v0lLVg90H21EOLACvtfcHk0lhB-VKNpB_tbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtbzL&md5=07571da612fc9344e5d6af86aa3eaf83</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd4308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4308%26sid%3Dliteratum%253Aachs%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26atitle%3DOpportunities%2520and%2520challenges%2520in%2520the%2520discovery%2520of%2520allosteric%2520modulators%2520of%2520GPCRs%2520for%2520treating%2520CNS%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D692%26epage%3D708%26doi%3D10.1038%2Fnrd4308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span> <span> </span><span class="NLM_article-title">Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">37409</span>– <span class="NLM_lpage">37414</span>, <span class="refDoi"> DOI: 10.1074/jbc.M106728200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1074%2Fjbc.M106728200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=11473130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD3MXns1eksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=37409-37414&author=K.+M.+Kimauthor=K.+J.+Valenzanoauthor=S.+R.+Robinsonauthor=W.+D.+Yaoauthor=L.+S.+Barakauthor=M.+G.+Caron&title=Differential+regulation+of+the+dopamine+D2+and+D3+receptors+by+G+protein-coupled+receptor+kinases+and+beta-arrestins&doi=10.1074%2Fjbc.M106728200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and β-arrestins</span></div><div class="casAuthors">Kim, Kyeong-Man; Valenzano, Kenneth J.; Robinson, Susan R.; Yao, Wei Dong; Barak, Larry S.; Caron, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">37409-37414</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The D2 and D3 receptors (D2R and D3R), which are potential targets for antipsychotic drugs, have a similar structural architecture and signaling pathway.  Furthermore, in some brain regions they are expressed in the same cells, suggesting that differences between the two receptors might lie in other properties such as their regulation.  In this study the authors investigated, using COS-7 and HEK-293 cells, the mechanism underlying the intracellular trafficking of the D2R and D3R.  Activation of D2R caused G protein-coupled receptor kinase-dependent receptor phosphorylation, a robust translocation of β-arrestin to the cell membrane, and profound receptor internalization.  The internalization of the D2R was dynamin-dependent, suggesting that a clathrin-coated endocytic pathway is involved.  In addn., the D2R, upon agonist-mediated internalization, localized to intracellular compartments distinct from those utilized by the β2-adrenergic receptor.  However, in the case of the D3R, only subtle agonist-mediated receptor phosphorylation, β-arrestin translocation to the plasma membrane, and receptor internalization were obsd.  Interchange of the second and third intracellular loops of the D2R and D3R reversed their phenotypes, implicating these regions in the regulatory properties of the two receptors.  Thus, the authors' studies indicate that functional distinctions between the D2R and D3R may be found in their desensitization and cellular trafficking properties.  The differences in their regulatory properties suggest that they have distinct physiol. roles in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOhqTknhrd_LVg90H21EOLACvtfcHk0lhB-VKNpB_tbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXns1eksrc%253D&md5=c94706df9516d391398753cc64a17fc5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M106728200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M106728200%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DValenzano%26aufirst%3DK.%2BJ.%26aulast%3DRobinson%26aufirst%3DS.%2BR.%26aulast%3DYao%26aufirst%3DW.%2BD.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DDifferential%2520regulation%2520of%2520the%2520dopamine%2520D2%2520and%2520D3%2520receptors%2520by%2520G%2520protein-coupled%2520receptor%2520kinases%2520and%2520beta-arrestins%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D37409%26epage%3D37414%26doi%3D10.1074%2Fjbc.M106728200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongetti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBounty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of selectivity and efficacy at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6699</span>, <span class="refDoi"> DOI: 10.1021/jm300482h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300482h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6689-6699&author=A.+H.+Newmanauthor=T.+Beumingauthor=A.+K.+Banalaauthor=P.+Donthamsettiauthor=K.+Pongettiauthor=A.+LaBountyauthor=B.+Levyauthor=J.+Caoauthor=M.+Michinoauthor=R.+R.+Luedtkeauthor=J.+A.+Javitchauthor=L.+Shi&title=Molecular+determinants+of+selectivity+and+efficacy+at+the+dopamine+D3+receptor&doi=10.1021%2Fjm300482h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor</span></div><div class="casAuthors">Newman, Amy Hauck; Beuming, Thijs; Banala, Ashwini K.; Donthamsetti, Prashant; Pongetti, Katherine; LaBounty, Alex; Levy, Benjamin; Cao, Jianjing; Michino, Mayako; Luedtke, Robert R.; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6689-6699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.  The high sequence homol. between the D3R and D2R, esp. within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compds. challenging.  Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compds. and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy.  We find that selectivity arises from divergent interactions within a second binding pocket (SBP) sep. from the OBS, whereas efficacy depends on the binding mode in the OBS.  Our findings reveal structural features of the receptor that are crit. to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies.  These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmBJU7uyvVg7Vg90H21EOLACvtfcHk0liRHseEEVFDFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFCkt7c%253D&md5=033dd49282723650828a3ec0a31211e5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm300482h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300482h%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DPongetti%26aufirst%3DK.%26aulast%3DLaBounty%26aufirst%3DA.%26aulast%3DLevy%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DMolecular%2520determinants%2520of%2520selectivity%2520and%2520efficacy%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6689%26epage%3D6699%26doi%3D10.1021%2Fjm300482h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweppe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janowsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel analogues of (R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (sumanirole) provide clues to dopamine D2/D3 receptor agonist selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2973</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01612</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01612" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2973-2988&author=M.+F.+Zouauthor=T.+M.+Keckauthor=V.+Kumarauthor=P.+Donthamsettiauthor=M.+Michinoauthor=C.+Burzynskiauthor=C.+Schweppeauthor=A.+Bonifaziauthor=R.+B.+Freeauthor=D.+R.+Sibleyauthor=A.+Janowskyauthor=L.+Shiauthor=J.+A.+Javitchauthor=A.+H.+Newman&title=Novel+analogues+of+%28R%29-5-%28methylamino%29-5%2C6-dihydro-4H-imidazo%5B4%2C5%2C1-ij%5Dquinolin-2%281H%29-one+%28sumanirole%29+provide+clues+to+dopamine+D2%2FD3+receptor+agonist+selectivity&doi=10.1021%2Facs.jmedchem.5b01612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity</span></div><div class="casAuthors">Zou, Mu-Fa; Keck, Thomas M.; Kumar, Vivek; Donthamsetti, Prashant; Michino, Mayako; Burzynski, Caitlin; Schweppe, Catherine; Bonifazi, Alessandro; Free, R. Benjamin; Sibley, David R.; Janowsky, Aaron; Shi, Lei; Javitch, Jonathan A.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2973-2988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 1-, 5-, and 8-substituted analogs of sumanirole (I), a dopamine D2/D3 receptor (D2R/D3R) agonist, were synthesized.  Binding affinities at both D2R and D3R were higher when detd. in competition with the agonist radioligand [3H]7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT) than with the antagonist radioligand [3H]N-methylspiperone.  Although I was confirmed as a D2R-preferential agonist, its selectivity in binding and functional studies was lower than previously reported.  All analogs were detd. to be D2R/D3R agonists in both GoBRET and mitogenesis functional assays.  Loss of efficacy was detected for the N-1-substituted analogs at D3R.  In contrast, the N-5-alkyl-substituted analogs, and notably the n-butyl-arylamides (II and III), all showed improved affinity at D2R over I with neither a loss of efficacy nor an increase in selectivity.  Computational modeling provided a structural basis for the D2R selectivity of I, illustrating how subtle differences in the highly homologous orthosteric binding site (OBS) differentially affect D2R/D3R affinity and functional efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCYS7hdbWljrVg90H21EOLACvtfcHk0liRHseEEVFDFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yqs70%253D&md5=504e9fde86b9cef1a3b52fa4a3ef2063</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01612%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DSchweppe%26aufirst%3DC.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DJanowsky%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520analogues%2520of%2520%2528R%2529-5-%2528methylamino%2529-5%252C6-dihydro-4H-imidazo%255B4%252C5%252C1-ij%255Dquinolin-2%25281H%2529-one%2520%2528sumanirole%2529%2520provide%2520clues%2520to%2520dopamine%2520D2%252FD3%2520receptor%2520agonist%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2973%26epage%3D2988%26doi%3D10.1021%2Facs.jmedchem.5b01612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Soto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, B. K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonye, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span> <span> </span><span class="NLM_article-title">A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">aaw5885</span> <span class="refDoi"> DOI: 10.1126/scisignal.aaw5885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1126%2Fscisignal.aaw5885" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&author=M.+Sanchez-Sotoauthor=R.+K.+Vermaauthor=B.+K.+A.+Willetteauthor=E.+C.+Gonyeauthor=A.+M.+Mooreauthor=A.+E.+Moritzauthor=C.+A.+Boatengauthor=H.+Yanoauthor=R.+B.+Freeauthor=L.+Shiauthor=D.+R.+Sibley&title=A+structural+basis+for+how+ligand+binding+site+changes+can+allosterically+regulate+GPCR+signaling+and+engender+functional+selectivity&doi=10.1126%2Fscisignal.aaw5885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aaw5885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aaw5885%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Soto%26aufirst%3DM.%26aulast%3DVerma%26aufirst%3DR.%2BK.%26aulast%3DWillette%26aufirst%3DB.%2BK.%2BA.%26aulast%3DGonye%26aufirst%3DE.%2BC.%26aulast%3DMoore%26aufirst%3DA.%2BM.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DA%2520structural%2520basis%2520for%2520how%2520ligand%2520binding%2520site%2520changes%2520can%2520allosterically%2520regulate%2520GPCR%2520signaling%2520and%2520engender%2520functional%2520selectivity%26jtitle%3DSci.%2520Signaling%26date%3D2020%26volume%3D13%26doi%3D10.1126%2Fscisignal.aaw5885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salahpour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span> <span> </span><span class="NLM_article-title">BRET biosensors to study GPCR biology, pharmacology, and signal transduction</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.3389/fendo.2012.00105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.3389%2Ffendo.2012.00105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22952466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BC38bksV2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=105&author=A.+Salahpourauthor=S.+Espinozaauthor=B.+Masriauthor=V.+Lamauthor=L.+S.+Barakauthor=R.+R.+Gainetdinov&title=BRET+biosensors+to+study+GPCR+biology%2C+pharmacology%2C+and+signal+transduction&doi=10.3389%2Ffendo.2012.00105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">BRET biosensors to study GPCR biology, pharmacology, and signal transduction</span></div><div class="casAuthors">Salahpour Ali; Espinoza Stefano; Masri Bernard; Lam Vincent; Barak Larry S; Gainetdinov Raul R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bioluminescence resonance energy transfer (BRET)-based biosensors have been extensively used over the last decade to study protein-protein interactions and intracellular signal transduction in living cells.  In this review, we discuss the various BRET biosensors that have been developed to investigate biology, pharmacology, and signaling of G protein-coupled receptors (GPCRs).  GPCRs form two distinct types of multiprotein signal transduction complexes based upon their inclusion of G proteins or β-arrestins that can be differentially affected by drugs that exhibit functional selectivity toward G protein or β-arrestin signaling.  BRET has been especially adept at illuminating the dynamics of protein-protein interactions between receptors, G proteins, β-arrestins, and their many binding partners in living cells; as well as measuring the formation and accumulation of second messengers following receptor activation.  Specifically, we discuss in detail the application of BRET to study dopamine and trace amine receptors signaling, presenting examples of an exchange protein activated by cAMP biosensor to measure cAMP, β-arrestin biosensors to determine β-arrestin recruitment to the receptor, and dopamine D2 receptor and trace amine-associated receptor 1 biosensors to investigate heterodimerization between them.  As the biochemical spectrum of BRET biosensors expands, the number of signaling pathways that can be measured will concomitantly increase.  This will be particularly useful for the evaluation of functional selectivity in which the real-time BRET capability to measure distinct signaling modalities will dramatically shorten the time to characterize new generation of biased drugs.  These emerging approaches will further expand the growing application of BRET in the screening for novel pharmacologically active compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI8fyvdZc3H-IHSmpohpd0fW6udTcc2eaVhP6XvY8Xb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bksV2qtw%253D%253D&md5=cf710c8ff571036e36f0f28603ba9817</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2012.00105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2012.00105%26sid%3Dliteratum%253Aachs%26aulast%3DSalahpour%26aufirst%3DA.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DMasri%26aufirst%3DB.%26aulast%3DLam%26aufirst%3DV.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DBRET%2520biosensors%2520to%2520study%2520GPCR%2520biology%252C%2520pharmacology%252C%2520and%2520signal%2520transduction%26jtitle%3DFront.%2520Endocrinol.%26date%3D2012%26volume%3D3%26spage%3D105%26doi%3D10.3389%2Ffendo.2012.00105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Soto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span> <span> </span><span class="NLM_article-title">Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1124/mol.115.101808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fmol.115.101808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26843180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWntrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=457-466&author=M.+S%C3%A1nchez-Sotoauthor=A.+Bonifaziauthor=N.+S.+Caiauthor=M.+P.+Ellenbergerauthor=A.+H.+Newmanauthor=S.+Ferreauthor=H.+Yano&title=Evidence+for+noncanonical+neurotransmitter+activation%3A+norepinephrine+as+a+dopamine+D2-like+receptor+agonist&doi=10.1124%2Fmol.115.101808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist</span></div><div class="casAuthors">Sanchez-Soto, Marta; Bonifazi, Alessandro; Cai, Ning Sheng; Ellenberger, Michael P.; Newman, Amy Hauck; Ferre, Sergi; Yano, Hideaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-466</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Gαi/o-coupled dopamine D2-like receptor family comprises three subtypes: the D2 receptor (D2R), with short and long isoform variants (D2SR and D2LR), D3 receptor (D3R), and D4 receptor (D4R), with several polymorphic variants.  The common overlap of norepinephrine innervation and D2-like receptor expression patterns prompts the question of a possible noncanonical action by norepinephrine.  In fact, previous studies have suggested that norepinephrine can functionally interact with D4R.  To our knowledge, significant interactions between norepinephrine and D2R or D3R receptors have not been demonstrated.  By using radioligand binding and bioluminescent resonance energy transfer (BRET) assays in transfected cells, the present study attempted a careful comparison between dopamine and norepinephrine in their possible activation of all D2-like receptors, including the two D2R isoforms and the most common D4R polymorphic variants.  Functional BRET assays included activation of G proteins with all Gαi/o subunits, adenylyl cyclase inhibition, and β arrestin recruitment.  Norepinephrine acted as a potent agonist for all D2-like receptor subtypes, with the general rank order of potency of D3R > D4R ≥ D2SR ≥ D2L.  However, for both dopamine and norepinephrine, differences depended on the Gαi/o protein subunit involved.  The most striking differenceswere obsd. with Gαi2, where the rank order of potencies for both dopamine and norepinephrine were D4R > D2SR = D2LR >> D3R.  Furthermore the results do not support the existence of differences in the ability of dopamine and norepinephrine to activate different human D4R variants.  The potency of norepinephrine for adrenergic α2A receptor was only about 20-fold higher compared with D3R and D4R across the three functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbXqWDRdlAsrVg90H21EOLACvtfcHk0lh8cCVj2_pp6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWntrbN&md5=df11300a8c0bb71ef35b5d2917bee471</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101808%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Soto%26aufirst%3DM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DH.%26atitle%3DEvidence%2520for%2520noncanonical%2520neurotransmitter%2520activation%253A%2520norepinephrine%2520as%2520a%2520dopamine%2520D2-like%2520receptor%2520agonist%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D457%26epage%3D466%26doi%3D10.1124%2Fmol.115.101808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel bivalent ligands based on the sumanirole pharmacophore reveal dopamine D2 receptor (D2R) biased agonism</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2890</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2890-2907&author=A.+Bonifaziauthor=H.+Yanoauthor=M.+P.+Ellenbergerauthor=L.+Mullerauthor=V.+Kumarauthor=M.+F.+Zouauthor=N.+S.+Caiauthor=A.+M.+Guerreroauthor=A.+S.+Woodsauthor=L.+Shiauthor=A.+H.+Newman&title=Novel+bivalent+ligands+based+on+the+sumanirole+pharmacophore+reveal+dopamine+D2+receptor+%28D2R%29+biased+agonism&doi=10.1021%2Facs.jmedchem.6b01875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism</span></div><div class="casAuthors">Bonifazi, Alessandro; Yano, Hideaki; Ellenberger, Michael P.; Muller, Ludovic; Kumar, Vivek; Zou, Mu-Fa; Cai, Ning Sheng; Guerrero, Adrian M.; Woods, Amina S.; Shi, Lei; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2890-2907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of bivalent ligands has attracted interest as a way to potentially improve the selectivity and/or affinity for a specific receptor subtype.  The ability to bind two distinct receptor binding sites simultaneously can allow the selective activation of specific G-protein dependent or β-arrestin-mediated cascade pathways.  Herein, we developed an extended SAR study using sumanirole (1) as the primary pharmacophore.  We found that substitutions in the N-1- and/or N-5-positions, physiochem. properties of those substituents, and secondary arom. pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by Gi/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment.  Compd. 19 was identified as a new lead for its selective D2 G-protein biased agonism with an EC50 in the subnanomolar range.  Structure-activity correlations were obsd. between substitutions in positions N-1 and/or N-5 of 1 and the capacity of the new bivalent compds. to selectively activate G-proteins vs. β-arrestin recruitment in D2R-BRET functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprfScHokUgP7Vg90H21EOLACvtfcHk0lgczRmGXP1Y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlSrsb0%253D&md5=24bf22a101756e44fbc8f8345d2c1fe4</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01875%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DM.%2BF.%26aulast%3DCai%26aufirst%3DN.%2BS.%26aulast%3DGuerrero%26aufirst%3DA.%2BM.%26aulast%3DWoods%26aufirst%3DA.%2BS.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520bivalent%2520ligands%2520based%2520on%2520the%2520sumanirole%2520pharmacophore%2520reveal%2520dopamine%2520D2%2520receptor%2520%2528D2R%2529%2520biased%2520agonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2890%26epage%3D2907%26doi%3D10.1021%2Facs.jmedchem.6b01875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudevan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, D. K.</span></span> <span> </span><span class="NLM_article-title">ERK activation pathways downstream of GPCRs</span>. <i>Int. Rev. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/bs.ircmb.2018.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fbs.ircmb.2018.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=29699693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslOqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2018&pages=79-109&author=R.+Jainauthor=U.+Watsonauthor=L.+Vasudevanauthor=D.+K.+Saini&title=ERK+activation+pathways+downstream+of+GPCRs&doi=10.1016%2Fbs.ircmb.2018.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">ERK activation pathways downstream of GPCRs</span></div><div class="casAuthors">Jain, Ruchi; Watson, Uchenna; Vasudevan, Lakshmi; Saini, Deepak K.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">G Protein-Coupled Receptors: Emerging Paradigms in Activation, Signaling and Regulation, Part A</span>),
    <span class="NLM_cas:pages">79-109</span>CODEN:
                <span class="NLM_cas:coden">IRCMAH</span>;
        ISSN:<span class="NLM_cas:issn">1937-6448</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">GPCRs, the 7-TM receptors, represent a class of cell surface receptors which modulate a variety of physiol. responses.  The serpentine structure in addn. to contributing the diversity of stimuli these receptors can sense also provides flexibility to the extracellular and intracellular regions where other proteins can interact with and can form functionally active multimeric entities.  The range in signaling and physiol. responses generated by these receptors can be attributed to a large repertoire of the receptor subtypes as well as their differential coupling to various classes of G-protein subunits and other proteins which facilitate multistate activation.  A multistate GPCR can engage diverse signaling mols., thereby modulating not only the canonical cellular responses but also noncanonical responses typically assocd. with activation of other cascades such as RTK and MAPK/ERK signaling.  Given the crucial involvement of MAP kinase/ERK signaling in cell fate detn. specially with respect to regulating cell proliferation, cellular apoptosis, and survival, GPCR-mediated cross-activation of MAPK has been explored in various systems and shown to involve functional integration of multiple pathways.  This review describes the present knowledge of the different mechanisms of ERK activation downstream of GPCRs and our present understanding of receptor-dependent and -independent MAPK activation cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5AuLkT6t3LVg90H21EOLACvtfcHk0lgczRmGXP1Y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslOqsbk%253D&md5=bd2cd11ef1314ed8933018602fd45d0d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fbs.ircmb.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.ircmb.2018.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%26aulast%3DWatson%26aufirst%3DU.%26aulast%3DVasudevan%26aufirst%3DL.%26aulast%3DSaini%26aufirst%3DD.%2BK.%26atitle%3DERK%2520activation%2520pathways%2520downstream%2520of%2520GPCRs%26jtitle%3DInt.%2520Rev.%2520Cell%2520Mol.%2520Biol.%26date%3D2018%26volume%3D338%26spage%3D79%26epage%3D109%26doi%3D10.1016%2Fbs.ircmb.2018.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E. V.</span></span> <span> </span><span class="NLM_article-title">Arrestin-mediated signaling: is there a controversy?</span>. <i>World J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.4331/wjbc.v9.i3.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.4331%2Fwjbc.v9.i3.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=30595812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BB3cnms12gsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=25-35&author=V.+V.+Gurevichauthor=E.+V.+Gurevich&title=Arrestin-mediated+signaling%3A+is+there+a+controversy%3F&doi=10.4331%2Fwjbc.v9.i3.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Arrestin-mediated signaling: Is there a controversy?</span></div><div class="casAuthors">Gurevich Vsevolod V; Gurevich Eugenia V</div><div class="citationInfo"><span class="NLM_cas:title">World journal of biological chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">25-35</span>
        ISSN:<span class="NLM_cas:issn">1949-8454</span>.
    </div><div class="casAbstract">The activation of the mitogen-activated protein (MAP) kinases extracellular signal-regulated kinase (ERK)1/2 was traditionally used as a readout of signaling of G protein-coupled receptors (GPCRs) via arrestins, as opposed to conventional GPCR signaling via G proteins.  Several recent studies using HEK293 cells where all G proteins were genetically ablated or inactivated, or both non-visual arrestins were knocked out, demonstrated that ERK1/2 phosphorylation requires G protein activity, but does not necessarily require the presence of non-visual arrestins.  This appears to contradict the prevailing paradigm.  Here we discuss these results along with the recent data on gene edited cells and arrestin-mediated signaling.  We suggest that there is no real controversy.  G proteins might be involved in the activation of the upstream-most MAP3Ks, although in vivo most MAP3K activation is independent of heterotrimeric G proteins, being initiated by receptor tyrosine kinases and/or integrins.  As far as MAP kinases are concerned, the best-established role of arrestins is scaffolding of the three-tiered cascades (MAP3K-MAP2K-MAPK).  Thus, it seems likely that arrestins, GPCR-bound and free, facilitate the propagation of signals in these cascades, whereas signal initiation via MAP3K activation may be independent of arrestins.  Different MAP3Ks are activated by various inputs, some of which are mediated by G proteins, particularly in cell culture, where we artificially prevent signaling by receptor tyrosine kinases and integrins, thereby favoring GPCR-induced signaling.  Thus, there is no reason to change the paradigm: Arrestins and G proteins play distinct non-overlapping roles in cell signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXFg0b3lPWBEQ0lWbKiCflfW6udTcc2ebC5HvLrguqxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnms12gsQ%253D%253D&md5=59b4f08141238f64410faa5b42181714</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.4331%2Fwjbc.v9.i3.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4331%252Fwjbc.v9.i3.25%26sid%3Dliteratum%253Aachs%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DGurevich%26aufirst%3DE.%2BV.%26atitle%3DArrestin-mediated%2520signaling%253A%2520is%2520there%2520a%2520controversy%253F%26jtitle%3DWorld%2520J.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D9%26spage%3D25%26epage%3D35%26doi%3D10.4331%2Fwjbc.v9.i3.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielcarek, N.</span></span> <span> </span><span class="NLM_article-title">The ins and outs of pertussis toxin</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">4668</span>– <span class="NLM_lpage">4682</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2011.08237.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fj.1742-4658.2011.08237.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=21740523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFygsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=4668-4682&author=C.+Lochtauthor=L.+Coutteauthor=N.+Mielcarek&title=The+ins+and+outs+of+pertussis+toxin&doi=10.1111%2Fj.1742-4658.2011.08237.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of pertussis toxin</span></div><div class="casAuthors">Locht, Camille; Coutte, Loic; Mielcarek, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4668-4682</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Pertussis toxin, produced and secreted by the whooping cough agent Bordetella pertussis, is one of the most complex sol. bacterial proteins.  It is actively secreted through the B. pertussis cell invelope by the Ptl secretion system, a member of the widespread type IV secretion systems.  The toxin is composed of 5 subunits (named S1 to S5 according to their decreasing mol. wts.) arranged in an A-B structure.  The A protomer is composed of the enzymically active S1 subunit, which catalyzes ADP-ribosylation of the α subunit of trimeric G proteins, thereby disturbing the metabolic functions of the target cells, leading to a variety of biol. activities.  The B oligomer is composed of 1S2:1S3:2S4:1S5 and is responsible for binding of the toxin to the target cell receptors and for intracellular trafficking via receptor-mediated endocytosis and retrograde transport.  The toxin is one of the most important virulence factors of B. pertussis and is a component of all current vaccines against whooping cough.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJhofih3mT-rVg90H21EOLACvtfcHk0lgczRmGXP1Y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFygsrs%253D&md5=c114959565a9049773f64adf64bf697a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2011.08237.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2011.08237.x%26sid%3Dliteratum%253Aachs%26aulast%3DLocht%26aufirst%3DC.%26aulast%3DCoutte%26aufirst%3DL.%26aulast%3DMielcarek%26aufirst%3DN.%26atitle%3DThe%2520ins%2520and%2520outs%2520of%2520pertussis%2520toxin%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D4668%26epage%3D4682%26doi%3D10.1111%2Fj.1742-4658.2011.08237.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangmool, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, H.</span></span> <span> </span><span class="NLM_article-title">G(i/o) protein-dependent and -independent actions of pertussis toxin (PTX)</span>. <i>Toxins</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.3390/toxins3070884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.3390%2Ftoxins3070884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=22069745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGqsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=884-899&author=S.+Mangmoolauthor=H.+Kurose&title=G%28i%2Fo%29+protein-dependent+and+-independent+actions+of+pertussis+toxin+%28PTX%29&doi=10.3390%2Ftoxins3070884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Gi/o protein-dependent and -independent actions of pertussis toxin (PTX)</span></div><div class="casAuthors">Mangmool, Supachoke; Kurose, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Toxins</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">884-899</span>CODEN:
                <span class="NLM_cas:coden">TOXIB7</span>;
        ISSN:<span class="NLM_cas:issn">2072-6651</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Pertussis toxin (PTX) is a typical A-B toxin.  The A-protomer (S1 subunit) exhibits ADP-ribosyltransferase activity.  The B-oligomer consists of four subunits (S2 to S5) and binds extracellular mols. that allow the toxin to enter the cells.  The A-protomer ADP-ribosylates the α subunits of heterotrimeric Gi/o proteins, resulting in the receptors being uncoupled from the Gi/o proteins.  The B-oligomer binds proteins expressed on the cell surface, such as Toll-like receptor 4 and activates an intracellular signal transduction cascade.  Thus, PTX modifies cellular responses by at least two different signaling pathways; ADP-ribosylation of the Gαi/o proteins by the A-protomer (Gi/o protein-dependent action) and the interaction of the B-oligomer with cell surface proteins (Gi/o protein-independent action).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpAETCXrweT7Vg90H21EOLACvtfcHk0lhv7mbDPFFxfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGqsrnI&md5=5db2f7f113457f3e4e1fb6198c530d93</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3390%2Ftoxins3070884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftoxins3070884%26sid%3Dliteratum%253Aachs%26aulast%3DMangmool%26aufirst%3DS.%26aulast%3DKurose%26aufirst%3DH.%26atitle%3DG%2528i%252Fo%2529%2520protein-dependent%2520and%2520-independent%2520actions%2520of%2520pertussis%2520toxin%2520%2528PTX%2529%26jtitle%3DToxins%26date%3D2011%26volume%3D3%26spage%3D884%26epage%3D899%26doi%3D10.3390%2Ftoxins3070884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.+P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0lhv7mbDPFFxfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creese, I.</span></span> <span> </span><span class="NLM_article-title">Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">6351</span>– <span class="NLM_lpage">6361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=6176582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaL38XktFyjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=6351-6361&author=D.+R.+Sibleyauthor=A.+De+Leanauthor=I.+Creese&title=Anterior+pituitary+dopamine+receptors.+Demonstration+of+interconvertible+high+and+low+affinity+states+of+the+D-2+dopamine+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Anterior pituitary dopamine receptors.  Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor</span></div><div class="casAuthors">Sibley, David R.; De Lean, Andre; Creese, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6351-61</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The interactions of dopaminergic agonists and antagonists with binding sites in bovine anterior pituitary membranes have been investigated with radioligand-binding techniques and computer-modeling procedures.  3H-labeled agonist (3H-agonist) binding is stereospecific, reversible, saturable, and of high affinity.  The rank order of catecholamines, phenothiazines, and related drugs in competing for 3H-agonist binding is indicative of interactions with a D-2 dopamine receptor.  Both agonist/3H-agonist and antagonist/3H-agonist competition curves are monophasic and noncooperative, with computer anal. indicating a single class of binding sites.  Sp. 3H-agonist binding can be completely inhibited by guanine nucleotides.  guanyl-5'-yl imidodiphosphate  [34273-04-6] Is the most potent nucleotide, followed by GTP  [86-01-1] and GDP  [146-91-8] which are equipotent.  The equil. binding capacity for 3H-labeled antagonists (3H-antagonists) is twice that for 3H-agonists.  Unlabeled antagonists inhibit 3H-antagonist binding competitively and exhibit antagonist/3H-antagonist competition curves which model best to a state of homogeneous affinity.  In contrast, unlabeled agonists inhibit 3H-antagonist binding in a heterogeneous fashion displaying multiphasic competition curves which can be resolved into high- and low-affinity binding sites.  In the presence of satg. concns. of guanine nucleotides, however, the agonist/3H-antagonist curves model best to a single affinity state which is identical with the low-affinity state seen in control curves.  The binding data can be explained by postulating 2 states of the D-2 dopamine receptor, inducible by agonists but not antagonists and modulated by guanine nucleotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPIbAAeUc1SLVg90H21EOLACvtfcHk0lhv7mbDPFFxfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XktFyjs7Y%253D&md5=a5474a2efe8c5e0c50e9bd939f759c9d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DDe%2BLean%26aufirst%3DA.%26aulast%3DCreese%26aufirst%3DI.%26atitle%3DAnterior%2520pituitary%2520dopamine%2520receptors.%2520Demonstration%2520of%2520interconvertible%2520high%2520and%2520low%2520affinity%2520states%2520of%2520the%2520D-2%2520dopamine%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D6351%26epage%3D6361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creese, I.</span></span> <span> </span><span class="NLM_article-title">Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=6835198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaL3sXhsFGmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=295-302&author=D.+R.+Sibleyauthor=L.+C.+Mahanauthor=I.+Creese&title=Dopamine+receptor+binding+on+intact+cells.+Absence+of+a+high-affinity+agonist-receptor+binding+state"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptor binding on intact cells:  absence of a high-affinity agonist-receptor binding state</span></div><div class="casAuthors">Sibley, David R.; Mahan, Lawrence C.; Creese, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">295-302</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The ligand binding characteristics of D-2 dopaminergic receptors on dispersed bovine anterior pituitary cells were investigated.  The binding of the radiolabeled butyrophenone antagonist, spiroperidol  [749-02-0], to intact cells was reversible, of high-affinity, and saturable, with an apparent dissocn. const. (KD) of 0.21 nM and a maximal binding capacity of 9.0 fmoles/106 cells.  The stereospecificity and rank order of neuroleptic antagonists, catecholamines, and related drugs in competing for [3H]spiroperidol binding were indicative of interactions with a dopamine  [51-61-6] receptor.  There was no high-affinity, stereospecific, or saturable binding of the radiolabeled dopamine agonist, N-propylnorapomorphine (NPA)  [18426-20-5] to these dispersed cells.  In contrast, washed membranes prepd. from these cells exhibited high-affinity [3H]NPA binding, with a KD of 0.25 nM.  Similarly, in membranes prepd. from dispersed cells, agonist/[3H]spiroperidol competition curves were heterogeneous, exhibiting high- and low-affinity displacement phases.  In the presence of exogenous guanine nucleotides, these curves were shifted to the right and became uniphasic.  Computer anal. indicated that agonist/[3H]spiroperidol curves in membranes are best explained by assuming a 2-state binding model, whereas in the presence of guanine nucleotides a 1-state model is sufficient to fit the data.  In intact cells, however, agonist/[3H]spiroperidol curves were monophasic and exhibited affinities similar to the corresponding low-affinity agonist binding state seen in membranes.  Addn. of guanine nucleotides did not alter the agonist/[3H]spiroperidol curves in intact cells.  Apparently, high-affinity dopamine agonist binding in pituitary membranes does not represent a distinct receptor subtype but rather a guanine nucleotide-sensitive, agonist-specific binding state of a single D-2 receptor.  In this model, endogenous or exogenous guanine nucleotides in intact cells or membranes, resp., mediate an interconversion from the high- to the low-affinity agonist binding state, thus effectively eliminating high-affinity agonist binding as measured directly with [3H]NPA or indirectly with agonist/[3H]spiroperidol competition expts.  Nonequil. binding expts. indicated that in the presence of guanine nucleotides the high-affinity agonist binding state is undetectable throughout the approach to equil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVwiqpEQxW97Vg90H21EOLACvtfcHk0ljPHZ1TmGKQig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhsFGmt74%253D&md5=177ecd033a8717307b895d3d68986662</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMahan%26aufirst%3DL.%2BC.%26aulast%3DCreese%26aufirst%3DI.%26atitle%3DDopamine%2520receptor%2520binding%2520on%2520intact%2520cells.%2520Absence%2520of%2520a%2520high-affinity%2520agonist-receptor%2520binding%2520state%26jtitle%3DMol.%2520Pharmacol.%26date%3D1983%26volume%3D23%26spage%3D295%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narendran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slifstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erritzoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kegeles, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abi-Dargham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laruelle, M.</span></span> <span> </span><span class="NLM_article-title">In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1002/syn.20013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fsyn.20013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=15065219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjslGgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=188-208&author=R.+Narendranauthor=D.+R.+Hwangauthor=M.+Slifsteinauthor=P.+S.+Talbotauthor=D.+Erritzoeauthor=Y.+Huangauthor=T.+B.+Cooperauthor=D.+Martinezauthor=L.+S.+Kegelesauthor=A.+Abi-Darghamauthor=M.+Laruelle&title=In+vivo+vulnerability+to+competition+by+endogenous+dopamine%3A+comparison+of+the+D2+receptor+agonist+radiotracer+%28-%29-N-%5B11C%5Dpropyl-norapomorphine+%28%5B11C%5DNPA%29+with+the+D2+receptor+antagonist+radiotracer+%5B11C%5D-raclopride&doi=10.1002%2Fsyn.20013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride</span></div><div class="casAuthors">Narendran, Rajesh; Hwang, Dah-Ren; Slifstein, Mark; Talbot, Peter S.; Erritzoe, David; Huang, Yiyun; Cooper, Thomas B.; Martinez, Diana; Kegeles, Lawrence S.; Abi-Dargham, Anissa; Laruelle, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">188-208</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">(-)-N-Propyl-norapomorphine (NPA) is a full dopamine (DA) D2 receptor agonist and [11C]NPA is a suitable radiotracer to image D2 receptors configured in a state of high affinity for agonists with positron emission tomog. (PET).  In this study the vulnerability of the in vivo binding of [11C]NPA to acute fluctuation in synaptic DA was assessed with PET in baboons and compared to that of the ref. D2 receptor antagonist radiotracer [11C]raclopride.  Three male baboons were studied with [11C]raclopride and [11C]NPA under baseline conditions and following administration of the potent DA releaser amphetamine (0.3, 0.5, and 1.0 mg kg-1 i.v.).  Kinetic modeling with an arterial input function was used to derive the striatal specific-to-nonspecific equil. partition coeff. (V3'').  [11C]Raclopride V3'' was reduced by 24 ± 10%, 32 ± 6%, and 44 ± 9% following amphetamine doses of 0.3, 0.5, and 1.0 mg kg-1, resp.  [11C]NPA V3'' was reduced by 32 ± 2%, 45 ± 3%, and 53 ± 9% following amphetamine doses of 0.3, 0.5, and 1.0 mg kg-1, resp.  Thus, endogenous DA was more effective at competing with [11C]NPA binding compared to [11C]raclopride binding, a finding consistent with the pharmacol. of these tracers (agonist vs. antagonist).  These results also suggest that 71% of D2 receptors are configured in a state of high affinity for agonists in vivo.  In conclusion, [11C]NPA might provide a superior radiotracer to probe presynaptic DA function with PET in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpopfT4WzpIyLVg90H21EOLACvtfcHk0ljPHZ1TmGKQig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjslGgt7g%253D&md5=1c61e44d1b32a62b3178a06e24a9f170</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20013%26sid%3Dliteratum%253Aachs%26aulast%3DNarendran%26aufirst%3DR.%26aulast%3DHwang%26aufirst%3DD.%2BR.%26aulast%3DSlifstein%26aufirst%3DM.%26aulast%3DTalbot%26aufirst%3DP.%2BS.%26aulast%3DErritzoe%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DT.%2BB.%26aulast%3DMartinez%26aufirst%3DD.%26aulast%3DKegeles%26aufirst%3DL.%2BS.%26aulast%3DAbi-Dargham%26aufirst%3DA.%26aulast%3DLaruelle%26aufirst%3DM.%26atitle%3DIn%2520vivo%2520vulnerability%2520to%2520competition%2520by%2520endogenous%2520dopamine%253A%2520comparison%2520of%2520the%2520D2%2520receptor%2520agonist%2520radiotracer%2520%2528-%2529-N-%255B11C%255Dpropyl-norapomorphine%2520%2528%255B11C%255DNPA%2529%2520with%2520the%2520D2%2520receptor%2520antagonist%2520radiotracer%2520%255B11C%255D-raclopride%26jtitle%3DSynapse%26date%3D2004%26volume%3D52%26spage%3D188%26epage%3D208%26doi%3D10.1002%2Fsyn.20013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Free, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8618</span>– <span class="NLM_lpage">8621</span>, <span class="refDoi"> DOI: 10.1039/C5CC02204E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1039%2FC5CC02204E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25896577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1Wnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=8618-8621&author=M.+Michinoauthor=R.+B.+Freeauthor=T.+B.+Doyleauthor=D.+R.+Sibleyauthor=L.+Shi&title=Structural+basis+for+Na%28%2B%29-sensitivity+in+dopamine+D2+and+D3+receptors&doi=10.1039%2FC5CC02204E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for Na+-sensitivity in dopamine D2 and D3 receptors</span></div><div class="casAuthors">Michino, Mayako; Free, R. Benjamin; Doyle, Trevor B.; Sibley, David R.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">8618-8621</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">To understand the structural basis for the Na+-sensitivity of ligand binding to dopamine D2-like receptors, using computational anal. in combination with binding assays, the authors identified interactions crit. in propagating the impact of Na+ on receptor conformations and on the ligand-binding site.  The authors' findings expand the pharmacol.-relevant conformational spectrum of these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonu0n6gq5E2bVg90H21EOLACvtfcHk0lgSdsnr8wLyOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1Wnuro%253D&md5=750d293936c4215a96a5deb95f6271d6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1039%2FC5CC02204E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC02204E%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DStructural%2520basis%2520for%2520Na%2528%252B%2529-sensitivity%2520in%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D8618%26epage%3D8621%26doi%3D10.1039%2FC5CC02204E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarzycka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span> <span> </span><span class="NLM_article-title">Harnessing ion-binding sites for GPCR pharmacology</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1124/pr.119.017863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fpr.119.017863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=31551350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhslOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=571-595&author=B.+Zarzyckaauthor=S.+A.+Zaidiauthor=B.+L.+Rothauthor=V.+Katritch&title=Harnessing+ion-binding+sites+for+GPCR+pharmacology&doi=10.1124%2Fpr.119.017863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Ion-Binding Sites for GPCR Pharmacology</span></div><div class="casAuthors">Zarzycka Barbara; Zaidi Saheem A; Roth Bryan L; Katritch Vsevolod</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-595</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Endogenous ions play important roles in the function and pharmacology of G-protein coupled receptors (GPCRs).  Historically the evidence for ionic modulation of GPCR function dates to 1973 with studies of opioid receptors, where it was demonstrated that physiologic concentrations of sodium allosterically attenuated agonist binding.  This Na(+)-selective effect was distinct from effects of other monovalent and divalent cations, with the latter usually counteracting sodium's negative allosteric modulation of binding.  Since then, numerous studies documenting the effects of mono- and divalent ions on GPCR function have been published.  While ions can act selectively and nonselectively at many sites in different receptors, the discovery of the conserved sodium ion site in class A GPCR structures in 2012 revealed the unique nature of Na(+) site, which has emerged as a near-universal site for allosteric modulation of class A GPCR structure and function.  In this review, we synthesize and highlight recent advances in the functional, biophysical, and structural characterization of ions bound to GPCRs.  Taken together, these findings provide a molecular understanding of the unique roles of Na(+) and other ions as GPCR allosteric modulators.  We will also discuss how this knowledge can be applied to the redesign of receptors and ligand probes for desired functional and pharmacological profiles.  SIGNIFICANCE STATEMENT: The function and pharmacology of GPCRs strongly depend on the presence of mono and divalent ions in experimental assays and in living organisms.  Recent insights into the molecular mechanism of this ion-dependent allosterism from structural, biophysical, biochemical, and computational studies provide quantitative understandings of the pharmacological effects of drugs in vitro and in vivo and open new avenues for the rational design of chemical probes and drug candidates with improved properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5AH-E4H-sd4McDoIzZtNkfW6udTcc2eb1WFTYeUiOa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhslOrsQ%253D%253D&md5=59b4c3be0c835ca26f9c2cb5d8b60142</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fpr.119.017863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.119.017863%26sid%3Dliteratum%253Aachs%26aulast%3DZarzycka%26aufirst%3DB.%26aulast%3DZaidi%26aufirst%3DS.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKatritch%26aufirst%3DV.%26atitle%3DHarnessing%2520ion-binding%2520sites%2520for%2520GPCR%2520pharmacology%26jtitle%3DPharmacol.%2520Rev.%26date%3D2019%26volume%3D71%26spage%3D571%26epage%3D595%26doi%3D10.1124%2Fpr.119.017863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Regulation of anterior pituitary D2 dopamine receptors by magnesium and sodium ions</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1842</span>– <span class="NLM_lpage">1849</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1985.tb10542.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fj.1471-4159.1985.tb10542.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=2932536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaL28XhtlWr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1985&pages=1842-1849&author=M.+Watanabeauthor=S.+R.+Georgeauthor=P.+Seeman&title=Regulation+of+anterior+pituitary+D2+dopamine+receptors+by+magnesium+and+sodium+ions&doi=10.1111%2Fj.1471-4159.1985.tb10542.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of anterior pituitary D2 dopamine receptors by magnesium and sodium ions</span></div><div class="casAuthors">Watanabe, Masayuki; George, Susan R.; Seeman, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1842-9</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">At D2 dopamine receptors in porcine anterior pituitary tissue, Mg2+ shifted receptors to agonist high-affinity states, but decreased the affinity of the antagonist [3H]spiperone.  Conversely, Na+ shifted the receptors to agonist low-affinity states, but increased the affinity of [3H]spiperone.  Mg is proposed to stabilize the hormone-receptor-guanine nucleotide regulatory protein complex, whereas Na appears to destabilize this ternary complex.  Thus, Mg and Na appear to mediate their regulatory effects via a common component at the D2 dopamine-receptor ternary complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHpRHyaW1tFrVg90H21EOLACvtfcHk0lgSdsnr8wLyOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhtlWr&md5=5f8b07cf6e45c1aa216acbba5c10b0c9</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1985.tb10542.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1985.tb10542.x%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DRegulation%2520of%2520anterior%2520pituitary%2520D2%2520dopamine%2520receptors%2520by%2520magnesium%2520and%2520sodium%2520ions%26jtitle%3DJ.%2520Neurochem.%26date%3D1985%26volume%3D45%26spage%3D1842%26epage%3D1849%26doi%3D10.1111%2Fj.1471-4159.1985.tb10542.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Drugs and valvular heart disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1056/NEJMp068265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1056%2FNEJMp068265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=17202450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=6-9&author=B.+L.+Roth&title=Drugs+and+valvular+heart+disease&doi=10.1056%2FNEJMp068265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and valvular heart disease</span></div><div class="casAuthors">Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-9</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaFEwabTP8rVg90H21EOLACvtfcHk0lgSdsnr8wLyOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D&md5=e5161a25f1a2596cef68030f0f8a7b61</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1056%2FNEJMp068265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp068265%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DDrugs%2520and%2520valvular%2520heart%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D6%26epage%3D9%26doi%3D10.1056%2FNEJMp068265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanettini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzoli, G.</span></span> <span> </span><span class="NLM_article-title">Valvular heart disease and the use of dopamine agonists for Parkinson’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa054830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1056%2FNEJMoa054830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=17202454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlCgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=39-46&author=R.+Zanettiniauthor=A.+Antoniniauthor=G.+Gattoauthor=R.+Gentileauthor=S.+Teseiauthor=G.+Pezzoli&title=Valvular+heart+disease+and+the+use+of+dopamine+agonists+for+Parkinson%E2%80%99s+disease&doi=10.1056%2FNEJMoa054830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Valvular heart disease and the use of dopamine agonists for Parkinson's disease</span></div><div class="casAuthors">Zanettini, Renzo; Antonini, Angelo; Gatto, Gemma; Gentile, Rosa; Tesei, Silvana; Pezzoli, Gianni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ergot-derived dopamine receptor agonists, often used in the treatment of Parkinson's disease, have been assocd. with an increased risk of valvular heart disease.  We performed an echocardiog. prevalence study in 155 patients taking dopamine agonists for Parkinson's disease (pergolide, 64 patients; cabergoline, 49; and non-ergot-derived dopamine agonists, 42) and 90 control subjects.  Valve regurgitation was assessed according to American Society of Echocardiog. recommendations.  The mitral-valve tenting area was also measured and used as a quant. index for leaflet stiffening and apical displacement of leaflet coaptation.  Clin. important regurgitation (moderate to severe, grade 3 to 4) in any valve was found with significantly greater frequency in patients taking pergolide (23.4%) or cabergoline (28.6%) but not in patients taking non-ergot-derived dopamine agonists (0%), as compared with control subjects (5.6%).  The relative risk for moderate or severe valve regurgitation in the pergolide group was 6.3 for mitral regurgitation (P = 0.008), 4.2 for aortic regurgitation (P = 0.01), and 5.6 for tricuspid regurgitation (P = 0.16); corresponding relative risks in the cabergoline group were 4.6 (P = 0.09), 7.3 (P < 0.001), and 5.5 (P = 0.12).  The mean mitral tenting area was significantly greater in ergot-treated patients and showed a linear relationship with the severity of mitral regurgitation.  Patients treated with ergot derivs. who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades.  The frequency of clin. important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non-ergot-derived dopamine agonists, as compared with control subjects.  These findings should be considered in evaluating the risk-benefit ratio of treatment with ergot derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBEYayXrLZ37Vg90H21EOLACvtfcHk0ljAAgBYWgBvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlCgsQ%253D%253D&md5=b41c2061f5deabc517e33a51ea15d1a7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa054830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa054830%26sid%3Dliteratum%253Aachs%26aulast%3DZanettini%26aufirst%3DR.%26aulast%3DAntonini%26aufirst%3DA.%26aulast%3DGatto%26aufirst%3DG.%26aulast%3DGentile%26aufirst%3DR.%26aulast%3DTesei%26aufirst%3DS.%26aulast%3DPezzoli%26aufirst%3DG.%26atitle%3DValvular%2520heart%2520disease%2520and%2520the%2520use%2520of%2520dopamine%2520agonists%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D39%26epage%3D46%26doi%3D10.1056%2FNEJMoa054830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boateng, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">Toward understanding the structural basis of partial agonism at the dopamine D3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">593</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=580-593&author=M.+Michinoauthor=C.+A.+Boatengauthor=P.+Donthamsettiauthor=H.+Yanoauthor=O.+M.+Bakareauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=T.+M.+Keckauthor=V.+Kumarauthor=C.+Zhuauthor=R.+Vermaauthor=J.+R.+Deschampsauthor=J.+A.+Javitchauthor=A.+H.+Newmanauthor=L.+Shi&title=Toward+understanding+the+structural+basis+of+partial+agonism+at+the+dopamine+D3+receptor&doi=10.1021%2Facs.jmedchem.6b01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor</span></div><div class="casAuthors">Michino, Mayako; Boateng, Comfort A.; Donthamsetti, Prashant; Yano, Hideaki; Bakare, Oluyomi M.; Bonifazi, Alessandro; Ellenberger, Michael P.; Keck, Thomas M.; Kumar, Vivek; Zhu, Clare; Verma, Ravi; Deschamps, Jeffrey R.; Javitch, Jonathan A.; Newman, Amy Hauck; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">580-593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both dopamine D3 receptor (D3R) partial agonists and antagonists have been implicated as potential medications for substance use disorders.  In contrast to antagonists, partial agonists may cause fewer side effects since they maintain some dopaminergic tone and may be less disruptive to normal neuronal functions.  Here, the authors report three sets of 4-phenylpiperazine stereoisomers that differ considerably in efficacy: the (R)-enantiomers are antagonists/weak partial agonists, whereas the (S)-enantiomers are much more efficacious.  To investigate the structural basis of partial agonism, the authors performed comparative microsecond-scale mol. dynamics simulations starting from the inactive state of D3R in complex with these enantiomers.  Anal. of the simulation results reveals common structural rearrangements near the ligand binding site induced by the bound (S)-enantiomers, but not by the (R)-enantiomers, that are features of partially activated receptor conformations.  These receptor models bound with partial agonists may be useful for structure-based design of compds. with tailored efficacy profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELFqc0pAf8LVg90H21EOLACvtfcHk0ljAAgBYWgBvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSgu7nK&md5=91e378048c5dfd4c44fb54746a2e1df2</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01148%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBoateng%26aufirst%3DC.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DKeck%26aufirst%3DT.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DVerma%26aufirst%3DR.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520partial%2520agonism%2520at%2520the%2520dopamine%2520D3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D580%26epage%3D593%26doi%3D10.1021%2Facs.jmedchem.6b01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1124/pr.114.009944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fpr.114.009944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25527701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVWqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=198-213&author=M.+Michinoauthor=T.+Beumingauthor=P.+Donthamsettiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=L.+Shi&title=What+can+crystal+structures+of+aminergic+receptors+tell+us+about+designing+subtype-selective+ligands%3F&doi=10.1124%2Fpr.114.009944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?</span></div><div class="casAuthors">Michino, Mayako; Beuming, Thijs; Donthamsetti, Prashant; Newman, Amy Hauck; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">198-213</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are integral membrane proteins that represent an important class of drug targets.  In particular, aminergic GPCRs interact with a significant portion of drugs currently on the market.  However, most drugs that target these receptors are assocd. with undesirable side effects, which are due in part to promiscuous interactions with close homologs of the intended target receptors.  Here, based on a systematic anal. of all 37 of the currently available high-resoln. crystal structures of aminergic GPCRs, we review structural elements that contribute to and can be exploited for designing subtype-selective compds.  We describe the roles of secondary binding pockets (SBPs), as well as differences in ligand entry pathways to the orthosteric binding site, in detg. selectivity.  In addn., using the available crystal structures, we have identified conformational changes in the SBPs that are assocd. with receptor activation and explore the implications of these changes for the rational development of selective ligands with tailored efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp88D-c63Tm3LVg90H21EOLACvtfcHk0lizgXTsm_n00w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVWqu7s%253D&md5=7ed6698fae95a5e045a8d4e12b18fef5</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009944%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DWhat%2520can%2520crystal%2520structures%2520of%2520aminergic%2520receptors%2520tell%2520us%2520about%2520designing%2520subtype-selective%2520ligands%253F%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D198%26epage%3D213%26doi%3D10.1124%2Fpr.114.009944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinquet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span> <span> </span><span class="NLM_article-title">A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1124/mol.113.087833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1124%2Fmol.113.087833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24061855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyitLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=854-864&author=M.+Michinoauthor=P.+Donthamsettiauthor=T.+Beumingauthor=A.+Banalaauthor=L.+Duanauthor=T.+Rouxauthor=Y.+Hanauthor=E.+Trinquetauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=L.+Shi&title=A+single+glycine+in+extracellular+loop+1+is+the+critical+determinant+for+pharmacological+specificity+of+dopamine+D2+and+D3+receptors&doi=10.1124%2Fmol.113.087833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors</span></div><div class="casAuthors">Michino, Mayako; Donthamsetti, Prashant; Beuming, Thijs; Banala, Ashwini; Duan, Lihua; Roux, Thomas; Han, Yang; Trinquet, Eric; Newman, Amy Hauck; Javitch, Jonathan A.; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">854-864</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Subtype-selective agents for the dopamine D3 receptor (D3R) have been considered as potential medications for drug addiction and other neuropsychiatric disorders.  Medicinal chem. efforts have led to the discovery of 4-phenylpiperazine derivs. that are >100-fold selective for the dopamine D3 receptor over dopamine D2 receptor (D2R), despite high sequence identity (78% in the transmembrane domain).  Based on the recent crystal structure of D3R, we demonstrated that the 4-phenylpiperazine moiety in this class of D3R-selective compds. binds to the conserved orthosteric binding site, whereas the extended aryl amide moiety is oriented toward a divergent secondary binding pocket (SBP).  In an effort to further characterize mol. determinants of the selectivity of these compds., we modeled their binding modes in D3R and D2R by comparative ligand docking and mol. dynamics simulations.  We found that the aryl amide moiety in the SBP differentially induces conformational changes in transmembrane segment 2 and extracellular loop 1 (EL1), which amplify the divergence of the SBP in D3R and D2R.  Receptor chimera and site-directed mutagenesis studies were used to validate these binding modes and to identify a divergent glycine in EL1 as crit. to D3R over D2R subtype selectivity.  A better understanding of drug-dependent receptor conformations such as these is key to the rational design of compds. targeting a specific receptor among closely related homologs, and may also lead to discovery of novel chemotypes that exploit subtle differences in protein conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHm99ZIZbabVg90H21EOLACvtfcHk0lizgXTsm_n00w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyitLvK&md5=225a4cfc272ec9897eeb010dd551c3b9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.087833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.087833%26sid%3Dliteratum%253Aachs%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DBanala%26aufirst%3DA.%26aulast%3DDuan%26aufirst%3DL.%26aulast%3DRoux%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DTrinquet%26aufirst%3DE.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DL.%26atitle%3DA%2520single%2520glycine%2520in%2520extracellular%2520loop%25201%2520is%2520the%2520critical%2520determinant%2520for%2520pharmacological%2520specificity%2520of%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D854%26epage%3D864%26doi%3D10.1124%2Fmol.113.087833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span> <span> </span><span class="NLM_article-title">Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors</span>. <i>Methods Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2FS1043-9471%2805%2980049-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1Kmtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1995&pages=366-428&author=J.+A.+Ballesterosauthor=H.+Weinstein&title=Integrated+methods+for+the+construction+of+three-dimensional+models+and+computational+probing+of+structure-function+relations+in+G+protein-coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors</span></div><div class="casAuthors">Ballesteros, Juan A.; Weinstein, Harel</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Neurosciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">366-428</span>CODEN:
                <span class="NLM_cas:coden">MENEE5</span>;
        ISSN:<span class="NLM_cas:issn">1043-9471</span>.
    </div><div class="casAbstract">A review, with 135 refs., on approaches that can be used to resolve the apparent ambiguities that burden the pharmacol. testing of G protein-coupled receptor (GPCR) models, based on the integration of structural information about the receptor, about mutants, and about the changes induced by ligand binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfENoRspqa7LVg90H21EOLACvtfcHk0lizgXTsm_n00w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1Kmtrk%253D&md5=d3f99e9d07cea245a770f3f099bc8cc7</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS1043-9471%2805%2980049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1043-9471%252805%252980049-7%26sid%3Dliteratum%253Aachs%26aulast%3DBallesteros%26aufirst%3DJ.%2BA.%26aulast%3DWeinstein%26aufirst%3DH.%26atitle%3DIntegrated%2520methods%2520for%2520the%2520construction%2520of%2520three-dimensional%2520models%2520and%2520computational%2520probing%2520of%2520structure-function%2520relations%2520in%2520G%2520protein-coupled%2520receptors%26jtitle%3DMethods%2520Neurosci.%26date%3D1995%26volume%3D25%26spage%3D366%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Benzoylation of dianions: preparation of monobenzoylated derivatives of symmetrical secondary diamines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7661</span>– <span class="NLM_lpage">7662</span>, <span class="refDoi"> DOI: 10.1021/jo9908501</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9908501" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK1MXls1Ojtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=7661-7662&author=T.+Wangauthor=Z.+Zhangauthor=N.+A.+Meanwell&title=Benzoylation+of+dianions%3A+preparation+of+monobenzoylated+derivatives+of+symmetrical+secondary+diamines&doi=10.1021%2Fjo9908501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoylation of Dianions: Preparation of Monobenzoylated Derivatives of Symmetrical Secondary Diamines</span></div><div class="casAuthors">Wang, Tao; Zhang, Zhongxing; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7661-7662</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Methodol. is presented for efficient monoarylation of sym. secondary diamines.  The problem of diaroylation being predominant was overcome by making the mono- or dilithium salt of the amine first, which is more reactive toward aroyl chlorides than the diamine, affording the monoacylated product under kinetic control.  When piperazine was treated with 2 equiv of n-butyllithium and 1 equiv of benzoyl chloride at room temp., the monobenzoylated product was found to predominate (35:1 mono/di).  The sequential, nonsym. functionalization of piperazine and homopiperazine via this methodol. was also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBK3IT93jOlrVg90H21EOLACvtfcHk0lizgXTsm_n00w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXls1Ojtrs%253D&md5=74f64965dbacbf9d60b2b62613de9063</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjo9908501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9908501%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DBenzoylation%2520of%2520dianions%253A%2520preparation%2520of%2520monobenzoylated%2520derivatives%2520of%2520symmetrical%2520secondary%2520diamines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D7661%26epage%3D7662%26doi%3D10.1021%2Fjo9908501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3739</span>– <span class="NLM_lpage">3743</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bmcl.2014.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25086680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKktLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3739-3743&author=L.+X.+Wangauthor=X.+B.+Zhouauthor=M.+L.+Xiaoauthor=N.+Jiangauthor=F.+Liuauthor=W.+X.+Zhouauthor=X.+K.+Wangauthor=Z.+B.+Zhengauthor=S.+Li&title=Synthesis+and+biological+evaluation+of+substituted+4-%28thiophen-2-ylmethyl%29-2H-phthalazin-1-ones+as+potent+PARP-1+inhibitors&doi=10.1016%2Fj.bmcl.2014.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors</span></div><div class="casAuthors">Wang, Ling-xiao; Zhou, Xin-bo; Xiao, Meng-liang; Jiang, Ning; Liu, Feng; Zhou, Wen-xia; Wang, Xiao-kui; Zheng, Zhi-bing; Li, Song</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3739-3743</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have developed a series of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors.  Preliminary biol. evaluation indicated that most compds. possessed inhibitory potencies comparable to, or higher than AZD-2281.  Among these compds., I appeared to be the most notable one, which displayed an 8-fold improvement in enzymic activity compared to AZD-2281.  These efforts lay the foundation for our further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn-zjG4BtXnbVg90H21EOLACvtfcHk0ljWseEygo0i9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKktLfN&md5=e5399d0975fa5c4b09a658c5fb985438</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%2BX.%26aulast%3DZhou%26aufirst%3DX.%2BB.%26aulast%3DXiao%26aufirst%3DM.%2BL.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DW.%2BX.%26aulast%3DWang%26aufirst%3DX.%2BK.%26aulast%3DZheng%26aufirst%3DZ.%2BB.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520substituted%25204-%2528thiophen-2-ylmethyl%2529-2H-phthalazin-1-ones%2520as%2520potent%2520PARP-1%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3739%26epage%3D3743%26doi%3D10.1016%2Fj.bmcl.2014.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marona-Lewicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monte, A.</span></span> <span> </span><span class="NLM_article-title">‘Hybrid’ benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6242</span>– <span class="NLM_lpage">6251</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bmc.2008.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=18467103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFegur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=6242-6251&author=D.+M.+Schultzauthor=J.+A.+Prescherauthor=S.+Kiddauthor=D.+Marona-Lewickaauthor=D.+E.+Nicholsauthor=A.+Monte&title=%E2%80%98Hybrid%E2%80%99+benzofuran-benzopyran+congeners+as+rigid+analogs+of+hallucinogenic+phenethylamines&doi=10.1016%2Fj.bmc.2008.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines</span></div><div class="casAuthors">Schultz, Danielle M.; Prescher, Jennifer A.; Kidd, Stephanie; Marona-Lewicka, Danuta; Nichols, David E.; Monte, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6242-6251</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phenylalkylamines that possess conformationally rigidified furanyl moieties in place of alkoxy arene ring substituents have been shown previously to possess the highest affinities and agonist functional potencies at the serotonin 5-HT2A receptor among this chem. class.  Further, affinity declines when both furanyl rings are expanded to the larger dipyranyl ring system.  The present paper reports the synthesis and pharmacol. evaluation of a series of hybrid' benzofuranyl-benzopyranyl phenylalkylamines to probe further the sizes of the binding pockets within the serotonin 5-HT2A agonist binding site.  Thus, five compds. were prepd. as homologs of the parent compd., 8-bromo-1-(2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminopropane 2, and their affinity, functional potency, and intrinsic activity were assessed using cells stably expressing the rat 5-HT2A receptor.  The behavioral pharmacol. of these new analogs was also evaluated in the two-lever drug discrimination paradigm.  Although all of the hybrid isomers had similar, nanomolar range receptor affinities, those with the smaller furanyl ring at the arene 2-position (I, II) displayed a 4- to 15-fold greater functional potency than those with the larger pyranyl ring at that position (III, IV).  When the furan ring of the more potent agonist II was aromatized to give 6, a receptor affinity similar to the parent difuranyl compd. 2 was attained, along with a functional potency equiv. to 2, I, and II.  In drug discrimination expts. using rats trained to discriminate LSD from saline, II was more than two times more potent than IV, with the latter having a potency similar to the classic hallucinogenic amphetamine 1 (DOB).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqplYj7r_9BLLVg90H21EOLACvtfcHk0ljWseEygo0i9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFegur4%253D&md5=9dee4f8d37c074a7631715750cf65703</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DSchultz%26aufirst%3DD.%2BM.%26aulast%3DPrescher%26aufirst%3DJ.%2BA.%26aulast%3DKidd%26aufirst%3DS.%26aulast%3DMarona-Lewicka%26aufirst%3DD.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMonte%26aufirst%3DA.%26atitle%3D%25E2%2580%2598Hybrid%25E2%2580%2599%2520benzofuran-benzopyran%2520congeners%2520as%2520rigid%2520analogs%2520of%2520hallucinogenic%2520phenethylamines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D6242%26epage%3D6251%26doi%3D10.1016%2Fj.bmc.2008.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurczab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jastrzebska-Wiesek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojarski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajdel, P.</span></span> <span> </span><span class="NLM_article-title">Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: multiobjective based design, synthesis, and antidepressant and anxiolytic properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.11.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.ejmech.2015.11.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=26698537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWis7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=334-346&author=V.+Canaleauthor=R.+Kurczabauthor=A.+Partykaauthor=G.+Satalaauthor=T.+Lendaauthor=M.+Jastrzebska-Wiesekauthor=A.+Wesolowskaauthor=A.+J.+Bojarskiauthor=P.+Zajdel&title=Towards+new+5-HT7+antagonists+among+arylsulfonamide+derivatives+of+%28aryloxy%29ethyl-alkyl+amines%3A+multiobjective+based+design%2C+synthesis%2C+and+antidepressant+and+anxiolytic+properties&doi=10.1016%2Fj.ejmech.2015.11.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties</span></div><div class="casAuthors">Canale, Vittorio; Kurczab, Rafal; Partyka, Anna; Satala, Grzegorz; Ledna, Tomasz; Jastrzebska-Wiesek, Magdalena; Wesolowska, Anna; Bojarski, Andrzej J.; Zajdel, Pawel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">334-346</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 39 arylsulfonamide/amide derivs. of (aryloxy)ethyl alkyl amines, was designed with the support of the Virtual Combinatorial Library-Virtual Screening protocol, and synthesized using solid-phase methodologies.  Representative compds. were biol. evaluated for their affinity for 5-HT7Rs and for their selectivity over related 5-HTRs (5-HT1ARs, 5-HT2ARs, 5-HT6Rs), dopamine D2Rs and adrenergic α1Rs.  The study identified two compds. 3-fluoro-N-[1-[2-(2-cyclopentylphenoxy)ethyl]piperidin-4-yl]benzenesulfonamide (PZ-1417) and 4-fluoro-N-[1-[2-[(propan-2-yl)phenoxy]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzenesulfonamide (PZ-1150) as being potent 5-HT7R antagonists with antidepressant and anxiolytic properties in the forced swim test (0.625-5 mg/kg and 0.625 mg/kg, resp.), the tail suspension test (0.625 mg/kg and 0.625 mg/kg, resp.), and in four plate test (0.625 mg/kg and 1.25-2.5 mg/kg, resp.) in mice.  It has to be stressed that new compds. displayed higher activity than that of SB-269970, a ref. 5-HT7R antagonist.  Finally, the study provided valuable insight into the development of potential therapeutic agents for the treatment of CNS disorders.  The synthesis of the target compds. was achieved using a BAL-MBHA-PS (backbone-amide-linker polystyrene resin) as solid phase support.  The title compds. thus formed included 4-fluoro-N-[1-(2-phenoxyethyl)-4-piperidinyl]benzenesulfonamide and azetidine analogs, 8-azabicyclo[3.2.1]octane analogs, 2,5-diazabicyclo[2.2.1]heptane analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4A7DvF2HXkLVg90H21EOLACvtfcHk0lhMRw6CbHBBBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWis7jL&md5=e7a8d356d230e2ffa60f7a3a39220fae</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.040%26sid%3Dliteratum%253Aachs%26aulast%3DCanale%26aufirst%3DV.%26aulast%3DKurczab%26aufirst%3DR.%26aulast%3DPartyka%26aufirst%3DA.%26aulast%3DSatala%26aufirst%3DG.%26aulast%3DLenda%26aufirst%3DT.%26aulast%3DJastrzebska-Wiesek%26aufirst%3DM.%26aulast%3DWesolowska%26aufirst%3DA.%26aulast%3DBojarski%26aufirst%3DA.%2BJ.%26aulast%3DZajdel%26aufirst%3DP.%26atitle%3DTowards%2520new%25205-HT7%2520antagonists%2520among%2520arylsulfonamide%2520derivatives%2520of%2520%2528aryloxy%2529ethyl-alkyl%2520amines%253A%2520multiobjective%2520based%2520design%252C%2520synthesis%252C%2520and%2520antidepressant%2520and%2520anxiolytic%2520properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D334%26epage%3D346%26doi%3D10.1016%2Fj.ejmech.2015.11.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valhondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fontecha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Villa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauterbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhamu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Rodriguez, M. L.</span></span> <span> </span><span class="NLM_article-title">New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7851</span>– <span class="NLM_lpage">7861</span>, <span class="refDoi"> DOI: 10.1021/jm400766k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400766k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVynsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7851-7861&author=M.+Valhondoauthor=I.+Marcoauthor=M.+Martin-Fontechaauthor=H.+Vazquez-Villaauthor=J.+A.+Ramosauthor=R.+Berkelsauthor=T.+Lauterbachauthor=B.+Benhamuauthor=M.+L.+Lopez-Rodriguez&title=New+serotonin+5-HT1A+receptor+agonists+endowed+with+antinociceptive+activity+in+vivo&doi=10.1021%2Fjm400766k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">New Serotonin 5-HT1A Receptor Agonists Endowed with Antinociceptive Activity in Vivo</span></div><div class="casAuthors">Valhondo, Margarita; Marco, Isabel; Martin-Fontecha, Mar; Vazquez-Villa, Henar; Ramos, Jose A.; Berkels, Reinhard; Lauterbach, Thomas; Benhamu, Bellinda; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7851-7861</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis of 32 new compds. based on two different openings (A and B) of the chromane ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand I.  The synthesized compds. were assessed for binding affinity, selectivity, and functional activity at the 5-HT1AR.  Selected candidates resulting from B opening were also evaluated for their potential antinociceptive effect in vivo and pharmacokinetic properties in vitro.  Analog II [2-(4-{[2-(2-ethoxyphenoxy)ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)dione, tested as HCl salt] has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 2.3 nM; EC50 = 19 nM).  Pharmacokinetic studies indicated that compd. II displays a good metabolic stability in human liver microsomes (t1/2 ∼ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM).  Interestingly, II (3 mg/kg, i.p., and 30 mg/kg, po) caused significant attenuation of formalin-induced behavior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was reversed by the selective 5-HT1AR antagonist WAY-100635.  Thus, the new 5-HT1AR agonist identified in this work, II, exhibits oral analgesic activity, and the results herein represent a step toward identifying new therapeutics for the control of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvXewqtJFSrVg90H21EOLACvtfcHk0lhMRw6CbHBBBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVynsrvO&md5=a13618fbc4ab81f159b66839539a1cc6</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm400766k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400766k%26sid%3Dliteratum%253Aachs%26aulast%3DValhondo%26aufirst%3DM.%26aulast%3DMarco%26aufirst%3DI.%26aulast%3DMartin-Fontecha%26aufirst%3DM.%26aulast%3DVazquez-Villa%26aufirst%3DH.%26aulast%3DRamos%26aufirst%3DJ.%2BA.%26aulast%3DBerkels%26aufirst%3DR.%26aulast%3DLauterbach%26aufirst%3DT.%26aulast%3DBenhamu%26aufirst%3DB.%26aulast%3DLopez-Rodriguez%26aufirst%3DM.%2BL.%26atitle%3DNew%2520serotonin%25205-HT1A%2520receptor%2520agonists%2520endowed%2520with%2520antinociceptive%2520activity%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7851%26epage%3D7861%26doi%3D10.1021%2Fjm400766k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buisson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braddock, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton-Rickardt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span> <span> </span><span class="NLM_article-title">Approaches to design non-covalent inhibitors for human granzyme B (hGrB)</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">8952</span>– <span class="NLM_lpage">8965</span>, <span class="refDoi"> DOI: 10.1039/C4OB01874E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1039%2FC4OB01874E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=25277547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyqsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=8952-8965&author=M.+S.+Kimauthor=L.+A.+Buissonauthor=D.+A.+Heathcoteauthor=H.+Huauthor=D.+C.+Braddockauthor=A.+G.+Barrettauthor=P.+G.+Ashton-Rickardtauthor=J.+P.+Snyder&title=Approaches+to+design+non-covalent+inhibitors+for+human+granzyme+B+%28hGrB%29&doi=10.1039%2FC4OB01874E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to design non-covalent inhibitors for human granzyme B (hGrB)</span></div><div class="casAuthors">Kim, Mi-Sun; Buisson, Lauriane A.; Heathcote, Dean A.; Hu, Haipeng; Braddock, D. Christopher; Barrett, Anthony G. M.; Ashton-Rickardt, Philip G.; Snyder, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">8952-8965</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A structure-based design campaign for non-covalent small mol. inhibitors of human granzyme B was carried out by means of a virtual screening strategy employing three constraints and probe site-mapping with FTMAP to identify ligand "hot spots".  In addn., new scaffolds of diverse structures were subsequently explored with ROCS shape-based superposition methods, following by Glide SP docking, induced fit docking and anal. of QikProp mol. properties.  Novel classes of moderately active small mol. blockers (≥25 μM IC50 values) from com. available libraries were identified, and three novel scaffolds have been synthesized by multi-step procedures.  Furthermore, we provide an example of a comprehensive structure-based drug discovery approach to non-covalent inhibitors that relies on the X-ray structure of a covalently bound ligand and suggest that the design path may be compromised by alternative and unknown binding poses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPUyBeYdwLLVg90H21EOLACvtfcHk0ljDYWudx6MsJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyqsL%252FM&md5=c8c016e007f9fdb60524533692010009</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1039%2FC4OB01874E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB01874E%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DBuisson%26aufirst%3DL.%2BA.%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DBraddock%26aufirst%3DD.%2BC.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAshton-Rickardt%26aufirst%3DP.%2BG.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26atitle%3DApproaches%2520to%2520design%2520non-covalent%2520inhibitors%2520for%2520human%2520granzyme%2520B%2520%2528hGrB%2529%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26spage%3D8952%26epage%3D8965%26doi%3D10.1039%2FC4OB01874E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boos, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, R. R.</span></span> <span> </span><span class="NLM_article-title">Maltose and maltotriose derivatives as potential inhibitors of the maltose-binding protein</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_fpage">2084</span>– <span class="NLM_lpage">2099</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200701139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fejoc.200701139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlOktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=2084-2099&author=H.+Malikauthor=W.+Boosauthor=R.+R.+Schmidt&title=Maltose+and+maltotriose+derivatives+as+potential+inhibitors+of+the+maltose-binding+protein&doi=10.1002%2Fejoc.200701139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Maltose and maltotriose derivatives as potential inhibitors of the maltose-binding protein</span></div><div class="casAuthors">Malik, Heinz; Boos, Winfried; Schmidt, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2084-2099</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1434-193X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Inhibition of substrate binding to maltose-binding protein (MBP) was investigated with structurally modified maltose and maltotriose derivs. that were designed based on the X-ray anal. of maltose and maltotriose bound to MBP.  In maltose, positions 1a, 2a, 2b, 4b and 6b were modified to produce maltose derivs., e.g. I, of which only two trivalent maltose derivs. exhibited high affinity to MBP.  Maltotriose modifications were carried out at position to produce maltotriose derivs., e.g. II.  Among them, one deriv. possessing a 6a-O-Pr group, and another deriv. where the 6c-hydroxy group is replaced by bromide, showed higher affinity to MBP than the parent maltotriose.  Hence, three structurally quite different compds. are important lead compds. for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr47meI-qeKZrVg90H21EOLACvtfcHk0ljDYWudx6MsJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlOktb4%253D&md5=35bc6e41ddd2277793d9655000483844</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200701139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200701139%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DH.%26aulast%3DBoos%26aufirst%3DW.%26aulast%3DSchmidt%26aufirst%3DR.%2BR.%26atitle%3DMaltose%2520and%2520maltotriose%2520derivatives%2520as%2520potential%2520inhibitors%2520of%2520the%2520maltose-binding%2520protein%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2008%26spage%3D2084%26epage%3D2099%26doi%3D10.1002%2Fejoc.200701139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalpando, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCandless, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartika, R.</span></span> <span> </span><span class="NLM_article-title">Chlorination of aliphatic primary alcohols via triphosgene-triethylamine activation</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3676</span>– <span class="NLM_lpage">3679</span>, <span class="refDoi"> DOI: 10.1021/ol301520d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol301520d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=3676-3679&author=C.+E.+Ayalaauthor=A.+Villalpandoauthor=A.+L.+Nguyenauthor=G.+T.+McCandlessauthor=R.+Kartika&title=Chlorination+of+aliphatic+primary+alcohols+via+triphosgene-triethylamine+activation&doi=10.1021%2Fol301520d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Chlorination of Aliphatic Primary Alcohols via Triphosgene-Triethylamine Activation</span></div><div class="casAuthors">Ayala, Caitlan E.; Villalpando, Andres; Nguyen, Alex L.; McCandless, Gregory T.; Kartika, Rendy</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3676-3679</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of primary aliph. alcs. with triphosgene and triethylamine mixts. afforded either alkyl chloride or diethylcarbamate products, and the switch in selectivity appeared to be driven by sterics.  The reaction conditions to achieve this highly useful transformation were unexceptionally mild and readily tolerated by a wide range of sensitive functionalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNrFDUtZsUirVg90H21EOLACvtfcHk0lhn5ap2DYjnbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtLzF&md5=cd8101dc8031daaa02bbf4dfd78309a0</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fol301520d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol301520d%26sid%3Dliteratum%253Aachs%26aulast%3DAyala%26aufirst%3DC.%2BE.%26aulast%3DVillalpando%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DA.%2BL.%26aulast%3DMcCandless%26aufirst%3DG.%2BT.%26aulast%3DKartika%26aufirst%3DR.%26atitle%3DChlorination%2520of%2520aliphatic%2520primary%2520alcohols%2520via%2520triphosgene-triethylamine%2520activation%26jtitle%3DOrg.%2520Lett.%26date%3D2012%26volume%3D14%26spage%3D3676%26epage%3D3679%26doi%3D10.1021%2Fol301520d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knochel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashima, K.</span></span> <span> </span><span class="NLM_article-title">Zinc-catalyzed esterification of N-β-hydroxyethylamides: removal of directing groups under mild conditions</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_fpage">5010</span>– <span class="NLM_lpage">5014</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201700748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1002%2Fejoc.201700748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOjsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=5010-5014&author=Y.+Nishiiauthor=T.+Hiraiauthor=S.+Fernandezauthor=P.+Knochelauthor=K.+Mashima&title=Zinc-catalyzed+esterification+of+N-%CE%B2-hydroxyethylamides%3A+removal+of+directing+groups+under+mild+conditions&doi=10.1002%2Fejoc.201700748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc-Catalyzed Esterification of N-β-Hydroxyethylamides: Removal of Directing Groups under Mild Conditions</span></div><div class="casAuthors">Nishii, Yuji; Hirai, Takahiro; Fernandez, Sarah; Knochel, Paul; Mashima, Kazushi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2017</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">5010-5014</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Amide transformations involving C-N bond cleavage are recognized as difficult reactions owing to the inert nature of amides resulting from resonance.  Accordingly, a strong inductive effect and geometrical distortion reasonably decrease the resonance stabilization to attenuate the C-N linkage.  Although the conversion of such activated amides has been studied intensively, reaction systems for "unactivated" amides are underdeveloped.  We herein report that a zinc(II) trifluoromethanesulfonate [Zn(OTf)2] catalyst achieves the esterification of a wide range of unactivated tertiary amides with the assistance of intramol. acyl rearrangement.  The reaction was applied to the one-pot removal of various amide-based directing groups under mild reaction conditions to afford the corresponding esters in high yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcUBNF3GL4l7Vg90H21EOLACvtfcHk0lhn5ap2DYjnbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOjsb%252FJ&md5=2bca305ddda3f1535a18b53d7a0cd98e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201700748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201700748%26sid%3Dliteratum%253Aachs%26aulast%3DNishii%26aufirst%3DY.%26aulast%3DHirai%26aufirst%3DT.%26aulast%3DFernandez%26aufirst%3DS.%26aulast%3DKnochel%26aufirst%3DP.%26aulast%3DMashima%26aufirst%3DK.%26atitle%3DZinc-catalyzed%2520esterification%2520of%2520N-%25CE%25B2-hydroxyethylamides%253A%2520removal%2520of%2520directing%2520groups%2520under%2520mild%2520conditions%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2017%26spage%3D5010%26epage%3D5014%26doi%3D10.1002%2Fejoc.201700748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuder, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunack, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiec-Kononowicz, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel nead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.2174/15734064113096660050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.2174%2F15734064113096660050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=24047214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKgs7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=588-599&author=K.+J.+Kuderauthor=M.+Stachnikauthor=W.+Schunackauthor=E.+Szymanskaauthor=K.+Kiec-Kononowicz&title=Discovery+of+novel+nead+in+the+group+of+N-substituted+piperazine+ether+derivatives+with+potential+histamine+H3+receptor+activity&doi=10.2174%2F15734064113096660050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Lead in the Group of N-substituted Piperazine Ether Derivatives with Potential Histamine H3 Receptor Activity</span></div><div class="casAuthors">Kuder, Kamil J.; Stachnik, Marta; Schunack, Walter; Szymanska, Ewa; Kiec-Kononowicz, Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">588-599</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The search for novel lead from the group of various substituted N-piperazine ether derivs. was performed.  Acyl- and pyridylpiperazine ethyl/propyl ethers were obtained via three different synthetic pathways.  Affinity to histamine H3 receptor was established, as well as, for selected compds., selectivity towards histamine H4R.  Docking studies to the histamine H3R homol. model strengthened the position of (4-(3-(4-(3-chlorobenzoyl)piperazin-1- yl)propoxy)phenyl)(cyclopropyl)methanone as a novel lead for further studies on histamine H3 receptor antagonist/inverse agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozKIeMkzFmSLVg90H21EOLACvtfcHk0lhn5ap2DYjnbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKgs7rM&md5=6fc18fe715423d987e871c18674b78d6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.2174%2F15734064113096660050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15734064113096660050%26sid%3Dliteratum%253Aachs%26aulast%3DKuder%26aufirst%3DK.%2BJ.%26aulast%3DStachnik%26aufirst%3DM.%26aulast%3DSchunack%26aufirst%3DW.%26aulast%3DSzymanska%26aufirst%3DE.%26aulast%3DKiec-Kononowicz%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520novel%2520nead%2520in%2520the%2520group%2520of%2520N-substituted%2520piperazine%2520ether%2520derivatives%2520with%2520potential%2520histamine%2520H3%2520receptor%2520activity%26jtitle%3DMed.%2520Chem.%26date%3D2014%26volume%3D10%26spage%3D588%26epage%3D599%26doi%3D10.2174%2F15734064113096660050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakefuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naritomi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17beta-hydroxysteroid dehydrogenase inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5261</span>– <span class="NLM_lpage">5270</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2Fj.bmc.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=23845281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOrt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=5261-5270&author=K.+Watanabeauthor=A.+Kakefudaauthor=M.+Yasudaauthor=K.+Enjoauthor=A.+Kikuchiauthor=T.+Furutaniauthor=Y.+Naritomiauthor=Y.+Otsukaauthor=M.+Okadaauthor=M.+Ohta&title=Discovery+of+2-methyl-1-%7B1-%5B%285-methyl-1H-indol-2-yl%29carbonyl%5Dpiperidin-4-yl%7Dpropan-2-ol%3A+a+novel%2C+potent+and+selective+type+5+17beta-hydroxysteroid+dehydrogenase+inhibitor&doi=10.1016%2Fj.bmc.2013.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: A novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor</span></div><div class="casAuthors">Watanabe, Kazushi; Kakefuda, Akio; Yasuda, Minoru; Enjo, Kentaro; Kikuchi, Aya; Furutani, Takashi; Naritomi, Yoichi; Otsuka, Yukio; Okada, Minoru; Ohta, Mitsuaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5261-5270</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Type 5 17β-hydroxysteroid dehydrogenase (17β-HSD5), also known as aldo-keto reductase 1C3 (AKR1C3), is a member of the aldo-keto reductase superfamily of enzymes and is expressed in the human prostate.  One of the main functions of 17β-HSD5 is to catalyze the conversion of the weak androgen, androstenedione, to the potent androgen, testosterone.  The concn. of intraprostatic 5α-dihydrotestosterone (DHT) in patients following chem. or surgical castration has been reported to remain as high as 39% of that of healthy men, with 17β-HSD5 shown to be involved in this androgen synthesis.  Inhibition of 17β-HSD5 therefore represents a promising target for the treatment of castration-resistant prostate cancer (CRPC).  To investigate this, we conducted high-throughput screening (HTS) and identified compd. (I), which displayed a structure distinct from known 17β-HSD5 inhibitors.  To optimize the inhibitory activity of compd. (I), we first introduced a primary alc. group.  We then converted the primary alc. group to a tertiary alc., which further enhanced the inhibitory activity, improved metabolic stability, and led to the identification of compd. (II).  Oral administration of compd. II to castrated nude mice bearing the CWR22R xenograft resulted in the suppression of androstenedione (AD)-induced intratumoral testosterone prodn.  Compd. II also demonstrated good isoform selectivity, minimal inhibitory activity against either CYP or hERG, and enhanced pharmacokinetic and physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1xQk8Ntpn7LVg90H21EOLACvtfcHk0lhJCUDT4ztGrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOrt7fE&md5=dcad39e26020f35400d19ba2e0670726</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DKakefuda%26aufirst%3DA.%26aulast%3DYasuda%26aufirst%3DM.%26aulast%3DEnjo%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DNaritomi%26aufirst%3DY.%26aulast%3DOtsuka%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-methyl-1-%257B1-%255B%25285-methyl-1H-indol-2-yl%2529carbonyl%255Dpiperidin-4-yl%257Dpropan-2-ol%253A%2520a%2520novel%252C%2520potent%2520and%2520selective%2520type%25205%252017beta-hydroxysteroid%2520dehydrogenase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D5261%26epage%3D5270%26doi%3D10.1016%2Fj.bmc.2013.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yung-Chi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=4202581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banala, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khatri, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roof, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">3581</span>– <span class="NLM_lpage">3594</span>, <span class="refDoi"> DOI: 10.1021/jm200288r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200288r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVyhsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3581-3594&author=A.+K.+Banalaauthor=B.+A.+Levyauthor=S.+S.+Khatriauthor=C.+A.+Furmanauthor=R.+A.+Roofauthor=Y.+Mishraauthor=S.+A.+Griffinauthor=D.+R.+Sibleyauthor=R.+R.+Luedtkeauthor=A.+H.+Newman&title=N-%283-fluoro-4-%284-%282-methoxy+or+2%2C3-dichlorophenyl%29piperazine-1-yl%29butyl%29arylcarboxamides+as+selective+dopamine+D3+receptor+ligands%3A+critical+role+of+the+carboxamide+linker+for+D3+receptor+selectivity&doi=10.1021%2Fjm200288r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as Selective Dopamine D3 Receptor Ligands: Critical Role of the Carboxamide Linker for D3 Receptor Selectivity</span></div><div class="casAuthors">Banala, Ashwini K.; Levy, Benjamin A.; Khatri, Sameer S.; Furman, Cheryse A.; Roof, Rebecca A.; Mishra, Yogesh; Griffin, Suzy A.; Sibley, David R.; Luedtke, Robert R.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3581-3594</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-(3-Fluoro-4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)arylcarboxamides were prepd. and evaluated for binding and function at dopamine D3 receptors (D3Rs) and dopamine D2 receptors (D2Rs).  In this series, we discovered some of the most D3R selective compds. reported to date (e.g., I, >1000-fold D3R-selective over D2R).  In addn., chimeric receptor studies further identified the second extracellular (E2) loop as an important contributor to D3R binding selectivity.  Further, compds. lacking the carbonyl group in the amide linker were synthesized, and while these amine-linked analogs bound with similar affinities to the amides at D2R, this modification dramatically reduced binding affinities at D3R by >100-fold, resulting in compds. with significantly reduced D3R selectivity.  This study supports a pivotal role for the D3R E2 loop and the carbonyl group in the 4-phenylpiperazine class of compds. and further reveals a point of sepn. between structure-activity relationships at D3R and D2R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLX7c82j9-5bVg90H21EOLACvtfcHk0lhJCUDT4ztGrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVyhsbw%253D&md5=4fecff363e5628b365e7aeba6a824f9d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm200288r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200288r%26sid%3Dliteratum%253Aachs%26aulast%3DBanala%26aufirst%3DA.%2BK.%26aulast%3DLevy%26aufirst%3DB.%2BA.%26aulast%3DKhatri%26aufirst%3DS.%2BS.%26aulast%3DFurman%26aufirst%3DC.%2BA.%26aulast%3DRoof%26aufirst%3DR.%2BA.%26aulast%3DMishra%26aufirst%3DY.%26aulast%3DGriffin%26aufirst%3DS.%2BA.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DN-%25283-fluoro-4-%25284-%25282-methoxy%2520or%25202%252C3-dichlorophenyl%2529piperazine-1-yl%2529butyl%2529arylcarboxamides%2520as%2520selective%2520dopamine%2520D3%2520receptor%2520ligands%253A%2520critical%2520role%2520of%2520the%2520carboxamide%2520linker%2520for%2520D3%2520receptor%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3581%26epage%3D3594%26doi%3D10.1021%2Fjm200288r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebres, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taussig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sternweis, P. C.</span></span> <span> </span><span class="NLM_article-title">Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">10576</span>– <span class="NLM_lpage">10584</span>, <span class="refDoi"> DOI: 10.1074/jbc.M609695200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1074%2Fjbc.M609695200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=17283075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Shsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=10576-10584&author=L.+I.+Jiangauthor=J.+Collinsauthor=R.+Davisauthor=K.+M.+Linauthor=D.+DeCampauthor=T.+Roachauthor=R.+Hsuehauthor=R.+A.+Rebresauthor=E.+M.+Rossauthor=R.+Taussigauthor=I.+Fraserauthor=P.+C.+Sternweis&title=Use+of+a+cAMP+BRET+sensor+to+characterize+a+novel+regulation+of+cAMP+by+the+sphingosine+1-phosphate%2FG13+pathway&doi=10.1074%2Fjbc.M609695200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate/G13 Pathway</span></div><div class="casAuthors">Jiang, Lily I.; Collins, Julie; Davis, Richard; Lin, Keng-Mean; DeCamp, Dianne; Roach, Tamara; Hsueh, Robert; Rebres, Robert A.; Ross, Elliott M.; Taussig, Ronald; Fraser, Iain; Sternweis, Paul C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">10576-10584</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Regulation of intracellular cAMP is integral in mediating cell growth, cell differentiation, and immune responses in hematopoietic cells.  To facilitate studies of cAMP regulation we developed a BRET (bioluminescence resonance energy transfer) sensor for cAMP, CAMYEL (cAMP sensor using YFP-Epac-RLuc), which can quant. and rapidly monitor intracellular concns. of cAMP in vivo.  This sensor was used to characterize three distinct pathways for modulation of cAMP synthesis stimulated by presumed Gs-dependent receptors for isoproterenol and prostaglandin E2.  Whereas two ligands, UDP and complement C5a, appear to use known mechanisms for augmentation of cAMP via Gq/calcium and Gi, the action of sphingosine 1-phosphate (S1P) is novel.  In these cells, S1P, a biol. active lysophospholipid, greatly enhances increases in intracellular cAMP triggered by the ligands for Gs-coupled receptors while having only a minimal effect by itself.  The enhancement of cAMP by S1P is resistant to pertussis toxin and independent of intracellular calcium.  Studies with RNAi and chem. perturbations demonstrate that the effect of S1P is mediated by the S1P2 receptor and the heterotrimeric G13 protein.  Thus in these macrophage cells, all four major classes of G proteins can regulate intracellular cAMP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEgBftC6CUb7Vg90H21EOLACvtfcHk0lgnwE61WTni2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Shsr4%253D&md5=4a6f1e5dc8ae6dc23d80ac234ee91179</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M609695200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M609695200%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%2BI.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DK.%2BM.%26aulast%3DDeCamp%26aufirst%3DD.%26aulast%3DRoach%26aufirst%3DT.%26aulast%3DHsueh%26aufirst%3DR.%26aulast%3DRebres%26aufirst%3DR.%2BA.%26aulast%3DRoss%26aufirst%3DE.%2BM.%26aulast%3DTaussig%26aufirst%3DR.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DSternweis%26aufirst%3DP.%2BC.%26atitle%3DUse%2520of%2520a%2520cAMP%2520BRET%2520sensor%2520to%2520characterize%2520a%2520novel%2520regulation%2520of%2520cAMP%2520by%2520the%2520sphingosine%25201-phosphate%252FG13%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D10576%26epage%3D10584%26doi%3D10.1074%2Fjbc.M609695200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennett, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bright, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, T. P.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1996.tb15208.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1111%2Fj.1476-5381.1996.tb15208.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=8821530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK28XpsVGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1996&pages=427-434&author=G.+A.+Kennettauthor=M.+D.+Woodauthor=F.+Brightauthor=J.+Ciliaauthor=D.+C.+Piperauthor=T.+Gagerauthor=D.+Thomasauthor=G.+S.+Baxterauthor=I.+T.+Forbesauthor=P.+Hamauthor=T.+P.+Blackburn&title=In+vitro+and+in+vivo+profile+of+SB+206553%2C+a+potent+5-HT2C%2F5-HT2B+receptor+antagonist+with+anxiolytic-like+properties&doi=10.1111%2Fj.1476-5381.1996.tb15208.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties</span></div><div class="casAuthors">Kennett, G. a.; Wood, M. D.; Bright, F.; Cilia, J.; Piper, D. C.; Gager, T.; Thomas, D.; Baxter, G. S.; Forbes, I. T.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-34</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole) displays a high affinity (pKI 7.9) for the cloned human 5-HT2C receptor expressed in HEK 293 cells and the 5-HT2B receptor (pA2 8.9) as measured in the rat stomach fundus prepn.  SB 206553 has low affinity for cloned human 5-HT2A receptors expressed in HEK 293 cells (pK1 5.8) and (pKI <6) for a wide variety of other neurotransmitter receptors.  SB 206553 appears to be a surmountable antagonist of 5-HT-stimulated phosphinositide hydrolysis in HEK 293 cells expressing the human 5-HT2C receptor (pKB 9.0).  The compd. potently (ID50 5.5 mg kg-1, p.o., 0.27 mg kg-1, i.v.) inhibited the hypolocomotor response to m-chlorophenylpiperazine (mCPP), a putative model of 5-HT2C/5-HT2B receptor function in vivo.  At similar doses (2-20 mg kg-1, p.o.) SB 206553 increased total interaction scores in a rat social interaction test and increased punished responding in a rat Geller-Seifter conflict test.  These effects are consistent with the possession of anxiolytic properties.  SB 206553 also increased suppressed responding in a marmoset conflict model of anxiety at somewhat higher doses (15 and 20 mg kg-1, p.o.) but also reduced unsuppressed responding.  These results suggest that SB 206553 is a potent mixed 5-HT2C/5-HT2B receptor antagonist with selectivity over the 5-HT2A and all other sites studied and possesses anxiolytic-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGhOi9PL6P5bVg90H21EOLACvtfcHk0lgnwE61WTni2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XpsVGgsg%253D%253D&md5=f6faa809154f400759171bfdedb17460</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1996.tb15208.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1996.tb15208.x%26sid%3Dliteratum%253Aachs%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DBright%26aufirst%3DF.%26aulast%3DCilia%26aufirst%3DJ.%26aulast%3DPiper%26aufirst%3DD.%2BC.%26aulast%3DGager%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DBaxter%26aufirst%3DG.%2BS.%26aulast%3DForbes%26aufirst%3DI.%2BT.%26aulast%3DHam%26aufirst%3DP.%26aulast%3DBlackburn%26aufirst%3DT.%2BP.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520profile%2520of%2520SB%2520206553%252C%2520a%2520potent%25205-HT2C%252F5-HT2B%2520receptor%2520antagonist%2520with%2520anxiolytic-like%2520properties%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D117%26spage%3D427%26epage%3D434%26doi%3D10.1111%2Fj.1476-5381.1996.tb15208.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span> <span> </span><span class="NLM_article-title">Novel procedure for modeling ligand/receptor induced fit effects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1021/jm050540c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050540c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=534-553&author=W.+Shermanauthor=T.+Dayauthor=M.+P.+Jacobsonauthor=R.+A.+Friesnerauthor=R.+Farid&title=Novel+procedure+for+modeling+ligand%2Freceptor+induced+fit+effects&doi=10.1021%2Fjm050540c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects</span></div><div class="casAuthors">Sherman, Woody; Day, Tyler; Jacobson, Matthew P.; Friesner, Richard A.; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a novel protein-ligand docking method that accurately accounts for both ligand and receptor flexibility by iteratively combining rigid receptor docking (Glide) with protein structure prediction (Prime) techniques.  While traditional rigid-receptor docking methods are useful when the receptor structure does not change substantially upon ligand binding, success is limited when the protein must be "induced" into the correct binding conformation for a given ligand.  We provide an in-depth description of our novel methodol. and present results for 21 pharmaceutically relevant examples.  Traditional rigid-receptor docking for these 21 cases yields an av. RMSD of 5.5 Å.  The av. ligand RMSD for docking to a flexible receptor for the 21 pairs is 1.4 Å; the RMSD is ≤1.8 Å for 18 of the cases.  For the three cases with RMSDs greater than 1.8 Å, the core of the ligand is properly docked and all key protein/ligand interactions are captured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3E6ctnPGSrVg90H21EOLACvtfcHk0lgnwE61WTni2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCgsr7I&md5=388811ead5cee1fd460951263de486cb</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm050540c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050540c%26sid%3Dliteratum%253Aachs%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DNovel%2520procedure%2520for%2520modeling%2520ligand%252Freceptor%2520induced%2520fit%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D534%26epage%3D553%26doi%3D10.1021%2Fjm050540c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Development of the CHARMM Force Field for Lipids</span>. <i>J. Phys. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1532</span>, <span class="refDoi"> DOI: 10.1021/jz200167q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jz200167q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntFSlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=1526-1532&author=R.+W.+Pastorauthor=A.+D.+Mackerell&title=Development+of+the+CHARMM+Force+Field+for+Lipids&doi=10.1021%2Fjz200167q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the CHARMM Force Field for Lipids</span></div><div class="casAuthors">Pastor, R. W.; MacKerell, A. D., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1526-1532</span>CODEN:
                <span class="NLM_cas:coden">JPCLCD</span>;
        ISSN:<span class="NLM_cas:issn">1948-7185</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of the CHARMM additive all-atom lipid force field (FF) is traced from the early 1990s to the most recent version (C36) published in 2010.  Though simulations with early versions yielded useful results, they failed to reproduce two important quantities, a zero surface tension at the exptl. bilayer surface area and the signature splitting of the deuterium order parameters in the glycerol and upper chain carbons.  Systematic optimization of parameters based on high-level quantum mech. data and free-energy simulations have resolved these issues, and bilayers with a wide range of lipids can be simulated in tensionless ensembles using C36.  Issues assocd. with other all-atom lipid FFs, success and limitations in the C36 FF, and ongoing developments are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgxTy0osyr8LVg90H21EOLACvtfcHk0lihfU9aVjUpdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntFSlsLg%253D&md5=41920c7e6fbd1aae3b1b7ae8e8234ec8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjz200167q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjz200167q%26sid%3Dliteratum%253Aachs%26aulast%3DPastor%26aufirst%3DR.%2BW.%26aulast%3DMackerell%26aufirst%3DA.%2BD.%26atitle%3DDevelopment%2520of%2520the%2520CHARMM%2520Force%2520Field%2520for%2520Lipids%26jtitle%3DJ.%2520Phys.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D1526%26epage%3D1532%26doi%3D10.1021%2Fjz200167q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3257</span>– <span class="NLM_lpage">3273</span>, <span class="refDoi"> DOI: 10.1021/ct300400x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct300400x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKqurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=3257-3273&author=R.+B.+Bestauthor=X.+Zhuauthor=J.+Shimauthor=P.+E.+Lopesauthor=J.+Mittalauthor=M.+Feigauthor=A.+D.+Mackerell&title=Optimization+of+the+additive+CHARMM+all-atom+protein+force+field+targeting+improved+sampling+of+the+backbone+phi%2C+psi+and+side-chain+chi%281%29+and+chi%282%29+dihedral+angles&doi=10.1021%2Fct300400x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone .vphi., ψ and Side-Chain χ1 and χ2 Dihedral Angles</span></div><div class="casAuthors">Best, Robert B.; Zhu, Xiao; Shim, Jihyun; Lopes, Pedro E. M.; Mittal, Jeetain; Feig, Michael; MacKerell, Alexander D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3257-3273</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">While the quality of the current CHARMM22/CMAP additive force field for proteins has been demonstrated in a large no. of applications, limitations in the model with respect to the equil. between the sampling of helical and extended conformations in folding simulations have been noted.  To overcome this, as well as make other improvements in the model, we present a combination of refinements that should result in enhanced accuracy in simulations of proteins.  The common (non-Gly, -Pro) backbone CMAP potential has been refined against exptl. soln. NMR data for weakly structured peptides, resulting in a rebalancing of the energies of the α-helix and extended regions of the Ramachandran map, correcting the α-helical bias of CHARMM22/CMAP.  The Gly and Pro CMAPs have been refitted to more accurate quantum-mech. energy surfaces.  Side-chain torsion parameters have been optimized by fitting to backbone-dependent quantum-mech. energy surfaces, followed by addnl. empirical optimization targeting NMR scalar couplings for unfolded proteins.  A comprehensive validation of the revised force field was then performed against a collection of exptl. data: (i) comparison of simulations of eight proteins in their crystal environments with crystal structures; (ii) comparison with backbone scalar couplings for weakly structured peptides; (iii) comparison with NMR residual dipolar couplings and scalar couplings for both backbone and side-chains in folded proteins; (iv) equil. folding of mini-proteins.  The results indicate that the revised CHARMM 36 parameters represent an improved model for modeling and simulation studies of proteins, including studies of protein folding, assembly, and functionally relevant conformational changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGnwGJMAMFvLVg90H21EOLACvtfcHk0lihfU9aVjUpdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKqurfP&md5=9a48a0c5770fb1e887c3bb34d45b1354</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fct300400x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct300400x%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DR.%2BB.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DLopes%26aufirst%3DP.%2BE.%26aulast%3DMittal%26aufirst%3DJ.%26aulast%3DFeig%26aufirst%3DM.%26aulast%3DMackerell%26aufirst%3DA.%2BD.%26atitle%3DOptimization%2520of%2520the%2520additive%2520CHARMM%2520all-atom%2520protein%2520force%2520field%2520targeting%2520improved%2520sampling%2520of%2520the%2520backbone%2520phi%252C%2520psi%2520and%2520side-chain%2520chi%25281%2529%2520and%2520chi%25282%2529%2520dihedral%2520angles%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2012%26volume%3D8%26spage%3D3257%26epage%3D3273%26doi%3D10.1021%2Fct300400x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span> <span> </span><span class="NLM_article-title">Automated force field parameterization for non-polarizable and polarizable atomic models based on ab initio target data</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3543</span>– <span class="NLM_lpage">3556</span>, <span class="refDoi"> DOI: 10.1021/ct4003477</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct4003477" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSns7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=3543-3556&author=L.+Huangauthor=B.+Roux&title=Automated+force+field+parameterization+for+non-polarizable+and+polarizable+atomic+models+based+on+ab+initio+target+data&doi=10.1021%2Fct4003477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Automated Force Field Parameterization for Nonpolarizable and Polarizable Atomic Models Based on Ab Initio Target Data</span></div><div class="casAuthors">Huang, Lei; Roux, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3543-3556</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Classical mol. dynamics (MD) simulations based on atomistic models are increasingly used to study a wide range of biol. systems.  A prerequisite for meaningful results from such simulations is an accurate mol. mech. force field.  Most biomol. simulations are currently based on the widely used AMBER and CHARMM force fields, which were parametrized and optimized to cover a small set of basic compds. corresponding to the natural amino acids and nucleic acid bases.  Atomic models of addnl. compds. are commonly generated by analogy to the parameter set of a given force field.  While this procedure yields models that are internally consistent, the accuracy of the resulting models can be limited.  The authors propose a method, general automated at. model parameterization (GAAMP), for generating automatically the parameters of at. models of small mols. using the results from ab initio quantum mech. (QM) calcns. as target data.  Force fields that were previously developed for a wide range of model compds. serve as initial guesses, although any of the final parameter can be optimized.  The electrostatic parameters (partial charges, polarizabilities, and shielding) are optimized on the basis of QM electrostatic potential (ESP) and, if applicable, the interaction energies between the compd. and water mols.  The soft dihedrals are automatically identified and parametrized by targeting QM dihedral scans as well as the energies of stable conformers.  To validate the approach, the solvation free energy is calcd. for >200 small mols. and MD simulations of three different proteins were carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjMGhS8IcFx7Vg90H21EOLACvtfcHk0lihfU9aVjUpdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSns7rP&md5=8f7c3d2fd1e29afe685a4e94a5e0943a</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fct4003477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct4003477%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DRoux%26aufirst%3DB.%26atitle%3DAutomated%2520force%2520field%2520parameterization%2520for%2520non-polarizable%2520and%2520polarizable%2520atomic%2520models%2520based%2520on%2520ab%2520initio%2520target%2520data%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2013%26volume%3D9%26spage%3D3543%26epage%3D3556%26doi%3D10.1021%2Fct4003477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feller, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, B. R.</span></span> <span> </span><span class="NLM_article-title">Constant pressure molecular dynamics simulation: the langevin piston method</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">4613</span>– <span class="NLM_lpage">4621</span>, <span class="refDoi"> DOI: 10.1063/1.470648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1063%2F1.470648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADyaK2MXotVentLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1995&pages=4613-4621&author=S.+E.+Fellerauthor=Y.+Zhangauthor=R.+W.+Pastorauthor=B.+R.+Brooks&title=Constant+pressure+molecular+dynamics+simulation%3A+the+langevin+piston+method&doi=10.1063%2F1.470648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Constant pressure molecular dynamics simulation: the Langevin piston method</span></div><div class="casAuthors">Feller, Scott E.; Zhang, Yuhong; Pastor, Richard W.; Brooks, Bernard R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4613-21</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    
            (<span class="NLM_cas:orgname">American Institute of Physics</span>)
        </div><div class="casAbstract">A new method for performing mol. dynamics simulations under const. pressure is presented.  In the method, which is based on the extended system formalism introduced by Andersen, the deterministic equations of motion for the piston degree of freedom are replaced by a Langevin equation; a suitable choice of collision frequency then eliminates the unphys. "ringing" of the vol. assocd. with the piston mass.  In this way it is similar to the "weak coupling algorithm" developed by Berendsen and co-workers to perform mol. dynamics simulation without piston mass effects.  It is shown, however, that the weak coupling algorithm induces artifacts into the simulation which can be quite severe for inhomogeneous systems such as aq. biopolymers or liq./liq. interfaces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZp5NIYiFpuLVg90H21EOLACvtfcHk0ljiL3dXIkFWQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotVentLo%253D&md5=219a4e0a48397a35fa2c62cf99bf225a</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1063%2F1.470648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.470648%26sid%3Dliteratum%253Aachs%26aulast%3DFeller%26aufirst%3DS.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPastor%26aufirst%3DR.%2BW.%26aulast%3DBrooks%26aufirst%3DB.%2BR.%26atitle%3DConstant%2520pressure%2520molecular%2520dynamics%2520simulation%253A%2520the%2520langevin%2520piston%2520method%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1995%26volume%3D103%26spage%3D4613%26epage%3D4621%26doi%3D10.1063%2F1.470648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerbini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span> <span> </span><span class="NLM_article-title">Transfection, selection, and colony-picking of human induced pluripotent stem cells TALEN-targeted with a GFP gene into the AAVS1 safe harbor</span>. <i>J. Visualized Exp.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>, <span class="NLM_elocation-id">e52504</span> <span class="refDoi"> DOI: 10.3791/52504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.3791%2F52504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvV2ntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=T.+Cerbiniauthor=Y.+Luoauthor=M.+S.+Raoauthor=J.+Zou&title=Transfection%2C+selection%2C+and+colony-picking+of+human+induced+pluripotent+stem+cells+TALEN-targeted+with+a+GFP+gene+into+the+AAVS1+safe+harbor&doi=10.3791%2F52504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Transfection, selection, and colony-picking of human induced pluripotent stem cells TALEN-targeted with a GFP gene into the AAVS1 safe harbor</span></div><div class="casAuthors">Cerbini, Trevor; Luo, Yongquan; Rao, Mahendra S.; Zou, Jizhong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Visualized Experiments</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">96</span>),
    <span class="NLM_cas:pages">e52504/1-e52504/9</span>CODEN:
                <span class="NLM_cas:coden">JVEOA4</span>;
        ISSN:<span class="NLM_cas:issn">1940-087X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Visualized Experiments</span>)
        </div><div class="casAbstract">A review.  Targeted transgene addn. can provide persistent gene expression while circumventing the gene silencing and insertional mutagenesis caused by viral vector mediated random integration.  This protocol describes a universal and efficient transgene targeted addn. platform in human iPSCs based on utilization of validated open-source TALENs and a gene-trap-like donor to deliver transgenes into a safe harbor locus.  Importantly, effective gene editing is rate-limited by the delivery efficiency of gene editing vectors.  Therefore, this protocol first focuses on prepn. of iPSCs for transfection to achieve high nuclear delivery efficiency.  When iPSCs are dissocd. into single cells using a gentle-cell dissocn. reagent and transfected using an optimized program, >50% cells can be induced to take up the large gene editing vectors.  Because the AAVS1 locus is located in the intron of an active gene (PPP1R12C), a splicing acceptor (SA)-linked puromycin resistant gene (PAC) was used to select targeted iPSCs while excluding random integration-only and untransfected cells.  This strategy greatly increases the chance of obtaining targeted clones, and can be used in other active gene targeting expts. as well.  Two weeks after puromycin selection at the dose adjusted for the specific iPSC line, clones are ready to be picked by manual dissection of large, isolated colonies into smaller pieces that are transferred to fresh medium in a smaller well for further expansion and genetic and functional screening.  One can follow this protocol to readily obtain multiple GFP reporter iPSC lines that are useful for in vivo and in vitro imaging and cell isolation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpreUnjkiWc-bVg90H21EOLACvtfcHk0ljiL3dXIkFWQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvV2ntb4%253D&md5=efef34580fcb534a231403a371bde2c0</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.3791%2F52504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3791%252F52504%26sid%3Dliteratum%253Aachs%26aulast%3DCerbini%26aufirst%3DT.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DM.%2BS.%26aulast%3DZou%26aufirst%3DJ.%26atitle%3DTransfection%252C%2520selection%252C%2520and%2520colony-picking%2520of%2520human%2520induced%2520pluripotent%2520stem%2520cells%2520TALEN-targeted%2520with%2520a%2520GFP%2520gene%2520into%2520the%2520AAVS1%2520safe%2520harbor%26jtitle%3DJ.%2520Visualized%2520Exp.%26date%3D2015%26doi%3D10.3791%2F52504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swistowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swistowska, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X.</span></span> <span> </span><span class="NLM_article-title">Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e6233</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0006233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=10.1371%2Fjournal.pone.0006233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;key=19597550" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&author=A.+Swistowskiauthor=J.+Pengauthor=Y.+Hanauthor=A.+M.+Swistowskaauthor=M.+S.+Raoauthor=X.+Zeng&title=Xeno-free+defined+conditions+for+culture+of+human+embryonic+stem+cells%2C+neural+stem+cells+and+dopaminergic+neurons+derived+from+them&doi=10.1371%2Fjournal.pone.0006233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0006233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0006233%26sid%3Dliteratum%253Aachs%26aulast%3DSwistowski%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DSwistowska%26aufirst%3DA.%2BM.%26aulast%3DRao%26aufirst%3DM.%2BS.%26aulast%3DZeng%26aufirst%3DX.%26atitle%3DXeno-free%2520defined%2520conditions%2520for%2520culture%2520of%2520human%2520embryonic%2520stem%2520cells%252C%2520neural%2520stem%2520cells%2520and%2520dopaminergic%2520neurons%2520derived%2520from%2520them%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26doi%3D10.1371%2Fjournal.pone.0006233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PBL','PDB','3PBL'); return false;">PDB: 3PBL</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i195"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00424">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_38561"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00424?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00424</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Bioanalysis of compound <b>20</b> in samples from mouse plasma and brain; functional profiling of CJ-1639 and pramipexole against an array of 168 known GPCRs; MS analysis for key analog <b>20</b>; HPLC and NMR spectra; and images of <sup>1</sup>H and <sup>13</sup>C NMR spectra for final analog compounds <b>1</b>–<b>109</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and SAR data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_002.csv">CSV</a>)</p></li><li><p class="inline">Protein data bank for D3R homology model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_001.pdf">jm0c00424_si_001.pdf (7.16 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_002.csv">jm0c00424_si_002.csv (12.26 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00424/suppl_file/jm0c00424_si_003.pdb">jm0c00424_si_003.pdb (399.89 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00424&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-10%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00424" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00424" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d3cf49463c40","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
